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Abstract	
	Care	 of	 patients	 with	 motor	 neurone	 disease	 (MND)	 is	 best	 provided	 by	 a	specialist,	 multidisciplinary	 team	 but	 access	 to	 this	 care	 is	 not	 universal.		Technology-enabled	care	has	the	potential	to	improve	access	to	specialist	care	in	MND.				A	telehealth	system	(TiM:	Telehealth	in	Motor	neurone	disease)	was	developed	to	allow	 patients	 and	 carers	 to	 share	 information	 about	 their	 condition	 using	 the	internet	with	a	specialist	MND	nurse.			An	18-month,	mixed	methods,	randomised,	controlled	pilot	and	feasibility	study	was	 conducted	 and	 a	 process	 evaluation	 explored	 the	 use,	 feasibility,	acceptability	and	potential	impact	of	the	TiM	system.		Clinical	outcomes	(such	as	quality	 of	 life)	were	 collected	 and	 semi-structured	 interviews	with	participants	and	 clinicians	 were	 conducted.	 	 40	 patients	 and	 37	 carers	 were	 recruited	 and	randomised	to	receive	usual	care	or	usual	care	plus	the	TiM	system.			Participants	and	clinicians	felt	that	the	TiM	system	was	an	acceptable	and	feasible	way	of	improving	access	to	specialist	care	and	thought	it	could	have	the	potential	to	 improve	 their	 care.	 	 	 Formal	 comparisons	of	 the	 two	 treatment	groups	were	not	 aims	 of	 the	 trial	 but	 only	 modest	 differences	 were	 observed.	 	 	 The	 study	identified	 further	 necessary	 improvements	 to	 the	 TiM,	 particularly	 focusing	 on	the	way	clinicians	act	upon	 the	 information	 received	and	 interact	with	patients	and	carers.					The	 trial	 methods	 appeared	 to	 be	 feasible.	 	 The	 main	 challenge	 posed	 by	 a	definitive	trial	appeared	to	be	how	to	effectively	measure	impacts	of	the	TiM	on	participants	and	the	clinical	service.		This	 thesis	 recommends	 that	 the	 next	 step	 of	 TiM	development	 should	 include	further	 iterative	 improvements	 to	 TiM	 system	 in	 parallel	 with	 research	 that	explores	how	the	system	would	be	used	best	in	different	MND	services.		If	these	evaluations	 also	 suggest	 the	 TiM	 system	 offers	 value,	 a	 definitive	 randomised	controlled	 trial	may	be	 feasible.	 	 	However,	 this	 thesis	 identifies	better	ways	 to	further	evaluate	this	complex	intervention.	 	
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Introduction	Specialist,	 multidisciplinary	 care	 for	 patients	 with	 motor	 neurone	 disease	 is	associated	 with	 better	 outcomes	 but	 access	 to	 this	 care	 is	 not	 universal.	 This	thesis	describes	the	work	to	develop	a	new	service	that	could	use	technology	to	improve	 access	 specialist	 multidisciplinary	 care	 for	 patients	 living	 with	 motor	neurone	disease	and	their	carers.				The	project’s	aims	were:	
• To	 develop	 a	 better	 understanding	 of	 the	 unmet	 needs	 of	 patients	with	MND	 and	 their	 carers	 and	 how	 these	 needs	 could	 be	 better	 met	 by	improving	healthcare	services;	
• To	explore	how	technology-enabled	care	could	 facilitate	better	access	 to	specialist	multidisciplinary	care	in	motor	neurone	disease;	
• To	 develop	 a	 new	 service	 using	 technology-enabled	 care	 to	 facilitate	better	access	to	specialist	care	(the	TiM	system);		
• To	conduct	a	pilot	and	 feasibility	randomised	controlled	 trial	of	 the	TiM	system	in	patients	with	MND	and	their	carers;	
• To	 conduct	 a	 process	 evaluation	 of	 the	 TiM	 system	 exploring	 the	acceptability	 and	 feasibility	 of	 the	 TiM	 system	 to	 patients,	 carers	 and	healthcare	professionals;	
• To	 explore	 the	wider	 acceptability	 and	 feasibility	 of	 technology-enabled	care	in	motor	neurone	disease	
• To	 use	 the	 findings	 to	 determine	 if	 and	 how	 the	 TiM	 system	 should	 be	developed,	evaluated	and	implemented	in	the	National	Health	Service.		Chapter	One	describes	the	clinical	features	of	motor	neurone	disease,	the	aims	of	multidisciplinary	care	and	highlights	the	need	for	better	access	to	patient-centred	specialist	 care.	 	 Chapter	 Two	 explores	 the	 existing	 evidence	 for	 the	 use	 of	technology-enabled	care,	in	particular	telehealth,	to	facilitate	access	to	specialist	care	 in	 motor	 neurone	 disease	 and	 describes	 some	 of	 the	 complexities	 of	implementation	and	evaluation	of	these	services	in	clinical	practice.				Chapter	Three	describes	the	development	of	the	TiM	system.		This	is	a	telehealth	system	 for	patients	with	motor	neurone	disease	 and	 their	 carers	 that	 aimed	 to	improve	access	to	specialist	care.		Chapter	Four	describes	the	aims	and	methods	of	evaluation	and	the	rationale	for	this	approach.		It	describes	a	mixed-methods,	pilot,	 randomised	 controlled	 trial	 which	 had	 two	 aims:	 	 to	 conduct	 a	 process	evaluation	to	examine	the	feasibility,	acceptability	and	the	potential	mechanisms	
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of	 impact	of	 the	TiM	system	on	patients,	carers	and	clinicians	and	to	determine	whether	 and	 how	 a	 larger,	 definitive	 trial	would	 be	 successful	 in	 assessing	 the	effectiveness	of	the	TiM	system.		Chapter	 Five,	 Six	 and	 Seven	 describe	 the	 results.	 	 Chapter	 Five	 describes	 and	discusses	 the	 results	 of	 the	 process	 evaluation,	which	 examined	 the	 use	 of	 the	telehealth	in	a	clinical	practice.		Supporting	quotes	from	this	chapter	are	available	in	Appendix	A.	Chapter	Six	describes	the	results	of	the	pilot	trial	and	explores	the	feasibility	 of	 a	 definitive	 randomised	 controlled	 trial.	 	 Additional	 results	 and	supporting	 quotes	 are	 available	 in	 Appendix	 B.	 Chapter	 Seven	 describes	additional	work	conducted	to	further	examine	the	feasibility	and	acceptability	of	technology-enabled	care	services	in	motor	neurone	disease.		Chapter	Eight	draws	from	 the	 results	 of	 all	 chapters,	 discussing	 the	 future	 of	 the	 TiM	 and	 makes	recommendations	for	future	development	and	evaluation	of	the	TiM	system.		Volume	Two	of	this	thesis	contains	Appendices	C	to	F.		These	include	publications	related	to	Chapter	Two	(Appendix	C)	and	Chapter	Seven	(Appendix	E).		Appendix	D	 contains	 documents	 relating	 to	 the	 trial	 methods	 (Chapter	 Four):	 the	 trial	protocol,	statistical	analysis	plan,	patient	information	leaflet,	topic	guides	and	an	example	 participant	 questionnaire.	 	 Appendix	 F	 contains	 a	 list	 of	 tables	 and	figures	and	abbreviations.		 	
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Chapter	One	
Motor	neurone	disease	
1.1 	Introduction		Motor	 neurone	 disease	 is	 a	 progressive,	 incurable,	 neurodegenerative	 disease	causing	physical	and	psychosocial	morbidity	and,	eventually	death.		Chapter	One	will	 discuss	 the	 clinical	 features	 of	 motor	 neurone	 disease	 and	 the	 impact	 the	disease	 has	 on	 both	 patients	 and	 informal	 carers.	 	 It	 will	 describe	 the	management,	 the	 role	 of	 the	 multidisciplinary	 team	 (MDT)	 and	 the	 important	care	needs	of	patients	 that	are	not	always	met	by	existing	services,	particularly	those	 associated	with	 difficulties	 accessing	 specialist	 care.	 	 It	 will	 describe	 the	current	UK	services	and	challenges	associated	with	delivering	this	specialist	care.	
1.2	The	clinical	features	of	motor	neurone	disease	
1.2.1	Definition	and	epidemiology	Motor	 neurone	 disease	 (MND)	 is	 a	 neurodegenerative	 disease	 causing	progressive	 weakness	 of	 skeletal	 muscles	 leading	 to	 disability	 and	 eventual	death,	usually	due	to	respiratory	 failure.	 	The	 incidence	of	MND	in	England	and	Wales	is	1.66	per	100,000	per	person	years,	peaking	in	the	late	60s	and	is	higher	in	men	 (female	 1.34,	males	 2.04)	 (1).	 	 The	 lifetime	 risk	 of	MND	 is	 1	 in	 472	 in	women	and	1	in	350	in	men	(2).	Survival	is	limited	to	an	average	of	2-4	years	and,	as	a	 result,	 the	prevalence	of	MND	 in	 the	UK	 is	only	approximately	5	000	 (7	 in	100	 000)	 (3).	 	 However	 survival	 is	 highly	 variable	 and	 a	 number	 of	 patients	experience	a	more	slowly	progressive	course,	with	some	living	for	over	a	decade.	
1.2.2	Classification		Amyotrophic	 lateral	 sclerosis	 (ALS)	 is	 the	 principal	 variant	 of	 MND,	 with	dysfunction	 of	 both	 upper	 motor	 neurones	 (causing	 weakness	 and	 spasticity),	and	 lower	motor	neurones	 (causing	weakness	 and	wasting)	 (4).	 	 Less	 common	clinical	 variants	 include	 a	 pure	 lower	 motor	 neurone	 disorder	 (progressive	muscular	 atrophy,	 PMA,	 approximately	 10%)	 and	 a	 pure	 upper	motor	 neurone	disorder	(primary	lateral	sclerosis,	PLS,	approximately	5%).				 	
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1.2.3	Pathology	and	aetiology	It	is	likely	that	multiple	genetic,	environmental	and	molecular	processes	interact	to	cause	dysfunction,	and	consequent	degeneration,	of	 the	motor	neurone	(5,6).		Proposed	mechanisms	involve	oxidative	stress,	excitotoxity,	protein	aggregation	and	damage	to	axonal	transport	and	mitochondrial	activity	as	well	as	changes	in	inflammatory	cascades	and	non-neuronal	cells.		Many	environmental	factors	have	been	proposed	but	supporting	evidence	is	lacking	(7).				5-10%	of	patients	exhibit	a	family	history	of	ALS.		A	specific	genetic	aetiology	can	be	 identified	 in	 approximately	 two	 thirds	 of	 these	 patients	 and	 some	 sporadic	cases	also	have	an	identifiable	mutation	(7).		By	far	the	most	common	mutation	is	a	 variable	 length	 hexonucleotide	 repeat	 expansion	 (GGGGCC)	 in	 the	 C9ORF72	gene	 on	 chromosome	9p21,	 evident	 in	 45%	of	 those	with	 familial	MND	 and	 5-11%	of	 sporadic	 cases	 (8,9).	 The	 C9ORF72	 repeat	 expansion	 is	 also	 associated	with	 other	 neurodegenerative	 diseases,	 most	 commonly	 frontotemporal	dementia	(10-12).		
1.2.4	Clinical	features	Limb	 involvement	causes	 loss	of	 fine	motor	skills,	 strength	and	 loss	of	mobility	(4).		Trunk	and	neck	involvement	causes	head	drop	and	poor	posture.		Spasticity,	cramps	 and	 spasms	 cause	 pain,	 sleep	 disturbance	 and	 pressure	 sores.	Dysfunction	of	the	bulbar	muscles	causes	dysphagia	and	dysarthria.	 	Worsening	dysphagia	results	 in	aspiration	of	 food	and	 fluids	and	eventual	complete	 loss	of	swallow.	 	 Dysphagia,	 upper	 limb	 weakness	 and	 the	 increased	 calorific	requirements	 observed	 in	MND	 can	 result	 in	malnutrition	 and	weight	 loss	 and	these	 complications	 are	 well	 recognised	 poor	 prognostic	 factors	 (13-16).		Dysarthria	worsens	until	eventually	patients	are	unable	to	communicate	verbally	and	must	rely	on	alternatives	such	as	writing	pads	or	communication	devices.		Respiratory	 failure	 is	 the	most	common	cause	of	death	 in	MND	(4).	 	 It	presents	insidiously.	 	 Initially,	 nocturnal	 respiratory	 insufficiency	 occurs	 causing	orthopnoea,	disturbed	sleep	and	daytime	sleepiness.	 	Later,	daytime	respiratory	insufficiency	results	 in	breathlessness.	 	Dysphagia,	combined	with	a	poor	cough	due	to	inadequate	glottis	closure	and	respiratory	ex-sufflation	weakness,	causes	excessive	 oropharyngeal	 and	 respiratory	 secretions.	 Approximately	 half	 of	patients	attending	the	MND	clinic	experience	excessive	secretions,	and	of	 these,	half	have	uncontrolled	symptoms.		Uncontrolled	secretions	are	common	and	are	distressing	 and	 cause	 social	 embarrassment	 and	 aspiration	 of	 secretions	 can	cause	pneumonia	(4,17).		
	 11	
Psychological	 symptoms	 are	 common.	 	 These	 symptoms,	 including	 depression	(between	 11	 and	 75%	of	 patients),	 anxiety	 (up	 to	 33%)	 and	 fatigue	 (75-83%),	and	 have	 a	 negative	 impact	 on	 quality	 of	 life	 (18-20).	 Whilst	 motor	 neurone	dysfunction	 is	 the	most	 prominent	 feature	 in	many	 patients	with	MND	 display	other	 neurological	 deficits	 (21).	 	 Emotional	 lability	 is	 present	 in	 approximately	half	of	patients	(22).		10-15%	of	patients	show	signs	of	frontotemporal	dementia	and	 a	 further	 50%	 experience	 mild	 cognitive	 or	 behavioural	 changes	 (23,24).	14%	 have	 been	 found	 to	 display	 other	 neurological	 signs	 such	 autonomic	dysfunction	or	ataxia	(21).		These	additional	deficits	are	associated	with	a	poorer	prognosis	(25).		
1.2.5	Disease	progression	and	prognosis	The	presentation	and	progress	of	MND	varies	between	individuals.		Patients	tend	to	 present	 with	 disability	 in	 one	 region	 and	 later	 the	 disease	 progresses	 to	involve	contiguous	regions.	 	 In	75%	of	cases,	the	disease	starts	 in	the	limbs	(3).		In	20%	of	cases,	disease	starts	in	the	bulbar	muscles	and	in	approximately	5%	of	patients,	 disease	 begins	 with	 respiratory	 insufficiency	 (3).	 	 Patients	 usually	develop	 respiratory	 failure	 in	 the	 later	 stages	 (26).	 	 Average	 survival	 from	symptom	onset	for	typical	ALS	is	two	to	four	years	however,	survival	can	range	from	months	to	decades.		Factors	that	predict	poor	prognosis	include	older	age	at	onset,	 rapid	 progression	 between	 clinical	 milestones,	 presence	 of	 other	neurological	 deficits	 and	 the	 presence	 of	 some	 genetic	 mutations	 (27).		Phenotypes	 associated	 with	 more	 slowly	 progressive	 disease	 typically	 include	PLS	 and	 PMA,	whereas	 those	with	 bulbar	 or	 respiratory	 onset	 disease	 tend	 to	have	a	worse	prognosis	(4).			
1.2.6	Living	with	motor	neurone	disease	The	day-to-day	experience	of	MND	changes	as	the	disease	progresses	(28).		There	may	be	a	considerable	delay	between	symptom	onset	and	diagnosis,	often	many	months	 to	 years	 during	 which	 time	 patients	 will	 experience	 uncertainty,	psychological	 and	 physical	 distress	 as	 they	 see	 themselves	 deteriorating	 along	with	a	failure	to	have	their	needs	met	(29).		The	impact	of	receiving	the	diagnosis	of	 this	 terminal	 condition	 can	 highly	 stressful,	 distressing	 and	 profoundly	upsetting	 (30).	 	 Patients	 experience	 the	 disease	 as	 a	 series	 of	 functional	 losses	(physical	but	 also	 in	vocational,	 occupational	 and	 family	 roles)	 (31).	 	They	also	describe	 a	 loss	 of	 normality	 as	well	 as	 their	 sense	 of	 self	 and	 social	 identify	 as	they	become	increasingly	dependent	on	others	(28,32).		Patients	express	feelings	of	uncertainty	and	powerlessness	whilst	others	feel	defiant	and	want	to	challenge	the	 disease	 (28,32).	 	 Adapting	 to	 the	 disease	 can	 be	 difficult	 but	maintaining	 a	sense	of	agency	and	control,	faith	and	dignity	and	their	relationships	with	family	
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and	 social	 support	 appear	 central	 to	 enabling	 patients	 to	 accept	 the	 diagnosis,	maintain	hope	and	adapt	to	the	challenges	faced	(31,32).				Along	with	the	diagnostic	delay,	even	when	diagnosed,	patients	described	a	lack	of	knowledge	of	the	disease,	interpreting	information	from	different	sources	and	not	 knowing	 whom	 best	 to	 turn	 to	 for	 support	 (28).	 	 Both	 patients	 and	professionals	 identified	 the	 need	 to	 improve	 the	 knowledge	 of	 healthcare	providers	 along	 with	 more	 coordinated	 care	 and	 communication	 between	hospitals	and	the	community	(28).		Near	 the	 end	 of	 life	 patients	 not	 only	 experience	 physical	 symptoms	 but	 also	emotional	 distress	 and	 uncertainty	 (32).	 	 The	 terminal	 phases	 can	 often	 be	unexpected	and	rapid,	leading	to	unplanned	interactions	with	emergency	care	or	hospitalisation	which	may	be	against	the	patients’	wishes,	many	of	whom	wish	to	die	at	home	(33).	 	Even	those	with	advanced	care	plans	had	difficulty	accessing	the	 appropriate	 care	 at	 key	 times	 (33).	 	 Patients	 may	 consider	 euthanasia	 or	assisted	 suicide.	 	 These	 are	 legal	 in	 some	 countries	 but	 not	 in	 the	 UK	 (25).			Patients	welcome	the	opportunity	to	discuss	end-of-life	choices	and	the	desire	to	end	 their	 lives	 appears	 to	 diminish	 as	 they	 discuss	 their	 underlying	 fears	 and	concerns	(34,35).		
1.2.7	Diagnosis	The	El	Escorial	criteria	(Box	1.1)	for	ALS	was	developed	through	an	international	consensus	and	 is	used	 in	research	 to	ensure	a	consistent	diagnosis	 (36).	 	 It	has	several	limitations:	a	“clinically	definite”	diagnosis	relies	on	extensive	evidence	in	different	 regions	 of	 both	 upper	 and	 lower	 motor	 neurone	 signs.	 	 Extensive	disease	may	not	be	present	in	many	of	those	attending	an	MND	clinic,	particularly	early	 in	 the	disease,	or	 those	with	PLS	or	PMA	(37).	 Some	patients	die	without	ever	fulfilling	these	criteria	(37).		Relying	on	these	criteria	means	many	patients	are	excluded	from	clinical	trials	(37).		Alternative	criteria	which	have	recognised	other	 clinical	 features	 of	 MND	 (such	 as	 the	 presence	 of	 a	 genetic	 mutation	 or	frontotemporal	 dementia)	 have	 been	 proposed	 to	 better	 reflect	 the	 different	disease	phenotypes	but	these	still	do	not	identify	all	those	with	MND	(38).	
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Box	1.1:	The	El	Escorial	criteria.		Adapted	from	(Brooks	et	al.	1994)	
Clinically	 Definite	 ALS:	 clinical	 evidence	 of	 the	 presence	 of	 upper	 motor	 neurone	(UMN),	as	well	as	lower	motor	neurone	(LMN)	signs,	in	three	regions.	
Clinically	Probable	ALS:	clinical	evidence	of	UMN	and	LMN	signs	in	at	least	two	regions	with	some	UMN	signs	necessarily	rostral	to	the	LMN	signs.	
Clinically	 Probable	 -	 Laboratory-supported	 ALS:	 clinical	 signs	 of	 UMN	 and	 LMN	dysfunction	in	only	one	region,	or	when	UMN	signs	alone	are	present	in	one	region,	and	neurophysiological	LMN	signs	are	present	in	at	least	two	limbs	
Clinically	Possible	ALS:	clinical	signs	of	UMN	and	LMN	dysfunction	are	found	together	in	only	one	region	or	UMN	signs	are	found	alone	in	two	or	more	regions;	or	LMN	signs	are	 found	 rostral	 to	 UMN	 signs	 and	 the	 diagnosis	 of	 Clinically	 Probable	 -	 Laboratory-supported	ALS	cannot	be	proven	clinically	or	using	laboratory	studies.	
1.3	The	management	of	motor	neurone	disease			The	focus	of	MND	care	is	to	promote	survival,	minimise	morbidity	and	maximise	quality	of	life	(25).	Due	to	the	variety	of	bio-psychosocial	complications	of	MND,	management	 requires	 a	 holistic,	 multidisciplinary	 team	 (MDT)	 approach	involving	 both	 patients	 and	 their	 family	 and	 carers.	 	 Whilst	 management	guidelines	 are	 available	 (such	 as	 the	 National	 Institute	 for	 Clinical	 Excellence	guidelines,	published	in	2016	(39),),	the	evidence	for	most	interventions	is	very	limited	 and	 mainly	 based	 on	 expert	 consensus	 (25,39-41).	 	 As	 the	 patient	progresses,	the	focus	of	care	shifts	from	promoting	function	and	independence	to	palliation	of	symptoms	and	psychological	support	(25).			
1.3.1	Disease	modifying	therapies	Riluzole	is	the	only	drug	that	has	been	shown	to	prolong	survival	in	patients	with	ALS,	by	an	average	of	three	months	(42,43).	Its	effects	are	likely	due	to	its	action	on	sodium	and	potassium	currents	causing	inhibition	of	repetitive	neurone	firing	as	well	as	inhibition	of	neurotransmitter	release	(44).	Phase	three	trials	of	other	potential	 disease	modifying	 therapies	 (e.g.	 lithium,	 dexpramipexole)	 have	 been	disappointing	with	other	treatments	currently	in	early	experimental	phases	(45-48).	
1.3.2	Physical	symptoms	There	 are	 many	 pharmacological	 and	 non-pharmacological	 strategies	 used	 to	treat	and	prevent	physical	symptoms	but	evidence	for	their	effectiveness	in	MND	is	limited	(25).		Table	1.1	outlines	the	approach	to	these	symptoms.		 	
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Table	1.1	The	management	of	common	symptoms	in	MND	Adapted	with	permission	from	Macmillan	publishers	Ltd.	©	2016	(25).1	 	 	
																																																								1	SSRIs:	selective	serotonin	re-uptake	inhibitors,	NIV:	non-invasive	ventilation	Grading	of	recommendation	proposed	by	the	Oxford	Centre	for	Evidenced-based	Medicine,	2009	www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/	Grade	A:	systematic	review	or	individual	RCT	with	narrow	confidence	interval.	Grade	B	includes	systematic	reviews	or	cohort	or	case-control	studies	or	extrapolations*	of	level	A	studies	Grade	C:	case-series	or	poor	quality	cohort	studies	or	extrapolations*	of	level	A	or	B	evidence	Grade	D:	expert	opinion	or	inconsistent	research	from	level	A,	B	or	C	evidence.	*extrapolations:	where	data	is	used	in	a	situation	with	potentially	important	differences	from	the	original	study	situation.	
Problem	 Pharmacological	
treatments	
Grade	 of	
evidence	
Non-
pharmacological	
strategies	
Grade	 of	
evidence	
Cramps	 Quinine		Levetiracetam		Mexiletine		 Grade	B	Grade	C	Grade	B	 Physical	 therapy,	exercise	 Grade	D	
Spasticity	 Baclofen,	 tizanidine,	dantrolene	Benzodiazepines	Intrathecal	baclofen	
Grade	D		Grade	D	Grade	C	
Prescribed	exercise		Hydrotherapy	Cryotherapy	
Grade	B		Grade	D	Grade	D	
Pain	 WHO	 Analgesic	Ladder	Opioids	 Grade	D	Grade	C	 N/A		 	N/A		
Emotional	
lability	
SSRIs		Dextromethorphan/quinidine		Amitriptyline	
Grade	 C	Grade	A	Grade	C	 N/A	 N/A	
Depression	 Selective	 serotonin	re-uptake	inhibitors	 Grade	D	 Psychological	therapy,	counselling	 Grade	D	
Anxiety	 Benzodiazepines	 Grade	D	 Psychological	therapy,	counselling	 Grade	D	
Fatigue	 Modafinil		 Grade	B	 N/A	 N/A	
Respiratory	
failure	
N/A	 N/A	 Non-invasive	ventilation		Cough	augmentation		
Grade	A		Grade	D	
Excessive	
respiratory	
secretions	
(thick)	
Carbocysteine	Nebulised	saline	 Grade	D	Grade	D	 Cough	augmentation	Humidification	of	NIV	Suction	Reduction	in	dairy	product	intake	Pineapple	juice	
Grade	D	Grade	D	Grade	D	None			None	
Excessive	
oral	
secretions	
(thin)	
Hyoscine	patches	Amitriptyline	Atropine	drops	Glycopyrrolate	Botulinum	toxin		
Grade	D	Grade	D	Grade	D	Grade	D	Grade	B	
Radiotherapy		Suction	 Grade	C	Grade	D	
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1.3.3	Psychological	and	cognitive	symptoms	Currently,	 there	are	no	 current	proven	 therapies	 for	psychological,	 cognitive	or	behavioural	 problems	 and	 a	 holistic	 approach	 involving	 early	 recognition,	counselling,	education	and	advanced	planning	 is	recommended	for	patients	and	their	families	(25).				
1.3.4	Communication	and	assistive	devices	and	rehabilitative	strategies	An	 array	 of	 rehabilitative	 strategies,	 aids	 and	 assistive	 devices	 are	 available	 to	help	patients	maintain	independence.	 	These	range	from	simple	switches	or	call	bells	to	bespoke	powered	wheelchairs	and	eye-gaze	systems	(49).		As	the	patient	progresses,	 their	needs	change	 (25).	 	A	physiotherapist’s	 role	may	change	 from	promoting	independence	and	maintaining	walking	to	providing	specialist	seating	and	preventing	pressure	sores.		As	a	patient’s	function	may	change	rapidly,	timely	recognition	 of	 deterioration	 and	 provision	 of	 the	 correct	 solution	 is	 important.		However	 access	 may	 be	 limited	 with	 barriers	 including	 cost,	 functionality	 and	acceptability	 of	 devices	 along	 with	 lack	 of	 awareness	 of	 what	 is	 available	 and	required	by	both	health	care	professionals	and	patients	(49,50).			
1.3.5	Respiratory	management	In	 patients	 with	 respiratory	 failure,	 use	 of	 non-invasive	 ventilation	 (NIV)	 to	support	 breathing	 can	 improve	 survival	 by	 on	 average	 seven	 months,	 whilst	sustaining	 quality	 of	 life	 and	 improving	 symptoms	 of	 respiratory	 failure	 (51).		NIV	 improves	 sleep	architecture	by	 reducing	hypoxia	and	hypercapnoea.	 	Early	initiation	 may	 lead	 to	 better	 outcomes	 (52,53)	 so	 patients	 require	 regular	monitoring	to	detect	the	symptoms	and	signs	of	respiratory	failure		(39).		There	has	been	considerable	variation	in	the	way	physicians	monitor	and	refer	for	NIV	and	 it	 appears	 that	 patients	 attending	 specialist	 centres	 are	 more	 likely	 to	 be	referred	for,	and	use	NIV	than	those	attending	a	general	neurology	clinic	(54,55).		The	variation	in	patient	use	of	NIV	demonstrates	the	importance	of	specialist	staff	to	initiate	and	support	NIV	use.		Even	within	a	research	trial,	half	of	patients	did	not	manage	to	use	NIV	for	at	least	four	hours	per	day,	meaning	they	are	unlikely	to	gain	the	full	benefit	(56).		Many	patients	find	it	difficult	to	adhere	to	NIV,	facing	barriers	such	as	claustrophobia	and	dry	mouth,	excessive	airway	secretions	and	increased	carer	strain	(57,58).	Frontotemporal	dementia	and	bulbar	dysfunction	also	pose	challenges	but	even	in	these	circumstance	NIV	may	offer	symptomatic	and	 survival	 benefit	 (51,59).	 Successful	 use	 of	 NIV	 requires	 perseverance	 by	patients	and	their	carers	and	intensive	specialist	support,	monitor	use	and	adjust	the	 equipment	 address	 barriers	 to	 adherence	 and	 accommodate	 for	 further	disease	progression	(57,58).		
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There	is	insufficient	evidence	to	recommend	any	other	respiratory	interventions.		Devices	that	have	been	explored	include	lung	volume	recruitment	or	mechanical	insufflation-exsufflation	devices	(“Cough	Assist”)	 (60).	 	Clinical	 trials	have	 faced	difficulties	 with	 small	 sample	 sizes,	 difficulties	 delivering	 the	 intervention	 and	measuring	outcomes.	Oropharngeal	suction	and	mechanical	cough	assist	devices	are	available	in	some	centres	but	the	pathways	to	access	and	provision	may	vary.			It	 was	 proposed	 that	 stimulating	 the	 weakened	 diaphragm	 muscle	 using	 an	external	 pacing	 system	might	 improve	 diaphragm	muscle	 function	 and	 restore	coordination	 of	 respiration,	 thereby	 improve	 sleep	 quality	 and	 survival.	 	 Early,	non-controlled	 data	 led	 to	 approval	 for	 the	 therapy	 in	 the	 US	 under	 the	Humanitarian	 Device	 Exemption	 process	 (61).	 However,	 two	 randomised	controlled	 trials	 have	 demonstrated	 that	 it	 is	 associated	 with	 poorer	 survival	(62,63).	 	 This	 highlights	 the	 importance	 of	 clinical	 trials	 to	 avoid	 patients	suffering	harm	from	dangerous,	untested	treatments.	
1.3.6	Nutrition	support	In	patients	whose	swallow	becomes	unsafe,	or	are	unable	to	maintain	adequate	nutrition	or	hydration	orally,	gastrostomy	insertion	can	enable	enteral	feeding	(64).		There	is	no	convincing	evidence	that	enteral	feeding	improves	survival,	nutritional	outcomes	or	quality	of	life	but	some	patients	and	carers	report	that	enteral	feeding	relieves	the	anxiety	associated	with	poor	oral	intake	and	many	perceive	it	to	have	had	survival	benefits	(65).		In	order	to	reduce	the	risk	of	complications	and	increase	likelihood	of	benefit,	it	is	recommended	that	gastrostomy	is	inserted	early,	prior	to	respiratory	failure	or	significant	weight	loss	(65).		Delay	in	identifying	swallowing	difficulties	or	respiratory	failure	(which	makes	gastrostomy	insertion	more	risky)	could	result	in	patients	being	too	unwell	to	undergo	the	procedure	or	failing	to	gain	the	benefit	of	enteral	feeding.		Therefore	it	is	recommended	that	patients	require	early	and	regular	counselling	and	monitoring	of	swallow,	diet,	nutritional	status	and	respiratory	function	to	enable	early	intervention	should	these	deteriorate	(65).		Monitoring	is	also	required	after	feeding	is	commenced	to	treat	complications	such	as	gastrointestinal	disturbance	and	insertion	site	infections	(65).	Patients	who	decline	gastrostomy	feeding	also	need	support	as	they	may	encounter	risk	of	dehydration,	malnutrition	and	aspiration	in	the	later	stages	of	their	disease	(25).	
1.3.7	Palliative	care	At	 the	 end	 of	 life	 patients	 develop	 distressing	 physical	 and	 psychological	symptoms	such	as	dyspnoea	and	anxiety	whilst	carers	may	experience	additional	strain.	 This	 experience	 can	 have	 a	 significant	 impact	 on	 patients	 and	 their	
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families	 (58,66,67).	 It	 is	 recommended	 that	 specialist	 palliative	 care	 services	should	work	with	the	MDT	to	provide	support	early,	and	throughout	the	disease	(39).	 Access	 to	 palliative	 care	 for	 those	 entering	 the	 terminal	 phases	 of	 the	disease	 can	 reduce	 fears	 associated	 with	 end-of-life	 events	 and	 improve	 the	likelihood	a	comfortable	death	in	the	patient’s	location	of	choice	(34).		However,	access	 to	specialist	 is	not	universal	and	often	 lacks	continuity	 (67,68).	 	Without	coordination	 and	 advanced	 planning,	 palliative	 services	 are	 accessed	 too	 late	(67).		Even	with	specialist	support,	complexities	such	as	anticipatory	prescribing,	advance	 decision	 making	 and	 declining	 or	 withdrawing	 medical	 interventions	means	management	may	not	be	straightforward	(69).		
1.3.8	Improving	quality	of	life		Complications	of	MND	impact	negatively	on	patients’	quality	of	life	(QoL).		These	include	 dysarthria	 (70),	 dysphagia	 (71),	 pain	 (72),	 respiratory	 failure	 (73)	 and	fatigue	(74).		A	small	number	of	interventions	have	been	shown	to	improve	QoL.		Improving	communication	using	assistive	technology	appears	to	have	a	positive	influence	(70,75)	and	NIV	sustains	QoL	in	patients	with	respiratory	failure	(51).	Other	 interventions	 aim	 to	 improve	 patients’	 psychological	 wellbeing	 by	promoting	 interpersonal	 relationships,	 self-efficacy	 and	 coping	 strategies	 by	using	 therapies	such	as	hypnosis	and	meditation	(76,77).	 	These	have	yet	 to	be	evaluated	in	controlled	trials.	
1.4	Healthcare	resource	use	in	motor	neurone	disease		The	 health	 costs	 associated	 with	MND	 include	 direct	 costs	 (e.g.	 MDT	 care	 and	equipment)	and	personal/social	care.		Informal	carers	(usually	family	members)	tend	 to	 provide	most	 of	 this	 care.	 	 Costs	 associated	with	MND	 are	 higher	 than	other	 neurological	 diseases	 (78).	 	 An	 assessment	 of	 medical	 costs	 in	 Ireland	estimated	the	cost	of	MND	care	per	month	was	€1795	(and	higher	in	those	using	NIV	 and	 gastrostomy)	 (79).	 	 72%	 of	 costs	 were	 due	 to	 community	 based	 care	rather	 than	hospital	care	(21%),	aids	and	appliances	(7%)	(79).	 	The	estimated	annual	total	cost	per	patient	in	other	countries	range	widely	($13,667	Denmark,	to	$	69,475,	US)	 (78).	 	There	 is	a	major	drive	 in	 the	NHS	 to	move	care	 into	 the	community	 and	 reduce	 emergency	 hospital	 admissions	 (80).	 	 The	 elderly	 and	those	 with	 pre-morbid	 conditions	 such	 as	 MND	 are	 at	 a	 much	 higher	 risk	 of	needing	 emergency	 admissions	 (80).	 	 Emergency	 hospital	 admissions	 (for	problems	such	as	respiratory	infections)	present	a	high	cost	to	the	health	service	and	the	cost	of	a	single	emergency	admission	can	be	 far	greater	 than	any	other	aspect	of	 a	patient’s	 care	 (81).	 	 Proposed	ways	 to	 reduce	avoidable	 admissions	include	 promoting	 self-management,	 improving	 and	 integrating	 hospital,	 local	
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and	 out-of-hours	 services	 and	 providing	 specialist	 case-monitoring	 and	management	 services,	 particularly	 to	 groups	 of	 patients	 with	 a	 high	 risk	 of	admissions	(80).				In	 2013/2014,	 NHS	 England	 hospital	 admission	 statistics	 recorded	 3791	emergency	 hospitals	 admissions	 for	 patients	 with	 MND	 (although	 this	 also	includes	a	smaller	group	of	patients	with	a	rarer	disease-	spinomuscular	atrophy)	(82).	 This	 is	 approximately	 9.3	 admissions	 per	 100	 000	 residents	 in	 Yorkshire	and	 Humber	 (approximately	 0.8	 admissions	 per	 year	 per	 person	 with	 MND).		There	is	significant	regional	variation	amongst	patients	who	attend	the	Sheffield	MND	clinic	(Figure	1.2)	from	5.5	admissions	per	100	000	in	York	to	20.1	per	100	000	in	North	Lincolnshire.		The	reasons	for	this	regional	variation	are	unclear.		It	is	possible	 that	a	small	number	of	patients	 requiring	multiple	admissions	could	be	influencing	the	figures,	but	this	pattern	appears	consistent	over	several	years.		It	is	possible	that	the	variation	in	regional	variations	in	emergency	admissions	of	patients	 with	 MND	 could	 be	 related	 to	 the	 quality	 of	 community	 services	available	 locally.	 	 It	 should	 be	 noted	 that	 patients	 living	 in	 the	 area	 with	 the	lowest	 admission	 (York)	 receive	 care	 from	 an	 experienced	 community	 MND	nurse	whereas	a	general	rehabilitation	team	leads	the	community	care	of	those	in	North	 Lincolnshire	with	 no	 nurse	 specialist.	 	 However,	 there	 is	 no	 evidence	 to	suggest	 whether	 one	 community	 model	 of	 care	 is	 superior	 to	 another.	 A	randomised	 controlled	 trial	 of	 community	 case	 management	 in	 additional	 to	usual	MDT	care	in	MND	failed	to	demonstrate	any	benefit	(83).				 	
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Figure	 1.2	 Number	 of	 emergency	 admissions	 (count)	 and	 rates	 per	 100	 000	population	living	in	each	area	(value)	in	Yorkshire	and	Humber	compared	to	the	England	 average.	 	 Dark	 blue	 indicates	 the	 lower	 25%	percentile,	 light	 blue	 the	higher	25%	percentile.	2	
1.5	The	experience	of	informal	carers		Informal	 carers	provide	 the	majority	of	day-to-day	 care	 for	patients	with	MND.		This	 is	 commonly	 the	 spouse	 or	 another	 family	 member.	 	 It	 is	 estimated	 that	informal	 carers	provide	an	estimated	£110	000	worth	of	 care	 to	a	patient	with	MND	in	one	year	(84).			
1.5.1	Carer	quality	of	life	Caring	 for	 someone	with	MND	has	 a	 significant	 impact	 on	 carers’	 physical	 and	emotional	 quality	 of	 life	 (66,85).	 Carers	 report	 practical	 difficulties	 including	physical	 demands,	 managing	 with	 unfamiliar	 equipment	 and	 being	 continually	tired	 (58,66,86).	 	 They	 describe	 worries	 for	 patients’	 safety,	 distress	 and	 fear	when	 witnessing	 suffering	 and	 feelings	 of	 anger,	 frustration	 and	 uncertainty	about	the	future	(87).	Carers	report	difficulties	with	the	loss	of	intimacy,	change	in	 their	 roles	and	 relationships	and	having	 to	 cope	with	a	progressive	 series	of	losses	(66,86).	After	death,	carers	experience	both	relief	and	also	regret,	guilt	and	self-criticism,	particularly	when	the	death	did	not	occur	as	preferred,	and	lack	of	bereavement	support	has	often	been	reported	(33,67).		Caring	 restricts	 carers’	 own	 lives,	 time,	 freedom	and	 finances	 (87).	 Carers	may																																																									2		Reproduced	with	permission.	©	Crown	copyright	2016.	Supplied	by	Public	Health	England	(82).	
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bear	many	financial	costs	of	MND	as	they	are	often	financially	interdependent	on	the	patient	and	may	be	required	to	give	up	work	to	provide	care	resulting	in	lost	earnings	 (at	 an	 age	 where	 earnings	 are	 often	 at	 their	 highest),	 pension,	 and	careers	(88).	Financial	support	 is	usually	 limited,	 for	example	carers’	allowance	in	the	UK	is	only	£62.50	per	week	(89).			Carer	reporting	poor	quality	of	life	are	not	necessarily	those	caring	for	the	most	disabled	 relatives	 (90).	 Carer	 distress	 does	 appear	 to	 be	 worse	 when	 patients	experience	 behavioural	 changes	 (e.g.	 apathy,	 dis-inhibition,	 impulsivity)	 which	may	have	negative	impact	on	relationships	and	coping	strategies	(91).		It	appears	that	factors	less	directly	related	to	health	are	also	important	in	determining	carer	quality	of	life,	for	example	religion	(92),	problem	solving	skills	(93),	hours	of	care	(94),	marital	relationships	and	social	support	(95,96).			As	the	disease	progresses,	carer	psychological	distress	increases	(97).		This	study	suggested	that	the	factors	influencing	their	distress	also	change.		Initially,	distress	appeared	to	be	related	to	the	psychosocial	impact	of	the	patient’s	disease,	emotional	lability	experienced	by	the	 patient	 and	 the	 number	 of	 other	 dependents	 for	whom	 the	 carer	was	 also	responsible	(97).	Later	in	the	disease,	carer	distress	was	best	predicted	by	a	lack	of	 social	 support	 and	 by	 their	 initial	 satisfaction	with	 their	 social	 relationships	(97).		
1.5.2	Current	support	for	carers	Carers	 are	 offered	 support	 by	 the	 patients’	multidisciplinary	 team	 and	 there	 is	also	 support	 available	 from	 charities	 and	 through	 the	 social	 care	 system	 (98).		One	randomised	controlled	trial	of	132	patients	in	the	Netherlands	of	community	based	case	management	examined	carer	outcomes	(83)	but	it	did	not	identify	any	impact	on	carer	strain.	 	The	 interaction	between	carers	and	healthcare	services	appears	to	influence	carer	wellbeing	(98).		Carers	may	be	unaware	of	the	services	available	 and	 yet	 find	 it	 challenging	 to	 accept	 the	 help	 of	 professionals	 and	allowing	others	to	take	over	caring	duties	(98).		They	may	face	difficulties	related	to	 the	 way	 care	 is	 organised	 and	 provided	 such	 as	 the	 timing	 of	 equipment	provision	and	service	delivery	(98).		Carers’	quality	of	life	and	carer	strain	scores	appear	to	be	related	to	the	number	of	problems	with	the	care	they	receive	(99).	Problems	include	a	lack	of	the	opportunity	to	discuss	the	amount	of	caring	with	a	professional,	 not	being	as	 involved	 in	 care	planning	as	 they	would	 like	and	not	having	enough	help	with	providing	physical	care	(99).	 	Another	study	suggested	that	the	single	biggest	impact	on	carers’	quality	of	life	appears	to	be	related	to	the	amount	of	 time	they	 feel	 is	required	to	carry	out	caring	duties	(100).	 	However	the	study	found	this	impact	did	not	appear	to	ease	when	substitute	carers	were	present.			
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1.5.3	Interventions	to	improve	carer	wellbeing	Despite	 the	 growing	 evidence	 identifying	 carer	 difficulties,	 to	 date,	 no	interventions	specifically	target	carers	of	those	with	MND.	A	recent	review	of	the	evidence	of	carer	experiences	also	emphasised	the	need	to	support	carers	in	their	roles	 (98).	 	 It	 suggested	 four	ways	 in	which	 carer	wellbeing	may	be	 improved:	early	 access	 to	 palliative	 care;	 providing	 disease	 specific	 information	 and	signposting	 to	 services;	 and	 teaching	 carers	 caring	 skills	 (98).	 	 It	 also	 suggest	encouraging	 a	 supportive	 relationship	 between	 patients	 and	 carers	 (98)	which	may	 explain	 why	 two	 small	 studies	 of	 assistive	 communication	 technology	suggested	this	may	improve	both	patient	and	carer	wellbeing	(75,101).				It	 is	 important	 to	 recognise	 that	 interventions	 could	 inadvertently	 have	 a	negative	impact	on	carer	wellbeing.		Interventions	that	improve	coping	strategies	may	mean	carers	take	on	more	tasks,	thereby	increasing	carer	burden.		Carers	are	often	 required	 to	 conduct	 complex	 tasks	 such	 as	 using	 NIV	 and	 gastrostomy	feeding	 with	 little	 training	 (68).	 Whilst	 these	 might	 improve	 the	 patient’s	condition	and	may	address	 some	carer	 concerns	 (e.g.	 by	 reducing	 the	 anxieties	related	to	poor	oral	intake)	they	may	increase	carer	burden.		One	study	observed	that	carer	QoL	deteriorated	following	NIV	initiation	with	the	physical	strain	and	impact	on	carer	time	being	highlighted	as	potential	factors	(58).	Similarly,	carer	strain	was	observed	to	increase	after	gastrostomy	insertion	(65)	and	a	negative	impact	on	both	physical	and	 time	requirements	was	also	reported	(102).	When	evaluating	any	new	intervention,	it	should	assess	the	impact	on	both	patients	and	carers.	
1.6	The	specialist	multidisciplinary	team		Given	 the	 complexity	 of	 the	 care	 needs	 of	 patients,	 carers	 and	 their	 families,	guidelines	 recommend	 that	 care	 is	 provided	 by	 a	 specialist	 multidisciplinary	team	 (MDT)	 (39-41).	 	 It	 is	 recommended	 that	 a	 core	 team	 of	 specialists	 with	experience	in	MND	care	provide	care	throughout	each	stage	the	disease	who	can	access	a	range	of	other	specialist	and	community	services	as	required.		Figure	1.3	describes	 the	 core	 and	 the	 additional	 components	 of	 an	MND	MDT.	 	 In	 the	UK,	over	the	last	decade,	22	specialist	MDT	MND	Care	Centres	have	been	established	(103,104).	Approximately	70%	of	patients	in	the	UK	attend	one	of	these	centres	at	 some	 point	 in	 their	 illness	 (105).	 	 Similar	 models	 are	 employed	 in	 other	developed	countries	(55,106-108).		
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	Figure	1.3	The	core	(orange)	and	additional	(blue)	components	of	a	MND	care	team	(39).	Reproduced	with	permission	from	Macmillan	publishers	Ltd.		©	Macmillan	publishers	Ltd	2016	(25)				Attendance	at	a	specialist	MDT	is	associated	with	improved	survival,	independent	of	the	use	of	non-invasive	ventilation,	riluzole	and	gastrostomy	feeding	(55,109-111).	 	 Furthermore,	 MDT	 care	 may	 also	 reduce	 the	 number	 of,	 and	 shorten	inpatient	stays	(106).		It	is	also	associated	with	increased	use	of	proven	therapies	i.e.	riluzole	and	non-invasive	ventilation	as	well	as	assistive	aids	and	devices	(55).		One	 study	 also	 suggests	 that	MDT	 care	 has	 a	 positive	 impact	 on	 patients’	 QoL	(106).	 	 Patients	 value	 the	 convenience	 and	 quality	 of	 unified	 care	 and	 single	appointments	could	reduce	travel	time	required	to	visit	multiple	specialist	(112).		Patients	and	carers	report	positive	experiences	when	they	are	able	to	be	involved	with	 the	MDT	 in	making	decisions	about	 their	 care	 (68).	 	They	also	 report	 that	clinicians	 provide	 them	 with	 the	 practical	 and	 emotional	 support	 required	 to	cope	with	the	disease	(113,114).		The	cause	of	the	observed	survival	benefit	associated	with	MDT	care	is	uncertain.		MDT	care	is	a	complex	intervention	consisting	of	many	component	parts	and	the	outcomes	will	depend	on	each	of	 these	 components	 (115).	 It	 is	 therefore	 likely	that	there	are	multiple	factors	that	influence	the	success	of	MDT	care.		There	are	considerable	variations	in	the	structure	of	MDT	services	and	this	does	appear	to	impact	 on	 patient	 survival	 (54,55).	 	 A	 study	 comparing	 models	 of	 care	 in	 the	Republic	of	Ireland	and	Northern	Ireland	found	that	centralised	multidisciplinary	hospital	 clinic	 care	 was	 associated	 with	 better	 survival	 than	 coordinated	 care	through	 a	 community	 specialist	 care	 network	 (55).	 	 It	 was	 suggested	 that	 the	survival	 benefits	 may	 relate,	 at	 least	 in	 part,	 to	 the	 complex	 decision-making	processes	and	communication	that	can	take	place	within	a	centralised	team	(55).		
Behavioural variant of FTD
The predominant symptoms of 
this disorder are executive 
dysfunction and behavioural 
changes.
effectiveness of different analgesics31,32. In the absence 
of ALS-specific evidence, we recommend a structured 
approach, using the WHO Analgesic Ladder32,33. All 
major categories of analgesia can be used; treatments can 
be selected according to the causes and severity of pain, 
increasing the potency of drugs as required. Opioids 
seem safe and effective and do not necessarily shorten 
life; moreover, they can also be useful in relieving 
dyspnoea34,35.
Cognitive and other neurological deficits
Overlap between ALS and other neurodegenerative dis-
eases, in particular frontotemporal dementia (FTD) and 
parkinsonism, is increasingly recognized. The presence 
of multiple neurodegenerative diseases in a patient with 
ALS or in their family should alert the clinician to the 
potential presence of abnormally long hexonucleotide 
repeat expansion C9ORF72 (REFS 36–38). This recently 
identified genetic abnormality occurs in approximately 
7% of patients with sporadic ALS and in 39% of those 
with a family history of ALS39.
Approximately 10–15% of patients with ALS 
show signs of FTD (although not all of them have 
the C9ORF72 expansion); typically behavioural variant 
of FTD40. A further 50% experience mild cognitive or 
behavioural changes. Patients with executive dysfunc-
tion have a worse prognosis, and behavioural changes 
have a negative impact on carer quality of life40,41.
Screening for cognitive deficits is recommended, 
because it enables the provision of patient and carer 
sup port8,10,12. Standard memory tests, such as the 
Mini-Mental State Examination, are insensitive to 
fronto temporal deficits42. A number of validated ALS-
specific cognitive screening tools exist, such as the 
ALS-Cognitive Behavioural Screen (ALS-CBS) and the 
more extensive University of California San Francisco 
(UCSF) Screening Battery42. The Edinburgh Cognitive 
Assessment Screen (ECAS) tool also includes the carer43. 
However, examining cognition, behaviour, language and 
affect is time-consuming and most tools covering all 
aspects of ALS require at least 30 minutes to complete42. 
According to one cohort study, other types of neuro-
logical dysfunction, including ataxia and autonomic 
dysfunction, were observed in 14% of patients with 
ALS. Individuals with these additional problems also 
had a poor prognosis44. Currently, no evidence exists to 
guide management of cognitive or other neurological 
deficits in ALS, and establishing evidence-based strate-
gies to manage such symptoms should be a priority for 
further research.
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Hospice or hospital-at-home service Gastrostomy services
Wheelchair services
Continence team
Assistive technology, orthotics
Augmentive and alternative communication services
Neuropsychology/psychiatry
Social worker/
beneﬁts advisor
Neurologist
Physiotherapy
Specialist nurse or 
care coordinator
Palliative care specialist
Speech therapy
Dietician
Respiratory specialist
Occupational 
therapy
Charities and health 
organizations, such as:
• MND Association (UK)
• ALS Association (USA)
Figure 1 | Recommended components of a multidisciplinary team for management of amyotrophic lateral 
sclerosis. The core components (orange) and other specialists and services (blue) that may be required in the 
management of amyotrophic lateral sclerosis (ALS), as listed by the National Institute for Clinical Excellence, UK. For list of 
various national ALS organizations, see http://www.alsmndalliance.org/directory/.
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However,	 further	 research	 is	 required	 to	 determine	 which	 are	 the	 important	factors	 that	 improve	 outcomes	 and	 how	 these	 factors	 can	 be	 consistently	delivered	to	ensure	all	patients	can	access	high	quality	care.	Whilst	a	centralised,	hospital-based	MDT	appears	to	be	the	most	effective	way	to	deliver	care,	there	remain	problems	with	this	model.	Given	the	low	prevalence	of	MND,	 the	 clinics	 cover	a	 large	geographical	 area,	 for	example,	until	 recently	 six	specialist	nurses	were	providing	care	for	300-400	patients	in	Scotland,	covering	an	area	of	over	78	000km2	(116).		Even	a	short	journey	to	a	hospital	clinic	can	be	extremely	difficult.				Between	visits,	or	when	travel	to	clinic	becomes	impossible,	much	of	the	day-to-day	 care	 is	 provided	 by	 non-specialists	 (117,118).	 	 The	 accessibility,	 structure	and	expertise	of	community	services	vary	greatly	(119).		Staff	may	have	a	special	interest	 in	MND	 (e.g.	 neurology	matrons),	many	of	whom	have	 close	 links	with	the	 local	MDT.	Many	 local	 services	 are	more	 generalist	 and	 are	 not	 integrated	with	the	MDT	making	coordinated	care	a	challenge	(68).	 	Some	teams	consist	of	one	key	worker	who	coordinates	 the	 involvement	of	other	specialists.	 	 In	other	areas,	care	is	less	coordinated	and	patients	and	carers	have	to	engage	with	many	different	healthcare	professionals.			When	 access	 to	 specialist	 staff	 and	 equipment	 is	 limited,	 patients	 and	 carers	experience	 significant	 difficulties	 (33,67,99,119-121).	 	 As	 described	 in	 1.3.7,	 a	lack	 of	 coordinated	 care	 and	 advanced	 planning	 makes	 continuity	 of	 care	 and	access	to	services	such	as	palliative	and	social	services	more	difficult	(68).	Non-specialist	staff	may	be	unfamiliar	with	the	needs	of	the	patients	or	with	medical	equipment,	such	as	NIV	(33,67).	Difficulties	accessing	specialist	services	may	also	lead	to	delays	in	accessing	appropriate	equipment	and	medical	treatments	(68).		Without	 specialist	 support	 interventions	 may	 not	 be	 used	 correctly,	 decision	making	 may	 be	 more	 difficult	 and	 patients	 and	 carers	 can	 become	 more	distressed	(33,57,67,99).			There	are	other	barriers	to	accessing	specialist	services.	 	Older	patients,	women	and	those	bulbar	onset	disease	appear	less	well	represented	in	specialist	clinics,	although	 the	 reasons	 for	 this	 are	 unclear	 (55).	 	 Clinic	 appointments	 can	 be	lengthy	 and	 tiring,	 particularly	 if	 the	 patient	 needs	 to	 see	 multiple	 specialists.		The	 traditional	model	 of	 hospital	 care	means	 hospitals	 are	 usually	 arranged	 at	fixed,	 often-inflexible	 intervals	 and	 appointments	 usually	 scheduled	 at	 their	previous	appointment.		This	schedule	may	not	reflect	the	patient’s	current	needs	and	services	not	prioritised	to	ensure	patients	receive	the	right	care	at	the	right	
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time.	 	 Patients	 whose	 disease	 changes	 rapidly	 may	 require	 more	 intensive	support	and	unexpected	complications	may	arise	between	scheduled	visits.	 	On	the	other	hand,	patients	with	slowly	progressive	disease	may	attend	unnecessary	appointments	 when	 their	 condition	 is	 stable	 whilst	 others	 find	 it	 difficult	 to	access	 care	 at	 short	 notice.	 	 Finally	 (as	 discussed	 earlier),	 there	 is	 increasing	pressure	 on	 services	 at	 a	 time	 when	 budgets	 are	 limited,	 with	 pressure	 for	healthcare	 to	 be	 delivered	 in	 the	 community	 rather	 than	 in	 hospital.	 	 This	 is	further	 compounded	 by	 a	 likely	 increasing	 prevalence	 of	 patients	 with	 MND	caused	 by	 an	 ageing	 population	 and	 interventions	 such	 as	 NIV	which	 increase	survival	 in	 patients	 later	 in	 the	 disease,	 many	 of	 whom	 are	 very	 disabled	 and	have	greater	care	needs.	 	Should	additional	disease	modifying	therapies	become	available,	MND	may	 become	 chronic	 disease,	 further	 increasing	 the	 prevalence	and	resource	requirements.	
1.6.1	The	Sheffield	Motor	Neurone	Disorders	Care	and	Research	Clinic	The	 specialist	 multidisciplinary	 MND	 team	 based	 at	 the	 Royal	 Hallamshire	Hospital,	 Sheffield	 Teaching	 Hospitals	 NHS	 Trust	 was	 established	 in	 2006.	 	 It	provides	 care	primarily	 to	patients	with	MND	across	South	and	East	Yorkshire,	North	Derbyshire	and	Lincolnshire.	 	Due	to	its	reputation	as	a	centre	for	clinical	and	research	excellence	 it	attracts	patients	 from	areas	throughout	the	Midlands	and	North	of	England.			Patients	 are	 reviewed	 regularly,	 usually	 at	 intervals	 of	 two	 to	 six	monthly.	 	 At	each	 clinic	 they	 see,	 at	 minimum,	 a	 specialist	 neurologist	 and	 nurse	 and	 their	disease	 is	 monitored	 using	 functional	 rating	 scales,	 weight	 and	 respiratory	measurements.		They	also	have	access	to	a	weekday	telephone	advice	line	to	the	specialist	 MND	 nurse.	 	 Community	 teams	 in	 close	 proximity	 to	 Sheffield	 meet	regularly	with	the	specialist	MDT	to	share	information	about	patients	and	share	experience	and	good	practice.		The	MDT	also	provides	opportunities	for	learning	and	 development	 through	 study	 days	 and	 outreach	 teaching.	 	 Patients	 who	attended	the	Sheffield	MDT	clinic	survived	longer	that	those	who	attended	prior	to	the	establishment	of	an	MDT	clinic,	even	when	accounting	for	NIV	use	(111).	
1.7	Discussion:	the	unmet	needs	in	MND	care		Chapter	One	highlights	 the	 complex	 and	 changing	 needs	 of	 patients	with	MND,	which	 are	 best,	 met	 by	 patient-centred,	 coordinated	 service	 that	 can	 provide	regular	 monitoring,	 and	 timely	 identification	 and	 management	 of	 problems	through	 the	 course	 of	 the	 disease.	 	 Holistic	 MDT	 care	 should	 ensure	 that	 the	patient	 and	 their	 families	 remain	 the	 central	 focus	 at	 all	 times.	 	 The	 Picker	
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Institute	 defines	 eight	 core	 principles	 of	 patient-centred	 care	 and	many	 unmet	needs	may	reflect	situations	where	care	is	not	patient-centred	(Figure	1.4)	(122).		This	 is	 reflected	 in	 the	 2016	 the	 NICE	 guidelines	 for	 the	management	 of	MND	which	recommends	that	care	is	patient-centred	and	delivered	through	an	MDT	of	coordinated,	 trusted	specialists	which	aims	 to	meet	 the	physical,	emotional	and	practical	the	needs	the	patients	and	their	carers	and	families	(39).	 	However,	as	highlighted	 in	 this	chapter	and	 in	 the	NICE	guidelines,	at	present	patients	often	lack	knowledge	and	education,	timely	access	to	expert	and	trusted	professionals	and	continuity	of	care,	particularly	where	care	shifts	from	hospital/specialist	care	to	 community/non-specialist	 care,	 for	 example,	 near	 the	 end	 of	 life.	 	 Specialist	MDT	services	which	address	all	these	eight	aspects	will	promote	patient-centred	care.	 	 This	 may	 be	 one	 reason	 why	 patients	 attending	 an	 MDT	 have	 better	outcomes.			Figure	1.4	The	8-core	principles	of	Patient	Centred	Care	identified	by	the	Picker	Institute	(122).			Despite	 an	 increase	 in	 specialist	 MDT	 services,	access	 to	 this	 standard	 of	 care	 is	 not	 universal.		Research	 to	 date	 has	 focused	 mainly	 on	 the	hospital	 MDT,	 but	 this	 is	 unlikely	 to	 be	 the	 only	factor	that	influences	outcomes.		Poor	experiences	of	community	care,	high	costs	of	community	care	along	with	the	widely	varying	emergency	admission	rates	of	patients	 suggests	 that	 there	 needs	 to	 be	 more	 focus	 on	 what	 occurs	 between	clinic	 visits	 and	make	 high	 quality	 specialist	 care	more	 accessible	 and	 patient-centred.	
1.8	Conclusion		Chapter	One	has	highlighted	 the	need	 to	 address	 the	 complex	 and	often	unmet	needs	 of	 patients	 and	 their	 carers	 by	 improving	 the	 standard	 of	 and	 access	 to	specialist	MND	care.	 	It	is	therefore	important	to	explore	ways	in	which	existing	services	can	be	 improved	or	alternative	services	offered.	 	The	rest	of	 this	thesis	aims	to	explore	one	way	in	which	this	could	be	achieved:	by	using	technology	to	enable	better	care	by	facilitating	better	communication	between	patients,	carers	and	 their	 healthcare	 team.	 	 Chapter	 Two	 will	 describe	 what	 is	 already	 known	about	 the	use	of	 technology	 to	 enable	 care	 for	patients	with	MND	and	 in	other	chronic	 diseases.	 	 Following	 this	 Chapter	 Three	 describes	 how	 a	 technology-enabled	 service	 for	 MND	 was	 developed	 and	 later	 chapters	 explain	 how	 this	service	was	tested	in	clinical	practice.	 	
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Chapter	Two		
	Using	technology	to	improve	access	to	specialist	care	in	
motor	neurone	disease:	a	review	of	the	evidence	
2.1	Introduction		Chapter	 One	 described	 the	 need	 to	 address	 the	 unmet	 needs	 in	 MND	 by	increasing	 access	 to	 specialist	 MND	 care.	 	 Technology-enabled	 care	 refers	 to	services	that	use	digital	technology	to	support	the	delivery	of	care	to	patient	and	includes	systems	such	as	telehealth	and	telemedicine	that	can	enable	interactions	between	patients	and	clinicians	in	order	to	deliver	clinical	care	at	a	distance.		This	chapter	 will	 describe	 a	 literature	 review	 focusing	 on	 technologies	 which	 have	been	 used	 to	 increase	 access	 to	MND	 care	 (123).	 It	will	 then	 describe	 relevant	services	 in	 other	 disease	 areas,	 focusing	mainly	 on	 telehealth	 services.	 	 It	 will	examine	 the	 challenges	 to	 evaluation	 and	 implementation	 they	 face	 and	 how	these	findings	can	be	applied	to	future	MND	services.			
2.2	Background		Chapter	 One	 argued	 that	 there	 is	 a	 need	 to	 improve	 access	 to	 care	 to	 patients	with	MND	who	experience	complex	and	specialist	needs.	 	There	 is	also	a	wider	drive	 in	 the	 UK	 to	 redesign	 care	 pathways	 to	 ease	 the	 pressure	 caused	 by	 the	increase	 in	 the	population	who	 are	 elderly	 or	 have	 chronic	 ill	 health	 (124).	 	 In	2012	 the	 UK	 Department	 of	 Health	 created	 the	 “3millionlives”	 initiative	 which	aimed	to	promote	the	use	of	digital	technology	to	support	more	innovative,	cost-effective	 ways	 to	 deliver	 healthcare	 along	 with	 encouraging	 patient	 education,	empowerment	 and	 self-management	 (124).	 This	 project	 aimed	 to	 foster	 NHS,	academic	and	industry	collaboration	in	order	to	provide	telehealth	services	to	up	to	 three	 million	 people	 with	 chronic	 health	 and	 social	 care	 needs	 in	 the	 UK.		Continuing	this	theme,	in	2014,	NHS	England	set	out	its	Five	Year	Forward	plan	identifying	the	clear	need	to	radically	change	the	way	in	which	people	are	cared	for	 by	 spanning	 community	 and	 hospital	 services	 across	 both	 the	 health	 and	social	care	sector	and	make	it	more	effective	and	reduce	costs	(125).		Innovations	utilising	digital	technology	were	felt	to	be	important	ways	in	which	to	assist	with	these	changes.			
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Digital	 technology	 is	 now	 a	 prominent	 and	 growing	 part	 of	 everyday	 life	 and	digitalisation	within	 healthcare	 reflects	 these	 trends	 as	 it	 becomes	 increasingly	part	of	routine	clinical	care.		Systems	are	now	affordable	and	accessible	meaning	clinicians	 and	 service	 users	 can	 access	medical	 records	 online,	 order	 tests	 and	medication	or	make	appointments	(126).	 	More	sophisticated	services	(referred	to	as	technology-enabled	care)	use	technology	to	allow	patients	and	carers	direct	access	 to	 medical	 and	 social	 care	 and	 health	 professionals.	 	 This	 chapter	 will	focus	on	telemedicine	and	telehealth	services.		Video	conferencing	(telemedicine)	along	with	email	and	telephone	can	allow	a	patient	and	clinician	to	communicate	remotely	 and	 can	 be	 particularly	 valuable	 in	 time-critical	 situations	 (e.g.	emergency	 stroke	 thrombolysis	 (127))	 or	 where	 travel	 to	 hospital	 is	 difficult	either	 because	 of	 the	 distance	 or	 because	 of	 frailty	 or	 disabilities	 (123).		
Telehealth	 services	 (sometimes	 called	 telemonitoring)	 are	 interactive	 systems	that	provide	clinicians	with	real-time	data	in	order	to	monitor	health	in	patients’	own	 home	 (123).	 This	 may	 involve	 monitoring	 of	 physical	 measures	 such	 as	blood	pressure	 or	 of	 patient	 reported	 outcome	measures.	 	 	 Telehealth	 has	 also	been	 used	 to	 promote	 care	 coordination,	 communication	 and	 relationships	between	patients	and	their	healthcare	specialists	and	empower	patients	to	better	understand	and	manage	their	own	disease	(128).	
	Use	 of	 other	 health-related	 technologies	 is	 also	 growing.	 	 Telecare	 facilitates	independent	 living,	 using	 equipment	 such	 as	 emergency	 call	 bells	 or	 falls	monitors.		Health-related	 “apps”	use	mainstream	technology	to	monitor	activity,	diet	and	other	health	and	lifestyle	measures	but	most	of	these	are	not	sufficiently	tested,	 reliable	 or	 secure	 to	 enable	 communication	 between	 clinicians	 and	patients	and	will	not	be	the	focus	of	this	thesis.		An	understanding	of	how	these	technologies	could	be	best	used	within	the	NHS	has	grown	over	 the	 last	decade	with	a	 large	number	of	 evaluations	of	different	services	 being	 conducted.	 	 A	 lot	 can	 be	 learnt	 from	 examining	 the	 use	 of	technology	enabled	care	in	other	diseases	as	there	will	be	barriers	and	incentives	to	 its	use	of	which	are	common	amongst	all	diseases.	 	However,	MND	has	some	particular	challenges:	 it	 is	a	 rare	disease	with	only	a	small	number	of	specialist	clinicians;	 patients	 are	 often	 elderly	 and	 disabled	 and	 their	 needs	 are	 complex	and	 changing	 and	 require	 the	 involvement	 of	multiple	 specialists	 and	 technical	equipment.	 	The	role	of	the	carer	and	shifting	focus	from	active	management	to	promoting	 survival	 and	 independence	 to	 palliation	 and	 end-of-life	 care	 adds	further	 complexities	 (25).	 	 However,	 technology	 also	 offers	 ways	 to	 overcome	some	of	 the	challenges	of	MND	care	such	as	geographical	barriers	and	the	need	
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for	 frequent	 contact	 with	 multiple	 specialists.	 	 The	 internet	 already	 offers	 a	wealth	of	information	and	education	in	MND;	through	charities	such	as	the	Motor	Neurone	 Disease	 Association	 that	 provide	 patients	 and	 their	 families	 with	reliable	 information	 about	 living	 with	 and	 managing	 MND.	 	 Websites	 such	 as	MyMND	 and	 MyTube	 can	 help	 people	 learn	 about	 the	 disease	 through	 the	experiences	 of	 others	 who	 live	 with	 MND	 as	 well	 as	 enabling	 peer	 support	(129,130).	 	 	 Along	 with	 providing	 education,	 technology-enabled	 care	 could	provide	 better	 links	 to	 specialist	 services	 that	 may	 also	 promote	 better	 self-management.	 	This	 is	 important	 in	MND	as	patients	and	carers	already	need	 to	self-manage	their	condition,	by	learning	how	to	cope	with	the	diagnosis	and	their	disabilities,	 use	 highly	 complex	medical	 devices	 (such	 as	 NIV	 and	 gastrostomy	feeding),	accessing	peer	support	and	by	making	choices	about	 their	 treatments,	planning	their	future	care	(131).	 	 	This	chapter	examines	the	available	evidence	for	services	that	use	technology	to	facilitate	access	to	specialist	care	in	both	MND	and	 in	 relevant	 services	 for	 other	 chronic	 diseases.	 	 It	 also	 identifies	 evidence	explaining	 how	 and	why	 these	 services	 had	 the	 outcomes	 observed	 as	 well	 as	potential	lessons	to	guide	future	development,	evaluation	and	implementation.				
2.3	 Technology-enabled	 care	 in	 motor	 neurone	 disease:	 a	
systematic	review	
2.3.1	Aims	A	 literature	 review	 aimed	 to	 identify	 technologies	 which	 have	 been	 used	 to	facilitate	 access	 to	 specialist	 care	 for	 patients	 with	 MND	 and/or	 their	 carers	(123).		It	aimed	to	identify	academic	papers	and	other	evaluations	that	described	the	clinical	services	and	technologies,	 their	use,	 feasibility	and	acceptability	and	the	impact	on	patient	and	carer	clinical	outcomes,	quality	of	life,	medical	services	and	health	resource	use.		
2.3.2	Search	strategy		A	search	was	conducted	using	Pubmed,	Google	Scholar	and	the	Cochrane	library	up	to	the	end	of	2014.	Following	publication	of	this	literature	review,	the	search	was	updated	to	include	recently	published	articles	up	until	November	2016.	The	search	 strategy	 is	 described	 in	 detail	 in	 the	 published	 paper	 in	 Appendix	 C.		Projects	 involving	MND	 that	were	 not	 published	were	 identified	 using	 internet	searches,	 Twitter	 and	 through	 information	 gathered	 by	 word-of-mouth	 and	conferences.		This	identified	a	number	of	services	that	did	not	fulfill	the	inclusion	criteria	for	the	published	systematic	review	but	were	relevant	to	the	project.	 	 It	would	 be	 impossible	 to	 describe	 all	 telehealth/telemedicine	 projects	 but	 those	
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felt	to	be	relevant	to	the	research	question	(NHS	based	neurology/MND	services,	outpatient	management	of	chronic	neurological	diseases	in	adults)	are	described.			Studies	selected	involved:	
• Patients	and/or	carers	of	those	with	any	form	of	MND;			
• Technology	 that	enabled	communication	between	a	patient	and/or	carer	and	the	clinician	who	were	not	in	the	same	location;			
• Reports	 in	 English	 describing	 original	 research	 or	 service	 evaluation	where	 sufficient	 information	 was	 available	 about	 the	 intervention,	population	and	outcome.			One	aim	of	the	review	was	to	describe	the	range	and	feasibility	of	interventions,	including	those	in	the	early	phases	of	development.	This	meant	that	the	quality	of	evidence	 was	 examined	 and	 reported	 but	 was	 not	 an	 inclusion	 criteria.		Interventions	 and	 study	 designs	 were	 diverse,	 so	 statistical	 analysis	 was	 not	appropriate	 and	 narrative	 synthesis	was	 undertaken.	 	 The	 author	 of	 one	 study	was	contacted	to	obtain	further	information	about	the	results	(132).			
2.4	Results				The	 initial	 search	 strategy	 identified	 445	 academic	 references,	 of	which	 31	 full	text	 articles	 and	 one	 conference	 abstract	 were	 reviewed	 for	 eligibility	 (123).		Sixteen	 original	 articles	 were	 selected	 for	 review:	 12	 described	 telehealth	services	and	four	telemedicine.		No	interventions	targeted	at	carers	of	those	with	MND	were	identified.		Tables	summarising	the	search	results	are	included	in	the	published	 paper	 (Appendix	 C).	 	 An	 update	 in	 November	 2016	 revealed	 no	additional	papers.			
2.4.1	Telemedicine	in	neurology	and	MND	Four	 papers	 were	 identified	 describing	 service	 evaluations	 of	 telemedicine	 in	MND	care	(108,133-135).	 	A	Dutch	study	used	an	 internet	chat	room	and	video	link	 to	 enable	 four	 patients	 to	 conduct	 individual	 consultations	 with	 a	rehabilitation	 team	 (133).	 	 Discussing	most	 aspects	 of	 care	 using	 telemedicine	was	 acceptable	 to	 patients	 and	 reduced	 travel	 to	 hospital,	 but	 patients	 still	expressed	a	preference	for	face-to-face	consultations	when	discussing	emotional	and	 psychological	 topics,	 including	 end-of-life	 decisions.	 	 Two	 services	 in	 the	United	 States	 published	 service	 evaluations	 suggesting	 that	 using	 telemedicine	had	 avoided	outpatient	 visits	 resulting	 in	patient	 travel	 cost	 savings	 (134,135).		An	Australian	study	described	using	telemedicine	between	a	tertiary	centre	and	local	 community	 hospitals	 to	 facilitate	 the	 care	 of	 patients	 living	 far	 from	 the	
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MND	 clinic	 (108).	 	 The	 Australian	 telemedicine	 service	 focused	 on	 symptom	control	and	end-of-life	care	and	enabled	contact	 for	an	extra	year	with	patients	who	would	otherwise	not	have	been	able	to	access	these	services.		An	 NHS	 Scotland	 initiative,	 the	 Scottish	 Centre	 for	 Telehealth	 and	 Telecare,	details	 six	 services	 in	 Scotland	 that	 use	 telemedicine	 in	 outpatient	 neurology	clinics	between	a	central	hospital	and	rural	areas	(136).		No	telehealth	services	in	neurology	were	identified.		None	of	the	projects	had	been	formally	evaluated	but	14	different	clinics	now	use	teleneurology	and	in	2015/2016	over	15	000	people	accessed	 services	 such	 as	 falls	 prevention,	 chronic	 illness	 management	 and	psychological	therapies	through	its	systems.				A	 number	 of	 other	 studies	 using	 telemedicine	 in	 Parkinson’s	 disease	 were	identified.	 	 These	 often	 used	 trained	 assistants	 at	 the	 bedside	 to	 facilitate	communication	and	examination.	One	randomised	controlled	trial	was	identified	which	suggested	 that	 telemedicine	could	reduce	 travel	whilst	offering	 the	same	level	of	care	as	face-to-face	visits	(137).		Online	speech	therapy	also	appeared	to	be	 non-inferior	 to	 face-to-face	 visits	 and	 satisfaction	was	 high	 (138).	 	 Services	were	described	as	expanding	in	scale	and	scope	to	include	not	just	care	delivery	but	also	training	of	remote	providers	(139).	The	main	barrier	identified	was	the	difficulties	 with	 reimbursement	 for	 these	 new	 service	 models.	 	 Facilitators	included	 improving	 technology	 and	 the	 development	 of	 integrated	 care	 and	education	networks.	 	Descriptions	of	 the	extensive	use	of	 telemedicine	 in	acute	stroke	 thrombolysis	 and	 in	 palliative	 care	 were	 identified	 but	 few	 have	 been	formally	evaluated	(127,140-145).	 	Those	that	did	suggested	that	 it	could	be	an	acceptable	alternative	to	face-to-face	consultation,	particularly	when	travelling	to	clinic	 is	 difficult,	 but	 some	 limitations	 were	 identified	 such	 as	 problems	 with	technology	and	the	 limitations	of	examinations	using	video	 instead	of	 in-person	assessments	(137,141,146,147).	
2.4.2	Telehealth	in	respiratory	failure	in	MND	
2.4.2.1	Study	characteristics	Five	telehealth	systems	are	described	in	12	papers.	 	All	these	used	telehealth	to	intensively	manage	patients	with	chronic	respiratory	failure	as	an	alternative	to	outpatient	 appointments.	 	 Some	 projects	 limited	 to	 MND,	 whilst	 others	 were	services	providing	 care	 for	 a	wider	number	of	diseases.	 	The	 interventions	and	studies	 are	 described	 first,	 following	 which	 the	 clinical,	 cost	 and	 feasibility	outcomes	are	discussed.	
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2.4.2.2	Study	quality	Only	two	trials	involving	patients	with	MND	were	identified	where	telehealth	was	compared	to	usual	care.	Only	one	was	a	randomised	controlled	trial	(148).		A	pilot	trial	 and	 economic	 analysis	was	 identified	which	was	 described	 as	 randomised	but	actually	assigned	patients	on	the	basis	of	their	geographic	location	(81,149).		Both	 trials	have	been	 included	 in	 this	 review	but	were	assessed	 to	have	a	high	risk	of	bias	and	neither	was	 sufficiently	powered	 to	detect	 clinical	or	economic	benefits.	 	The	other	papers	 identified	were	observational	studies	but	have	been	included	 in	 the	 review	 because	 they	 describe	 the	 feasibility	 and	 potential	economic	impact	of	telehealth	on	the	clinical	service.		
2.4.2.3	Studies	included	in	the	review	
Tele-assistance	in	patients	with	chronic	respiratory	failure		An	 Italian	 rehabilitation	 service	 evaluated	 a	 complex	 telehealth	 system	 for	patients	with	respiratory	failure.		Pulse	oximetry	data	was	collected	and	patients	were	 assessed	 weekly	 by	 a	 respiratory	 nurse	 using	 a	 predefined	 clinical	algorithms	 (150).	 	 A	 12-month	 randomised	 controlled	 trial	 followed	 which	involved	240	patients	with	chronic	respiratory	failure,	22	of	whom	had	MND	and	50	 of	 whom	 had	 other	 neurological	 disorders	 (148).	 	 One	 hundred	 and	 one	patients	 used	 non-invasive	 ventilation	 and	 43	 used	 tracheostomy	 ventilation.		The	 primary	 outcome	 was	 rate	 of	 hospital	 admissions.	 Secondary	 outcomes	included	mortality,	 respiratory	 exacerbations,	 emergency	 room	admissions	 and	urgent	 general	 practitioner	 calls.	 	 Patients	 were	 randomised	 to	 usual	 care	(routine	three-monthly	hospital	appointments)	or	 to	 the	telehealth	service	with	no	scheduled	outpatient	appointments.			A	 five-year	 observational	 study	 and	 economic	 analysis	 of	 the	 same	 telehealth	service	examined	the	staffing	and	financial	 impact	of	caring	for	396	patients,	91	of	whom	had	MND	 (151).	 	Two	papers	describe	 the	use	of	 this	 service	 in	MND	patients	 alone:	 a	 pilot,	 non-randomised	 observation	 study	 (40	 patients)	 and	 a	five-year	 service	 evaluation	 (73	 patients)	 (152,153).	 	 It	 is	 unclear	whether	 the	same	patients	were	involved	in	more	than	one	of	these	evaluations.			The	 same	 Italian	 telehealth	 system	was	 used	 to	monitor	 39	 patients	 with	 ALS	(154).	 	 When	 the	 telehealth	 system	 identified	 a	 respiratory	 exacerbation,	 a	mechanical	 insufflation-exsufflation	 device	 (“Cough	 Assist”)	 was	 provided.	 The	same	 group	 conducted	 a	 pilot	 study	using	 long-term	monitoring	 of	 peak	 cough	flow	(a	measure	of	a	patient’s	capacity	 to	cough	effectively),	oxygen	saturations	and	symptoms	to	identify	respiratory	deterioration	in	12	patients	with	ALS	using	
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non-invasive	 ventilation	 (155).	 The	 patient	 recorded	 these	measures	 daily	 and	reported	bi-weekly	via	a	telephone	call	to	a	physiotherapist.		
Home	 telemonitoring	 of	 non-invasive	 ventilation	 in	 patients	 with	 amyotrophic	
lateral	sclerosis.		A	 telehealth	 service	 based	 in	 an	 MND	 clinic	 in	 Lisbon	 (Portugal)	 tested	 a	telehealth	system	which	used	data	collected	from	NIV	ventilators	relayed	to	the	clinical	team	via	the	internet.		A	set	of	algorithms	and	guidelines	were	developed	to	 enable	 clinicians	 to	 assess	 patients	 and	 schedule	 telephone	 calls	 or	 hospital	visits	(156).	 	 Forty	 patients	 with	 MND	 commencing	 NIV	 were	 recruited	 into	 a	pilot	 trial	 and	 economic	 evaluation	 (81,149).	 	 Primary	 outcomes	 were;	 the	number	of	visits	to	hospital	and	the	number	of	ventilator	setting	changes	needed	to	reach	full	compliance.		Whilst	the	trial	was	described	as	randomised,	patients	were	assigned	a	study	arm	according	to	whether	they	lived	within	Lisbon	(usual	hospital	 appointments)	 or	 outside	 Lisbon	 (intervention:	 telehealth	 plus	 usual	three	 monthly	 appointments)(149).	 	 Furthermore,	 whilst	 limited	 clinical	characteristics	collected	at	baseline	suggested	the	groups	were	similar,	baseline	health	 resource	 use,	 socio-economic	 status	 and	 co-morbid	 diseases	 were	 not	reported.		
Other	feasibility	studies	The	 literature	 search	 identified	 two	 other	 feasibility	 studies	 that	 also	 used	telehealth	to	manage	patients	with	MND	using	NIV.		Both	services	were	felt	to	be	feasible	and	acceptable	to	patients	but	no	comparative	trials	of	the	services	were	identified	(157,158).	 	Telehealth	can	also	be	used	 to	monitor	adherence	 to	non-invasive	ventilation:	a	pilot	trial	in	MND	is	in	progress	in	Sheffield	(159).		Another	pilot	trial	of	telemonitoring	of	NIV	in	MND	is	also	underway	at	the	Liverpool	MND	care	centre	(160).			
2.4.2.4	Outcomes	
Clinical	outcomes	The	 Italian	 randomised	controlled	 trial	of	240	patients	 (22	of	whom	had	MND)	reported	 that	 telehealth	 care	 was	 associated	 with	 significantly	 fewer	hospitalisations	 (the	 primary	 outcome),	 respiratory	 exacerbations	 and	 urgent	calls	 to	 general	 practitioners	(148).	 	Mortality	 and	 emergency	 room	attendance	rates	 did	 not	 differ	 significantly	 (148).	 These	 differences	 only	 reached	significance	in	the	group	of	patients	with	chronic	obstructive	pulmonary	disease.		No	significant	differences	were	detected	 in	 the	22	patients	with	MND	(although	the	study	was	not	powered	to	detect	a	difference	in	this	sub-group).				
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The	Lisbon	pilot	trial	of	40	MND	patients	reported	that	telehealth	was	associated	with	 significantly	 fewer	 outpatient,	 emergency	 room	 and	 hospital	 visits	 (the	primary	outcomes)	(81,149).		Conclusions	should	be	made	with	caution	given	the	limitations	 in	 methodology	 described	 earlier.	 	There	 was	 also	 a	 trend	 towards	longer	survival	in	the	telehealth	group.		However,	median	time	between	patients	developing	symptom	and	requiring	NIV	was	much	longer	in	the	telehealth	group	suggesting	 these	 patients	 had	 a	 slower	 disease	 course	 (and	 therefore	 likely	 to	survive	longer)	than	those	in	the	control	group.	
Cost	effectiveness	Whilst	the	Italian	randomised	controlled	trial	was	not	powered	to	provide	a	cost-evaluation,	 the	 authors	 did	 suggested	 that,	 given	 the	 significant	 reduction	 in	hospitalisations	 in	 the	 telehealth	 group,	 the	 healthcare	 costs	 for	 patients	 using	telehealth	would	be	less.	(132,148).	 	However,	estimates	were	imprecise	and	no	formal	statistical	comparison	was	possible.		Half	of	all	cost	savings	were	due	to	a	small	difference	in	the	small	number	of	very	costly	intensive	care	admissions	(14	vs.	16)	(148).		Given	that	there	were	no	significant	differences	in	outcomes	in	the	MND	patients,	no	cost	savings	were	demonstrated	(148).				When	 the	 service	 was	 evaluated	 over	 five	 years,	 cost	 savings	 were	 reported	(151,153).		The	savings	were	made	in	staffing	costs	as	nurses	took	over	the	roles	of	physicians.		One	nurse	was	able	to	manage	a	caseload	of	25	patients,	costing	an	estimated	 €105-108	 per	 patient	 per	 month.	 Cost	 savings	 were	 also	 reported	when	the	same	telehealth	system	was	used	to	detect	respiratory	exacerbations	in	order	 to	 supply	 Cough	 Assist	machines	when	 required	(154).	 	 The	 service	was	reported	to	have	prevented	30	hospital	admissions	and	was	estimated	to	be	59%	cheaper	than	providing	machines	to	all	the	patients,	all	the	time	(154).				In	 the	 Lisbon	 study	 healthcare	 costs	 in	 the	 telehealth	 group	were	 significantly	lower	 due	 to	 reduced	 inpatient	 and	 transport	 costs	 (81,149).	 	 These	 results	should	 be	 interpreted	 with	 caution	 given	 the	 limitations	 of	 the	 study.	 	 In	particular,	patients	were	assigned	a	study	arm	based	on	whether	they	lived	in	a	rural	 or	 urban	 location	 -	 a	 factor	 that	 may	 independently	 influence	 hospital	attendances	and	other	health	resource	use.		
Quality	of	life,	feasibility,	acceptability	and	adherence	None	of	the	identified	studies	examined	patient	or	carer	burden	or	quality	of	life.		The	 Lisbon	 study	 examined	 patient’s	 attitudes	 to	 the	 service:	 93%	 of	 patients	rating	the	service	as	“good”	or	“very	good”	but	only	36%	of	patients	considered	it	to	 be	 a	 method	 of	 improving	 their	 life	 (152).	 	 The	 reasons	 for	 this	 are	 not	
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described,	but	these	telehealth	regimes	were	very	intensive	requiring	patients	to	make	 frequent	 contact	 with	 the	 MND	 team.	 	 The	 Italian	 study	 found	 that	 the	majority	 of	 contacts	 were	 routine	 and	 did	 not	 result	 in	 a	 change	 in	 their	 care	(153).	 	 Similarly,	 only	 12	 of	 the	 39	 patients	who	 took	 part	 in	 the	 cough	 assist	study	were	supplied	with	the	device,	meaning	that	most	were	using	the	telehealth	daily	 but	 gaining	 no	 benefit.	 	 Using	 a	 burdensome	 system	 without	 seeing	 any	benefit	to	their	care	may	be	demoralising	to	service	users.		Whilst	dropout	in	the	long-term	evaluations	was	 low,	 the	author	of	 the	 Italian	study	suggested	 that	 it	was	difficult	 to	 recruit	 patients	with	MND	 to	 the	 trials	 because	 they	had	heard	about	 the	 potential	 benefits	 of	 the	 telehealth	 system	 and	 did	 not	 wish	 to	 be	randomised	to	the	control	arm	(132,148).				Poor	 patient	 adherence	 impacted	 on	 the	 success	 of	 the	 service	 in	 which	 the	telehealth	 system	 monitoring	 cough	 strength	 was	 used	 to	 detect	 respiratory	exacerbations	(155).	 	The	system	was	so	complex	 for	 the	patients	 that	 they	did	not	adhere	to	the	regime	or	provide	sufficient	readings	for	the	system	to	detect	a	change	in	their	condition.		In	another	feasibility	study	using	telehealth	to	support	NIV	 use,	 those	 who	 adhered	 well	 to	 the	 telehealth	 regime	 experienced	 a	reduction	 in	 hospitalisations,	 whereas	 those	 who	 failed	 to	 send	 data	 regularly	experienced	 an	 increase	 in	 hospitalisations	 (158).	 However,	 baseline	hospitalisation	rates	were	much	higher	in	the	“good”	adherence	group	compared	to	 the	 “poor”	 group	 and	 this	 study	 did	 not	 explore	 other	 factors	 that	 might	influence	 hospitalisations	 and	 adherence	 behaviour.	 	 Despite	 these	 problems,	factors	that	might	influence	patient	acceptance	and	adherence	were	not	explored.			
2.5	Technology-enabled	care	in	other	chronic	diseases		There	 have	 been	 numerous	 trials	 of	 different	 technology-enabled	 systems	 in	other	 chronic	 diseases.	 	 For	 reasons	 described	 later,	 in	 the	Discussion	 (Section	2.6),	 this	 section	 will	 focus	 mainly	 on	 telehealth	 rather	 than	 telemedicine.		Systematic	 reviews	 of	 telehealth	 in	 the	 most	 common	 diseases	 (asthma,	 heart	disease	 and	 chronic	 lung	 disease)	 have	 attempted	 to	 draw	 together	 evidence	from	the	many	different	services	in	different	trials.	It	seems	that	there	is,	at	best,	weak	evidence	from	poor	quality	trials	that	there	may	be	some	positive	impact	on	clinical	 outcomes	 and	 health	 resource	 use	 (161-164).	 	 However,	 interventions,	diseases,	populations	and	clinical	services	vary	widely	and	therefore	little	can	be	drawn	from	these	reviews.	 	It	was	therefore	more	helpful	to	examine	individual	interventions	 that	 are	 relevant	 to	MND	 services	 in	 the	 UK.	 	 Two	 services	 have	been	selected	for	closer	inspection:	the	Whole	System	Demonstrator	and	Simple	Telehealth	(Florence).	 	They	reflect	the	range	of	technology	services	available	in	
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the	 UK	 and	 serve	 as	 examples	 that	 demonstrate	 the	 challenges	 faced	 in	development	 of	 services,	 evaluation	 and	 implementation.	 	 Other	 studies	 which	provide	 evidence	 for	 the	 broad	 benefits	 and	 challenges	 of	 telehealth	 are	described	in	Section	5.6.	
2.5.1	The	Whole	System	Demonstrator	The	Whole	System	Demonstrator	(WSD)	was	the	 largest	ever	trial	of	 telehealth.		It	was	a	UK	Department	of	Health	funded	cluster-randomised	controlled	trial	of	telehealth	 and	 telecare	 in	 three	 areas	 of	 the	 south	 of	 England	was	 launched	 in	2008.	 	 The	 aim	 was	 to	 determine	 (or	 “demonstrate”)	 whether	 large-scale	telehealth	was	 an	 effective	 and	 affordable	model	 of	 delivering	 care	 in	 common	chronic	diseases.		Patients	were	selected	if	they	had	either	one	or	more	common	chronic	 diseases	 (e.g.	 heart	 failure,	 chronic	 lung	 disease,	 diabetes)	 and/or	required	home	 telecare.	 	 Call	 centres	 staffed	 by	 specialist	 nurses	 took	 over	 the	monitoring	and	management	of	patients	randomised	to	the	intervention	and	this	was	compared	to	usual	care.	 	Outcomes	 included	mortality,	hospital	admissions	and	 health	 resource	 use	 and	 semi-structured	 interviews	 were	 also	 conducted	with	 participants	 to	 explore	 the	 barriers	 and	 incentives	 to	 the	 new	 service	models.		The	 study	 results	 were	 disappointing:	 it	 identified	 only	 a	 slightly	 reduced	hospital	admission	rate	at	12-months	(odds	ratio	0.82,	95%	confidence	 interval	0.70	to	0.97,	P=0.017)	and	only	a	small	difference	in	mortality	between	the	two	groups	 (4.6%	 8.3%;	 odds	 ratio	 0.54,	 0.39	 to	 0.75,	 P<0.001).	 	 No	 significant	differences	 in	 quality	 of	 life	 were	 found	 (165).	 	 The	 cost	 associated	 with	 the	intervention	 meant	 that,	 even	 when	 small	 (non-significant)	 differences	 in	treatment	 groups	 were	 identified,	 the	 estimated	 cost	 per	 quality	 adjusted	 life	year	 gained	 was	 extremely	 large	 (approximately	 £90	 000)	 (166,167).	 	 These	findings	are	similar	 to	results	of	meta-analyses	of	 telehealth	 in	chronic	diseases	which	 find	 at	 best,	 weak	 evidence	 of	 their	 impact	 with	 uncertain	 costs	 (e.g.	(161,162)).	 The	 study	 faced	 many	 challenges	 that	 highlighted	 the	 difficulties	evaluating	and	implementing	telehealth.		These	are	discussed	in	section	2.6.		
2.5.2	Simple	telehealth:	“Florence”	In	contrast	 to	 the	WSD,	“Florence”	 is	a	very	simple	and	cheap	telehealth	system	developed	 by	 Staffordshire	NHS	 hospital	 trust.	 	 A	 text	message	 system	 enables	patients	to	report	symptoms	and	measurements	(e.g.	blood	pressure)	and	receive	motivational	 messages	 and	 reminders	 to	 encourage	 behaviour	 such	 as	medication	adherence	and	healthy	living.	 	It	can	been	adapted	to	be	used	in	any	simple	clinical	pathway	and	has	been	used	in	a	range	of	diseases.	 	 It	sends	very	
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basic,	pre-agreed	messages	to	patients	and	returns	only	simple	information	to	the	clinician.	 	 It	 does	 not	 promote	 complex	 decision-making	 or	 manage	 multiple	tasks.				Evaluations	 of	 the	 services	 have	 been	 limited	 to	 examining	 acceptability	 and	feasibility.	 	 Interviews	of	patients	and	carers	suggest	 it	may	 improve	a	patient’s	ability	to	self-manage	and	reduce	the	impact	of	their	disease	on	their	day-to-day	living.	 	 One	 published	 service	 evaluation	 concluded	 that	 using	 the	 system	 to	manage	 hypertension	was	 feasible	 and	was	 associated	with	 a	 small	 (11mmHg)	reduction	 in	 blood	 pressure	 (168).	 	 Traditional	 efficacy	 and	 cost-effectiveness	studies	 have	 not	 yet	 been	 undertaken	 but	 may	 be	 impractical	 given	 the	 large	number	 of	 ways	 the	 system	 is	 being	 used	 and	 the	 complexity	 of	 the	 services	within	which	 it	 is	being	evaluated.	 	However,	given	the	simplicity	of	 the	system	risks	are	likely	to	be	low.	“Florence”	is	currently	offered	to	NHS	trusts	at	no	cost	to	local	providers	or	patients	and	highlights	the	benefits	of	a	simple,	low	cost	and	adaptable	service	which	could	be	incorporated	into	current	clinical	care.		
2.6	Discussion	
2.6.1	Future	use	of	technology	in	MND	care	The	studies	described	in	this	chapter	suggest	that	telemedicine	appears	feasible	and	 acceptable	 to	 patients	 and	 clinicians	 including	 those	 with	 MND	 and	 may	strengthen	 networks	 and	 relationships	 between	 patients	 and	 providers	 who	would	 otherwise	 find	 it	 difficult	 to	 access	 specialists.	 	 However,	 Chapter	 One	identified	 the	 need	 to	 increase	 the	 frequency	 of	 contact	 and	 monitoring	 of	patients	 between	 clinic	 visits	 rather	 than	 just	 make	 contact	 more	 convenient.		Telemedicine	would	not,	on	its	own,	be	able	to	increase	the	frequency	of	contact	with	 clinicians	 without	 associated	 costs,	 clinician	 time	 and	 workload.	 	 On	 the	other	 hand	 whilst	 evidence	 in	 this	 chapter	 supporting	 the	 use	 of	 telehealth	 in	MND	 is	 limited,	 basic	 services	 appear	 feasible,	 can	 facilitate	 more	 frequent	monitoring	and	contact	with	even	severely	disabled	patients.		Evidence	identified	in	 this	 chapter	 suggests	 that	 telehealth	 may	 allow	 redistribution	 of	 workload	from	 physicians	 to	 nurses	 and	 offer	 the	 potential	 to	 reduce	 clinic	 visits	 and	hospital	admissions.	 	This	may	offer	cost	savings	and	could	improve	the	lives	of	patients.	 	 It	 also	 suggests	 that	 more	 complex	 telehealth	 services	 may	 not	 be	feasible	because	of	the	burden	on	patients	and	costs	and	availability	of	specialist	staff.	 	The	limited	research	suggests	that	remote	care	may	be	less	acceptable	for	addressing	some	aspects	of	MND	care	such	as	psychological	difficulties	and	may	not	 be	 sufficient	 to	 replace	 in-person	 physical	 examination,	 so	 consideration	should	 be	 given	 to	 how	 these	 needs	 are	 best	met	 with	 or	 without	 technology.			
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Methods	 for	 future	 development	 and	 evaluation	 of	 these	 services	 must	 reflect	these	 complexities	 and	 uncertainties	 surrounding	 telehealth:	 Section	 2.6.4	describes	how	these	services	could	be	developed	and	evaluated	in	light	of	these	uncertainties.	
2.6.2	Challenges	of	evaluating	telehealth		The	studies	identified	in	this	chapter	highlight	many	of	the	challenges	associated	with	 evaluating	 and	 implementing	 technology-enabled	 care.	 	 Section	 2.6.2	describes	 the	challenges	associated	with	evaluating	 telehealth	and	Section	2.6.3	describes	 the	 challenges	 of	 implementation.	 The	 main	 challenges	 that	 will	 be	discussed	 in	 section	 2.6.2	 are:	 the	 difficulties	 evaluating	 the	 costs,	 impact,	mechanisms	 of	 action	 and	 safety	 of	 the	 interventions	 within	 traditional	 trial	models.	 	The	main	challenges	with	implementation	discussed	are	due	to	service	user	factors,	clinical	staff	factors	and	service	and	commissioning	factors.	
2.6.2.1	Evaluating	the	costs	of	telehealth	The	most	obvious	cost	of	 telehealth	 is	 the	costs	associated	with	 the	 technology.		Both	 the	 telehealth	 studies	 in	MND	 and	 the	WSD	were	 hampered	 by	 relatively	high	 costs	 of	 the	 intervention	 associated	 with	 small	 clinical	 improvements.		Technology	 costs	 are	 reducing	 making	 technology	 like	 “Florence”	 affordable	meaning	 it	 could	 be	 cost-effective.	 	 Keeping	 up	 with	 the	 changing	 costs	 is	challenging	when	clinical	trials	may	take	several	years.				The	 additional	 costs	 associated	 with	 service	 delivery	 should	 not	 be	underestimated	 and	may	 be	 far	 higher	 than	 the	 cost	 of	 the	 technology.	 	 These	novel	 services	 require	 service	 reconfiguration	 and	 have	 significant	 set-up	 and	staffing	 costs.	 	 The	 WSD	 employed	 additional	 specialist	 nurses	 to	 deliver	 the	telemonitoring	 and	 clinical	 care.	 	 Similarly,	 the	 Italian	 MND	 telehealth	 service	required	 additional	 specialist	 nurses	 estimating	 that	 one	 specialist	 nurse	 could	only	 manage	 25	 patients	 (153).	 	 The	 costs	 and	 requirement	 for	 such	 a	 large	number	 of	 additional	 specialist	 staff	 means	 these	 systems	 would	 currently	 be	unfeasible	in	the	UK.	 	For	example,	the	Sheffield	MND	clinic	has	one	respiratory	specialist	caring	for	approximately	130	patients,	approximately	a	third	of	whom	use	NIV	meaning	additional	trained	specialists	would	be	needed.				Assessing	 cost-effectiveness	 is	 challenging.	 	 Measuring	 health	 resource	 use	 is	difficult,	 particularly	 in	 MND	 where	 patients	 may	 receive	 care	 from	 many	different	 sources	 in	 both	 the	 health	 and	 social	 care	 sector.	 	Whilst	 technology-enabled-care	 may	 enable	 more	 efficient	 use	 of	 resources	 (e.g.	 by	 reducing	admissions	 or	 preventable	 complications),	 if	 unmet	 needs	 are	 identified	 there	
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may	be	a	cost	associated	with	providing	this	additional	care.		Furthermore,	as	the	Italian	telehealth	study	found,	a	small	difference	in	the	number	of	high	cost	rare	events	 (in	 this	 case	 intensive	 care	 admissions)	 can	dwarf	 any	other	differences	observed	in	the	trial	(148).	
2.6.1.2	Evaluating	the	safety	of	telehealth	It	 might	 be	 presumed	 that	 interventions	 that	 improve	 monitoring,	communication	or	education	would	not	be	associated	with	any	negative	effects.		This	 seems	 to	 mostly	 be	 the	 case	 but	 interventions	 which	 increase	 the	medicalisation	 of	 a	 patient’s	 life	 may	 also	 increase	 patient/carer	 burden	 and	could	 have	 a	 negative	 effect	 on	 quality	 of	 life	 (65,169).	 	 This	 has	 not	 been	explored	extensively	in	previous	research.				Two	 large	 studies	 have	 also	 reported	 increased	 mortality	 associated	 with	telehealth	 (170,171).	 	 One	 study	 using	 telehealth	 to	 manage	 patients	 with	congestive	 cardiac	 failure	 found	 excess	 mortality	 in	 the	 telehealth	 arm.	 	 It	suggested	the	telehealth	triggered	extra	healthcare	interventions	that	could	have	resulted	in	increased	mortality	(171).		This	highlights	a	wider	uncertainty	around	the	 risk-benefit	 balance	 of	 more	 active	 management	 of	 chronic	 diseases.	 	 For	example	 aggressive	 treatment	 to	 lower	 blood	 sugar	 is	 actually	 associated	with	more	 side	 effects	without	 offering	 any	benefit	 (172).	 	 A	 second	 study	 of	 a	 self-management	 program	 for	 chronic	 lung	 disease	 was	 stopped	 early	 due	 to	excessive	mortality.	 	The	authors	suggest	that	the	intervention	could	have	had	a	detrimental	 change	 in	patients’	 behaviour,	 for	 example	by	making	patients	 less	likely	to	seek	help	during	exacerbations	(170).		Conversely,	the	WSD	trial	saw	an	increase	 in	 hospital	 admissions	 during	 the	 first	 few	months	 of	 the	 trial	 in	 the	control	 patients,	 perhaps	 because	 the	 trial	 processes	 had	 identified	 problems	with	 which	 staff	 were	 not	 confident	 or	 experienced	 in	 managing	 without	 the	additional	telehealth	systems	with	which	they	had	been	trained	to	use	(173).				These	 unexpected	 outcomes	 highlights	 the	 limitations	 of	 using	 traditional	randomised	controlled	trials	to	evaluate	complex	telehealth	interventions	(115).		These	 trials	 did	 not	 provide	 the	 opportunity	 to	 explore	 these	 unexpected	outcomes	 or	 understand	 why	 an	 intervention	 did	 not	 work	 as	 expected.	 	 It	highlights	 the	 importance	 of	 developing	 a	 good	 understanding	 of	 the	intervention,	 how	 it	 might	 be	 used	 and	 how	 it	 brings	 about	 change	 before	embarking	on	 a	definitive	 clinical	 trial.	 	 It	 is	 also	 important	not	 to	 assume	 that	telehealth	 services	 will	 automatically	 have	 only	 positive	 outcomes	 and	 design	trials	that	can	identify	problems	that	might	be	difficult	to	qualify	using	traditional	methods,	such	as	changes	in	behaviour	or	rare	events.	
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2.6.2.3	 Evaluating	 the	 mechanisms	 and	 outcomes	 of	 telehealth	 using	
traditional	clinical	trials	To	justify	the	cost,	the	impact	on	service	redesign	and	burden	on	service	users,	it	remains	 important	 to	 demonstrate	 that	 telehealth	 offers	 some	 clinical	 benefit.		Many	 of	 the	 numerous	 trials	 of	 telehealth	 have	 failed	 to	 demonstrate	 clinically	significant	 benefits.	 	 Most	 failed	 to	 gain	 an	 understanding	 of	 the	 potential	mechanisms	that	could	bring	about	change	or	how	these	 findings	apply	to	“real	life”	 services	 in	 which	 these	 technologies	 would	 be	 used.	 	 They	 also	 failed	 to	explain	why	 the	observed	outcomes	have	occurred.	 	 This	 is,	 in	part,	 due	 to	 the	evaluation	methods	 adopted	 and	 the	 challenges	 of	 using	 traditional	 evaluation	methods	 to	 evaluate	 such	 complex	 services	 involving	 patient	 engagement	 and	self-management	where	the	mechanisms	of	action	and	the	context	in	which	these	occur	may	not	yet	be	fully	understood	(174).			The	 majority	 of	 telehealth	 trials	 used	 the	 randomised	 controlled	 trial	 (RCT)	methods.	 	Traditional	RCTs	are	reductionist:	 their	aim	 is	 to	determine	whether,	when	 keeping	 all	 other	 factors	 the	 same,	 a	 single	 factor	 can	 bring	 about	 an	impact.		They	fail	to	take	into	account	the	real-world	circumstances	in	which	the	intervention	 is	 embedded	 and	 cannot	 take	 into	 account	 the	 other	 complex	 and	changing	 factors	 that	 can	 influence	 outcomes.	 	 This	 means	 their	 results	 are	unlikely	 to	 be	 applicable	 if	 the	 telehealth	 service	 were	 changed	 or	 used	 in	 a	different	setting.				The	 studies	 identified	 in	 this	 chapter	 highlight	many	 of	 problems	 encountered	when	using	traditional	models	to	evaluate	telehealth	in	a	“real-life”	environment.	For	example,	whilst	the	WSD	did	include	patients	in	different	settings,	the	three	services	 in	which	 the	 telehealth	was	 embedded	were	 unlikely	 to	 reflect	 all	 the	varied	 and	 changing	 service	 environments	 in	 the	 NHS.	 	 In	 addition,	 even	 if	 all	other	variables	were	similar,	it’s	not	clear	which	component	parts	of	this	service	were	 vital	 to	 bring	 about	 change	 and	 how	 these	 could	 be	 reliably	 reproduced.		Given	the	complexities	of	the	interventions	and	the	services	they	delivered,	 it	 is	hardly	 surprising	 that	 the	 common	outcome	measures	used	 in	 traditional	RCTs	(such	as	survival,	hospital	admission	rates)	were	not	sufficiently	comprehensive	to	 capture	 the	 full	 impact	 of	 the	 interventions.	 	 For	 example,	 telehealth	 may	improve	 patient	 confidence,	 self-efficacy	 and	 ability	 to	 self	 manage	 or	 reduce	carer	stress.	 	Reduction	in	hospital	attendances	or	home	visits	may	increase	the	productiveness	of	patients	and	carers	or	improve	the	quality	of	family	life.		These	outcomes	are	rarely	captured	in	traditional	trials.				
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It	 is	 also	difficult	 for	 trials	 to	 reflect	 the	 rapid	developments	 in	 technology	and	clinical	services.		The	WSD	started	in	2008	and	outcomes	were	finally	published	in	 2012/2013.	 	 In	 2008	 the	WSD	 technology	was	 very	 basic	 with	 only	 limited	functions,	meaning	staff	and	patient	experience	and	engagement	was	poor	(175).		This	had	a	negative	effect	on	recruitment	and	the	use	of	the	intervention.		In	the	nine	 years	 since	 the	 trial	 commenced,	 the	 use	 of	 devices,	 device	 functionality,	accessibility	and	affordability	of	devices	has	changed	dramatically.	These	changes	render	 the	WSD	technology	 (and	 thus	 the	 trial	 results)	obsolete.	 	To	avoid	 this,	future	 studies	 should	 ideally	 be	 shorter,	 use	 up	 to	 date	 technology	 and	 aim	 to	gain	an	understanding	of	how	future	chances	might	affect	their	conclusions.	
2.6.3	Developing	and	implementing	telehealth	Adoption	 of	 technology-enabled	 care	 has	 increased	 over	 the	 last	 decade	 in	 the	UK.	 However,	 despite	 a	 clear	 need	 for	 service	 improvement	 such	 as	 extensive	investment	 in	 testing	 and	 delivery	 the	 uptake	 of	 technology-enabled	 care	 is	limited	(176).							The	 studies	 described	 in	 this	 review	 have	 identified	 various	 barriers	 and	incentives	 including	 barriers	 associated	 with	 the	 service	 users,	 clinical	 staff,	service,	commissioning	and	funding.	
2.6.3.1	Service	user	factors	In	order	to	be	successful,	a	service	must	be	acceptance	and	accessible	in	order	for	service	users	to	engage	with	the	technology	and	the	service.		Qualitative	research	of	 telehealth	 projects	 suggests	 that	 successful	 implementation	 of	 telehealth	depends	on	whether	the	 intervention	can	be	well	 integrated	 into	everyday	life	 and	 health	 care	 routines	 (128).	 	 Success	 also	 requires	 services	 to	promote	 relationships	 between	 professionals	 and	 users	 and	 engage	 and	empower	users.		Ways	in	which	this	can	be	achieved	include	by	delivering	positive	 feedback,	 promoting	 interaction	 between	 users	 and	 staff,	delivering	improvements	in	knowledge	and	reinforcing	positive	behaviour	change.	 	Without	 these	 services	 are	 likely	 to	 remain	 unacceptable	 to	 all	 users.		This	was	evident	in	the	WSD	trial.		After	the	trial	interviews	with	22	patients	who	declined	 to	 participate	 or	withdrew	 from	 the	 study	were	 conducted	 to	 identify	barriers	to	telehealth	(175).	Some	patients	were	unwilling	to	change	the	way	they	self-manage	and	receive	care.	 	Some	perceived	the	WSD	to	represent	a	potential	threat	to	their	identity	as	they	saw	their	experience	of	ageing	and	self-reliance	as	positive	 experiences	 and	 worried	 that	 interventions	 could	 undermine	 their	ability	 to	 self-care	and	cope.	 	They	also	highly	valued	 their	existing	service	and	were	reluctant	to	risk	changing	to	a	new	team	(175).		In	addition,	a	major	barrier	
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was	the	perceived	technical	competence	required	to	use	the	equipment.	Patients	were	concerned	that	special	skills	were	needed	to	operate	equipment	and	were	worried	about	 installing	unfamiliar	equipment	 in	 their	homes.	 	The	staff	 tasked	with	recruiting	to	the	trial	did	not	correct	these	misperceptions.	These	staff	also	knew	 little	 about	 the	 technology	 and	 in	 some	 cases	 they	 were	 only	 able	 to	provide	pictures	of	the	equipment.	Even	though	public	skills	and	confidence	has	improved	 over	 the	 last	 few	 years,	 this	 barrier	 is	 still	 posing	 problems	 to	recruitment	in	telehealth	trials	(177).			Along	 with	 these	 barriers	 faced	 by	 patients	 with	 all	 conditions,	 patients	 with	MND	may	 find	 technology	particularly	difficult	given	many	are	elderly,	severely	disabled	 or	 have	 language	 or	 cognition	 problems.	 However,	 evidence	 suggests	that	some	patients	with	MND	and	their	carers	already	use	the	technology	for	self-management	through	self-diagnosis,	education	and	social	networking	within	the	MND	 community	 (178-181).	 	 Some	 monitor	 their	 own	 progress	 and	 compare	their	 disease	 and	 treatment	 to	 others	 using	 websites	 like	 PatientsLikeMe	(180,182).	 	 In	 the	 wider	 population	 there	 also	 seems	 support	 for	 digital	healthcare	 technology:	 a	 recent	 survey	 of	 2,004	 adults	 suggested	 that	 47%	 are	already	 willing	 to	 be	 diagnosed	 digitally	 instead	 of	 face-to-face	 with	 their	 GP	(183).	 	Exposure	 to	computers	and	 training	 for	 those	who	are	 less	 likely	 to	use	technology	 (such	 as	 older	 adults	 and	 those	 with	 disabilities)	 is	 improving	attitudes	 towards	 technology	 (184-186)	 and	 internet	 and	 computer	 use	 in	 the	over	65s	in	the	UK	is	rapidly	increasing	from	6%	in	2006	to	42%	in	2014	(186).		It	 is	not	clear	however,	whether	patients	with	MND	who	mainly	use	technology	for	 leisure	will	be	willing	 to	use	 it	 to	access	healthcare	services	where	physical	barriers,	 security	 and	 confidentiality	 may	 pose	 concerns.	 	 These	 potential	barriers	 aspects	 merit	 further	 evaluation	 as	 part	 of	 any	 process	 evaluation	 of	telehealth.	
2.6.3.2	Clinical	staff	factors	Technology-enabled	 care	 involves	 a	 dramatic	 shift	 in	 the	 way	 in	 which	 staff	interact	with	 service	 users,	 how	 they	develop	 relationships,	 obtain	 information	and	how	they	make	assessments	and	decisions	(176).	 	The	success	of	telehealth	will	therefore	also	depend	on	the	clinical	staff	acceptance	and	engagement	(128).		Since	the	WSD	was	published	other	studies	have	explored	these	factors.				A	pilot	trial	of	telehealth	also	identified	many	important	barriers	in	both	evaluation	and	implementation	 (187).	 	 Like	 the	 WSD,	 this	 trial	 was	 also	 hampered	 by	 slow	recruitment	 rates	 and	 this	 also	mainly	 due	 to	 factors	 related	 to	 staffing.	 	 Staff	“buy-in”	 was	 felt	 to	 be	 a	 problem	 but	 the	 reasons	 for	 this	 included	 an	unanticipated	reduction	in	these	staff,	high	staff	turnover	and	poor	funding	of	the	
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research.	 	The	study	relied	on	existing	clinical	staff	 for	most	aspects	of	 the	 trial	meaning	there	was	not	adequate	time	for	staff	to	recruit,	deliver	the	intervention	or	 collect	 data.	 	 Another	 study	 explored	 staff	 experiences	 finding	 that	 attitudes	could	 range	 from	 resistance	 to	 enthusiasm,	 with	 varied	 opinions	 about	 the	motives	for	investing	in	telehealth	and	the	potential	impact	on	professionals	roles	(188).	 	 Staff	 identified	 issues	 such	 as	difficulties	with	 the	 set-up,	 reliability	 and	flexibility	of	the	technology	and	services	into	which	they	were	embedded	leading	to	demoralisation.		Conversely,	success	was	seen	when	early	positive	experiences	and	achievements	were	shared	with	its	staff.		This	was	felt	to	be	a	key	enabler	to	staff	 acceptance	 and	 encouraged	 further	 recruitment	 of	 patients	 to	 the	 service.		As	 telehealth	 services	 often	 involve	 multiple	 healthcare	 professionals,	 “local	champions”	 were	 also	 identified	 as	 having	 a	 positive	 influence	 on	 staff	engagement	and	service	adoption	(189).		Their	roles	helped	increase	awareness,	highlight	success	and	tackle	problems	as	well	as	to	help	secure	future	funding	for	the	services.		These	studies	highlight	the	need	for	reliable	and	flexible	technology,	dedicated	 resources	 for	 telehealth	 and	 work	 to	 overcome	 early	 barriers	 to	acceptance,	along	with	appropriately	trained	and	engaged	staff	working	within	a	partnership	 approach	 in	 order	 to	 successful	 develop	 and	 implement	 new	services.		
2.6.3.3	Service	and	commissioning	factors	As	these	studies	have	demonstrated,	the	success	of	telehealth	will,	in	part	depend	on	 the	 technology	 and	 how	 it	 is	 implemented	 and	 used	 within	 the	 service.		Leadership	will	be	required	to	address	the	barriers	highlighted	in	this	chapter	to	ensure	 both	 top-down	 and	 bottom-up	 stakeholder	 buy-in.	 	 There	 must	 be	financial	 investment	 in	 infrastructure,	 training	and	service	redesign.	Although	it	is	now	recommended	that	technology	“should	be	routinely	considered	in	the	design	
and	 commissioning	 of	 any	 care	 pathway”	 it	 is	 unclear	 how	 many	 patients	 are	current	using	the	services	or	what	the	costs	are	(124).	 	Learning	from	3	Million	Lives	and	the	WSD	suggested	the	need	for	further	development	and	testing	whilst	other	 schemes	 such	 as	 the	 NHS	 Digital	 Technology	 scheme	 and	 Technology	Enabled	 Care	 Services	 aim	 to	 promote	 the	 commissioning	 of	 telehealth,	telemedicine	 and	wider	 digital	 services	 (such	 as	 electronic	 communications	 or	health	record)	(190).			Case	studies,	resources	and	toolkits	have	been	developed	(e.g.	 (191))	 to	 help	 services	 plan	 and	 implement	 technology-enabled	 care.		However,	 despite	 the	 drive	 to	 adopt	 technology,	 a	 survey	 of	 acute	 trusts	suggested	 that	 only	 a	 minority	 already	 have	 systems	 in	 place	 for	 telehealth.		Whilst	 108	out	 of	 176	 clinical	 commissioning	 groups	have	 commissioned	 some	technology	services,	spending	£15.2	million	in	2013/14	(192),	these	figures	seem	small	given	the	number	of	patients	with	chronic	diseases	in	the	UK.		This	suggests	
	 43	
there	is	a	way	to	go	before	these	technologies	are	commonplace	in	the	NHS	and	much	work	is	needed	to	make	technology-enabled	care	an	effective	part	of	usual	medical	care.				
2.6.4	Methods	for	future	development	and	evaluation	of	telehealth	A	 telehealth	 service	 is	 a	 complex	 intervention	 because	 it	 has	 a	 number	 of	interacting	components	which	can	act	both	independently	and	inter-dependently		(for	 example	 the	 system	 itself,	 the	 existing	 healthcare	 service)	 (193).	 	 Success	also	depends	on	the	behaviours	of	those	delivering	the	intervention	(for	example	the	clinical	MND	team)	and	those	receiving	the	intervention	(e.g.	the	patients	and	carers)	(193).	The	Medical	Research	Council	(MRC)	has	developed	a	 framework	for	 the	 development	 and	 evaluation	 of	 complex	 interventions	 (193).	 	 It	recommends	that	a	development	and	evaluation	of	complex	interventions	should	follow	 an	 iterative	 process	 rather	 than	 the	 traditional	 phased-model,	 better	suited	 to	 trials	 of	 pharmaceutical	 agents	 (Figure	 2.1).	 	 There	 may	 be	 several	cycles	of	development,	testing,	evaluation	and	implementation	in	order	to	deliver	success.			Figure	2.1	The	MRC’s	recommended	process	for	developing	and	evaluating	complex	interventions.	Adapted	with	permission	from	BMJ	Publishing	group.	©	Craig,	P.et	al	(2008).	BMJ	(Clinical	Research	Ed.				Development	of	telehealth	should	apply	the	recommendations	of	MRC	framework	in	 order	 to	 understand	 and	 address	 the	 barriers	 to	 success	 identified	 in	 this	chapter	 (193).	 	Early	 stages	 should	 look	 to	explore	 the	 theory	around	how	and	why	telehealth	services	may	work	in	MND	care	as	well	as	the	value	and	impact	of	these	 technologies	prior	 to	 any	definitive	 trial.	 	 This	may	 involve	 examining	he	current	literature,	guidelines,	best	and	current	practice	(such	as	that	described	in	this	 and	 the	 previous	 chapter).	 	 It	 may	 also	 involve	 research	 to	 explore	 the	attitudes	 and	 experience	 of	 potential	 users	 of	 telehealth	 (both	 patients/carers	and	staff)	 in	order	to	identify	how,	why	and	in	what	context	these	services	may	work.	These	results	should	feed	into	the	development	of	telehealth	interventions	but	consideration	should	also	be	given	to	how	the	service	may	be	best	evaluated	in	the	clinical	setting.					
Feasibility	/	piloting	
Evaluation	
Implementation	
Development	Figure removed for copyright reasons
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The	MRC	 framework	 recognises	 the	need	 to	develop	 the	 theory	 that	 underpins	the	intervention	in	order	to	answer	some	of	the	uncertainties	like	those	faced	in	WSD.		It	recommends	time	should	be	spent	piloting	and	testing	the	feasibility	of	the	 methods	 of	 evaluation	 in	 order	 to	 identify	 and	 overcome	 some	 of	 the	challenges	 in	 recruitment,	 adoption	 of	 the	 intervention	 and	 evaluation.		Understanding	how	the	intervention	may	work	in	“real-life”	will	also	help	predict	and	 address	 the	 challenges	 of	 implementation.	 	 A	 more	 detailed	 “process	evaluation”	may	be	required	to	assess	the	“fidelity	and	quality	of	implementation,	
clarify	causal	mechanisms	and	identify	contextual	factors	associated	with	variation	
in	 outcomes”	 (194)	 (Figure	 2.2).	 	 Information	 gathered	 in	 a	 process	 evaluation	would	help	translate	the	key	aspects	of	the	intervention	into	a	clinical	service.  		Figure	2.2	Recommended	steps	in	a	complex	intervention	process	evaluation.3		
	In	 order	 conduct	 a	 process	 evaluation,	 alternatives	 to	 the	 traditional	 RCTs	 are	required:	these	need	gain	a	deeper	understanding	of	the	intervention	when	it	 is	used	 in	real	life,	how	it	 is	used,	 the	mechanisms	of	 impact	and	context	 in	which	these	 occur.	 	 	 Examples	 of	methods	 that	may	 be	more	 applicable	 to	 telehealth	interventions	 include	 realist	 evaluations	 methods	 which	 aim	 to	 explore	mechanisms	and	outcomes	within	the	context	of	“real-life”	in	order	to	understand	what	 works,	 for	 whom,	 under	 what	 circumstances	 (195).	 	 Mixed	 methods	comparative	or	observation	trial	designs	may	be	more	useful	as	they	can	be	used	to	 both	measure	 and	 explore	mechanisms	 in	 detail	 in	 order	 to	 capture	 overall	effects,	and	can	employ	realist	methods	in	order	to	consider	which	intervention	activities	work,	and	in	what	context,	whilst	also	developing	and	validating	theory	(196).	 	 Whichever	 methods	 are	 used,	 prior	 to	 a	 definitive	 trial,	 pilot	 and	feasibility	studies	are	recommended	by	the	MRC	framework	to	understand	more																																																									3	Reproduced	with	permission	from	BMJ	Publishing	group.	©	Moore,	GF	et	al.	(2015).	BMJ	(Clinical	Research	Ed).		
Figure removed for copyright reasons
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about	 the	 how	 a	 definitive	 study	 should	 be	 undertaken	 but	 also	 to	 understand	more	 about	 how	 the	 key	 aspects	 of	 the	 intervention	 will	 be	 delivered	 and	assessed	(115,193).	 	Following	a	successful	definitive	study,	 longer	term	testing	may	also	be	required	to	understand	how	the	intervention	is	implemented	in	the	wider	 health	 service	 with	 further	 evaluations	 planned	 to	 explore	 longer	 term	impacts	of	the	service.		
2.7	Conclusion		There	is	currently	limited	evidence	to	recommend	the	use	of	technology-enabled	care	in	the	care	of	patients	with	MND.		However,	current	evidence	suggests	that	these	technologies	could	be	valuable	if	the	challenges	to	development,	evaluation	and	 implementation	are	addressed.	Based	on	 these	 findings,	Chapter	Three	will	describe	how	the	TiM	telehealth	was	developed	and	Chapter	Four	will	describe	the	evaluation	methods	used	in	this	project.		 	
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Chapter	Three	
The	TiM	system	
3.1	Introduction		The	“TiM”	(Telehealth	 In	Motor	neurone	disease)	 is	a	software	system	that	was	developed	 to	 improve	access	 to	 the	specialist	care	 the	MND	service	offers.	 	The	TiM	system	consists	of	a	piece	of	software	used	on	a	tablet	computer	or	mobile	device	into	which	patients	and	carers	enter	information	about	their	condition	on	weekly	basis	(referred	to	as	the	Patient	App).		This	information	is	then	sent	and	displayed	on	a	secure	website	that	 is	accessed	by	the	MND	team	(referred	to	as	the	Clinical	Portal).	This	chapter	will	describe	the	development	of	the	TiM	system.			
3.2	The	aims	of	the	TiM	system		The	TiM	system	was	developed	as	a	tool	to	increase	the	involvement	of	specialist	clinicians	 in	 the	 day-to-day	management	 of	 patients	 with	MND	 and	make	 care	more	patient-centred	and	make	it	more	responsive	to	patients’	and	carers’	needs.		The	 need	 for	 better	 access	 to	 specialist	MND	 care	 for	 both	 patients	 and	 carers	was	a	 research	priority	 identified	by	 the	patient	and	public	 involvement	group,	the	Sheffield	MND	Research	Advisory	Group	(SMND	RAG).		This	research	priority	also	concurred	with	the	limitations	of	the	current	service	model	and	unmet	needs	of	patients	and	carers	described	in	previous	chapters.			It	was	proposed	that	TiM	system	could:			
• Enable	frequent	monitoring	of	patients	and	carers	in	order	to	identify	and	treat	complications	in	a	timely	fashion;	
• Provide	 a	 source	 of	 education	 and	 communication	 to	 promote	 self-management;	
• Allow	 the	 MND	 team	 to	 use	 the	 information	 to	 prioritise	 clinic	appointments;	
• Provide	access	to	the	MND	multidisciplinary	team	for	patients	and	carers	who	are	unable	to	attend	clinic;	
• Reduce	 health	 resource	 use,	 in	 particular,	 unnecessary	 clinic	 visits	 and	avoidable	emergency	hospital	admissions.		
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3.3	Initial	development	of	the	TiM	system		The	 development	 was	 based	 on	 guidelines	 from	 the	 Medical	 Research	 Council	framework	 for	 complex	 interventions	 (115).	 	 As	 discussed	 in	 Chapter	 Two,	 a	telehealth	system	is	defined	as	a	complex	intervention	because	it	has	a	number	of	interacting	 components	 and	 its	 success	 depends	 on	 the	 behaviours	 of	 those	delivering	 and	 receiving	 the	 intervention.	 	 Furthermore,	 use	 of	 telehealth	depends	on	the	service	in	which	it	is	used	and	in	the	UK,	the	way	in	which	MND	services	deliver	care	does	vary.		The	 development	 phase	 aimed	 to	 identify	 existing	 evidence,	 define	 the	requirements	for	and	develop	an	intervention	and	to	perform	some	initial	testing.		Chapters	Four	to	Six	describe	piloting	and	evaluation	of	the	feasibility	of	the	TiM	within	 a	 clinical	 trial.	 	 During	 the	 trial	 further	 potential	 improvements	 were	identified	and	further	development	work	was	undertaken.	 	 	A	second	version	of	TiM	 system	 was	 launched	 12	 months	 after	 the	 trial	 started.	 	 This	 allowed	 six	months	where	the	improved	system	could	be	used	and	further	evaluated.			
3.3.1	Parties	involved	in	the	development	The	content	and	proposed	use	of	 the	TiM,	 the	 look	and	feel	of	 the	software	and	the	 Clinical	 Portal	 on	 which	 information	 about	 the	 patient	 is	 displayed	 was	developed	 by	 Esther	 Hobson	 (EH),	 with	 advice	 from	members	 of	 the	 Sheffield	MND	 clinical	 and	 research	 team	 in	 collaboration	 with	 telehealth	 companies.		Initial	 development	 was	 supported	 by	 Cogent	 Healthcare	 Systems	 but	 this	company	went	into	receivership	so	Abbott	Healthcare	Products	Ltd	took	over	this	role	 in	March	2014	and	later	this	section	of	the	business	was	moved	to	another	pharmaceutical	 company:	 Mylan.	 	 Abbott/Mylan	 provided	 guidance	 about	telehealth	processes,	 provided	 the	 software	 and	 infrastructure	 to	 receive,	 store	and	 display	 the	 information	 on	 the	 Clinical	 Portal	 as	 well	 as	 providing	 the	Samsung	 Galaxy	 tablets	 and	 mobile	 data	 packages.	 	 However,	 they	 had	 no	involvement	in	the	trial	methods,	conduct	or	analysis.	 	Advice	was	also	received	from	 Device	 for	 Dignity	 (Sheffield	 Teaching	 Hospitals	 NHS	 Trust)	 and	 the	Telehealth	 and	 Care	 Technologies	 theme	 of	 Yorkshire	 and	 Humber	 NIHR	Collaboration	for	Leadership	in	Applied	Health	Research	and	Care.		Some	of	the	development	was	conducted	prior	to	the	commencement	of	this	PhD	(developing	 the	 broad	 aims	 of	 the	 TiM,	 the	 questions,	 many	 of	 the	 clinical	algorithms)	 however	 further	 work	 with	 the	 software	 developer	 (including	developing	 the	 final	 look	 and	 feel	 of	 the	 software,	 refining	 and	 testing	 the	
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algorithms,	 and	 determining	 how	 it	would	 be	 used)	was	 conducted	 during	 the	PhD	and	further	developments	made	during	the	clinical	trial	are	also	described.	
3.3.2	Defining	the	intervention:	Identifying	the	scope	of	the	TiM	system		As	outlined	in	the	Chapter	One,	the	important	aspects	of	the	specialist	MDT,	and	the	 mechanisms	 by	 which	 it	 improves	 survival	 remain	 unclear.	 	 Chapter	 Two	explained	 that	 the	use	of	 this	 type	of	 telehealth	 in	 this	population	has	not	been	explored	and	therefore	the	aim	of	the	initial	scoping	work	was	to	identify	some	of	patients'	and	carers'	needs,	experiences	and	expectations	of	MND	care	along	with	their	attitudes	to	technology	and	towards	potential	telehealth	models.		Therefore,	initial	 development	 aimed	 to	 develop	 a	 better	 understanding	 of	 what	 the	requirements	were	 for	a	 specialist	 service	and	how	 telehealth	 could	be	used	 to	deliver	 them.	 	 It	 also	 aimed	 to	 understand	 how	 the	 intervention	 could	 vary	depending	 on	 the	 individuals	 receiving	 or	 delivering	 the	 intervention.	 	 Once	 a	basic	version	of	the	TiM	system	was	developed,	it	also	explored	the	feasibility	of	using	the	system	from	the	perspectives	of	both	patients	and	clinicians.		
3.3.3	Stakeholder	consultation	Informal	 consultations	 were	 conducted	 with	 patients,	 carers,	 ex-carers	 and	volunteers:	
o User-centred	co-design	focus	groups	(see	below);	
o A	 Patient	 and	 Public	 Involvement	 Group:	 the	 Sheffield	 MND	Research	 Advisory	 Group	 (three	 meetings	 were	 attended)	 where	the	TiM	design	and	research	methods	were	presented	and	feedback	received	from	patients,	carers,	ex-carers	and	volunteers;	
o The	 South	 Yorkshire	 MND	 Association	 branch	 meetings	 (two	meetings	were	 attended)	where	 the	 TiM	 proposal	was	 presented	and	 feedback	 received	 from	 patients,	 carers,	 ex-carers	 and	volunteers;	
o One	 patient	 and	 carer	 underwent	 an	 in-depth,	 semi-structured	interview	establishing	their	experiences	of	unmet	care	needs;	
o Five	patients	with	upper	 limb	weakness	were	observed	using	 the	Patient	 App	 and	 gave	 feedback	 on	 the	 accessibility	 and	acceptability	of	the	questions.						
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Healthcare	professionals	were	consulted:	
o Two	 specialist	 MND	 consultants	 and	 four	 specialist	 MND	nurses/therapists	based	in	SITraN	reviewed	the	TiM	questions;	
o One	specialist	MND	occupational	therapist	based	in	the	community	who	was	 interviewed	about	her	experience	of	 the	unmet	needs	 in	MND	care	in	her	area;	
o One	MND	Association	home	visitor	and	one	Motor	Neurone	Disease	Association	 care	 coordinator	 who	 reviewed	 the	 TiM	 design	 and	research	proposal	and	provided	feedback.		Literature	 reviews	 were	 conducted	 and	 updated	 throughout	 the	 PhD.	 	 These	informed	the	aims,	scope	and	functions	of	the	TiM	system.		These	were:	
• The	 clinical	 features	 of	 MND,	 management	 (25),	 and	 unmet	 needs	 of	patients	and	carers	(Chapter	One);		
• The	use	of,	and	potential	value	of	telehealth	in	MND	(123)	(Chapter	Two);	
• The	 attitudes	 towards	 digital	 technology	 of	 patients	 and	 carers	 (197)	(Chapter	Seven)	
• The	evidence	underpinning	technology	enabled	care	(Chapter	Two).	
3.3.4	User-centred	co-design	Service	design	has	moved	from	considering	users	as	“subjects”	to	involving	users	as	 “partners”.	 	The	TiM	project	recognised	understanding	 the	needs	of	all	 those	involved	in	MND	care	in	order	for	the	service	to	be	successful.	Therefore,	a	user-centred	design	approach	was	adopted	to	develop	the	patient	and	carer	software.	User-centred	 design	 is	 an	 approach	 for	 developing	 products	 that	 involves	 end-users	throughout	the	development	process	allowing	users	to	influence	the	design	in	order	ensure	that	the	product	meets	users’	needs	(198).		Users	can	offer	their	experience	and	unique	perspectives	and	preferences	to	ensure	the	focus	remains	on	the	end-user	and	improve	the	success	of	the	product	but	there	is	also	a	moral	argument	that	those	who	are	ultimately	 likely	to	be	affected	by	something	have	the	right	 to	have	a	say	 in	what	 that	outcome	will	be	(199).	 	Co-design	has	been	increasingly	used	 in	health	service	development	 to	make	products	and	services	more	patient-centred	and	user	friendly	(for	example	(200-202)).		Patients,	carers,	volunteers	and	healthcare	professionals	have	already	been	involved	in	co-design	projects	 using	 their	 experiences	 of	MND	 to	develop	 solutions	 to	 problems	 they	themselves	 identified.	 	 These	 include	 the	 Sheffield	 Support	 Snood	 (a	 more	acceptable	 and	 effective	 replacement	 for	 traditional	 neck	 collars	 (203))	 and	educational	websites	aimed	at	patients	and	carers	responding	to	their	identified	need	for	more	information	about	gastrostomy	and	NIV(129).	
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Two	focus	groups	employing	user-centred	design	techniques	were	conducted	in	November	 2012,	 funded	 by	 a	 grant	 from	 the	 National	 Institute	 for	 Health	Research,	Research	Design	Service	(Yorkshire	and	Humber).		In	line	with	INVOLV	guidelines,	 ethical	 approval	 was	 not	 for	 these	 patient	 and	 public	 involvement	sessions	 as	 the	 participants	 were	 acting	 as	 specialist	 advisors	 to	 inform	 the	priorities,	 planning	 and	 design	 of	 the	 research	 rather	 than	 acting	 as	 subjects	themselves	(204).			The	 two	 focus	 groups	 were	 facilitated	 by	 EH	 with	 support	 from	 a	 member	 of	Cogent	Healthcare	and	a	facilitator	from	the	Sheffield	Hallam	University,	both	of	whom	had	experience	of	user-centred	design.		Participants	were	recruited	via	the	South	 Yorkshire	MND	Association,	 the	 SMND	RAG	 and	 through	 the	MND	 clinic	and	 consisted	 of	 three	 patients,	 six	 carers	 or	 ex-carers	 and	 an	 MND	 specialist	nurse	(Chair	of	the	Sheffield	Research	Advisory	Group).		The	 focus	 group	 meetings	 were	 held	 at	 SITraN.	 	 Written	 consent	 from	participants	was	obtained.		Whilst	formal	analysis	was	not	conducted,	the	groups	were	 audio-recorded	 and	 relevant	 themes	 were	 identified	 and	 fed	 back	 to	 the	TiM	 development	 team.	 	 An	 introductory/ice	 breaker	 session	 established	 the	group	 rules	 and	 allowed	 members	 of	 the	 group	 to	 become	 familiar	 with	 each	other	and	understand	the	aim	of	the	session.		Participants	introduced	themselves	and	were	provided	with	puzzles	to	complete	together.		Following	this,	an	exercise	exploring	the	experiences	of	a	patient	and	carer	journey	to	specialist	MND	clinic	was	 conducted	 (See	 Figure	 3.1).	 	 Participants	were	 provided	with	 pictures	 and	captions	 describing	 the	 different	 stages	 of	 a	 clinic	 visit	 (from	 receiving	 the	appointment	letter	to	returning	home	after	the	visit).		They	were	asked	to	order	the	pictures	and	captions,	and	this	prompted	them	to	identify	their	experiences,	emotions	and	difficulties	at	each	stage	of	this	journey.		Example	patient	vignettes	allowed	 participants	 to	 consider	 the	 experiences	 of	 other	 patients	 or	 carers.		Notes	were	made	 on	 Post-Its	 by	 the	 facilitators	 and	 placed	 on	 the	 table.	 	 This	allowed	participants	to	describe	their	experiences	of	MDT	care,	the	pros	and	cons	of	specialist	MND	services	and	non-specialist	community	services.				The	concept	of	telehealth	was	introduced	to	the	groups	and	a	round-robin	game	asked	 participants	 to	 describe	 how	 they	 would	 use	 a	 tablet	 computer	 in	 their	daily	life.		This	allowed	participants	to	discuss	their	attitudes	towards	technology	and	how	MND	affected	 their	use	of	 technology.	 	Following	 this,	 the	participants	took	a	hands-on	trial	of	the	first	version	of	the	TiM	patient/carer	software	using	a	click	 dummy	 (a	 partly	 interactive	 prototype	 of	 the	 application),	 loaded	 onto	 a	
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Samsung	Galaxy	tablet	computer.		This	was	created	by	the	software	developers	in	Hypertext	 Mark-up	 Language	 (HTML).	 Observing	 participants	 using	 the	 click	dummy	 allowed	 the	 facilitators	 to	 assess	 the	 ease	 of	 use	 of	 the	 tablet,	participants’	reactions	to	the	system	and	the	questions	and	the	way	in	which	they	were	presented.	Patients	with	poor	hand	function	were	videoed	to	observe	how	they	used	 the	 touch	screen	device.	 	The	acceptability	of	 a	 clinical	 trial	was	also	discussed.	 Participants	 described	 their	 experiences	 in	 previous	 trials,	 the	acceptability	of	the	trial	methods	and	outcome	measures.	
3.3.5	Outcomes	of	the	stakeholder	consultation		Participants	 in	 the	 focus	 groups	 felt	 that	 using	 technology	 and,	 in	 particular	telehealth	 to	access	 the	MND	service	could	be	acceptable.	 	They	also	 felt	 it	was	acceptable	 for	 the	 MND	 team	 to	 monitor	 the	 wellbeing	 of	 carers	 as	 well	 as	patients.	 	 The	 TiM	 questions	 were	 felt	 to	 offer	 an	 acceptable	 and	 thorough	assessment	of	the	impact	of	MND	on	patients	and	carers.		It	also	established	that	those	with	significant	upper	limb	weakness	or	fatigue	could	use	the	patient/carer	software.			The	consultation	also	identified	aspects	of	the	specialist	MND	services	that	were	important	 to	 stakeholders	 and	 should	 therefore	 be	 considered	when	 designing	the	TiM	system.	 	These	included	access	to	evidence-based	treatments	and	trials,	monitoring	of	progress	and	access	to	specialist	information.			
“Without	coming	to	clinic	you	are	left	in	the	dark”	Patient,	focus	group		The	personal	aspect	of	clinic	was	also	important	with	patients	valuing	the	ability	to	be	able	to	talk	to	experts	who	could	understand	and	solve	their	often-complex	problems	as	well	as	provide	empathy	and	reassurance.			
“It’s	nice	to	be	told	you’re	doing	well”	Patient,	focus	group			 	
	Figure	3.1	The	results	of	one	user-centred	design	group	activity	that	used	pictures	to	explore	a	patients’	journey	to	an	MND	clinic	
appointment.	
	
	
	
The	expert	care	received	in	clinic	was	contrasted	with	experiences	of	care	provided	by	non-specialist	community	services	(such	as	GPs	or	district	nurses).		Patients	and	carers	felt	 community	 clinicians	 lacked	 the	 knowledge	 required	 to	manage	MND.	 	 This	 was	particularly	apparent	for	problems	unique	to	neurological	disease,	where	lack	of	expert	knowledge	 resulted	 in	 difficulties	 such	 as	 delayed	 access	 to	 specialist	 equipment	 or	poor	 management	 of	 specialist	 interventions	 such	 as	 gastrostomy	 tubes	 and	 NIV.		Patients	and	carers	also	wanted	more	 information	and	signposting	 to	help	 them	cope	with	the	disease.	This	information	was	often	lacking	at	important	times,	such	as	out	of	hours	or	when	faced	with	an	acute	deterioration	e.g.	a	chest	infection.		These	difficulties	were	 also	 identified	 by	 clinicians	 working	 in	 the	 community.	 	 They	 encountered	problems	with	providing	timely	response	to	problems	and	highlighted	the	limits	of	their	own	expertise.		They	often	identified	problems	with	patients	and	needed	support	from	the	specialist	MND	team	to	resolve	them.		Difficulties	posed	by	the	nature	of	the	clinic-based	service	model	were	identified.		These	included	the	inflexible	nature	of	clinic	appointment	schedules.		These	did	not	reflect	the	complexity	and	rapidly	changing	nature	of	the	disease	meaning	delays	in	identification	and	treatment	of	problems	occurred.		
“I	waited	so	long	for	this	special	chair	that	by	the	time	it	arrived	I	had	got	worse	and	
couldn’t	use	it.”	Patient,	focus	group.				Lack	of	rapid	access	to	specialists	meant	some	patients	described	delays	identifying	and	treating	 problems	 such	 as	 chest	 infections,	 which	 often	 led	 to	 avoidable	 emergency	hospital	admissions.		Patients	and	carers	described	difficulties	travelling	to	clinic	when	they	were	 in	a	 frail	 condition.	 	They	also	described	anxieties	around	 the	 time	of	 their	hospital	appointment	and	worried	about	whether	 the	clinic	would	 identify	milestones	in	their	disease	such	as	deteriorating	respiratory	function.		 	
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3.4	Developing	the	TiM	questions	and	clinical	algorithm		Work	 with	 clinicians	 established	 the	 set	 of	 questions	 and	 the	 clinical	 algorithm	 to	identify	the	relevant	problems	and	complications	of	MND	and	determine	which	could	be	assessed	using	telehealth.				Areas	in	which	it	was	felt	telehealth	could	be	used	to	bring	about	improvements	were	those	where	self-reported	measures	were	possible	and	interventions	could	improve	the	clinical	condition	and	quality	of	life	by	more	rapid	access	to	treatment	and	monitoring.		These	included:	
• Monitoring	 overall	 progression	 in	 disease	 using	 established	 functional	 rating	scales	and	biomarkers	which	could	identify	deteriorations	in	the	disease;	
• Identification	of	serious	complications	which	have	an	impact	on	patient	survival	and	quality	of	life	such	as	choking,	falls,	respiratory	failure	or	chest	infections;	
• Identification	of	other	MND	related	symptoms	which	have	a	negative	impact	on	patient	 quality	 of	 life	 such	 as	 pain,	 excessive	 oro-pharyngeal	 secretions,	 carer	strain	or	depression;	
• Identifying	problems	with	specialist	equipment	(gastrostomy	and	NIV);	
• Identifying	problems	that	could	be	resolved	by	signposting	patients	and	carers	to	specialist	services.		The	scope	of	the	TiM	system	was	agreed	by	the	MND	clinical	team	with	advice	from	the	software	 developers.	 	 It	 was	 agreed	 that	 the	 TiM	would	 not	 aim	 to	 assess	 urgent	 or	emergency	problems	and	would	instead	instruct	patients	to	seek	help	through	the	usual	channels.	 	 Instructions	 were	 added	 to	 the	 TIM	 system	 to	 reinforce	 this	 message.		Patients	 and	 carers	 felt	 weekly	 sessions	 would	 be	 acceptable	 and	 clinicians	 felt	 this	would	provide	sufficient	information.		Methods	to	promote	adherence	were	considered.		These	included	alarms	on	the	app	or	clinician	alerts	should	patients	fail	to	adhere	to	the	weekly	sessions.		Additional	features	were	considered	such	as	using	different	question	sets	depending	on	the	patient’s	condition,	or	systems	that	allowed	patients	to	request	a	call	back	from	their	nurse	or	to	send	messages.		These	additional	features	were	felt	to	be	outside	the	capabilities	of	the	system	in	this	iteration.		Telehealth	systems	commonly	use	physiological	measures	such	as	blood	pressure	and	oxygen	 saturations.	 	 The	 only	 physiological	measures	 recommended	 to	monitor	MND	were	 a	 patient’s	 weight	 and	 measures	 of	 respiratory	 function	 (such	 as	 forced	 vital	capacity)	 (40,59).	 	 Early	 diagnosis	 and	 treatment	 of	 respiratory	 failure	 is	 associated	with	 improved	 survival	 and	 National	 Institute	 for	 Health	 Research	 Guidelines	
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recommend	 that	 weight	 and	 respiratory	 function	 are	 monitored	 regularly	 (25,39).		There	 is	 no	 one	 single	 measure	 of	 respiratory	 function	 that	 is	 used	 to	 identify	respiratory	 failure.	 Instead,	 respiratory	 monitoring	 should	 involve	 a	 combination	 of	assessment	 for	 symptoms	 of	 respiratory	 failure	 (such	 as	 sleep	 disturbance	 and	orthopnoea)	 and	 the	 use	 of	 objective	 measures	 of	 respiratory	 function	 (39).	 	 Whilst	daytime	 pulse	 oximetry	 is	 recommended	 as	 a	 screening	 tool,	 clinicians	 felt	 that	 this	measure	was	insensitive	to	early	neuromuscular	respiratory	failure	and	therefore	it	was	felt	 it	 would	 be	 an	 unhelpful	 addition	 to	 a	 telehealth	 system.	 	 Forced	 or	 slow	 vital	capacity	and	sniff	nasal	inspiratory	pressures	are	recommended	to	measure	respiratory	muscle	strength	but	these	require	specialist	devices	and	use	by	experienced	clinicians	and	an	affordable	home	monitoring	device	was	not	available	in	2014	(59).		Therefore,	it	was	 decided	 that	 weight	 would	 be	 recorded	 where	 possible	 and	 patients	 would	 be	asked	about	symptoms	of	respiratory	failure	in	every	session.		As	the	weight	scales	used	also	provided	a	measure	of	balance	(by	recording	the	length	of	time	it	took	for	patients	to	become	stable	on	the	scales)	this	was	also	included.			The	 way	 in	 which	 the	 questions	 would	 be	 presented	 to	 patients	 was	 discussed	extensively	during	stakeholder	consultations.		One	concern	was	that	patients	would	be	distressed	by	seeing	options	describing	the	later	stages	of	MND	(such	as	being	unable	to	swallow).	 	One	option	explored	showing	patients	only	a	 limited	number	of	options	or	allowing	 patients	 to	 skip	 through	 questions	 if	 they	 had	 not	 changed.	 	 Feedback	 from	patients	indicated	that	this	was	not	such	a	problem	as	they	were	already	aware	of	the	implications	of	MND	having	seen	other	patients	in	e.g.	clinic.	 	Furthermore,	presenting	only	a	 limited	number	of	options	to	patients	was	thought	to	 increase	the	 likelihood	of	incorrect	 answers	 and	 also	 increased	 the	 number	 of	 questions	 in	 the	 TiM	 session	significantly.	 	 Therefore,	 all	 the	 disease	 state	 options	 were	 presented	 and	 patients’	reactions	to	these	questions	were	explored	during	the	trial.				
3.5	Software	development		The	 iterative	 development	 allowed	 SITraN	 to	 produce	 a	 list	 of	 specifications	 and	requirements	 which	 enabled	 Cogent	 Healthcare	 Systems,	 and	 later,	 Carematix,	 to	develop	 the	software.	The	 initial	 informal	consultations	 formed	the	basis	of	 the	 initial	questionnaire	 and	 structure	 of	 the	 TiM	 patient	 /carer	 software.	 	 This	 software	 was	made	 in	 the	 form	of	an	 “app”:	a	piece	of	 software	designed	 to	be	used	on	an	Android	tablet	computer	(referred	to	as	the	Patient	App).		The	Patient	App	allowed	patients	and	carers	 to	 enter	 data	 about	 themselves.	 	 SITraN	 developed	 the	 look-and-feel	 of	 the	Patient	 App	 in	 collaboration	 with	 Cogent.	 	 Other	 telehealth	 systems	 were	 examined	
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which	allowed	the	development	of	the	Patient	App,	Clinical	Portal	and	question	design.		Modifications	to	the	Patient	App	were	made	following	feedback	from	focus	groups	and	other	stakeholders.		Further	modifications	to	the	Patient	App	were	made	by	the	second	telehealth	company	(Carematix),	based	on	the	 initial	wireframe.	 	The	Patient	App	was	then	coded	by	Carematix	and	later	beta	tested	(the	second	phase	of	software	testing	in	which	 a	 sample	 of	 the	 intended	 audience	 tries	 the	 product	 out)	 by	 EH	 and	 a	 small	number	 of	 patients.	 An	 online	 secure	website	 (referred	 to	 as	 the	 Clinical	 Portal)	was	designed	 to	 be	 used	 by	 the	 clinicians	 to	 view	 the	 patient/carer	 answers.	 	 It	 was	developed	using	an	example	of	a	pre-existing	portal	used	by	Cogent	Healthcare	Systems	and	adapted	to	meet	the	required	specifications.		These	specifications	were	then	used	to	develop	 a	 portal	 designed	 by	 Carematix	 in	 collaboration	with	 Abbott.	 	 This	was	 then	beta	tested	by	EH.		Minor	 amendments	 were	 made	 during	 the	 initial	 few	 months	 of	 the	 trial.	 	 Later,	following	feedback	from	those	using	the	system,	further	work	in	collaboration	between	SITraN,	 Abbott	 (and	 later	 Mylan)	 and	 Carematix	 produced	 a	 second	 iteration	 of	 the	Patient	 App	 (adding	 some	 additional	 questions),	 and	 an	 updated	 Clinical	 Portal.	 	 The	details	 of	 these	 changes	 are	 found	 later	 in	 this	 chapter	 (3.7	 Development	 of	 the	 TiM	during	the	trial).		Abbott	provided	Samsung	Galaxy	Tab	3	tablets	and	the	tablets	were	set	up	and	tested	by	EH.		This	involved	registering	the	tablet	with	the	Clinical	Portal,	loading	the	Patient	App,	the	additional	patient	information	and	adjusting	the	functions	of	the	tablet	to	make	it	accessible	and	to	discourage	use	of	the	tablet	 for	activities	unrelated	to	the	trial	e.g.	browsing	the	internet.			
3.6	The	TiM	system	
3.6.1	Overview	of	the	TiM	system	The	 TiM	 system	 enabled	 patients	 and	 carers	 to	 complete	 a	 series	 of	 questions	 every	week	 (Figure	 3.2).	 	 The	 answers	 were	 sent	 to	 the	 Clinical	 Portal	 where	 they	 were	automatically	 analysed	 using	 a	 pre-specified	 clinical	 algorithm	 in	 order	 to	 detect	problems	with	 the	patient	or	carer.	 If	problems	are	detected	alerts	are	generated	and	displayed	 using	 a	 red-amber-green	 traffic	 light	 system.	 	 The	 Telehealth	 Nurse	 can	review	the	answers	and	can	contact	 the	patient/carer	 if	 there	 is	any	concern	or	 liaise	with	other	members	of	 the	specialist	MDT.	 	The	Telehealth	Nurse	was	an	experienced	specialist	nurse	who	worked	in	the	Sheffield	care	and	research	centre.				 	
	Figure	3.2	An	overview	of	the	TiM	system.			
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3.6.2	TiM	Patient	App	The	 TiM	 system	 consisted	 of	 an	 Android	 software	 application,	 installed	 on	 a	 7	 inch	Samsung	Galaxy	Tab	3	 (although	 it	 can	be	used	on	any	Android	device).	 	 The	Patient	App	enabled	patients	and	carers	to	login	separately	and	complete	a	sequence	of	weekly	questions.	The	TiM	system	also	used	Blipcare	Wi-Fi-enabled	weight	scales	to	record	the	patient’s	 weight.	 	 These	 scales	 also	 provided	 a	 measure	 of	 balance	 from	 0-100	 (no	reference	values	are	available).		The	answers	were	transmitted	by	3G	mobile	internet	or	broadband	 to	 a	web-based	 server,	 undergo	automatic	 computational	 analysis	 and	 the	results	are	displayed	on	a	Clinical	Portal	(Figure	3.2).	 	A	pre-defined	clinical	algorithm	assigned	each	answer	an	alert	 level	(green,	amber,	red).	Some	of	the	questions	closely	match	validated	scoring	scales	(e.g.	the	ALS	Revised	Functional	Rating	Score:	ALS-FRS-R	(205)	 and	 the	 depression	 and	 anxiety	 short	 screening	 tool:	 PHQ-4	 (206,207)).	 	 The	Clinical	Portal	displayed	the	scores	for	these	questions.		The	questions	aimed	to	cover	all	aspects	of	MND	(Figure	3.3).	A	number	of	the	ALS-FRS-R	questions	had	to	be	slightly	shortened	to	fit	onto	the	Patient	App	screen	but	were	as	close	a	possible	to	the	validated	self-administered	version	of	the	scale	(208).		Additional	questions	 using	 the	 ALS-FRS-EX	were	 added	 in	 response	 to	 patient	 feedback.	 	 These	assess	 functional	 ability	 in	 patients	who	 have	 severe	 disability	where	 the	 ALS-FRS-R	may	not	adequately	measure	change	(for	example	the	ability	to	control	switches	or	the	ability	to	direct	one’s	own	care)	(209).		Others	have	been	designed	for	the	TiM	system	and	 based	 on	 clinical	 questions	 such	 symptom	 scales	 (Figure	 3.5)	 or	multiple	 option	answers	to	identify	specific	problems	such	as	potential	symptoms	of	respiratory	failure	(Figure	3.6).	Carers	were	provided	with	their	own	log-in	details.	 	This	presented	them	with	different	questions.			These	were	a	carer	strain	score	(Modified	Carer	Strain	Index	(210))	which	was	 licensed	 and	modified	with	 permission	 from	 the	 copyright	 owners	and	the	PHQ-4	depression	and	anxiety	screen.				The	Patient	App	was	designed	to	be	used	weekly	but	could	be	completed	at	any	point	in	the	 week	 if	 issues	 arose.	 	 The	 questions	 were	 the	 same	 each	 week	 but	 differed	depending	 on	 the	 patient’s	 answer:	 for	 example,	 additional	 questions	 were	 added	 if	patients	used	NIV	or	a	gastrostomy	or	reported	experiencing	complications	(Figure	3.6).			 	
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Figure	 3.3	 The	 TiM	 Patient	 App	 home	 page.	 The	 patient	 questions	 are	 split	 into	 five	sections:	 “Arms	 and	 Legs”;	 “Speech	 and	 Swallow”;	 “Breathing”;	 “Well	 being”	 and		“Nutrition”.	 												After	answering	all	of	the	questions,	patients	were	prompted	to	weigh	themselves	using	Blipcare	weighing	scales.		These	scales	were	separately	connected	to	the	internet	using	Wi-Fi	 or	Bluetooth.	 	 Patients	 and	 carers	were	 given	 automatic	 feedback	based	on	 the	alert	 flag	 generated	by	 their	 answers	 (a	 Final	Message).	 	 If	 their	 answers	produced	 a	green	flag,	the	Final	Message	reassured	the	patient	that	the	answers	had	generated	no	alert.	 	 If	 an	 amber	 flag	was	 generated,	 the	message	 stated	 that	 the	MND	 team	would	review	the	answers	and	contact	them	within	two	weeks.		If	a	red	flag	was	generated	the	message	 stated	 that	 the	 MND	 team	 would	 contact	 them	 within	 three	 working	 days.	However,	during	early	testing	it	became	clear	that	amber	and	red	flags	were	generated	much	more	 frequently	 than	 was	 anticipated.	 Consultation	 with	 the	 Telehealth	 Nurse	who	would	 be	 using	 the	 system	 established	 that	 she	would	 prefer	 to	 use	 her	 clinical	judgment	to	determine	her	actions	to	an	alert	and	this	may	not	involve	contacting	the	patient,	 for	 example,	 if	 she	was	not	 concerned	or	had	made	alternative	arrangements	(e.g.	 reviewing	 the	patient	 in	clinic).	 	Therefore,	 this	was	explained	 to	patients	during	training	and	they	were	advised	to	ignore	the	Final	Message	on	the	Patient	App.					 	
	 60	
Figure	 3.4	 An	 example	 of	 a	single-choice	question	from	the	 TiM	 Patient	 App.	 This	assessed	 the	 patient’s	walking.	 	 This	 is	 based	 on	the	questions	adapted	from	the	 ALS-FRS-R.	 	 The	answers	 graduate	 from	 top	to	 bottom	 from	 normal	 to	severe	disability.			 	Figure	3.5	An	example	of	a	symptom	severity	question	from	the	TiM	Patient	App.		This	assessed	the	severity	of	the	patient’s	pain.												Figure	 3.6	 An	 example	 of	 a	Patient	 App	 question	 where	multiple	 answers	 were	allowed.								 	
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3.6.3	The	TiM	Clinical	Portal	The	Clinical	Portal	was	a	website	which	displays	the	answers	and	trends	generated	by	the	 Patient	 App	 and	 was	 accessible	 to	 the	 MDT	 clinicians	 using	 a	 username	 and	password.	 	 The	 answers	 undergo	 analysis	 and	both	 individual	 answer	 and	 any	 alerts	and	 scores	were	presented.	 	 The	 clinical	 alerts	were	determined	during	development	based	on	the	likely	seriousness	associated	with	an	answer	or	the	speed	at	which	action	would	 be	 expected	 to	 occur.	 	 Alerts	were	 either	 red:	 serious,	 requiring	 action	within	three	working	days,	amber:	less	serious,	requiring	action	within	two	weeks,	and	green:	no	alert.		Each	patient	session	was	assigned	the	following	flags	(see	Figure	3.7):	
• “Individual	flags”	for	each	question;	
• “Section	flags”	indicating	the	most	serious	alert	raised	by	individual	flags	in	the	section	(“sections”	were	limbs,	bulbar,	respiratory,	nutrition	and	wellbeing);	
• “Top	level”	flag	based	on	the	most	serious	alert	generated	during	the	session.			Red	 alerts	 were	 raised	 for	 severe	 symptoms	 and	 serious	 complications	 whereas	 the	amber	alerts	 identified	more	minor	problems	or	sustained	progression	 in	 the	disease.		To	 avoid	 unnecessary	 alerts,	 minor	 problems	 would	 only	 be	 highlighted	 if	 they	persisted	 for	 more	 than	 one	 session.	 Some	 answers	 were	 not	 associated	 with	 a	 flag	because	they	were	designed	for	information	only	(e.g.	Do	you	use	NIV?).				There	were	limits	to	the	capabilities	of	the	system	because	of	the	cost	and	time	required	for	 coding	 and	 development	 associated	 with	 any	 improvements.	 	 Negotiations	 with	Mylan	 (who	 were	 funding	 the	 software	 development)	 and	 Carematix	 (who	 were	developing	the	system)	meant	some	changes	could	be	made	but	it	was	accepted	that	not	all	would	not	be	possible.		This	meant	that	some	improvements	were	not	incorporated	(such	as	flags	which	alerted	the	team	to	a	patient	who	had	lost	more	than	25%	of	their	baseline	weight)	and	none	of	the	questions	added	in	the	second	version	of	the	Patient	App	were	associated	with	flags.			 	
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Figure	 3.7	 TiM	 system	 scoring	 algorithm.	 ©	 Sheffield	 Institute	 for	 Translational	Neurosciences,	2013.	 Items	 in	 italics	were	added	 in	 the	second	version	of	 the	system.		Each	question	 could	generate	 a	 red,	 amber	or	 green	 flag.	 	Answers	 in	 the	 red	 shaded	boxes	 indicate	 those	 answers	 that	 generated	 a	 red	 flag	 and	 answers	 in	 the	 amber	shaded	boxes	indicate	answers	that	generated	an	amber	flag.		A	“Section	flag”	(the	most	serious	 flag	 of	 all	 the	 answers	 in	 that	 section)	 was	 generated	 for	 the	 patient	 then	 a	patient	 or	 carer	 “top	 level	 flag”	 was	 generated	 which	 reports	 the	 most	 serious	 flag	generated	for	the	patient/carer’s	whole	session.		
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The	Clinical	Portal	displayed	each	patient	 and	 carer	 answers.	 	The	 front	page	 (Figure	3.8)	 displayed	 a	 summary	 of	 every	 patient	 and	 carer	 assigned	 to	 that	 clinician.	 This	included:		
• The	date	of	the	most	recent	questionnaire;	
• The	patient	and	carer	“Top	level	flag”		
• The	last	Problem	List	completed	(see	Additional	Features,	below)	
• 	Weight;	
• Balance	score;	
• ALS-FRS	score;		
• Modified	Carer	Strain	Index	(MCSI)	score;			
• Action	column	(displays	the	number	of	alerts	that	have	not	been	actioned	by	the	clinician	(not	included	in	picture	Figure	3.8).				Following	feedback	during	the	trial,	the	second	page	(Figure	3.9)	was	added	to	allow	the	Telehealth	Nurse	 to	 assess	 how	 the	 condition	 of	 each	 patient	 and	 carer	 had	 changed	over	 time.	 	 This	 displays	 a	 Heatmap	 (a	 graphical	 representation	 of	 data	 where	 the	individual	section	flags	over	the	last	six	months	are	represented	as	colours)	and	graphs	of	ALS-FRS-R,	weight	 (compared	to	baseline),	balance	score	and	modified	carer	strain	index.		The	individual	patient	page	(Figure	3.10)	displays:	
• Each	individual	answer;		
• The	level	of	alert	associated	with	each	answer;		
• Notes	made	by	clinicians.				The	 “Action”	 column	on	 the	 front	page	aimed	 to	record	a	count	of	all	alerts	 that	were	awaiting	response	by	a	clinician.	Clinicians	could	save	free	text	notes	about	each	patient	and	carer.	 	If	a	note	was	saved	this	cancelled	this	“Action”	was	cancelled.	 	However	an	“Action”	was	 generated	 each	 time	 any	 alert	was	 generated.	 	 A	 patient	 or	 carer	might	generate	several	alerts	in	the	same	session	(for	example	one	in	the	bulbar	section	and	one	 in	 the	 wellbeing	 section).	 	 If	 a	 clinician	 made	 a	 note	 it	 would	 not	 cancel	 every	“Action”	 generated	 which	 meant	 many	 patients	 had	 a	 large	 number	 of	 un-cancelled	actions.		As	a	result,	the	clinicians	using	the	TiM	tended	to	ignore	this	column.		A	 further	 addition	 allowed	 the	 Telehealth	 Nurse	 to	 review	 the	 last	 five	 answers	 for	individual	 questions	 and	 “pause”	 alerts	 for	 a	 number	 of	 weeks	 (Figure	 3.11).	 	 This	meant	 the	 answer	would	 still	 be	 displayed	 but	 that	 flag	would	 not	 contribute	 to	 the	overall	section	or	top-level	flag.	
	Figure	3.8	The	TiM	Clinical	Portal	front	page.		The	initial	page	for	clinicians	displaying	the	entire	caseload	and	top	level	flags.		
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Figure	3.9	The	TiM	Clinical	Portal	Heatmap.			
	Figure	3.10	The	TiM	Clinical	Portal	individual	patient	page	displaying	one	patient’s	answers	to	all	the	“Arms	and	Legs”	questions.			
Circled	are	the	top	level	flag	(amber),	the	section	flag	(green)	and	individual	answer	flags	(green).	
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	Figure	3.11	The	TiM	Clinical	Portal	“pause”	option.		Alerts	associated	with	individual	answers	can	be	paused	by	the	MND	team	using	the	
Clinical	Portal.	
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3.6.4	TiM	system	clinical	team	The	 Telehealth	 Nurse	 was	 responsible	 for	 logging	 into	 the	 Clinical	 Portal	daily	during	the	working	week.		She	has	over	a	decade	of	experience	in	MND	and	 is	 the	 first	 point	 of	 call	 for	 the	MND	 specialist	 care	 centre	 and	 runs	 a	daytime	 telephone	 helpline.	 	 It	 is	 usual	 in	 an	MND	 care	 centre	 to	 have	 at	least	one	MND	coordinator	available	by	telephone	who	is	commonly	a	nurse,	but	may	be	another	professional	such	as	a	physiotherapist.				Should	 the	 Telehealth	 Nurse	 be	 alerted	 to	 problems,	 she	 could	 contact	members	of	 the	hospital	and	community	multidisciplinary	 teams	 including	the	consultant	neurologist	in	charge	of	the	patient.		The	majority	of	her	work	is	not	governed	by	specific	protocols	and	other	than	regularly	logging	in	and	making	notes	on	the	system	it	was	agreed	that	she	would	decide	herself	how	to	 respond	 to	 alerts.	 	 It	 was	 agreed	 that	 she	would	 respond	 to	 red	 alerts	within	 two	 days	 and	 amber	 alerts	 within	 two	 weeks.	 This	 would	 involve	contacting	 the	patient	or	carer	 to	gain	more	 information,	acknowledge	 the	problem	 and	 take	 any	 necessary	 action.	 	 She	 could	 also	 liaise	 with	 other	members	 of	 the	 MDT	 or	 arrange	 hospital	 appointments	 but	 could	 not	prescribe	medication	or	 visit	 patients	 at	 home.	 	No	hospital	 appointments	could	 be	 delayed	 and	 no	 clinical	 decisions	 could	 be	 made	 automatically	using	the	TiM	without	contacting	the	patient	or	clinical	team.		EH	was	 responsible	 for	 setting	up	 the	TiM,	 training	patients	 and	 staff	 and	resolving	 technical	 problems	 with	 the	 TiM	 system.	 	 She	 also	 provided	clinical	 care	 to	 a	 number	 of	 the	 participants,	 under	 the	 supervision	 of	 the	consultant	 neurologist	 but	 the	 initial	 responsibility	 to	 react	 to	 alerts	 was	with	the	Telehealth	Nurse.	 	When	the	Telehealth	Nurse	was	on	holiday	she	opted	not	 to	delegate	 this	 role	 to	another	member	of	 the	 team	so	 the	TiM	system	 was	 not	 monitored.	 	 	 The	 technology	 does	 allow	 patients	 to	 be	assigned	to	different	clinicians	meaning	more	than	one	clinician	could	share	a	caseload.	
3.6.5	Addition	features	of	the	TiM	system	Interspersed	 between	 questions	 are	 information	 messages	 (Figure	 3.12).		The	education	was	generic	and	focused	mainly	on	explaining	how	symptoms	could	 be	managed	 and	 signposting	 patients	 to	 sources	 of	 support.	 	 These	changed	 depending	 on	which	 answer	was	 selected.	 	 The	messages	 appear	when	an	answer	was	first	selected	but	do	not	appear	again	until	the	answer	changes.		Patients	could	turn	these	messages	off.							 	
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Figure	 3.12	 An	example	 of	 an	information	message	 that	appears	between	questions.								A	 “Problem	 list”	was	 also	 part	 of	 the	 Patient	 App	 and	 enabled	 patients	 to	make	a	 list	 of	 issues	 they	would	 like	 to	discuss	with	 their	 clinicians.	 	 This	feature	was	suggested	by	the	focus	groups	as	an	important	way	for	patients	to	 lead	 their	 consultations.	 	 The	 tablet	 also	 provide	 a	 link	 to	 the	www.myMND.org.uk	website	(which	contains	information	about	using	NIV)	and	 number	 of	 information	 booklets	 designed	 by	 EH	 and	 the	 MND	Association	 (UK)	 loaded	 into	 an	 eBook	 reader	 application	 (Pocketbook)	referred	to	as	the	“Knowledge	Centre”.			
3.6.7	Training	and	installation	The	TiM	was	designed	to	be	used	with	minimal	training	and	the	Patient	App	could	 be	 used	 on	 any	 Android	 device	 (including	 smart	 phones).	 	 Patients	were	 provided	 with	 a	 tablet	 computer	 and	 face-to-face	 instructions	 were	given	to	patients	and	carers	along	with	written	instructions	explaining	how	to	 troubleshoot	 simple	 problems	 and	 access	 to	 a	 telephone	 helpline	 for	further	 technical	 support.	 	 The	 tablet	was	 connected	 to	 the	 internet	 using	the	 tablet’s	 3G	 mobile	 data	 service	 or	 using	 the	 patient’s	 own	 Wi-Fi	broadband.	 	 Initially,	 the	 scales	 were	 connected	 to	 the	 internet	 using	Bluetooth.		However,	this	was	found	to	be	unreliable	and	instead	the	scales	were	connected	to	the	patient’s	Wi-Fi:	this	involved	changing	the	settings	on	the	 scales.	 	 In	 order	 to	 do	 this,	 the	 scales	 needed	 to	 be	 connected	 to	 a	computer.	 For	 those	without	 broadband,	 an	EE	 “Mifi”	 3G	wireless	 hotspot	was	provided	which	enabled	both	the	tablet	and	the	scales	could	connect	to	the	internet.			EH	 installed	 the	Patient	App	on	 each	device	 and	 registered	 them	with	 the	Clinical	Portal	and	also	tested	the	Patient	App	and	the	tablet,	which	meant	she	was	familiar	with	the	device	and	software	and	could	identify	and	resolve	problems	prior	to	the	study	starting.				EH	attended	the	patient’s	home	to	train	the	both	patients	and	carers	to	use	the	Patient	App.		This	allowed	patients	to	be	observed	using	the	Patient	App	to	 identify	 potential	 difficulties	 with	 the	 software.	 	 The	 prevalence	 of	cognitive	 impairment	 and	 difficulties	 with	 acceptance	 of	 the	 disease	 and	
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patients	unconsciously	or	unconsciously	minimising	 their	problems	means	it	was	possible	that	the	answers	given	may	not	be	accurate.		Patients,	carers	and	EH	could	discuss	the	question	and	possible	answers	and	EH	could	give	guidance	 if	 the	patient	was	not	 sure	how	 to	answer	 the	questions.	 	 It	 also	gave	 the	 opportunity	 for	 both	 EH	 and	 the	 carers	 to	 identify	 answers	 that	they	thought	were	inaccurate	and	resolve	them.		Patients	were	encouraged	to	make	 the	 final	 decisions	 and	 chose	 the	 answer	 that	 they	 thought	most	reflected	their	 feelings	but	were	also	encouraged	to	 take	advice	 from	their	carers.		
3.6.8	Security	The	 Clinical	 Portal	 was	 stored	 on	 a	 secure	 web-based	 server	 hosted	 by	Carematix	 (a	 US	 based	 telehealth	 company	with	medical	 device	 FDA510K	approval	for	the	software).		Carematix	have	CE	marks	for	all	their	software	applications	and	clinical	software	and	ISO27001	data	security	certification.		Patient/carer	 answers	 were	 transferred	 to	 the	 server	 anonymously.	 The	Clinical	Portal	 recognises	 the	 individual	number	of	 tablet	 computer	 (IMEI)	and	serial	numbers	of	 the	weight	 scales.	 	During	set-up	 these	details	were	registered	 on	 the	 Clinical	 Portal	 and	 patients	 were	 identified	 using	 first	name	and	initial	and	tablet	number	only.		This	meant	no	patient	identifiable	information	was	 stored,	 in	 compliance	with	 the	Data	 Protection	Act	 1998.		Access	 required	 two-factor	 identification	and	 individual	passwords	ensure	clinicians	could	only	view	their	own	patients’	data	and	any	notes	made	by	clinicians	 are	 logged	 under	 their	 name.	 	 Carematix	 provided	 IT	 support,	including	user	access	and	password	services	by	email	or	telephone.			
3.6.9	Intellectual	property	The	 research	 team	 developed	 approximately	 half	 the	 questions	 and	 the	validated	 questionnaires	 were	 available	 to	 use	 without	 charge	 with	 the	exception	 of	 the	 Modified	 Carer	 Strain	 Index	 for	 which	 a	 license	 was	obtained	to	modify	the	questionnaire	and	use	in	the	Patient	App	during	the	trial.	 	 Intellectual	 property	 was	 shared	 between	 SITraN	 and	 Mylan	 with	SITraN	holding	the	rights	to	the	questions	and	clinical	algorithm	and	Mylan	holding	the	rights	to	the	Patient	App	and	Clinical	Portal.		 	
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3.7	Development	of	the	TiM	during	the	trial		Following	 experience	 in	 the	 trial	 and	 feedback	 from	 users	 important	improvements	to	the	TiM	was	identified.		It	was	agreed	that	changes	to	the	Patient	App	and	Clinical	Portal	could	be	made	only	once	during	the	trial	and	only	 limited	software	changes	were	possible.	 	Changes	 to	 the	 flag	or	 score	algorithms	were	not	made.	 	A	second	 iteration	of	 the	TiM	Patient	App	was	developed	 and	 updates	 to	 the	 Clinical	 Portal	were	 also	 developed.	 	 These	were	launched	in	October	2015	allowing	the	majority	of	patients	to	use	the	new	Patient	App	 for	 the	 final	 4-5	months	 of	 the	 trial.	 	 As	 discussed	 early,	developments	 were	 limited	 due	 to	 the	 time	 and	 cost	 associated	 with	changing	the	system	as	well	as	the	limitations	of	the	platform	on	which	the	TiM	system	was	run.		The	Patient	App	was	changed	by:	
• Adding	additional	questions:	
o Gastrointestinal	symptoms;		
o Additional	information	about	mobility;			
o Questions	 adapted	 from	 the	 ALS-FRS-EX	 scale	 which	 adds	additional	 question	 to	 the	 ALS-FRS	 to	 capture	 changes	 in	patients	with	severe	disabilities	(209);			
• Free-text	boxes	to	enable	patients	to	type	in	additional	information;	
• The	login	screen	was	also	changed	following	difficulties	experienced	by	two	participants.		More	 extensive	 amendments	 were	 made	 to	 the	 Clinical	 Portal.	 	 These	included:	
• The	 addition	 of	 a	 basic	 Heatmap	 front	 page	 for	 each	 patient	 (see	Figure	3.9);	
• A	facility	that	allowed	the	Telehealth	Nurse	to	“	pause”	alerts	which	meant	 they	 no	 longer	 contributed	 to	 the	 top	 level	 flag	 (see	 Figure	3.11);	
• Displaying	 balance	 scores	 and	 the	modified	 carer	 strain	 score	 (see	Figure	3.8).		Other	 improvements	were	 felt	 to	be	outside	 the	scope	of	 this	phase	of	 the	developments.	 	These	 included	ways	 to	allow	messages	 to	be	 sent	back	 to	the	 patient/carer	 from	 the	 Telehealth	 Nurse	 or	 for	 patients	 to	 receive	feedback	about	their	scores.			
3.8	Conclusion		This	 development	 phase	 produced	 a	 Patient	 App	 and	 Clinical	 Portal	 that	could	assess	the	important	aspect	of	MND	care	that,	if	delivered	successfully,	could	result	in	an	improved	MND	service.		The	next	step	was	to	conduct	an	exploratory	 trial	 to	 understand	 whether	 and	 how	 the	 intervention	 would	work	within	a	real	life	setting.		 	
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Chapter	Four	
Methods.	A	randomised	controlled	pilot,	feasibility	
study	of	the	TiM	system	in	clinical	practice.	
4.1	Introduction		Chapter	Four	outlines	the	aims,	objectives	and	rationale	for	the	randomised	control	 trial.	 It	 describes	 the	 methods	 and	 any	 changes	 to	 the	 protocol	during	 the	 trial.	 Esther	 Hobson	 (EH)	 conducted	 all	 procedures	 unless	otherwise	stated.		The	 trial	 protocol,	 statistical	 analysis	 plan	 and	 an	 example	 patient	information	sheet,	interview	topic	guides	and	patient	questionnaire	booklet	are	included	in	the	Appendix	D.			
4.2	Trial	aims	and	objectives		The	aims	of	the	study	were:	
• To	conduct	a	process	evaluation	of	the	TiM	system;	
• To	conduct	a	pilot,	feasibility	randomised	controlled	trial	of	the	TiM	telehealth	in	patients	with	MND	and	their	carers;		The	process	evaluation	aimed	to	develop	an	understanding	of:	
o The	 key	 problems	 and	 benefits	 of	 the	 MND	 service	 and	 the	mechanisms	by	which	technology	may	bring	about	change;	
o The	acceptability	of	the	TiM	system	to	patients,	carers	and	clinicians;	
o The	 use	 and	 potential	 impacts	 of	 the	 telehealth	 on	 patients,	 carers,	clinical	staff	and	the	MND	services;	
o Potential	factors	that	may	influence	the	success	of	the	intervention.		The	 pilot	 trial	 aimed	 to	 determine	 the	 feasibility	 and	 acceptability	 of	 a	larger,	definite,	multi-centre	trial	by	examining	factors	such	as:	
o The	potential	 recruitment	 and	 retention	 rates	 and	 factors	 that	may	influence	these	outcomes;		
o Potential	 factors	 that	 may	 influence	 participation	 in	 a	 definitive	study;	
o A	estimate	of	the	variations	in	outcomes	in	order	to	provide	a	more	accurate	predictor	of	sample	size;	
o The	feasibility	and	acceptability	of	outcome	measurements;	
o Whether	the	outcome	measures	reflect	important	aspects	of	life	with	MND	and	the	impact	of	the	TiM;	
o The	research	and	clinical	staff	requirements	to	conduct	a	trial.			 	
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4.2.1	 Justification	 of	 the	 pilot,	 mixed	 methods	 trial	 and	 process	
evaluation	As	described	in	Chapter	Two,	many	telehealth	randomised	controlled	trials	failed	 to	detect	 any	positive	 impacts	or	explain	what	happened	during	 the	trial	or	why	 the	observed	events	occurred.	 	One	reason	 for	 this	 is	because	the	 TiM	 system	 is	 a	 complex	 interventions	 with	 multiple	 interacting	components	 and	multiple	 potential	 outcomes	 (115).	 	 A	 traditional	 RCT	 is	usually	seen	as	the	“gold	standard”	way	of	measuring	the	important	impacts	of	 an	 intervention	 on	 outcomes	 such	 as	 survival	 cost	 and	 quality	 of	 life.			However,	for	something	as	complex	as	telehealth,	a	traditional	RCT	will	not,	on	 its	own,	establish	how,	why	and	 in	what	circumstances	 these	outcomes	occur.	 	 It	 would	 also	 fail	 to	 provide	 a	 deeper	 understanding	 on	 the	intervention	required	to	determine	how	the	results	of	the	clinical	trial	could	be	translated	into	wider	practice	(such	as	in	different	centres	or	for	different	patients)	or	what	resources	would	be	required	and	factors	would	influence	its	adoption	and	success.			Chapter	Two	identified	uncertainties	that	warrant	evaluation	and	these	are	best	explored	in	a	“real-life”	situation	by	examining	the	processes	occurring	during	use	of	the	intervention.	 	A	process	evaluation	can	be	used	to	assess	important	aspects	of	an	intervention	that	will	influence	its	success	and	begin	to	 develop	 a	 deeper	 understanding	 of	 what	 works	 and	 whether	 an	intervention	 will	 work	 (194).	 	 A	 process	 evaluation	 examines	 how	 the	intervention	 is	 implemented,	 identifies	 the	 potential	 mechanisms	 of	 the	impact	 of	 the	 intervention	 and	how	 context	 affects	 these	 two	 components	(Figure	 2.1,	 Section	 2.6.4).	 	 	 In	 the	 case	 of	 the	 TiM	 system,	 it	 needs	 to	understand	 what	 was	 delivered	 when	 using	 the	 TiM	 service,	 how	 and	whether	the	TiM	system	was	used	as	intended	and	why	it	was	used	in	that	way.		This	would	also	allow	a	clearer	understanding	of	how	the	TiM	service	might	work	in	real	life/outside	of	a	clinical	trial.		It	aimed	to	capture	aspects	relating	 to	 both	 intervention	 fidelity	 (whether	 the	 TiM	 was	 used	 as	intended)	and	dose	(the	quantity	of	intervention	implemented).	It	used	data	collected	 automatically	 by	 the	 TiM	 (for	 example,	 adherence	 to	 the	 TiM	weekly	 sessions,	 the	 activities	 of	 the	 Telehealth	 Nurse)	 along	 with	 user	interviews	 and	 field	 notes	 describing	 the	 experiences,	 training	 and	adaptations	 that	 were	 required	 during	 the	 trial.	 	 The	 trial	 did	 not	 aim	 to	measure	the	impact	of	the	TiM	on	clinical	outcomes	or	compare	the	results	to	 control	 participants	 but	 it	 did	 try	 to	 identify	 potential	 mechanisms	 of	impact	to	identify	how,	and	in	what	way	the	TiM	might	bring	about	change	by	 exploring	 users’	 response	 and	 experiences	 using	 the	 TiM	 system	 along	with	identifying	any	unexpected	consequences	of	the	TiM.	 	It	also	aimed	to	identify	 contextual	 factors	which	might	 affect	 implementation,	 impact	 and	outcomes	 and	 identify	 barriers	 and	 incentives	 to	 use	 and	 implementation	such	as	user	acceptability	and	accessibility	of	the	TiM	technology,	the	way	in	which	care	is	delivered	to	both	patients,	carers	and	the	healthcare	team.		Whilst	a	process	evaluation	 is	an	 important	part	of	developing	 the	TiM,	as	discussed	in	Chapter	Two,	it	was	felt	important	to	try	to	objectively	measure	the	important	impacts	of	an	intervention	such	as	survival,	quality	of	life,	cost	
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and	 healthcare	 resources	 in	 order	 to	 determine	 whether	 an	 intervention	should	be	 adopted	 into	 clinical	practice.	 	At	 the	 time	 the	 study	 started,	 an	RCT	was	still	felt	to	be	the	best	way	to	determine	this.		As	recommended	by	the	 MRC	 framework,	 a	 pilot	 and	 feasibility	 study	 was	 necessary	 prior	 to	commencement	of	a	definitive	trial	(193).			A	feasibility	study	asks	whether	and	 how	 a	 study	 could	 be	 done	 by	 collecting	 data	which	 could	 determine	factors	such	as	sample	size,	 the	number	of	potentially	eligible	patients	and	the	resources	required	to	carry	out	the	study	(211).		A	pilot	study	provides	the	opportunity	for	aspects	of	a	definitive	study	to	be	tried	and	optimised	at	small	 scale,	 prior	 to	moving	 to	 a	 larger	 study	 (such	 as	 the	 procedures	 for	recruitment,	 retention	 and	 randomisation)	 (211).	 	 In	 the	 case	 of	 the	 TiM,	both	 of	 these	 were	 felt	 to	 be	 necessary	 and	 it	 was	 felt	 that	 the	 mixed	methods	 adopted	 for	 a	 process	 evaluation	 could	 also	 be	 used	 to	 answer	these	 questions	 by	 examining	 both	 quantitative	 outcomes	 (such	 as	recruitment	 rates,	 outcome	 measure	 standard	 deviation	 etc.)	 but	 also	explore	 in	 more	 detail	 participants’	 attitudes	 towards	 the	 research	 and	identify	 barriers	 and	 incentives	 to	 a	 successful	 larger	 scale	 trial.	 	 These	questions	were	particularly	 important	 in	MND	where	barriers	 such	 as	 the	small	 available	 pool	 of	 patients	 in	 the	 UK	 and	 the	 frailty	 of	 patients	 have	historically	made	clinical	trials	challenging.	
4.3	Trial	funding	and	development	of	the	trial	protocol			The	 trial	 protocol	 was	 developed	 in	 collaboration	 with	 the	 thesis	supervisors	as	part	of	an	Academic	Clinical	Fellowship	in	preparation	for	an	NIHR	 doctoral	 research	 fellowship	 application	 (Appendix	 D).	 	 Ethical	approval	was	gained	from	Leeds	Bradford	Research	Ethics	Committee	(REC	reference	14/YH/1068)	and	the	sponsor	(Sheffield	Teaching	Hospitals	NHS	Foundation	 Trust	 Clinical	 Research	Office).	 	 The	 research	was	 undertaken	according	 to	 the	 CONSORT	 principles	 and	 Guidance	 on	 Good	 Clinical	Practice	 based	 upon	 the	 rules	 and	 regulations	 by	 the	 International	Conference	 on	 Harmonization	 (212,213).	 	 The	 trial	 was	 funded	 by	 the	National	 Institute	 for	 Health	 Research	 doctoral	 research	 fellowship.	 	 A	research	collaboration	with	Abbott	Healthcare	(later	 transferred	to	Mylan)	was	developed	(described	 in	Chapter	Three).	 	A	small	 research	grant	 from	the	 MND	 Association	 UK	 provided	 funding	 for	 Wi-Fi-enabled	 weighing	scales	and	the	software	development	to	integrate	the	scales	into	the	Clinical	Portal.		The	funders	did	not	influence	the	protocol,	methods	or	results,	with	the	 exception	 of	 a	 requirement	 for	 the	 study	 team	 to	 report	 anonymised	adverse	 events	 associated	 with	 Abbott	 pharmaceuticals	 to	 the	 company.		Interim	 results	 were	 shared	 with	 funders	 during	 the	 study.	 	 Reports	 to	Abbott/Mylan	did	enable	their	team	to	contribute	to	the	development	of	the	software,	as	described	in	Chapter	Three.	
4.3.1	Patient	and	public	involvement	Patient	 and	 public	 involvement	 (PPI)	 was	 sought	 prior	 to	 and	 during	 the	trial	through	the	Sheffield	Motor	Neurone	Disease	Research	Advisory	Group	(SMND	 RAG).	 	 The	 proposal	 was	 discussed	 at	 SMND	 RAG	 meetings	 and	members	 reviewed	 the	patient	and	carer	 information	sheets,	 lay	summary	and	 self-completed	 questionnaires.	 	 Feedback	 was	 also	 gained	 during	 the	
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development	work	described	in	Chapter	Three.	 	One	member	of	the	SMND	RAG	 also	 attended	 the	 Trial	 Management	 Group	 (TMG)	 and	 one	 member	attended	the	Trial	Steering	Group.			PPI	 feedback	 suggested	 that	TiM	system	questions	and	 the	 study	methods	were	thorough	and	acceptable.		One	patient	described	the	questionnaires	as	
“thorough,	nice	and	quick	and	easy	to	use”.		Improvements	to	the	wording	on	the	 lay	 summary,	 information	 sheets	 and	 questionnaire	 introduction	booklets	 were	 suggested,	 for	 example,	 patients	 identified	 some	 questions	that	 covered	 sensitive	 aspects	 of	MND	 (such	 as	 swallowing	problems)	but	patients	felt	it	was	important	to	include	these	questions.		One	carer	felt	that	they	may	be	unable	to	participate	in	the	research	at	a	time	when	the	burden	of	 their	 caring	 responsibilities	 was	 high	 but	 would	 have	 entered	 into	 the	study	and	considered	dropping	out	at	a	later	stage.		As	a	result	of	this	feedback,	where	possible,	the	participant	information	was	improved.	Participants	were	also	given	 the	opportunity	 to	 look	at	 the	TiM	and	 self-completed	 questionnaires	 prior	 to	 consent	 to	 ensure	 they	 felt	comfortable	 with	 participating.	 	 They	 were	 offered	 the	 opportunity	 to	complete	 the	 initial	questionnaire	booklet	at	 the	recruitment	visit	 in	order	to	address	any	queries	or	concerns.		The	acceptability	and	burden	of	the	TiM	and	the	questionnaires	became	one	focus	of	the	qualitative	sub-study.		
4.4	Trial	procedures	Figure	4.1	presents	an	overview	of	the	trial.		 	
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Figure	4.1:	The	TiM	trial	flow	chart
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4.4.1	Screening	A	 list	 of	 patients	with	MND	under	 the	 care	 of	 the	 Sheffield	MND	 care	 and	research	clinic	was	created	using	the	“ARC”	database.		This	database	collects	data	on	all	patients	attending	the	Sheffield	MND	care	centres	as	part	of	usual	clinical	 care.	 	 A	 randomly	 generated	 sequence	 of	 numbers	 was	 produced	using	 Microsoft	 Excel	 to	 determine	 the	 order	 in	 which	 patients	 were	screened.	 	 A	 screening	 log	 was	 kept	 (212).	 	 Eventually	 all	 the	 eligible	patients	were	exhausted	so	all	new	patients	were	invited.			
4.4.2	Recruitment	Patients	 likely	 to	 meet	 the	 inclusion	 criteria	 were	 sent	 an	 invitation,	including	the	Patient	Information	Sheet	(Appendix	D).		The	letter	invited	the	patient	to	identify	their	main,	informal	carer,	for	whom	a	Carer	Information	Sheet	 was	 provided.	 	 A	 reply	 slip	 and	 return	 freepost	 envelope	 were	provided.		Postal	invitations	were	selected	to	avoid	overburdening	patients	in	busy	MND	clinics	and	also	in	order	to	invite	patients	who	could	not	attend	clinic.	 	 If	 patients	 indicated	 that	 they	were	 interested	 they	were	 visited	 at	home	by	EH	to	complete	screening	and	recruitment.	
4.4.2.1	Inclusion	criteria	The	initial	inclusion	criteria	were:	
• Patients	aged	18	years	or	older;	
• Receiving	care	from	the	Sheffield	Motor	Neurone	Disorders	Care	and	Research	Centre;		
• Living	within	120	minutes	of	Sheffield;	
• Patients	with	diagnosis	of	clinically	definite	or	probable	amyotrophic	lateral	sclerosis	according	to	the	El	Escorial	criteria.		Analysis	 of	 200	 patients	 in	 the	 ARC	 database	 (Table	 4.1)	 was	 conducted.		Patients	 were	 categorised	 at	 diagnosis	 and	 in	 some	 circumstances	 these	categories	 were	 refined	 later	 in	 the	 condition.	 	 The	 database	 records	 the	clinical	 diagnosis	 (ALS,	 PMA,	 PLS)	 based	 on	 the	 clinician’s	 impression	 at	diagnosis.	 	In	those	recorded	to	have	ALS,	an	MND	research	nurse	uses	the	Revised	El	Escorial	Criteria	 (36)	 to	categorise	 the	patient	using	a	standard	operating	procedure	(214).	 	 	There	is	some	overlap	in	these	categories	and	the	clinician’s	diagnosis	 is	that	recorded.	 	For	example,	clinically	suspected	patients	might	refer	those	with	only	 lower	motor	neurone	signs	where	the	clinician	 does	 not	 feel	 a	 diagnosis	 of	 PMA	 can	 be	 made.	 	 Categorising	patients	 in	 this	 way	 suggests	 that	 the	 diagnostic	 criteria	 alone	 would	exclude	58%	of	the	patients,	including	all	those	with	PMA	and	PLS,	many	of	whom	could	benefit	 from	more	intensive	MDT	care	(37).	 	 It	also	highlights	the	 difficulties	 using	 a	 complex	 diagnostic	 system	 where	 a	 patient’s	diagnosis	 may	 change	 over	 time	 meaning	 records	 may	 not	 be	 accurate	without	repeated	and	time	consuming	examinations	by	specialists.			
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p	Table	4.1:	The	most	recent	diagnosis	in	a	selection	of	200	patients.	
Diagnosis	 Number	of	patients	(%)	ALS	 Clinically	definite	 27	(14%)	Clinically	probable	 56	(28%)	Clinically	laboratory	supported	 38	(19%)	Clinically	possible	 27	(14%)	Clinically	suspected	 10	(5%)	Other	diagnosis	 	Primary	Lateral	Sclerosis	 24	(12%)	Progressive	Muscular	Atrophy	 12	(6%)	No	data	available	 6	(3%)		In	 order	 to	 include	 all	 patients	 who	 may	 benefit	 from	 telehealth,	 an	amendment	was	made	to	the	protocol	to	extend	the	diagnosis	to:	
• Patients	 with	 amyotrophic	 lateral	 sclerosis	 with	 symptom	 onset	within	the	last	three	years;	OR	
• Any	 variant	 of	 MND	 (amyotrophic	 lateral	 sclerosis,	 progressive	muscular	atrophy	or	primary	lateral	sclerosis)	with	a	progression	in	the	 condition	 as	 evidenced	by	 a	deterioration	 in	 the	ALS	 functional	rating	score	(ALSFRS-R)	by	at	least	two	points	during	the	previous	18	months.			All	those	with	ALS	within	three	years	of	symptom	onset	were	included	as	it	was	expected	that	the	majority	of	these	patients	will	experience	progression	of	 their	 disease	 during	 the	 study	 and	 therefore	 might	 benefit	 from	 more	intensive	 MDT	 care.	 	 Patients	 with	 characteristics	 suggestive	 of	 a	 slower	disease	course	(i.e.	ALS	with	a	 longer	disease	course,	or	 those	with	PLS	or	PMA)	were	also	included	if	they	demonstrated	signs	of	progressive	disease	in	the	last	two	years.	 	This	was	determined	using	the	ALS-functional	rating	scale	(ALS-FRS-R	(205))	where	deterioration	of	two	points	in	the	ALS-FRS-R	represents	a	clinically	significant	progression.	 	For	example,	progression	of	at	least	two	points	is	noted	when	walking	declines	from	normal	to	using	an	aid	 or	when	 a	patient	 commences	non-invasive	 ventilation.	 	 This	 could	be	assessed	using	the	ARC	database,	which	collects	ALS-FRS-R	scores	as	part	of	usual	 care.	 	 It	 would	 also	 be	 assessed	 by	 taking	 a	 brief	 history	 or	 by	examining	 clinic	 letters.	 	 This	may	be	more	practical	 in	 centres	where	 the	ALS-FRS-R	is	not	commonly	collected.	
4.4.2.2	Exclusion	criteria:	The	exclusion	criteria	were:	
• Patients	attending	another	MND	care	centre	in	the	UK;	
• Patients	unable	to	use	the	TiM	system	and	were	unwilling	to	permit	their	carer	operating	it	on	their	behalf;	
• Patients	 with	 any	 other	 major	 impairment	 that	 may	 affect	 their	ability	to	consent	or	participate	in	the	study;	
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• Patients	with	no	form	of	telephone	and/or	internet	communication.		The	 TiM	 system	 requires	 internet	 access	 and	 the	 tablets	 use	 3G	 mobile	internet.	 	 Initially,	 the	 study	 planned	 to	 exclude	 those	 without	 3G	mobile	reception	at	home,	however,	initial	visits	established	that	participants	in	this	situation	 were	 willing	 to	 use	 their	 own	 broadband	 internet	 to	 use	 the	system	and	this	change	was	adopted	in	the	protocol.		
4.4.2.3	Carer	inclusion	criteria	The	patients	were	 asked	 to	 identify	 an	 informal	 carer,	 defined	as	 an	 adult	who	was	the	major	provider	of	unpaid,	 informal	care	providing	more	than	one	 hour	 per	 week	 of	 care.	 	 Carers	 were	 required	 to	 consent	 to	 allow	information	they	provide	during	the	trial	to	be	shared	with	their	own	doctor	in	the	event	of	serious	clinical	need.				Initially,	 to	 be	 eligible	 for	 the	 trial,	 patients	 were	 required	 to	 participate	with	a	carer	in	order	to	maximise	the	data	acquired	during	the	study.	 	The	study	protocol	was	later	amended	and	submitted	to	the	ethics	committee	as	a	major	amendment	in	April	2015	to	allow	patients	to	participate	without	a	carer	(Appendix	D).	 	The	first	patient	was	recruited	without	a	carer	in	May	2015.	
4.4.2.4	Carer	exclusion	criteria	Carers	were	excluded	if	they	had	any	major	impairment	that	may	affect	their	ability	to	consent,	use	the	TiM	system	or	participate	in	the	study.			Changing	the	 inclusion	 criteria	 allowed	 patients	 to	 participate	 even	 if	 a	 carer	 was	excluded.	
4.4.3	Consent		Written	consent	(or	witnessed	verbal	consent)	was	taken	from	both	patient	and	 carer.	 Those	 who	 declined	 participation	 were	 invited	 to	 give	 their	reasons	 in	 order	 to	 identify	 common	 factors.	 	 Basic	 anonymised	details	 of	those	invited	were	collected	to	inform	the	CONSORT	flow	chart.			
4.4.4	Randomisation	Randomisation	was	performed	using	the	website	www.sealedenvelope.com.		This	uses	variable	block	(block	size	unknown)	randomisation.		Patients	(and	their	 carers)	 were	 allocated	 either	 to	 receive	 the	 TiM	 plus	 usual	 care	(intervention)	 or	 to	 receive	 usual	 care	 (control)	 using	 1:1	 randomisation.		Given	the	small	sample	size,	minimisation	was	not	employed.		
4.4.5	Sample	size	The	study	aimed	to	recruit	a	total	of	40	patients	plus	up	to	40	carers.		Since	the	trial’s	aims	were	primarily	to	assess	the	acceptability	of	the	intervention	and	the	feasibility	of	a	full	trial,	the	sample	size	was	not	based	on	standard	statistical	 parameters	 such	 as	 a	 clinically	 relevant	 difference	 between	groups.	Instead,	the	sample	size	was	justified	on	the	grounds	of	quantifying	patient	variance	in	the	proposed	outcome	measures	(in	particular,	quality	of	life	measures)	 and	 on	 feasibility	 of	 a	 definitive	 trial.	 	 A	 sample	 size	 of	 40	patients	allows	a	standard	deviation	to	be	estimated	to	within	a	precision	of	±20%	of	its	true	underlying	value	with	90%	confidence.	This	estimate	could	
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then	be	 synthesised	with	 standard	deviations	observed	 in	other	published	studies	 (e.g.	 (51,60,62,215,216)).	 This,	 combined	 with	 estimates	 of	recruitment	 and	 retention	 figures,	 could	 provide	 a	 robust	 estimate	 of	sample	size	for	use	in	the	sample	size	calculation	for	the	full	trial.				Given	 the	 rarity	 of	 MND,	 any	 definitive	 study	 would	 be	 infeasible	 if	 the	required	sample	size	is	substantial.	It	was	assumed	that	the	upper	limit	for	a	feasible	UK	study	is	around	200-300	patients	in	total	and	a	full	study	would	need	 to	 be	 powered	 to	 detect	 a	 standardised	 effect	 size	 of	 at	 least	 0.4	standard	deviations.	 This	 trial	would	 provide	 a	 preliminary	 assessment	 of	whether	the	intervention	might	feasibly	achieve	this	and	inform	the	choice	of	outcome	measures	for	the	proposed	full	study.			Finally,	 the	 sample	 size	 is	 also	 in	 keeping	 with	 the	 suggestion	 that	 12	evaluable	 patients	 per	 trial	 arm	 would	 provide	 sufficient	 data	 in	 a	 pilot	study	(after	allowing	for	withdrawal	or	drop-out)	(88,217).			
4.6	Intervention		The	 TiM	 telehealth	 was	 provided	 to	 all	 patients	 allocated	 to	 receive	 the	intervention.	 	The	 intervention	 is	described	 in	Chapter	Three.	 	All	patients	and	carers	were	visited	at	home,	shown	the	TiM	system	and	completed	the	questions	once	prior	to	recruitment.		Those	randomised	to	the	intervention	arm	were	then	trained	how	to	use	 the	Patient	App.	 	A	written	 information	leaflet	 about	 the	TiM	 technology	 and	 an	 email	 and	 telephone	 support	 line	were	provided.		If	no	sessions	were	received	after	two	weeks,	patients	were	contacted	to	ensure	they	were	not	having	difficulties	using	the	system.		
4.7	Quantitative	data	collection	
4.7.1	Clinical	outcomes	Tables	4.2	and	4.3	describe	the	participant	measures	collected	at	each	stage	of	the	trial.		Baseline	measures	were	completed	at	the	recruitment	visit.	Follow-up	data	were	 collected	 at	 three	 and	 six	 months,	 12	 and	 18	 months	 using	 self-administered	 questionnaires.	 Appendix	 D	 provides	 an	 example	 of	 the	patient	 questionnaire	 booklets.	 At	 baseline,	 participants	 could	 either	complete	the	questionnaires	during	or	after	the	recruitment	visit.		Follow-up	questionnaires	 were	 sent	 by	 post.	 	 A	 pre-paid	 envelope	 was	 provided	 to	return	 questionnaires.	 	 If	 participants	 did	 not	 return	 questionnaires	 they	were	 reminded	 by	 telephone,	 email	 or	 in	 person	 a	 maximum	 of	 once	although	 this	 was	 not	 always	 possible	 due	 to	 time	 constraints.	 	 These	reminders	was	 not	 recorded	 during	 the	 trial.	 	 In	 order	 to	 avoid	 potential	bias,	 an	 independent	 research	 nurse	 was	 available	 to	 help	 participants	complete	 the	 follow-up	 questionnaires.	 The	 instructions	were	 amended	 in	February	2015	 (with	ethical	 approval)	 to	 include	an	email	 address	 for	 the	study	nurse	and	the	writing	reworded	to	inform	participants	that	they	could	complete	the	questionnaires	over	several	days	to	reduce	burden.			
	 81	
Table	4.2		Patient	outcome	measures	collected.4		 Baseline	 3	months	 6	months	 12	months	 18	months	 Clinic	visits	
Patient	characteristics	Age,	gender	 X	 	 	 	 	 	Frequency	of	technology	use	 X	 	 	 	 	 	Broadband/mobile		internet	access	 X	 	 	 	 	 	Difficulties	using	TiM	 X	 	 	 	 	 	Need	for	help	using	TiM	 X	 	 	 	 	 	
Medical	history	Diagnosis	 X	 	 	 	 	 	Disease	duration	 X	 	 	 	 	 	Comorbidities		 X	 	 	 	 	 	Drug	history	 X	 	 	 	 	 	
Quality	of	life	ALSAQ-40	(218)	 X	 X	 X	 X	 X	 	SF-36	v1	(219)	 X	 X	 X	 X	 X	 	EQ-5D+D	 X	 X	 X	 X	 X	 	
Clinical	measures	ALS-FRS-R	(205)	 X	 X	 X	 X	 X	 	Pain	score	(current	and	worst)**	 X	 X	 X	 X	 X	 	CSS-MND	saliva	scale	(220)	 X	 X	 X	 X	 X	 	Hospital	Anxiety	and	Depression	score	(221)	 X	 X	 X	 X	 X	 	Survival	 	 	 	 	 	 X	
Adverse	events	 	 X	 X	 X	 X	 X	
Health	resource	use	Clinician	encounters**	 X	 X	 X	 X	 X	 X	Hospital	admissions**	 X	 X	 X	 X	 X	 X	Informal	care	use**	 X	 X	 X	 X	 X	 	Formal	care	use**	 X	 X	 X	 X	 X	 	
Satisfaction	MND	care	satisfaction**	 X	 X	 X	 X	 X	 	TiM	satisfaction**	 	 X*	 X*	 X*	 X*	 																																																									4	*intervention	arm	only	**	questionnaires	designed	for	the	trial		
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	Table	4.3	Carer	outcome	measures	collected.			 Baseline	 3	
months	
6	
months	
12	
months	
18	
months	
Clinic	
visits	
Carer	characteristics	Age,	gender	 X	 	 	 	 	 	Relationship	 to	patient	 X	 	 	 	 	 	Frequency	 of	technology	use	 X	 	 	 	 	 	Difficulties	using	TiM	 X	 	 	 	 	 	
Quality	of	life	SF-36	v1	(219)	 X	 X	 X	 X	 X	 	
Clinical	measures	Hospital	 Anxiety	and	 Depression	score	(221)	 X	 X	 X	 X	 X	 	Zarit	 Burden	Interview	(222)	 X	 X	 X	 X	 X	 	
Adverse	events	 	 X	 X	 X	 X	 X	
Satisfaction	MND	 care	satisfaction**	 X	 X	 X	 X	 X	 	TiM	satisfaction**	 	 X*	 X*	 X*	 X*	 	*intervention	arm	only,	**	questionnaires	designed	for	the	trial				 	
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4.7.1.1	Safety	and	Shadow	Monitoring	Protocol	As	 this	 was	 the	 first	 time	 the	 TiM	 had	 been	 used,	 it	 was	 agreed	 that	 no	changes	would	 be	made	 to	 a	 patient’s	 usual	 clinic	 visits	 and	 no	 decisions	would	 be	 made	 without	 contacting	 the	 patient	 or	 carer.	 	 Patients	 were	encouraged	 to	 continue	 to	 attend	 their	 usual	 appointments	 (between	 two	and	 six	monthly)	 and	 adverse	 events	were	 collected	 at	 each	 appointment	using	 the	 “Shadow	 Monitoring”	 case	 report	 form.	 Database	 reconciliation	ensured	 that	 all	 admissions	 recorded	 on	 any	 case	 report	 form	 or	 patient	questionnaire	 were	 entered	 as	 serious	 adverse	 events.	 	 Where	 possible,	hospital	 admission	 and	 discharge	 dates	 and	 reason	 for	 admission	 were	confirmed	using	discharge	summaries.				Clinicians	 were	 asked	 to	 review	 the	 TiM	 answers	 prior	 to	 the	 patient’s	appointment	 and	 give	 their	 impression	 of	 the	 system	 using	 a	 Shadow	Monitoring	form.	 	 It	was	planned	that	clinicians	would	review	the	answers	prior	to	the	appointment	and	state	whether,	based	on	the	TiM	information,	they	would	postpone	or	change	the	appointment	schedule.			As	 this	 was	 a	 pilot	 study,	 no	 interim	 analysis	 was	 planned	 so	 whilst	 the	intervention	 and	 trial	 were	 felt	 to	 be	 low	 risk,	 the	 Trial	 Steering	 Group	requested	 that	 some	 monitoring	 of	 participant	 wellbeing	 would	 be	appropriate.		Patients’	wellbeing	would	be	monitored	in	clinic	but	carers	did	not	 receive	 such	monitoring.	 	 Instead,	 the	clinical	 team	was	alerted	 to	any	Hospital	Anxiety	and	Depression	scores	provided	by	the	carer	that	exceeded	the	normal	range.	 	These	were	recorded	as	adverse	events	and	fed	back	to	the	clinical	team	and/or	carer	to	take	action	if	required.	
4.7.2	Outcome	measure	selection	One	of	the	aims	of	the	research	was	to	determine	which	outcome	measures	would	best	assess	the	impact	of	the	TiM	system.		Prior	to	the	study	starting	it	was	unclear	which	aspects	of	a	participants’	wellbeing	would	be	affected	by	 the	 TiM.	 	 Therefore,	 a	 number	 of	 different	 clinical	 outcome	 measures	were	 selected	 to	 enable	 comparisons	 to	 be	 made	 during	 the	 study.	 	 The	following	 properties	 were	 considered	 when	 selecting	 suitable	 outcome	measures	 to	 examine	 in	 this	 trial.	 	 These	 included	 the	 validity,	 reliability,	responsiveness	 to	 change	 and	 any	 floor/ceiling	 effects	 in	 the	 MND	population	 (223).	 	 In	 the	 development	 phase	 of	 the	 TiM	 (Chapter	 Three),	some	 of	 the	 participants	 explained	 that	 they	 found	 some	 research	questionnaires	unacceptable	(in	particular,	carer	burden	scales).		Therefore,	questionnaire	 acceptability	 and	 ease	 of	 completion	 was	 also	 considered	prior	 to	 selecting	 outcome	measures	 and	 also	 evaluated	 during	 this	 trial.	Finally,	 outcome	 measures	 used	 in	 the	 TiM	 system	 (the	 PHQ	 depression	questionnaire,	the	Modified	Carer	Strain	Index,	ALS-FRS-R)	were	not	used	as	outcome	measures	 in	the	trial	except	for	the	ALS-FRS-R,	 for	which	there	 is	no	alternative	measure.		 	
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4.7.2.1	Quality	of	life	It	 was	 anticipated	 that	 the	 primary	 impact	 of	 the	 TiM	 would	 be	 by	improving	 patient	 quality	 of	 life	 (QoL).	 	 QoL	 has	 been	 used	 as	 a	 primary	outcome	 in	many	 trials	 in	MND	 (51).	 QoL	 is	 influenced	 by	many	 physical,	psychological	 and	 social	 factors	 and	 the	 TiM	 could	 potentially	 influence	some	or	all	of	 these	domains.	 	Therefore,	 it	was	 important	 to	explore	how	MND	influences	QoL,	how	the	TiM	system	could	influence	QoL	and	how	this	could	 best	 be	 measured.	 	 Two	 outcome	 measures	 specifically	 focused	 on	QoL	were	selected	for	comparison:	a	generic	measure	(SF-36	v1	(219))	and	an	MND-specific	measure	(ALSAQ-40)	(218).		In	definitive	trials	it	would	be	important	 to	 assess	 the	 cost-effectiveness	 of	 the	 TiM	 system	 so	 the	 short	standard	measure	of	health	utility	was	also	used	(EQ-5D-3L)	along	with	the	EQ-5D	self-reported	 state	of	health	 “thermometer”.	An	additional	question	which	 incorporates	a	measure	of	dignity	was	also	used:	 this	questionnaire	and	scoring	system	is	unpublished	(224).			The	SF-36	v1	is	a	self-completed	patient	reported	outcome	measure	with	36	questions,	 from	 which	 can	 be	 expressed	 two	 summary	 scores,	 Physical	Component	 Score	 PCS	 and	 Mental	 Component	 Score	 MCS.	 	 It	 is	 the	 most	extensively	used	and	validated	QoL	questionnaire	in	clinical	trials	(225).		In	has	 been	 used	 to	 demonstrate	 that	 both	 NIV	 and	 MDT	 care	 can	 have	 a	positive	 impact	 on	 QoL	 (51,106).	 	 However,	 it	 has	 a	 floor	 effect	 for	 those	with	severe	disability	and	scores	may	not	be	sensitive	to	change	over	time	(223).		A	second	version	of	the	SF-36	may	reduce	this	floor	effect	but	version	1	was	selected	because	more	population	data	is	available	in	MND	(226).			The	ALSAQ-40	is	a	40-question,	ALS-specific	QoL	questionnaire.		It	examines	five	components:	physical	mobility;	activities	of	daily	living;	communication;	eating	 and	 drinking;	 and	 emotional	 components.	 	 As	 a	 disease	 specific	questionnaire,	 it	 was	 expected	 to	 capture	 more	 of	 the	 impacts	 of	 MND.		Furthermore,	 the	 questionnaire	 design	 is	more	 uniform	 than	 the	 SF-36	 as	each	question	is	posed	in	the	same	way.	This	may	influence	its	acceptability	in	 this	 patient	 group.	 	 It	 has	 been	 extensively	 used	 and	 validated	 in	MND,	with	 data	 available	 for	 large	 populations	 and	 is	 felt	 to	 be	 responsive	 to	change	without	 a	 floor	 or	 ceiling	 effect	 (223).	 It	 appears	 to	 correlate	well	with	disease	severity	(227)	and	demonstrates	good	concurrent	validity	with	the	SF-36	(215)	and	EQ-5D	visual	analogue	scale	(227).		Other	QoL	measures	were	considered	but	discounted.	These	included:	
• SEIQoL:	it	was	not	possible	to	use	a	self-administered	questionnaire.			
• Whilst	 designed	 for	 patients	 with	 terminal	 illnesses	 the	 McGill	Quality	 of	 Life	 Questionnaire	 as	 no	 studies	 had	 examined	 the	reliability	or	validity	in	MND	(223).			
• The	Sickness	Impact	Profile	(SIP):	this	had	been	amended	to	include	MND	specific	questions	(SIP-ALS-19)	but	the	evidence	for	its	validity	when	compared	to	other	MND	measures	or	QoL	measures	was	not	as	strong	 as	 the	 ALSAQ-40	 and	 no	 reliability	 or	 sensitivity	 data	 was	available	(223).	
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4.7.2.2	Clinical	characteristics	and	symptoms	Patients’	functional	ability	was	measured	using	the	ALS-FRS-R	which	is	the	most	 commonly	 used	 and	 well	 validated	 functional	 rating	 scale	 in	 MND	(205)	which	assesses	limb,	bulbar	and	respiratory	function.		It	is	also	a	valid	measure	 of	 clinical	 progression.	 	 The	 King’s	 staging	 system	 was	 used	 to	describe	the	clinical	stage	of	patients	(26).		The	stages	are	based	on	the	loss	of	functional	ability:	the	ALS-FRS-R	was	used	as	an	indicator	of	disability.				As	 the	 TiM	 system	 aims	 to	 improve	 the	 identification	 and	 treatment	 of	distressing	 complications	 of	 MND,	 measures	 assessing	 these	 symptoms	were	included	with	preference	for	those	which	had	been	previously	used	in	MND	(e.g.	 the	Hospital	Anxiety	and	Depression	Score	and	the	Zarit	Burden	Interview).	 	Pain	was	measured	using	a	modified	Likert	scale	as	other	pain	inventories	used	 in	MND	 (for	 example,	 the	Brief	Pain	 Inventory)	were	 too	complex	to	be	used	without	supervision	(228).				Measures	were	also	included	to	capture	any	potential	negative	impact	of	the	TiM	 system.	 	 Given	 previous	 telehealth	 trials	 have	 been	 associated	 with	increased	 mortality	 (170,229)	 and	 increased	 hospital	 admissions	 (which	was	suggested	could	be	due	to	identification	of	unmet	need	early	in	the	trial)	(173),	survival,	adverse	events	and	health	resource	use	data	was	collected.		Health	 resource	 use	 and	 hospital	 admission	 data	 were	 collected	 in	questionnaires.		Patient-completed	diaries	had	been	used	in	the	DiPALS	trial	(Diaphragmatic	 pacing	 in	ALS)	 (56).	 These	 collected	 data	more	 frequently	but	were	 often	 returned	 incomplete	 and	 therefore	 felt	 to	 be	 unsuitable	 in	this	population.		There	 are	 no	 disease	 specific	 tools	 to	 measure	 carer	 QoL	 in	 MND	 so	 the	generic	 SF-36	 v1	 was	 selected.	 	 There	 is	 no	 single,	 uniform	 definition	 of	carer	 burden	 or	 strain	 and	 its	 distinction	 from	 QoL	 is	 unclear	 (230)	 but	given	that	the	TiM	could	increase	the	responsibilities	of	the	carer,	it	was	felt	important	 to	 assess	 this	 separately	 from	 QoL.	 	 Only	 generic	 tools	 that	measure	 carer	 burden	 are	 available.	 	 The	 12-item	 Zarit	 Burden	 Interview	was	 selected	 because	 it	 has	 been	 shown	 to	 accurately	 reflected	 burden	 in	carers	 of	 those	 with	 advanced	 diseases	 and	 was	 not	 excessively	 lengthy	(222,231).			
4.8	Evaluating	the	feasibility	of	a	definitive	trial		Data	was	 collected	 to	evaluate	 feasibility	of	 the	 trial	methods.	 	No	 specific	feasibility	criteria	were	pre-specified	because	a	range	of	activities	needed	to	be	tested	such	as:	
• Screening,	recruitment	and	withdrawal	rates;	
• Rates	of	completion	of	outcome	measures;	
• Participant	attitudes	towards	clinical	trials.		 	
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4.9	TiM	system	process	evaluation			Process	 evaluation	 measures	 examined	 the	 use,	 impact	 of	 and	 potential	mechanisms	and	explanations	 for	 these	 findings.	This	was	done	 in	 several	ways.		This	was	done	through	the	collection	of	the	following	information:	
• Patient	and	carer	experience:	
o Patient	and	carer	interviews;	
o MND	care	satisfaction	questionnaire	(patient	and	carer);	
o TiM	satisfaction	questionnaire	(patient	and	carer);	
• Clinician	experience:	
o Telehealth	Nurse	interviews	(early	and	late	in	trial);	
o Community	MND	nurse	interview	(late	in	trial);			
o Physician	 satisfaction	 with	 TiM	 in	 clinic	 using	 Shadow	Monitoring;	
• Adverse	events	including	any	associated	with	the	TiM	system;	
o Shadow	monitoring	protocol	(see	4.7.1.1);	
o Patient/carer	questionnaires	(e.g.	hospital	admissions);	
o TiM	system	reports;		
o Interviews;	
o Field	notes;	
• Usage	of	the	TiM	system:	
o Date	of	each	TiM	session;	
o All	patient	and	carers	answers	and	alerts	generated;	
o Notes	made	by	the	clinicians;	
• Technical	problems	with	the	TiM	system:	
o Field	notes;	
o Shadow	monitoring	protocol;	
o TiM	system	notes.		It	was	 not	 possible	 to	 use	 the	 TiM	 technology	 to	 automatically	 determine	how	long	clinicians	spent	using	the	TiM	system	or	how	much	additional	time	was	 taken	 responding	 to	 alerts.	 	 A	 diary	 was	 provided	 to	 the	 Telehealth	Nurse	at	 intervals	during	 the	 trial	but	 this	diary	was	 returned	 incomplete.		Instead,	 the	 time	burden	and	 impact	on	daily	work	of	health	professionals	was	explored	in	interviews.		 	
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4.10	Qualitative	interviews		Semi-structured	 interviews	 were	 conducted	 with	 participants	 and	clinicians-the	MND	hospital	nurse	using	the	TiM	(the	Telehealth	Nurse)	and	an	MND	community	nurse	 (Community	Nurse)	who	 cared	 for	 some	of	 the	participants	in	the	study.		Semi-structured	 qualitative	 interviews	 were	 selected	 because	 they	 could	explore,	in	more	depth,	the	processes	occurring	when	participants	and	staff	were	 using	 the	 TiM	 system.	 	 They	 also	 provided	 a	 more	 detailed	understanding	 of	 the	 study	 methods,	 in	 particular	 focusing	 on	 what	 was	occurring	 during	 recruitment	 and	 initial	 data	 collection.	 	 Semi-structured	interviews	were	used	because	they	could	be	conducted	in	a	patient’s	home	meaning	the	study	remained	low	in	burden.		Interviews	could	be	adapted	to	involve	even	the	most	disabled	patient.	Furthermore,	they	aimed	to	explore	issues	relating	to	participants’	medical	condition	and	care,	topics	that	many	participants	 may	 not	 feel	 conformable	 discussing	 with	 strangers,	 for	example,	 in	 focus	groups.	 	 	Similarly,	 interviews	were	used	to	capture	staff	experiences	for	reasons	both	of	convenience	but	also	because	staff	may	not	feel	 comfortable	 discussing	 their	 practice	 or	 experiences	 with	 individual	patients	in	front	of	other	staff	members.	
4.10.1	Interview	conduct	Participants	in	the	intervention	arm	underwent	semi-structured	interviews	at	 one	 and	 six	months.	 	 Participants	 in	 the	 control	 arm	were	 interviewed	only	at	baseline.	 	Patients	and	carers	were	usually	 interviewed	together	as	experience	in	previous	studies	suggested	that	this	was	preferred	(102)	and	allowed	carers	to	help	with	communication	and	attend	to	the	patients’	needs	during	 the	 interviews.	 	 It	 also	 enabled	 discussions	 between	 patients	 and	carers.	 	 Prior	 to	 the	 interview	 the	 aim	 of	 the	 interview	 and	 the	 “ground	rules”	 of	 qualitative	 interviews	 were	 explained	 and	 consent	 was	reconfirmed.	 	 Some	 interviews	 were	 paused	 or	 shortened	 if	 a	 lengthy	interview	was	 felt	 to	 be	 tiring	 and	 communication	 aids	were	 used.	 Three	participants	 whose	 speech	 was	 poor	 were	 sent	 additional	 questions	 by	email	and	two	were	provided	with	an	outline	of	 the	questions	prior	 to	 the	interview	to	help	them	prepare	their	answers.		Interviews	were	audio	recorded	and	transcribed	verbatim.	Reflective	notes	were	made	immediately	after	the	interviews,	after	review	of	the	transcript,	and	 during	 the	 trial	 to	 record	 new	 events	 e.g.	 patient	 contact	 with	 the	research	team.		Some	interviews	were	transcribed	by	EH:	initial	interviews	to	 improve	 interview	 technique	 and	 familiarity	 with	 the	 data,	 and	interviews	 where	 dysarthria	 meant	 transcription	 would	 be	 difficult.		Professional	 transcription	was	 used	 for	 the	 other	 interviews	 but	 all	 were	checked	 with	 the	 audio	 recording	 for	 accuracy.	 	 Wendy	 Baird,	 an	experienced	 qualitative	 researcher,	 reviewed	 initial	 interviews.	 	 She	provided	 feedback	 on	 the	 topic	 guide,	 interview	 technique	 and	 potential	
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themes,	 as	 well	 as	 providing	 an	 independent	 assessment	 of	 data	interpretation.			
4.10.2	Interview	structure	Semi-structured	 interviews	 using	 predefined	 topic	 guides	 (Appendix	 D).		The	 topic	 guides	 were	 developed	 to	 include	 questions	 reflecting	 the	objectives	 of	 the	 trial	 and	 research	 questions	 and	 were	 influenced	 by	 a	literature	 review	 of	 telehealth	 in	 MND	 and	 other	 diseases	 (described	 in	Chapter	 One).	 	 The	 topic	 guide	 developed	 throughout	 the	 trial	 to	 further	explore	 emerging	 themes	 and	 the	 events	 of	 the	 study	 (for	 example,	problems	with	the	TiM	system).		It	also	aimed	to	explore	the	impact	on	the	TiM	 on	 clinical	 events	 that	 occurred	 in	 individual	 patients	 (e.g.	 after	 NIV	initiation).		Topics	guides	were	used	at	each	time	point	(Appendix	D).	Where	possible,	all	 patients	 are	 carers	 were	 asked	 about	 the	 following	 subjects	 (although	some	interviews	were	shortened	due	to	time	limits	or	patient	fatigue):			
• The	experiences	of	hospital	and	community	MND	care;		
• The	impact	of	MND	on	participants’	quality	of	life;	
• The	unmet	needs	in	MND	care;	
• Participants’	attitudes	towards	technology;		
• Participants’	attitudes	towards	research	and	experience	of	research	during	the	study	(all	patients	and	carers).		Control	participants	were	also	asked	about:	
• Participants’	attitudes	towards	the	baseline	questionnaires	and	how	they	 reflect	 the	 quality	 of	 life	 of	 those	with	MND	 (control	 patients	and	carers	only).		Participants	 in	 the	 intervention	 arm	 were	 asked,	 at	 one	 and	 six	 months	about:		
• Participants’	 expectations	 of	 and	 experiences	 of	 using	 the	 TiM	system;	
• The	potential	 impact	of	TiM	system	on	participants’	care,	and	 their	wellbeing.		The	nurses	were	asked	about	
• The	experiences	of	hospital	and	community	MND	care;		
• The	impact	of	MND	on	participants’	quality	of	life;	
• The	unmet	needs	in	MND	care;	
• The	nurses’	attitudes	towards	and	use	of	the	TiM	system	
• The	impact	and	future	use	of	telehealth	on	clinical	services.		The	 topic	 guides	 evolved	 throughout	 the	 trial	 to	 explore	emerging	 themes	and	the	events	of	the	study	(for	example,	problems	with	the	TiM	system).		It	also	aimed	to	explore	the	impact	on	the	TiM	on	clinical	events	that	occurred	in	individual	patients	(e.g.	after	NIV	initiation).			 	
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4.10.3	MND	clinical	team	interviews	Interviews	with	the	MND	clinical	team	were	conducted.		Staff	were	provided	with	 a	 Staff	 Information	 Leaflet	 and	 gave	 written	 consent.	 	 Topic	 guides	were	used	(Appendix	D).		Two	 interviews	 were	 conducted	 with	 the	 MND	 Telehealth	 Nurse.	 	 An	interview	was	conducted	at	four	months	and	explored	the	role	of	the	MND	nurse,	 the	 challenges	 faced	 by	 patients	 and	 carers,	 and	 her	 initial	experiences	 using	 the	 TiM	 system.	 	 Wendy	 Baird	 conducted	 a	 further	interview	at	14	months.		The	interview	was	conducted	independently	of	the	clinical	team	using	topic	guide	prepared	by	both	WB	and	EH.		This	aimed	to	explore	her	 experiences	of	 using	 the	TiM	and	 the	 challenges	posed	by	 the	TiM.	 	 These	 included:	 the	MND	 nurses’	 reaction	 to	 any	 problems	 or	 flags	identified	 by	 the	 TiM,	 the	 potential	 impact	 it	 could	 have	 on	 participant	outcomes	and	the	challenges	that	would	be	faced	implementing	the	system	into	the	NHS	service.		At	the	end	of	the	study	an	interview	was	conducted	with	a	community	MND	nurse	 who	 had	 had	 the	 most	 patients	 using	 the	 TiM.	 	 This	 explored	 her	experience	as	a	community	nurse,	the	interaction	she	had	with	the	hospital	team	 and	 the	 unmet	 needs	 of	 her	 patients.	 	 She	 reviewed	 the	TiM	 system	and	provided	feedback	on	the	system	and	on	the	patients	using	the	TiM.				
4.11	Analysis		
4.11.1	Quantitative	data	management	Data	collection	 forms	were	generated	 in	collaboration	with	data	managers	at	 the	 University	 of	 Sheffield	 Clinical	 Trials	 Unit	 who	 then	 developed	 a	Clinical	Trials	Research	Unit	Epigenesis	database.		Data	was	entered	into	the	database	by	EH	with	the	exception	of	follow-up	participant	questionnaires.		These	 were	 entered	 by	 an	 independent	 study	 nurse.	 Early	 in	 the	 trial	database	managers	 compared	 three	 participants’	 paper	 case	 report	 forms	with	 the	 data	 entered	 on	 the	 database.	 	 Irregularities	were	 identified	 and	corrected.	 The	 database	was	 also	 amended	 to	 address	 common	 errors,	 in	particular	 allowing	 annotations	 to	 be	 made	 to	 the	 answers	 where	participants	 had	 written	 comments	 on	 their	 questionnaires	 rather	 than	completing	 the	 questions.	 	 Discrepancies	 identified	 by	 the	 database	 were	highlighted	and	corrected	throughout	the	trial.	 	These	included	unexpected	entries	and	reconciliation	of	errors.		Any	hospital	admissions	were	identified	and,	 where	 discrepancies	 occurred,	 data	 was	 confirmed	 using	 hospital	records.	 	Following	database	 freeze,	 the	trial	statistician	reviewed	the	data	and	further	discrepancies	were	highlighted	and	resolved	prior	to	release	for	analysis.			 	
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4.11.2	Blinding	Due	to	the	nature	of	the	intervention,	it	is	impossible	for	participants	or	the	clinical	team	to	be	blinded.		As	the	analysis	would	be	performed	by	EH	who	knew	the	patients	well,	 it	was	felt	unlikely	that	blinding	would	be	possible	even	 if	 measures	 were	 taken	 to	 conceal	 the	 two	 allocated	 groups.	 	 The	following	measures	were	therefore	put	in	place	to	reduce	bias	due	to	lack	of	blinding:	
• Participant	 follow-up	 questionnaires	 were	 completed	 at	 home,	independent	of	the	study	team;	
• Follow-up	data	was	entered	by	an	 independent	research	nurse	who	was	 also	 available	 to	 help	 the	 participants	 complete	 the	questionnaires,	either	by	telephone,	email	or	in	person	in	the	Clinical	Research	Facility;			
• Analysis	 was	 conducted	 according	 to	 a	 pre-specified	 statistics	analysis	plan	and	supervised	by	the	trial	statistician	and	the	TMG.	
4.11.3	Statistical	analysis	A	 Statistical	 Analysis	 Plan	 was	 prepared	 prior	 to	 release	 of	 the	 data	(Appendix	 D).	 	 Data	 collected	 in	 the	 database	 was	 reviewed	 by	 the	 trial	statistician	and	released	for	analysis	in	Microsoft	Excel	and	GraphPad	Prism.		All	analysis	was	conducted	by	EH	except	the	scores	for	the	SF-36	and	EQ-5D,	which	were	generated	by	the	trial	statistician	using	the	statistical	software	Stata	and,	in	the	case	of	SF-36,	compared	to	US	population	norms.		The	EQ-5D	 was	 calculated	 in	 two	 ways:	 firstly	 using	 all	 data	 collected	 whilst	 the	patient	was	alive,	 and	 secondly	 calculated	 including	 scores	of	0	where	 the	patient	had	died	(which	corresponds	to	the	state	of	death	for	this	inventory)	for	 all	 time-points	 between	 death	 and	 scheduled	 end	 of	 follow-up.		Incomplete	data	was	handled	for	the	RAND-36,	ALSAQ-40	and	HADS	scores	according	to	methods	described	in	the	Statistics	Analysis	Plan	(Appendix	D).		Where	imputation	was	not	possible,	the	data	was	excluded	from	analysis.			Descriptive	statistics	were	used	to	describe	the	participant	characteristics	in	both	 treatment	 groups	 and	 in	 the	 population	 as	 a	whole.	 	 These	 could	 be	compared	 to	 those	 in	 the	 general	 MND	 population.	 	 To	 explore	 the	sensitivity	 of	 the	 outcome	 measures	 to	 capture	 relevant	 changes	 in	participants’	condition,	individual	scores	at	each	follow-up	time	point	were	compared	 to	 baseline	 and	 the	mean	 change	 and	95%	 confidence	 intervals	were	 calculated.	 	 For	 categorical	 outcomes,	 the	 number	 and	 percentages	falling	into	different	categories	and	potential	differences	between	groups	in	terms	of	 the	percentages	 in	each	category	will	be	presented,	 together	with	their	 confidence	 intervals.	 	 	 Whilst	 normal	 hypothesis	 testing	 was	 not	planned	in	this	small	sample,	any	noteworthy	differences	between	groups	or	changes	during	the	trial	were	identified.		Details	of	every	individual	TiM	session	were	downloaded	by	Carematix	and	analysed	 using	 Excel	 and	 GraphPad	 Prism.	 	 This	 included	 the	 dates	 and	times	 of	 each	 session,	 answers	 provided	 by	 participants,	 flag	 and	 scores	generated	and	staff	notes.			
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4.11.4	Qualitative	data	management	and	interview	analysis	Thematic	analysis	of	the	data	was	conducted	(232).	 	Thematic	analysis	is	a	structured	 method	 for	 identifying,	 analysing	 and	 reporting	 patterns	(themes)	within	data	in	order	to	organise	and	describe	the	dataset	in	detail	(232).		This	approach	was	chosen	for	a	number	of	reasons.			It	can	be	used	to	compare	 themes	 across	 an	 entire	 data	 set	 including	 different	 participant	types	(patients,	carers	and	clinicians).	It	can	be	used	to	examine	the	variety	different	 of	 research	 questions	 posed	 in	 this	 project	 (such	 as	 both	participants	 experiences,	 views	 and	 perceptions)	 (213).	 	 It	 can	 explore	participants’	 experiences	 of	 MND	 care,	 TiM	 and	 research	 but	 can	 also	explore	more	specific	questions	posed	during	the	trial	such	as	why	events	or	behaviours	 occurred	 in	 context	 (232).	 	 	 Whilst	 analysis	 is	 sequential,	 it	allows	movement	back	and	forth	between	each	stage	which	allows	analysis	to	 commence	 early	 in	 the	 trial	which	 can	 inform	 development	 of	 the	 TIM	system	and	the	trial	methods.		This	also	allows	triangulation	with	other	data	which	may	be	available	later	in	the	trial	(e.g.	problems	with	recruitment,	or	later,	 adherence	 to	 the	 TiM	 system).	 	 As	 it	 does	 not	 require	 the	 detailed	theoretical	and	technological	knowledge	of	other	approaches	to	analysis	it	is	also	 felt	 to	 be	 accessible	 to	 a	 researcher	 early	 in	 their	 qualitative	 career	(213)		A	 stepwise	 approach	 to	 analysis	was	 taken.	 	 Familiarisation	with	 the	 data	involved	rereading	transcripts	and	field	notes	whilst	listening	to	the	audio-recordings.	 	This	allowed	initial	 ideas	(codes)	and	early	broader	themes	to	be	 generated.	 	 Discussion	 of	 the	 emerging	 themes	 occurred	 at	 trial	management	meetings	and	during	supervisions.	 	Data	was	organised	using	NVivo	(233).		Themes	and	codes	were	refined	and	initial	results	reviewed	by	Wendy	 Baird	 before	 overarching	 themes	 were	 identified,	 the	 coding	structure	 refined	 and	 the	 data	 reviewed	 to	 ensure	 the	 results	 were	consistent	with	the	data.		No	rigid	definition	of	a	theme	was	made	(e.g.	how	many	times	it	occurred	in	the	data	set).		Instead	it	was	considered	whether	the	theme	captured	something	important	in	relation	to	the	overall	research	questions	or	whether	it	was	relevant	to	other	observations	during	the	trial.			Eventually	subthemes	were	arranged	in	tables	with	supporting	quotes.				Analysis	began	following	the	first	three	interviews.		These	were	transcribed	and	 coded	 to	 ensure	 that	 emerging	 themes	 were	 explored	 in	 subsequent	interviews.	 	 	Early	results	provided	some	 insight	 into	how	the	TIM	system	was	being	used	and	informed	medication	of	the	TiM	system.		It	was	possible	to	 identify	 which	 participants	 using	 the	 TiM	 system	 regularly	 or	infrequently	 and	 the	 reasons	 for	 this	were	 explored	 during	 the	 six-month	interviews.		However,	as	interviews	were	planned	only	at	six	months	it	was	not	 possible	 to	 explore	 the	 experiences	 and	 reasons	 for	 poor	 adherence	later	 in	 the	 trial	 although	 this	was	explored	during	 the	 interview	with	 the	Telehealth	 Nurse	 and	 Community	 Nurse	 who	 were	 interviewed	 at	 month	h14	and	month	18	respectively.		 	
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4.11.5	Triangulation	of	the	results	Following	 completion	 of	 the	 trial,	 a	 triangulation	 process	 examined	 the	quantitative	and	qualitative	data	which	aimed	to	answer	questions	relating	to	the	process	evaluation.		Quantitative	data	included	participant	adherence,	participant	satisfaction	questionnaires,	the	alerts	generated	by	the	TiM,	the	nurse’s	 use	 of	 and	 reaction	 to	 the	 TiM	 system	 and	 the	 physician	 shadow	monitoring	data.		The	qualitative	data	was	then	reviewed	with	these	results	in	mind	 and	 the	 two	 combined	 to	 answer	 each	 research	 question.	Where	unexpected	results	occurred,	the	data	was	reviewed	to	try	to	explore	what	happened.	 	 For	 example,	 to	 try	 to	 explain	 the	 patterns	 of	 adherence	 by	participants	or	to	explain	whether	and	how	participants’	expectations	of	the	TiM	 differed	 from	 the	 nurses’	 experiences.	 	 Important,	 incongruent	 or	unexpected	 results	 obtained	 from	 the	 quantitative	 data	were	 discussed	 at	trial	meetings	and	the	qualitative	data	was	then	reviewed	again	in	order	to	provide	explanations	for	these	results.		This	data	was	presented	to	the	TMG	before	the	final	results	were	produced.			
4.12	Conclusion	Chapters	Five	describes	the	results	of	the	process	evaluation	examining	how	the	TiM	system	was	used	in	the	trial.	 	Chapter	Six	describe	the	results	that	determine	whether	a	definitive	trial	would	be	feasible		 	
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Chapter	Five	
Results:	A	process	evaluation	of	the	TiM	system		
5.1	Introduction		Chapter	 Five	 describes	 the	 process	 evaluation	 of	 the	 TiM	 system.	 	 It	 will	describe	 how	 the	 TiM	 system	 functioned	 by	 examining	 how	 it	 was	implemented,	the	experiences	of	and	the	potential	mechanisms	of	impact	on	those	 who	 used	 it,	 and	 the	 contextual	 factors	 that	 may	 explain	 how/why	these	 impacts	 occurred.	 Qualitative	 and	 quantitative	 data	 has	 been	presented	 together	 to	 inform	answers	 to	 the	research	questions.	 	 	Chapter	Six	 describes	 the	 results	 that	examine	 the	 feasibility	 of	 the	 study	 and	 also	describes	 the	 participant	 characteristics	 and	 outcome	 measures	 in	 more	detail.		It	is	recognised	that	the	two	research	questions	overlap	at	times	and	it	 is	 usual	 to	 report	 the	 quantitative	 results	 first.	 	 In	 this	 case	 the	 process	evaluation	 has	 been	 reported	 first	 because	 it	 describes	 in	 detail,	 what	occurred	within	 study	 and	whether/how	 the	TiM	 impacted	 on	 the	 clinical	outcomes	recording	during	the	trial	as	it	was	felt	important	to	explain	what	occurred	during	the	trial	in	order	to	explain	the	observed	clinical	outcomes	of	the	trial	described	in	Chapter	Six.				This	 chapter	 will	 report	 in	 the	 results	 three	 sections	 and	 summarise	 the	findings	after	each	section	and	together	in	the	later	discussion	section.			Each	section	 will	 draw	 together	 the	 data	 from	 interviews,	 TiM	 data,	 patient	reported	 outcomes	 and	 field	 notes	 to	 answer	 the	 research	 questions	 and	will	 summarise	 the	 results	 at	 the	 end	 of	 each	 section.	 	 Section	 5.2	 will	outline	and	summarise	the	characteristics	of	the	participants	recruited	and	the	 interviews	 conducted.	 	 Section	 5.3	 will	 then	 describe	 participants’	experiences	of	 and	 satisfaction	with	 their	 current	hospital	 and	 community	MND	 care	 and	 their	 unmet	 needs	 associated	 with	 difficulties	 accessing	specialist	care.		Section	5.4-5.9	reports	the	processes	occurring	in	the	trial	related	to	the	use	of	the	TiM	system:		
• Setting	up	and	delivery	of	the	TiM	system;	
• Participant	use	and	adherence	to	the	TiM	system;	
• Participants’	 expectations	 of,	 satisfaction	 with,	 and	 experiences	 of	using	the	TiM	technology;	
• Clinicians’	use	of	 the	TiM	system	and	reaction	to	 the	data	collected	by	the	TiM	system;	
• Clinicians’	 impressions	 of	 the	 acceptably,	 safety	 and	 impact	 of	 the	TiM	system	in	clinical	practice.				
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Whilst	the	aim	of	the	trial	was	not	to	assess	the	efficacy	of	the	TiM	system,	Section	 5.8	 and	 5.9	 describe	 circumstances	 in	 which	 the	 participants	 and	clinicians	felt	the	TiM	system	might	have	impacted	on	them	and	their	MND	care.		It	focuses	on	the	mechanisms	for	these	potential	impacts,	why	and	in	what	context	they	occurred	by	examining:	
• Participants’	 and	nurses’	perceptions	on	 the	potential	 impact	of	 the	TiM	on	their	condition	and	their	MND	care;	
• Participants	and	nurses’	 interactions	with	the	TiM	and	reasons	why	participants	did	not	feel	the	TiM	made	any	impact;			
• Participants’	and	nurses’	attitudes	towards	the	future	of	the	TiM.		Finally,	 Section	5.10	discusses	whether	 these	 results	 indicate	 that	 the	TiM	system	 is	 feasible	 and	 acceptable	 and	 whether	 and	 what	 value	 the	 TiM	system	may	have.		It	also	describes	ways	in	which	the	TiM	system	needs	to	be	improved,	and	makes	recommendations	how	these	developments	should	be	implemented	and	further	evaluated.	
	Figures	and	quotes	have	been	used	 to	 summarise	 the	 relevant	 themes	and	subthemes	 in	each	section.	Additional	quotes	 to	support	 these	 findings	are	available	in	tables	in	Appendix	A.		
5.2	Participant	characteristics		40	patients	and	37	carers	were	recruited.	The	characteristics	of	the	patients	and	 carers	 are	described	 in	Tables	5.1	 and	5.2.	 	 	 Patients’	mean	 age	 (60.2	years,	range	30-78	years)	and	gender	(28,	70%	male)	broadly	reflected	the	population	 of	 patients	who	 have	 attended	 the	 Sheffield	MND	 clinic	 (111).	Carers	were	mainly	female	(28,	76%)	and	were	mostly	the	patient’s	partner	(34,	92%).		
5.2.1		Baseline	patient	disease	characteristics		Table	 5.3	 reports	 the	 baseline	 disease	 characteristics.	 The	 baseline	characteristics	of	each	group	appear	similar.	 	Most	patients	 (35,	88%)	had	ALS	 but	 only	 18	 (45%)	met	 the	 criteria	 for	 clinically	 definite	 or	 clinically	probable	 ALS.	 	 	 Patients	 were	 recruited	 at	 all	 stages	 of	 disease	 with	 13	(33%)	 patients	 using	 NIV	 and/or	 gastrostomy	 (26).	 	 	 Median	 duration	 of	disease	was	41	months.	 	17	(42.5%)	patients	had	symptoms	for	more	than	four	years,	the	longest	was	203	months.			Four	patients	(10%)	were	recently	diagnosed,	including	one	patient	diagnosed	in	the	previous	two	months.	
5.2.2		Participants’	experience	of	technology		Most	 participants	 (32,	 80%	 of	 patients,	 28,	 76%	 of	 carers)	 already	 used	some	 form	 of	 technology	 device	 (computer,	 tablet	 or	 smart	 phone)	 daily	(Table	 5.4).	 	 	 However,	 four	 patients	 (10%)	 and	 nine	 carers	 (24%)	 used	technology	 once	 a	 week	 or	 less.	 	 Two	 (5%)	 patients	 had	 no	 computer	technology	or	 internet	broadband.	 	 	Seven	(18%)	had	no	3G	mobile	phone	reception	 in	 their	homes.	 	All	 of	 these	had	broadband	and	were	willing	 to	use	 it	 for	 the	 trial.	 	 	 27	 patients	 (68%)	 reported	 upper	 limb	 disability	affecting	 their	 use	 of	 a	 tablet	 computer.	 	 34	 (85%)	 could	 use	 the	 TiM	independently.	
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	Table	5.1	Patient	characteristics.			
	 Telehealth	
(n=20)	
Control	
(n=20)	
Total	
(n=40)	
Age	Years	(SD)	 60.4	(11.7)	 60	(10.0)	 60.2	(10.7)	Range	 30-78	 39-73	 30-78	
Sex	Male	 14	(70%)	 14	(70%)	 28	(70%)	Female	 6	(30%)	 6	(30%)	 12	(30%)	
Potential	problems	using	TiM	device	Hand/arm	weakness/arthritis	 14	(70%)	 13	(65%)	 27	(68%)	Vision	difficulties	 1	(5%)	 0	(0%)	 1	(3%)	Language	 or	 reading	difficulties	 0	(0%)	 0	(0%)	 0	(0%)	
Use	of	the	TiM	device	Independently	 17	(85%)	 17	(85%)	 34	(85%)	Help	from	carer	 1	(5%)	 1	(5%)	 2	(5%)	Patient	instructs	carer	 2	(10%)	 2	(15%)	 4	(10%)	Carer	answers	on	patient’s	behalf	 0	(0%)	 0	(0%)	 0	(0%)			Table	5.2	Carer	characteristics.		
	 Telehealth	
(n=18)	
Control	
(n=19)	
Total	
(n=37)	
Age	Mean	(SD)	 59	(11.6)	 60.8	(10.9)	 60.1	(11.1)	Range	 42-84	 38-73	 38-84	
Sex	Male	 4	(21%)	 5	(28%)	 9	(24%)	Female	 15	(79%)	 13	(72%)	 28	(76%)	
Relationship	to	patient	 	Partner	 18	(95%)	 16	(89%)	 34	(92%)	Child	 0	(0%)	 1	(6%)	 1	(3%)	Parent	 1	(5%)	 1	(6%)	 2	(5%)	
Potential	problems	using	TiM	device	Hand/arm	weakness/arthritis	 0	(0%)	 0	(0%)	 0	(0%)	Vision	difficulties	 0	(0%)	 0	(0%)	 0	(0%)	Language	 or	 reading	difficulties	 0	(0%)	 0	(0%)	 0	(0%)	
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Table	5.3	Patient	disease	characteristics.			
	 Telehealth	
(n=20)	
Control	
(n=20)	
Total	
(n=40)	
Diagnosis	ALS																																							Total	 17	(85%)	 18	(90%)	 35	(88%)	ALS	clinically	definite	or	clinically	probable		 8	(40%)	 10	(50%)	 18	(45%)	ALS	clinically	probable	-	laboratory-supported	 9	(45%)	 8	(40%)	 17	(43%)	ALS	clinically	possible	 0	(0%)	 0	(0%)	 0	(0%)	Primary	lateral	sclerosis	 2	(10%)	 2	(10%)	 4	(10%)	Progressive	muscular	atrophy	 1	(5%)	 0	(0%)	 1	(3%)	
Duration	of	disease	(months)*	Mean	(SD)	 56	(51)	 47	(35)	 50	(43)	Median	(IQR)	 41	(18,	61)	 39	(16.5,	71))	 41	(17,	62)	Range	 11-203	 7-129	 7-203	<12	months	 2		(10%)	 2	(10%)	 4	(10%)	12-24	months	 4	(20%)	 6	(30%)	 10	(25%)	24.1-48	months	 5	(25%)	 4	(20%)	 9	(22.5%)	48.1-72	months	 5	(25%)	 3	(15%)	 8	(20%)	>72.1	months	 4	(20%)	 5	(25%)	 9	(23%)	
Duration	since	diagnosis	(months)	Mean	(SD)	 32	(36)	 21	(20)	 27	(30)	Range	 2-143	 1-63	 1-143	
Site	of	onset		Upper	limb	 4	(20%)	 7	(35%)	 11	(23%)	Lower	limb	 11	(55%)	 10	(50%)	 21	(53%)	Bulbar	 4	(20%)	 3	(15%)	 7	(18%)	Respiratory	 1	(5%)	 1	(5%)	 2	(5%)	
Treatments		Using	non-invasive	ventilation	 6	(30%)	 3	(15%)	 9	(23%)	Gastrostomy	 3	(15%)	 6	(30%)	 9	(23%)	Taking	Riluzole	 16	(80%)	 15	(75%)	 31		(78%)	
King’s	ALS	clinical	stage5		 n=20	 n=20	 n=40	1	 3	(15%)	 2	(10%)	 5	(13%)	2	 4	(20%)	 5	(25%)	 9	(23%)	3	 5	(25%)	 8	(40%)	 13	(33%)	4	 8	(40%)	 5	(40%)	 13	(33%)			 																																																									5	King’s	stage	1	refers	to	patients	with	functional	deficit	in	1	domain,	stage	2	refers	to	disability	in	2	domains,	stage	3	refers	to	disability	in	3	domains	and	stage	4	refers	to	patients	requiring	NIV	and/or	gastrostomy.		King’s	stage	was	calculated	using	the	ALS-FRS-R	scale	at	baseline.	
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Table	5.4	Participants’	use	of	computers	and	availability	of	home	broadband	and	3G	mobile	phone	reception.				 Telehealth	 Control	 Total	
Patient	computer	use		 n=20	 n=20	 n=40	Daily	 14	(70%)	 18	(90%)	 32	(80%)	A	few	times	per	week	 3	(15%)	 1	(5%)	 4	(10%)	Once	a	week	 1	(5%)	 1	(5%)	 2	(5%)	Every	few	weeks	 0	(0%)	 0	(0%)	 0	(0%)	Never	 2	(10%)	 0	(0%)	 2	(5%)	
Home	technology		Broadband	 18	(100%)	 20	(100%)	 38	(95%)	3G	mobile	reception	 18	(90%)	 15	(75%)	 33	(83%)	
Carer	computer	use	
	 n=18	 n=19	 n=37	Daily	 12	(67%)	 16	(84%)	 28	(76%)	A	few	times	per	week	 0	(0%)	 0	(0%)	 0	(0%)	Once	a	week	 1	(6%)	 2	(11%)	 3	(8%)	Every	few	weeks	 1	(6%)	 1	(5%)	 2	(5%)	Never	 4	(22%)	 0	(0%)	 4	(11%)					 	
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5.2.3	Interview	conduct	Semi-structured	participant	interviews	were	conducted	at	baseline	(control	participants)	 and	 after	 one	 and	 six	 months	 of	 starting	 using	 the	 TiM	(intervention)	 (Figure	 5.1).	 	 Interviews	 aimed	 to	 continue	 until	 data	saturation	was	reached	but	new	themes	were	identified	later	in	the	trial	(for	example,	 the	 experiences	 of	 using	 the	 TiM	 system	 by	 patients	 who	 were	recently	diagnosed,	reactions	to	the	second	version	of	the	TiM	app)	and	so	interviews	continued	until	the	end	of	the	trial.				54	participant	 interviews	were	conducted.	36	patients	and	32	carers	were	interviewed	 at	 least	 once.	 Patients	 preferred	 to	 be	 interviewed	with	 their	carer	 but	 14	 patients	 and	 five	 carers	were	 interviewed	 alone.	 	 Interviews	were	 conducted	 at	 home	 apart	 from	 one	 conducted	 in	 a	 café	 (at	 the	participants’	 request).	 It	 was	 possible	 to	 involve	 all	 patients	 in	 the	interviews.	 	 Many	 used	 communication	 devices.	 	 Two	 patients	 who	 were	severely	disabled	took	a	passive	role	but	care	was	taken	to	check	that	they	were	 in	 agreement	with	 statements	made	 by	 the	 carer	 on	 their	 behalf	 by	asking	yes/no	questions	and	 they	were	offered	 the	opportunity	 to	 answer	questions	 by	 email	 (which	 they	 declined).	 A	 small	 number	 of	 interviews	were	conducted	by	telephone	(where	the	participants	lived	at	a	distance)	or	email	(where	participants	had	severe	dysarthria).		Semi-structure	interviews	were	conducted	with	the	Telehealth	Nurse	(based	at	 the	Sheffield	MND	clinic)	at	month	 four	and	month	14.	 	One	community	MND	nurse	was	interviewed	at	month	18.		Anonymised	 quotes	 from	 the	 interviews	 have	 been	 included	 in	 the	 thesis.		Patients	and	carers	are	identified	by	their	trial	number	e.g.	P111	(patient)	or	C111	 (carer).	 	 A	 summary	 of	 individual	 characteristics	 of	 each	 participant	(e.g.	age,	sex,	diagnosis)	is	not	reported	because	it	was	felt	that	reporting	all	these	characteristics	together	would	make	it	much	easier	for	participants	to	be	identified.			Whilst	participants	had	consented	to	this	possibility,	some	of	the	 issues	 identified	 were	 particularly	 sensitive	 (such	 as	 those	 discussing	carer	 roles	 or	 marital	 relationships).	 	 Instead,	 only	 relevant	 participant	characteristics	are	reported	in	the	text	to	provide	context	to	the	quote.	 	No	characteristics	 of	 the	 Community	 Nurse	 have	 been	 presented	 and	 any	reference	 to	 her	 place	 of	work	 has	 been	 removed.	 	 It	was	 not	 possible	 to	anonymise	the	Telehealth	Nurses’	comments	however	this	was	explained	to	her	during	the	consent	process	and	stated	on	the	consent	form.				 	
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Figure	5.1	The	qualitative	interviews	conducted	with	participants	during	the	each	stage	of	the	trial.	
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5.3	Participants’	experiences	of	the	current	MND	service		Patients’	and	carers’	experiences	of	the	current	MND	service	were	explored	using	 questionnaires	 at	 baseline,	 three,	 six,	 12	 and	 18	months	 and	 during	interviews.	 	 Figure	 5.2	 and	 5.3	 display	 the	 results	 of	 the	 questionnaires.			Most	patients	in	both	control	and	intervention	arms	were	very	satisfied	with	their	MND	care.		The	areas	in	which	some	patients	indicated	less	satisfaction	were	with	were	 their	 community	nurse,	with	knowing	enough	about	MND	and	the	speed	at	which	problems	are	solved.		The	same	pattern	was	seen	at	three	and	six	months.		Participants	remaining	in	the	trial	at	12	months	were	very	 satisfied	with	 their	 care.	 	Whilst	 no	 formal	 comparisons	were	made,	there	appeared	to	be	little	difference	between	the	treatment	groups.				At	 six	months,	 satisfaction	 amongst	 the	patients	using	 the	TiM	 system	did	appear	better	than	at	baseline.		However,	one	patient	using	the	TiM	system	still	 felt	 that	 his/her	 problems	 were	 not	 being	 solved	 quickly	 and	 three	“unsure”.	 	 	 One	 patient	 using	 the	 TiM	 system	 felt	 his/she	 did	 not	 know	enough	about	the	condition	and	four	were	unsure.			Carers	were	 in	general	 less	satisfied	with	the	MND	service.	 	At	baseline,	 in	total	13	(40%)	did	not	agree	that	they	were	in	close	contact	with	the	MND	team	or	 that	problems	with	MND	got	 solved	quickly.	 	However	 things	had	improved	at	six	months:	all	carers	knowing	whom	to	contact	with	problems.		At	 six	months,	 only	 one	 (9%)	 carer	 in	 the	 telehealth	 treatment	 group	 felt	that	 they	 did	 not	 receive	 help	 from	 the	 MND	 team,	 had	 their	 problems	solved	quickly	or	were	 involved	 in	decisions	about	care.	 	Whilst	no	 formal	comparisons	were	made,	satisfaction	 in	some	areas	appeared	better	 in	 the	telehealth	 arm,	particularly	 at	 six	months	with	only	 two	 (18%)	 carers	not	feeling	 in	 close	 contact	with	 the	MND	 team	 compared	 to	 six	 (40%)	 in	 the	control	arm.			
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Figure	5.2	Patient	experience	at	baseline,	three,	six	and	12	months	(Green:	agree/definitely,	grey:	unsure,	red:	disagree/definitely	
disagree). 	*	
	
	
																																																									
*	Patients	who	indicated	that	they	did	not	have	a	community	MND	nurse	were	excluded	from	analysis	of	this	question	
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Figure	5.3	Carer	experience	at	baseline,	three,	six	and	12	months	(Green:	agree/definitely,	grey:	unsure,	red:	disagree/definitely	
disagree).	
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5.3.1	Benefits	of	the	hospital	MND	clinic	Participants	were	also	asked	about	their	experiences	of	MND	care	during	the	interviews.		The	main	identified	benefits	of	the	hospital	MDT	and	the	clinic	were	similar	to	those	described	in	Chapter	One	as	vital	components	of	patient-centred	care:	continuity	and	coordination	of	care,	regular	contact	with	specialist	and	trusted	professionals	and	the	medical	and	emotional	care	and	involvement	of	patients,	family	and	carers	(Figure	5.4,	Appendix	A5.1	and	A5.2).		
“Everyone	involved	with	my	MND	care	has	been	first	class.	 	It	is	everything	we	could	
ask	 for	and	more.	Royal	Hallamshire	Hospital	Sheffield,	NHS	Neurological	Outreach	
team,	 OT,	 community	 nurse,	 PEG	 nurse,	 dietician,	 speech	 therapist,	 local	 GP.”	 P229	
baseline		Figure	5.4	The	benefits	of	the	hospital	MND	clinic	reported	by	participants.															Patients	 felt	 that	 the	hospital	multidisciplinary	 team	(MDT)	 took	an	active	and	 positive	 approach	 to	 managing	 their	 care	 and	 had	 a	 “global”	 role	coordinating	 the	different	healthcare	professionals.	 	Patients	also	reported	that	 the	hospital	MDT	 referred	 them	without	delay	 to	 the	 correct	 services	meaning	their	needs	were	quickly	addressed.		The	interaction	with	the	MND	nurse	 either	 at	 clinic	 or	 through	 the	 MND	 telephone	 helpline	 was	particularly	valuable:		
“Q:	If	you	did	have	a	problem,	how	would	you	go	about	sorting	it?	
P:	I	think	I’d	ring	[Hospital	MND	nurse].		
Q:	You’d	ring	[Hospital	MND	nurse]?	What’s	your	experience	of	ringing	[her]?		
P:	Oh,	I	love	her!		
Q:	What	is	it	you	find	helpful?		
P:	Friendly	and	helpful.		
C:	Yes.	She’s	quite	informal	about	things.		
P:	I	think	I	could	ring	her	anytime.”	P217	
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Participants	 explained	 that	 the	 hospital	 MND	 nurse	 was	 knowledgeable,	approachable,	 accessible	 and	 always	 available	 should	 they	 have	 problems	and	 found	 that	 the	 nurse	 resolved	 them	 quickly.	 	 As	 they	 met	 the	 nurse	regularly	 in	clinic,	participants	developed	a	good	relationship	and	she	was	often	 their	 first	 point	 of	 contact,	 as	 well	 as	 a	 reassuring	 back	 up	 to	 the	community	 team.	 	She	was	also	an	 important	contact	point	 for	carers	who	would	phone	her	about	many	issues	(even	those	unrelated	to	MND)	and	felt	very	reassured	by	her	advice.		The	psychological	benefits	of	attending	clinic	were	also	highlighted:	participants	valued	being	able	to	talk	to	experts	who	offered	 hope,	 understanding	 and	 empathy.	 	 A	 common	 theme	 was	 the	importance	of	speaking	to	staff	with	a	positive	attitude	towards	the	disease.		This	attitude	was	transferred	to	the	patients	and	gave	them	a	psychological	
“boost”.	 	This	was	often	in	contrast	to	non-specialists,	who	participants	felt	could	appear	negative	or	unfamiliar	with	the	disease.		
	“I	didn't	find	them	gloom	merchants,	they	were	very	positive	in	their	approach	and	in	
their	opinions	and	their	comments.”	C229		Regular	monitoring	of	patients’	progress	was	also	an	important	aspect	of	the	MND	clinic.	 	Faced	with	an	uncertain	prognosis,	patients	were	very	keen	to	know	 how	 they	 were	 progressing.	 	 Physical	 monitoring,	 particularly	respiratory	 testing	 gave	 them	 an	 objective	measure	 of	 their	 progress.	 	 	 If	their	 progress	was	 slow,	 patients	 felt	 positive	 and	 reassured.	 	However,	 if	things	 had	 changed,	 the	 patients	were	 pleased	 that	 the	monitoring	would	allow	the	team	to	pre-empt	problems	and	intervene	early.	
5.3.2	Problems	with	hospital	MND	clinic	The	main	 problem	with	 the	 hospital	 clinic	 was	 the	 difficulty	 travelling	 to	clinic,	 although	 the	 clinic	 organisation	 also	 posed	 problems	 (Figure	 5.5,	Appendix	A5.3-5.5).		Finally,	there	was	a	sense	of	frustration	that,	given	the	lack	of	effective	treatments,	the	clinic	made	no	difference	to	their	condition.		Figure	5.5	The	problems	with	the	hospital	clinic	reported	by	participants.																 	
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Difficulty	 travelling	 to	 hospital	was	 the	main	 reason	 patients	 had	 stopped	attending	clinic.			
	
“Q:	Was	there	anything	you’d	change?	
C:	Move	the	hospital	somewhere	more	accessible!	It’s	a	nightmare	getting	in	and	out	
of	Sheffield.”	P172		Attending	 an	 appointment	 could	 often	 involve	 an	 entire	 day	 away	 from	home	 with	 long,	 expensive	 journeys	 as	 well	 as	 long	 waits	 in	 clinic.	 	 The	hospital	 location	 was	 unfamiliar	 to	 most	 and	 parking	 was	 also	 a	 major	problem.		A	day	out	at	clinic	could	be	physically	tiring:	one	patient	felt	tired	for	days	after	the	clinic.		This	became	more	of	a	problem	as	patients	became	more	disabled	 and	 found	 activities	 of	 daily	 living	much	harder.	 	However,	along	with	the	stress	of	travelling,	participants	found	clinic	was	emotionally	tiring	due	 to	 the	anxieties	associated	with	 the	disease	as	well	as	 impact	of	seeing	others	in	the	later	stages	of	the	disease.			
	
“We	 always	 feel	 a	 bit	 shattered	 by	 the	 time	we	 get	 back	 trying	 to	 hold	 everything	
going.”	C318		There	were	also	problems	with	the	fixed	appointment	schedule,	which	could	be	unresponsive	to	the	patients’	needs.		The	clinics	were	also	busy	and	some	patients	felt	rushed	or	lacked	privacy,	although	despite	this,	participants	did	think	 they	 had	 the	 opportunity	 to	 talk	 to	 the	 MND	 team	 about	 their	problems.				A	number	of	participants	felt	that	the	MND	clinic	offered	them	few	benefits.		They	felt	frustrated	that	the	clinic	was	unlikely	to	provide	them	with	a	“cure”	and	 a	 number	 expressed	 the	 feeling	 that	 the	 clinic	was	 simply	measuring	their	physical	decline	(of	which	they	were	already	acutely	aware	themselves	without	needing	additional	assessments).					
“All	you’re	doing	currently	is	monitoring	my	progress,	so	at	the	minute	I’ve	really	got	
nothing	out	of	the	clinic.”	P318		One	 patient	 felt	 strongly	 that	 the	 clinic	 offered	 insufficient	 psychological	support	 and	had	 to	 seek	 this	 elsewhere.	 	Participants	also	 identified	other	areas	 of	 need	 including	 the	 availability	 of	 complementary	 therapies	(physiotherapy,	 hydrotherapy)	 and	 more	 timely	 access	 to	 wheelchair	services.		Carers	did	value	attending	the	clinic,	particularly	to	meet	the	MND	nurse	but	most	felt	the	focus	of	the	clinic	was	on	the	patient,	not	on	carers.						 	
	 106	
5.3.3	Benefits	of	the	community	team	The	 community	 teams	 provided	 both	 practical	 and	 emotional	 care	 to	participants	as	well	as	care-coordination	and	liaison	with	other	members	of	the	MDT	 (Figure	 5.6,	 Appendix	 A5.7	 and	 A5.8).	 	 Participants	 felt	 satisfied	when	the	community	teams	liaised	with	other	healthcare	professionals	such	as	 the	 hospital	 team	 and	 their	 GP,	 meaning	 the	 help	 offered	 by	 the	community	team	was	complementary	to	that	offered	by	the	hospital.				
“My	community	team	visit	every	month.	This	comprises	of	a	community	nurse	and	a	
Senior	 OT.	 They	 have	 sorted	 me	 out	 with	 a	 wheelchair	 and	 have	 started	 the	 ball	
rolling	with	MNDA	for	funding	with	a	wet	room,	a	bio	bidet	and	a	rollator.	They	have	
also	organised	me	visits	to	the	hospice	for	occupational	therapies.”	P229	
	Home	 visits	 were	 not	 just	 convenient,	 but	 they	 also	 provided	 the	opportunity	 to	assess	 the	home	environment	and	physical	problems	 (such	as	 pressure	 sores)	 in	 the	 later	 stages	 of	 the	 disease.	 	 Many	 participants	enjoyed	 receiving	 community	 therapy	 sessions,	 tailored	 around	 their	lifestyle	which	made	them	feel	more	positive,	improved	their	quality	of	life	but	 also	 promoted	 self-efficacy	 by	 providing	 them	 with	 information	 and	encouragement	 to	 confidently	 deal	 with	 what	 were	 often	 challenging	problems.		Figure	5.6	Benefits	of	community	MDT.	
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5.3.4	Problems	with	community	care	The	difficulties	of	community	care	mainly	occurred	due	to	a	lack	of	coordination	of	care	and	a	lack	of	specialist	staff	(Figure	5.7,	Appendix	A5.9	and	A5.10).					 Figure	5.7	Poor	experiences	of	community	care.												Often	 multiple	 healthcare	 professionals	 were	 involved	 and	 participants	were	 not	 always	 certain	 of	 their	 role	 or	 when	 they	 should	 be	 contacted.		Some	participants	 found	 that	 a	 sudden	 influx	 of	 professionals	 at	 the	 same	time,	who	wanted	to	deal	with	sensitive	issues,	could	be	very	overwhelming	or	upsetting.		
“	When	you	are	first	diagnosed	you	are	emotional...	But	once	you	are	diagnosed	
everything	happens:	OT,	physio,	dietician,	all	at	once.	It’s	nice	because	it	feels	like	you	
are	being	looked	after.	But	on	the	other	side	they	were	talking	about	things	I	wasn’t	
really	aware	of	and	asking	me	questions	too	early	to	ask.”	P172		Some	patients	identified	a	main	point	of	contact	in	the	community	who	could	advocate	and	coordinate	their	care.		This	could	be	a	GP,	community	nurse	or	therapist.		However,	others	had	not	developed	such	a	strong	relationship	with	one	person	when	multiple	staff	were	involved,	who	could	change	as	the	patients’	needs	changed.		Some	patients	found	that	staff	did	not	understand	the	condition	or	failed	to	communicate	with	each	other:	one	patient	(P091)	had	to	live	upstairs	whilst	waiting	to	get	a	stair	lift	fitted.		He	had	already	been	assessed	by	four	different	occupational	therapists.				
“Q:	You	told	me	a	bit	about	the	difficulties	you’ve	had	getting	your	stair	lift.		
P:	Well	yeah,	because	that’s	outta	your	hands	because	it’s	controlled	by	government	
bodies,	it’s	not	controlled	by	you...They’ve	gone	through	four	different	OTs	to	get	the	
same	results.		
C:	Basically	they	should	go	out	with	a	dedicated	MND	team...”	P091		Whilst	the	core	community	team	was	usually	felt	to	be	very	expert,	participants	thoughts	that	some	members	of	the	extended	team	were	unfamiliar	with	MND,	or	lacked	the	skills	or	positive	attitudes	towards	the	condition	that	patients	and	carers	hoped	for.		Patients	found	contact	with	
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therapists	and	nurses	helpful	and	reassuring	but	once	the	problem	had	been	resolved	they	might	be	discharged	from	therapy.		This	made	both	the	carer	and	patient	anxious	and	could	make	it	difficult	or	cause	delays	accessing	the	services	when	a	new	problem	was	encountered.					
“	Well	C’s	been	on	at	me	for	a	while	to	see	physio	again,	I	haven’t	seen	anybody	since	
December,	which	is	down	to	me	...	it’s	not	down	to	them,	they	just	said	give	us	a	ring	
when	you	need	us.	So	I	rang	up	...	the	lady	said	“Well	you	have	to	be	referred	through	
your	doctor.”	I	said	“Well	I’ve	never	had	to	do	that	before”		She	said	“Well	no,	it’s	
changed	now,	you	have	to	be	referred	back	through	your	doctor.””	P145	
5.3.5	Experiences	of	general	practitioners	Participants’	experiences	of	their	GP	were	extremely	variable	(Figure	5.8	Appendix	A5.11	and	A5.12).				Figure	5.8	The	good	and	poor	experiences	of	GP	care.				
	
	
	
	
	
					Some	had	very	good	experiences	of	their	GP,	who	they	felt	took	an	interest	in	the	condition	and	their	family,	might	have	some	knowledge	of	MND	and	would	arrange	to	see	patients	regularly,	even	when	they	were	well.		Where	patients	saw	their	GP	regularly	they	could	become	the	patients’	main	point	of	contact.				
“The	previous	one	was	a	fantastic	GP	and	he	had	a	little	bit	of	knowledge	about	the	
disease...	he	kept	saying	I’ll	see	you	in	three	months,	just	to	keep,	see	how	you’re	
doing.”	P056		Some	knew	they	could	get	priority	access	to	GP	appointments,	which	made	them	feel	reassured	that	they	would	be	able	to	access	help	if	they	became	unwell.			In	contrast,	some	patients	thought	their	GP	showed	no	interest	in	or	knowledge	of	their	condition.		A	number	had	never	attended	an	appointment	to	discuss	the	diagnosis.		It	was	common	for	patients	to	not	know	their	GP	prior	to	the	diagnosis	because	they	had	previously	been	well.		Now,	they	explained	that	they	did	not	feel	ill	and	did	not	have	a	particular	
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reason	to	book	an	appointment	meaning	they	rarely	saw	their	GP.		One	patient	(P184)	contrasted	this	to	his	diabetes,	where	he	knew	he	was	expected	to	attend	regularly	for	check-ups.		Access	to	appointments	was	a	problem.			Patients	expected	that	MND	would	mean	they	would	be	prioritised	but	some	did	not	want	to	book	appointments	for	fear	of	not	bothering	GPs	who	they	thought	would	be	already	busy.		As	a	result	of	these	experiences,	patients	and	carers	worried	because	they	knew	that	as	they	became	more	unwell	they	would	be	relying	on	their	GP	for	support.		
“Never	ever	had	contact	in	all	the	two	years	he’s	been	diagnosed.	So	you’ve	got	no	
confidence.	Eventually	I	know	that	we	both	are	going	to	be	reliant	on	our	GP	at	some	
stage.	We	are	going	to	need	our	GP,	aren’t	we?	And	we’ve	no	confidence	at	this	
moment	in	time”	C184			
5.3.6	Importance	of	regular	contact		A	recurring	theme	was	the	value	of	regular	meetings	with	specialist	teams	at	the	hospital	and	in	the	community.		The	two	main	benefits	of	this	were	felt	to	be	the	continuity	and	contact	with	experts,	and	the	monitoring	provided	in	the	hospital	clinic	(Figure	5.9,	Appendix	A5.13).				Figure	5.9	The	benefits	of	regular	clinic	visits.																Participants	 were	 happy	 that	 the	 hospital	 clinic	 scheduled	 regular	 visits,	meaning	 they	 had	 had	 regular	 opportunities	 to	 access	 help.	 	 This	 was	particularly	 important	 because	many	 patients	were	 reluctant	 to	 seek	 help	and	 this	 provided	 an	 opportunity	 for	 problems	 to	 be	 identified	 or	anticipated.	 	Regular	meetings	also	meant	participants	could	keep	in	touch	and	develop	a	good	relationship	with	trusted	specialists	in	the	MDT.				Whilst	 they	 received	 good	 care	 in	 clinic,	 a	 number	 of	 patients	 found	 that	they	faced	difficulties	between	hospital	appointments	and	were	unsure	how	to	address	these	problems.			
“I	know	when	I	come	down	to	Sheffield	I	can	get	...to	know	anything	I	want	basically	
and,	they’ve	been	fantastic.	...It’s	just	that	time	between…[clinics]”	P056	
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	Whilst	many	 patients	 felt	 happy	 to	 contact	 the	MND	 team	 between	 visits,	those	who	were	recently	diagnosis	or	who	did	not	attend	regularly	had	not	built	 a	 strong	 relationship	 with	 the	 MND	 nurse	 meaning	 they	 were	 less	confident	 in	 seeking	 telephone	 support	 from	her	 between	 visits.	 This	was	particularly	 important	when	patients	were	not	receiving	 frequent	visits	by	the	 community	 teams,	 either	 because	 they	 did	 not	 have	 many	 active	problems	 that	 required	 therapy,	 or	 because	 they	 had	 declined	 regular	contact.		For	them,	the	clinic	provided	a	reliable	“backup”.		
“I	 just	 think	 when	 P	 was	 diagnosed	 that	 everybody	 came	 to	 see	 us	 and	 then	
everybody’s	left	us,	apart	from	the	clinic...	at	first	I	found	it	a	bit	strange	that	we	were	
just	left	to	get	on	with	things..”	C145					In	 the	 time	 immediately	 following	 diagnosis,	 participants	 needed	information	and	psychological	support	to	deal	with	the	diagnosis.		The	gaps	between	clinics	meant	they	did	feel	unsupported,	uncertain	and	alone.	One	patient	explained:	
	
“I	could	have	camped	in	[MND	Consultant]'s	house	for	the	first	six	months,	just	so	she	
was	 there,	 so	 I	 could	 say:	 but	 what	 about	 this?	 What	 about	 that?	 You	 imagine	
symptoms,	or	I	did,	you	think:	God,	this	is	happening	and	that	must	be	related	to	the	
MND...	and	what	does	this	mean?		I	settled	down,	at	some	point...to	pretty	much	know	
what's	MND	related	and	what's	not.”	P047		Some	community	teams	were	also	proactive	in	arranging	regular	visits	and	it	seemed	that	these	visits	increased	in	frequency	at	times	of	need	(such	as	immediately	after	diagnosis	or	when	a	patient	developed	new	problems).		In	these	 cases	 it	 appeared	 the	 patients	 developed	 good	 relationships,	 they	could	easily	report	problems	and	tended	to	call	on	them	for	support	much	more	 than	 those	 without	 such	 regular	 contact.	 	 It	 was	 also	 common	 for	community	teams	not	to	arrange	a	regular	schedule,	rather	to	suggest	that	the	 patient	 initiated	 contact	 if	 they	 thought	 they	 needed	 it.	 	 In	 addition,	other	 professionals	 outside	 the	 core	 MDT	 (e.g.	 district	 nurses,	physiotherapists)	 would	 work	 with	 a	 patient	 for	 a	 short	 period	 before	discharging	them	meaning	patients	could	find	it	difficult	to	get	further	help	if	they	encountered	a	new	problem.		 	This	meant	that,	if	the	patient	had	no	current	practical	 need	 (e.g.	 for	new	equipment	 for	 therapy),	 he/she	might	not	have	much	contact	with	services.		
“Because	it’s	slow	with	P	and	he	doesn’t	need	as	much	attention	and	care,	it’s	easy	to	
feel	detached	from	any	positive	interaction.”	C122		Expecting	the	patient	to	contact	the	team	if	needed	was	acceptable	for	some	patients,	particularly	those	who	wanted	to	control	their	own	care.		Some	felt	empowered	to	contact	 the	MDT	if	 they	had	a	problem.	 	 	Many	participants	were	reticent	to	request	additional	support	either	because	of	denial,	for	fear	of	admitting	they	were	not	coping	or	as	a	way	to	cope	by	trying	to	maintain	normality.	 	 Some	 were	 not	 aware	 of	 whom	 to	 turn	 to,	 or	 what	 help	 was	available.	 	 This	 meant	 that	 there	 could	 be	 a	 delay	 in	 identifying	 new	
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problems	 (particularly	 emotional	 needs).	 	 This	 could	 put	 additional	 strain	on	 the	 family	 on	 whom	 much	 of	 the	 caring	 responsibilities	 fell	 and	 who	often	recognised	the	need	for	additional	help	before	the	patient.		
5.3.7	Information	needs		At	diagnosis,	most	patients	lacked	any	knowledge	of	MND	or	of	the	support	services	available	(Figure	5.10,	Appendix	A5.14	–A5.16).		If	they	were	aware	of	MND	it	was	usually	framed	very	negatively.		After	diagnosis,	many	patients	had	a	need	for	immediate	information,	usually	about	practical	issues	such	as	financial	support	and	found	the	information	available	could	be	very	complex.		However,	there	was	often	a	gap	of	weeks	between	the	first	clinic	visit	and	later	appointments	during	which	these	period,	these	needs	were	not	met.			Participants	were	asked	about	how	they	found	out	about	MND.			Information	from	healthcare	professionals	was	the	most	highly	valued.		Some	patients	found	it	empowering	and	helpful	to	seek	out	information	and	peer	support	and	most	used	the	internet	at	some	point.		Most	limited	themselves	to	learning	about	specific	questions	but	some	aimed	to	seek	out	as	much	information	as	possible.		Others	found	it	more	difficult,	feeling	overwhelmed,	upset	or	in	denial	and	explained	that	they	had	to	“desensitise”	themselves	prior	to	learning	more.			A	few	patients	found	the	information	distressing,	particularly	regarding	life	expectancy	whilst	some	patients	recalled	clinicians	telling	them	to	avoid	using	the	internet	but	this	meant	they	delayed	accessing	information	when	they	needed	it.		
“P:	When	we	went	to	see	...[MND	consultant]	a	couple	of	months	later	and	she	said,	
don’t	go	looking	on	the	internet	any	more...and	that	was	fine	but	when	you’re	on	your	
own,	in	the	first	stages	that	is	what	you	do.”	P380	
	Figure	5.10	Participants’	approaches	to	information.			
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5.3.8	Summary	This	 data	 suggests	 that	 the	 hospital	 MND	 clinic	 offers	 regular,	 specialist	holistic	care	and	the	opportunity	for	patients	and	carers	to	develop	valuable	relationships	 with	 trusted	 experts.	 	 These	 services	 are	 available	 to	 all	patients	as	long	as	they	are	able	to	travel.		Regular	monitoring	identifies	and	pre-empts	 problems	 and	 is	 also	 valuable	 for	 the	 patients’	 psychological	wellbeing.	 	 Some	patients	have	developed	a	 good	and	 trusted	 relationship	with	 a	 healthcare	 professional	 in	 the	 community.	 	 The	 main	 contact	 was	usually	 a	 community	 nurse	 although	 other	 healthcare	 professionals	 could	play	an	important	role	making	patients	feel	reassured	that	their	holistic	care	needs	would	continue	to	be	met,	even	if	clinic	becomes	less	accessible.			This	data	highlights	 the	unmet	needs	associated	with	 lack	of	access	 to	 the	right	care,	 at	 the	 right	 time.	 	 Attending	 clinic	 can	 be	 a	 major	 burden	 meaning	many	patients	struggle	to	attend	and	 lose	their	relationship	with	the	MDT,	particularly	with	 the	MND	nurse.	 	 Between	 clinics,	 or	 later	 in	 the	 disease,	lack	of	access	to	the	hospital	clinic	means	patients	and	carers	cannot	always	access	 the	 services	 they	need	 and	do	not	 always	 have	 confidence	 that	 the	community	 teams	 can	 offer	 the	 same	 level	 of	 expertise.	 	 Some	manage	 to	access	 specialists	 in	 the	 community	or	 can	maintain	 communications	with	the	hospital	 team	and	 can	 seek	help	 at	 appropriate	 times.	 	Others	 are	not	able	 to	 access	 this	 level	 of	 care.	 	 As	 a	 result,	 patients	 and	 carers	 are	 not	receiving	 the	physical	care	and	emotional	support	 they	need	which	causes	distress	and	potentially	poorer	clinical	outcomes.			In	these	patients,	a	more	coordinated,	consistent	service	would	be	welcomed	by	patients	and	carers.			 	
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5.4	Delivering	the	TiM	service		The	next	sections	described	how	the	TiM	system	was	set	up	and	used	during	the	 trial.	 	 Section	 5.4.1	what	 occurred	 during	 the	 set	 up	 stage	 of	 the	 TiM	system,	 the	 problems	 encountered	 and	 the	 solutions	 found.	 	 Section	 5.4.2	reports	how	frequently	the	TiM	system	was	used	by	patients	and	carers	and	also	how	often	they	thought	they	should	be	using	the	TiM.		Section	5.4.3	uses	the	 interview	 data	 to	 describe	 the	 reasons	 identified	which	might	 explain		the	observed	adherence	that	were	identified.	
5.4.1	Delivering	the	TiM	service	All	 participants	 randomised	 to	 the	 intervention	 group	 received	 the	 TiM	system	 and	 completed	 at	 least	 one	 session	 within	 two	 weeks	 of	 training.		Training	 gave	 participants	 the	 opportunity	 to	 ask	 questions	 and	 queries	were	easily	resolved.			The	 technical	 problems	 encountered	 during	 the	 trial	 and	 suggested	solutions	are	summarised	in	Table	5.6	and	Table	5.7.		When	problems	with	the	 app	 or	 tablet	 device	 were	 encountered,	 in	 most	 cases	 they	 could	 be	resolved	with	telephone	or	face-to-face	support.		The	most	 common	 reasons	 for	 the	 TiM	 system	 failing	 to	 transmit	 results	occurred	when	the	patient	had	provided	date	but	it	had	not	being	uploaded	to	the	internet.	 It	was	not	possible	for	the	nurse	to	determine	whether	the	patient	was	just	not	using	the	TiM	or	whether	there	was	a	technical	problem	and	 finding	 and	 resolving	 this	 problem	 usually	 required	 a	 visit	 to	 the	patient’s	home.		These	problems	were	not	due	to	the	TiM	software	but	due	to	the	connection	between	the	tablet/weighing	scales	and	the	internet.			On	two	occasions,	the	patients	had	accidently	switched	off	the	tablet’s	Wi-Fi.		It	also	 occurred	 when	 using	 the	 tablet	 to	 connect	 the	 weight	 scales	 to	 the	internet	as	this	quickly	drained	the	batteries	of	both	devices.	 	To	solve	this	problem,	the	weighing	scales	were	connected	directly	to	the	patient’s	home	broadband.	 	For	 the	 two	patients	who	did	not	have	broadband,	a	 separate	device	 (“Mifi”)	was	provided	which	acted	as	 a	3G	wireless	 router	 for	both	the	tablet	and	scales.		This	worked	well	but	for	both	solutions	the	process	of	connection	was	not	straightforward	and	 it	 required	a	home	visit.	 	Weights	were	often	missed	and	it	was	concluded	that	the	equipment	used	was	not	a	feasible	 way	 to	 record	 weight.	 	 A	 more	 straightforward	 solution	 would	involve	simply	using	a	normal	set	of	scales	and	asking	the	patients	to	record	their	weight	on	the	Patient	App.		
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Table	5.6	Technology	problems	encountered	during	the	trial.		Some	of	these	problems	are	described	further	in	Sections	5.7	and	5.14.		It	
also	describes	the	solutions	adopted,	the	impact	these	problems	had	on	TiM	system	use	and	recommendations	for	the	future	TiM	use.				
	
	
Problem
	
Solution	adopted	
Im
pact	on	the	use	of	the	TiM
	
R
ecom
m
endations	for	future	
TiM
	app	
Poor	finger	dexterity	
(sections	5.7.2.3	and	
5.7.2.6)	
Handheld	stylus	provided	
to	all	patients	
85%	could	use	the	TiM	
independently.	
Provide	stylus	to	all	patients.	
Carer	help	to	use	device	Interview	data	suggested	that	help	
from	carers	was	acceptable.	
Encourage	carer	support.	
Login	page	not	intuitive	Telephone	support		
Problem	resolved	with	second	TiM	
app	release	
Provide	face-to-face	training.	
Provide	telephone	technical	support.	
Login	page	redesigned	No	further	problems	reported.	
Make	local	staff	familiar	with	the	software.	
Lack	of	confidence	
using	the	app	or	other	
features	on	the	TiM	
(Section	5.5)	
Face	to	face	training	
Partner/family	helped	
None:	all	participants	could	use	the	
app	
Provide	face-to-face	training	plus	an	additional	
contact	after	a	few	weeks	to	reinforce	learning.	
Identify	users	with	low	confidence/experience	
and	provide	additional	training	
Patients	not	giving	
correct	
answers	
(Section	5.7.4)	
Patient	completing	TiM	
with	their	family	
Uncertain	impact		
A	short	capacity	assessment	at	recruitment.	
Observe	patients	using	TiM	during	training	
Check	TiM	answers	in	clinic.	
Sam
sung	galaxy	tablet	
Tablet	stored	in	place	
not	accessible	to	patient	 No	solution	available.	
Interviews	suggested	that	adherence	
was	reduced	for	two	patients.	
Use	patients’	own	equipment	where	possible.	
Tablet	battery	drained,	
unable	to	switch	on	
Telephone	advice:	fully	
charge	using	correct	
equipment.	
No	impact.	
Use	patients’	own	equipment.	Ensure	local	staff	
are	familiar	with	hardware.	
Unexpected	screens/	
software	updates		
Telephone	advice.	
Reduced	patient	confidence	in	tablet	
but	no	impact	on	use,	
Use	patients’	own	equipment.		Use	a	basic	
tablet	that	only	displays	the	TiM	app.	
User	fear	of	“breaking”	
the	tablet	
Face	to	face	training	to	
improve	user	confidence	 Patients/carers	reluctant	to	use	the	
additional	features	on	the	tablet		
Use	patients’	own	equipment.	
Face	to	face	training.	
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Table	5.7	Further	descriptions	of	the	problems	encountered	with	the	TiM	system.	
	
Problem	
Solution	adopted	
Im
pact	on	the	use	of	the	TiM
	
system	
R
ecom
m
endations	for	future	
Internet	connection	
Poor	3G	phone	signal	Used	patients’	own	
broadband.	
Check	TiM	connection	
works	at	patients’	home.	 No	impact:	internet	connection	
solution	found	for	all	patients	
using	either	3G	or	patients’	own	
broadband.	
Use	patients’	own	broadband.		Check	internet	
availability	prior	to	TiM	enrolment.	
Staff	setting	up	TiM	need	to	have	internet	
access	at	the	patients’	home	to	access	clinical	
portal.	
Wi-fi	on	tablet	switched	
off		
Home	visit	required.	
Several	TiM	sessions	failed	to	
download.	
Monitor	adherence	and	alert	the	clinician	if	
adherence	is	low.		App	alert	if	no	internet	
connection	is	available.			
W
eight/balance	scales		
	
	
Unreliable	connection	
between	scales	and	
tablet	
A	separate	3G	Wi-Fi	route	
provided	(“Mifi”).	
Additional	home	visits	required	
and	loss	of	weight	data	for	
several	weeks.	
Manual	entry	for	weight.	Avoid	using	
additional	peripheral	devices	wherever	
possible.	
Unreliable	connection	
between	scales	and	
patients’	
home	
broadband.	
This	problem	remained	
unsolved.	
Additional	home	visits	required	
and	loss	of	weight	data	for	
several	weeks.	
Manual	entry	for	weight.	Avoid	using	
additional	peripheral	devices	wherever	
possible.	
Clinician	portal	
Password/login	
problems	
Password	
support	
provided	from	Carematix	
team	in	Chicago.	
Delayed	access	clinical	portal	
during	clinic.	
Local	systems	access	support.	
Integrate	portal/password	into	systems	
already	used	in	the	hospital.		
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5.4.2	Participant	TiM	system	adherence	
5.4.2.1	Patient	and	carer	adherence	to	weekly	TiM	sessions	Participant	 adherence	 was	 calculated	 based	 on	 the	 number	 of	 sessions	completed	over	the	course	of	the	trial6	and	described	as:	
• “High”	adherence:	>	75%	of	weekly	sessions	completed		
o 40%	of	patients	
o 33%	of	carers	
• “Medium”	adherence:	50-75%	of	weekly	sessions	completed		
o 30%	of	patients	
o 22%	of	carers	
• “Low”	adherence:	<50%	of	weekly	sessions	completed		
o 30%	of	patients	
o 44%	of	carers		Table	5.8	and	5.9	describe	the	level	of	adherence	to	TiM	sessions	at	different	points	 throughout	 the	 trial	 and	 Figures	 5.11	 and	 5.12	 displays	 each	individual’s	use	of	the	TiM	during	the	whole	trial.	 	Following	completion	of	the	 TiM	 study,	 the	 Telehealth	 Nurse	 was	 asked	 how	 often	 she	 felt	participants	needed	to	answer	the	questions	to	provide	a	useful	assessment	of	 the	 their	 progress.	 	 She	 felt	 that	 if	 patients	 completed	 the	 TiM	 once	 a	fortnight	this	would	give	her	sufficient	 information	(approximately	50%	of	the	 weekly	 sessions	 completed).	 	 This	 means	 over	 70%	 of	 patients	 who	sustained	 “medium”	 or	 “high”	 adherence	 throughout	 the	 trial	 were	providing	sufficient	data.		These	users	continued	to	use	the	system	regularly	throughout	the	trial.			Usage	tailed	off	later	in	the	trial,	particularly	amongst	the	less	frequent	users	or	 those	nearing	the	end	of	 their	 lives.	 	Some	patients	completed	 less	 than	50%	 of	 the	weekly	 sessions	 but	 continued	 to	 send	 in	 data	 regularly.	 	 For	example,	 P317	missed	 sessions	when	 she	was	 on	 holiday	 but	 also,	 as	 her	disease	 was	 progressive	 slowly	 chose	 to	 use	 the	 TiM	 less	 frequently.		Despite	this	she	continued	to	provide	data	regularly	throughout	the	trial.		Adherence	by	carers	was	not	as	high	as	the	patients	but	over	half	of	carers	continued	 to	 complete	 at	 least	 50%	 of	 weekly	 sessions.	 	 Many	 of	 those	completing	 sessions	 less	 frequently	 still	 continued	 to	 use	 the	 TIM	 system	every	few	weeks.		The	nurse	felt	carers	did	not	need	to	provide	information	so	frequently	as	patients	and	carers	providing	information	every	few	weeks	was	usually	sufficient	to	keep	her	up-to-date	with	their	progress.			Similar	to	the	 patients,	 frequent	 users	 continued	 to	 use	 the	 system	 regularly	throughout	 the	 trial.	 	Usage	 tailed	off	 later	 in	 the	 trial	 in	 the	 less	 frequent	users.		
																																																								6	The	system	did	allow	patients	to	complete	multiple	sessions	per	week	but	only	two	patients	completed,	on	average,	more	than	one	session	per	week.	
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Table	5.8	Patient	adherence	to	weekly	TiM	sessions	overall	and	at	different	points	during	the	trial.		
Adherence	
to	TiM	
Total	 0-4		
weeks	
0-12	
weeks	
12-24	
weeks	
24-36	
weeks	
36-48	
weeks	
48-60	
weeks	
60-72	
weeks		 n=20	 n=20	 n=19	 n=16	 n=11	 n=10	 n=5	 n=2	
Mean	 65%	 91%	 76%	 72%	 72%	 63%	 73%	 46%	Minimum	 13%	 50%	 33%	 17%	 33%	 8%	 25%	 0%	Maximum	 104%	 100%	 108%	 108%	 100%	 100%	 100%	 92%	SD	 28%	 20%	 24%	 30%	 32%	 32%	 28%	 65%	Patients	completing	>75%	of	sessions	
40%	 90%	 50%	 53%	 67%	 55%	 80%	 50%	
Patients	
completing	
>50%	of	
sessions	
70%	
	
100%	 75%	 80%	 78%	 73%	 80%	 50%	
			Table	5.9	Carer	 adherence	 to	weekly	TiM	 sessions	overall	 and	at	different	points	during	the	trial.		
			 	
Adherence	
to	TiM	
Total	 0-4	
weeks	
0-12	
weeks	
12-24	
weeks	
24-36	
weeks	
36-48	
weeks	
48-60	
weeks	
60-72	
weeks		 n=18	 n=18	 n=17	 n=14	 n=11	 n=9	 n=4	 n=2	
Mean	 57%	 83%	 67%	 67%	 53%	 54%	 46%	 4%	Minimum	 12%	 25%	 25%	 8%	 17%	 0%	 0%	 0%	Maximum	 95%	 125%	 100%	 100%	 100%	 100%	 92%	 8%	SD	 29%	 29%	 24%	 33%	 33%	 39%	 48%	 6%	Carers	completing	>75%	of	sessions	
39%	 78%	 47%	 57%	 67%	 44%	 50%	 0%	
Carers	
completing	
>50%	of	
sessions	
56%	 82%	 75%	 71%	 55%	 44%	 50%	 8%	
Carers	completing	>33%	of	sessions	
72%	 94%	 82%	 79%	 54%	 67%	 50%	 0%	
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Figure	5.11	A	visual	representation	of	individual	patient	adherence	over	the	duration	of	the	trial.		Each	black	dot	on	the	figure	
represents	a	completed	session.		Each	coloured	dot	indicates	the	end	of	follow-up.	
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Figure	5.12	A	visual	representation	of	individual	carer	adherence	over	the	duration	of	the	trial.		Each	coloured	dot	indicates	the	end	of	
follow-up.	
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5.4.2.2	Patient	and	carer	preferences	for	the	frequency	of	TiM	system	
sessions		Figure	 5.13	 shows	 that	 most	 participants	 preferred	 to	 complete	 the	 TiM	weekly,	although	some,	particularly	carers,	preferring	the	complete	the	TiM	less	often.	 	The	results	at	three	and	12	months	are	available	in	Appendix	A	Table	5.1.	 	The	 interviews	suggested	that	weekly	sessions	were	acceptable	to	participants	and	presented	little	burden.		Weekly	sessions	also	promoted	adherence	 by	 becoming	 part	 of	 their	 weekly	 routine	 (Appendix	 A5.17).		Some	 participants	 (particularly	 those	 with	 slowly	 progressive	 disease)	preferred	 to	 use	 the	 TiM	 less	 often	 and	 some	 felt	 they	 might	 vary	 the	frequency	depending	 the	progress	of	 their	disease	 (although	 there	was	no	facility	to	allow	this	on	the	current	version	of	the	app)	such	as	this	patient	who	was	a	high	TiM	user:	
	
“Q:	How	often	do	you	think	you’d	need	to	do	it	to	make	it	worthwhile…?	
P:	Probably	every	month.	
Q:	…and	if	things	changed	how	would	you	then	approach	it,	would	you	go	back	and	do	
it	again	or	would	you	wait	for	the	month…?	
P:	If	things	were	changing	quicker	I’d	go	back	in	and	do	it	again…”	P423			Carers	 noticed	 that,	 their	 answered	 changed	 more	 slowly	 compared	 to	patients,	suggesting	that	it	may	be	feasible	to	ask	carers	to	do	it	fortnightly	or	monthly	sessions.	 	At	12	months	more	carers	preferred	to	complete	the	TiM	monthly.		However,	carers	also	found	doing	the	sessions	weekly	helped	them	 remember	 and	many	did	 it	 together	with	 the	patient.	 	 They	 thought	that	 the	 situation	 could	 change	 quickly	 but	 they	 also	 thought	 it	 should	 be	possible	for	carers	to	do	it	less	frequently	if	they	felt	things	were	stable.	
	Figure	5.13	Participants’	preferred	frequency	of	use	of	the	TIM	system	at	six	months	(n=15).				
Patient	
	
										
Carer		 	
Every few days (n=1)
Weekly (n=12)
Fortnightly (n=1)
Monthly (n=1)
Weekly (n=8)
Fortnightly (n=3)
Monthly (n=4)
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5.4.3	Exploring	TiM	system	participant	adherence	and	acceptability		
5.4.3.1	Barriers	to	and	facilitators	of	frequent	adherence	to	the	TiM	The	interviews	explored	the	reasons	for	frequent	and	infrequent	adherence.		The	 main	 themes	 and	 subthemes	 are	 summarised	 in	 Figure	 5.14	 and	Appendix	A5.18.		Figure	5.14		Reasons	for	participants’	frequent	and	infrequent	TiM	use.																Participants	explained	that	the	TiM	presented	little	burden	that	it	was	easy	to	 fit	 the	 TiM	 sessions	 into	 their	 weekly	 routine.	 	 However,	 they	 also	suggested	 ways	 adherence	 could	 be	 promoted	 such	 as	 completing	 the	sessions	on	the	same	day	each	week,	by	setting	alarms,	or	using	the	TiM	on	their	own	device	which	they	were	already	using	every	day.					Most	 participants	 missed	 the	 occasional	 session:	 forgetting,	 illnesses	 or	holidays	were	common.	 	Only	a	 few	sessions	were	missed	due	to	technical	difficulties.		Some	carers	forgot	because	they	did	not	complete	it	at	the	same	time	 as	 the	 patient.	 	 Those	 patients	 who	 were	 “infrequent”	 adherers	explained	this	was	due	to	two	main	barriers.	 	The	practical	barriers	to	TiM	use	(upper	limb	weakness	and	language/cognitive	problems)	are	described	in	Section	5.5.2	(Barriers	to	the	TiM	app	use).		Some	participants	found	the	TiM	did	not	meet	their	expectations	and	did	not	feel	it	provided	them	with	benefit	and	stopped	using	it.		This	is	described	in	Section	5.8.		However,	even		“infrequent”	adherers	felt	the	TiM	was	easy	to	use	and	could	be	a	valuable	additional	to	their	care.		
“No	doubt	at	the	end	of	it,	[what]	works	is	that	it	flags	up	that	I	need	help	or	I	don’t	
need	help.”	P134	(High	technology	user,	Low	TiM	user)		Adherence	also	decreased	during	the	last	few	weeks	of	patients’	lives.		Three	patients	died	during	the	study	and	two	(P354,	P063)	stopped	using	the	TiM	
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system	four	to	six	weeks	prior	to	their	death.		The	reasons	for	this	could	not	explored	 in	 interviews,	but	participants	who	were	 interviewed	did	explain	that	they	did	not	use	the	TiM	system	when	they	were	ill,	particularly	when	they	were	already	receiving	face-to-face	support	from	local	services.		In	the	later	stages	of	the	disease,	patients	tend	to	be	in	frequent	contact	with	local	healthcare	 professionals	 and	 formal	 carers	 with	 the	 patients	 requiring	immediate	 medical	 care,	 something	 the	 TiM	 system	 was	 not	 designed	 to	provide.	
5.4.3.2	Carer	adherence		The	reasons	 for	 lower	carer	adherence	(when	compared	 to	patients)	were	explored	 in	 interviews	 and	 again	 at	 the	 end	 of	 the	 trial	 once	 the	 full	adherence	 data	 was	 available.	 	 Several	 possible	 reasons	 were	 identified,	these	were:	
• Carers	being	too	busy/forgetting;	
• Carers	did	not	 think	 that	 the	MDT	or	 the	TiM	 system	was	 there	 to	help	carers.	Most	 carers	 reacted	 positively	 to	 the	 TiM	 and	 had	 intended	 to	 use	 the	system.		Some	said	at	times	they	were	too	busy	with	caring	duties	to	use	the	TiM.		A	common	theme	throughout	the	interviews	was	the	importance	of	the	patient	being	a	carer’s	first	priority	and	that	MND	care	was	focused	on	the	patient,	not	the	carer.		This	theme	is	described	in	more	detail	in	Section	5.8.		Because	 of	 this,	 some	 carers	 did	 not	 expect	 the	 TiM	 system	 to	 offer	 them	benefit.	 	A	number	of	the	carers	did	indicate	that	they	were	completing	the	study	 simply	 for	 the	 benefit	 of	 the	 patient,	 or	 for	 the	 benefit	 of	 other	patients.	 	 	Despite	 this,	 some	carers	 (e.g.	C217)	 continued	 to	 complete	 the	sessions	regularly.			
	
“P:	I	don’t	mind	doing	it.		
Q:	What	do	you	think?		
C:	Not	a	lot.		
Q:	So	would	you	send	[the	TiM	system]	back?		
C:	I	don’t	know,	I	would...	no...	To	me,	it’s	for	P.	So	if	she	did	not	want	to...	participate	
on	it,	that’s	it.		
Q:	Yep.	So	it’s	about	her	and	how	she	is?		
C:	...	if	it’s	helps	other	people	with	these	things	then	fair	enough.”	P&C217	
	
5.4.4	Summary	In	 summary,	 setup	of	 the	TiM	system	went	well	once	 initial	problems	had	been	 resolved	 and	participant	 adherence	 to	 the	TiM	 system	was,	 for	most	participants,	 sufficient	 to	 enable	 the	 Telehealth	 Nurse	 to	 assess	 their	condition.		The	frequency	of	use	(every	one	or	two	weeks)	was	acceptable	to	participants.	 	 Few	 barriers	 to	 use	 and	 adherence	 were	 experienced	 and	these	 could	 be	 overcome	 by	 a	 short	 face	 to	 face	 training	 session,	encouraging	participants	to	incorporate	TiM	sessions	into	a	weekly	routine	and	using	an	alert	to	remind	users	to	complete	weekly	sessions.		 	
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5.5	Participants’	experiences	using	the	TiM	technology		Sections	5.5	and	5.6	describe	the	participants’	experiences	of	using	the	TiM	system,	drawing	on	information	gained	from	field	notes,	the	notes	made	on	the	 TiM	 system	 and	 interviews	 with	 the	 MND	 nurses	 (nurses’	 and	physicians’	 experiences	 are	 described	 in	 more	 detail	 in	 the	 section	 5.7).			Section	 5.5	 describes	 participants’	 initial	 experiences	 using	 the	 TiM	technology	along	with	the	barriers	and	enablers	to	technology	use	amongst	participants	 including	 the	 experiences	 of	 those	with	 low	 confidence	 using	technology.	 	 Section	 5.6	 describes	 participants’	 expectations	 and	understanding	of	the	TiM	system,	their	reactions	to	the	questions	posed	on	the	 TiM	 system	 and	 whether	 they	 accurately	 capture	 the	 key	 problems	experienced	in	MND.			
5.5.1	TiM	system	acceptability	questionnaires	Figures	 5.15	 and	 5.16	 display	 patient	 and	 carer	 satisfaction	with	 the	 TiM	system	 at	 six	 months	 when	 most	 participants	 provided	 feedback.		Satisfaction	was	 similar	 at	 each	 follow-up	 time	 point	 (the	 results	 at	 three	and	twelve	months	are	reported	in	Appendix	A	Table	5.2-5.3).		Participants	were	 also	 given	 the	opportunity	 to	write	 comments	 in	 the	questionnaires.		The	 key	 themes	 mirrored	 those	 identified	 in	 the	 interviews,	 which	 are	described	below.								
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	Figure	5.15		Patient	satisfaction	with	TiM	telehealth	at	6	months	(n=15).	
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Figure	5.16		Carer	satisfaction	with	TiM	telehealth	at	6	months	(n=15)	
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5.5.2	Initial	experiences	using	the	TiM	app	At	six	months,	all	 the	patients	and	14	(93%)	of	 the	carers	 felt	 the	TiM	system	was	 easy	 to	 use	 (only	 one	 carer	was	 unsure).	 	 14	 (93%)	 of	 the	 patients	 and	carers	did	not	think	the	system	was	tiring	(one	patient	and	carer	were	unsure)	and	13	(87%)	did	not	think	the	questions	were	distressing	(two	were	unsure).	Participants	in	the	interviews	explained	that	the	TiM	app	was	extremely	easy	to	use	and	of	low	burden	(Appendix	A5.19).			
“It's	so	easy	to	do;	it	literally	takes	five	minutes	from	home.”		P317			Using	 it	weekly	meant	participants	became	confident	quickly	and	participants	did	not	find	completing	the	questions	weekly	was	an	intrusion	on	their	lives,	or	reminded	them	unduly	about	MND.	 	One	patient	who	was	early	 in	 the	disease	explained:		
“To	be	honest,	it	doesn’t	bother	me.		When	I	was	first	diagnosed	I	was	not	keen	on	talking	
about	it.	 	I’ve	since	got	better	and	I	think	that	helps.		So	to	me,	I’m	quite	happy	to,	if	you	
like,	be	reminded.	To	be	honest,	I	think	you	are	reminded	every	day.		That	tablet	makes	no	
difference	to	that.”	P381			The	Telehealth	Nurse	also	felt	that	patients	had	responded	positively	to	the	TiM	and	 found	 it	 easy	 to	 use.	 	 She	 initially	 thought	 some	 patients	would	 be	 faced	with	barriers	that	would	mean	they	would	not	participate	in	the	trial	or	use	the	TiM	 system	 such	 as	 age	 or	 inexperience	 with	 technology.	 However,	 she	 was	surprised	 because	 some	 patients	 faced	 by	 these	 barriers	 used	 the	 system	regularly.		
“[There	are]	some	patients	that,	I’m	surprised	they	took	it	up.	I’m	surprised;	actually	that,	
I	never	thought	that	he	would	use	that…	and	he	sends	his	back	very,	very	well.”	Telehealth	
Nurse	
5.5.2.1	Barriers	and	enablers	to	the	use	of	the	TiM	Patient	App		There	 were	 two	 main	 types	 of	 barriers	 experienced	 during	 the	 trial:	 those	relating	to	the	technology,	and	those	relating	to	the	participants.		Problems	with	TiM	 technology	 were	 described	 earlier	 in	 Section	 5.4	 (Setting	 up	 the	 TiM	system).	 	 This	 section	 describes	 the	 participant	 characteristics	 that	 posed	barriers	and	enablers	to	using	the	TiM	(Figure	5.17	and	5.18).		Practical	barriers	(e.g.	 upper	 limb	disability	or	 language/cognitive	problems)	were	 encountered	but	 the	 most	 important	 barrier	 was	 participant	 attitude	 towards	 digital	technology.	 	 	 Despite	 these	 barriers,	 even	 those	who	were	not	 confident	with	using	 technology	 found	 the	 system	 easy	 to	 use	 and	 became	 confident	 to	 deal	with	any	difficulties	that	they	experienced.				 	
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Figure	5.17	The	participant		factors	that	influence		the	use	of	the	TiM	app.																						
	
	
5.5.2.2	The	impact	of	upper	limb	disability	on	TiM	use	27	patients	(68%)	reported	some	difficulty	using	technology	due	to	upper	limb	disability.	 	 However,	 when	 given	 the	 opportunity	 to	 try	 the	 tablet,	 34	 (85%)	found	 they	 could	 use	 the	 TiM	 tablet	 computer	 independently	 (although	 they	may	need	a	carer	to	help	e.g.	to	plug	it	in).				
“My	fingers	are	too	heavy.	...	I’ll	end	up	phoning	somebody.”	P378			Patients	with	 upper	 limb	weakness	 found	 the	 tablet	 touch	 screen	helpful	 and	several	 found	 it	 much	 easier	 with	 a	 stylus	 pen	 (provided	 with	 the	 tablet).		Patients	 who	 could	 not	 operate	 it	 independently	 were	 happy	 to	 allow	 their	carers	 to	operate	 it	on	their	behalf	although	they	would	prefer	 to	use	 the	TiM	system	 on	 their	 own	 device	 which	 had	 been	 adapted	 for	 their	 disability	 e.g.	using	Eye	gaze	technology.		 	
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5.5.2.3	The	characteristics	of	participants	with	low	confidence	in	technology			The	 main	 barrier	 to	 participation	 identified	 by	 participants	 was	 the	 concern	that	they	would	not	be	able	to	use	the	system.			
“…we’re	quite	happy	to	deal	with	it,	as	long	as	it	wasn’t	too	techy”		C062		
	Many	participants,	including	those	using	technology	daily,	described	themselves	as	lacking	an	intrinsic	ability	to	use	technology	saying	that	they	were	“bad”	at	it,	thinking	 others	 were	 more	 “wired”	 to	 using	 technology.	 	 	 Those	 with	 low	confidence	 or	 experience	 using	 technology	 shared	 common	 attitudes	 towards	their	 abilities,	 their	 experience	 and	 approach	 to	 technology	 (Figure	 5.17,	Appendix	A5.20	and	A5.21).	 	They	said	they	struggled	to	“catch-on”	or	learn	to	use	 new	 technology.	 	 They	 found	 technology	 stressful	 and	 were	 fearful	 of	making	 a	 mistake	 or	 it	 breaking	 the	 device.	 	 They	 did	 not	 feel	 in	 control	 of	technology,	expressing	frustration	when	technology	did	not	“obey”	 them.	 	This	meant	they	were	not	confident	adapting	to	unfamiliar	technology.		They	tended	to	give	up	quickly	if	they	encounter	a	problem	as	they	were	unwilling	or	lacked	confidence	to	solve	problems	with	technology.		Instead	they	relied	on	others	to	set	 up	 new	 technology	 or	 resolve	 problems	 when	 technology	 “went	 wrong”.		Some	 low	 users	 explained	 they	 never	 learnt	 or	 did	 not	 see	 the	 need	 to	 use	technology,	particularly	if	their	partner	used	it	on	their	behalf		
	
“I	 just	 haven’t	 used	 it	 much	 because	 I	 haven’t	 really	 had	 the	 need	 and	 P	 does	 all	 [the	
technology]”	C380		Those	who	lacked	experience	or	confidence	tended	to	use	a	limited	number	of	basic	 applications	 but	 many	 enjoyed	 using	 leisure	 facilities	 e.g.	 on-demand	television,	 Facebook,	 Kindle,	 information	 websites.	 	 These	 sites	 tended	 to	require	little	interaction	and	they	felt	less	confident	using	technology	for	more	complex	 tasks	 such	 as	 internet	 banking,	 when	 needing	 to	 use	 passwords	 etc.		Box	5.1	explores	a	case	in	more	detail.		 	
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	Box	5.1	Case	vignette:	negative	attitudes	towards	technology	Four	 participants	 did	 not	 use	 technology	 at	 all	 and	 three	 said	 they	 had	 little	interest	or	need	for	technology	and	did	not	see	it	as	offering	value	to	their	lives.		One	gentleman	in	his	70s	(C166)	explained	he	had	a	negative	attitude	towards	technology	(Appendix).		The	couple	had	no	technology	in	the	house,	see	no	need	for	 technology,	 and	 describe	 themselves	 as	 “technophobes”.	 	 C166	 sees	 the	continued	involvement	of	technology	into	everyday	life	as	an	intrusion	and	feels	that	they	were	becoming	isolated	because	they	chose	not	to	use	it.		
“I'm	not	against	it	but	I	don't	want	it	and	I	can	do	without	it	and	I	don't	need	it.”	C166		Both	 C166	 and	 another	 patient	 P378	 felt	 they	 were	 being	 increasingly	pressured	 to	 use	 technology	 in	 every	 day	 life	with	 a	 resulting	 loss	 of	 reliable	alternatives.			
“I	got	pushed	down	that	road	while	I	were	in	teaching”	P378			C166	also	mentioned	the	potential	for	technology	to	be	misused,	“hacked”	or	to	become	“Big	brother”:	intruding	into	their	lives.		The	couple	thought	technology	had	 negative	 impact	 on	 human	 interactions	 (turning	 people	 into	 “zombies”).		C166	valued	having	the	security	of	physical	records	and	saw	digital	records	as	worthless	and	not	“real”.		Despite	these	concerns,	the	couple	were	willing	to	use	the	TiM	system	because	they	trusted	their	MND	care	team	to	provide	them	with	a	 secure	 and	 safe	 system	 and	 had	 tested	 it	 out	 prior	 to	 agreeing	 to	 join	 the	study.	 	 	 In	 fact,	 following	some	additional	 training,	 they	were	the	second	most	frequent	users	of	 the	TiM	system	(patient	99%	of	expected	sessions	and	carer	95%).	 	 In	the	second	interview	they	even	mentioned	that	they	would	consider	purchasing	technology	if	they	saw	a	reason	to	use	it.		
“It’s	unbelievable	that	sort	of	technology,	but	equally	it’s	open	to	anybody	to	get	into	it.	So,	
I	might	be	persuaded	eventually,	but	[laughs]	it’s	a	slow	process”	C166	
	
5.5.2.4	The	experience	of	using	the	TiM	app	by	low	technology	users	Only	 one	 couple	 had	 problems	 that	 stopped	 them	 using	 the	 app	 (P166)	 and	their	problems	were	 resolved	with	 some	additional	 training	 (see	Section	5.4).		One	carer	in	his	80s	(C217)	said	he	had	difficulties	with	language	and	struggled	to	adapt	to	new	things.		His	wife	helped	him	to	use	the	tablet.		He	had	little	prior	experience	with	technology	and	had	worked	in	a	manual	job	and	had	a	medical	condition	 affecting	 his	 language	 although	 he	 did	 not	 raise	 these	 problems	during	training.		He	said	by	the	time	he	returned	to	use	the	TiM	a	week	later	he	had	forgotten.			
“C:	It’s	the	system	that’s	all.	I	don’t	catch	on	very	well	with	it,	that’s	ok.	Like	phones,	
I	don’t	bother	them	really.	
P:	Couldn’t	read	a	text	message.	
C:	Oh	I	couldn’t	do	anything	like	that.”	C217			
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Despite	 participants’	 concerns,	 following	 face-to-face	 training	 only	 C217	reported	on-going	difficulties	using	the	app,	the	rest	all	felt	the	TiM	was	easy	to	use.		Participants	explained	that	the	more	they	used	the	system,	the	more	they	developed	confidence	(Figure	5.18,	Appendix	A5.22).		
“It	is	now	easy	to	use	but	was	hard	originally”	P228	3	month	questionnaire		C366	 also	 admitted	 having	 little	 confidence	 in	 technology	 and	 asked	 her	husband	to	“set-up”	the	tablet.		Despite	this	she	reported	no	problems	once	she	started	using	the	app.	 	Having	received	help	from	his	wife	to	use	the	TiM	app,	even	 C217	 managed	 to	 complete	 sessions	 and	 was	 also	 a	 high	 TiM	 user,	completing	87%	of	expected	weekly	TiM	sessions.				Participants	thought	that	face-to-face	training	was	very	important.	They	wanted	clear	 instructions	 designed	 for	 those	 who	were	 not	 experts	 that	 assumed	 no	knowledge	 or	 experience.	 	 All	 the	 participants	 found	 the	 face-to-face	 training	helped	enable	 them	 to	use	 the	TiM.	 	 Some	were	pleasantly	 surprised	by	 their	achievements.		
“I	thought	I	wouldn't	be	able	to	do	it	(laughter)	but	I	can…	I'm	not	really…	I	don't	
want	computer	or	anything	like	that,	so	it's	only	that	only	because	of	that.”	C228			Figure	5.18	Enablers	of	TiM	app	use.	
	Most	 patients	 completing	 the	 questionnaire	 were	 “unsure”	 whether	 the	additional	features	on	the	TiM	system	(the	Problem	List	and	Knowledge	Centre)	were	helpful.		When	interviewed,	many	commented	that	they	hadn’t	used	these	features,	some	because	they	did	not	want	to	learn	more	about	MND	and	others	because	 they	 did	 not	 feel	 confident	 using	 other	 features	 of	 the	 tablet	 device.		Two	reported	during	the	interviews	that	they	had	found	the	Knowledge	Centre	helpful	 and	 they	 had	 used	 it	 to	 find	 out	more	 about	MND.	 	 Others	 felt	 happy	these	features	were	available	if	they	needed	them.			The	 only	 other	 barrier	 identified	was	 the	 existence	 of	 language	 and	 cognition	problems:	one	patient	could	use	the	TiM	technology	but	during	training	it	was	noted	 to	 be	 giving	 answers	 that	 did	 not	 appear	 accurate	 (P073).	 	 He	 was	severely	 disabled,	 unable	 to	 communicate	 verbally	 and	 exhibited	 behaviours	suggestive	of	mild	frontotemporal	deficits.		He	and	his	family	agreed	they	would	complete	the	questions	together.		Due	to	later	illness	he	was	unable	to	take	part	in	an	interview	so	his	use	of	the	TiM	could	not	be	fully	evaluated.	
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5.6	Participants’	experiences	using	the	TiM	system	
5.6.1	Participants’	expectations	of	telehealth	Participants	 felt	 the	 TiM	 system	 could	 offer	 various	 benefits	 (Figure	 5.19,	Appendix	 A5.23	 and	 A5.24).	 	 The	 main	 expectations	 were	 that	 TiM	 could	improve	 communication,	 monitoring	 and	 accessibility	 of	 the	 MND	 care	 team	and	that	this	would	bring	psychological	benefits	to	participants.		Figure	 5.19	 Participants’	 expectations	 of	 the	 potential	 benefits	 of	 the	 TiM	service.	
			Participants	thought	TiM	system	could	provide	them	with	a	“direct	link”	to	the	MND	 team,	 which	 would	 improve	 the	 speed,	 frequency	 and	 quality	 of	communication	 between	 the	MND	 team,	 patients,	 carers	 and	 their	wider	 care	team.					
“If	 I	 put	 it	 on	 the	 tablet	 and	 I	 send	 it	 to	 you,	 you	 get	 it	 there	 and	 then.	 	 So	 if	
anything	…	happens	to	me	in	that	period	of	time	you	know	straightaway	…	So	the	
quicker	you	can	pick	up	on	something,	it’s	better	for	you	as	a	doctor,	as	well	as	me	
as	a	patient.”	P091		Participants	 thought	 increased	monitoring	could	pick	up	problems	earlier	and	between	 hospital	 visits,	 could	 stimulate	 discussions	 about	 new	 problems	 and	enable	 them	to	monitor	 their	own	progress.	 	As	a	result	 they	 thought	 the	TiM	could	 reassure	 them	 that	 they	 were	 being	 monitored	 and	 that	 important	problems	 would	 be	 identified,	 which	 would	 reduce	 the	 isolation	 they	 felt	between	 clinic	 appointments.	 They	 felt	 that	 the	 TiM	 could	 help	 improve	 the	accessibility	 of	 the	 service,	 reducing	 travel	 and	 clinic	 time	 and	 provide	 an	alternative	if	they	were	too	unwell	to	attend	(Figure	5.19)		
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“Sometimes	it’s	just	the	fact	that,	“should	somebody	know	about	this?”	or	“should	
you	 be	 telling	 somebody	 that.	Wouldn’t	 it	 be	 nice	 if	 somebody	 knew	 this?”	 	 Just	
small	 details	 that	 you	 sometimes	 think,	 “Does	 it	make	 a	 difference	 if	 somebody	
knew	about	it?”	And	that	telemed	makes	that	difference.”	C184	
	
5.6.2	Participants’	attitudes	towards	the	TiM	questions	The	 participant	 satisfaction	 questionnaires	 examined	 participants’	 attitudes	towards	 the	 TiM	 questions	 (Section	 5.5,	 Figure	 5.15	 and	 5.16).	 13	 (87%)	patients	 felt	 the	 TiM	 questions	 were	 relevant	 to	 them	 although	 two	 (13%)	disagreed.		11	(73%)	patients	felt	they	were	able	to	report	all	the	problems	they	experienced	using	the	TiM,	although	two	(13%)	disagreed	and	two	(13%)	were	unsure.	 	 13	 (87%)	 of	 carers	 felt	 the	 questions	were	 relevant	 to	 them	 and	 11	(73%)	felt	the	TiM	enabled	them	to	report	all	the	problems	they	were	faced	as	a	carer.		When	interviewed,	participants	were	satisfied	that	the	TiM	questions	provided	a	 good	 coverage	 all	 aspects	 of	 MND	 and	 they	 were	 not	 distressed	 by	 the	questions	 (Appendix	 A5.25	 and	 A5.26).	 	 Reporting	 deterioration	 in	 their	condition	 using	 the	 TiM	 was	 not	 upsetting	 because	 patients	 would	 already	know	 themselves	 if	 they	 had	 changed.	 Instead,	 they	 welcomed	 being	 able	 to	report	 and	 discuss	 their	 current	 and	 future	 problems	 as	 they	 felt	 this	 might	present	 an	 opportunity	 for	 them	 to	 receive	 support	 from	 the	 MND	 team.		Furthermore,	 those	 that	 had	 not	 changed	 found	 completing	 the	 questions	reassuring	as	they	could	see	their	answers	had	not	changed.	
	
“It’s	good	 that	you	can	change	 [the	answers]…keep	everybody	up-to-date.	Cos	you	don’t	
know	when	things	are	going	to	change,	 it’s…a	grey	area	isn’t	 it?…as	long	as	people	who	
need	to	know	see	that	information…not	waiting	till	your	next	visit	at	the	clinic.”	P122		Participants	felt	 it	was	very	important	that	the	information	they	provided	was	accurate	 and	 that	 the	 MND	 team	 received	 the	 right	 information.	 Participants	often	wanted	to	give	more	information	in	their	answers,	either	by	using	the	TiM	app	or	by	calling	the	MND	team	directly.		A	number	of	the	participants	thought	the	 questions	 were	 repetitive,	 particularly	 the	 carer	 questions.	 	 Some	 were	reporting	the	same	problems	(e.g.	falls)	every	week.		Participants	thought	some	variation	 would	 be	 helpful.	 Some	 felt	 some	 answers	 (particularly	 the	 PHQ4	anxiety/depression	score)	were	insufficiently	sensitive	to	reflect	the	day-to-day	fluctuation	in	their	condition.			The	 interviews	 did	 provide	 an	 opportunity	 to	 identify	 changes	 that	 could	 be	made	to	the	TiM	app.		A	number	of	important	symptoms	that	were	not	included	in	 the	 original	 TiM	 app	were	 identified.	 	 	 These	were	 diarrhoea,	 constipation	and	 incontinence.	 	 Diarrhoea	 and	 constipation	 were	 added	 to	 the	 second	version	of	 the	app.	 	One	patient	explained	 that,	now	she	had	become	severely	disabled,	many	of	the	questions	no	longer	changed.		To	reflect	this,	the	ALS-FRS-EX	 scale	was	 added	which	 includes	 questions	 designed	 to	 identify	 changes	 in	patients	with	severe	disability	(209).		
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One	carer	suggested	that	the	questions	should	use	other	ways	to	assess	carers’	lives	more	critically,	 for	example	by	assessing	whether	they	were	able	to	have	free	time	or	to	take	part	 in	other	activities	unrelated	to	caring.	 	She	suggested	that	this	could	be	a	trigger	to	encourage	carers	to	consider	their	own	wellbeing	and	encourage	them	to	adopt	coping	strategies.		
“...whereas	 the	 carers	 [questions]	 have	 really	 been	 “are	 you	 ok?”	 “Are	 you	 struggling	 a	
bit?”	but	by	the	nature	of	being	a	fulltime	carer	you	are	going	to	be	struggling	a	little	bit.		
And	 it’s	about,	have	you	managed	 to	have	any	 time	on	your	own	this	week	or	have	you	
done	a	social	activity?		Maybe	that	type	of	questionnaire?	How	many	times	have	you	been	
out	in	the	last	two	weeks	with	a	group	of	friends?	As	apposed	to	“have	you	had	to	change	
arrangements?”	well	yes	but	we	have	to	change	arrangements	all	the	time...maybe	if	they	
say,	 “No,	 I’ve	not	 been	out	 for	 a	 fortnight”,	 that	 it	makes	 them	 think,	well	 actually	why	
haven’t	I.	 	And	it	would	highlight,	well	that	persons	not	getting	out	of	the	house	and	not	
doing	something	themselves	and	they	are	continually	there.	 	 Is	that…	do	they	need	a	bit	
more	support?”	C122	
5.6.3	Participants’	understanding	of	the	TiM	system	Most	participants	understood	that	the	purpose	of	the	TiM	was	to	monitor	their	condition	 and	 that	 the	 information	 recorded	on	 the	TiM	was	being	 relayed	 to	the	MND	centre	to	promote	clinical	care	(Appendix	A5.27).		Participants	had	not	been	shown	the	Telehealth	Nurses’	clinical	portal	but	thought	that	the	answers	would	 be	 collected	 and	 someone	 would	 be	 looking	 for	 trends,	 be	 alerted	 to	problems	 out	 of	 the	 ordinary	 and	 be	 able	 to	 compare	 their	 results	 to	 other	patients.		
“I	could	see	the	reason	why	you	were	doing	it;	I	realised	that	all	the	data	was	going	to	be	
collated	and	you	can	see	then	at	a	glance…	you	can	see	the	statistics	and	everything,	and	
it	would	highlight	to	you…	if	I	had	a	dramatic	change.”		P317		However,	there	were	some	participants	who	did	not	fully	understand	the	role	of	the	TiM	system,	particularly	early	 in	the	trial.	 	Some	thought	 it	would	be	used	for	 research	or	be	used	 to	 create	a	database	of	patients	 for	 trials,	 rather	 than	direct	 clinical	 care.	 	 They	 were	 often	 not	 clear	 who	 was	 looking	 at	 the	information.	 	 Some,	 having	 never	met	 the	 Telehealth	 Nurse,	 thought	 that	 EH	would	be	 looking	 at	 the	 system.	 	The	Telehealth	Nurse	 also	noticed	 this.	 	 She	said	they	were	surprised	when	she	called	them.			However,	when	they	did	get	a	call	they	were	pleased	and	reassured	that	the	TiM	worked.		By	the	later	stages	of	the	trial	the	participants	were	clear	about	the	role	of	the	TiM.		
“I	didn’t	realise	that	[Telehealth	Nurse]	was	involved	and	she	would	ring	us	if	our	answers	
drastically	 changed,	 cos	 obviously	 they’ve	 stayed	 very	much	 the	 same.	 	 	 Then	 I’m	 quite	
encouraged	 by	 that,	 I	 just	 presume	 that	 you	 do	 it	 yourself…and	 if	 you’d	 got	 a	 problem	
you’d	ring	[Telehealth	Nurse]	up	for	a	bit	of	help.”	C392		When	interviewed,	all	participants	trusted	that,	because	medical	staff	used	the	TiM,	it	would	be	secure	and	their	data	would	be	kept	securely.	These	sentiments	were	 also	 reflected	 in	 the	 questionnaire	 answers	 with	 the	 majority	 of	participants	 confident	 that	 the	 TiM	 system	 respected	 their	 privacy	 and	confidentiality.	 	 	Two	patients	 (14%)	did	disagree	with	 this	 statement	but	did	not	explain	their	reasoning.	
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5.6.4	Summary	of	participants’	experiences	using	the	TiM	The	TiM	system	was	found	to	be	easy	to	use	and	did	not	represent	a	burden	to	participants.	 	The	 technology	was	accessible	 even	 to	participants	with	 limited	experience	 and	 confidence	 using	 digital	 devices.	 	 Participants	 were	 positive	about	 the	 concept	 of	 telehealth	 to	 enable	 better	 access	 to	 MND	 services	 and	thought	that	it	could	offer	a	more	timely	and	effective	service	and	maintain	links	with	 the	 MND	 team,	 something	 which	 they	 welcomed.	 	 Initially,	 some	participants	did	not	fully	understand	the	concept	of	telehealth	but	trusted	that	their	 data	 would	 be	 used	 appropriately	 and	 stored	 securely.	 	 Once	 they	 had	interacted	 with	 the	 Telehealth	 Nurse	 they	 understood	 the	 system	 better	 and	remained	satisfied	with	concept	of	telehealth.		
5.7	Clinicians’	experiences	using	the	TiM	system		This	section	uses	describes	how	the	Telehealth	Nurse	and	physicians	used	the	system	and	whether	the	data	provided	was	accurate	and	felt	to	be	useful.		Data	from	the	TiM	portal	was	used	which	detailed	all	the	participants’	answers,	alerts	generated	 and	 notes	 made	 by	 the	 clinicians.	 	 Interviews	 with	 the	 Telehealth	Nurse	 and	 the	 Community	 Nurse	 also	 help	 understand	 how	 the	 system	 was	used	 and	 the	 technical	 problems	 encountered.	 	 Data	 collected	 as	 part	 of	 the	Shadow	Monitoring	Protocol	was	used	to	understand	physicians’	impressions	of	the	 system	and	 explores	 the	 accuracy	of	 the	 system	along	with	data	 from	 the	interviews	 with	 the	 Telehealth	 Nurse.	 	 Accuracy	 is	 explored	 further	 by	comparing	 data	 collected	 on	 the	 TiM	 system	 with	 data	 collected	 using	 the	validated	patient	reported	outcome	measures.	
5.7.1	The	Telehealth	Nurses’	use	of	the	clinical	portal	When	 interviewed,	 the	Telehealth	Nurse	 felt	 the	clinical	portal	was	 “very,	very	
easy”	to	use	following	minimal,	face-to-face	training.	(Appendix	A5.28)		She	was	able	to	navigate	through	the	screens	easily	and	was	confident	enough	to	use	all	features	 of	 the	 system	 without	 fear.	 The	 only	 technical	 difficulty	 she	experienced	was	with	 passwords.	 	 This	 required	 contact	with	 the	 IT	 team	 in	Chicago	whereas	she	would	have	preferred	a	local	solution.		She	explained	was	unfamiliar	with	 the	Patient	App,	as	she	had	not	been	given	the	opportunity	 to	use	it	before	the	trial.		As	a	result,	she	passed	all	technical	problems	to	EH.				The	 Telehealth	 Nurse	 did	 not	 find	 using	 the	 TiM	 system	 was	 particularly	burdensome.			“It	only	takes	minutes”	Telehealth	Nurse		During	the	 trial	a	maximum	of	17	patients	were	using	the	app.	 	She	explained	she	was	responsible	for	approximately	120	patients	in	total.		The	consequences	of	scaling	up	the	service	were	not	explored	in	the	interviews.		The	Telehealth	Nurse	explained	that	initially	she	looked	at	the	system	every	day	but	 by	 the	 end	 of	 the	 trial	 she	 said	 she	 would	 look	 less	 often	 (weekly,	 and	sometimes	 a	 little	 less	 often).	 She	would	 look	 at	 each	 patient	 but	was	 drawn	
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particularly	to	the	alerts	and	to	changes	in	the	alerts	since	the	last	session.		She	felt	that	a	green	flag	indicated	everything	was	“ok”,	orange	meant	“there’s	maybe	
some	 elements	 that	 might	 need	 to	 be	 looked	 at”	 whilst	 a	 red	 flag	 indicated	 a	problem.	 	 	The	additional	 information	(e.g.	whether	 they	used	NIV,	what	 their	previous	answers	were)	helped	her	understand	why	the	flags	had	occurred.		She	explained	 that	 she	 found	 the	 addition	 of	 the	 “trends”	 front	 page	 helpful	 to	enable	 her	 to	 get	 an	 overview	 of	 things	 she	 thought	 were	 important	 (e.g.	weight)	and	to	see	which	category	had	changed.	
5.7.2	TiM	system	alerts,	notes	and	actions	Patients	completed	a	total	of	585	TiM	sessions.	 	Each	session	was	divided	into	sub-sections	 assessing	 limb	 function,	 bulbar	 function,	 respiratory	 function,	wellbeing	 and	nutrition.	 	 	 Each	 session	was	 automatically	 awarded	 a	 “session	flag”,	which	was	calculated	as	the	most	serious	flag	awarded	in	that	session.		A	large	 number	 of	 sessions	 generated	 an	 alert:	 322	 (55%)	 of	 patient	 sessions	alerts	were	red,	244	(42%)	were	amber	and	only	19	(3%)	were	green	(Figure	5.20).				Figure	5.20	The	frequency	of	red,	amber	and	green	flags	generated	by	the	TiM	sessions.		The	total	sessions	reports	the	frequency	of	“top	level”	flag	for	all	585	sessions	completed.			Below	this	are	the	frequencies	of	“section	flags”	generated	by	10	patients	who	completed	a	total	of	334	sessions.	
		Each	 sub-section	 also	 generated	 an	 alert.	 	 It	was	 very	 time	 consuming	 to	 use	data	 downloaded	 to	 analysis	 all	 the	 alerts	 at	 individual	 question	 level	 so	 the	answers	 for	 the	 first	 ten	 patients	 (T047-T217)	were	 reviewed-	 a	 total	 of	 334	sessions.	 	Figure	5.20	shows	the	 frequency	of	 these	sub-section	alerts.	 	Bulbar	questions	caused	most	red	alerts	(usually	due	to	choking	difficulties),	followed	by	 limb	 function	 (usually	 due	 to	 falls).	 	 It	 was	 also	 extremely	 common	 for	patient	 to	 report	 some	 problem	 with	 their	 breathing	 or	 NIV	 with	 very	 few	sessions	generating	a	green	breathing	alert.		The	wellbeing	and	nutrition	alerts	were	less	common	but	they	still	generated	a	red	or	amber	alert	nearly	50%	of	the	time.				The	TiM	 system	clinical	 portal	 provided	 a	 free	 text	 box	 for	 clinicians	 to	 enter	notes.	 	 The	 Telehealth	 Nurse	 using	 the	 portal	 was	 asked	 to	 make	 notes	 in	
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response	 to	any	alerts	or	problems	she	 identified.	 	Clinicians	 could	also	made	notes	following	clinic	visits	but	only	the	Telehealth	Nurse	and	EH	did	this.	 	99	notes	documenting	clinical	events	were	identified.		46	(47%)	notes	were	made	by	 the	 Telehealth	 Nurse	 and	 53	 (53%)	 by	 EH	 (these	 usually	 described	 the	response	 made	 by	 the	 Telehealth	 Nurse).	 The	 TiM	 system	 did	 not	 require	clinicians	to	make	notes	in	response	to	an	alert	or	require	that	notes	contained	specific	 information.	 	 	Therefore,	 it	was	not	 always	possible	 to	 capture	all	 the	alerts	 that	 the	 nurse	 responded	 to	 or	 actions	 triggered	 by	 the	 TiM.	 	 It	 is	therefore	 possible	 that	 this	 data	 underestimates	 the	 number	 of	 alerts	 and	actions	taken.		Each	clinical	note	was	reviewed	and	Figure	5.21	presents	the	problem	identified	and	Figure	5.22	presents	the	types	of	action	reported	in	the	clinical	notes.					Figure	5.21		The	problems	reported	in	clinical	notes	made	on	the	TiM	clinical	portal.		99	notes	were	made	detailing	a	total	of	132	problems.											 Figure	5.22	Actions	reported	 in	 the	 99	clinical	notes	made	on	 the	 portal.		Sometimes	 more	than	 one	 action	was	reported.			
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Swallowing	and	choking	were	common	along	with	various	symptoms	reported	by	 the	 TiM	 system.	 	 32%	of	 the	 clinical	 notes	made	 suggested	 that	 the	 nurse	took	 action:	 the	most	 common	 actions	were	 telephone	 advice	 or	 liaison	with	other	members	of	 the	MDT	to	share	 information	and	coordinate	care.	 	17%	of	the	 time	 she	 planned	 to	 review	 the	 problem	 when	 the	 patient	 next	 came	 to	clinic.			However,	on	over	50%	of	occasions	the	nurse	documented	that	she	took	no	 action	 and	 in	 only	 18%	 of	 occasions	 the	 nurse	 documented	 that	 she	 had	contacted	 the	 patient	 or	 carer.	 	 	 The	 nurse	 often	 took	 no	 action	 because	 she	already	 was	 aware	 of	 the	 problem	 or	 that	 the	 patient/carer	 was	 awaiting	treatment	 or	 had	 declined	 to	 accept	 the	 treatment/advice	 she	 had	recommended.	 	 The	 most	 common	 reason	 for	 this	 was	 when	 the	 nurse	 was	alerted	to	patients	choking	but	the	patient	had	elected	to	continue	to	eat	despite	the	risks	associated	with	this	choice.		She	explained	that	in	these	circumstances	she	would	 like	to	temporarily	“pause”	 the	alert	 to	reduce	the	number	of	alerts	about	known	problems.		
5.7.3	Physicians’	experiencing	using	the	TiM	system		
5.7.3.1	Pre-clinic	shadow	monitoring	Initially,	 plans	 were	 made	 for	 clinicians	 to	 review	 the	 TiM	 answers	 a	 few	days/weeks	 prior	 to	 a	 patient	 attending	 the	 hospital	 clinic	 as	 well	 as	 an	additional	report	following	the	consultation	(the	Shadow	monitoring	protocol).		Prior	to	clinic,	 it	was	planned	that	clinicians	would	make	an	assessment	of	the	accuracy	 and	 potential	 usefulness	 of	 the	 system	 and	 indicate	 whether	 they	would	 change	 the	patient’s	 appointment	date.	 	The	approach	was	 found	 to	be	unfeasible	 without	 additional	 administration	 support	 due	 to	 the	 following	problems	encountered	during	the	trial:	
• Clinic	appointments	were	not	be	booked	sufficiently	far	in	advance;		
• Clinic	appointments	would	change	without	notice	(either	by	the	patient	or	the	clinic	booking	team);		
• The	clinician	had	no	regular	time	scheduled	to	review	the	system;	
• Clinicians	needed	to	be	reminded	to	review	the	TiM	at	the	correct	time;	
• Clinicians	 need	 to	 be	 provided	 with	 the	 paper	 notes	 to	 familiarise	themselves	with	the	patient	(no	electronic	notes	were	available	during	the	trial).	
5.7.3.2	Clinic	shadow	monitoring	38	shadow	monitoring	 forms	were	completed	when	patients	 in	 the	Telehealth	group	attended	clinic.	A	record	of	all	clinic	visits	attended	by	patients	in	the	trial	was	not	kept	and	the	number	of	visits	between	patients	so	it	is	not	possible	to	determine	how	often	shadow	monitoring	forms	were	completed.		Some	shadow	monitoring	forms	were	not	completed,	either	because	EH	was	not	present	in	the	clinic	 or	was	 too	 busy	 seeing	 other	 patients	 to	 provide	 the	 doctor	 seeing	 the	patient	 with	 a	 form	 during	 clinic.	 	 	 The	 majority	 of	 forms	 (20,	 54%)	 were	completed	 by	 the	 investigator	 (EH)	 as	 most	 patients	 recruited	 to	 the	 study	happened	to	be	under	the	care	of	one	consultant	with	whom	EH	worked	but	18	(46%)	were	completed	by	other	physicians.			
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Observations	 during	 training	 established	 that	 the	 clinicians	 were	 able	 to	navigate	around	the	different	screens	after	very	basic	instructions.		Figure	5.23	described	 the	answers	 to	a	satisfaction	survey	completed	by	 the	 treated	clinic	doctor	for	every	patient	and	carer	in	the	intervention	arm.			Responses	were	all	positive:	 all	 clinicians	 agreed	 the	 TiM	 was	 useful	 and	 accurate	 and	 was	 a	positive	 influence	 on	 the	 consultation.	 	 Clinicians	 were	 also	 asked	 to	 make	comments.	 	On	five	occasions	the	clinician	described	a	benefit	of	TiM.	 	On	four	occasions	the	comments	suggested	that	the	TiM	identified	problems,	important	trends	or	provided	additional	information	about	a	patient.				
“Weight	is	useful	as	gives	a	more	accurate	track	of	his	nutrition	in	last	few	weeks:	
I	have	asked	 the	dietician	 to	 review	his	nutrition	as	he	 is	 losing	weight.”	EH	r.e.	
P409		Two	patients	using	the	TiM	had	telephone	consultations.	It	was	noted	that	the	consultation	was	shorter	than	normal	because	many	direct	questions	had	already	been	answered.				
“Quick	consultation	as	most	of	the	questions	already	being	answered	[using	TiM].”	
EH	r.e.	P166		Prior	 knowledge	 of	 one	 patient’s	 condition	 enabled	 the	 staff	 to	 better	 care	patient	 P248.	 	 He	 had	 telephoned	 the	 secretary	 to	 cancel	 his	 appointment	because	he	was	too	ill	to	travel.		A	review	of	the	TiM	answers	indicated	that	he	had	deteriorated,	was	experiencing	distressing	symptoms	and	increasing	carer	strain.	 	 	The	Telehealth	Nurse	discussed	this	with	the	clinical	team	and,	rather	than	 cancelling	 the	 appointment,	 arranged	 a	 telephone	 appointment	 with	 a	physician.		The	patient	and	carer	received	advice	to	improve	his	symptoms	and	follow-up	monitoring	was	initiated.		The	patient	was	then	able	to	attend	clinic	a	few	weeks	later	by	which	time	he	had	improved.	
	When	 asked	whether	 the	 TiM	 could	 be	 used	 to	make	 remote	 decisions,	 on	 a	number	of	occasions	clinicians	answered	“neutral”	(Figure	5.25).			One	clinician	reported	that	they	could	manage	a	stable	patient	by	telehealth	plus	a	telephone	consultation,	 but	 not	 by	 telehealth	 alone.	 	 In	 four	 cases,	 clinicians	wrote	 that	patients	 required	 a	 face-to-face	 consultation	 to	 evaluate	 symptoms	 of	respiratory	failure	highlighted	by	the	TiM	or,	in	one	case,	where	telehealth	had	not	 identified	 a	 pressure	 sore.	 	 In	 one	 case	 the	 physician	 explained	 that	 the	patient	communicated	by	pen	and	paper	and	this	would	not	have	been	possible	on	the	telephone.							 	
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Figure	 5.23	 Physicians’	 satisfaction	 with	 TiM	 system	 (n=15-28).	 	 Responses	were	excluded	if	it	was	not	possible	to	review	the	TiM	system	during	clinic.		No	clinician	disagreed	with	any	of	the	statements.		
	
5.7.4	Accuracy	of	the	TiM	information	The	 shadow	 monitoring	 results	 found	 that	 all	 clinicians	 agreed	 that	 the	 TiM	answers	 were	 a	 useful	 and	 accurate	 reflection	 of	 participants’	 condition.		Despite	the	complexity	of	the	scoring	and	flagging	system,	the	Telehealth	Nurse	trusted	 the	 information	 was	 accurate	 enough	 to	 use	 it	 to	 inform	 her	 clinical	decisions	 making	 (Appendix	 A5.29	 and	 A5.30).	 	 However,	 she	 often	 felt	 the	limited	 amount	 of	 information	 provided	 meant	 the	 TiM	 was	 not	 sufficiently	sensitive	 or	 specific	 on	 its	 own	 to	 enable	 her	 to	 identify	 important	 problems.		She	 felt	 that,	 in	 order	 for	 the	 TiM	 to	 be	 useful,	 she	 often	 needed	 more	information,	 either	 through	 discussion	 with	 the	 patient	 or	 carer	 or	 other	members	of	 the	MDT.	 	She	also	 thought	having	a	 facility	where	patients	could	write	comments	or	elaborate	on	their	answers	would	add	value,	could	save	her	time	and	would	not	be	an	additional	burden.		The	Telehealth	Nurse	 and	Community	Nurse	 also	 suggested	 that	 patients	 and	carers	might	not	always	give	accurate	answers	about	their	condition	(Box	5.2).		Often	the	nurse	needed	to	sensitively	“delve”	further,	often	looking	to	the	carers	for	 more	 information.	 	 	 The	 nurses	 interviewed	 thought	 that	 patients	 may	minimise	 or	 lack	 insight	 into	 their	 problems,	may	 be	 embarrassed	 or	 did	 not	want	to	trouble	their	care	team.		This	reflects	the	comments	made	by	the	carers	(described	above	 in	Section),	who	found	it	hard	to	admit	they	were	struggling	and	would	often	try	to	minimise	problems.		 	
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Box	5.2	Case	vignette:	the	accuracy	of	the	answers	on	the	TiM	system.	The	trial	identified	two	patients	who	gave	answers	that	were	unexpected.		One	patient	(P228)	had	severe	problems	with	excessive	saliva	but	did	not	report	this	on	 the	 TiM.	 	 His	wife	 thought	 he	 chose	 not	 to	 report	 this	 because	 he	 did	 not	want	 to	 think	 that	 his	 condition	 had	 changed	 whereas	 the	 Telehealth	 Nurse	thought	 he	 did	 not	 report	 problems	 because	 he	 not	 want	 additional	interventions.		His	wife	did	explain	that	they	were	a	private	couple	and	avoided	involvement	from	healthcare	professionals.				In	 another	 case,	 the	 TiM	 identified	 problems	 that	 were	 unknown	 to	 the	Community	 MND	 nurse:	 P172	 reported	 choking	 on	 food	 and	 losing	 weight.		These	problems	had	been	discussed	at	her	hospital	appointment	and	the	patient	had	been	advised	to	use	feed	supplements	via	a	gastrostomy.	 	 	P172	had	been	reporting	choking	episodes	on	the	TiM	but	not	told	her	Community	Nurse.			Her	Community	Nurse	had	noticed	 that	P172	had	been	 losing	weight	and	was	not	using	the	prescribed	dietary	supplements.	She	thought	P172	might	not	want	to	admit	new	problems	because	the	couple	were	struggling	to	accept	that	she	had	deteriorated.		She	also	wondered	whether	P172	knew	that	if	she	admitted	that	she	 was	 choking	 she	 would	 need	 to	 stop	 being	 able	 to	 eat	 and	 drink	 and	becoming	dependent	on	gastrostomy	feeding,	something	she	did	not	want.	She	wondered	 whether	 patients	 and	 carers	 might	 be	 more	 honest	 using	 the	 TiM	system	if	they	did	not	see	it	leading	directly	to	these	unwelcome	consequences.		In	this	case,	the	Community	Nurse	thought	it	would	have	been	helpful	to	know	about	the	choking	difficulties	but	the	information	had	not	been	communicated	to	her.		No	 formal	 validation	 of	 the	 TiM	 answers	 was	 planned	 but	 it	 was	 possible	 to	compare	the	ALS-FRS-R	scores	collected	by	TiM	system	to	the	scores	generated	by	the	validated	self-administered	questionnaire	at	baseline	and	each	follow-up	interval	 (208).	 	 Answers	 from	 the	 self-administered	 questionnaire	 were	compared	 to	 the	 closest	TiM	session.	 	Data	was	 included	 if	 a	TiM	session	was	completed	within	 +/-	 14	 days	 of	 the	 questionnaire.	 	 	 51	 pairs	 of	 scores	were	compared	 (in	 some	 cases	 up	 to	 four	 scores	 from	 the	 same	 patient	 were	compared).	 	Figure	5.24	shows	the	correlation	between	the	two	sets	of	scores.		The	 correlation	 was	 very	 high	 with	 a	 coefficient	 of	 0.94	 (p<0.0001).	 	 This	 is	comparable	to	the	correlation	found	when	the	self-administered	questionnaire	was	 compared	 to	 the	 in-clinic	 ALS-FRS-R	 (208)	 (0.94,	 0.93,	 95%	 CI:	 088	 to	0.96).		A	 difference	 plot	 (Bland	 Altman)	 method	 was	 used	 for	 analysing	 agreement	between	 the	 scores	 with	 a	 two-tailed	 value	 of	 p<0.01	 considered	 significant	(Figure	2.25).		The	mean	difference	between	scores	(bias)	was	small	-0.67	(95%	upper	 and	 lower	 limits	 -5.57,	 4.24).	 	 On	 only	 one	 occasion	 (2%)	 were	 the	differences	 in	scores	outside	 these	 limits.	 	This	suggested	 that,	on	average	 the	total	 TiM	 scores	were	 slightly	 higher	 (0.67	 points)	 than	 the	 self-administered	scores.	 The	 distribution	 of	 differences	 suggests	 patients	 with	 less	 disability	tended	 to	answer	slightly	more	consistently	 than	 those	with	 lower	ALS-FRS-R	scores.	
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	Figure	2.26	shows	how	often	the	scores	differ.		On	only	five	(10%)	occasions	the	TiM	and	self-administered	ALS-FRS-R	were	the	same	but	most	scores	(34,	67%)	were	within		+/-	two	points.		There	were	some	outliers:	on	four	(8%)	occasions	the	scores	differed	by	five	points	and	one	patient	scored	five	points	lower	on	the	TiM	 questionnaires	 on	 two	 occasions.	 	 Table	 5.10	 displays	 the	 differences	 in	score	at	individual	question	level.		There	was	no	single	question	that	accounted	for	 the	 differences	 in	 the	 overall	 score.	 	 However,	 patients	 tended	 to	 report	better	 function	 (higher	 scores)	 in	 the	Walking	 and	 Climbing	 stairs	 questions	using	the	TiM	than	the	self-administered	questionnaire.				Figure	5.24	Correlation	between	self-administered	questionnaire	ALSFRS-R	and	TiM	ALSFRS-R	(n=51,	r2	goodness	of	fit	0.94;	p<0.0001).																				Figure	5.25	A	Bland	Altman	plot	of	ALSFRS-R	self-administered	and	TiM	scores	(n=51,	mean	difference	–0.67;	limits	of	agreement	-5.57	and	4.24).																			
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	5.26	The	 frequency	of	occasions	where	 total	ALS-FRS-R	calculated	on	 the	TiM	differed	from	the	paper	questionnaires	(n=51).			
		Table	5.27	The	 frequency	of	 occasions	where	 individual	 answers	provided	on	the	TiM	ALS-FRS-R	differed	from	the	self-administered	scores.				 TiM	score	
higher	than	
self-administered	
score	
No	
difference	
TiM	score	
lower	than	
self-administered	
score	
Score	 2	 1	 0	 1	 2	 3	
Question	 	 	 	 	 	 	Speech	 0	(0%)	 6	(12%)	 36	(71%)	 9	(18%)	 0	(0%)	 0	(0%)	Saliva	 0	(0%)	 2	(4%)	 40	(78%)	 7	(14%)	 1	(2%)	 1	(2%)	Swallow	 0	(0%)	 4	(8%)	 43	(84%)	 4	(8%)	 0	(0%)	 0	(0%)	Handwriting	 0	(0%)	 4	(8%)	 44	(86%)	 3	(6%)	 0	(0%)	 0	(0%)	Using	utensils/	PEG	tube	 0	(0%)	 8	(16%)	 34	(67%)	 8	(16%)	 1	(2%)	 0	(0%)	Washing	and	dressing	 0	(0%)	 7	(14%)	 39	(76%)	 4	(8%)	 1	(2%)	 0	(0%)	Turning	in	bed	 0	(0%)	 6	(12%)	 39	(76%)	 4	(8%)	 2	(4%)	 0	(0%)	Walking	 3	(6%)	 11	(22%)	 36	(71%)	 0	(0%)	 1	(2%)	 0	(0%)	Climbing	stairs	 1	(2%)	 10	(20%)	 35	(69%)	 2	(4%)	 3	(6%)	 0	(0%)	Dyspnoea	 0	(0%)	 5	(10%)	 39	(76%)	 6	(12%)	 1	(2%)	 0	(0%)	Orthopnoea	 6	(2%)	 1	(2%)	 45	(88%)	 1	(2%)	 1	(2%)	 0	(0%)	NIV	use	 0	(0%)	 2	(4%)	 47	(92%)	 2	(4%)	 0	(0%)	 0	(0%)	
Total	 7	(1%)	 66	(11%)	 477	(78%)	 50	(8%)	 11	(2%)	 1	(0.2%)			 	
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These	 results	 indicate	 that	 whilst	 the	 TiM	 and	 the	 self-administered	questionnaire	 results	 are	well	 correlated,	 a	 difference	 in	 scores	was	 common	and	on	a	 third	of	occasions	 total	ALS-FRS-R	scores	differed	by	more	 than	 two	points.	 	 This	 suggests	 that	 the	 two	 methods	 of	 scoring	 should	 not	 be	 used	interchangeably.		However,	it	also	suggests	that	those	patients	are	consistently	over-	or	under-reporting	their	symptoms	using	the	TiM	system.		The	differences	could	 be	 due	 to	 inaccuracies	 in	 either	 the	 TiM	 or	 the	 self-completed	questionnaire,	or	due	 to	 the	natural	 variation	 in	answers	 in	patients’	who	are	experiencing	 day-to-day	 changes	 in	 their	 function.	 	 	 When	 interviewed,	 the	nurse	did	not	feel	that	patients’	answers	varied	disproportionately	from	week-to-week.		Figure	5.27	presents	the	TiM	ALS-FRS-R	scores	during	the	trial	for	ten	patients	and	supports	the	nurse’s	assertions.		Whilst	the	TiM	ALS-FRS-R	scores	tended	 to	 deteriorate	 at	 different	 rates	 (as	 expected	 for	 this	 population)	 but	week-to-week	variations	was	minimal	in	most	patients.				Figure	5.27	The	ALS-FRS-R	scores	for	ten	patients	using	the	TiM	app	during	the	trial.																					Some	improvements	to	the	TiM	questionnaire	and	the	way	patients	are	trained	to	 use	 it	may	 improve	 the	 accuracy	 and/or	 consistency	 of	 answers.	 	 The	 TiM	question	wording	can	be	reviewed	with	a	 focus	on	 those	questions	where	 the	two	 scores	 differed	 the	 most.	 	 Patients’	 understanding	 of	 the	 TiM	 questions	should	be	checked	at	baseline	but	also	at	intervals,	e.g.	when	the	patient	attends	clinic.		Patients	could	be	encouraged	to	ask	questions	and	discuss	their	answers	with	 their	 family.	 	 In	 addition,	 comparing	 the	 TiM	 scores	 against	 a	 same-day	measure	 in-clinic	 could	determine	more	 reliably	whether	 the	TiM	answers	do	reflect	patients’	true	functional	ability.				 	
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5.7.5	Summary	of	the	clinicians’	experiences	using	the	TiM	system	The	TiM	system	was	easy	to	use	by	clinicians.			Reviewing	the	data	of	the	small	number	of	participants	who	took	part	did	not	pose	a	significant	burden	to	the	Telehealth	Nurse	or	physicians.	 	However,	there	were	a	large	number	of	alerts	generated	 by	 the	 system.	 	 The	 nurse	 did	 not	 always	 respond	 to	 the	 alerts.			Responding	 to	 every	 alert	 would	 have	 been	 very	 time	 consuming	 and	 was	demoralising	 for	 the	Telehealth	Nurse.	 	 The	Telehealth	Nurse	wished	 to	 have	the	facility	to	pause	alerts.	 	It	was	not	possible	for	clinicians	to	review	the	TiM	system	 outside	 of	 the	 scheduled	 clinic	 visits	 without	 receiving	 additional	administrative	support	and	time.		The	data	suggests	that	the	TiM	could	provide	helpful	 and	 accurate	 additional	 information	 to	 supplement	 a	 clinical	consultation	either	 in	person,	or	by	 telephone	as	a	viable	alternative	 to	 clinic,	particularly	when	the	patient	couldn’t	travel	to	clinic.		The	TiM	system	appeared	to	be	reasonably	accurate	and	a	good	reflection	of	the	participants’	progress	and	clinicians	were	happy	to	use	the	information	to	assist	them	making	decisions	as	long	as	the	option	was	available	to	telephone	or	see	the	patient	in	person.			
5.8	Exploring	the	potentials	impacts	of	the	TiM	system			As	 discussed	 in	 the	 introduction,	 neither	 the	 trial	 nor	 the	 process	 evaluation	aimed	 to	 establish	 the	 efficacy	 of	 the	 TiM.	 	 However,	 questionnaires	 and	interviews	 did	 explore	 participants’	 experience	 of	 their	MND	 care	 during	 the	trial	along	with	their	interactions	with	the	Telehealth	Nurse.		Section	5.8	and	5.9	describes	 the	potential	 impacts	 the	TiM	may	have	 and	how	 the	TiM	might	 be	used	in	the	future.	 	 	Section	5.8	describes	ways	in	which	participants’	care	and	wellbeing	might	be	affected	by	using	the	TiM	and	the	context	and	mechanisms	that	 may	 be	 underpinning	 them.	 It	 also	 explores	 how	 the	 Telehealth	 Nurse	interacted	 with	 the	 TiM	 and,	 in	 particular,	 explores	 the	 reasons	 why	 many	participants	 felt	 the	 TiM	 system	 had	 no	 impact	 on	 their	 care.	 	 Section	 5.9	describes	participants’	and	clinicians’	thoughts	about	how	the	TiM	system	might	be	used	in	the	future.	
5.8.1	The	potential	impacts	of	the	TiM	system	on	patients	When	 interviewed,	 all	 participants	 apart	 from	 P047	 expressed	 overall	satisfaction	with	the	TiM	system	(Figure	5.28,	Appendix	5.30).				Figure	5.28	Potential	mechanisms	of	impacts	of	the	TiM	on	patients’	care	identified	during	the	interviews							
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The	main	mechanisms	by	which	participants	thought	the	TiM	might	impact	on	their	 care	 were:	 by	 increasing	 monitoring;	 providing	 better	 connection	 with	specialists;	 improving	 awareness	 of	 their	 own	 condition	 and	 enabling	 earlier	identification	of	problems.				
“I	think	it’s	probably	one	of	the	best	ideas	to	come	out	of	the	NHS	for	years.”	P122		Weight	was	identified	by	patients	and	the	Telehealth	Nurse	as	a	useful	measure.		
“Weights	have	been	quite	interesting,	cos	if	they	can	use	the	weighing	scales	…	we	can	
monitor	their	weight...otherwise	you	wouldn’t	necessarily	see	that	variation.”	Telehealth	
Nurse		Many	participants	thought	that	the	TiM	improved	their	awareness	of	their	own	condition.	Whilst	 they	 felt	 that	 they	did	not	need	to	track	their	progress	using	the	 system	 (they	 knew	 themselves	 how	 they	 were	 changing),	 weighing	themselves	 weekly	 meant	 patients	 were	 more	 aware	 of	 their	 weight	 and	nutrition,	 something	 they	 knew	 they	 could	 do	 themselves	 to	 keep	 healthy.		Those	with	slowly	progressive	disease	also	noticed	 that	 their	answers	did	not	change	 rapidly.	 	 Rapid	 progression	 was	 something	 all	 patients	 feared	 so	 this	made	them	feel	positive.			They	felt	they	were	being	carefully	monitored	which	was	 reassuring,	particularly	 for	 carers.	 	 It	 also	enabled	 them	 to	keep	 in	 touch	with	the	team.				Box	 5.3	 below	describes	 one	 case	where	 interviews	 captured	 an	 event	where	information	on	the	TiM	did	trigger	earlier	action	by	the	MDT	and	an	improved	outcome	for	the	patient	and	carer	was	observed.		In	 a	 small	 number	of	 cases,	 participants	 remembered	 reporting	 a	problem	on	the	 Patient	 App	 that	 resulted	 in	 the	 Telehealth	 Nurse	 contacting	 them	 and	giving	them	advice.		Often	all	the	Telehealth	Nurse	did	was	offer	reassurance	or	advice	that	the	patient	had	heard	before.	 	Whilst	the	Telehealth	Nurse	felt	that	she	did	not	do	anything,	the	patients	were	very	pleased	that	this	occurred	and	were	 happy	with	 the	 consultation.	 	 This	 reinforced	 the	notion	 that	 specialists	were	monitoring	them	closely.		In	the	face	of	a	relentlessly	progressing	disease,	these	interactions	were	welcomed.		
“...I	did	the	second	questionnaire,	and	within	a	day	[Telehealth	Nurse]	called	saying	“I’ve	
got	a	red	flag	on	one	of	your	answers.”	And	it’s	the	fact	that	I’d	fallen	twice	while	I	was	
away	on	holiday	and	I’d	put	on	[the	TiM]...	it	said	“have	you	fallen	recently,	how	many	
times?”	So	she	phoned	me,	and	said,	“Are	you	ok?	Is	there	a	reason	why	you	fell?”	No,	just	
my	usual	clumsiness....		
Q:	Were	you	expecting	her	to	call?		
P:	No,	I	wasn’t	actually.	It	was	just	a	bolt	out	of	the	blue...I	find	that	quite	positive.	It	shows	
that	the	whole	idea	of	it	works.		
Q:	Has	it	changed	your	behaviour	at	all?		
P:	No.	Not	really.”	P122	
	
“I	think	the	benefit	to	P	is	real.		Because	…	somebody	is	there	on	hand	looking	at	things…	
Because	it’s	slow	with	P	and	he	doesn’t	need	as	much	attention	and	care,	it’s	easy	to	feel	
detached	from	any	positive	interaction.”	C122		
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	Patient	 047	 did	 not	 find	 the	 system	 had	 helped	 her	 but	 thought	 that	 the	reassurance	 offered	 by	monitoring	would	 have	 been	 very	 helpful	 for	 patients	early	in	the	disease.		She	explained	her	experiences	when	first	diagnosed:		
“…	for	the	first	year	no	day	was	normal,	no	day	looked	like	any	other	day	in	my	life	before	
that.	 …	 You	 imagine	 symptoms,	 …	 you	 think	 God,	 this	 is	 happening	 and	 that	 must	 be	
related	to	the	MND...?”	P047				As	a	result,	she	felt	that	an	additional	contact	could	have	been	helpful	to	support	her.		
“Q:	 Do	 you	 think	 there	might	 have	 been	 a	 point	 in	 your	 disease	where	 those	 questions	
…were	useful?	
P:	Nearer	the	beginning,	definitely…If	I	could	have	camped	in	[neurologist]'s	house	for	the	
first	six	months	I	would	have	done,	just	so	she	was	there,	so	I	could	say;	“but	what	about	
this,	what	about	that?”…	in	the	first	year	I	would	have	filled	that	in	every	day,	just	to	have	
that	touch	point”	P047	
	 	
	 147	
Box	5.3	Case	vignette:	making	earlier,	better-informed	decisions	The	 Telehealth	 Nurse	 identified	 one	 patient	 who	 she	 felt	 had	 gained	 benefit	from	using	the	TiM	system.		The	TiM	detected	that	the	patient’s	weight,	swallow	and	mobility	were	declining	quickly	and	the	carer	reported	high	levels	of	strain.			The	 couple	 was	 struggling	 to	 accept	 his	 decline	 and	 the	 patient	 tried	 to	minimise	his	symptoms.	 	The	nurse	was	able	inform	his	community	team	who	encouraged	them	to	accept	additional	support.		The	patient	wrote:		
“The	questions	nudged	me	to	facing	what	I	could	do	and	not	what	I	can't.”	P409			The	TiM	alerted	 the	clinical	 team	to	P’s	rapidly	declining	weight	(Figure	5.29)	who	 contacted	 him	between	 clinics	 to	 highlight	 this	 information	 and	 strongly	encouraged	him	 to	 consider	gastrostomy	 insertion.	 	At	 the	end	of	 the	 trial,	he	did	opt	 for	a	gastrostomy	and	was	asked	about	whether	 the	TiM	affected	 this	decision.		He	agreed:		
“Q:	 We	 kept	 an	 eye	 on	 your	 weight	 and	 I	 wonder	 whether	 you	 think	 that	 may	 have	
influenced	your	decision	to	have	a	feeding	tube	or	not?	
P:I	was	 frightened	by	 the	speed	of	 loss	of	weight	but	was	convinced	how	much	muscle	 I	
lost.”	P409		Figure	5.29	The	“heat	map”	showing	mobility	and	bulbar	alerts	and	15%	weight	loss	from	baseline		
	The	 carer	 explained	 that	 she	 struggled	 to	 admit	 that	 she	 was	 finding	 things	difficult	and	found	it	easier	to	do	this	using	the	TiM	system.		
“I	think	for	me	it	was	the	ability	to	be	able	to	answer	those	questions	without	[P]	knowing	
what	I'm	putting,	cos	...I	didn't'	want	to	upset	you,	I	didn't	want	to	worry	you,	so	to	be	able	
to	answer	them	just	like	that,	just	on	the	Telehealth	thing...	without;	somebody	being	here	
asking	me	in	front	of	P.”	C409			The	 community	 therapist	 referred	 the	 couple	 to	 the	 local	 hospice	 and	 care	agency	and	the	carer	was	persuaded	to	accept	some	additional	support,	which,	in	the	six	month	interview	she	described	as	becoming	a	“lifeline”.		
“...she	got	 the	ball	 rolling	 there;	 and	with	 the	 [care]	Agency	as	well,	 she	definitely	 kick-
started	that...Initially,	you're	torn	because	you're	so	grateful	...that	people	care	and	want	
to	help,	but	 then	 for	me	 it	was	 this	 is	another	person	 in	 the	house.	 I	 remember	 the	 first	
time	([to	P]	I've	not	told	you	this),	the	first	time	B	came	from	[the]	hospice	and	sat	with	
you,	I	think	I	spent	the	first	hour	sobbing	in	a	lay-by	somewhere	because	to	my	mind	I'd	
left	you	with	a	stranger	and	it	just	felt	so,	so	alien,	it	really	did.	But	then	as,	as	the	weeks	
go	by	and	...everything's	in	place	week	after	week	after	week,	it	becomes	a	lifeline.”	C409	
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5.8.2	The	potential	impacts	of	the	TiM	system	on	carers	The	interviews	identified	many	circumstances	where	the	carers	felt	the	TiM	had	impacted	 up	 them,	 either	 by	 reassuring	 them	 that	 their	 loved	 one	was	 being	monitored,	or	that	problems	could	be	identified	and	solved	more	rapidly.		It	also	provided	them	with	an	important	opportunity	to	highlight	their	own	problems,	separately	from	the	patients.		Carers	welcomed	 the	 additional	monitoring	 of	 their	 loved	 one	 and	 additional	contact	 provided	 by	 the	 TiM	 system	 and	 felt	 reassured	 that	 it	 could	 identify	problems	 quickly.	 	 This	was	 important	 because	 carers	were	 often	 the	 first	 to	recognise	a	problem	and	some	found	it	hard	to	persuade	their	loved	one	to	raise	it	 with	 the	 MDT.	 	 One	 wife	 of	 a	 patient	 with	 slowly	 progressive	 disease	explained:		
“I	think	the	benefit	to	P	is	real.	Because	…	somebody	is	there	on	hand	looking	at	things.	I	
think	 it’s	 a	 brilliant	 tool	 to	 be	 used	 to	 be	 able	 to	 have	 instant…	 not	 instant	 access	 to	
professionals,	 but...Because	 it’s	 slow	with	 P	 and	 he	 doesn’t	 need	 as	much	 attention	 and	
care,	it’s	easy	to	feel	detached	from	any	positive	interaction.		Whereas	with	that,	you	know	
somebody’s	 there	and	 if	 there	was	something	you’d	pick	up	quite	quickly	as	apposed	 to,	
you’ve	gotta	wait	until	your	next	twelve	week	appointment”	C122				A	 common	 theme	 identified	 in	 interviews	 was	 that	 a	 carer’s	 wellbeing	 was	directly	 linked	 to	 the	patient’s.	 	Carers	 felt	 that	 improving	 their	ability	 to	care	for	 their	 loved	 one	 would	 improve	 their	 own	 wellbeing	 too.	 	 However,	 they	explained	that	it	was	hard	to	accept	help	from	the	MDT,	either	because	they	did	not	feel	ready	to	accept	or	admit	that	they	needed	help	(case	example	described	in	Box	5.3).		They	particularly	found	it	hard	to	accept	help	from	external	carers.		Participants	 were	 reticent	 to	 ask	 for	 extra	 help:	 the	 ability	 to	 remain	independent	was	seen	as	a	positive	coping	strategy	whereas	needing	additional	help	was	perceived	as	“not	coping”.		“Not	coping”	was	a	concept	associated	with	fear	 and	 failure	 and	was	 a	major	 negative	milestone	 in	 their	 disease.	 	 Carers	found	it	difficult,	or	even	felt	guilty	delegating	some	of	their	duties	to	unfamiliar	people.	 	 They	would	 often	 try	 to	 remain	 available	 for	 the	 patient	 even	when	other	 carers	 were	 present.	 	 In	 addition,	 accepting	 additional	 help	 also	 had	 a	negative	 impact	on	another	 “coping”	strategy	 identified	by	participants:	 trying	to	 maintain	 life	 as	 “normal”	 as	 possible.	 	 External	 carers	 entering	 the	 home	could	 impact	 on	 a	 family’s	 lifestyle,	 privacy	 and	 home	 environment	 and	 was	often	inflexible	and	not	responsive	to	the	carer’s	needs.				As	 a	 result	 of	 these	 barriers,	 carers	 tried	 to	 avoid	 accepting	more	 help	 even	though	 they	 recognised	 they	needed	help.	 	 Carers	 explained	 that	 the	needs	of	their	 loved	one	meant	they	had	to	take	priority,	meaning	their	own	needs	and	identify	could	be	neglected.		As	a	result,	they	were	pleasantly	surprised	that	the	TiM	would	consider	their	needs	as	they	felt	the	MDT’s	focus	was	also	primarily	on	the	patient.		One	patient’s	wife	explained:		
“You	 become	 a	 bit	 of	 a	 non-person	 because	 the	 concentration	 is	 on	 the	 person	 who	 is	
diagnosed	with	MND,	and	rightly	so,	but	then	if	affects	the	partner	in….	it	affects	them	as	
well,	but	they	don’t	suffer	the	symptoms.”	C122			
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This	additional	focus	on	them	prompted	carers	to	consider	their	own	wellbeing	and	receive	help	if	they	were	experiencing	difficulties.	 	They	explained	that,	as	the	patient	is	usually	present	in	meetings	with	the	MDT,	it	was	difficult	for	them	to	 discuss	 their	 own	 wellbeing	 because	 they	 worried	 about	 the	 impact	disclosing	their	concerns	would	have	on	the	patient.		
Q:	When	people	 like	 [community	OT]	 come	 to	 see	 you	 do	 they	 ask	 you	about	 your	 own	
circumstances	and	how	you	are?	
C:	I	don’t	think	particularly.	I’m	aware	that	I	could	discuss	it	with	her...	but,	we’re	always	
together	so	sometimes	it’s	a	bit	difficult...	to	say	what	you	think	and	what	you	feel....	
[later]	Q:	If	you	do	have	a	bad	time,	how	do	you	tell	people	about	that...?	
P:	Well	you	don’t,	you	just	grin	and	bear	it.”	P&C062		
	
“I	find	being	able	to	have	individual...	meeting,	as	apposed	to	meeting	as	a	couple:	when	
you	are	at	the	hospital	you	are	together,	at	home	you	are	together	...should	you	say	how	
are	you	feeling	in	front	of	the	other	person	because	you	don’t	want	them	to	feel	bad.”	C122			Carers	thought	that	the	TiM	system	could	provide	them	with	an	opportunity	for	them	to	express	their	feelings	in	private,	separately	from	the	patient.		This	could	be	 done	 in	 their	 own	 home,	 without	 having	 to	 leave	 the	 patient.	 	 They	 felt	comfortable	 that	 the	 MND	 care	 team	 could	 contact	 them	 if	 they	 detected	 a	problem	 to	offer	 additional	 support.	 In	 fact,	 the	 impersonal	nature	of	 the	TiM	system	was	 an	 advantage	 as	 it	 enabled	 carers	 to	 be	more	 honest	 about	 their	difficulties.		One	wife	of	a	patient	with	rapidly	progressive	disease	explained:		
“I	 think	 it's	 a	 really,	 really	 good	way	 of	 doing	 it.	 	 Because	whereas	 I	 probably	 try	 and	
flower	things	up	a	lot	of	the	time	and	be	upbeat	about	everything,	I	found	that,	because	it	
was	just	me	and	the	tablet	and	I	was	able	just	to	be	totally,	totally	honest	about	it,	about	
how	I	was…	feeling	at	 that	particular	time…	The	 impersonal	 format…	of	 the	way	 it	was	
actually	 done;	 the	 questions	 weren't	 impersonal	 but	 the	 actual	 way	 you	 could	 answer	
them,	for	me,	has	been	a	real	help	just	to	be	able…	to	do	that.”		C409			Box	 5.3	 (above)	 describes	 the	 experience	 of	 a	 carer	 who	 reported	 problems	with	carer	strain	and	subsequently	received	help	from	the	MDT.		The	Telehealth	Nurse	 thought	 that	 the	 additional	 information	 on	 the	 TiM	 system	meant	 the	couple	 could	 be	 supported	 in	 accepting	 the	 diagnosis	 and	 the	 problems	 they	were	 facing,	 and	 enable	 them	 to	 look	 positively	 towards	 receiving	 additional	medical	and	social	care.	 	
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5.8.3	Nurses’	attitudes	towards	the	potential	value	of	the	TiM		Despite	the	problems	she	encountered,	the	Telehealth	Nurse	felt	the	TiM	system	had	potential	to	be	of	value	“As	a	tool	to	aid	the	patient	and	then	aid	the	nurse”.	(Appendix	A5.31).		She	felt	she	could	use	the	TiM	to	gain	more	information	and	alert	her	earlier	to	problems,	on	which	she	could	intervene.	She	thought	could	facilitate	sharing	of	information	and	reduce	her	workload.	 	She	also	noted	that	the	 TiM	 was	 picking	 up	 important	 problems	 of	 which	 she	 was	 unaware,	 the	patient	and	carer	trying	to	minimise.	 	She	remarked	that	seeing	weight	trends	had	 been	 useful	 and	 had	 enabled	 her	 to	 discuss	 problems	 with	 patients,	particularly	when	she	saw	them	in	clinic.				
	The	Telehealth	Nurse	explained	that	she	recognised	that	clinics	were	a	burden	to	 patients	 and	 sometimes	 patients	 felt	 they	 offered	 little	 value.	 	 She	 thought	that	if	TiM	could	reduce	the	burden	of	clinics,	it	would	be	welcomed	by	nurses.		Whilst	 she	 felt	 it	might	be	possible	 to	use	 the	TiM	 to	delay	appointments,	 she	had	 some	 doubts	 because,	 like	 the	 patients	 interviewed,	 she	 valued	 the	 role	clinic	 played	 in	 developing	 her	 relationship	 with	 the	 patient	 and	 carer	 and	gaining	 information	 about	 their	 problems.	 	 She	was	 also	 unsure	whether	 the	TiM	 alone	 provided	 enough	 information	 to	 make	 decisions.	 	 She	 felt	 some	aspects	of	their	care	(in	particularly,	respiratory	monitoring)	required	face-to-face	visits	whereas	other	 issues	would	need	a	 combination	of	 the	TiM	system	and	communication	with	the	patients/carers	and	other	members	of	the	MDT.	
5.8.4	 Exploring	 why	 participants	 felt	 the	 TiM	 system	 did	 not	 have	 an	
impact	on	patient	care		Whilst	the	participants	did	react	positively	to	the	TiM	system,	many	felt	 it	had	not	 had	 a	 significant	 impact	 on	 their	 care.	 At	 six	 months	 only	 seven	 (47%)	patients	and	five	(33%)	of	carers	agreed,	“The	MND	team	contacted	me	quickly	if	
my	condition	changed	or	I	had	a	problem”.	 	 	Some	reasons	 for	 this	 identified	 in	the	interviews	relate	to	the	participants	themselves:	
• Participants	felt	their	condition	had	not	changed	during	the	trial;	
• Help	was	offered	but	declined.	However,	 the	 main	 themes	 identified	 in	 the	 trial	 surrounded	 the	 interaction	between	the	participants	and	the	Telehealth	Nurse:	
• Participants	had	not	received	feedback	from	the	Telehealth	Nurse;	
• The	TiM	 system	had	 identified	 problems,	 the	Telehealth	Nurse	 did	 not	acknowledge	the	problem	or	act	in	the	way	participants	expected;		
• The	Telehealth	Nurse	took	action	but	did	not	inform	the	patient/carer;	
• The	 TiM	 system	 had	 identified	 problems	 but	 either	 no	 action	 was	required	or	they	were	already	receiving	treatment;			
• Participants	 did	 not	 remember	 the	 TiM	 system	 being	 mentioned	 in	consultations	with	the	hospital	MDT.		Many	patients	explained	their	disease	had	not	changed	greatly	during	the	trial	and,	as	a	result	they	did	not	think	they	needed	help	from	the	MDT	(such	as	the	case	 described	 in	 Box	 5.4	 and	 5.5).	 	 In	 some	 cases	 participants	 reported	problems	but	they	did	not	think	the	MDT	could	help	with	the	problems	or	that	the	MDT	was	not	there	to	help	with	their	problems	(e.g.	carer	strain,	discussed	in	5.9.2).			
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5.8.5	The	interaction	between	participants	and	the	Telehealth	Nurse	
5.8.5.1	Participant	experiences	The	main	 reason	participants	 felt	 the	TiM	system	had	no	 impact	was	because	they	had	had	insufficient	feedback	from	the	telehealth	team	(Appendix	A5.32).		This	was	the	case	even	when	their	condition	had	changed	little	as	participants	still	 expected	 feedback	 in	 these	 circumstances.	 	 Participants	 could	 feel	demoralised	 when	 they	 were	 expecting	 feedback	 but	 were	 not	 contacted.		Patient	047	was	particularly	dissatisfied,	writing:	
	
“I	have	not	received	any	feedback/contact	from	the	MND	team	while	using	the	TiM”	P047				She	 had	 reported	 emotional	 difficulties	 and	 was	 expecting	 contact	 from	 the	MDT.		The	Telehealth	Nurse	had	been	alerted	to	the	problems	but	had	not	acted	because	she	knew	the	patient	was	already	receiving	psychology	therapy.		 	As	a	result	the	patient	was	so	demoralised	that	she	stopped	using	the	system.	
	
“The	emotional	psychological	depths	that	I've	been	to,	I	was	putting	the	stuff	in	Telehealth	
and	 thinking	 but	 nobody's	 acknowledged	 this	 or	 contacted	me	 about	 it,	 and	 I	 thought:	
well	they're	not	going	to	because	that	isn't	what	the	clinic's	about,	and	that	made	me	stop	
using	it.”	P047		The	TiM	system	did	not	provide	automatic	feedback:	it	relied	on	the	clinicians	to	inform	 the	participants	 if	 they	had	 reviewed	 the	 results	 or	 taken	 any	 actions.		Most	participants	had	received	little	or	no	feedback	from	the	Telehealth	Nurse	and	they	could	not	recall	it	being	mentioned	during	the	clinic	visits.		Interviews	with	participants	and	the	Telehealth	Nurse	suggested	that,	on	many	occasions,	problems	 were	 being	 identified	 by	 the	 TiM	 system	 but	 the	 nurse	 was	 either	taking	no	action	or	taking	actions	but	not	informing	the	participant.		It	was	also	noted	that	 the	nurse	might	 talk	 to	a	patient	about	a	problem	identified	by	 the	TiM	 system	but	 not	mention	 that	 she	 had	 used	 the	TiM	 system	 to	 identify	 or	monitor	 the	problem.	 	For	example,	carer	409	had	reported	carer	strain	using	the	 TiM	 system	 but	was	 not	 aware	 that	 it	was	 the	 information	 from	 the	 TiM	system	that	had	initiated	the	offers	of	help	that	she	had	received.		The	 interviews	 suggested	 that	 there	was	 a	 significant	 difference	 between	 the	attitudes	 and	 expectations	 of	 the	 participants	 towards	 the	 TiM	 and	 the	problems	 they	were	 reporting	 and	 the	 attitudes	 and	actions	of	 the	Telehealth	Nurse	 (Appendix	 A5.33).	 	 Participants	 described	 problems	 that	 they	 would	expect	 to	 be	 acknowledged	 by	 the	 Telehealth	 Nurse.	 	 The	 most	 frequently	reported	were:	 chest	 infections;	 swallowing	difficulties;	 falls	 (particularly	 first	falls	 or	 continued	 falls)	 and	 emotional	 strain.	 	 Falls	 were	 a	 very	 common	problem	mentioned	by	participants.	 	When	discussing	the	course	of	their	MND	they	saw	 their	 first	 fall	 as	a	 significant	milestone	 in	 their	disease	and	 it	had	a	lasting	impression	on	them.		Participants	were	frightened	of	falls	and	a	fall	could	knock	their	confidence.	 	They	identified	falls	as	an	important	problem	that	the	Telehealth	Nurse	should	be	alerted	to,	and	they	thought	action	could	be	taken.				 	
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“...if	 it	goes	through	on	the	TiM	and	it	says	I've	had	a	fall	then	I	would	expect	somebody	
would	ring	and	say	have	you	sorted	 it,	are	you	OK...	 ...get	some,	 let's	get	somebody	 in	 to	
make	 sure	 it	 don't	 happen	 again,	 because	 I	 mean	 I	 could	 have	 tripped	 over	 anything,	
couldn't	I?”	P317		Important	 incidents	 included	 the	 first	 fall,	 frequent	 falls	 and	 new	 falls.	 	 In	contrast,	the	Telehealth	Nurse	explained	that	falls	were	an	expected	problem	in	MND	and	she	may	only	contact	the	patient	if	falls	were	a	new	event.			Falls	were	also	a	very	common	alert	raised	by	the	TiM	system.		
“She	red	flagged	that	she’d	fallen,	which	is	quite	a	common	occurrence	on	a	lot	of	patients,	
and	I	don’t	particularly	worry	unless	they’ve	been	very,	very	well	and	then	suddenly.	So	if	
it	happens	over	a	few	weeks	and	I’ve	spoken	to	them	and	I	know	the	situation	then	I	don’t,	
I’m	not	always	alerted	by	that	red	flag.”	Telehealth	Nurse		Whilst	participants	expected	the	nurse	to	make	contact	they	did	not	have	an	expectation	of	what	the	Telehealth	Nurse	should	be	doing	to	help	but	they	did	expect	their	problems	to	be	taken	seriously.		They	expected	and	valued	any	form	of	contact,	even	if	they	did	not	want	help	or	did	not	think	there	was	anything	additional	that	could	be	done.					
“Q:	Would	[the	newly	identified	problem]	be	something	that	you	think	they'd	need	to	call	
you	 about,	 or	would	 it	 be	 something	 you'd	 expect	 them	 to	 deal	with	 the	 next	 time	 you	
came	to	clinic?	
P:	I	would	probably;	but	because	the	clinic	visits...	there's	quite	a	few	months	in-between	
[visits],	I	would	expect	the	whole	team	then	to	come	together	and	for	you	to	maybe	
highlight	it	to	my	[community]	MND	nurse	and	say:	you'd	better	go	out	and	see	P	because	
her	breathing's	always	been	great	and	now	she	says	that	she's	struggling,	so	see	what	
help	you	can	give	her.”	P317		Whereas	the	participants	valued	highly	contact	from	the	MDT,	even	if	it	was	just	to	acknowledge	 their	problems	and	offer	advice,	 the	Telehealth	Nurse	did	not	think	she	was	offering	anything	during	these	calls.			This	was	further	reinforced	when	she	did	telephone	and	patients	tried	to	dismiss	the	problem,	not	wanting	to	 admit	 that	 they	 were	 experiencing	 difficulties.	 	 This	 made	 both	 the	participant	 and	 the	 nurse	 feel	 that	 they	 were	 not	 helping	 and	 this	 made	 the	nurse	less	inclined	to	contact	patients	again.		
“P:	[OT]	said	last	week,	[Telehealth	Nurse]	said	twice	there	had	been	a	red	alert	because	
I’d	fallen,	I’d	put	that	I’d	fallen.	
Q:	And	what	did	[OT]	say?	
P:	[inaudible]	I	over	balanced,	I	don’t	fall	over.”	P217								 	
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Box	5.4	Case	vignette:	the	importance	of	interaction	and	feedback	P134	 is	 middle-aged	 man	 with	 severe	 disability.	 He	 felt	 his	 disease	 was	 not	progressing	rapidly	so	did	not	currently	require	many	changes	to	his	MND	care.			He	had	high	expectations	of	the	MND	care	service	but	was	motivated	to	comply	with	medical	advice	when	he	could	see	the	benefits.		He	was	a	good	user	of	NIV,	despite	struggling	with	the	equipment.		He	felt	this	was	because	he	experienced	clear	 short-term	 benefits	 of	 NIV	 as	 well	 as	 the	 long-term	 potential	 survival	benefit.		
“Q:	And	why	do	you	think	you	do	persevere	so	much	with	[NIV]?	
P:	 Because	 I	 think	 it	 gives	me,	 it's	 useful.	 I	wouldn't	 sleep	 on	my	 back	 until	 I	wore	 the	
mask;	...I've	got	pressure	on	my	shoulder	because	I	sleep	on	my	left	side.	So	being	able	to	
roll	onto	my	back	gives	that	a	bit	of	ease	at	times	as	well.”	P134	(High	technology	user,	
low	TiM	user)		He	was	enthusiastic	about	technology	and	felt	that	the	TiM	system	was	a	good	idea,	promoting	better	links	with	the	care	team,	and	potentially	reducing	clinic	visits,	 which	 he	 often	 found	 unnecessary,	 given	 his	 current	 disease	 stability.		However,	he	was	an	infrequent	user	of	the	TiM.		He	thought	the	main	reason	for	low	adherence	was	 the	accessibility	of	 the	 tablet.	 	However,	he	also	explained	that	the	TiM	system	was	not	a	priority	for	him.		
“It	was	always	a	Monday	I'd	try	and	do	it	on.	But...	with	all	the	[house]	renovations	and	
stuff	it's	sort	of	not	become	a	priority	at	the	moment.”	P134		In	contrast	to	NIV,	he	found	the	TiM	system	did	not	offer	him	any	benefits.		He	felt	that	his	condition	had	changed	little	over	the	time	he	was	in	the	study	and	did	not	experience	any	feedback.		He	accepted	that	this	was,	in	part,	because	his	adherence	was	low.	 	 	His	attitude	was	further	reinforced	when	he	developed	a	chest	 infection	and	was	advised	by	the	TiM	system	to	expect	contact	 from	the	MND	team	but	he	did	not	receive	a	call.		
“I	had	a	chest	infection,	and	they	said	that	your	[Telehealth]	MND	nurse	will	be	in	touch	
within	 the	 next;	 and	 I've	 never,	 not	 heard	 back,	 so.	 	 To	 me	 it	 feels	 like	 a...	 gathering	
exercise	at	the	moment	where	you're	just	getting	information.”	P134		Despite	this,	when	interviewed	at	six	months	he	still	felt	the	TiM	system	was	a	potentially	 valuable	 resource	 if	 used	 correctly.	 	 He	 felt	 it	 would	 be	 a	 useful	replacement	for	clinic,	as	long	as	he	did	not	miss	out	on	any	information.	
	
“I'm	happy	 to	 fill	 it	 in,	 if	 it	gives	us	 three	months	off	or	 something,	 that's	 fine.	 	But,	you	
know,	maybe	a	sort	of,	a	way	of	updating	it	and	saying,	“	We've	been	doing	this	research	
or	something”,	using	it...		
Q:	So	you	getting	messages?		
P:	...as	a	two-way	thing,	yeah.”	P134			 	
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5.8.5.2	The	Telehealth	Nurse	behaviour	towards	alerts	The	 interviews	 also	 explored	 why	 the	 Telehealth	 Nurse	 was	 not	 acting	 upon	problems	as	expected.		Her	comments	mirrored	the	findings	in	Section	5.7	that	on	more	 than	 50%	of	 occasions,	 the	 TiM	 system	was	 generated	 an	 alert.	 The	Telehealth	 Nurse	 felt	 that	 she	 was	 seeing	 the	 same	 problems	 every	 week,	particularly	falls	and	swallowing	difficulties	(Appendix	A5.34-A5.35).				
“I	 have	 concerns	 about	 it,	 cos	we	 have	 some	 patients	 that	 red	 flag	 every	week”	
Telehealth	Nurse		This	was	particularly	 frustrating	when	alerts	kept	occurring	on	which	she	had	already	taken	action	or	she	felt	there	was	no	action	required.	Whilst	she	did	not	feel	 the	 TiM	 system	 took	 up	 a	 lot	 of	 her	 time,	 the	 requirement	 to	 deal	 with	multiple	 problems	 for	 which	 she	 saw	 no	 solution	 added	 to	 the	 psychological	burden	of	using	the	system.		As	she	had	wanted	to	be	the	only	nurse	to	use	the	system	 regularly,	 the	 responsibility	 fell	 to	 her	 to	 manage	 the	 problems	identified	and/or	ignore	alerts	that	were	unnecessary.	 	 	Despite	the	number	of	alerts	encountered,	she	felt	she	should	justify	why	she	was	taking	no	action	for	each	 alert,	 particularly	 if	 the	 problem	 could	 be	 potential	 dangerous	 (such	 as	choking).	 	 She	 could	 not	 control	 how	 the	 alerts	 were	 generated	 and	 she	explained	 that	she	would	stop	ringing	about	problems	that	kept	recurring,	 for	which	she	could	take	no	further	action	and	would	prefer	to	“pause”	these	alerts.		She	also	thought	that	the	patients	could	also	become	demoralised	if	they	were	reporting	the	same	problems	every	week.		
“Maybe	to	them,	the	fact	that	it’s	the	same	thing	week	in	week	out,	they’ve	got	an	
insight	 into	 that	 problem,	 it’s	 not	 changing	 and,	 so	 they’re	 not	 looking	 for	
something	to	help	with	it	really.”	Telehealth	Nurse		The	 Telehealth	 Nurse	 explained	 that	 the	 information	 on	 the	 TiM	 system	was	often	insufficient	to	make	decisions	so	she	might	telephone	the	patient	for	more	information.	 	 She	would	 also	 use	 her	 experience	 and	wider	 knowledge	 of	 the	patient	 to	 decide	 how	 to	 act.	 	 In	 some	 circumstances	 she	 also	 delayed	responding	until	the	patient	was	attending	clinic.	In	these	circumstances	she	did	not	 communicate	 these	 decisions	 to	 the	 patient.	 	 The	 Telehealth	 Nurse	prioritised	problems	that	were	unexpected	and	placed	less	priority	on	problems	she	expected	to	occur	in	MND.		As	discussed	earlier,	some	of	the	problems	she	said	 she	 did	 not	 prioritise	 were	 problems	 identified	 by	 patients	 as	 being	significant:	for	example	falls	or	breathing	difficulties.				
“She	red	flagged	that	she’d	fallen,	which	is	quite	a	common	occurrence	on	a	lot	of	
patients,	 and	 I	 don’t	 particularly	 worry	 unless	 they’ve	 been	 very,	 very	 well	 and	
then	 suddenly.	 So	 if	 it	 happens	 over	 a	 few	weeks	 and	 I’ve	 spoken	 to	 them	and	 I	
know	the	situation	then	I	don’t,	I’m	not	always	alerted	by	that	red	flag.”	Telehealth	
Nurse		She	also	commented	that	she	considered	whether	the	problem	identified	could	be	solved	or	whether	the	problem	required	a	solution.	 	The	patient	interviews	captured	one	such	episode	(P122).	 	 In	 this	case,	 the	perspective	of	 the	patient	
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differed:	 whereas	 the	 nurse	 felt	 she	 had	 not	 added	 anything	 to	 the	 patients’	care,	in	contrast,	the	patient	felt	reassured	that	he	or	she	was	being	monitored.		
“...I	did	the	second	questionnaire,	and	within	a	day	[Telehealth	Nurse]	called	saying	“I’ve	
got	a	red	flag	on	one	of	your	answers.”	...	I’d	fallen	twice	while	I	was	away	on	holiday	and	
I’d	put	on	[the	TiM]...	it	said	“have	you	fallen	recently,	how	many	times?”	So	she	phoned	
me,	and	said,	“Are	you	ok?	Is	there	a	reason	why	you	fell?”	No,	just	my	usual	clumsiness....		
Q:	Were	you	expecting	her	to	call?		
P:	No,	I	wasn’t	actually.	It	was	just	a	bolt	out	of	the	blue...I	find	that	quite	positive.	It	shows	
that	the	whole	idea	of	it	works.		
Q:	Has	it	changed	your	behaviour	at	all?		
P:	No.	Not	really.”	P122		The	 nurse	 found	 it	 easier	 to	 manage	 patients	 whom	 she	 already	 knew	 well,	either	 from	 directly	 meeting	 them,	 through	 telephoning	 them,	 or	 via	 the	community	 teams	 with	 whom	 she	 communicates	 regularly.	 	 She	 described	developing	important	relationships	with	patients	through	hospital	visits	and	via	her	 telephone	helpline.	 	 She	described	getting	 a	 “snapshot”	 of	 their	 lives.	 	 She	would	 often	 liaise	 with	 the	 community	 MDT	 with	 whom	 she	 has	 good	connections.	Box	5.5	describes	 the	difficulty	 the	Telehealth	Nurse	 faced	when	caring	 for	 those	 patients	with	whom	 she	 had	 less	 contact,	 or	where	 her	 links	with	 the	community	 teams	were	not	as	good.	 	 In	 these	cases	 it	could	be	more	difficult	to	interpret	the	information	from	the	TiM	and	liaison	with	the	MDT	was	less	easy.		She	was	even	more	reluctant	to	call	carers	although	she	also	felt	she	had	responsibility	for	their	wellbeing	too.		She	explained	that	she	often	did	not	know	 carers	 so	well	 and	 sometimes	 felt	 there	were	 less	 obvious	 solutions	 to	carer	 distress.	 	 This	 is	 in	 contrast	 to	 the	 carers	 who	 were	 mostly	 extremely	positive	that	the	nurse	provided	vital	counseling	and	advice.		When	she	did	not	know	the	participants	well,	she	said	she	found	it	easier	in	this	case	to	liaise	with	the	community	MDT	rather	than	calling	the	patient	directly.				
Box	5.5	Case	vignette:	building	the	nurse-patient	relationship	One	patient	reacted	positively	to	the	idea	of	the	TiM	system	but	did	not	feel	the	TiM	 had	 had	 an	 impact	 on	 her	 during	 the	 study	 because	 she	 had	 progressed	slowly	and	did	not	receive	any	feedback	from	the	Telehealth	Nurse.		As	a	result	she	did	not	see	the	point	in	using	it	again:		
“Q:		Do	you	think	it's	had	an	impact	on	your	condition	at	all,	using	tablet?		
P:	No.		
Q:	OK.	And	do	you	think	you'd	continue	to	use	it	if	it	wasn't	part	of	a	study?		
P:	Well	there'd	be	no	point,	would	there?”		P317		When	the	Telehealth	Nurse	was	asked	about	this	patient,	she	explained	that	she	had	not	yet	developed	a	relationship	with	P317	or	her	carer.		This	was	because	she	had	only	recently	been	diagnosed	and	had	not	attended	clinic	many	times.		She	 also	 lived	 at	 a	 distance	 from	 the	 centre	 and	was	 also	 under	 the	 care	 of	 a	community	MND	 nurse.	 	 Her	 condition	was	 slowly	 progressive	 therefore	 had	less	involvement	with	the	hospital	MDT.			The	nurse	found	telephoning	patients	with	whom	she	had	little	relationship	more	difficult	and	she	felt	more	reluctant	to	call	if	problems	were	minor.		
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The	nurse	explained	that	whilst	she	had	seen	the	TiM	questions	and	Patient	App	in	 development,	 she	 said	 she	 had	 not	 seen	 the	 final	 Patient	 App	 and	 did	 not	know	exactly	what	questions	and	answers	it	used.		The	Telehealth	Nurse	did	not	have	the	opportunity	to	discuss	the	TiM	system	with	participants	at	the	start	of	the	 study	 and	 during	 the	 interviews	 it	 was	 established	 that	 she	 had	 rarely	discussed	the	TiM	system	with	participants	when	they	attended	clinic.		She	also	found	that	patients	did	not	always	know	she	was	responsible	for	looking	at	the	data.		This	meant	she	did	not	have	the	opportunity	to	understand	what	patients	knew	about	or	expected	from	the	TiM	system.	
5.9	Attitudes	towards	future	use	of	the	TiM	system	
5.9.1	Participants’	attitudes	towards	future	use	of	the	TiM	system	Participants	were	asked	whether	they	would	use	the	TiM	system	again.	 	In	the	questionnaires,	at	six	months	12	(80%)	patients	and	11	(73%)	carers	would	use	it	as	part	of	their	usual	care	and	14	(93%)	patients	and	10	(67%)	carers	would	use	the	TiM	as	part	of	a	research	trial.		13	(87%)	patients	and	11	(73%)	carers	would	 recommend	 it	 to	 another	 patient.	 	 The	 participants	who	 did	 not	 agree	replied	 that	 they	 were	 “unsure”	 as	 none	 disagreed.	 	 Participants	 were	 asked	whether	 the	 TiM	 could	 be	 used	 as	 a	 substitute	 to	 clinic.	 14	 (93%)	 patients	would	use	the	TiM	if	they	were	unable	to	travel	to	clinic	and	11	(73%)	felt	that	they	would	be	happy	to	have	their	appointment	delayed	if	 the	doctor	felt	they	were	 stable.	 	 	However,	 3	 (20%)	were	not	 sure	 and	one	 (7%)	disagreed	with	this	statement.				Participants	 thought	 that	 the	 individual	 should	 chose	 how	 they	 used	 the	 TiM	depending	 on	 their	 needs,	 preferences	 and	 speed	 of	 progression	 (Appendix	A5.36).		A	number	of	patients	felt	they	were	progressing	slowly	and	did	not	feel	frequent	clinics	were	valuable	meaning	they	were	happy	to	use	the	TiM	instead	to	 reduce	 the	 frequency	 of	 appointments.	 	 One	 was	 happy	 to	 reduce	appointments	from	two	to	six	months	as	long	as	he	could	communicate	with	the	team	and	access	the	service	quickly	should	he	need	help.			
“P:	Well	I	think	for	me	currently,	if	you	put	dialogue	boxes	in	there,	which	is	what	I	would	
have	 said	 you	 need	 them,	 I	 would	 be	 quite	 happy	 personally	 to	 use	 that	 and	 not	 have	
appointments,	but	be	able	to	ask	for	one	on	that,	but	you	would	need	to	be	able	to	do	that	
at	short	notice	rather	than	going	to	have	one	in	two	months.	So	to	me	that	way	is	ideal.”	
P381	(Early,	slowly	progressive	disease)	A	 number	 of	 participants	 highlighted	 the	 importance	 of	 attending	 clinic	 for	respiratory	monitoring	 and	 suggested	 that	 this	 aspect	 of	 care	 would	 need	 to	remain	an	essential	part	of	MDT	care.		
“Q:	How	do	you	think	this	would	fit	in	around	your	clinic	visits	and	the	support	you	would	
get	from	[hospital	MND	nurse]?	If	this	was	to	become	a	part....	rather	than	a	research	
project,	part	of	standard	care,	how	do	you	think	you	would	suggest	using	it?	
P:	Well	I	think	in	my	case	I	would	be	happy	to	use	that	and	lengthen	the	time	between	
visits.		...	the	only	difference	to	me	is	the	breathing	test.”	P381	
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One	 patient	 suggested	 that	 it	 might	 save	 time	 in	 clinic	 because	 he	 could	complete	questions	and	weigh	himself	at	home	before	attending.		Other	patients	were	 ambivalent,	 feeling	 that	 clinic	 attendance	 was	 valuable	 to	 them,	particularly	 to	benefit	 from	 the	psychological	 support	or	 to	 address	problems	when	 their	 disease	 is	 progressing.	 	 Some	patients	 felt	 that	 they	would	 not	 be	able	 to	 be	 fully	 involved	 in	 telephone	 conversations,	 particularly	 when	discussing	sensitive	matters.		
“Q:	Using	the	tablet.		Do	you	think	you’d	accept	a	telephone	call	rather	than	coming	[to	
clinic]	if	things	were	too	tricky	for	you?	
C:	[to	P]	Well	telephone	calls	aren’t	that	practical	are	they	for	you.		Because	if	you	are	
tired,	it’s	difficult	to	convey.”	C172	(Patient	with	severe	dysarthria)	
	Patients	did	feel	that	they	were	the	centre	of	care	when	involved	in	discussions	but	one	patient	pointed	out	the	importance	of	conversations	to	ensure	that	they	could	discuss	all	important	topics,	not	simply	those	on	the	TiM	system.	
	
“MND	appointments	allow	discussion	on	other	topics	other	than	TiM”	P248		Patients	 were	 asked	 what	 additional	 features	 they	 would	 want	 in	 the	 TiM.		Participants	wanted	 the	 system	 to	be	more	of	 a	 “two-way	thing”,	as	discussed	above.		They	were	asked	whether	they	wanted	to	see	graphs	or	analysis	of	their	answers.		Many	explained	that	they	did	not	need	this	type	of	feedback	because	they	can	judge	their	progress	themselves	either	through	observing	their	day-to-day	 lives	or	 tracking	 their	 answers	on	 the	TiM.	 	 	 Some	 thought	 this	would	be	interesting	but	none	wished	this	type	of	feedback	to	be	automatic	as	they	were	concerned	 about	 the	 impact	 of	 seeing	 their	 decline	 plotted	 without	 any	interpretation	 from	 their	 clinical	 team.	 	 Instead	patients	 thought	 they	wanted	feedback	delivered	by	 their	 clinical	 team	either	 in	clinic	or	during	discussions	with	the	Telehealth	Nurse.		Participants	thought	that	various	ways	of	communication	would	be	acceptable	and	 the	 choice	 depended	 on	 the	 patient	 and	 the	 problem.	 	 Face-to-face	conversations	were	felt	to	be	important	for	personal	discussions.			
“I	 think	 it's	not	personal...	 I'd	 rather	 see	 somebody	or	 talk	 to	 somebody	 than,	 than	read	
about	it	on	something	on	a	screen.”	C366		Some	found	using	email	to	contact	their	care	team	helpful.	 	Those	with	speech	problems	found	it	particularly	helpful	as	they	found	it	hard	to	use	the	phone	and	email	 also	 allowed	 patients	 to	 answer	 at	 their	 convenience.	 	 They	 could	 take	time	 to	 answer,	 rather	 than	 feeling	 rushed	 in	 a	 phone	 call.	 	 For	 some,	 email	could	be	seen	as	 impersonal	and	telephone	was	more	preferable	 for	problems	needing	solving	immediately	and	some	felt	telephone	was	better	for	sensitive	or	complex	 problems	 to	 ensure	 that	 the	 information	 exchanged	 was	 accurate.		Participants	 had	 reasonable	 expectations	 of	 the	 speed	 at	 which	 they	 might	receive	 a	 reply	 if	 they	 sent	 a	 message.	 	 They	 felt	 happy	 if	 they	 received	 an	acknowledgement	and	were	happy	to	wait	for	a	definitive	answer	or	wait	until	they	attended	clinic	in	order	to	discuss	more	sensitive	matters.		
	
	 158	
Q:	And	if	you	put	in	a	question,	maybe	something	like	your	citalopram,	like	you	said	you	
had	spoken	to	[Telehealth	Nurse].		How	long	would	you	expect	before	you	got	an	answer?	
P:	Well	normally	[Telehealth	Nurse]	gets	back	to	me	within	a	day	or	so.		So	I	would	expect	
two	days,	almost	maximum.	
Q:	OK.	So,	reasonably	quickly.	
P:	Even	if,	it	was:	“we’ve	got	your	question:	we’re	thinking	about	it”	
Q:	So,	just	an	acknowledgement	that	you’ve	email?	
P:	 Yeah.	 	 It	may	 be	 [Telehealth	Nurse]	 can’t	 answer	me	 first	 time.	 Like	 the	 citalopram.		
What	she	said	was:	“I’ll	discuss	it	with,	(I	think)	you”	and	then	came	back	to	me.”	P381		Participants	supported	the	idea	that	their	answers	could	be	shared	more	widely	with	their	clinical	team.	They	identified	their	community	nurse,	GP	and	hospice	and	people	with	whom	they	would	like	information	sharing.	
5.9.2	Nurses’	attitudes	towards	the	future	use	of	the	TiM	The	 interviews	explored	how	the	nurses	 felt	 the	TiM	system	could	be	used	as	part	of	routine	clinical	care	or	within	a	larger	trial	(Appendix	A5.37	and	A5.38).		The	Telehealth	Nurse	explained	that	she	elected	to	use	the	system	herself	rather	than	 delegate	 it	 to	 another	 nurse	 as	 she	 was	 oversaw	 the	 clinical	 care	 of	 all	patients.	 	 She	 felt	 that	 a	 more	 formalised	 protocol,	 which	 outlined	 how	 she	should	 respond	 to	 alerts,	would	 likely	 increase	 the	number	 of	 telephone	 calls	made	 to	patients.	 	However,	 she	explained	 that	during	 the	 trial	 she	 felt	 it	was	important	 that	 she	could	use	her	knowledge	and	experience	 to	 independently	decide	how	to	respond	to	the	information	presented	and	would	find	it	difficult	working	to	a	formalised	protocol.				
“If	 it	was	written	down,	 [that]	 I	had	 to	ring	and	 I	had	 to	ring	 straightaway,	…	 I	
don’t	know	whether,	I	would	have	found	that	quite	difficult	not	being	able	to	use	
my	initiative	and	how	I’m	familiar	with	the	patients	and,	don’t	know	I	might	not	
have,	I	might	have	found	that	a	bit	more	difficult.”		Telehealth	Nurse		Participants	were	happy	for	the	TiM	answers	to	be	looked	at	by	any	member	of	the	 community	 team.	 	 	 The	 Telehealth	 Nurse	 thought	 this	 could	 be	 possible	because	 liaison	 between	members	 of	 the	 care	 team	was	 very	 helpful	 but	 she	also	highlighted	the	need	for	the	community	teams	to	have	capacity	to	do	this.			The	Community	MND	nurse	felt	the	TiM	would	be	useful	to	enable	her	to	learn	more	 about	her	patients	 and	would	 find	 it	 useful	 to	 receive	 information	 from	other	members	of	 the	care	team.	 	However,	she	explained	that	she	would	 find	the	clinical	portal	difficult	to	access	because,	due	to	the	nature	of	her	job,	which	was	mostly	community,	based,	she	does	not	use	computers	regularly.		She	also	explained	she	was	“not	good	with	computers.”	and	was	in	her	60s	and	about	to	retire	and	had	not	felt	the	need	to	adopt	technology	in	her	work.		However,	she	would	 be	 happy	 receiving	 alerts	 and	 information	 from	 someone	 else.		Discussions	with	other	community	 teams	establish	 that	 they	do	use	electronic	records	and,	may	have	better	access	to,	and	confidence	with	computer	systems.			Their	opinions	were	not	explored	in	this	thesis.		The	Telehealth	Nurse	was	asked	whether	she	thought	other	MND	centres	would	use	 it.	 	 She	explained	 that	other	centres	have	responded	positively	 to	 the	TiM	
	 159	
and	 she	 thought	 they	 are	 be	motivated	 to	 improve	 the	 care	 for	 patients	 and	would	be	willing	to	change	as	long	as	they	thought	the	TiM	was	useful.				
5.9.3	Summary		The	 potential	 positive	 impacts	 identified	 in	 this	 study	 included	 increased	monitoring	 to	 pick	 up	 problems	 earlier	 and	 between	 clinic	 visits.	 	 This	 is	particularly	valuable	 to	patients	who	are	changing	rapidly	or	 for	patients	who	cannot	 or	 would	 prefer	 not	 to	 attend	 clinic.	 	 In	 addition	 it	 could	 offer	reassurance,	particularly	 in	 the	context	of	early	or	slowly	progressive	disease.		It	 could	 also	 promote	 contact	 between	 participants	 and	 trusted	 specialists	which	would	be	particularly	valuable	 in	 those	without	established	 links	 in	 the	community.			In	some	cases,	identification	of	problems	meant	support	could	be	put	 in	place	 earlier	 to	 act	 upon	problems	and	help	 the	patient	 come	 to	 terms	with,	and	cope	with	the	change	in	their	disease.			The	 TiM	 system	 provides	 the	 opportunity	 to	 monitor	 carers’	 wellbeing	separately	 from	patients	 in	a	way	that	 fits	 in	around	their	caring	duties.	 	 	The	clinicians	using	the	TiM	felt	it	could	be	a	useful	addition	to	the	current	service	and	could	be	used	to	triage	or	reschedule	appointments	according	to	need	if	the	problems	with	alerts	were	improved.				Whilst	 on	 some	 occasions	 the	 TiM	 did	 appear	 to	 impact	 positively	 on	participants’	care	this	was	not	occurring	as	much	as	was	expected.		The	reasons	for	 this	 included	 that	 the	 Telehealth	 Nurse	 was	 not	 responding	 to	 the	 high	number	of	alerts,	or	was	not	communicating	her	actions	to	the	participants.		The	results	 also	 highlight	 the	 difficulty	 of	 capturing	 the	 impact	 of	 complex	interventions	 during	 a	 clinical	 trial,	 especially	 when	 relying	 on	 participant	interviews	to	recall	what	happened.				In	the	future,	the	study	suggested	that	an	ideal	service	would	be	flexible	enough	to	meet	the	needs	of	participants	who	may	differ	in	their	disease	course	as	well	as	the	way	in	which	they	need	to	interact	with	the	specialist	team.		This	service	should	 include	 opportunities	 for	 face-to-face,	 telephone	 and	 email	 contact	 to	maintain	 links	with	 the	 specialist	MDT.	 	 These	 results	 suggested	 that	 the	TiM	system	 could	 play	 a	 part	 in	 this	 service	 and	 help	 the	 teams	 care	 for	 patients	according	to	the	NICE	best	practice	guidelines.			 	
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5.10	Discussion:	The	 feasibility	and	potential	 value	of	 the	TiM	
system		This	section	will	discuss	the	feasibility	and	acceptability	of	the	TiM	technology,	its	use	as	a	remote	monitoring	tool	and	as	a	patient	alternative	to	hospital	visits.		It	 discusses	 how	 the	TiM	 system	might	 be	 used	 to	 improve	 patient	 and	 carer	care.		Given	the	findings	of	the	trial,	it	also	discusses	how	it	should	be	improved.		
5.10.1	Feasibility	and	acceptability	of	the	TiM	system	
5.10.1.1	Feasibility	and	acceptability	of	TiM	technology	This	study	has	demonstrated	that	the	TiM	technology	can	collect	information	on	patient	and	carer	progress	in	MND	requiring	only	minimal	training	and	support.		Participant	 adherence	 to	 the	 TiM	 system	 was	 good	 and	 better	 than	 many	telehealth	studies	where	adherence	ranged	from	40%	to	90%	(234).			The	keys	to	success	were	the	simple	technology,	user-centred	design	and	providing	face-to-face	 training	 and	 support.	 	 It	 also	 involved	 patients	 and	 carers	 who	 were	motivated	to	be	involved	in	research	to	improve	the	way	in	which	they	engage	with	 the	 MND	 team.	 	 However,	 as	 discussed	 in	 Chapter	 One,	 these	 results	suggest	 that	patients	and	carers	do	want	better	access	 to	MND	specialists	and	therefore	 it	 is	 likely	 that	other	patients	and	carers	will	also	engage	 in	 the	TiM	system,	 as	 long	 as	 they	 thought	 the	 TiM	 system	 did	 provide	 this	 additional	benefit.		Other	telehealth	projects	found	adherence	tends	to	drop	off	with	time	(234),	but	in	this	study	many	participants	maintained	good	adherence	throughout.	 	Some	did	reduce	adherence,	usually	because	participants	became	too	unwell	at	which	point	they	were	often	receiving	domiciliary	care,	something	the	TiM	system	did	not	aim	to	offer.		A	number	of	patients	stopped	using	the	TiM	because	they	had	become	 demoralised	 because	 they	were	 not	 receiving	 any	 feedback	 from	 the	MND	team	and	therefore	the	TiM	was	not	felt	to	be	valuable.		This	highlights	the	need	 for	 the	TiM	 to	be	more	 interactive,	 even	 at	 times	when	patients	 require	little	more	 than	monitoring.	 	 This	 is	 supported	 by	 the	 literature	which	 found	that	 studies	 involving	 a	 patient	 education	 programme	 had	 much	 better	compliance	 than	 those	without	 (234)	and	whilst	participants	 in	 this	 study	did	not	 tend	 to	 use	 the	 additional	 education	 services	 on	 the	 TiM	 system,	 many	patients	 thought	 that	 the	 ability	 to	 monitor	 their	 own	 disease	 and	 the	opportunity	to	learn	more	offered	them	benefit.		Further	 improvements	 would	 make	 the	 TiM	 technology	 work	 better.	 	 It	 is	recommended	 that,	where	 possible,	 patients’	 own	 equipment	 is	 used.	 	 This	 is	likely	 to	be	more	 successful	 as	 they	 are	more	 familiar	with	 their	 own	devices	and	would	 be	 better	 able	 to	 resolve	 problems	without	 relying	 on	 the	 clinical	team.			Avoiding	the	use	of	different	and	complex	devices	that	were	found	to	be	unreliable	 in	 this	 trial	 (for	 example,	 the	 Wi-Fi-enabled	 weight	 scales)	 would	reduce	 the	 chances	 of	 system	 failure.	 Whilst	 these	 conclusions	 appear	reasonably	obvious,	our	findings	are	in	contrast	with	the	problems	identified	in	Chapter	Two	where	telehealth	services	often	use	bespoke,	outdated	technology	with	which	staff	are	unfamiliar.	The	clinical	portal	was	also	successful	with	few	
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technical	 problems	 but	 will	 require	 adequate	 training	 and	 on-going	 technical	support	 to	 ensure	 user	 engagement	 to	 ensure	 smooth	 running	 of	 the	 service,	particularly	if	the	system	would	be	used	alongside	“normal”	practice	(235).		
5.10.1.2	 Feasibility	 and	 acceptability	 of	 the	 TiM	 system	 as	 a	 remote	
monitoring	tool	Using	 TiM	 to	 monitor	 the	 condition	 of	 patients	 and	 carers	 appeared	 to	 be	feasible	 as	 well	 as	 appearing	 broadly	 acceptable	 to	 patients	 and	 carers	 and	clinical	 staff.	 	 TiM	 provided	 the	 clinical	 staff	 with	 information	 that	 appeared	relevant	and	 reliable	and,	 in	 some	patients,	 enabled	problems	 to	be	 identified	and	monitored	earlier	 than	would	have	otherwise	been	 the	case.	 It	 could	also	help	patients	be	reassured	that	their	condition	is	progressing	more	slowly	that	they	feared,	or	conversely,	provide	patients	with	information	to	help	them	come	to	terms	with	their	deterioration.	However,	in	order	for	the	TiM	to	be	a	feasible	addition	 to	 the	 clinical	 service,	 changes	 to	 the	 TiM	 system	 are	 required	 to	improve	 the	 way	 in	 which	 the	 clinicians	 (in	 particular	 the	 Telehealth	 Nurse)	responds	 to	 the	 information	 provided	 by	 the	 TiM	 system	 and	 interact	 with	patients	and	carers.					The	main	problems	with	the	TiM	encounter	in	this	trial	were	the	high	number	of	alerts	and	a	lack	of	interaction	between	the	MND	team	and	the	patients/carers.		In	 this	 trial,	 more	 than	 50%	 of	 sessions	 generated	 an	 alert,	 to	 which	 the	Telehealth	Nurse	was	expected	to	respond.		The	large	number	of	alerts	(many	of	which	 were	 not	 felt	 to	 be	 appropriate)	 made	 the	 nurse	 frustrated	 and	demotivated.	 	 “Alert	fatigue”	was	an	 important	reason	why	she	 felt	disinclined	to	act	upon	alerts.		These	findings	reflect	those	of	other	studies	where	alerts	are	often	 clinically	 irrelevant	 but	 increase	work	 for	 the	 clinician	 by	 requiring	 the	alert	to	be	“over-ridden”	(236).	Furthermore,	excessive	alerts	do	not	just	cause	clinicians	 to	 be	 frustrated	 and	 fail	 to	 respond	 to	 alerts,	 it	 also	 makes	 them	anxious	that	they	were	missing	important	alerts	amongst	the	multitude	of	other,	less	 important	 alerts	 (237).	 	As	 services	 adapt	 to	new	 systems	users	may	not	use	 the	 system	 as	 originally	 intended	 meaning	 safety	 systems	 can	 be	inadvertently	bypassed	(237).					The	 TiM	 was	 designed	 to	 facilitate	 a	 flow	 of	 information	 only	 from	 the	patient/carer	 to	 the	 clinical	 team.	 	 The	 TiM	 system	 did	 not	 provide	opportunities	 for	 the	 Telehealth	 Nurse	 to	 understand	 the	 expectations	 of	participants	 using	 the	 TiM	 and	 vice	 versa.	 	 Without	 this	 interaction	 patient-centred	care	is	not	promoted	and	users	remained	unsatisfied.		This	study	found	that	there	was	a	mismatch	between	participant	expectations	of	the	TiM	and	the	nurses’	attitudes	and	actions	towards	the	problems	the	TiM	identified.		Lack	of	interaction	 between	 the	 participants	 and	 the	 clinicians	 using	 the	 TiM	contributed	 to	 the	mismatch	 in	 expectations.	This	disconnect	was	particularly	evident	when	the	Telehealth	Nurse	believed	that	 the	problems	reported	were,	in	 her	 experience,	 a	 reflection	 of	 the	 natural	 history	 of	 the	 disease,	 or	 were	problems	 she	 felt	 she	was	 unable	 to	 solve.	 	 In	 contrast,	 participants	 expected	acknowledgement	even	if	no	action	were	taken	whereas	the	nurse	tended	not	to	acknowledge	these	problems.		The	Telehealth	Nurse	found	interactions	in	these	circumstances	 unsatisfactory	 as	 she	 felt	 she	 had	 nothing	 to	 contribute.	 	 She	
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undervalued	her	 role	 and	 felt	 she	was	 adding	nothing.	 	 In	 fact,	 she	was	 often	taking	 actions	 such	 as	 liaising	 with	 the	 MDT	 and	 offered	 valuable	 advice,	support	 and	 reassurance	 to	 patients	 and	 carers.	 These	 calls	 also	 provided	opportunities	 to	discuss	other	 concerns	or	 ideas	 and	 review	 their	 treatments.		For	 a	 patient,	 any	 new	or	 changing	 problem	 is	 unfamiliar	 for	 them	and	 these	milestones	in	their	disease	are	experienced	as	a	series	of	losses,	with	reactions	similar	 to	 a	 grief	 process	 (31,238).	 	 Patients	 in	 our	 study	 explained	 that	 they	wanted	these	milestones	to	be	acknowledged,	even	if	they	thought	that	nothing	specific	could	be	done	about	the	problem.		Future	services	should	ensure	there	staff	 understand	 the	 value	 they	 offer	 patients	 and	 carers	 as	well	 as	 providing	opportunities	 for	 the	 expectations	 of	 users	 to	 be	 better	 understood	 to	 enable	better	 patient-centred	 care	 and	 that	 the	 patient	 and	 carer	 participation	 in	decision-making.		Use	 of	 the	 TiM	 system	 also	 disrupted	 the	 traditional	way	 in	which	 the	 nurse	would	 gather	 information	 and	 respond	 to	 patient	 difficulties	 (176).	 	 New	routines	that	change	in	the	way	nurses	usually	work	can	pose	a	barrier	to	staff	acceptance.		Unlike	some	studies	it	did	not	appear	that	the	Telehealth	Nurse	felt	her	own	expertise	were	undermined	by	the	system	but	should	the	system	have	been	more	prescriptive	it	is	likely	that	this	would	have	represented	a	significant	barrier	 to	 her	 acceptance.	 	 She	 did	 highlight	 the	 difficulties	 interacting	 with	participants	with	who	she	did	not	have	a	good	relationship.		Participants	in	this	study	 highlighted	 the	 great	 importance	 of	 their	 relationship	 with	 their	 MND	nurse	and	this	study	suggests	that	good	relationships	are	still	required	in	order	to	maintain	effective	communication	and	acceptance.		
5.10.1.3	Feasibility	of	the	TiM	system	as	an	alternative	to	face-to-face	
appointments	This	study	did	not	evaluate	the	TiM	service	as	an	alternative	to	clinic.		However,	it	did	identify	a	number	of	challenges	to	this,	mainly	due	to	the	organisation	of	the	 hospital	 clinic.	 	 	 This	 study	 found	 that	 outpatient	 appointment	 schedules	were	 unpredictable:	 Sheffield	 does	 not	 have	 a	 dedicated	 service	 to	 arrange	appointments	 at	 regular	 intervals.	 This	 means	 clinicians	 are	 unable	 review	patients’	 results	 and	 reschedule	 appointments	 easily.	 An	 analysis	 of	 the	appointments	made	in	the	three	Sheffield	neuromuscular	clinics	during	the	year	2015/2016	supports	this	assertion.		Of	the	908	follow-up	appointments	booked,	110	 (12%)	 appointments	 were	 not	 conducted	 because	 the	 patient	 did	 not	attend	appointments.	761	 (84%)	were	 rescheduled:	459	were	 rescheduled	by	the	hospital	and	317	by	patients.		The	service	would	be	more	feasible	if	the	MND	team	could	book	and	change	appointments	and	schedule	TiM	clinician	reviews.		More	administrative	support	and	 the	use	of	electronic	records	and	scheduling	would	also	help	facilitate	a	more	flexible	service.	A	flexible	service,	using	TiM	rather	than	face-to-face	appointments	would	need	to	consider	the	needs	and	preferences	of	patients	but	some	patients	did	feel	that	this	would	be	 an	 acceptable	way	 to	 access	MND	care,	 particularly	 at	 the	 later	stages	of	the	disease	and	some	would	be	happy	to	delay	their	appointments	as	
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long	as	they	could	be	seen	at	short	notice	if	required.		If	this	change	is	instigated,	it	 is	recommended	that	impact	of	changing	the	model	of	care	on	safety	and	on	the	service	as	a	whole	is	evaluated	further.	
5.10.2	The	potential	impact	of	TiM	system	
5.10.2.1	The	potential	impact	of	the	TiM	on	patients	The	interviews	and	satisfaction	questionnaires	suggest	that	there	remain	many	unmet	needs	in	MND	that	could	be	met	by	improving	access	to	specialist	care.	This	 study	 suggests	 that	 the	 TiM	 has	 the	 potential	 overcome	 some	 of	 the	barriers	to	accessing	specialist	care	and	could	complement	the	existing	service	by	 facilitating	 communication	 and	 care	 coordination.	 	 The	 TiM	 system	 could	also	 be	 used	 to	 provide	 information	 and	 promote	 self-management	 and	 self-efficacy.	 	 There	were	 a	 number	 of	 incidences	 during	 the	 trial	 where	 the	 TiM	system	 appeared	 to	 helping	 the	 clinical	 team	 to	 manage	 patients	 and	 carers	more	proactively,	particularly	where	patients	were	progressing	rapidly.	 	There	were	times	when	participants	and	nurses	felt	it	identified	new	problems	and	the	nurse	used	it	to	monitor	patients’	progress	or	treatment	(such	as	NIV).		The	TiM	system	was	a	low-burden	way	of	collecting	information	and	whilst	it	may	seem	impersonal,	this	appeared	to	be	an	advantage	to	some	users.		It	is	possible	that	those	who	may	 try	 to	minimise	problems	or	 feel	 frightened	 to	admit	 they	are	not	coping	may	be	more	likely	to	report	problems	on	the	TiM	system.		This	was	particularly	 important	 for	 carers	 who	were	 clear	 that	 providing	 a	 facility	 for	them	to	be	easily	monitored	away	from	the	patient	was	very	important	and	that	the	 TiM	 could	 be	 part	 of	 this	 service.	 	 The	 Telehealth	Nurse	 felt	 a	 number	 of	carers	were	offered	additional	support	as	a	result	of	using	the	TiM	system.				However,	 whilst	 the	 current	 TiM	 system	 appears	 feasible,	 many	 participants	interviewed	 felt	 the	 TiM	 had	 not	 made	 a	 difference	 to	 their	 clinical	 care.		Chapter	 Six	will	 report	 that	 there	was	 little	 difference	between	 the	 treatment	groups	and	describes	reasons	for	these	observations.	 	This	trial	did	not	aim	to	measure	efficacy	and	results	drawn	entirely	from	the	participants’	perspective	should	 be	 interpreted	 with	 caution.	 	 Interviews	 may	 not	 capture	 all	 the	interactions	 between	 the	 patients	 and	 their	MND	 team	 and	 participants	were	not	always	aware	of	actions	taking	place	“behind	the	scenes”.		The	value	of	the	TiM	in	 these	patients	may	be	reassurance,	education	and	the	option	to	reduce	clinic	frequency	rather	than	in	changing	their	medical	management	and	it	may	be	difficult	to	record	these	changes.			
5.10.2.2	The	potential	impact	of	the	TiM	system	on	carers	This	study	found	that	the	carer	derived	benefits	from	the	MDT	service,	both	by	improving	 patient	 care	 and	 offering	 carer	 support.	 	 Research	 supports	 the	findings	 of	 this	 study	 that	 attention	 to	 the	 patients’	 needs	 may	 alleviate	caregiver	distress	(239).		It	suggests	that	the	TiM	system	could	be	valuable	if	it	were	used	to	promote	patient	wellbeing	and	make	them	confident	that,	should	they	need	it,	support	would	be	provided	in	a	timely	and	expert	fashion.				Chapter	 One	 argued	 that	 carers	 suffer	 from	 anxiety	 and	 carer	 strain.	 	 These	findings	 are	 reflected	 in	 the	 interview	data	 and	 objective	measures	 described	later	 in	 Chapter	 Six.	 	 Carers	 welcomed	 the	 monitoring	 of	 their	 wellbeing.	 A	
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system	such	as	the	TiM	system,	which	monitored	carers	in	a	convenient	and	low	burden	way,	separate	from	patients	may	offer	a	solution	to	this	need.		This	has	wider	 relevance	 as	 it	 also	 highlights	 the	 need	 to	 provide	 support	 to	 carers	 in	ways	 that	 fit	 into	 their	 lives	 and	 preferences.	 	 Carers	 described	 the	 need	 to	deprioritise	their	own	needs	and	a	constant	need	to	be	available	for	their	loved	ones,	 a	 fear	 of	 admitting	 they	 were	 “not	 coping”	 and	 feelings	 of	 guilt	 if	 they	prioritised	 their	 own	 needs.	 	 Carers	 did	 not	 feel	 traditional	 forms	 of	psychological	support	 they	were	offered	which	requires	 the	carer	 to	 leave	 the	patient	 (such	 as	 counseling	 or	 respite)	 were	 acceptable.	 	 They	 found	 that	completing	the	TiM	system	was	easy	and	fitted	 into	their	 lives	as	 they	did	not	need	to	leave	the	patient	to	use	it.		Furthermore,	it	suggested	that	future	digital	services	 could	 be	 useful	 as	 they	 might	 better	 fit	 in	 around	 carers’	 needs	 by	providing	online	support	accessed	at	times	convenient	to	the	carer,	or	through	telemedicine	which	would	avoid	the	carer	needing	to	leave	the	home.	
5.11	Improving	the	TiM	system				The	findings	from	this	study	suggest	that	the	current	TiM	system	is	acceptable	and	feasible	to	patients	but	many	participants	felt	that	the	TiM	system	did	not	impact	on	their	care	and	many	aspects	of	the	service	require	improvements	in	order	 to	make	 it	 a	 system	which	 is	 likely	 to	 have	 a	 significant	 impact	 on	 the	MND	 population.	 	 The	 next	 stage	 of	 development,	 evaluation	 and	implementation	of	the	TiM	system	should	be	an	iterative	process	to	develop	and	test	 the	 system	 in	more	 services	 and	 improve	 it	 to	meet	 the	 requirements	 of	different	MND	centres	 in	which	the	TiM	could	be	used.	 	This	concurs	with	 the	MRC	guidelines	for	developing	and	evaluating	complex	interventions.		The	TiM	system	needs	to	do	more	to	meet	the	expectations	of	both	patients/carers	and	clinicians	and	 the	 technology	needs	 to	work	better	within	 the	existing	 clinical	service.		In	particular,	improvements	need	to	focus	the	alert	system	and	the	way	in	which	users	interact	with	the	clinical	team.			
5.11.1	Improving	the	TiM	clinical	algorithms	and	alerts	Over	50%	of	sessions	generated	an	alert	in	this	trial.	This	problem	will	need	to	be	 addressed	 in	 future	 versions.	 	 The	 TiM	 study	 has	 collected	 data	 from	 20	patients	 and	 carers.	 	 With	 a	 better	 understanding	 of	 the	 significance	 of	 the	information	 provided	 by	 the	 TiM	 (e.g.	 which	 answers	 represent	 a	 serious	problem	 and	 which	 could	 be	 ignored),	 improved	 clinical	 algorithms	 can	 be	developed.		This	has	already	been	explored	for	the	carer	algorithms:	the	scores	at	which	the	Telehealth	Nurse	is	alerted	can	be	raised	to	only	alert	the	nurse	to	scores	 that	 are	 much	 higher	 than	 the	 other	 carers,	 or	 have	 increased	significantly	 over	 time.	 	 Early	 analysis	 has	 suggested	 that	 this	 would	significantly	reduce	the	number	of	carer	alerts	generated.				Developing	a	protocol,	which	describes	how	Telehealth	Nurses	are	expected	to	react	to	alerts,	is	one	way	to	increase	the	number	of	actions	taken/documented.	This	may	be	appropriate	for	problems	where	protocols	already	exist	and	targets	are	 clearly	 defined	 such	 as	 medication	 prescribing	 or	 hypertension	management.	 	Many	of	 the	 telehealth	 systems	described	 in	Chapter	Two	used	clinical	protocols,	but	it	was	unclear	how	rigidly	nurses	adhered	to	these.	This	approach	 is	 less	 appropriate	 in	 MND	 where	 care	 must	 reflect	 the	 patients’	
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individual	goals	and	wishes	and	the	limitations	rather	than	specific	targets.		The	Telehealth	Nurse	wanted	to	use	her	judgment,	experience	and	knowledge	of	the	patient	to	determine	the	best	way	to	respond	to	problems	and	she	felt	this	was	likely	 to	 be	 the	 approach	 adopted	 in	 other	MND	 cares	 centres.	 	However,	 the	recent	 publication	 of	 assessment	 and	management	 guidelines	 in	 the	 UK	 (39)	means	there	are	now	clear	standards	to	which	MDTs	should	be	aiming.		Further	consultations	 with	 MND	 care	 centres	 (using	 approaches	 such	 as	 a	 Delphi	consensus	(237))	could	influence	the	development	of	better	clinical	algorithms.	A	 framework	 could	 also	 be	 developed	which,	 along	with	 the	NICE	 guidelines,	could	 guide	nurses	 and	help	 them	understand	what	 is	 expected	of	 them,	how	they	 could	 get	 the	 most	 out	 of	 the	 TiM	 system	 and	 how	 they	 should	 be	interacting	with	patients.	An	iterative	process	could	use	this	data	to	model	and	tests	 the	 alerts	 and	 new	 facilities	 (such	 as	 the	 “pause”	 feature),	 in	 clinical	settings	to	identify	feasible	and	acceptable	procedures.				
5.11.2	Improving	patient/carer-clinical	team	interactions	using	TiM	It	is	clear	that	participants	wanted	much	more	interaction	with	the	MND	team.		A	number	of	levels	of	interaction	could	be	integrated	into	the	TiM	system.		The	most	 basic	 interaction	 could	 be	 automated.	 	 This	 could	 include	 information	about	adherence	or	 informing	participants	about	 the	alerts	generated	and	 the	action	taken	by	the	nurse.		Feedback	could	be	bespoke,	that	is,	generated	by	the	Telehealth	Nurse	in	response	to	problems.		This	could	use	technologies	such	as	instant	messaging,	email,	phone	or	video	calls.		The	TiM	could	enable	clinicians	to	provide	educational	materials	relating	to	the	alerts	generated	e.g.	providing	a	booklet	 or	website	 detailing	 information	 about	 falls	 prevention.	 	 A	 system	 to	monitor	 and	 request	 telephone/video	 calls	 or	 hospital	 visits	 could	 also	 be	included.	 	 All	 of	 these	 methods	 of	 interaction	 are	 technically	 feasible	 using	simple	 technology,	 although	 any	 non-automated	 interaction	 could	 increase	clinician	 burden.	 	 The	 Telehealth	 Nurse	 felt	 receiving	 additional	 information	may	actually	reduce	her	burden.				
5.11.3	Using	the	TiM	to	promote	self-efficacy	Improving	 the	opportunities	 for	 interaction	 could	 also	 enable	 a	more	 tailored	approach	to	user	education.	 	Participants	 in	 this	study	suggested	 that	 the	TIM	could	be	used	in	a	more	positive	way	to	promote	coping	strategies.		This	might	improve	 self-efficacy,	 a	major	 factor	 influencing	 quality	 of	 life	 in	MND	 (240).		Self-efficacy	is	defined	as	a	held	belief	about	one’s	own	capabilities	to	produce	and	 influence	 events	 that	 affect	 one’s	 life	 (25).	 	 Those	with	 a	 strong	 sense	 of	self-efficacy	approach	tasks	with	the	assurance	that	they	can	control	them	and	see	 difficult	 tasks	 as	 challenges	 to	 be	 mastered	 rather	 than	 as	 threats	 to	 be	avoided.		They	are	resilient	to	failure	and	can	sustain	themselves	in	the	face	of	setbacks.	 	 Those	 who	 doubt	 their	 capabilities	 have	 lower	 aspirations,	 less	commitment	 to	goals	and	see	 failure	as	a	personal	deficit.	 	 Faced	with	 failure,	they	 will	 quickly	 lose	 faith	 in	 their	 abilities	 that	 can	 result	 in	 stress	 and	depression.			 	
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Many	aspects	of	 life	with	MND	can	negatively	influence	perceived	self-efficacy.		Faced	 with	 a	 relentlessly	 progressive	 disease	 outside	 of	 their	 control	 and	 a	series	 of	 losses	 of	 function,	 patients	 constantly	 have	 to	 reappraise	 their	 own	abilities,	experiencing	feelings	of	frustration	and	failure.		Patients	may	perceive	few	 opportunities	 in	 which	 they	 can	 influence	 the	 disease,	 particularly	 those	lacking	 knowledge	 about	 the	 disease	 or	 those	 with	 severe	 disability.	 	 They	describe	 restricted	 access	 to	 tools	 designed	 to	 help	 them	 cope	 and	 are	frustrated	 that	 services	 are	 not	 patient-centred	 or	 do	 not	 promote	 positive	approaches	 to	 coping.	 	 Perceived	 lack	 of	 control	 and	 fear	 of	 the	 future	 is	reinforced	 by	 seeing	 others	 with	 MND	 (for	 example	 when	 attending	 hospital	clinic)	 in	 situations	where	 they	 too	 are	 unable	 to	manage	 their	 disease.	 	 This	chapter	highlighted	the	common	but	potentially	harmful	approaches	to	“coping”	such	 as	 avoidance	 of	 the	 diagnosis	 or	 trying	 to	 maintain	 normality	 (both	 of	which	 will	 inevitably	 fail).	 	 This	 further	 reduces	 their	 capacity	 to	 cope	 with	future	 problems.	 This	 may	 explain	 why	 good	 psychological	 wellbeing	 is	associated	with	 survival,	 even	 after	 adjustment	 for	 confounding	 factors	(241).	Self-efficacy	can	be	gained	by	mastery	of	experience	(i.e.	experiencing	one’s	own	success)	(26).		It	is	possible	to	strengthen	self-belief	by	persuading	people	that	they	have	the	capabilities	to	succeed,	giving	them	situations	in	which	they	can	succeed,	avoiding	unrealistic	expectations	and	by	changing	the	way	events	are	perceived	and	interpreted.	 	Participants	 in	this	trial	(along	with	those	that	are	later	 reported	 in	 Chapter	 Seven),	 described	 other	 positive	 but	 achievable	strategies	 to	 maintain	 control	 over	 their	 disease,	 such	 as	 seeking	 out	information	or	 taking	an	active	part	 in	 their	management.	 	Participants	highly	valued	the	positive	“can-do”	attitude	of	some	members	of	the	MDT	and	felt	they	improved	with	outlook	and	quality	of	life.		Carer	coping	strategies	identified	in	the	literature	are	also	associated	with	self-efficacy.		This	include	taking	pride	in	and	finding	positive	meaning	in	caring	(239,242).	 	The	interviews	suggest	that	perceived	 self-efficacy	 and	 desire	 and	 ability	 to	 self-manage	 varied	 amongst	participants	 in	 this	study.	 	Even	the	most	prepared	and	motivated	patient	will	be	 faced	 with	 unfamiliar	 problems	 outside	 their	 control	 and	 the	 balance	 of	responsibility	may	shift	between	patient,	carer	and	the	healthcare	professional	as	the	patient	progresses.			Participant	 interviews	 suggest	 that	 the	 TiM	 system	 could	 be	 used	 to	 improve	self-efficacy.		The	TiM	already	provides	information	about	self-management	but	a	 more	 interactive	 telehealth	 service	 could	 further	 promote	 self-efficacy	 by	enabling	patients	and	carers	to	play	an	active	role	in	aspects	of	their	care.		For	example,	TiM	could	be	used	to	set	and	monitor	achievable	short-term	goals	and	expectations,	 for	 example	 when	 initiating	 NIV	 or	 during	 a	 period	 of	physiotherapy.	 Conversely,	 it	 could	 also	 support	 patients	 who	 experience	difficulties	 with	 self-management	 or	 reduce	 the	 stress	 associated	 with	perceived	 failure,	 such	 as	 when	 the	 patient	 needs	 to	 adapt	 to	 a	 new	 loss	 of	function.	 	 There	 is	 evidence	 that	 telehealth	 programmes	 can	 improve	 patient	
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and	 carer	 self-efficacy	 and	 ability	 to	 self	manage	 although	 the	 evidence	 is	 far	from	 conclusive	 and,	 as	 discussed	 earlier,	 success	will	 depend	 heavily	 on	 the	service	and	how	it	us	used	by	individual	(243-246).	
5.11.4	Changing	staff	behaviour	A	 recent	 systematic	 review	 of	 health	 care	 providers’	 attitudes	 towards	telehealth	(247)	also	supports	these	results,	suggesting	that	the	way	a	clinician	interacts	 with	 telehealth	 and	 adapts	 to	 their	 role	 depends	 on	 their	 attitude	towards	the	system	and	its	potential	benefits	for	patients.		The	willingness	and	ease	in	which	the	clinician	adapted	to	their	role	using	the	telehealth	is	related	to	clinicians’	perception	of	the	benefit	of	telehealth	to	patients	and	the	belief	that	they	 can	 be	 part	 of	 a	 system	 which	 brings	 about	 positive	 change	 (247,248).	Clinicians	who	held	more	positive	views	about	telehealth	were	more	willing	to	consider	 changing	 their	 roles	 to	 incorporate	 telehealth	 (247).	When	 clinicians	could	 see	 the	 positive	 impacts,	 they	 were	 less	 concerned	 about	 technical	glitches.	 	 Individual	 staff	 characteristics	 related	 to	 successful	 telehealth	 use	included	willingness	 to	 change,	 creative	 attitudes	 to	 cross	 discipline	working,	open-mindedness,	 adaptability	 and	 flexibility	 (247).	 This	 review	 also	highlighted	 the	 importance	 of	 the	 knowledge	 of	 the	 patient	 and	 the	establishment	 of	 a	 good	 clinician-patient	 relationship	which	 resulted	 in	more	frequent	 and	 effective	 interactions	 (247).	 	 Telehealth	 systems	 do	 change	 the	way	 in	which	staff	work,	 their	roles	and	responsibilities	and	the	way	 in	which	the	overall	service	works.		Whilst	a	framework	might	guide	clinicians	to	use	the	TiM	more	effectively,	clinicians’	“readiness	to	change”	should	also	be	promoted.		This	 study	 suggests	 that	 clinicians	 using	 the	 TiM	 need	 to	 have	 good	understanding	 of	 the	 technology,	 the	 value	 of	 the	 services	 they	 offer	 and	expectations	 of	 their	 patients	 and	 carers	 and	 the	 importance	 of	 interaction,	feedback	and	the	promotion	of	self-management	and	self-efficacy.		This	could	be	achieved	 through	 training	 for	 clinicians	 to	 understand	 the	 aims	 and	 the	potential	benefits	of	the	TiM	system	in	their	service,	how	it	can	be	best	used	and	the	expectations	of	patients	and	carers	prior	to,	and	during	use	of	the	service.			
5.11.5	The	future	development	of	the	TiM	This	 study	 suggests	 that	 TiM	 system	 has	 potential	 to	 add	 value	 to	MND	 care	centres	both	 in	 the	UK	and	 internationally.	 	However,	 the	 interviews	with	 the	MND	 nurses	 and	 discussions	 with	 other	 clinicians	 during	 this	 study	 have	established	 that	 care	 centre,	 community	 service,	 staff	 and	 the	 patients	 differ	widely.	 	 For	 example,	 some	 centres	 already	 use	 telephone	 or	 telemedicine	consultations,	 others	 use	 of	 a	 network	 of	 home	 visiting	 nurses	 (55).	 	 If	 care	centres	do	try	to	use	technology-enabled	care	such	as	the	TiM,	it	would	need	to	be	adaptable	to	meet	their	needs.		Things	that	work	well	in	one	centre	may	not	be	effective	in	others.	 	 It	will	 therefore	be	important	that	further	development	and	evaluation	of	the	TiM	system	is	conducted	within	a	range	of	target	services	that	reflect	these	differences.				
5.12	Limitations	of	the	process	evaluation		There	were	a	number	of	limitations	to	this	process	evaluation.		This	evaluation	was	conducted	in	a	single	centre	by	the	developers	of	the	TiM.		There	is	a	risk	of	bias	in	the	way	the	data	was	collected	and	interpreted.		The	different	roles	of	EH	
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as	 TiM	 developer,	 researcher	 and	 doctor	 may	 have	 influenced	 the	 findings.		Some	patients	had	already	met	EH	in	a	clinical	capacity	and	it	was	explained	to	participants	about	EH’s	role	of	the	research.		However,	as	expected,	a	number	of	problems	 were	 raised	 at	 study	 visits,	 usually	 triggered	 by	 completing	 the	questionnaires	 or	 TiM	 system.	 	 These	 were	 passed	 to	 the	 Telehealth	 Nurse	wherever	possible	and	attempts	were	made	to	avoid	clinical	discussions	during	the	interviews	or	data	collection	visits.		However,	it	is	possible	that	contact	with	EH	 influenced	 participants’	 satisfaction	 or	 clinical	 outcomes.	 	 In	 a	 definitive	trial,	staff	independent	of	the	clinical	team	and	the	TiM	should	conduct	research	visits.				It	 is	 also	possible	 that	participants	may	have	been	more	willing	 to	participate	and	 engage	 with	 the	 trial	 and	 the	 TiM	 system	 because	 it	 was	 provided	 by	 a	doctor.	 	They	may	also	report	their	experiences	more	favourably,	for	the	same	reason.		The	interview	data	suggests	that	participants	actually	took	part	because	they	 wanted	 to	 be	 part	 of	 research	 or	 because	 they	 wanted	 to	 use	 the	 TiM.	Participants	 were	 critical	 of	 the	 existing	 MND	 care	 system	 and	 of	 many	 of	aspects	of	 the	TiM	system.	 	The	experiences	described	 in	 interviews	mirrored	those	 provided	 by	 the	 self-administered	 questionnaires	 that	 were	 collected	independently	of	the	researchers.				The	professional	background	of	a	doctor	may	actually	have	aided	the	building	of	a	research	relationship,	allowing	participants	to	be	more	open	and	comfortable	with	 discussing	 their	 health	 with	 someone	 who	 is	 in	 a	 trusted	 role	 (249).		Participants	 explained	 that	 they	 thought	 the	 research	 would	 be	 conducted	correctly	because	they	trusted	their	clinicians	would	act	in	their	best	interests.		They	 also	 explained	 that	 they	 were	 motivated	 to	 participate	 because	 they	wanted	 to	 help	 improve	 the	 care	 for	 people	 with	MND	 and	 believed	 that,	 by	taking	part	 in	 research	 in	 the	Sheffield	MND	care	 centre,	 their	 involvement	 in	this	research	could	make	a	positive	impact.			At	 the	 start	 of	 the	 study	 it	 was	 expected	 that	 participants’	 use	 of	 technology	would	 be	 the	main	 barrier	 to	 the	TiM	 service	 so	 the	 interviews	with	 patients	and	carers	were	scheduled	to	occur	early	in	the	trial.		Early	interviews	provided	the	opportunity	 to	change	the	TiM	system	during	the	 trial	but	did	not	explore	some	of	the	issues	that	occurred	later	in	the	trial,	that	is,	after	six	months.		This	was	 the	 point	 where	 adherence	 did	 decline	 in	 some	 participants	 and	 when	participants	were	experiencing	more	difficulties	and/or	were	not	able	to	attend	clinic.	 	 Interviews	were	also	carried	out	at	predefined	times	and	may	not	have	captured	 important	 events	 in	 the	 patient’s	 disease	 where	 the	 TiM	 could	potentially	 be	 particularly	 valuable	 such	 during	 the	 initiation	 of	 NIV.	 	 In	addition,	 using	 interviews	 to	 capture	 events	 that	 led	 to	 a	 change	 in	patient/carer	management	was	 limited	 because	 it	 relied	 on	 the	 patient/carer	knowing	an	action	had	occurred	and	that	it	had	occurred	as	a	result	of	the	TiM	system.	 	 As	 the	 Telehealth	Nurse	 did	 not	 always	 feed	 back	 her	 actions	 to	 the	patient	 they	 were	 unaware	 of	 the	 impact	 of	 the	 TiM	 meaning	 it	 was	 not	captured	in	interviewed.	 	These	interviews	did	manage	to	capture	some	of	the	possible	ways	 in	which	patients’	 care	 could	 change	using	 the	TiM	 (e.g.	 earlier	
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awareness	of	 a	new	problem)	but	 these	 impacts	maybe	better	 captured	more	systematically	by	using	the	TiM	clinician	portal	itself.				It	was	also	not	possible	 to	 interview	the	 two	patients	who	dropped	out	of	 the	study	 due	 to	 ill	 health	 or	 participants	 who	 declined	 to	 participate	 although	participants	 with	 severe	 disabilities	 did	 participate	 in	 interviews.	 	 It	 is	 also	possible	that	the	trial	captured	the	views	of	a	limited	selection	of	patients,	those	who	were	highly	motivated	to	participate	in	research	or	those	who	liked	using	technology.	 	As	a	result,	a	further	study	was	conducted	to	capture	the	views	of	patients	 who	 may	 not	 have	 wished	 to	 participate	 in	 the	 TiM	 study.	 	 This	 is	described	in	Chapter	Seven.		Reassuringly,	these	results	align	with	the	TiM	trial	results.		The	study	found	that	the	main	barrier	to	TiM	success	appears	to	be	how	the	TiM	is	used	by	the	clinical	team.		Whilst	feedback	from	clinicians	was	captured,	this	was	mainly	from	the	one	Telehealth	Nurse	using	the	system	so	did	not	capture	the	range	of	experiences	that	might	have	been	seen	had	different	staff	used	the	system	and	in	different	services.	 	Whilst	 it	 identified	a	number	of	barriers	and	facilitators	to	staff	behaviour	change,	future	studies	should	focus	on	these	areas	of	uncertainty.		It	should	be	acknowledged	that	the	Telehealth	Nurse	was	also	a	member	of	the	research	team	that	developed	the	TiM	and	this	may	have	led	her	to	respond	favourably	 in	 interviews.	 	An	independent	 interviewer	was	used	in	the	second	interview	to	allow	her	to	express	her	views	openly	but	she	remained	aware	 that	 the	 research	 team	would	 be	 able	 to	 identify	 her	 views	 and	 could	potentially	 be	 critical	 of	 her	 actions.	 	Despite	 this,	 she	was	 critical	 of	 the	TiM	system	and	 identified	various	barriers	 to	 its	success.	 	Relying	on	one	nurse	 to	deliver	 the	 TiM	 system	 was	 also	 a	 limitation.	 	 The	 Telehealth	 Nurse	 was	 an	experienced	member	of	staff	who	was	involved	in	the	development	of	the	MND	service	 and	 therefore	 her	 current	 role	 has	 likely	 been	 shaped	 to	 reflect	 her	needs	 and	 preferences.	 	 Whilst	 she	 was	 consulted	 informally	 during	 the	development	of	the	TiM	and	reported	that	she	was	willing	and	had	time	in	her	job	 plan	 to	 use	 the	 TiM	 system,	 she	 explained	 in	 the	 interviews	 that	 she	preferred	working	 in	 a	 particular	way.	 	 She	 admitted	 other	 nurses	may	 have	different	attitudes,	may	be	more	“ready	to	change”	and	might	use	the	system	in	different	ways.		Future	evaluations	should	aim	to	include	a	more	diverse	range	of	services	and	staff	in	order	to	reflect	these	uncertainties.	
5.13	Conclusion		The	 TiM	 system	 is	 accessible	 and	 acceptable	 to	 patients	 and	 carers	 but	 a	number	of	problems	were	identified	that	meant	that,	at	present,	the	value	of	the	TiM	 is	uncertain.	 	Further	 improvements	are	required	 to	 tackle	 issues	such	as	the	excessive	alerts	generated	by	the	TiM	and	the	way	in	which	the	clinical	team	and	 patients	 and	 carers	 interact.	 	 Chapter	 Six	 describes	 whether	 a	 larger,	definitive	randomised	controlled	trial	of	the	TiM	would	be	feasible.		However,	it	is	clear	that	prior	to	any	definitive	trial,	the	TiM	system	would	need	significant	development.		This	would	be	best	done	as	an	iterative	process,	within	the	target	clinical	setting	and	should	allow	individual	care	centres	to	adapt	the	TiM	system	to	fit	in	with	their	existing	models	of	care.	
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Chapter	Six	
Results:	Evaluation	of	the	feasibility	of	the	study	
6.1	Introduction		Chapter	 Six	 describes	 how	 and	 whether	 conducting	 a	 definitive,	 randomised	controlled	trial	of	the	TiM	system	would	be	feasible.	 	 It	will	explore	whether	a	larger	 study	 could	 recruit	 and	 retain	 sufficient	 participants	 and	 whether	 a	larger	trial	could	determine	whether	the	TiM	system	is	effective.				Chapter	 Five	 reported	 the	 characteristics	 of	 the	 participants	 at	 baseline.		Chapter	Six	reports	the	results	of	screening,	recruitment	rates,	patient	and	carer	clinical	 outcomes	 and	 health	 resource	 use	 during	 the	 trial.	 	 It	 reports	 any	changes	in	the	outcomes	during	the	trial	and	whilst	it	does	not	aim	to	compare	the	 outcomes	 in	 the	 two	 treatment	 groups	 it	 does	 report	 any	 notable	differences.		Where	possible,	it	also	compares	the	characteristics	of	participants	to	published	population	data	 in	order	 to	understand	whether	 the	participants	are	representative	of	those	attending	an	MND	clinic.			Chapter	Six	then	uses	both	qualitative	and	quantitative	data	collected	to	discuss	whether	a	definitive	randomised	controlled	trial	would	be	feasible	considering	whether	the	outcome	measures	collected	were	acceptable	to	participants,	valid	and	 accurate	 and	whether	 the	 data	 collection	methods	 are	 feasible	 and	 are	 a	valid	reflection	of	participants’	experiences	of	life	with	MND.		Finally,	 it	 discusses	 the	 strengths	 and	 weaknesses	 of	 the	 study	 design	 and	makes	recommendations	for	ways	in	which	TiM	may	be	better	evaluated.				Not	 all	 data	 collected	during	 the	 trial	 is	presented	 in	 this	 chapter.	 	Additional	data	 is	 contained	 in	 Appendix	 B	 where	 stated.	 Quotes	 from	 interviews	 have	been	 used	 to	 illustrate	 relevant	 points	 and	 supporting	quotes	 are	 reported	 in	tables	in	Appendix	B.	 	
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6.2	Screening,	recruitment	and	participant	characteristics	
6.2.1	Screening	and	recruitment	Screening	 commenced	 in	 September	 2014.	 	 Recruitment	 of	 the	 target	 40	patients	took	14	months	(approximately	3	patients	per	month)	(Figure	6.1).				Figure	6.1	Recruitment	in	the	TiM	trial.		
		Figure	 6.2	 displays	 the	 CONSORT	 flow	 diagram	 describing	 the	 processes	 of	screening,	 recruitment,	 follow-up	 and	 data	 analysis.	 306	 patients	 were	 pre-screened	using	the	ARC	MND	clinical	database.		Two	patients	were	followed	up	for	 the	 entire	 18	 months.	 	 To	 maximise	 the	 use	 of	 the	 TiM	 system,	 all	participants	 remained	 in	 the	 study	 and	 those	 in	 the	 intervention	 group	continued	to	use	the	TiM	until	the	study	finished	in	April	2016.	This	meant	15	patients	 completed	 between	12	 and	17	months	 in	 the	 trial	 and	20	 completed	between	six	and	11	months.		Participants	whose	follow-up	finished	before	each	time-point	 are	 included	 in	 the	 CONSORT	 diagram	 and	 referred	 to	 as	“Patients/carers	follow-up	finished”.			 	
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	Figure	 6.2	 CONSORT	 flow	 diagram.	 All	 participants	 were	 followed	 up	 for	 six	months	unless	 they	withdrew	or	died.	 	Participants	 recruited	 later	 in	 the	 trial	were	 not	 followed	 up	 for	 the	 entire	 18	 months.	 These	 are	 included	 in	 the	CONSORT	diagram	and	referred	to	as	“Patients/carers	follow-up	finished”.		
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Table	6.1	describes	the	reasons	for	excluding	211	patients	at	pre-screening.	88	patients	 were	 excluded	 on	 clinical	 grounds	 and	 123	 patients	 were	 excluded	because	the	Sheffield	MND	clinic	was	not	currently	their	main	MND	care	centre.			This	included	69	patients	who	lived	within	two	hours	drive	of	Sheffield	but	no	data	was	available	within	the	last	two	years	on	ARC.	 	Although	information	on	patient	deaths	are	automatically	updated	by	the	NHS	Spine	system,	this	can	be	incomplete.	 	These	patients	may	had	died	or	moved	 to	another	centre	or	may	have	stopped	attending	clinic.			All	95	patients	identified	as	potentially	eligible	were	invited	to	participate.	 	42	(44%)	 patients	 expressed	 an	 interest	 in	 participating	 and	 40	 (42%)	 were	recruited.		Figure	5.1	describes	the	reasons	why	patients	declined.		28	patients	were	 recruited	 from	 the	 population	 of	 patients	 already	 diagnosed	 (the	prevalent	population).	 	During	the	trial,	a	 further	12	newly	diagnosed	patients	were	recruited.		Recruitment	of	all	40	patients	took	14	months.	The	40	eligible	patients	who	expressed	an	interest	in	participating	received	a	visit	at	home.		All	these	 patients	were	 recruited,	 randomised	 and	 received	 the	 correct	 allocated	intervention.		37	carers	were	recruited.		Three	patients	who	were	recruited	did	not	have	an	eligible	carer.		Three	 patients	 died	 (15%)	 and	 two	 patients	 (5%)	 withdrew	 from	 the	 study:	both	 were	 severely	 disabled	 at	 recruitment	 (requiring	 both	 NIV	 and	gastrostomy	 feeding)	 and	 shortly	 after	 recruitment	 felt	 too	 ill	 to	 continue	 to	participate.		All	participants	continued	to	remain	in	contact	with	the	MND	centre	and	 therefore	 no	 patients	were	 lost	 to	 follow-up.	 	 No	 carers	withdrew	 except	those	who	were	automatically	withdrawn	when	the	patients	withdrew	or	died.					 	
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Table	 6.1	 Reasons	 for	 patient	 exclusion	 at	 pre-screening	 using	 ARC	 database.		309	patients	were	screened	and	a	total	of	211	patients	(68%)	excluded.		
Reason	for	exclusion		 Number	 of	
participants	
Sheffield	not	currently	the	main	MND	care	centre		Live	>	2	hours’	drive	from	Sheffield	 32	(10%)	Attend	another	care	centre	 22		(7%)	No	data	on	ARC	in	last	two	years7	 69	(22%)	Total	 123	(40%)	
Attending	the	Sheffield	MND	care	centre,	excluded	on	
clinical	grounds	No	evidence	of	symptom	progression	 36	(12%)	Severe	cognitive	impairment	 12	(4%)	Terminal	stage	of	the	disease	 11	(4%)	Symptom	onset	unclear	 1	(0.3%)	Patient	unable	to	read	English	 1	(0.3%)	Previously	declined	all	research	 2	(0.7%)	Recent	diagnosis:	insufficient	data	 16	(5%)	No	eligible	carer8	 1	(0.3%)	Residing	in	a	nursing	home/hospital	 8	(3%)	Total	 88	(28%)			 	
																																																								7	This	was	because	the	patient	had	not	attended	the	MND	service	in	Sheffield.		It	is	possible	that	many	of	these	patients	had	died.	8	Patient	died	before	the	eligibility	criteria	changed	to	allow	patients	to	participate	without	a	carer.		
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6.3	Patient	clinical	outcomes			This	 section	 summarises	 the	patient	 reported	outcomes	 at	 baseline,	 three,	 six	and	12	months.	 	Participant	18-month	follow-up	outcomes	are	not	reported	as	only	one	questionnaire	was	returned.		Patient	quality	of	life	(QoL)	is	reported	in	most	detail	as	it	was	proposed	to	be	the	most	likely	primary	outcome	measure	in	 a	 definitive	 trial	 with	 other	 clinical	 and	 economic	 outcomes	 used	 as	secondary	 outcome	 measures.	 	 The	 aim	 of	 the	 study	 was	 not	 to	 determine	whether	 the	 TiM	 was	 superior	 to	 usual	 care,	 therefore	 no	 formal	 hypothesis	testing	is	performed.	Instead,	in	the	tables	the	mean	and	standard	deviation	at	each	time-point	is	reported.		As	discussed	in	Section	4.11.3,	in	order	to	explore	whether	 the	 outcome	 measures	 were	 sensitive	 to	 changes	 in	 participants’	condition,	the	mean	change	from	baseline	is	also	reported	along	with	the	95%	confidence	interval	to	estimate	the	precision	of	the	mean	change.	In	the	figure,	mean	 score	 and	 standard	 error	 of	 the	 mean	 are	 reported.	 	 When	 the	 mean	difference	between	baseline	and	follow-up	values	is	observed	to	be	significantly	different	from	zero		(p<0.05),	the	follow-up	score	is	highlighted	in	bold	in	tables	and	with	an	asterisk	(*)	in	figures.	
6.2.1	Patient	quality	of	life	Figures	 6.3-4	 and	 Table	 6.2	 displays	 the	 SF-36,	 ALSAQ-40	 scores	 at	 baseline,	three,	six	and	12	months.	 	Appendix	B	A6.1	displays	the	SF-36	scores	in	detail.		Table	6.3	summarises	 the	baseline	QoL	data,	and	compares	 the	TiM	results	 to	population	norms	from	adults	aged	55-64	years	and	other	studies	of	MND	(250-252).		The	 average	 ALSAQ-40	 emotional	 subdomain	 scores	 remained	 stable	throughout	the	trial.	 	Physical	QoL	scores	deteriorated.	By	six	months,	average	ALSAQ-40	 sub-scores	 in	 all	 physical	 domains	 worsened	 and	 changes	 in	 the	Activities	 of	 Daily	 Living	 (ADLs),	 Eating	 and	 Drinking	 domains	 reached	significance	(indicated	in	bold	in	Table	6.2	and	with	an	asterisk	in	Figure	6.3).		Physical	 Mobility,	 Eating	 and	 Drinking	 and	 Communication	 sub-scores	 also	showed	 a	 trend	 towards	 deterioration.	 	 At	 12	months,	 these	 trends	 persisted	but	the	Activities	of	Daily	Living	sub-score	was	the	only	difference	that	reached	significance.	 	Similarly	to	the	ALSAQ-40,	 the	average	SF-36	Mental	Component	Score	 (MCS)	 remained	 stable	 throughout	 the	 trial	 whilst	 the	 SF-36	 Physical	Component	 Score	 (PCS)	 deteriorated	 and	 was	 significantly	 different	 from	baseline	at	 twelve	months.	 	A	 similar	pattern	of	deterioration	 in	physical	QoL	scores	and	stable	emotional	scores	is	seen	in	larger	MND	populations	(253,254).					There	was	little	difference	between	the	intervention	and	the	control	arms	either	in	 the	 baseline	 or	 follow-up	 QoL	 scores	 but	 the	 samples	 were	 small	 and	confidence	intervals	wide.		On	 average,	 participants	 reported	 a	 poorer	 physical	 QoL	 (SF-36)	 than	population	norms	for	adults	aged	55-64	years	whereas	emotional	SF-36	scores	were	 similar	 to	 those	 of	 the	 general	 population	 (252)	 (Table	 6.2).	 	 However,	participants’	 ALSAQ-40	 and	 SF-36	 were	 better	 in	 all	 domains	 than	 those	 in	larger	samples	of	MND	patients	(250,251)	(Table	6.3).		
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	Figure	6.3:	Mean	ALSAQ-40	sub-scores	and	standard	errors	at	baseline,	 three,	six,	and	twelve	months.		Scores	range	from	0	(best	possible	QoL)	to	100	(worse	possible	 QoL).	 	 An	 *	 indicates	 scores	 where	 the	 mean	 change	 from	 baseline	differs	significantly	from	baseline	(p<0.05).		
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Table	6.2	Patient	ALSAQ-40	index	scores:	mean,	standard	deviation	(SD),	mean	change	 from	 the	baseline	and	95%	confidence	 intervals.	 	 Scores	 range	 from	0	(best	 possible	 QoL)	 to	 100	 (worse	 possible	 QoL).	 	 Cells	 highlighted	 in	 bold	indicate	where	scores	are	significantly	different	to	baseline.	
Patient	
ALSAQ-40	
Base-
line	
3	months	 6	months	 12	months	
ALSAQ
-40	
Mean	
(SD)	
ALSAQ
-40	
Mean	
(SD)	
Mean	
change		
from	
baseline	
	(CI)	
ALSAQ
-40	
Mean	
(SD)	
Mean	
change	
	from	
baseline	
	(CI)	
ALSAQ-
40	
Mean	
(SD)	
Mean	
change	
from	
baseline	
	(CI)	
Telehealth			 n=18	 n=16	 n=15	 n=16		 n=16	 n=6	 n=6	Physical	mobility	 50.4	(36.6)	 47.5	(34.6)	 -4.7	(-15.4,	6.1)	 54.5	(30.9)	 5.8	(-3.8,	15.4)	 68.3	(26.8)	 10.4	(-3.6,	24.4)	Activities	of	daily	living	 39.2	(30.2)	 44.2	(35.6)	 5.8	(-0.1,	11.8)	 45.9	(33.1)	 8.4	(1.6,	15.3)	 51.7	(45.2)	 15.8	(-1.5,	33.1)	Eating	and	drinking	 19.9	(32.5)	 22.9	(27.6)	 6.1	(-1.4,	13.6)	 27.6	(31.7)	 11.5	(2.6,	20.3)	 22.2	(30.6)	 13.9	(-16.7,	44.5)	Communic-ation	 38.3	(39.0)	 35.1	(35.9)	 0.5	(-5.0,	5.9)	 39.9	(39.1)	 3.6	(-2.1,	9.3)	 28.6	(45.2)	 13.1	(-12.1,	38.3)	Emotional	 32.6	(16.8)	 30.6	(20.0)	 0	(-6.4,	6.4)	 32.6	(16.9)	 1.4	(-4.6,	7.5)	 34.2	(24.3)	 3.8	(-13.0,	20.5)	Total	 38.8	(22.5)	 38.4	(22.2)	 0.83	(-2.6,	4.3)	 42.1	(21.2)	 5.4	(0.2,	10.6)	 45.2	(26.3)	 10.8	(-1.5,	23.2)	
Control									 n=20	 n=15	 n=15	 n=12	 n=12	 n=7	 n=6	Physical	mobility	 46.9	(28.7)	 52.2	(27.6)	 1.6	(-12.9,	16.1)	 51.3	(28.6)	 8.3	(-8.2,	24.9)	 63.2	(26.1)	 15.0	(-17.6,	47.6)	Activities	of	daily	living	 49.3	(28.7)	 53.8	(24.2)	 2.3	(-7.0,	11.6)	 59.7	(24.6)	 9.0	(-9.6,	18.9)	 63.6	(30.4)	 15.8	(1.9,	30.0)	Eating	and	drinking	 17.5	(28.2)	 18.9	(22.6)	 0.6	(-7.1,	8.3)	 19.5	(30.1)	 8.3	(-10.7,	27.4)	 22.6	(26.2)	 2.8	(-6.3,	11.8)	Communic-ation	 28.6	(32.2)	 31.4	(35.8)	 1.5	(-5.9,	8.9)	 28.8	(38.1)	 8.0	(-20.5,	36.6)	 31.6	(28.2)	 9.5	(-9.8,	28.9)	Emotional	 27.5	(17.0)	 27.3	(22.0)	 -1.4	(-9.2,	6.3)	 29.1	(20.5)	 -2.3	(-16.4,	11.8)	 27.9	(18.6)	 -3.8	(-23.6,	16.1)	Total	 37.3	(17.2)	 40.3	(17.7)	 0.8	(-2.6,	4.3)	 41.5	(14.9)	 5.8	(-3.7,	15.3)	 45.9	(12.5)	 10.8	(-1.5,	23.2)	
Total												 n=38	 n=31	 n=30	 n=28	 n=28	 n=13	 n=12	Physical	mobility	 48.6	(32.3)	 49.8	(31.0)	 0.9	(-6.7,	8.6)	 53.1	(29.4)	 6.9	(-1.4,	15.2)	 65.6	(25.5)	 12.7	(-1.8,	27.3)	Activities	of	daily	living	 44.5	(29.5)	 48.9	(30.5)	 1.6	(-12,9,	16.1)	 51.8	(30.0)	 8.7	(3.3,	14.0)	 58.1	(29.0)	 15.8	(6.8,	24.9)	Eating	and	drinking	 18.6	(28.4)	 21.0	(25.0)	 2.3	(-7.0,	8.3)	 24.1	(30.8)	 10.1	(1.3,	19.0)	 22.4	(27.1)	 8.3	(-5.2,	21.9)	Communic-ation	 33.3	(35.4)	 33.3	(35.3)	 01.5	(-5.9,	8.9)	 35.2	(38.3)	 5.5	(-6.1,	17.1)	 30.2	(35.3)	 11.3	(-1.7,	24.3)	Emotional	 29.9	(16.9)	 29.0	(20.7)	 -1.4	(-9.2,	6.3)	 31.1	(18.2)	 -0.2	(-6.6,	6.3)	 30.8	(20.8)	 0	(-10.9,	10.9)	Total	 38.0	(19.6)	 39.3	(19.9)	 0.88	(-2.9,	4.7)	 41.8	(18.5)	 5.6	(0.9,	10.2)	 45.6	(19.1)	 8.6	(-0.4,	17.6)	
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Figure	6.4	Mean	SF-36	physical	component	scores	(PCS)	and	mental	component	scores	 (MCS)	 and	 standard	 errors.	 	 SF-36	 scores	 are	 standardised	 to	 a	normative	 reference	 population	 (mean	 is	 50	 and	 SD	 is	 10.)	 	 Telehealth	 and	controls	 arms	 are	 displayed	 separately	 (left)	 and	 together	 (right).	 	 An	 *	indicates	 scores	 where	 the	 mean	 change	 from	 baseline	 differs	 significantly	different	from	baseline	(p<0.05).	
			Table	 6.3	 The	 TiM	 population	 ALSAQ-40	 and	 SF-36	 means	 and	 standard	deviations	at	baseline	compared	to	larger	population	studies	(250-252).	
ALSAQ-40	
TiM	study	
Mean	(SD)	
ALSAQ-40	
population	
Mean	9	n=38	 n=144	Physical	mobility	 48.6	(32.3)	 69.9	Activities	of	daily	living	 44.5(29.5)	 69.4	Eating	and	drinking	 18.6	(28.4)	 37.9	Communication	 33.3	(35.4)	 50.3	Emotional	 29.9	(16.9)	 50.6	
SF-36	 TiM	study	Mean	(SD)	 ALS-HPS	study	Mean	(SD)	 Population	norms	Mean	(SD)	n=38	 n=337	 	Physical	component	score	 29.0	(8.8)	 26.45	(11.62)	 45.1	(12.2)	Mental	component	score	 53.3	(9.7)	 43.69	(13.50)	 52.2	(9.8)																																																									9	Standard	deviation	not	reported.		n	varied		from	142	and	144	due	to	missing	data	in	some	subscores.	
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6.3.2	Additional	patient	clinical	outcomes	
6.3.2.1	Health	utility:	patient	EQ-5D	Figure	6.4	displays	 the	EQ-5D-3L	scores.	 	Tables	of	EQ-5D-3L	scores	with	and	without	 the	 additional	 dignity	 “bolt	 on”	 question	 are	 available	 in	 Appendix	 B	A6.2	and	A6.3.			The	calculations	displayed	in	Figure	6.4	excluded	patients	who	died	 from	 subsequent	 analysis.	 	 A	 further	 analysis	 assigned	patients	who	had	died	 a	 score	 of	 0	 at	 all	 future	 time	 points.	 This	 additional	 calculation	 had	 no	substantial	impact	on	the	scores.			There	were	no	notable	differences	in	EQ-5D	or	self-rated	thermometer	between	the	two	treatment	groups	at	any	time	point.		EQ-5D-3L	TiM	scores	were	worse	than	the	population	norms	for	adults	aged	55-64	years	(TiM	mean	0.53,	SD	0.29	SD	vs.	general	population	0.8,	SD	0.26)	(255).	Self-rated	thermometer	scores	were	also	lower	(TiM	63.1,	SD	21.3,	vs.	79.7	SD	18.2)	(255).			EQ-5D-3L	and	thermometer	scores	did	worsen	during	the	trial	but	only	the	total	EQ-5D-3L	score	changed	significantly	from	baseline	at	six	months	(Appendix	 A6.2	 B,	 indicated	 in	 bold).	 	 Health	 utility	 data	 for	MND	 patients	 is	very	limited	with	only	two	studies	identified	but	 in	these	studies	health	utility	scores	 were	 also	 worse	 in	 patients	 with	 MND	 compared	 to	 the	 general	population	with	scores	worsening	over	time	(56,227).				Figure	 6.4	 EQ-5D-3L	 plus	 dignity	 bolt-on	 scores	 (EQ-5D+D)	 and	 the	 EQ5D	thermometer.	 	EQ-5D+D	scores	range	 from	1	(best	QoL)	 to	 -0.59	(worst	QoL).	Thermometer	scores	range	from	100	(best	QoL)	to	0	(worst	QoL).	
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6.3.2.2	ALS-FRS-R	Figure	6.5	and	Appendix	B	A6.4	displays	the	average	ALSFRS-R	scores.	 	Scores	declined	(indicating	worsening	 function)	during	 the	study	by,	on	average	0.27	points	per	month	at	six	months	and	0.39	points	per	month	at	12	months.	 	The	rate	 of	 functional	 decline	 is	 comparable	 to	 the	 monthly	 rate	 of	 decline	 of	ALSALS-R	 in	 a	 historical	 study	 of	 patients	 attending	 the	 Sheffield	MND	 clinic	(0.34	in	the	second	year)	but	much	slower	than	many	clinical	trials	(decline	of	between	 0.76	 and	 1.60	 per	 month)	 where	 patients	 with	 slowly	 progressive	disease	are	often	excluded	(256,257).	 	By	12	months	the	decline	from	baseline	reached	significance	in	the	telehealth	arm	and	when	both	arms	were	combined.				Again,	there	did	not	appear	to	be	any	notable	differences	between	the	two	arms.		Figure	6.5	Mean	ALS-FRS-R	and	standard	error	during	 the	 trial.	 	 Scores	 range	from	0	(severe	disability)	to	48	(no	disability).		An	*	indicates	scores	where	the	mean	change	from	baseline	differs	significantly	from	baseline	(p<0.05).		
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6.3.2.3	Patient	Anxiety	and	depression	The	 baseline	 and	 follow-up	 data	 is	 displayed	 in	 Appendix	 B	 A6.5-A6.7	which	includes	a	comparison	with	the	UK	population	norms	broken	down	into	gender	as	 the	 incidence	 of	 depression	 and	 anxiety	 differs	 between	men	 and	 women	(258).	 Average	 patient	 HADS	 depression	 scores	 were	 low	 and	 the	 average	scores	were	 similar	 to	 the	 UK	 population	 (study	mean	 score	 4.8	 females,	 4.2	males	vs.	UK	population	4.1	 females,	3.9	males)	(258).	 	 	Seven	patients	(19%)	had	 scores	 indicating	mild	 symptoms	 (score	 8-10),	 and	 one	 patient	 (3%)	had	scores	indicating	moderate	to	severe	symptoms	of	depression	(score	>11).			The	incidence	of	higher	scores	was	similar	to	the	general	population.	Average	 patient	 HADS	 anxiety	 scores	 were	 low,	 and	 also	 similar	 to	 the	 UK	population	 (study	 mean	 score	 6.9	 females,	 4.8	 males	 vs.	 UK	 population	 6.3	females,	 4.9	 males).	 8	 patients	 (22%)	 had	 scores	 indicating	 mild	 symptoms	(score	 8-10),	 and	 three	 (8%)	 had	moderate	 to	 severe	 symptoms	 (score	 >11).			However,	 these	rates	of	higher	anxiety	scores	were	also	similar	 to	 the	general	population.	 	 	There	are	no	 large	population	studies	of	 the	HADS	score	 in	MND	with	which	to	compare.		During	the	trial,	average	anxiety	and	depression	sub-scores	and	the	incidence	of	abnormal	scores	did	not	change	appreciably.		There	were	no	notable	differences	between	the	two	treatment	groups.			
6.3.2.4	Pain	scores	Pain	 scores	 are	 available	 in	 Appendix	 B	A6.8.	 	 Baseline	 pain	 scores	were	 low	(current	pain	mean	1.5	out	of	10,	SD	1.7,	worst	pain	this	week	mean	3.0,	SD	2.7)	and	 did	 not	 change	 significantly	 during	 the	 study.	 	 There	 was	 no	 notable	difference	between	the	two	arms	of	the	trial.			
6.3.2.5	Saliva	severity	scores	A	summary	of	the	Saliva	Severity	Scores	(CSS-MND)	is	available	 in	Appendix	B	A6.9.		At	the	time	of	writing,	this	version	of	the	CSS-MND	had	not	been	formally	validated	 and	 no	 published	 population	 norms	 were	 available	 making	interpretation	limited.		Mean	scores	were	low	indicating	low	levels	of	excessive	saliva	 (4.1,	 SD	 5.5,	 scores	 range	 from	 0	 to	 36)	 but	 individual	 scores	 varied	greatly	 during	 follow	 up.	 	 For	 example,	 one	 patient’s	 score	 worsened	 by	 15	points	 in	 six	 months	 whilst	 another	 improved	 by	13	points.	 	 However,	 mean	scores	did	not	change	significantly	during	the	study	and	did	not	appear	to	differ	between	the	two	treatment	groups.					 	
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6.4	Carer	outcomes	
6.4.1	Carer	quality	of	life	Figure	6.6	and	Appendix	B	A6.10	reports	the	carer	SF-36	scores.	 	Physical	and	mental	 component	scores	were	similar	 to	population	norms	and	were	slightly	better	than	a	larger	population	of	carers	of	those	with	MND	(PCS	TiM	52.7,	SD	9.3	vs.	ALS-HPS	46.5,	SD	12.3,	MCS	TiM	49.3,	SD	11.6	vs.	ALS-HPS	41.5,	no	SD	reported)	(251).		The	mean	MCS	remained	stable	through	the	trial	but	the	PCS	did	show	a	trend	to	worsen	but	this	change	only	reached	significance	in	the	control	group	at	six	months.	 	 The	 intervention	 group	 appeared	 to	 have	 slightly	worse	MCS	 at	 the	start	of	the	study	than	the	control	group.			The	intervention	group	MCS	average	deteriorated	 by,	 on	 average	 2.9	 points	 (95%	 CI	 -9.6,	 3.8)	whereas	 the	 control	group	scores	improved	by,	on	average,	2.4	points	(95%	CI	-4.5,	9.3).		However,	the	differences	were	small	and	confidence	intervals	wide	so	no	firm	conclusions	should	be	drawn	from	these	findings.		Figure	6.6	Mean	SF-36	physical	component	scores	(PCS)	and	mental	component	scores	(MCS).		Treatment	groups	are	displayed	separately	(above)	and	together	(Total,	below).				
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6.4.2	Carer	anxiety	and	depression	Tables	 6.4	 and	 6.5	 reports	 the	 carer	 HADS	 scores	 and	 Appendix	 B	 A6.5	compares	 carer	 baseline	 scores	 to	 those	 of	 patients	 and	 the	 UK	 population	(258).		Average	 carer	HADS	depression	 scores	were	 low	and	 similar	 to	 both	patients	and	the	UK	population	(carer	mean	score	5.6	females,	3.8	males	vs.	population	4.1	 females,	 3.9	 males)	 (See	 Table	 5.14)	 (258).	 	 One	 carer	 (3%)	 had	 scores	indicating	mild	symptoms	and	two	carers	(5%)	had	scores	indicating	moderate	to	 severe	 symptoms.	 	 	 The	 incidence	 of	 higher	 scores	was	 also	 similar	 to	 the	general	population.			Average	 patient	 HADS	 anxiety	 scores	 were	 low	 and	 also	 similar	 to	 the	 UK	population	 and	 to	 patients	 (carer	 mean	 score	 6.1	 females,	 5.6	 males	 vs.	population	6.3	females,	4.9	males).	 	More	carers	had	mild	or	severe	symptoms	of	anxiety	than	depression:		9	(24%)	had	scores	indicating	mild	symptoms	and	four	(11%)	had	moderate	to	severe	symptoms.			However,	these	rates	of	higher	anxiety	 scores	were	 also	 similar	 to	 patients	 and	 the	 general	 population.	 	 	 As	with	patients,	there	are	no	large	population	studies	of	carer	HADS	score	in	MND	with	which	to	compare.		The	average	score	remained	similar	throughout	the	trial.	However,	the	number	of	 carers	 with	 moderate/severe	 symptoms	 of	 anxiety	 increased	 (11%	 at	baseline,	21%	at	6	months	and	31%	at	12	months,	highlighted	in	bold	in	Table).			This	trend	was	seen	in	both	the	telehealth	and	control	groups.	
6.4.3	Carer	burden	Carer	strain	scores	using	the	Zarit	Burden	Inventory	(ZBI)	are	reported	in	Table	6.6.		The	mean	baseline	score	was	12.3	(SD	8.8).		Nine	(27%)	carers	scored	>	17	at	 baseline	 indicating	 they	 were	 experiencing	 high	 burden.	 	 Average	 scores	remained	 similar	 throughout	 the	 trial	 although	 there	 was	 a	 small,	 non-significant	 increase	 in	 the	 Telehealth	 scores	 at	 12	 months.	 Unlike	 the	 HADS	anxiety	 scores,	 the	 number	 of	 carers	 reporting	 high	 burden	 scores	 remained	similar	 throughout	 the	 trial:	at	 twelve	months	 four	carers	(33%)	had	scores	>	17.	 	 The	 incident	 of	 high	 scores	was	 lower	 than	 a	 larger	 sample	 of	 carers	 of	those	with	MND	(27%	TiM	vs.	48%	population)	(84)	but	these	findings	do	show	that	high	burden	is	a	problem	for	many	carers	and	requires	attention.		
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Table	6.4	Carer	HADS	depression	sub	scores	and	the	number	(%)	of	patients	with	borderline	scores	or	abnormal	scores.		Scores	0-7	are	
normal,	8-10	borderline/mild	symptoms,	11-21	abnormal:	moderate/severe).	
	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
	
M
ean	(SD
)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline		
M
ean	(CI)	
Telehealth	D
epression	
	n=16	
n=14	
n=13	
n=15	
n=14	
n=6	
n=6	
Mean		
(SD/CI)	
4.0	(3.2)	
4.6	(4.1)	
0.1	(-1.0,	1,2)	
4.3	(3.9)	
0.1	(-0.9,	1.0)	
4.8	(3.5)	
1.3	(-1.5,	4.1)	
Score	>8	1	(6%)	
3	(21%)	
-	
3	(20%)	
-	
1	(14%)	
-	
Score	>11	1	(6%)	
1	(7%)	
-	
1	(7%)	
-	
0	(0%)	
-	
Control	D
epression		n=18	
n=14	
n=14	
n=11	
n=11	
n=7	
n=7	
Mean		
(SD/CI)	
3.3	(2.8)	
4.8	(4.2)	
1.4	(0.0,	2.8)	
4.3	(4.5)	
2.1	(0.4,	4.6)	
3.4	(3.4)	
1.3	(-0.8,	3.4)	
Score	>8	2	(11%)	3	(21%)	
-	
3	(27%)	
-	
1	(14%)	
-	
Score	>11	1	(6%)	
1	(7%)	
-	
1	(9%)	
-	
0	(0%)	
-	
Total	D
epression		n=34	
n=28	
n=27	
n=26	
n=25	
n=13	
n=13	
Mean		
(SD/CI)	
3.6	(3.0)	
4.7	(4.0)	
0.8	(-0.1,	1.7)	
4.3	(4.0)	
1.0	(-0.2,	2.1)	
4.1	(3.4)	
1.3	(-0.2,	2.7)	
Score	>8	2	(6%)	
6	(21%)	
-	
6	(21%)	
-	
2	(15%)	
-	
Score	>11	1	(3%)	
2	(7%)	
-	
2	(7%)	
-	
0	(0%)	
-	
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Table	6.5	Carer	HADS	anxiety	sub	scores	and	the	number	(%)	of	patients	with	borderline	scores	or	abnormal	scores.		Scores	0-7	are	
normal,	8-10	borderline/mild	symptoms,	11-21	abnormal:	moderate/severe).		
	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
	
M
ean	(SD
)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline		
M
ean	(CI)	
Telehealth	Anxiety	
	n=16	
n=14	
n=13	
n=15	
n=14	
n=6	
n=6	
Mean			
(SD/CI)	
6.3	(4.6)	
7.1	(4.6)	
0.0	(-1.8,	1.7)	
6.0	(5.1)	
-0.8	
(-2.9,	1.3)	
7.3	(5.0)	
0.3	(-1.4,	1.9)	
Score	>8	7	(44%)	3	(21%)	
-	
5	(33%)	
-	
3	(43%)	
-	
Score	>11	2	(13%)	
1	(7%)	
-	
3	(20%)	
-	
3	(43%)	
-	
Control	Anxiety		n=18	
n=14	
n=14	
n=11	
n=11	
n=7	
n=7	
Mean			
(SD/CI)	
5.9		(3.5)	
6.2	(4.4)	
-0.2	
(-1.8,	1.4)	
6.4	(4.8)	
0.3	(-2.1,	2.7)	
5.6	(4.0)	
-0.6	
(-1.6,	0.5)	
Score	>8	6	(33%)	6	(43%)	
-	
4	(36%)	
-	
2	(29%)	
-	
Score	>11	2	(11%)	2	(14%)	
-	
3	(27%)	
-	
1	(14%)	
-	
Total	Anxiety		
n=34	
n=28	
n=27	
n=26	
n=25	
n=13	
n=13	
Mean		
(SD/CI)	
6.1		(4.0)	
7.1	(4.6)	
-0.1	
(-1.2,	1.0)	
6.2	(4.8)	
-0.3	
(-1.8,	1.1)	
6.4	(4.4)	
-0.2		
(-1.4,	1.9)	
Score	>8	13	(35%)	3	(11%)	
-	
9	(31%
)	
-	
5	(38%
)	
-	
Score	>11	4	(11%)	5	(18%)	
-	
6	(21%
)	
-	
4	(31%
)	
-	
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Table	6.6	The	12-item	Zarit	Burden	Interview	scores.		Scores	range	from	0	(no	burden)	to	48	(severe	burden).		A	cut-off	of	scores	>17	suggests	high	burden	(222).	
	
	 Base-line	 3	months	 6	months	 12	months	
	 Mean	(SD)	
Mea
n	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Telehealth		 n=18	 n=14	 n=14	 n=15	 n=15	 n=6	 n=6	Mean		(SD/CI)	 11.5	(9.9)	 12.7	(11.2)	 1.6	(-1.6,	4.8)	 13.7	(10.7)	 2.4	(-1.3,	6.1)	 13.8	(12.6)	 4.3	(-1.2,	9.9)	Score	>17	 3		(19%)	 4	(29%)	 	 4	(27%)	 	 2		(33%)	 	
Control			 n=16	 n=13	 n=13	 n=10	 n=10	 n=6	 n=6	Mean			(SD/CI)	 12.9	(7.9)	 15.9	(8.9)	 3.0	(-0.6,	6.6)	 12.4	(9.5)	 2.6	(-0.5,	5.7)	 13.5	(9.6)	 -0.3	(-7.9,	6.2)	Score	>17	 6		(33%)	 4	(31%)	 -	 2	(20%)	 	 2		(33%)	 	
Total	 	 n=34	 n=27	 n=27	 n=25	 n=25	 n=12	 n=12	Mean			(SD/CI)	 12.3	(8.8)	 14.2	(10.1)	 2.6	(0.0-4.5)	 13.2	(9.0)	 2.5	(0.1,	4.8)	 13.7	(10.7)	 1.8	(-2.3,	5.8)	Score	>17	 9		(27%)	 8	(30%)	 	 6	(24%)	 	 4		(33%)	 								
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6.5	Adverse	events		Adverse	 events	 were	 all	 expected	 complications	 of	 MND,	 e.g.	 pneumonia,	gastrostomy	site	infection	(Appendix	B	A6.11).		No	adverse	events	were	reported	to	 be	 caused	 by	 telehealth	 but	 four	 adverse	 events	 were	 reported	 to	 be	connected	to	 telehealth.	 	TiM	had	 identified	two	problems	recorded	as	adverse	events:	acid	reflux	causing	swallowing	difficulties	and	excessive	carer	strain.		On	two	occasions	the	TiM	alerted	the	Telehealth	Nurse	to	worsening	dysphagia	and	weight	loss	that	prompted	staff	to	discuss	gastrostomy	with	the	patients.		In	both	cases	the	patient	went	on	to	have	a	gastrostomy	inserted	and	this	was	reported	as	an	adverse	event.		More	adverse	events	were	recorded	in	the	telehealth	arm.		It	 is	 likely	 that	 this	was	due	to	reporting	bias	because	 these	patients	had	more	contact	with	 the	 study	 team.	 	A	 true	 comparison	of	 adverse	 event	 rates	would	have	required	regular	research	visits	to	capture	every	event.		It	would	be	feasible	to	 arrange	 regular	 (e.g.	 three	 monthly	 visits)	 but	 the	 TiM	 provides	 weekly	contact.	 	 It	would	be	both	unfeasible	 and	 far	different	 from	usual	 care	 to	offer	this	 level	 of	 contact.	 Therefore,	 observing	 more	 adverse	 events	 in	 the	intervention	 group	 would	 be	 an	 inevitable	 and	 acceptable	 price	 to	 pay	 when	evaluating	a	monitoring	system.		Participants	 reported	 that	 the	 TiM	 did	 not	 appear	 to	 change	 their	 behaviour	when	unwell	(something	which	Chapter	Two	suggested	could	be	a	problem	with	telehealth).		Patients	did	not	delay	seeking	help	and	felt	able	to	initiate	contact	if	they	 had	 a	 problem	with	which	 they	 thought	 the	Telehealth	Nurse	 could	 help.		Chapter	Five	reports	that	on	a	number	of	occasions,	participants	encounter	acute	problems	that	the	patient	or	carer	thought	they	had	recorded	on	the	TiM,	such	as	chest	infections	and	falls.			On	many	of	those	occasions	the	patient/carer	had	not	been	contacted	by	 the	Telehealth	Nurse.	 	However,	 the	 interviews	and	adverse	event	log	identified	no	situations	where	participants	suffered	any	adverse	events	as	a	result	of	the	Telehealth	Nurse	not	making	contact.	
6.6	Health	resource	use		
6.6.1	Health	encounters.	Figure	 6.7	 summarises	 the	 mean	 number	 of	 encounters	 with	 healthcare	professionals	per	patient	in	the	three	months	prior	to	starting	the	study.	Figure	6.8	 breaks	 this	 down	 with	 each	 individual	 health	 professional	 in	 the	 three	months	prior	to	the	study.		In	total	the	average	number	of	encounters	was	9.1	in	the	 three	months	with,	 on	 average,	 2.2	 encounters	with	 a	 physician	 (usually	 a	neurologist),	 3.0	 encounters	with	 a	 nurse	 and	 3.7	 encounters	with	 a	 therapist	(such	 as	 a	 dietician,	 speech	 or	 physiotherapist).	 	 Encounters	 with	 a	 GP	 were	uncommon	(mean	0.7	in	three	months).				The	mean	number	of	encounters	with	healthcare	professionals	in	both	treatment	groups	 increased	 during	 the	 study	 but	 the	 number	 of	 encounters	 reported	 by	individual	 patients	was	 extremely	 variable:	 a	 quarter	 of	 patients	 reported	 less	than	 four	 encounters	 whilst	 one	 patient	 had	 30	 encounters	 over	 the	 previous	three	months.	 	Later	in	the	study	one	patient	recorded	121	encounters	in	three	months.	Most	encounters	were	 the	specialists	 in	neurology/palliative	care	who	
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were	either	part	of	the	MND	MDT	or	related	therapists	(see	Appendix	B	A6.12-A6.16	 for	 additional	 data).	 	 However,	 many	 patients	 were	 not	 sure	 of	 the	background	 of	 all	 the	 professionals	 they	 met	 and	 it	 was	 not	 possible	 to	determine	 whether	 some	 (particularly	 therapists)	 were	 part	 of	 the	 specialist	MDT	or	from	a	non-specialist	background.				Figure	6.7	The	number	of	patient-reported	MND	related	healthcare	encounters	in	the	three	months	prior	to	the	study	(baseline)	and	during	the	study	(mean	and	range).																			Figure	6.8	Patient	encounters	with	healthcare	professionals	due	 to	MND	 in	 the	three	months	prior	to	the	study	commencement	(mean	and	range,	n=38).			 	
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6.6.2	Hospital	admissions	In	 the	 three	months	prior	 to	 the	study	starting,	patients	reported	a	 total	of	 ten	hospital	 admissions	 (34	overnight	 stays)	 (Appendix	B	A6.16).	 	 Five	emergency	hospital	 admissions	were	 reported	 (27	 days,	 0.52	 admissions	 per	 patient,	 per	year).				During	 the	 trial,	 admission	rates	were	 low:	nine	MND-related	admissions	were	reported	(64	nights	in	total	were	recorded	not	including	one	hospice	admission	for	 which	 the	 duration	 of	 stay	 was	 not	 collected)	 (Appendix	 B	 A6.16).	 	 No	patients	required	admission	to	high	dependency	unit	or	intensive	care.		The	most	common	 reason	 for	 admission	 was	 for	 gastrostomy	 insertion.	 	 	 MND	 related	emergency	 admissions	 were	 uncommon:	 four	 emergency	 admissions	 due	 to	MND	 occurred	 during	 the	 trial	 (23	 days).	 	 The	 number	 of	 admissions	was	 too	small	to	make	a	meaningful	comparing	between	the	two	treatment	groups.				
6.6.3	Personal	care	requirements	Figures	6.9	and	6.10	display	the	informal	(unpaid)	and	formal	(paid)	carer	hour	requirements	estimated	by	patients	per	week	(Appendix	B	A6.17).		Both	formal	and	 informal	carer	requirements	were	extremely	variable.	 	Formal	carer	hours	ranged	 from	 0	 to	 168	 hours	 per	 week	 with	 most	 patients	 still	 not	 requiring	formal	care	at	12	months.		Individual	patients	did	report	a	significant	increase	in	formal	 care	 early	 during	 the	 study,	 these	were	mostly	 in	 the	 telehealth	 group.		The	results	from	this	small	number	of	patients	meant	the	means	are	skewed	with	the	mean	formal	care	hours	in	the	telehealth	group	increasing	much	more	than	the	control	group	whereas	the	median	carer	hours	remained	less	than	five	hours	throughout	in	both	arms.					Informal	carer	hours	also	ranged	from	0	to	168.			The	median	number	of	hours	of	informal	care	received	at	baseline	was	14.5	hours.	A	group	of	patients	reported	they	 received	more	 than	 160	 hours	 per	week	 of	 informal	 care	 throughout	 the	study	 whilst	 a	 number	 also	 reported	 fewer	 than	 five	 hours	 per	 week.	 	 The	median	number	of	carer	hours	received	did	not	show	a	particular	trend	in	either	group,	 in	 fact,	 in	 the	 Telehealth	 group	 it	 reduced	 over	 time.	 	 Again,	 the	 small	number	of	patients	reporting	over	160	hours	of	care	per	week	means	the	means	are	 skewed	and	 this	 large	 variability	makes	drawing	 any	 conclusions	 from	 the	results	impossible.				Figure	6.9	Mean	patient	estimated	hours	of	informal	(unpaid)	and	formal	(paid)	care	received	per	week	and	the	interquartile	range.	0 3 6 9 12025
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Figure	6.10	Individual	patient	estimated	median	hours	of	informal	(unpaid)	and	formal	(paid)	care	received	per	week	and	the	interquartile	range.	
	
6.7	Summary	of	outcomes		In	summary,	where	it	was	possible	to	compare,	participants	in	this	study	appear	to	 have	 better	 outcomes	 at	 baseline	 and	 during	 the	 study	 than	 those	 in	 the	general	MND	population.		During	the	trial,	some	outcome	measures	appeared	to	be	sensitive	to	change,	detecting	deterioration	in	participants’	condition	as	they	progressed.	 These	 tended	 to	 be	 the	 outcome	 measures	 recording	 physical	wellbeing,	health	encounters	 in	patients	and	 the	 incidence	of	 severe	anxiety	 in	carers.		In	most	cases,	these	changes	from	baseline	did	not	reach	significance	but	the	sample	sizes	were	too	small	to	draw	firm	conclusions.	In	contrast,	emotional	QoL	 scores	 in	 both	 patients	 and	 carers	 were	 comparable	 with	 the	 general	population	and	remained	stable	throughout	the	trial.		For	most	measures,	there	were	no	clear	differences	between	the	two	arms	in	any	measure	 but	 the	 sample	 size	 was	 too	 small	 to	 draw	 firm	 conclusions.	 The	estimated	 treatment	 effects	 at	 six	months	 (n=28)	were	 calculated	 for	 the	most	likely	 outcome	 measures	 thought	 to	 reflect	 the	 impact	 of	 the	 TiM:	 QoL	(ALSAQ40,	SF-36),	the	EQ5D	and	ALSFRS.		To	aid	comparability,	the	differences	are	reported	using	the	standardised	effect	sizes	at	six	months	(the	point	at	which	
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most	patients	had	completed	outcome	measures).		The	standardized	effect	size	is	defined	as	the	difference	between	the	treatment	groups	as	a	ratio	of	the	baseline	standard	 deviation.	 These	 were	 calculated	 by	 the	 trial	 statistician,	 based	 on	 a	regression	 model	 in	 which	 the	 estimated	 difference	 is	 TiM-control	 (the	coefficient	 for	 treatment	 effect	 from	 the	 model)	 (Figure	 6.11	 and	 Appendix	 B	A6.18).		Whilst	the	confidence	intervals	are	wide,	the	standardised	effect	sizes	do	favour	the	intervention	in	most	cases,	suggesting	a	larger	trial	might	reveal	some	significant	treatment	benefit.			In	this	trial,	estimated	standardised	effect	sizes	of	around	0.2-0.3	were	observed	in	many	of	the	outcome	measures.		These	results	should	be	interpreted	with	extreme	caution,	given	the	aim	of	this	study	was	not	to	 detect	 a	 difference	 in	 effect.	 	However,	 it	 does	 support	 the	 results	 from	 the	qualitative	data	 that	suggest	 that	 the	TIM	might	be	of	benefit	 in	some	ways,	 to	some	patients,	but	that	the	current	impact	is	not	sizeable.		What	this	graph	may	also	 suggest	 is	 that,	 whilst	 the	 sample	 sizes	 are	 small,	 there	 was	 no	 evidence	from	either	the	quantitative	or	qualitative	data	that	TiM	led	to	worse	outcomes.				Given	MDT	care	 is	known	to	 improve	survival,	 this	would	be	another	potential	outcome	 measure.	 	 Dates	 of	 death	 were	 also	 collected	 and	 participant	 status	checked	 at	 the	 end	 of	 the	 trial.	 	 There	were	 10	 deaths	 (25%,	 six	 intervention	group,	 four	control	group)	but	comparing	Kaplan-Meier	survival	curves	did	not	add	any	additional	information	(Appendix	B	A6.19).			Figure	6.11	The	estimated	treatment	effect	for	the	quality	of	life	and	health	utility	measures	and	ALS-FRS-R.	 		 	
ALSAQ
Physical mobility
Activities of daily living
Eating and drinking
Communication
Emotional
Total
SF-36
Physical component
Mental component
EQ-5D
EQ-5D-3L
ALS-FRS-R
ALS-FRS-R
Outcome
0.05 (-0.30, 0.39)
0.25 (-0.12, 0.61)
-0.25 (-0.64, 0.13)
0.05 (-0.18, 0.28)
-0.07 (-0.71, 0.58)
0.08 (-0.30, 0.47)
-0.03 (-0.74, 0.68)
0.30 (-0.44, 1.05)
0.11 (-0.46, 0.68)
0.28 (-0.13, 0.69)
SMD (95% CI)
Favours control Favours intervention 
0-.75 -.5 -.25 .25 .5 .75
Standardised effect size
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6.8	Evaluating	the	feasibility	of	the	study		This	section	examines	whether	the	results	of	this	study	suggest	that	a	larger	TIM	trial	would	be	feasible	by	examining,	recruitment,	retention,	data	collection	and	acceptability	and	perceived	sensitivity	of	the	outcome	measures.		
6.8.1.1	Study	retention	and	outcome	measure	collection	Table	6.7	summarises	the	number	of	participants	in	the	study	at	each	time-point	and	 the	 number	 of	 participants	 who	 completed	 the	 follow-up	 questionnaires.		Appendix	B	A6.20	and	A6.21	report	the	results	in	detail.		Return	and	completion	of	the	follow-up	questionnaires	was	excellent:	80%	of	eligible	patients	and	82%	of	 carers	 returning	 questionnaires	 at	 6	months.	 	 Compliance	 fell	 at	 12	months	but	remained	high	at	71%	(patients)	and	67%	(carers).				No	 participant	 sought	 help	 from	 the	 independent	 research	 nurse	 when	completing	 the	 questionnaires	 and,	 as	 shown	 in	 Table	 6.8,	 the	majority	 of	 the	questionnaires	were	sufficiently	complete	to	analyse.			It	was	possible	to	analyse	all	 the	 ALSAQ-40	 answers	 whereas	 SF-36	 was	 incomplete	 in	 2%	 of	questionnaires.	 	 The	most	 common	 questions	 left	 incomplete	 were	 those	 that	asked	 patients	 how	 many	 hours	 per	 week	 of	 informal	 and	 formal	 care	 they	received.	 9%	 of	 these	 questions	were	 left	 blank,	 several	 stated	 “24x7”	 (which	was	 imputed	 at	 168	 hours	 per	 week).	 	 The	 interviews	 (reported	 below)	suggested	 these	 were	 left	 blank	 because	 patients	 thought	 it	 was	 difficult	 to	quantify	the	amount	of	additional	time	their	carer	spent	helping	them.			Section	6.9.1.3	describes	possible	reasons	for	these	observations	and	may	explain	why,	when	 these	 questions	 were	 analysed	 the	 results	 differed	 much	 more	 greatly	between	patients	than	expected.				
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Table	6.7	Patient	and	carer	compliance	with	questionnaires.		
	 Base-
line	
3	
months	
6	
months	
12	
months	
18	
months	
Total	patients	Patients	available	for	follow	up	 n=40	 n=39	 n=35	 n=17	 n=2	
%	Eligible	questionnaires	
completed	
98%	 87%	 80%	 71%	 50%	
Total	carers	Carers	available	for	follow-up	 n=37	 n=35	 n=33	 n=18	 n=2	
%	Eligible	questionnaires	
completed	
97%	 80%	 82%	 67%	 50%	
			Table	6.8	The	number	of	questionnaires	returned	by	participants	which	could	not	be	analysed	because	they	were	either	blank,	or	had	insufficient	data	from	which	to	calculate	a	score/total	(where	possible	standard	imputations	were	performed	for	SF-36,	ALSAQ-40	and	HADS	to	account	for	missing	data).		
Patient	questionnaire	 %	incomplete	
questionnaires	
Carer	
questionnaire	
%	incomplete	
questionnaires	ALS-FRS-R	 0%	 SF-36	 2%	SF-36	 2%	 HADS		 0%	ALSAQ-40	 0%	 ZBI	 0%	EQ-5D	 1%	 Carer	satisfaction	 0%	HADS	 0%	CSS-MND	 0%	 TiM	satisfaction	 0%	Pain	scores	 0%	Health	encounters	 1%	Hospital	admissions	 1%	Formal	and	informal	carer	needs	 9%	Patient	satisfaction	 0%	TiM	satisfaction	 0%			 	
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6.8.1.2	Barriers	and	enablers	to	participation	in	research	As	mentioned	earlier,	nearly	half	of	all	patients	 invited	to	participate	expressed	an	interest	in	being	involved	in	this	study	and	all	of	those	who	were	eligible	went	on	to	take	part.		Patients	said	they	took	part	for	two	main	reasons:	because	they	liked	 the	 concept	 of	 the	 TiM	 system	 (this	 was	 described	 in	 Chapter	 Five)	 or	because	 they	 wanted	 to	 take	 part	 in	 as	 much	 research	 as	 they	 could.	 	During	interviews,	 participants	 identified	 barriers	 and	 enablers	 to	 participating	 in	 the	TiM	research,	 these	are	shown	 in	Figure	6.12	(additional	quotes	 in	Appendix	B	Q6.1-6.4).				Figure	6.12	Participants’	motivations	for	participating	in	the	TiM	trial.	
	The	main	reasons	why	participants	felt	able	to	take	part	was	because	they	were	highly	motivated	to	participate	in	any	research	but	also	because	they	study	was	low	in	burden	(completed	at	home,	minimal	visits	and	a	clear	understanding	of	what	would	be	expected	of	them).		Participants	also	had	a	strong	altruistic	desire	to	be	 involved	 in	 research,	 to	help	others	 and	 in	 gratitude	 to	 the	 clinical	 team.		They	also	thought	that	they	might	gain	benefit	from	being	involved	in	research:	by	learning	more	about	research,	MND	and	their	own	condition	or	prognosis,	to	improve	 their	chances	of	 taking	part	 in	a	 treatment	 trial	and	 to	have	 increased	
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contact	with	the	MND	team.		Being	part	of	something	positive	made	patients	felt	they	still	had	a	valuable	contribution	to	make,	even	when	severely	disabled:		
“I	love	being	part	of	something	worthwhile.”		P229	Participants	did	identify	some	barriers	to	research	(Figure	6.12)	but	the	nature	of	the	TiM	study	(low	burden,	outcomes	collected	at	home)	meant	they	found	it	easy	to	participate	and	taking	part	was	worth	the	burden.	 	Participants	felt	that	they	had	been	provided	with	sufficient	information	to	take	part.		Some	admitted	that	 they	 had	 not	 read	 the	 information	 leaflet	 and	 most	 identified	 the	recruitment	visit	as	the	main	source	of	information	about	the	trial.		Whilst	some	participants	expressed	a	preference	for	the	intervention	arm,	they	were	happy	to	be	randomised	and	those	in	the	control	arm	were	content	with	their	allocation.		Most	 participants	 had	 some	 understanding	 of	 research,	 most	 having	 been	involved	 in	 other	 research.	 	 Participants	 felt	 frustrated	 about	 the	 speed	 of	research	to	find	a	treatment	and	felt	time	was	running	out	for	them	to	be	cured.		They	 all	 wanted	 to	 see	 treatments	 that	 had	 tangible	 benefits	 i.e.	 a	 reversal	 of	their	 disability.	 	 Participants	 wanted	 to	 learn	 about	 research	 from	 various	sources	as	this	gave	them	hope	although	they	recognised	that	some	information	could	be	unreliable	and	could	be	giving	“false	hope”.		A	small	number	were	willing	to	use	unproven	therapies	or	 take	part	 in	 trials	even	 if	 they	had	 to	potential	 to	harm	them	in	return	for	an	opportunity	for	a	cure.		They	trusted	the	trials	would	be	“safe”	if	it	involved	a	doctor	whom	they	trusted.		
6.8.1.3	Participants’	attitudes	towards	the	outcome	measures:	acceptability	
and	validity	In	 interviews	 at	 baseline,	 participants	 in	 the	 control	 arm	 described	 their	attitudes	 towards	 the	 self-administered	 questionnaires.	 	 Detailed	 themes	 and	supportive	quotes	are	displayed	in	Appendix	B	Tables	Q6.5	and	Q6.6.		The	most	common	themes	were:	
• The	importance	of	assessing	all	aspects	of	life	with	MND;	
• The	questionnaires	were	acceptable;	
• Most	questionnaires	provided	an	accurate,	fair	and	thorough	assessment	of	life	with	MND;	
• Questions	 examining	 emotional	 health	 and	 strain	 were	 the	 best	assessment	of	their	experiences	of	MND;	
• The	 SF-36	 questions	 were	 too	 subjective	 and	 did	 not	 reflect	 the	experiences	of	life	with	MND	or	as	a	carer;			
• Estimating	the	number	of	hours	of	care	patients	receive	is	difficult.		Participants	 felt	 that	 the	 questionnaires	 provided	 a	 “fair	 assessment”	 of	 their	experience	 living	with	MND	and	 felt	 it	was	 important	 for	 the	questionnaires	 to	cover	 all	 aspects	 of	 the	 disease	 including	 those	 that	 might	 be	 perceived	 as	distressing	 e.g.	 breathlessness,	 dysphagia.	 	 They	 were	 already	 aware	 of	 the	future	problems	they	may	face:	this	did	not	distress	them.					
“To	be	quite	frank,	doctor,	I	wouldn't	care	a	monkey's	what	you	ask	…I	have	no	hang-ups	
about	any	questions,	however	personal,	the	team	think	it's	necessary	to	ask;	I've	seen	it	all,	
done	it	all	and	got	the	t-shirt.”	C229	
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All	 participants	 felt	 that	 completing	 the	questionnaires	was	 an	 acceptable	 task	and	most	were	easy	to	complete	accurately.	 	 	They	were	content,	as	they	knew	the	answers	would	be	of	benefit	to	the	research	and	felt	comfortable	answering	personal	questions.			Carers	also	thought	it	was	important	to	ask	them	questions	about	their	physical	and	mental	wellbeing	and	burden	of	caring.		They	remarked	that	 both	 carer	 and	 patient	 wellbeing	 did	 suffer	 when	 they	 experienced	 carer	strain.	 	 	 Carers	 felt	 the	 questions	 examining	 their	 burden	 reflected	 the	experiences	of	being	a	carer.		
“It	was	a	 strange	one	cos	 [the	Zarit	Burden	 Interview]	was	asking	you	what	 I	 feel	about	
spending	the	time	with	him,	that	I	don’t	have	time	for	meself.…	Yeah,	it	is	quite	a	thing	cos	
you’re	always	thinking…	“Has	he	got	enough	drinks?	…	then,	anything	to	eat?”…	I	don’t	like	
to	be	too	far	away	from	him,	even	though	I’m	in	the	house	…	in	case	summat	happened	and	
he	needs	me.”	C091		The	 ALSAQ-40	 was	 felt	 to	 be	 the	 most	 straightforward	 QoL	 questionnaire	 to	complete.		Patients	found	the	questions	detailed,	relevant	to	their	disabilities	and	easy	to	answer	because	the	questions	were	clear	and	the	multiple	choice	options	used	similar	to	the	way	patients	described	their	difficulties	(e.g.	having	walking	difficulties	“sometimes”	or	“often”).		Participants	found	the	SF-36	and	the	health	utility	 measure	 EQ-5D	 difficult	 to	 complete.	 	 The	 language	 was	 felt	 to	 be	 too	subjective,	 for	 example	 the	generic	 term	 “health”	used	 in	 the	SF-36	and	EQ-5D	was	confusing	and	meant	it	difficult	to	describe	their	own	health	state.		Some	felt	they	were	 entirely	 healthy	 and	 did	 not	 see	MND	 to	 be	 a	 “health”	 problem	and	some	 carers	did	not	 feel	 they	had	 any	health	problems.	 	Others	were	not	 sure	whether	to	take	into	account	MND	or	age-related	problems	when	answering	the	questions.	SF-36	asked	about	the	impact	of	their	health	on	their	“daily	activities”.		As	 their	 lives	 had	 changed	 so	 significantly,	 both	 patients	 and	 carers	 found	 it	difficult	 to	 assess	 the	 impact	 of	MND.	 	Most	 no	 longer	worked	 and	 those	with	moderate	 or	 severe	 disabilities	 no	 longer	 completed	 many	 of	 the	 activities	assessed	in	the	SF-36	meaning	the	questions	were	insensitive	to	changes	in	their	condition.	 	Three	patients	 (five	questionnaires	 in	 total)	 left	 the	EQ-5D	mobility	sub-question	blank	because	the	answers	were	too	broad	to	capture	their	disease	state.		The	patient	explained:		
“Well	 I'm	 not	 confined	 to	 bed,	 so	 has	 it	 got	 to	 be	 I	 have	 some	 problems	 with	 walking	
about?”	P137		Patients	 found	 reporting	 the	 number	 of	 hours	 of	 care	 they	 received	 to	 be	 the	most	difficult	to	answer.		This	was	the	most	common	question	left	blank	(9%	of	occasions,	see	Section	6.9.1.1).	Couples	explained	that	 their	roles	had	gradually	changed	as	carers	took	over	many	of	the	domestic	jobs	that	were	usually	shared	making	it	difficult	to	quantify	how	much	of	their	role	was	“caring”	and	how	much	was	 part	 of	what	 they	 expected	 of	 a	 partnership.	 	 Some	 carers	 explained	 that	even	 if	 they	weren’t	 directly	 providing	 care	 they	 always	had	 to	 be	 alert	 to	 the	needs	of	their	loved	one	and	so	many	patients	wrote	that	they	required	care	“all	
the	time”.		The	questionnaire	did	not	capture	patients	who	had	multiple	carers	or	where	professional	carers	took	over	the	role	of	an	informal	carer.	
	 197	
6.8.1.4	Validity	of	the	outcome	measures	Participant	 interviews	 suggest	 that	 the	 questionnaires	 were	 easy	 to	 complete	without	guidance	 from	the	research	 team.	 	There	were	no	opportunities	 in	 the	trial	 to	 verify	 the	 accuracy	 of	 the	 data	 collected	 in	 the	 self-reported	questionnaires.	However,	the	database	did	automatically	identify	responses	that	were	 outlying	 or	 unexpected.	 They	 were	 then	 verified	 using	 the	 original	participant	 questionnaires.	 	 There	 appeared	 to	 be	 no	 particular	 individual	 or	questionnaire	that	provided	unexpected	answers.		Examination	of	the	individual	ALS-FRS-R	scores	did	identify	six	patients	whose	functional	scores	improved	by	three	 points	 or	 more	 between	 baseline	 and	 three	 months.	 	 Three	 of	 these	patients	continued	to	report	this	sustained	function	at	six	months.			It	is	not	clear	why	this	occurred.		It	is	unusual	for	a	patient’s	disease	to	spontaneously	reverse	but	 it	has	been	observed	 in	 clinical	 trials	 (259,260).	 	Patients	 reported	day-to-day	variations	 in	 their	 function	but	 it	 is	also	possible	 for	 treatment	 to	 improve	function	 (for	 example,	 using	 medication	 that	 treats	 excessive	 secretions	 or	therapy	 which	 improves	 mobility).	 	 It	 is	 also	 possible	 that	 the	 way	 patients	answered	 the	 baseline	 questionnaires	 could	 have	 been	 influenced	 by	 the	investigator	or	 the	 trial	procedures.	 	 It	would	 therefore	be	advisable	 to	ensure	that	the	method	of	completion	remained	consistent	throughout	the	trial.			The	only	outcome	where	there	appeared	to	a	clear	difference	between	controls	and	the	 telehealth	group	was	 the	number	of	 informal	and	 formal	hours	of	care	reported.	 	 The	 telehealth	 group	 reported	 an	 increase	 in	 the	 mean	 number	 of	formal	hours	of	 care	 received	whilst	 the	control	group	reported	an	 increase	 in	informal	hours	of	care.		It	has	already	been	discussed	that	the	individual	results	were	so	variable	and	skewed	by	a	small	number	of	participants	reporting	very	high	 numbers	 of	 hours.	 	 The	 participants	 themselves	 also	 highlighted	 the	difficulty	reported	these	figures.		Whilst	these	results	were	not	known	when	the	interviews	 were	 conducted,	 the	 interview	 data	 was	 reviewed	 to	 consider	whether	 these	 results	 are	 important.	 	 Participants	 interviewed	 did	 identify	 a	potential	 link	 between	 formal	 and	 informal	 care:	 that	 formal	 carers	 took	 over	duties	 from	 the	 main	 informal	 carer	 (although	 most	 carers	 who	 received	additional	 support	 felt	 the	 difference	 this	 made	 to	 their	 own	 duties	 was	marginal).	 	 An	 alternative	 explanation	 is	 that	 the	 TiM	 could	 bring	 about	 in	 an	increase	in	formal	carer	hours.		It	is	possible	that,	by	identifying	problems	earlier	and	initiating	medical	interventions	(which	require	additional	carer	support)	or	encouraging	carers	under	strain	to	accept	additional	help,	the	TiM	could	actually	increase	 the	 number	 of	 formal	 care	 hours	 received.	 	 However,	 a	 direct	 link	between	 the	 TiM	 and	 carer	 arrangements	 was	 not	 identified.	 	 These	 findings	support	the	notion	that	future	evaluation	of	the	TiM	should	also	use	some	formal	measure	of	both	carer	strain	and	hours	of	care	received.		A	better	questionnaire	might	ask	carers	to	record	their	details	in	more	detail,	quantifying	hours	where	they	 provide	 direct	 care	 and	 hours	 carers	 have	 to	 be	 available	 for	 their	 loved	one.				 	
	 198	
6.9	Discussion:	study	strengths	and	weaknesses		The	TiM	study	design	had	many	strengths	and	weakness.	 	The	main	challenges	and	suggested	solutions	that	were	either	used	in	this	trial	or	could	be	adopted	in	future	trials	are	described	in	Table	6.9.			Table	6.9:	Challenges	related	to	study	methods	encountered	in	the	TiM	trial	and	potential	solutions.	
Challenges	 Solution	
Sample	size	Improving	patient	response	to	invitation	to	participate	in	trials	 Improve	information	in	the	patient	invitation	processes	and	patient	information	leaflets.	Keep	participant	burden	low	and	highlight	the	benefits	and	accessibility	of	trials	to	potential	participants.	Involve	the	control	arm	participants	in	qualitative	aspects	of	the	study	to	avoid	resentful	demoralisation.	Small	pool	of	eligible	patients	 Keep	a	broad	and	pragmatic	inclusion/exclusion	criteria	that	reflects	the	research	question.		All	participants	use	the	intervention:	use	historical	controls/before/after	evaluations.	National	registries	to	allow	mass	screening	and	identification	of	potentially	eligible	patients	in	other	centres.	
Collecting	outcome	measures	Compliance	with	questionnaires		 Telephone	contact	to	remind	participants	to	complete	the	questionnaires.	Provide	low	burden	and	alterative	ways	of	participating	e.g.	telephone	visits,	postal,	online	questionnaires.	Participants	inaccurately	completing	questionnaires	
Schedule	opportunities	to	help	participants	complete	questionnaires	early	in	the	trial	(e.g.	at	baseline	visit).	Provide	participant	information	and	training	in	accessible	forms	e.g.	videos.	Use	alternative/additional	methods	of	data	collection	e.g.	interviews,	observations.	Use	alternative	ways	to	collect	safety/adverse	event	data	e.g.	regular	telephone	calls/diaries/electronic	records	
Assessing	the	impact	of	the	TiM	Outcome	measures	not	accurately	assessing	participant	experience	or	impact	of	the	TiM	
Use	measures	that	better	reflect	the	likely	mechanisms	of	TiM	impact	e.g.	Generalised	self-efficacy	scale.	Use	disease	specific	and	intervention	specific	questionnaires.	Improve	participant	selection	to	recruit	patients	likely	to	benefit	from	improved	MDT	care	(e.g.	including	those	with	more	rapidly	progressive	MND).	Measuring	impact	of	the	TiM	on	service	users		
Measure	impacts	relevant	to	stakeholders	e.g.	self-efficacy,	carer	strain,	emotional	quality	of	life.	Use	mixed/qualitative	methods	at	different	stages	of	the	process	to	capture	the	range	of	experiences.		Measuring	the	impact	of	TiM	of	staff	and	healthcare	resources	
Automated	collection	of	staff	time	using	the	TiM	system.	Evaluate	the	TiM	in	centres	that	use	billing	or	appointments	software	to	collect	healthcare	resources	use.	
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6.9.1	Strengths	of	the	study	design	This	 study	 achieved	 good	 levels	 of	 recruitment,	 retention	 and	 compliance.		Figures	are	comparable	with	more	intensive	MND	clinical	trials	(e.g.	(56).		It	also	enabled	a	wider	range	of	patients	 than	 is	usually	seen	 in	clinical	 trials	of	MND,	including	 those	with	severe	disability	and	 longer	disease	duration.	 	This	meant	the	 population	was	 a	 better	 reflection	 of	 the	 patients	 attending	 a	 typical	MND	service.	 	This	was	helped	by	the	broad	inclusion	criteria,	 the	 low	burden	of	the	intervention	 and	 the	 study	methods,	 which	 were	 developed	 consultation	 with	patients	 ensured	 the	 study	 was	 acceptable.	 	 	Having	 dedicated	 research	 staff	embedded	within	the	clinical	team	with	time	to	support	the	participants	during	the	study	is	also	key	to	the	success	of	telehealth	trials	(187).					Similarly	to	other	studies	in	terminal	diseases,	patients	in	this	trial	were	highly	motivated	 to	participate	 in	research,	not	simply	because	of	 feelings	of	altruism	and	 gratitude,	 but	 also	 because	 they	 believed	 they	may	 also	 gain	 benefit	 from	participation	 (261).	 It	 should	 be	 recognised	 that	 many	 patients	 want	 to	participate	 in	 research	 and	 efforts	 should	 be	 made	 to	 reduce	 barriers	 to	involvement,	 even	 for	 those	patients	who	may	be	 severely	disabled	or	nearing	the	end	of	their	lives.				As	described	in	Chapters	Two	and	Four,	recruitment	into	telehealth	trials	is	often	limited	 by	 negative	 attitudes	 towards	 technology	 (234).	 	 This	 study	 did	 not	appear	to	face	this	problem	as	patients	participated	who	faced	various	barriers	such	as	a	lack	of	experience	of	technology	or	severe	disability.			Adopting	a	user-centred	approach	to	the	design	of	the	TiM,	introducing	the	TiM	in	a	positive	way	and	 providing	 support	 and	 training	 to	 participants	meant	 all	 participants	who	tried	the	TiM	system,	were	willing	to	participate	in	the	study	and	most	would	use	the	system	again.		Furthermore,	the	study	interviews	(described	in	Chapter	Five)	provided	 an	 opportunity	 to	 capture	 participants’	 experiences	 of	 the	 study	 and	the	TiM	meaning	the	intervention	and	the	trial	procedures	could	be	adapted	to	further	improve	the	way	in	which	participants	were	recruited.				Future	 studies	 could	 build	 on	 the	 success	 and	 lessons	 from	 this	 study:		publicising	the	trial	and	adapting	the	trial	literature	to	highlight	the	acceptability	of	 the	TiM	may	 increase	 uptake.	 	 	Many	 participants	 felt	 that	 face-to-meetings	delivered	more	useful	information	than	information	leaflets.	Alternative	ways	of	delivering	the	key	messages	in	research	(such	as	how	the	TiM	works	and	its	ease	of	use)	could	be	used.		These	might	include	pictures,	videos,	cartoons	or	patient	stories.			Postal	invitations	were	used	in	this	study	to	reduce	the	burden	on	clinic	but	 an	 additional	 face-to-face	 invite	 by	 staff	 that	 are	 confident	 using	 the	equipment	and	feel	invested	in	the	TiM	service	may	also	address	these	barriers.		
6.9.2	Limitations	of	the	study	design	Table	6.11	describes	some	of	the	challenges	identified	in	this	trial	that	would	be	faced	in	a	larger	evaluation	of	the	TiM	and	some	of	the	ways	in	which	these	could	be	addressed.	This	pilot	study	did	not	aim	to	detect	differences	between	the	two	treatment	 groups	 and	 the	 sample	 size	 was	 too	 small	 to	 make	 it	 likely	 that	 a	meaningful	 difference	 between	 groups	 would	 be	 statistically	 significant.	 	 The	
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observed	 magnitude	 of	 differences	 between	 the	 two	 groups	 is	 small,	 more	specifically;	 the	point	 estimates	of	 the	differences	between	 the	 groups	were	 at	best	modest.		This	could	be	due	to	one	or	a	number	of	potential	factors:	
• The	study	methods:	
o The	sample	size	was	too	small	to	estimate	changes	in	participants’	outcomes	with	sufficient	accuracy;	
o The	outcome	measures	were	not	 sensitive	enough	 to	 capture	 the	impact	of	MND,	or	of	the	TiM	on	participants.	
• The	TiM	system:	
o The	TiM	system	did	not	make	a	meaningful	impact	on	participant	care	or	wellbeing;	
o The	 TiM	 did	 not	 have	 a	 demonstrable	 impact	 on	 the	 specific	patients	who	participated	in	the	study;	
o The	TiM	system	was	not	used	to	its	full	potential.		Chapter	Five	described	reasons	why	 the	TiM	system	may	be	 ineffective	or	was	not	 used	 to	 its	 full	 potential.	 	 It	 also	 described	 the	 characteristics	 and	experiences	of	participants	who	may	not	benefit	from	MND	care	or	who	already	receive	good	care.	 	This	chapter	explores	the	other	explanations	for	this	lack	of	observed	difference	and	the	implications	they	have	for	future	evaluations.					
6.9.3	Capturing	the	effectives	of	the	TiM	in	a	trial	One	of	the	aims	of	the	study	was	to	better	understand	which	outcome	measures	would	be	most	 suitable	 to	use	 in	 a	 future	 trial	 and	 the	 sample	 size	 this	would	require.	 	 This	 last	 section	 of	 Chapter	 Six	 discusses	 which	 outcome	 measures,	sample	size	and	MND	population	would	be	best	 likely	 to	capture	 the	 impact	of	the	TiM	 in	a	definitive	study	and	whether	a	 trial	using	 these	recommendations	could	be	feasible.	
6.9.3.1	Selecting	the	best	patient	outcome	measures	Whilst	 this	 thesis	 has	 argued	 that	 using	 traditional	 RCT	 methods	 to	 evaluate	complex	interventions	like	telehealth	has	many	flaws,	it	will	still	be	important	to	capture	 the	 important	 impacts	 of	 the	 TiM	 in	 order	 to	 determine	 whether	 it	should	 be	 implemented	 and	 commissioned.	 	 Whilst	 it	 appears	 that	 the	 TiM	system	 is	 likely	 to	 be	 safe,	 it	 would	 also	 need	 to	 be	 seen	 to	 deliver	 either	 an	improvement	 or	 reduce	 any	 deterioration	 associated	 with	 progression	 of	 the	disease	or	provide	a	service	at	the	same	standard	but	with	reduced	cost.		Ideally,	This	will	 require	 the	use	of	outcome	measures	 that	are	sufficiently	sensitive	 to	the	consequences	of	MND	upon	which	the	TiM	is	thought	to	impact.				As	one	of	 the	main	goals	of	MDT	care	(and	therefore	the	TiM)	 is	 to	 improve	or	sustain	QoL,	 this	was	felt	 to	be	an	appropriate	primary	outcome	measure.	 	The	trial	explored	which	QoL	outcome	measure	would	best	capture	the	impact	of	the	TiM	in	this	population.			Participants	felt	that	the	ALSAQ-40	was	a	better	tool	to	capture	their	experiences	living	with	MND,	compared	to	the	SF-36.		In	this	small	trial,	the	ALSAQ-40	did	capture	deterioration	in	some	aspects	of	QoL	at	both	six	and	 12	 months.	 	 It	 is	 suggested	 that	 a	 deterioration	 of	 six	 points	 over	 three	months	is	a	meaningful	change	(262)	and	changes	in	scores	at	12	months	ranged	from	eight	to	16	which	suggests	it	did	capture	meaningful	change.		The	modeled	
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standardised	effect	 sizes	 (described	earlier	 in	Section	6.8,	 Figure	6.10)	 suggest	that	 TiM	 may	 have	 some	 impact	 on	 ALSAQ-40	 physical	 domains.	 	 	 These	observations	 suggest	 that	 the	 ALSAQ-40	 is	 both	 an	 acceptable	 and	 sensitive	measure	that	could	be	used	to	capture	meaningful	change	in	this	population	in	a	future	trial.		Whilst	SF-36	was	felt	to	be	less	reflective	of	patients’	experiences	of	life	with	MND,	the	physical	component	score	also	detected	a	change	during	the	trial	and	Figure	6.10	also	suggested	there	might	be	a	treatment	effect	associated	with	 the	 TiM.	 	 The	 SF-36,	 along	 with	 the	 EQ-5D,	 also	 offer	 valuable	 ways	 of	comparing	 interventions	 in	 different	 disease	 and	 could	 be	 used	 as	 secondary	outcome	 measures	 and	 would	 provide	 important	 evidence	 if	 the	 TiM	 was	considered	for	commissioning.				Given	MDT	 care	 is	 also	 associated	with	 improved	 survival,	 it	may	 be	 expected	that,	by	increasing	access	to	the	MDT,	the	TiM	system	would	also	be	associated	with	better	survival.		Therefore,	survival	this	should	also	be	measured	as	the	TiM	system,	by	increasing	access	to	MDT	care	may	also	improve	survival.	 	However,	given	75%	of	participants	in	this	trial	were	alive	at	12	months	and	the	average	patient	 survives	 two	 to	 four	 years,	 detecting	 a	 survival	 gain	 would	 require	follow-up	 far	 greater	 than	12-18	months.	 	 Extending	 the	 trial	 follow-up	would	not	 only	make	 the	 trial	 less	 feasible	 to	 conduct,	 as	 discussed	 in	 Chapter	 Two,	lengthy	trials	are	likely	to	be	hindered	by	changes	in	technology	and	the	services	in	which	they	are	embedded.		Therefore	survival	would	also	be	most	useful	as	a	secondary	outcome	measure.		The	TiM	would	also	require	an	assessment	of	cost-effectiveness	and	the	impact	on	factors	such	as	hospital	admission	and	health	resource	use.	Funders	of	future	research	 and	 eventually	 commissioning	 bodies	would	 expect	 an	 assessment	 of	cost-effectiveness	in	order	to	make	funding	decisions.		Whilst	the	focus	should	be	on	 the	clinical	outcomes	 that	can	be	more	reliably	estimated,	an	assessment	of	cost-effectiveness	 should	 still	 be	 planned	 and	 should	 take	 into	 account	 the	challenges	encountered	in	this	trial.		The	problems	encountered	in	this	trial	were	also	seen	in	the	studies	reported	in	Chapter	Two	and	are	faced	by	many	trials	of	complex	 interventions.	 	 Emergency	 hospital	 admission	 rates	 were	 low	 in	 all	participants	 in	 the	 trial	 meaning	 a	 large	 sample	 size	 would	 be	 required	 to	determine	whether	TiM	made	a	meaningful	difference.	 	In	addition,	any	savings	brought	 about	 by	 telehealth	 can	 be	 dwarfed	 by	 any	 difference	 in	 very	 costly	hospital	admission	which	may	be	entirely	unrelated	to	TiM	(81).		The	number	of	health	encounters	varied	very	widely	between	patients	and	may	not	necessarily	bear	 any	 relation	 to	 the	 quality	 of	 care	 received	 or	 the	 patient	 wellbeing	 or	quality	of	life.		It	is	uncertain	whether	a	higher	number	of	encounters	indicates	a	patient	with	 a	 great	morbidity	 or	 conversely	may	 reflect	 better	 access	 to	 local	services.	Improving	access	to	specialist	care	may	increase	the	number	of	health	encounters	 due	 to	 the	 identification	 of	 patients’	 unmet	 needs.	 This	 may	 be	beneficial	 to	 the	 patient	 but	may	 be	 associated	with	more	 cost	 and	 increasing	staff	requirements.		Alternatively,	earlier	access	to	specialist	services	may	result	in	 earlier	 treatment,	 fewer	 non-specialist	 encounters	 and	 avoidance	 of	 costly	emergency	 admissions.	 	 Despite	 these	 problems,	 this	 study	 demonstrates	 that	collecting	health	resource	use	is	not	infeasible.		Health	encounters	can	be	easily	collected	 using	 self-reported	 questionnaires.	 	 Planning	 research	 contacts	 with	
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the	 patient	 during	 the	 trial	 along	 with	 the	 use	 of	 electronic	 records	 will	 data	collection	more	systematic	reliable.	
6.9.3.2	Selecting	the	best	carer	outcome	measures	Any	 future	 trials	 of	 the	 TiM	 system	 involving	 carers	 should	 adopt	 different	outcome	measures	to	evaluate	the	impact	on	this	population.			Carers	highlighted	many	 problems	with	 the	 SF-36	 and	 the	 scores	 did	 not	 differ	 from	 the	 general	population	norms,	nor	do	they	change	as	the	patient	progresses.		Carers	felt	the	Zarit	Burden	Index	better	reflected	their	experiences	but	this	also	did	not	change	during	the	study.	This	could	also	be	because	carers	adapt	to	their	experiences.		It	is	also	possible	that	carer	strain	is	influenced	by	the	increasing	support	provided	by	healthcare	professionals	or	formal	carers	as	patients	deteriorated.		However,	a	third	of	carers	had	high	Zarit	Burden	Index	scores	and	the	incidence	of	severe	HADS	anxiety	scores	increased	during	the	study.		This	may	indicate	carers	who,	faced	with	sustained	and	increasing	demands,	may	not	have	the	coping	support	mechanisms	required	to	adapt	to	their	experiences.		If	the	TiM	could	be	used	to	identify	carers	in	difficulty	and	provide	ways	to	improve	their	coping	strategies	it	 could	 reduce	 or	 avoid	 an	 increase	 in	 carer	 strain	 compared	 to	 controls	 and	therefore	these	outcome	measures	appear	to	be	the	most	promising.	
6.9.3.3	Potential	alternative	outcome	measures		One	 limitation	 of	 examining	participants’	 response	 to	 the	 questionnaires	 using	interviews	 is	 that,	 whilst	 participants	 reported	 that	 questionnaires	 examining	their	 emotional	 quality	 of	 life	 better	 reflected	 their	 experience	 of	 living	 with	MND,	 this	 study,	 along	 with	 others,	 found	 that	 patient	 and	 carer	 emotional	quality	of	life	scores	do	not	change	as	the	condition	progresses	(224,	244).		It	has	been	 suggested	 that	 this	 is	 because	patients	 continuously	 change	 and	 adapt	 to	their	 current	 situation	 (263)	 and	 this	 was	 reflect	 in	 the	 TiM	 interviews	 with	patients	explaining	that	their	priorities	changed	as	their	activities	become	more	limited	 but	 they	 still	 gained	 fulfillment	 from	 family	 relationships	 and	 lives	 as	carers	and	partners.		One	patient	explained:			
“You	do	adapt	because	you	have	to,	but	your	world	gets	so	much	smaller.”	(P166)				Alternatively,	 the	 experience	 of	 MND	 progression	 is	 described	 as	 a	 series	 of	losses	that	were	often	associated	with	complex	feelings	of	frustration,	guilt	and	failure.		(31).		These	reactions	may	make	it	difficult	to	quantify	the	impact	of	the	disease	 on	 their	 QoL.	 	 	 These	 limitations	 suggest	 that	 whilst	 QoL	 outcome	measures	are	acceptable,	they	may	not	be	sensitive	to	the	impact	of	the	TiM	and	alternative	 outcome	 measures,	 which	 encompass	 the	 holistic	 aims	 of	 MDT,	should	be	explored.		A	number	of	participants	felt	that	outcome	measures	should	capture	more	positive	aspects	of	 their	day-to-day	 lives	and	how	they	cope	and	remain	 resilient.	 	 As	 described	 in	 Chapter	 Five,	 the	 TiM	 has	 the	 potential	 to	improve	 users’	 self-efficacy,	 which	 is	 an	 important	 influence	 on	 QoL.	 	 As	 the	relationship	between	self-efficacy	and	QoL	has	only	recently	been	implicated	in	MND,	measures	 of	 self-efficacy	were	 not	 captured	 in	 this	 study	 and	 are	 rarely	used	in	RCTs.		Future	studies	of	the	TiM	should	examine	patient	behaviour	more	carefully	and	more	objective	such	as	the	Generalised	Self	Efficacy	Scale	could	be	employed	 (264).	 	However,	 even	 if	 this	better	 reflects	 the	 impact	of	 the	TiM,	a	trial	 demonstrating	 improvements	 in	 self-efficacy	 alone	 is	 unlikely	 to	 be	 as	
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persuasive	as	one	using	commonly	used	outcome	measures	such	as	survival	and	QoL.	 	 Therefore,	 it	 is	 recommended	 that	 both	 self-efficacy	 and	 quality	 of	 life	should	 be	 adopted	 as	 the	 most	 important	 outcome	measures	 explored	 in	 any	future	trials.		In	 summary,	 these	 findings	 suggest	 that,	of	 the	outcome	measures	used	 in	 this	study,	the	ALSAQ-40	would	be	most	likely	to	capture	a	meaningful	impact	of	the	TiM	in	a	definitive	trial.		Other	measures,	such	as	survival,	SF-36,	disability	(such	as	 ALS-FRS-R),	 and	 health	 resource	 use	 remain	 important	measures	 to	 assess	could	be	useful	secondary	outcome	measures	along	with	carer	QoL.		Non-clinical	measures	that	better	reflect	the	mechanisms	of	TiM	such	as	self-efficacy	should	also	be	included.	However,	even	with	the	ideal	outcome	measures,	an	RCT	will	be	very	 challenging	 for	 the	 reasons	 described	 above	 and	 would	 not	 on	 it’s	 own	allow	 future	 development	 of	 the	 TiM	 system.	 	 Therefore,	 for	 the	 next	 stage	 of	development,	alternative	ways	of	evaluating	 the	TiM	should	be	explored;	 these	are	discussed	in	Chapter	Eight	(Section	8.4).		
6.9.3.4	 Patient	 selection:	 capturing	 the	 impact	 of	 TiM	 in	 different	 patient	
populations		Chapter	 Five	 described	 two	different	mechanisms	whereby	 the	TiM	may	bring	about	 change.	 	 These	 impacts	 may	 be	 of	 a	 different	 magnitude	 in	 different	participants.	 	The	TiM	could	 improve	care-coordination,	provide	education	and	reassurance	and	improve	self-efficacy.		The	interviews	suggest	that	patients	at	all	stages	of	 the	disease	may	benefit	 from	increasing	knowledge	of	 their	condition	but	those	with	slowly	progressive	or	mild	disease,	or	early	after	diagnosis	may	gain	most	 from	 this	 approach.	 	 	 The	TiM	 could	 also	 improve	 the	 identification	and	 treatment	 of	 complications	 of	 MND	 and	 potentially	 prevent	 hospital	admissions.		These	problems	tend	to	occur	later	in	the	disease	when	patients	are	more	 disabled.	 	 If	 a	 definitive	 RCT	 were	 to	 be	 conducted,	 evaluations	 could	potentially	 use	 two	 trials,	with	 two	populations	 (for	 example,	 early/mild	MND	and	later/more	severe	disease).		Different	primary	endpoints	that	are	thought	to	be	most	sensitive	to	changes	in	that	subgroup	could	be	used.		This	would	require	twice	 the	 sample	 size.	 Alternatively,	 one	 trial	 could	 use	 a	 composite	 endpoint	that	 aims	 to	 capture	 the	 outcomes	 in	 both	 groups	 and	 could	 also	 capture	 a	measure	of	carer	outcome.		This	does	have	drawbacks:	firstly	it	may	be	difficult	to	interpret	the	meaning	of	a	composite	measure.		Secondly	this	measure	is	likely	to	 be	 less	 sensitive	 than	 a	 single	 outcome	 and	would	 therefore	 need	 a	 greater	sample	size,	though	perhaps	not	as	much	as	if	two	trials	were	conducted.	This	 study	 also	 highlights	 the	 problem	 with	 having	 a	 broad	 patient	 inclusion	criteria.	Patients	whose	disease	was	mild	or	slowly	progressive	did	not	feel	the	TiM	made	an	impact	on	their	care	because	they	did	not	encounter	many	of	these	problems.	 	 These	 patients	 could	 be	 excluded	 from	 future	 trials	 and	 this	 may	increase	 the	 likelihood	 of	 observing	 a	 positive	 impact	 of	 the	 TiM.	 	 However,	further	narrowing	 the	 inclusion	criteria	would	make	 it	more	difficult	 to	recruit	sufficient	patients	and	excluding	a	considerable	number	of	the	MND	population	attending	clinic	may	make	the	results	less	generalisable.				
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	Another	reason	why	the	TiM	may	not	have	appeared	to	have	a	positive	impact	on	this	 particular	 group	 of	 patients	 is	 because	 participants	 in	 the	 TiM	 study	may	already	be	experiencing	good	care	and/or	better	outcomes	than	other	patients.		A	 number	 of	 the	 outcome	measures	 recorded	 in	 this	 study	 indicated	 that	 TiM	participants	 at	 baseline	 have	 better	 outcomes	 than	 other	 patients	 with	 MND.		Participants	 in	 this	 trial	 had,	 on	 average	 a	 longer	 disease	 course,	 slower	progression,	 fewer	hospital	admissions,	better	QoL	and	lower	carer	strain	(91).		It	seems	unlikely	that	the	positive	outcomes	were	due	to	the	research	processes	alone	because	baseline	data	was	already	better	than	in	other	MND	studies.		Trials	are	 likely	 to	 have	 a	 tendency	 to	 select	 participants	 who	will	 experience	more	favourable	outcomes:	patients	that	volunteer	for	research	may	be	better	able	to	access	specialist	services	or	may	be	those	with	better	psychological	wellbeing,	or	already	 experiencing	 less	 family	 strain.	 It	 is	 also	 possible	 that	 the	 MDT	 care	provided	 in	 Sheffield	 is	 already	 of	 a	 high	 standard.	 	 	 Caution	 is	 advised	when	comparing	current	outcomes	to	historical	data,	as	MND	care	has	improved	over	the	last	decade	(265).	 	However,	these	observations	should	not	be	a	reason	not	to	continue	to	develop	the	TiM.		In	fact,	these	differences	between	outcomes	for	TiM	patients	and	others	with	MND	highlight	the	need	to	ensure	that	all	patients	have	 access	 to	 good	 MDT	 care	 and	 this	 study	 demonstrates	 that	 even	 those	patients	 and	 carers	 who	 attend	 a	 specialist	 centre	 experience	 variations	 in	outcomes	 and	have	many	unmet	 needs,	many	 of	which	 could	 be	 addressed	 by	better	access	to	MDT	care.			
6.9.3.5	Sample	size		A	 definitive	 study	 requires	 an	 adequate	 sample	 size	 to	 make	 the	 chances	 of	detecting	 a	 significant	 change	 in	 outcomes	 likely.	 	 Potential	 patient	 primary	outcomes	that	encompass	the	holistic	nature	of	MDT	care	that	were	explored	in	this	trial	were:	quality	of	 life;	survival;	and	disease	progression	(using	the	ALS-FRS-R).		In	 order	 to	 estimate	 the	 total	 sample	 size	 required	 for	 a	 definitive	 study,	 the	following	assumptions	were	made:	
• Significance	testing	would	adopt	a	90%	power	and	5%	significance	level;	
• Follow	up	should	last	for	12	months	which	would	be	long	enough	to	allow	sufficient	 time	for	 the	TiM	to	have	an	 impact	but	short	enough	to	retain	sufficient	 patients	 in	 the	 study.	 	 Two	 approaches	 to	 calculating	 the	endpoint	could	then	be	adopted:	a) A	single	time-point	at	12	months;		b) A	 longitudinal	 composite	of	 end	points	at	 four	 follow-up	 time	periods	(for	example,	3,6,9	and	12	months);		
• A	trial	completion	rate	of	70%	at	12	months	(75%	of	the	patients	in	this	trial	were	alive	at	12	months);	
• A	likely	effect	size	of	0.3-0.4	standard	deviations.		When	 determining	 whether	 an	 intervention	 has	 made	 a	 clinically	 significant	difference,	the	standardised	effect	sizes	(in	which	the	difference	is	given	in	terms	of	 standard	 deviation	 units)	 can	 be	 used	 to	 determine	 the	 strength	 of	 any	
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difference	between	the	two	treatment	groups.		In	general,	an	observed	treatment	difference	 of	 0.2	 standard	 deviations	 is	 felt	 to	 be	 small	 but	 not	 trivial,	 with	 a	difference	 of	 0.5	 medium	 and	 0.8	 large	 (266).	 	 More	 specifically	 in	 MND,	 a	difference	of	0.12-0.26	standard	deviations	 in	 the	ALSAQ-40	represented	small	but	 clinically	meaningful	 differences	 in	 quality	 of	 life	 in	MND	 (these	were	 the	average	 difference	 in	 ALSAQ-40	 sub-domain	 scores	 observed	 in	 patients	 who	reported	that	they	were	“slightly	worse”	in	follow-up)	(254).	In	addition,	ALSAQ-40	scores	in	patients	who	reported	that	they	were	“much	worse”	differed	by	0.3-0.45.	 	 	Whilst	 the	TiM	system	 is	not	a	disease	modifying	 therapy	 (meaning	 the	TiM	is	unlikely	to	have	a	very	large	effect	on	outcome)	the	interview	data	and	the	standardised	effect	sizes	calculated	using	the	modeled	trial	data	(see	Section	6.8)	suggest	it	might	have	a	modest	effect.		Whilst	the	system	is	likely	to	be	safe	and	not	associated	with	high	costs,	it	would	be	unlikely	that	the	TiM	system	would	be	commissioned	if	a	study	demonstrated	that	the	TiM	system	offered	only	a	very	small	benefit.	 	 	Therefore,	calculating	the	sample	size	based	on	expectation	that	the	TiM	 should	have	 a	modest	 effect	 sizes	 (defined	as	 a	difference	 in	 standard	deviations	of	0.3-0.4	(standard	deviations))	would	be	realistic.				These	 assumptions	 would	 suggest	 that,	 for	 a	 single	 time-point,	 with	 30%	dropout,	a	total	sample	size	of	between	377	and	669	patients	would	be	required	(Table	6.10).		For	a	longitudinal	end-point	this	reduces	to	between	143	and	251	(i.e.	71-126	patients	per	arm).		It	seems	reasonable	to	use	a	longitudinal	measure	given	 the	 aim	 of	 MND	 care	 is	 to	 improve	 the	 patients’	 lives	 throughout	 their	disease,	not	simply	to	impact	upon	a	single	point	in	time.		Table	 6.10	 The	 calculated	 total	 sample	 sizes	 for	 the	 two	 approaches	 to	calculating	 the	endpoint	at	different	effect	 sizes.	 	These	were	calculated	by	 the	trial	statistician	and	based	on	the	parameters	stated	above.		 Single	time	point	 Longitudinal10	
Unadjusted	 +30%	drop-
out	
Unadjusted	 +30%	drop-
out	
Effect	size	0.2	SD		 n=1052	 n=1503	 n=396	 n=566	0.3	SD			 n=	468	 n=	669	 n=176	 n=251	0.4	SD	 n=	264	 n=	377	 n=100	 n=143	0.5	SD	 n=	170	 n=	243	 n=64	 n=91		A	target	sample	size	of	250	is	realistic	but	not	without	challenge.		Sheffield	MND	clinic	 being	 one	 of	 the	 largest	 in	 the	 UK,	 and	 even	 using	 very	 broad	 inclusion	criteria,	 as	 described	 in	 Section	 6.2,	 68%	 of	 patients	 recorded	 on	 the	 clinical	database	were	ineligible	to	participate	in	the	TiM	study.	Of	the	30%	of	patients	identified	 in	 Sheffield	 that	 appeared	 eligible,	 55%	 did	 not	 reply	 to	 the	 study	invitation.	 This	 suggests	 a	 best-case	 scenario	 with	 between	 10	 and	 20%	 of	patients	 at	 any	 other	 MND	 care	 centre	 would	 be	 eligible	 and	 willing	 to	participate	 in	 a	 future	 trial	 of	 the	 TiM.	 	 	 For	 a	 sample	 size	 of	 250	 this	 would	therefore	require	the	 involvement	of	MND	care	centres	with	a	total	caseload	of																																																									10	Assuming	one	baseline	and	four	follow-ups	with	a	common	correlation	of	0.5.	
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between	1250	and	2000	patients,	 involving	between	one	quarter	and	half	of	all	centres	 caring	 for	 patients	 with	 MND	 in	 the	 UK.	 	 A	 multi-centre	 study	 that	addressed	some	of	the	barriers	to	recruitment	identified	in	this	trial	(see	Table	6.16)	could	improve	the	number	of	patients	recruited	but	other	factors,	such	as	participant	 burden	 are	 unlikely	 to	 be	 improved	 given	 the	 study	 was	 already	designed	to	be	low	in	burden	for	patients	and	staff.		Competing	trials	in	different	centres	 may	 also	 limit	 recruitment	 but	 links	 between	 UK	 MND	 care	 centres	through	 networks	 such	 as	 the	 NIHR	 Dementias	 and	 Neurodegeneration		(DeNDRoN)	 Specialty	 mean	 multi-centred	 trials	 already	 receive	 excellent	support	and	this	could	enable	even	small	centres	to	participate.				Problems	with	recruitment	are	not	unique	to	MND:	one	review	suggests	that	less	than	 31%	 of	 trials	managed	 to	meet	 recruitment	 targets	 and	 half	 required	 an	extension	(267).		Whilst	this	study	faced	some	problems	with	recruitment,	it	has	also	 developed	 better	 understanding	 of	 the	 barriers	 and	 facilitators	 of	recruitment	and	 retention.	 	This	 should	 improve	 future	 trials	of	 telehealth	and	other	complex	interventions	in	MND.		Other	developments	such	as	the	new	UK-wide	MND	registry	(268)	(which	allows	patients	to	register	themselves	for	trials	and	provide	clinical	details)	may	also	help	and	could	even	allow	patients	to	pre-screen	 themselves	 and	 take	 part	 in	 trials	 even	 when	 they	 cannot	 attend	 a	research	centre.	
6.10	Conclusion		This	 chapter	 identifies	 several	 strengths	 in	 this	 pragmatic,	 low	 burden	 clinical	trial	which	enabled	successful	recruitment,	retention	and	collection	of	outcome	measure	in	a	patient	population	who	are	a	good	representative	those	attending	an	MND	clinic.	 	 	 It	has	also	identified	some	problems	that	suggest	that	the	next	stage	of	 the	TiM	 should	not	 involve	 a	definitive	RCT	because	 this	would	be	 an	inappropriate	 approach.	 	Whilst	 there	may	 have	 been	 some	 trends	 towards	 a	treatment	benefit,	a	lack	of	a	clinically	notable	differences	between	the	trial	arms	and	 the	 clear	 need	 for	 future	 cycles	 of	 development	 indicates	 that	 further	improvements	are	required	prior	to	any	comparative	trial.		Should	 an	 RCT	 be	 undertaken,	 there	 are	 some	 uncertainties	 about	 whether	 it	would	 be	 possible	 to	 recruit	 an	 adequate	 sample	 size,	 to	 capture	 the	 relevant	impacts	 of	 the	 TiM	 and	 determine	 the	 clinical	 effectiveness	 and	 cost-effectiveness	 of	 the	 TiM	 using	 the	 current	 outcome	 measures	 in	 the	 typical	population	attending	an	MND	clinic.		Furthermore,	conducting	an	RCT	in	TiM	in	multiple	centres	would	make	it	challenging	to	do	this	when	working	within	the	various	different	MDTs	in	the	UK	that	will	have	different	expectations	of	the	TiM	and	would	be	likely	to	want	to	use	it	in	different	ways.			Chapter	Eight	discusses	alternative	ways	in	which	the	TiM	could	be	evaluated	in	the	future.			Chapter	 Seven	 explores	 whether	 using	 technology	 within	 an	 MND	 service	 is	likely	 to	 be	 acceptable	 to	 the	wider	 patient	 population	 outside	 this	 small	 trial.		Finally,	Chapter	Eight	discusses	what	conclusions	can	be	drawn	from	this	study,	the	 lessons	 learnt	 and	 recommendations	 for	 the	 further	 of	 the	 development,	evaluation	and	implementation	of	the	TiM.	
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Chapter	Seven	
Exploring	the	use	of	digital	technology	by	people	living	
with	motor	neurone	disease		
7.1	Introduction		This	 chapter	 describes	 work	 conducted	 and	 published	 during	 the	 PhD	 to	capture	 the	views	of	a	 the	broader	population	of	people	 living	with	MND	than	just	 those	 in	 the	TiM	 trial,	 and	explore	 some	of	 the	barriers	and	 incentives	 to	successful	use	of	telehealth	and	technology	(49).			This	work	was	conducted	together	with	an	MSc	student	Saima	Fazal	(SF).	 	The	project	was	 conceived	 and	 designed	 by	 Esther	Hobson	 (EH).	 	 EH	 trained	 and	supervised	 SF	 who	 collected	 the	 questionnaire	 data,	 gained	 consent	 and	conducted	the	interviews	with	participants.		Analysis	was	conducted	by	EH	and	SF.		SF	prepared	the	initial	results	and	report	to	submit	for	a	master’s	degree	in	clinical	 neurology.	 	 Following	 this	 EH	 re-analysed	 the	 data	 and	 prepared	 a	manuscript	for	publication.			
7.2	Background		As	 described	 in	 Chapter	 Two,	 the	 use	 of	 digital	 technology	 devices	 is	 now	 a	prominent	 part	 of	 normal	 life	 and	 healthcare.	 	 As	 described	 in	 Chapter	 One,	specialist	assistive	equipment	also	offers	ways	to	overcome	disability	caused	by	MND.	 	However,	 there	has	been	 limited	evidence	 to	help	understand	whether	digital	technology	will	be	acceptable	or	accessible	to	people	with	MND	and	their	carers.	 	 This	 warranted	 further	 exploration.	 	 The	 TiM	 trial	 provided	 an	opportunity	 to	 explore	 the	use	 of	 the	TiM	 system	 in	 “real-life”.	 	However,	 the	patients	who	put	themselves	forward	to	participate	in	the	TiM	trial	are	unlikely	to	be	representative	of	all	 the	attitudes	or	experiences	of	all	 those	who	attend	the	MND	clinic.		For	example,	the	TiM	trial	may	have	excluded	participants	who	were	 not	 confident	 to	 volunteer	 for	 a	 study	 involving	 technology	with	which	they	 were	 unfamiliar.	 	 This	 study	 was	 developed	 to	 explore	 the	 use	 of,	 and	attitudes	 towards	digital	 technology	 in	 a	wider	 group	of	patients,	 their	 family	members	and	friends.				 	
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7.3	Methods		A	detailed	description	of	the	methods	and	link	to	the	online	supplementary	data	are	available	in	the	published	paper	(Appendix	E).		Attitudes	towards	digital	technology	were	examined	focusing	attention	on:	
• Everyday	 digital	 technologies	 (such	 as	 the	 internet,	 laptops	 and	 tablet	computers);		
• Everyday	 technologies	 that	 had	 been	 adapted	 for	 disabilities	 (such	 as	communication	software	applications	on	tablet	computers);			
• Digital	“assistive	technologies”,	i.e.	those	designed	specifically	for	people	with	disabilities	(such	as	environmental	controls	and	switches).			A	postal	and	an	online	questionnaire	were	used	and,	 to	explore	 the	subject	 in	more	 depth,	 semi-structured	 qualitative	 interviews	 were	 conducted.	 	 The	research	 questions,	 questionnaires	 and	 interview	 topic	 guide	were	 developed	following	a	literature	review	and	consultations	with	clinicians	and	the	Sheffield	Motor	 Neurone	 Disorders	 Research	 Advisory	 Group	 who	 reviewed	 the	questionnaire	and	suggested	improvements.		
	
7.3.1	Questionnaire		Patients	 with	 motor	 neurone	 disease	 (pwMND)	 who	 were	 cared	 for	 by	 the	Sheffield	 MND	 clinic	 in	 June	 2015	 were	 identified	 using	 the	 ARC	 clinical	database.	Patients	and	an	informal	carer,	friend	or	family	member	(fMND)	were	also	 invited	 to	 complete	 a	 questionnaire.	 	 Others	 pwMND,	 their	 friends	 and	family	 members	 to	 complete	 an	 online	 GoogleDocs	 questionnaire	 advertised	using	 social	 media	 and	 the	 Motor	 Neurone	 Disease	 Association	 UK	 research	newsletter.		
7.3.2	Interviews	Convenience	 sampling	 was	 used.	 Patients	 with	 any	 type	 of	 motor	 neurone	disease	 and	 their	 accompanying	 carer	who	were	 attending	 their	 routine	MND	clinic	 appointment	 were	 invited	 to	 participate	 in	 semi-structured	 interviews.		Patients	were	excluded	if	they	could	not	give	consent,	were	too	unwell	to	spend	extra	time	in	clinic,	or	who	had	been	interviewed	in	the	TiM	study.				Interviews	 were	 recorded	 and	 transcribed	 verbatim	 and	 data	 was	 organised	using	 NVivo	 (269).	 	 Thematic	 analysis	 was	 used	 to	 interpret	 the	 data	 (232).		Transcripts	were	 read	 independently	 by	 SF	 and	 EH	 to	 familiarise	 themselves	with	the	data	and	generate	initial	codes.		Codes	and	themes	were	reviewed	and	refined	 together.	 	 The	 interviews	 were	 completed	 before	 the	 results	 of	 the	questionnaire	were	available.	 	However,	 following	 initial	analysis,	a	process	of	methods	 triangulation	 compared	 the	 data	 sets	 to	 determine	 whether	 the	findings	 from	each	data	 set	were	 consistent	 (269).	 	Where	 important	 themes,	similarities	and	differences	were	identified,	the	datasets	was	reviewed	looking	for	explanation	for	these	findings.		Results	were	then	discussed	with	the	wider	
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research	 team	 and	 the	 qualitative	 data	 was	 reviewed,	 codes	 were	 further	refined	and	EH	recoded	each	interview	and	prepared	the	final	manuscript.				Ethical	approval	was	gained	for	the	postal	questionnaire	and	interviews	(NRES	Committee	North	West-Preston).	 	Written	or	witnessed	consent	was	obtained.		Ethical	approval	was	not	required	for	the	anonymous	online	questionnaire	but	participants	 were	 directed	 to	 a	 website	 containing	 a	 participant	 information	sheet	 and	 were	 required	 to	 confirm	 their	 understanding	 and	 willingness	 to	participate.			
7.4	Results	
7.4.1	Questionnaire	participants	126	 patients	 were	 invited.	 	 49	 patients	 (39%	 response	 rate)	 completed	 the	patient	 postal	 questionnaire	 (Table	 7.1)	 and	 37	 completed	 the	 friend/family	postal	questionnaire	(Table	7.2).		28	of	the	participants	were	also	participating	in	 the	 TiM	 study.	 	 36	 patients	 and	 19	 family	 member/friends	 completed	 the	online	 questionnaire.	 	 It	was	 not	 possible	 to	 calculate	 a	 response	 rate	 for	 the	online	questionnaire.			One	 patient	 questionnaire	 was	 excluded	 because	 no	 written	 consent	 was	returned.	 	 One	 online	 response	 was	 excluded	 because	 it	 was	 impossible	 to	determine	whether	the	patient	had	also	completed	a	postal	questionnaire.	 	All	friend	 and	 family	 member	 responses	 were	 combined	 and	 are	 referred	 to	 as	“fMND”.		
7.4.2	Interview	participants			Eight	patients	were	approached	for	interviews.		Two	patients	rescheduled	their	appointments	and	could	not	be	interviewed.		Five	patients,	all	female,	and	five	carers	(all	family	members)	were	interviewed	in	six	interviews,	ranging	from	16	to	37	minutes	(Participants	are	described	in	detail	in	Appendix	E).		One	patient	declined	but	his	son	was	interviewed.		Two	patients	had	dysarthria	and	their	carer	helped	them	to	communicate.		One	patient	used	communication	aids	but	chose	not	to	use	them	during	the	interview.		One	couple	was	participating	in	the	TiM	trial.		They	were	in	the	control	group	and	had	not	been	interviewed	during	that	study.															
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The	main	themes	identified	were:	the	value	of	technology	to	enable	patients	to	continue	with	normal	life;	the	role	of	the	internet	in	providing	information;	the	barriers	to	using	technology;	and	the	role	of	technology	in	MND	care.		
7.4.3	Technology	enabling	a	normal	life	Most	patients	(82%)	and	fMND	(87%)	surveyed	used	at	least	one	digital	device	every	day.		Participants	used	a	range	of	technologies	and	adaptations	(reported	in	 Appendix	 E).	 	 iPads	 and	 laptops	 were	 the	 most	 frequently	 used	 everyday	devices	 (Figure	 7.2).	 	 Use	 of	 the	 internet,	 particularly	 for	 leisure,	 was	 also	common	 (Figure	 7.3).	 	 Those	 interviewed	 were	 very	 positive	 about	 using	everyday	technology	because	they	found	technology	enabled	them	to	continue	to	lead	as	normal	a	life	as	possible.				
“Anything	that	makes	life’s	journey,	when	necessary,	better:	she	will	accept	it.”	Husband	6		Participants	interviewed	also	valued	technologies	with	which	they	were	already	familiar,	could	be	used	for	multiple	purposes	(including	leisure	and	assistance),	and	were	easy	 to	use.	 	 Internet	 services	were	described	as	particularly	useful	when	MND	made	daily	activities	difficult.	 	For	example,	for	a	patient	with	poor																																																									11	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	Amyotrophic	Lateral	Sclerosis	&	
Frontotemporal	Degeneration,	2016;	1–10.		12	*Calculated	using	a	3x2	contingency	table	using	Chi-squared	comparing	the	types	of	fMND	in	the	online	and	postal	questionnaire	
Table	7.1	Characteristics	of	patients	(questionnaire).1	
	 Online		(n=35)	 Postal	(n=48)	 p	value	Age	-	years,	mean	(range)	 59	(30-80)	 66	(45-86)	 p=0.001	Gender	-	female	(%)	 15	(43%)	 20	(42%)	 p=1	Time	since	symptom	onset	-	months,	median	(range)	 41	(11-410)	 41	(11-234)	 p=0.46	Upper	limb	disability	 36	(75%)	 21	(43%)	 p=0.003	Lower	limb	disability	 36	(79%)	 32	(66%)	 p=0.2	Bulbar	disability		 30	(63%)	 36	(74%)	 p=0.3	Respiratory	disability	 18	(38%)	 14	(29%)	 p=0.48	Using	non-invasive	ventilation		 14	(29%)	 16	(34%)	 p=0.6	Using	gastrostomy	 5	(10%)	 7	(14%)	 p=0.7			Table	7.2	Characteristics	of	friends	and	family	members	(questionnaire).11	
	 Online		(n=19)	 Postal	(n=35)	 p	value12	Age	–	years,	mean	(range)	 47	(27-67)	 61	(23-87)	 p=0.0004	Gender	–	female	(%)	 11	(58%)	 28	(80%)	 p=0.11	Family	member	 2	(11%)	 9	(26%)	 	Friend	 8	(42%)	 1	(2%)	 p=0.001*	Partner/spouse	 9	(47%)	 25	(71%)	 		 	 	
Table 7.1 and Table 7.2 removed for copyright reasons
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mobility,	 the	 ability	 to	 shop	 online	 independently	 was	 a	 “life	 saver”,	 (Son	 3).		Another	found	that	email	had	helped	avoid	the	social	isolation	associated	with	speech	and	language	problems	(Patient	6).				Figure	7.2	Frequency	of	use	of	everyday	technology	by	patients	(pwMND)	(postal	and	online	questionnaire	combined).13	
					Figure	7.3	Uses	of	the	internet	by	patients	and	fMND	
		 	
																																																								13	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	“Anything	that	makes	life’s	journey	better.”	Exploring	the	use	of	digital	technology	by	people	living	with	motor	neurone	disease.	Amyotrophic	
Lateral	Sclerosis	&	Frontotemporal	Degeneration,	2016;	1–10.	
Figure 7.2 removed for copyright reasons
Figure 7.3 removed for copyright reasons
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7.4.4	Using	the	internet	to	access	information	and	support	All	 those	 completing	 the	online	questionnaire	 and	60%	of	 fMND	 in	 the	postal	questionnaire	used	the	internet	to	seek	information	about	MND.		Fewer	patients	in	 the	 postal	 questionnaire	 sought	 information	 this	 way	 (40%).	 	 The	 most	commonly	 visited	 website	 was	 the	 Motor	 Neurone	 Disease	 Association	 (UK)	website	 and	 many	 revisited	 the	 site	 (Figure	 7.4).	 	 Even	 in	 the	 postal	questionnaire,	 78%	 of	 patients	 had	 visited	 the	 site.	 	 Participants	 wanted	 to	know	 more	 about	 all	 aspects	 of	 the	 disease	 (Figure	 7.5).	 	 Most	 preferred	information	 to	 be	 available	 on	 websites,	 with	 written	 information,	 videos	 or	information	 via	 email	 also	 being	 popular	 (Figure	 7.6).	 	 However,	 books	 and	written	leaflets	were	also	popular	particularly	amongst	fMND	and	low	users	of	technology.				Of	the	patients	who	could	remember,	79%	thought	that	at	diagnosis,	their	MND	care	 team	 had	 recommended	 looking	 on	 the	 internet	 although	 of	 these,	 only	30%	had	been	recommended	a	specific	site.		21%	recalled	being	advised	not	to	look	 on	 the	 internet.	 	 The	 internet	 also	 provided	 a	 way	 of	 receiving	 support	from	other	people	living	with	MND:	77%	of	patients	in	the	online	questionnaire	used	 the	 internet	 to	 talk	 to	 others	 with	 the	 condition	 although	 only	 14%	 of	those	 in	 the	postal	 questionnaire	did.	 	 fMND	used	 this	 less	 commonly	 (online	42%	and	postal	11%).				Figure	7.4	Frequency	of	visits	to	MND	related	websites	by	patients	and	fMND.14	
																																																									14	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	“Anything	that	makes	life’s	journey	better.”	Exploring	the	use	of	digital	technology	by	people	living	with	motor	neurone	disease.	Amyotrophic	
Lateral	Sclerosis	&	Frontotemporal	Degeneration,	2016;	1–10.		MNDA:	MND	Association	UK.		
Figure 7.4 removed for copyright reasons
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	Figure	7.5	pwMND’s	and	fMND’s	preferred	topics	of	information	about	MND6.										Figure	7.6	pwMND’s	and	fMND’s	preferred	methods	of	receiving	information	about	MND15.			 						Interview	participants	 described	 turning	 to	 the	 internet	 to	 learn	 how	 to	 cope	with	 their	 condition	 and	 how	 to	 be	 prepared	 for	 the	 future.	 	 Researching	alternative	 treatments	 offered	 hope	 and	 the	 feeling	 that	 they	 were	 doing	something	themselves	to	fight	the	disease.			
“I	would	suggest	 that	 the	 family	go	on	the	 internet	and	study	the	 illness	 themselves.	 	So	
that	 they	 can	 learn	 of	 how	 this	 disease	 works,	 how	 it	 affects,	 because	 they	 need	 to	 be	
prepared.	The	family	needs	to	prepare	themselves	so	that	they	can	be	strong	for	the	MND	
sufferer.”		Patient	1		Interview	participants	 found	 the	practical	 and	emotional	 support	 available	on	the	 forums	 even	more	 valuable	 because	 of	 the	 experiences	 they	 shared	 with	fellow	“comrades”	living	with	the	disease.		
	
	“The	internet	is	a	wonderful	thing.	I	use	it	stay	in	touch	with	my	fellow	MND	sufferers	as	
we	do	support	each	other	when	one	of	us	 is	 feeling	very	 scared.	 	We’ll	all	gather	on	 the	
internet	 and	 just	 try	 and	be	a	 support,	 reassure	 them	 they’ll	 get	 through	 this;	we’re	 all																																																									15	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	“Anything	that	makes	life’s	journey	better.”	Exploring	the	use	of	digital	technology	by	people	living	with	motor	neurone	disease.	Amyotrophic	
Lateral	Sclerosis	&	Frontotemporal	Degeneration,	2016;	1–10.	
Figure 7.5 removed for copyright reasons
Figure 7.6 removed for copyright reasons
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here	 for	 them.	 I’m	 learning	 so	 much	 more	 about	 the	 illness	 through	 other	 sufferers.”	
Patient	1	Not	all	experiences	of	the	internet	were	positive,	particularly	around	the	time	of	diagnosis	when	participants	naturally	turned	to	the	internet	to	seek	information	about	the	disease.				
“It’s	 natural,	 isn’t	 it?	 There’s	 something	 you	 don’t	 know,	 you	 go	 online	 now	don’t	 you?”		
Husband	2			Most	 had	 little	 knowledge	 of	 MND	 and,	 following	 the	 shock	 of	 the	 diagnosis,	most	of	what	participants	could	recall	was	negative:	 for	example,	 the	terminal	nature	of	the	disease,	the	lack	of	treatment	and	poor	prognosis.		Information	on	the	internet	reinforced	these	ideas.	
	
	“It	was	a	shock,	to	be	told	you	was	going	to	die	and	especially,	not	having	any	awareness	
of	the	disease.	…	I	was	just	told	to	go	home,	get	my	affairs	 in	order,	tell	the	family.	That	
was	it	really.”	Patient	2	
	
“If	you	just	Google	‘MND’…	you	get	all	the	gory	bits	first”	Husband	2	
	Many	felt	the	information	on	the	internet	was	unreliable	or	confusing	and	some	stopped	looking.	 	Like	those	surveyed,	most	preferred	to	use	official	sites	such	as	 the	Motor	Neurone	Disease	 Association	 explaining	 that	 they	 thought	 these	sites	were	more	reliable.		
	
“There’s	as	much	misinformation	as	good	information	but	you	don’t	know	which”		
Husband	4	
	Two	patients	did	not	go	online	at	all,	explaining	that	they	were	fearful	of	facing	the	 future	 and	 preferred	 instead	 to	 approach	 problems	 as	 they	 encountered	them.		
	
“I	will	never	go	online	because	I’m	the	kind	of	person	that	deals	better	with	what	I	don’t	
know-I	can’t	worry	about.	I’m	not	going	to	change	anything	by	reading	all	the	bad	things	
about	it.	I	know	what’s	going	to	happen.	I’ll	deal	with	it	when	it	comes.”	Patient	2		Participants	 preferred	 to	 receive	 information	 from	a	professional	 because	 the	information	was	felt	to	be	more	reliable,	specific	to	their	circumstances	and	was	delivered	with	the	correct	detail	and	pace.				
“Online	has	its	place,	but	it	all	needs	to	be	talked	about.”	Husband	2				Whilst	 patients	 could	 access	 reliable	 information	 from	 their	 health	professionals,	 wider	 family	 members	 relied	 on	 the	 internet	 for	 information.		This	 could	be	helpful	when	 they	wished	 to	 learn	more	about	 the	disease	 than	the	 patients.	 	 However,	 this	 could	 also	 cause	 tension,	 with	 three	 participants	describing	 difficulties	 when	 their	 extended	 families	 had	 developed	 overly	negative	impressions	of	MND	following	research	on	the	internet.		
	
“My	 son	went	 on	 the	 internet	 and	 frightened	 himself	with	 the	 information	 that	was	 on	
there.		He	thought	I	was	immediately	going	to	die”		Patient	3	
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7.4.5	Barriers	to	using	technology			Figure	7.7	describes	the	barriers	identified	in	this	study.		Common	themes	were:	barriers	due	to	disability,	 the	devices	themselves	and	users’	negative	attitudes	towards	 technology.	 	 Lack	 of	 experience	 or	 confidence	 using	 devices	 was	 a	common	 barrier	 to	 using	 technology.	 	 The	 postal	 questionnaire	 identified	 12	low	users	of	technology:	nine	(19%)	patients	and	three	(9%)	fMND	used	it	less	than	once	a	month.	 	They	were	older	than	the	other	participants	(median	74.5	years,	p<0.0001).		Reasons	given	for	not	using	technology	were:	having	no	need	(four),	 not	 knowing	 how	 to	 use	 it	 (four),	 poor	 hand	 function	 (three),	 fear	 of	breaking	 it	 (one),	and	having	a	bad	experience	of	computers	 (one).	 	However,	nine	of	the	twelve	thought	that	they	could	use	digital	technology	if	they	had	the	appropriate	 equipment	 and	 training.	 	 They	 all	 preferred	 to	 receive	 written	information	about	MND,	although	some	thought	email	(four)	and	books	(three)	would	be	helpful	with	none	wishing	to	access	information	using	the	internet.				Figure	7.7	Barriers	to	technology	use	identified	in	this	study	16.	
	Three	 carers	 interviewed	described	 their	 loved	 ones	 as	 not	 being	 “technology	
people”	thinking	that	they	lacked	an	innate	ability	to	use	devices.		They	thought	they	 lacked	confidence	 in	problem	solving	and	would	rely	on	 family	members																																																									16	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	“Anything	that	makes	life’s	journey	better.”	Exploring	the	use	of	digital	technology	by	people	living	with	motor	neurone	disease.	Amyotrophic	
Lateral	Sclerosis	&	Frontotemporal	Degeneration,	2016;	1–10.		
Figure 7.7 removed for copyright reasons
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for	 help.	 	 One	 son	 thought	 his	 father	 was	 not	 interested	 in	 using	 technology	because	he	had	always	been	too	busy	to	use	it.	 	Difficulties	with	cognition	and	language	caused	 further	problems	that	severely	restricted	one	patient’s	use	of	technology	 (Patient	 6):	 reading	 and	 concentration	were	 difficult	 and	 she	was	unable	to	learn	to	use	new	devices	such	as	a	new	mobile	phone.		Patient	6	found	text-to-speech	software	too	slow,	instead	relying	on	basic	drawing	software.		
“When	[she]	writes,	even	 in	 there	 [note	pad],	 it	missed	words	out.	 	The	brain	 is	working	
but	 the	 brain	 isn’t	 actually	 interpreting	 it	 to	 say	 ‘speak	 it	 properly’	 or	 even	 ‘write	 it	
properly’.	 	 She	 knows	 what	 she	 wants	 to	 say	 and	 she	 knows	 what	 she	 wants	 to	 do,	 it	
doesn’t	always	come	in	the	right	order.”		Husband	6	
	Husband	 6	 was	 concerned	 what	 would	 happen	 if	 his	 wife	 could	 not	 use	technology.		She	relied	on	it	to	avoid	the	social	isolation	associated	with	speech	and	language	difficulties	and	they	were	unaware	of	any	suitable	alternatives.		Arm	weakness	was	 a	 common	 problem,	 but	many	 patients	 adapted	 everyday	technologies	 to	 overcome	 this	 with	 a	 preference	 expressed	 for	 devices	 that	were	light	and	not	bulky.	 	33	(40%)	of	patients	surveyed	purchased	additional	equipment,	mostly	everyday	technologies	such	as	tablets	and	computers,	but	six	patients	had	purchased	specialist	voice	recognition	or	eye	gaze	software	(Figure	1).		Cost	and	lack	of	awareness	was	particularly	a	barrier	to	accessing	unfamiliar	or	 specialist	 technology.	 	 Four	 couples	 felt	 they	 did	 not	 know	 enough	 about	available	 specialist	 assistive	 technology	 and	 wanted	 more	 guidance	 from	experts.	 	 Two	 patients	 wished	 that	 they	 had	 accessed	 specialist	 technology	earlier	 in	 the	 disease	 in	 order	 to	 make	 the	 most	 of	 its	 benefits.	 	 Some	experienced	delays	 in	receiving	equipment	or	 training	and	 in	one	case,	by	 the	time	 equipment	 was	 available,	 the	 disease	 had	 progressed	 making	 the	technology	unusable.		
“We	should	have	known	six	months	ago”	Husband	2	
“…when	I	could	still	talk	properly”	Patient	2	[referring	to	voice	banking]		Whilst	 technology	 was	 often	 recommended	 by	 health	 professionals	 and	 the	MND	 Association,	 many	 learnt	 about	 adaptive	 and	 assistive	 technologies	through	 word	 of	 mouth,	 internet	 research,	 the	 media	 or	 through	 personal	recommendations	on	internet	forums.				Everyday	 digital	 technologies,	 particularly	 those	 that	 patients	 were	 already	using	before	the	diagnosis,	were	perceived	to	be	part	of	normal	life.	 	However,	patients	 recognised	 that	 there	 would	 inevitably	 be	 a	 time	 when	 they	 would	need	 to	 depend	 on	 more	 specialist	 assistive	 technology.	 	 There	 was	 more	resistance	to	using	this	type	of	technology,	even	when	they	thought	it	would	be	valuable.	 	 Some	 patients	 had	 delayed	 thinking	 about,	 or	 accessing	 more	specialist	 technology	until	 they	 felt	 “ready”	or	until	 they	really	needed	 it.	 	The	need	 to	 rely	 on	 technology	 represented	 a	 significant	milestone	 in	 the	 disease	and	fighting	to	remain	independent	helped	maintain	a	positive	outlook.	
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“It	takes	about	a	year	to	persuade	her	to	have	them,	and	then	when	she	has	them	then	she	
really	 likes	[it]...	Once	she	stops	going	up	and	down	the	stairs,	 that’s	 like	a	battle	 lost….”	
Son	3		
7.4.6	Using	technology	to	access	MND	care		Only	 a	 minority	 of	 patients	 surveyed	 already	 used	 the	 telephone	 (27%)	 and	email	 (17%)	 to	 communicate	with	 their	 specialist	 care	 team.	 	Using	 everyday	technology	 to	 communicate	 with	 the	 MND	 team	 was	 generally	 acceptable,	particularly	using	email	and	the	telephone	(Figure	7.8).	 	In	the	12	low	users	of	technology	 in	 the	 postal	 questionnaire,	 six	 supported	 telephone	 contact	 with	their	care	team	(answering	“Yes”	or	“Maybe”).		There	was	less	support	for	using	other	 technology,	 only	 one	 thinking	 email/computer	 contact	 was	 acceptable.		There	was	 less	support	 for	using	technology	as	an	alternative	to	clinic.	 	 In	 the	low	users	of	technology,	five	thought	the	telephone	was,	or	“maybe”	acceptable	but	only	two	supported	email	and	one,	video	contact.				Figure	7.8	Acceptability	of	using	technology	to	communicate	with	their	MND	team	and	as	an	alternative	to	MND	clinic	appointments	(online	and	postal	survey	results	are	combined)17.			All	 the	patients	 interviewed	had	telephoned	the	MND	specialist	nurse	at	some	time	 and	 one	 had	 used	 email.	 	 All	 reported	 positive	 experiences	 and	 thought	technology	 could	 speed	 up	 communication.	 	 Whilst	 no	 patients	 had	 used	telephone	or	video	conferencing	as	an	alternative	to	hospital	appointments,	one	thought	it	could	be	useful	as	she	became	more	unwell,	as	did	a	number	of	those	who	completed	the	questionnaire.	 	Questionnaire	participants	were	concerned	about	 data	 security	 and	 the	 potential	 for	 loss	 of	 face-to-face	 contact	 if	appointments	were	replaced.				
“I	would	rather	speak	to	people	in	person	not	machine”	fMND	postal	survey		The	other	concern	raised	was	that	communication	with	the	MND	team	could	be	difficult	 using	 technology	 and	 that	 patients	 who	 are	 unable	 to	 speak	 or	 type	quickly	may	be	excluded	from	the	consultation.	
	
																																																								17	Reproduced	with	permission	from	Taylor	and	Francis	©	Hobson,	E.	V	et	al.	(2017).	“Anything	that	makes	life’s	journey	better.”	Exploring	the	use	of	digital	technology	by	people	living	with	motor	neurone	disease.	Amyotrophic	
Lateral	Sclerosis	&	Frontotemporal	Degeneration,	2016;	1–10.	
Figure 7.8 removed for copyright reasons
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7.5	Discussion		This	study	supports	the	findings	in	Chapter	Five	that	suggests	that	pwMND	have	a	positive	attitude	 toward	 technology.	 	The	 increasing	availability	of	everyday	technology	 that	 is	 familiar,	 accessible	 and	 affordable	 enables	 patients	 to	continue	 to	 participate	 in	 many	 aspects	 of	 normal	 life.	 	 There	 are	 many	adaptable	 solutions	 that	 can	 help	 solve	 some	 of	 the	 different	 and	 changing	problems	posed	by	MND.	 	However,	mirroring	 a	 survey	 of	 pwMND	 leaving	 in	Australia,	 there	 remains	 a	 need	 for	 greater	 awareness	 amongst	 clinicians	 and	those	living	with	MND	about	technology	(50).		Despite	this,	number	of	patients	who	had	access	to	up-to-date	digital	devices	that	could	access	TiM	is	reassuring.		This	suggests	that	it	would	be	feasible	for	most	patients	to	use	their	own	device,	with	 which	 they	 are	 familiar,	 something	 the	 TiM	 participants	 suggested	 in	interviews.	 	Even	most	of	 those	who	did	not	use	 technology	seemed	happy	 to	learn,	reflecting	the	findings	in	the	TiM	trial.				In	addition	to	the	findings	in	the	TiM	trial,	participants	in	study	identified	other	barriers	 to	 telehealth	 such	 as	 accessibility,	 ease	 of	 use	 and	 concerns	 about	security.	 	 	 Even	 high-tech	 solutions	 may	 not	 meet	 patients’	 expectations	(270,271).		Reassuringly,	in	the	TiM	trial,	these	barriers	did	not	seem	to	impact	on	 uptake	 of	 the	 TiM	where	 these	 barriers	 were	 overcome	 by	 careful	 device	design	and	face-to-face	training	and	support.	This	study	suggests	that	reducing	costs,	 improving	 awareness	 amongst	 patients	 and	 clinicians	 of	 solutions	 that	meet	their	changing	disabilities	will	be	important	when	using	new	technology.		Finally,	 whilst	 the	 use	 of	 assistive	 technologies	 represents	 a	milestone	 in	 the	disease,	introducing	new	solutions	sensitively,	with	hope	and	optimism	(whilst	managing	expectations	where	technology	is	imperfect)	could	overcome	some	of	the	negative	perceptions	of	technology	use.			Participants	in	this	study	also	describe	a	need	for	information	about	MND	that	can,	 in	 some	 circumstances	 be	met	 by	 using	 the	 internet,	 as	 long	 as	 they	 still	have	access	to	reliable	information	from	their	MND	team.		Given	the	importance	of	internet	information,	advising	patients	to	avoid	the	internet	may	be	counter	productive	(272).		These	studies	have	identified	challenges	not	unique	to	MND.		Information	 available	 on	 the	 internet	 is	 important	 to	 the	 wider	 public,	 but	information	 from	 health	 professionals	 remains	 more	 valued	 (273,274).	Clinicians	should	signpost	patients	 to	reliable	sources	of	 information	and	help	patients	 interpret	 their	 findings.	 	 In	 this	 study	 participants,	 tended	 to	 prefer	information	 available	 on	 websites,	 in	 written	 and	 video	 form	 meaning	informative	 websites	 such	 as	 MyNIV	 (129)	 are	 valuable	 resources.	 	 It	 also	suggests	that	telehealth	can	play	a	role	in	providing	trusted	and	reliable,	“bite-sized”	amounts	of	information	and	signposting,	that	is	relevant	to	the	problems	experienced	by	the	patient.		There	 was	 not	 universal	 support	 for	 telehealth	 amongst	 this	 population	 but	most	 comments	 suggested	 that	 participants	 supported	 the	 concept	 of	technology-enabled	 care	 to	 improve	 access	 to	 the	 MDT,	 particularly	 as	 an	addition	to	face-to-face	care.	The	acceptability	of	telehealth	as	an	alternative	to	clinic	may	depend	on	individual	preferences	and	circumstances	and	how	much	
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patients	 feel	 able	 to	engage	 in	 communication	 through	 technology.	Difficulties	with	cognition	and	language	were	also	raised	in	this	study	and	they	pose	more	challenging	 barriers	 to	 patients	 and	 to	 the	 success	 of	 telehealth.	 	 If	 these	barriers	are	not	overcome,	patients	 risk	 losing	access	 to	medical	 services	 that	would	actually	further	increase	inequalities.		It	is	likely	that	some	people	living	with	 MND	 will	 remain	 unable	 or	 unwilling	 to	 use	 technology.	 	 As	 digital	technology	is	becoming	an	increasing	part	of	healthcare	delivery,	care	should	be	taken	 to	 ensure	 that	 these	 patients	 continue	 to	 have	 their	 needs	 met	 in	alternative	ways;	 however,	 they	 should	 be	 given	 the	 option	 to	 try	 technology	and	be	offered	additional	support	and	assistive	devices.				
7.5.1	Limitations		This	 study	 involves	 a	 small	 sample	 from	 one	 care	 centre	 supplemented	 by	 a	small	 number	 of	 online	 responses.	 	 There	 was	 some	 overlap	 with	 the	participants	in	the	TiM	study.		As	such,	the	findings	may	not	be	representative	of	the	wider	MND	population.	 	There	may	be	an	over	representation	of	the	views	of	 younger	 people	 living	 with	 MND	 and	 those	 who	 already	 use	 technology.		Given	the	median	disease	duration	was	41	months,	our	results	may	not	reflect	those	with	more	rapidly	progressive	disease	who	may	have	different	technology	and	 information	 needs.	 	 Similar	 to	 the	 TiM	 study,	 spouses	 were	 the	 most	common	carers	but	 the	online	questionnaire	managed	 to	capture	 the	views	of	friends	and	wider	family	members	using	the	online	survey.		Along	with	the	TiM	interviews,	 these	 results	 suggest	 that	 the	 wider	 family	 often	 have	 different	attitudes	towards	the	diagnosis	and	their	access	to	reliable	 information.	 	They	also	 appear	 to	 have	 an	 influence	 on	 and	 enable	 patients	 to	 use	 technology.		Their	 attitudes	 warrant	 further	 investigation.	 	 Participants	 identified	 the	hospital	MND	centre	as	a	major	source	of	information.		The	experiences	of	those	who	attend	a	different	MND	service	may	be	different	and	warrant	consideration	if	telehealth	is	to	be	adopted	in	other	service	models.			Despite	 these	 limitations,	 the	 results	 are	 consistent	 with	 those	 in	 a	 smaller	survey	of	patients	 in	Australia	(50).	 	Furthermore,	a	rich	range	of	experiences	and	 barriers	 to	 technology	 has	 been	 identified.	 	 	 Both	 high	 and	 low	 users	 of	technology	 shared	 many	 of	 these	 experiences.	 	 The	 additional	 interviews	identified	more	 sensitive	 and	potentially	more	 challenging	barriers	 specific	 to	MND	such	as	 the	 fear	of	dependence	on	 technology.	 	 Identifying	 the	 impact	of	language	 and	 cognitive	 impairment	on	 technology	use,	which	may	affect	 their	ability	to	engage	with	telehealth	is	particularly	important.		
7.6	Conclusion		These	results	support	the	findings	of	the	TiM	trial	 that	suggest	that	the	digital	technologies	 such	as	 the	TiM	are	 likely	 to	be	acceptable	and	accessible	by	 the	majority	 of	 people	 living	 with	 MND	 in	 the	 UK.	 There	 was	 support	 for	 some	telehealth	 in	 MND	 care	 but,	 as	 already	 discussed	 in	 Chapter	 Five,	 it	 will	 be	important	 to	 address	 the	 concerns	 and	 barriers	 identified	 and	 ensure	 that	acceptability	and	use	is	monitored	to	ensure	patients	are	not	excluded	from	the	services.			
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Chapter	Eight	
Discussion:	The	future	of	the	TiM		
8.1	Introduction		This	chapter	summarises	the	results	of	the	thesis	and	suggests	what	the	future	should	hold	 for	 the	TiM	 system.	 	 It	 discusses	whether	 the	 results	 support	 the	proposed	need	to	 improve	access	 to	specialist	MDT	care	 for	people	with	MND	and	whether	technology-enabled	care	could	meet	that	need.			It	summarises	the	required	improvements	to	the	TiM	system	that	have	been	identified.		It	explains	whether	 a	 definitive	 RCT	 is	 feasible	 and	whether	 it	 is	most	 appropriate	 next	step	in	the	TiM	project	and	makes	recommendations	for	how	future	evaluations	should	be	 conducted.	 	 Finally,	 it	 describes	 the	 implications	 of	 the	 findings	 for	other	areas	of	MND	research	and	more	widely	in	technology-enable	care.		
8.2	The	aims	of	the	TiM	project		The	aims	of	this	project	were	to	develop	and	test	a	telehealth	service	that	could	improve	 access	 to	 specialist	 MND	 care	 for	 patients	 and	 their	 carers.	 	 It	 has	argued	 that	 the	 complex	 and	 changing	 nature	 of	 MND	 means	 that	 specialist	management	from	an	MDT	is	currently	the	best	way	to	care	for	those	living	with	the	condition.		The	evidence	identified	in	the	literature,	along	with	the	evidence	from	 this	 project	 does	 support	 the	 need	 to	 improve	 access	 to	 specialist	MND	services.	 	 	 The	 results	 of	 this	 thesis	 also	 support	 the	 argument	 that	 carers	 of	those	 with	 MND	 experience	 significant	 strain	 and	 require	 ways	 for	 their	wellbeing	to	be	monitored	and	promoted	that	fit	in	with	their	preferences	and	duties	as	a	carer.		The	 thesis	 identified	 evidence	 that	 technology-enabled	 care	 can	 help	 patients	with	 many	 diseases	 access	 clinicians.	 	 The	 literature	 suggests	 that	 telehealth	appears	 particularly	 promising	 as	 it	 could	 enable	 additional	 monitoring	 and	communication	without	the	patient	having	to	travel	to	appointments.	Evidence	from	 other	 research	 outlined	 in	 this	 thesis	 suggests	 that	 telehealth	 may	 be	feasible	as	an	addition	or	adjunct	to	 in-person	appointments	and	may	be	cost-effective	 if	 it	 reduces	 physician	 time	 and	 hospital	 attendance.	 	 Prior	 to	 this	project	 commencing,	 it	was	 established	 that	 no	 telehealth	 system	designed	 to	manage	MND	 in	 a	 holistic	manner	 had	 been	developed	 or	 evaluated,	 nor	was	there	 evidence	 to	 determine	 how,	 or	 whether	 telehealth	 would	 be	 useful	 in	these	cases.					This	 study	 used	 some	 of	 the	 literature	 and	 previous	 experiences	 of	 using	telehealth	 in	 chronic	 disease	 and	 MND	 to	 inform	 a	 user-centred	 design	approach	 to	develop	 the	 first	 version	of	 the	TiM	 system.	 	 Following	 this,	 user	testing	 in	 “real	 life”	 as	 part	 of	 the	 TiM	 trial	 to	 make	 a	 wider	 assessment	 of	patient	 and	 carer	 experiences	 has	 established	 that	 technology-enabled	 care	
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could	 be	 acceptable	 to	 patients	 and	 carers,	 as	 long	 as	 the	 services	 and	technology	 are	 developed	 and	 adapted	 to	 meet	 their	 needs	 and	 preferences.		The	 study	 found	 that	 the	 TiM	 system	 appears	 to	 be	 an	 acceptable	 way	 for	patients	 to	provide	 information	about	 their	 condition	and	has	 the	potential	 to	be	 used	 to	 improve	 communication,	 education	 and	 support	 and	 provide	 an	alternative	or	adjunct	to	routine	hospital	visits.	 	If	used	to	its	full	potential,	the	results	 suggest	 that	 the	 TiM	 system	 might	 able	 to	 deliver	 better	 patient	outcomes	 through	 mechanisms	 such	 as	 by	 ensuring	 monitoring	 and	 better	access	to	the	MDT	and	by	promoting	positive	patient	attitudes	and	behaviours	such	as	self-efficacy.	
8.3	Improvements	to	the	TiM	system	and	development	of	the	TiM	service		This	study	identified	a	number	of	problems	with	the	TiM	system	that	impact	on	its	 effective	 use	 and	 acceptability.	 	 The	main	 challenges	 in	 this	 study	 lay	 not	with	the	technology,	rather	with	the	way	in	which	it	is	used	(particularly	by	the	clinical	 team)	 and	 the	 way	 it	 would	 be	 integrated	 within	 the	 clinical	 service.			This	 reflects	 the	 experiences	 from	 other	 telehealth	 trials	 outlined	 in	 Chapter	Two,	 where	 new	 interventions	 that	 need	 to	 be	 integrated	 within	 existing	services	were	met	with	many	barriers.	 	This	 study	has	 identified	a	number	of	developments	that	will	be	key	to	overcoming	these	barriers.	These	are:	
• Providing	 ways	 for	 patients,	 carers	 and	 the	 hospital	 and	 community	health	teams	to	interact	better;	
• Improving	the	clinical	alert	system	to	make	the	alerts	more	sensitive	and	specific	to	relevant	problems;	
• Improving	 the	 adaptability	 of	 the	 system	 and	 developing	 a	 framework	within	which	different	clinical	teams	can	operate;		
• Developing	a	TiM	system	that	could	be	used	on	any	device.	The	 results	 of	 this	 trial	 reflect	 the	 wider	 evidence	 which	 emphasises	 the	importance	 of	 developing	 relationships	 and	 promoting	 interaction	 between	staff	and	users,	something	that	the	current	version	of	the	TiM	system	does	not	do	(176,275).		Lack	of	interaction	was	not	just	due	to	the	technology	or	the	large	number	 of	 alerts	 faced	by	 the	 nurse	 but	 also	 due	 to	 difficulties	 establishing	 a	relationship	using	digital	technologies.		One	option	would	be	to	introduce	other	ways	 of	 communication	 such	 as	 messaging	 services	 or,	 for	 more	 complex	consultations,	phone	calls	or	telemedicine.		Chapter	Seven	suggested	that	these	additional	 digital	 communications	 would	 be	 acceptable,	 particularly	 when	patients	were	unable	to	attend	clinic.				Telehealth	 and	 telemedicine	 (video	 consultations)	 appear	 complementary:	collecting	 routine	 information	 about	 a	 patient	 at	 their	 own	 convenience,	allowing	 the	 Telehealth	 Nurse	 to	 better	 triage	 patients	 and	 arrange	 more	detailed	 consultations	 with	 patients	 at	 home	 that	 focussed	 on	 the	 patient’s	current	needs.	 	More	recently,	two	small	evaluations	suggest	that	telemedicine	could	 be	 a	 valuable	 adjunct	 to	 the	 MND	 service	 (276,277).	 	 Both	 services	involved	 a	 nurse	 telephoning	 the	 patient	 before	 the	 clinic	 visits	 to	 gain	
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information,	much	of	which	could	be	collected	using	telehealth.	Therefore	 it	 is	recommended	that	the	use	of	these	two	services	together	be	explored.				This	 study	 found	 that	 that	 some	 aspects	 of	 MND	 care	 cannot	 be	 delivered	remotely.		The	community	team	is	important	source	of	support	to	participants,	arranging	 home	 adaptations	 and	 providing	 a	 lot	 of	 medical	 and	 psychosocial	support,	particularly	near	the	end	of	 life.	 	However,	clinicians	and	participants	felt	 the	hospital	MDT	still	had	a	role	 to	play,	even	near	 the	end	of	 life	and	the	MND	 nurses	 felt	 that	 the	 links	 between	 the	 hospital	 and	 community	 enabled	teams	to	share	information,	work	together	and	promote	good	practice.		The	TiM	system	 could	 enable	 information	 to	 be	 shared	 between	 teams	 and	 enable	 a	smoother	 transition	 into	 the	 time	 when	 patients	 can	 no	 longer	 travel	 to	appointment,	 a	 time	 that	many	patients	 in	 this	 study	 feared	because	 they	 felt	they	 would	 no	 longer	 be	 able	 to	 access	 the	 services	 they	 need.	 	 The	 way	 in	which	 the	 teams	work	 together	 using	 the	 TiM	warrants	 further	 evaluation	 in	different	centres.		At	 the	 time	of	design	of	 the	TIM	system,	weight	was	 the	only	useful	objective	measure	of	 a	 patient’s	 condition	 that	 could	be	 collective	 remotely.	 	 The	 study	found	that	weight	was	a	valuable	objective	measure	of	a	patient’s	condition	and			participants	also	valued	monitoring	their	weight.		In	addition,	both	patients	and	clinicians	also	 felt	objective	monitoring	of	respiratory	 function	was	 important.		Since	 the	 TiM	 system	 was	 developed,	 the	 Airsmart	 Spirometer	 has	 been	launched.	 This	 can	 use	 a	 patient’s	 smartphone	 to	 transmit	 measures	 of	respiratory	 function	 to	 an	 online	 portal	 (278).	 	 It	 costs	 €69	which	may	 be	 a	reasonable	 price	 to	 allow	 patients	 to	 avoid	 attending	 hospital	 simply	 for	 this	test.	 	 	Other	apps	 in	the	early	stages	of	development	can	measure	aspects	of	a	patient’s	voice,	breathing	pattern	and	fine	motor	skills	or	can	alert	the	physician	to	patients	who	are	admitted	 to	hospital	but	 their	 feasibility	and	usefulness	 is	yet	to	be	determined	(279).	 	The	Wi-Fi-enabled	weight	scales	used	in	this	trial	also	 provided	 a	 measure	 of	 balance.	 	 The	 meaning	 and	 clinical	 value	 of	 the	balance	scores	has	yet	to	be	explored	but	further	analysis	of	the	data	collected	along	with	validation	of	 the	weight	 in	healthy	volunteers	and	other	patients	 is	planned	and	this	may	be	a	useful	tool	in	identifying	mobility	problems	or	risk	of	falls.	 	The	TiM	system	could	use	 telemonitoring	 to	measure	blood	oxygen	and	carbon	dioxide	to	detect	nocturnal	respiratory	insufficiency	or	monitor	the	use	of	 non-invasive	 ventilation.	 	 Technology	 has	 advanced	 since	 the	 studies	described	in	Chapter	Two	were	commenced	and	a	pilot	trial	of	 telemonitoring	of	NIV	is	already	underway	(159).	 	Devices	that	record	oxygen	saturations	are	already	available	and	the	trials	described	in	Chapter	Two	suggested	this	could	be	a	feasible	addition	to	the	TiM.		However,	measuring	arterial	carbon	dioxide	is	much	more	expensive	and	technically	difficult	with	machines	currently	costing	£9000	 meaning	 at	 present,	 this	 facility	 is	 not	 feasible	 and	 needs	 further	development	(280).		Discussions	with	the	TiM	developers	(Mylan,	Carematix)	have	indicated	that	 it	would	be	possible	to	make	the	recommended	improvements	to	the	TiM	system.	It	 will	 be	 important	 to	 continue	 to	 use	 a	 user-centred,	 iterative	 approach	 to	inform	further	developments.		It	is	therefore	recommended	that	after	the	simple	
	 223	
improvements	recommended	in	this	thesis	have	been	completed,	the	next	stage	should	involve	testing,	feedback	and	further	redesign.		It	is	planned	to	conduct	this	 in	 a	 larger	 number	 of	 different	 MND	 centres.	 	 Any	 modification	 to	 the	technology	is	associated	with	a	cost	so	further	iterations	should	be	limited	but	there	 should	 be	 capacity	 for	 individual	 centres	 to	 modify	 the	 TiM	 system	 to	meet	 their	needs.	 	 Some	adaptability	will	 be	built	 into	 the	next	 version	of	 the	TiM	system	(for	example,	to	modify	the	clinical	algorithms	or	to	integrate	it	into	their	own	IT	systems)	and	evaluations	should	determine	whether	this	flexibility	satisfies	the	requirements	of	different	centres.		These	 next	 steps	 should	 also	 provide	 the	 opportunity	 for	 a	 framework	 to	 be	developed	to	describe	in	broad	terms	ways	in	which	the	TiM	could	be	used	to	its	full	potential	and	ensure	that	the	service	meets	the	expectations	of	users.	 	The	framework	 should	 outline	 the	 potential	 uses	 and	 benefits	 of	 the	 TiM	 and	recommend	ways	in	which	staff	could	interact	with	patients	and	carers.		It	was	clear	 from	 this	 trial	 that	 a	 framework	 that	 is	 too	 prescriptive	 would	 not	 be	acceptable	to	clinical	teams	who	like	to	use	their	own	judgments	when	making	decisions.		Other	telehealth	studies	have	also	highlight	the	risks	associated	with	staff	disenfranchisement	should	they	feel	their	clinical	practices	are	threatened	or	 undermined	 (188,275).	 	 	 Therefore,	 rather	 than	 aim	 for	 a	 completely	standarised	 approach	 to	 using	 the	 TiM	 system,	 a	 framework	 would	 allow	flexibility	 to	 ensure	 can	 be	 integrated	 into	 the	 local	 service	 and	 remain	acceptable	 to	 the	 clinical	 team.	 	However,	whilst	 teams	may	work	 in	different	ways,	 the	 introduction	 of	 evidence	 based	 clinical	 guidelines	 (e.g.	 NICE	guidelines	 (39))	 means	 that	 clinician	 teams	 will	 be	 taking	 a	 more	 consistent	approach	and	broad	framework	can	reflect	this	best	practice.			
8.4	The	future	evaluation	of	the	TiM	system			Whilst	 a	 randomised	 controlled	 trial	 was	 previously	 held	 to	 be	 the	 gold	standard	approach	 to	 demonstrate	 the	 clinical	 impact	 of	 an	 intervention,	 it	 is	increasingly	 recognised	 that	an	RCT	may	not	be	 the	best	approach	 to	 support	the	successful	development	and	implementation	of	complex	interventions	such	as	the	TiM	system	(281).			This	study	demonstrated	some	of	the	limitations	of	an	RCT:	 it	 allowed	 only	 limited	 development	 of	 the	 intervention	 during	 the	 trial	and	it	would	not	be	possible	to	carry	out	the	further	stages	of	development	and	testing	 recommended	 in	 this	 thesis	within	 an	 definitive	 RCT.	 	 In	 addition	 the	difficulties	experienced	in	this	study	reflect	the	view	of	others	that	that	an	RCT	would	 fail	 to	 clarify	 the	complex	clinical,	professional	and	 institutional	 factors	that	 influence	the	success	or	 failure	of	such	a	complex	 intervention	(176,281).		Therefore	it	should	be	concluded	that,	at	this	stage,	a	definitive	RCT	would	not	be	recommended.	Instead	of	an	RCT,	it	is	recommended	that	the	next	steps	should	aim	to	develop	the	 intervention	 further	 and	 explore	 how	 it	 may	 be	 integrated	 into	 different	services.	 	 	 Initially,	 the	 basic	 changes	 recommended	 in	 Section	 8.3	 should	 be	implemented	before	further	testing	in	clinical	practice	occurs.		Following	this,	a	further,	 a	 more	 iterative	 process	 of	 evaluation	 and	 development	 should	 be	adopted	 in	order	 to	understand	of	 the	processes	 involved	 in	using	 the	TiM	 in	
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real-life	in	different	MND	care	centres	and	to	evaluate	any	changes	made	to	the	system.	 	 Realist	 evaluation	methods	 adopting	mixed	methods	 techniques	 that	seek	 to	 better	 understand	how	 the	TiM	works	 are	 likely	 to	 be	 better	ways	 to	meet	these	aims	(179,180).	They	could	be	used	to	facilitate	step-wise	testing	of	different	 versions	 of	 the	 technology,	 gain	 feedback	 and	 test	 further	improvements.	 	 	 Realist	 methods	 allow	 emerging	 theories	 to	 be	 tested.	 For	example,	if	a	particular	pattern	of	adherence	is	identified,	or	a	particular	impact	is	observed	in	the	context	of	particular	subgroup	of	patients,	the	reasons	of	this	could	be	explored	in	more	depth	with	staff	interviews	(180).	These	methods	are	now	more	 seen	 to	 be	 acceptable	 ways	 to	 produce	 rigorous	 evidence	 and	 are	being	adopted	in	the	NHS	(281).			For	example,	the	seven	NHS	England	Test	Bed	projects	are	adopting	 these	approaches	 to	enable	a	more	rapid	and	pragmatic	evaluation	techniques	to	develop	and	evaluate	new	digital	interventions	within	clinical	services	(189).			It	is	has	been	established	in	this	study	that	patients,	carers	and	staff	can	use	the	TiM	 technology	 and	 that	 the	 principle	 of	 telehealth	 is	 acceptable	 to	 most	patients	and	carers.		As	discussed	in	Section	8.3,	the	main	challenge	for	the	TiM	in	the	future	(and	therefore	the	main	focus	of	the	next	stage	in	development)	is	to	enable	the	TiM	to	be	used	to	its	full	potential	in	each	service	by	ensuring	that	clinicians	 are	making	 use	 of	 the	 system,	 responding	 to	 alerts	 and	 interacting	with	participants.		In	addition,	as	already	discussed	earlier,	staff	acceptance	is	a	key	component	to	the	success	of	telehealth	and	barriers	to	engagement	remain.		Technology-enabled	care	requires	a	 fundamental	shift	 in	 the	way	services	and	delivered	 and	 how	 clinical	 staff	 interact	 with	 patients	 therefore	 future	development	and	evaluations	must	establish	if	and	how	clinical	staff	can	adapt	and	 use	 the	 telehealth	 to	 their	 satisfaction	 whilst	 continuing	 to	 deliver	 high	quality	service	(176).				It	 is	 recommended	 that	 the	 next	 stages	 of	 the	 TiM	 should	 adopt	 a	 range	 of	methods	 that	 reflect	 the	 complexity	 of	 the	 unanswered	 questions.	 	 More	quantitative	data	should	be	collected	to	observe	and	understand	the	processes	involved	in	TiM	in	more	detail	than	was	done	in	this	trial.		Intervention	fidelity	should	be	explored	further	than	it	was	in	this	trial	by	determining	whether	and	how	 the	 TiM	 was	 used	 and	 compare	 this	 to	 what	 is	 expected	 by	 observing	aspects	such	as	how	staff	adhere	to	the	TiM	framework	and	react	to	alerts.	 	 	It	should	 also	 explore	 more	 about	 the	 impacts	 that	 occur.	 This	 could	 be	 done	better	 by	 capturing	 interactions	 between	 staff	 and	 users	 more	 closely	 by	recording	 events	 and	 staff	 actions	 automatically	 on	 the	 TiM	 system	 and	 then	exploring	 these	 specific	 events	 in	 more	 depth	 using	 qualitative	 methods.		Comparing	 current	 practice	 to	 historical	 clinical	 practice	 (such	 as	 examining	clinic	 visit	 frequency)	 will	 determine	 whether	 a	 service	 is	 likely	 to	 reduce	overall	 healthcare	 costs	 or	 be	 feasible	 given	 the	 available	 resources.	 	 Proxy	measures	 of	 quality	 such	 as	 adherence	 to	 clinical	 guidelines	 or	 frequency	 of	contact	 with	 the	 MDT	 can	 be	 collected	 to	 determine	 whether	 a	 new	 service	delivers	the	same	standards	of	care	as	usual	care.					In	parallel,	staff	experiences	and	behaviours	in	different	delivery	settings	should	be	 explored	 using	mainly	 qualitative	methods	 (e.g.	 interviews,	 focus	 groups).		
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Theoretical	 frameworks	 such	 as	 the	 Normalization	 Process	 Theory	 could	 be	applied	 to	 help	 understand	 how	 these	 changes	 occur	 and	 to	 promote	 future	development	 of	 the	 service	 (282).	 This	 theory	 has	 been	 applied	 to	 process	evaluations	of	other	complex	interventions	in	healthcare	to	study	how	and	why	some	 interventions	but	not	others	become	embedded	 (normalised)	 in	 routine	practice	 (283).	 	Without	 the	constraints	of	an	RCT,	 continuous	evaluation	and	reflection	on	ways	in	which	individuals	and	teams	respond	and	adapt	to	novel	services	can	be	used	to	determine	 if	and	how	a	successful	service	can	become	embedded	 into	 normal	 practice.	 	 This	 would	 be	 particularly	 important	 to	understand	how	staff	might	react	both	as	individuals,	and	as	members	of	a	team	to	 using	 the	 TiM	 framework	 and	 how	 this	 could	 help	 deliver	 the	 important	aspects	of	the	MDT	care	service.				In	summary,	future	evaluations	of	the	TiM	should	examine	its	use	in	real-life,	in	larger	numbers	and	in	different	centres.		Complementary	methodologies	should	be	used	in	different	centres	to	understand	the	various	uncertainties	highlighted	in	this	study.			
8.5	The	feasibility	of	evaluating	the	TiM	in	a	randomised	controlled	
trial		MND	 services	 and	 technology	 are	 changing	 and	 patients	 do	 not	 have	 time	 to	wait	 for	 new	 developments	 to	 improve	 their	 lives.	 	 It	 is	 clear	 that	 the	 TIM	system	requires	further	developments,	however,	if	the	evaluations	proposed	in	Section	8.4	 indicate	 it	 to	have	good	potential	 to	 improve	care,	 there	should	be	minimal	 delay	 between	 development	 and	 implementing	 the	 service	 more	widely	in	clinical	practice.		In	order	for	it	to	be	implemented	widely,	the	service	would	 require	 commissioning	 for	 any	 additional	 technology	 and	 staff	 costs.	Decision-makers	 do	 usually	 expect	 traditional	 evidence	 of	 a	 service’s	 efficacy	and	 cost-effectiveness	 in	 order	 to	 decide	which	 interventions	 to	 fund	with	 its	limited	resources.	 	Despite	 the	arguments	outlined	 in	 this	 thesis,	a	 future	RCT	should	not	be	discounted	as	this	type	of	evidence	remains	the	most	persuasive	to	 support	 a	 service	 being	 approved	 and	 commissioned.	 	 This	 study	demonstrates	that	a	randomised	controlled	trial	of	telehealth	in	MND	could	be	conducted:	 that	 is,	 it	 could	 recruit,	 retain	 and	 collect	 data	 from	 participants	attending	an	MND	care	centre.	 	A	 large	sample	size	would	be	required	but	the	numbers	would	not	be	infeasible	as	 long	as	the	study	remained	low	in	burden	for	 participants	 and	MND	 centres.	 	 A	 composite	 endpoint	measure,	 using	 the	most	 relevant	 outcome	measures	 (such	 as	 ALSAQ-40,	 SF-36	 and/or	 survival)	taking	 into	 consideration	 the	 treatment	 group	 differences	 over	 a	 number	 of	time	points	would	provide	a	more	sensitive	estimate	of	the	impact	of	the	TiM.			However,	 as	 exemplified	 by	 the	 Whole	 System	 Demonstrator,	 an	 RCT	 faces	major	 challenges	 and	 is	 at	 high	 risk	 of	 failing	 to	 demonstrate	 the	 relevant	impacts	of	the	TiM.		In	addition,	lengthy	trials	will	not	allow	the	technology	keep	up	with	the	rapid	changes	in	technology	or	health	services	outlined	in	the	2014	NHS	Five	Year	Forward	vision.		Therefore,	it	should	be	concluded	that	an	RCT	is	not	 the	 correct	way	 to	 produce	 the	 rigorous	 evidence	 required	 to	 further	 the	implementation	of	 the	TiM	 in	 the	NHS.	 	The	methods	described	 in	Section	8.3	will	be	far	better	placed	to	do	this.	 	 In	addition,	 if	the	TiM	system	does	indeed	
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produce	positive	 impacts	 for	 patients	 and	 carers,	 the	proposed	next	 stages	 of	evaluation	 should	 demonstrate	 to	 local	 teams	 that	 it	 is	 something	 worth	commissioning.	 	 These	 local	 “champions”	 who	 witness	 the	 successes	 of	 new	services	can	deliver	persuasive	arguments	to	support	commissioning	of	services	(189).		Finally,	weight	of	support	from	patients	and	carers	who	also	support	the	need	improve	the	care	of	those	living	with	MND	along	with	positive	narratives	of	those	who	have	used	the	TiM	would	only	help	local	champions	strengthen	the	argument	for	adoption	of	the	TiM	system	into	their	MND	service	(203).	
8.6	Implications	for	future	research		This	study	shows	the	value	of	 iterative,	user-centred	design	and	focus	on	end-users	 prior	 to	 and	 during	 evaluations	 of	 telehealth	 in	 order	 to	 ensure	interventions	 are	 acceptable	 and	 feasible.	 	 It	 also	 highlights	 the	 benefit	 of	process	evaluations	in	“real-life”	settings	prior	to	comparative	trials	in	order	to	understand	the	users’	needs,	expectations	and	goals	as	well	as	the	mechanisms	of	change	brought	about	by	 the	 telehealth	which	may	need	 to	be	measured	 in	future	 trials.	 	 	Much	 of	 the	 telehealth	 literature	 examines	 the	 technology	 and	participant	experiences.		There	is	less	focus	on	staff	and	service	factors	and	it	is	recommended	that	this	be	the	focus	of	future	research.	This	study	also	has	implications	of	other	trials	of	interventions	in	MND,	many	of	which	 have	 faced	 challenges	 that	 have	 affected	 their	 success.	 	 The	recommendations	 contained	 in	 the	 MRC	 framework	 for	 developing	 and	evaluating	 complex	 interventions	 and	 conducting	 process	 evaluations	 are	relevant	 to	many	other	clinical	 trials.	 	The	 importance	of	careful	planning	and	piloting	of	the	trial	design	can	overcome	problems	with	recruitment,	retention	and	 outcome	 measure	 collection.	 	 Ensuring	 a	 good	 understanding	 of	 how	interventions	 should	 be	 used,	 tested	 and	 delivered	 is	 also	 vital.	 	 These	considerations	should	be	made	long	before	a	definitive	trial	commences.	
8.7	Conclusions		This	 study	has	 demonstrated	 that	 the	TiM	 system	 is	 an	 acceptable	method	of	facilitating	 access	 to	 MND	 services	 and,	 if	 improvements	 are	 made,	 could	improve	 the	 care	of	patients	 and	carers	with	MND.	 	Further	 improvements	 to	the	 TiM	 are	 required	 and	 an	 iterative	 approach	 to	 development	 should	 be	adopted	 use	 methodologies	 better	 able	 to	 capture	 the	 complexities	 of	 the	intervention.	 	A	randomised	controlled	trial	could	be	used	to	compare	the	TiM	to	 usual	 care	 but	 it	 is	 unlikely	 to	 be	 successful	 in	 understanding	 all	 the	important	 aspects	 of	 the	 TIM	 system.	 	 Instead,	 the	 alternative	 methods	described	 in	 this	 chapter	 may	 be	 better	 placed	 to	 provide	 more	 rigorous	evidence	of	the	TiM’s	impact	on	clinical	care	and	cost-effectiveness	and	enable	it	to	be	integrated	successfully	within	the	specialist	MND	care	service		 	
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Table	5.3	Carer	satisfaction	with	Tim	system	at	3	and	12	months.	A5.1	The	benefits	of	the	MND	hospital	multidisciplinary	team.	
Care	coordination	Coordinates	care			 “If	there’s	any	problems	[MND	centre’s	input	has]	been	more	global,		rather	than	equipment	and	stuff	that’s	wanted	here.”	P248	Referrals	to	specialists		 “...people	just	came	out	of	the	woodwork	when	I	was	first	diagnosed.”	P134	MDT	actively	manage	condition	 “Sheffield	seems	to	be	showing	a	lot	of	interest,	which	is	reassuring.	I	know	when	we	go	and	see	[local	neurologist],	there’s	not	much	she	can	do,	to	be	fair.	We	go	and	she	says	how	are	you	and	we	say,	all	
right	and	we	have	a	bit	of	a	chat	and	off	we	go	and	that’s	it.	You	sort	
of	expect	a	physician	to	heal	you.”	C172	
Sheffield	MND	helpline	Nurse	first	point	of	contact	for	many	
“Q:	And	if	you	had	a	problem	and	you	thought	it	might	be	something	
to	do	with	your	MND	what,	who	would	you,	how,	what	would	be	your	
sort	of	method	of	contacting	or	finding	out	about	it?		
P:	I’d	always	phone	[MND	nurse].		
Q:	And,	and	how	do	you	find	it	when	you,	you	do	phone?		
P:	Excellent.		
C:	Yeah,	she	sorted	the	first	initial	things	out…she	made	the	contacts	
P:	Well	if	I	have	a	problem	with	the	drugs	I’m	currently	on;	so	I	
phoned	[MND	nurse]	and	she	answered	me	there...	So	I	think	that,	to	
me,	is	the	best	route.”	P&C381	Nurse	is	familiar	 “I	know	all...	you	over	there	are	pretty	good,	every	time	I	phone	[MND	nurse]	up	...if	I’ve	left	her	a	message	she’s	usually	back	to	me	as	soon	
as	she	can.	So	yeah,	my	first	call...	if	I	thought	it	were	MND	related	
then	ring	Sheffield	and	[MND	nurse],	which	is	reassuring.”	P145	Nurse	approach-able	 “Q:	If	you	did	have	a	problem,	how	would	you	go	about	sorting	it?	P:	I	think	I’d	ring	[MND	nurse].		Q:	You’d	ring	[MND	nurse]?	What’s	your	experience	of	ringing	[her]?		
P:	Oh,	I	love	her!		
Q:	What	is	it	you	find	helpful?		
P:	Friendly	and	helpful.		
C:	Yes.	She’s	quite	informal	about	things.		
P:	I	think	I	could	ring	her	anytime.”	P217	Always	available	 “I	now,	within	myself,	would	have	no	hesitation	in	picking	up	the	phone	and	making	a	phone	call	if	I	thought	that	there	was	something	
that	I	needed	[PJS]'s	help	or	intervention”	P046	
	Problems	get	resolved	quickly	 “C:	…you’re	on	the	phone	and	they	answer;	even	if	they’re	not	there,	they	ring	back	immediately	and	the	answer	is	there…”	P137	Provides	carers	emotional	support	
“	[MND	nurse],	she's	so	lovely,	she	really	is.	And	I	know	there	was	
summat	once	wrong,	a	while	since,	and	I	rang	her	up	and	she	put	me	
mind	at	rest.	Yeah,	[MND	nurse]	I	think	is	lovely,	yeah,	yeah.”	C228	Backup	for	community	team		 “Q:	And	if	you	had	a	question	now	or	a	problem	what	do	you	do?		C:	Well	I	can	go	to...,our	occupational	therapist	who	comes	out	to	see	us,	and	we’ve	got	her	email	and	we’ve	got	her	phone	number;	so	[OT]	
would	be	the	first	one,	or,	if	not	available	[MND	nurse].”	P062				 	
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A5.2	The	psychological	benefits	of	the	hospital	MDT.	
Psychological	benefits	of	the	hospital	MDT	Positive	attitude	 	“Q:	And,	and	when	you	come	to	the	clinics	now,	what	it	is	that	you	want	to	get	out	of	coming?		
P:	Well	what	I'd	like	to	get	out	of	it	is	any	information	that's	going	
on,	any	positives,	any	trials	going	on,	any	success	stories.	I	like	to,	I	
like	people	to	tell	me	that	they've	known	somebody	that's	had	ALS	
for	ten	years;	that	makes	me	happy.”	P317	
	“I	didn't	find	them	gloom	merchants,	they	were	very	positive	in	
their	approach	and	in	their	opinions	and	their	comments.”	C229	Staff	are	caring	 “No,	she's	a	nice	lady,	she	knows,	she	can	empathise,	which	is	nice	
and	she,	she's	obviously	caring	the	way	she	comes	across.”	C317	Able	to	speak	to	an	expert	 “When	I	saw	[MND	neurologist],	we’ve	had	a	really	good	relationship	from	day	one.		So	he	tells	it	as	it	is	and	I	ask	it	how	it	is	
...	upfront	really,	which	I	think	is	the	best	way.	That’s	the	way	I	
wanted	to	be	cos	then	I	can,	you	know,	I	can	deal	with	it	then.”P056	MND	provides	practical	information	 “[referring	to	a	benefit	assessment	form]	[MND	nurse]	told	us	how	to	answer	the	questions.”	C392	“I	was	first	introduced	to	the	PIP	on	the	day	that,	[MND	nurse]	told	
me	about	that…”	P248	Confidence	in	the	expertise	of	a	specialist	centre	
“The	diagnosis	at	[district	hospital]	...	was	a	bit	lackadaisical.		
When	I	went	to	Sheffield	the	diagnosis	was,	well	obviously	
Sheffield’s	got	more	experience	...	haven’t	they?		I	think	maybe	if	the	
first	place	that	you	go	to	for,	you	know,	to	research	it,	if	they’re	not	
really	experienced	on	the	disease.”	P056	
“Knowing	what	they	talk	about,	which	is	comforting.”		C229	Close	connection	to	research		 “I	was	looking	on	Facebook	and	I	noticed	that	there’s	a	[man]	whose	wife	apparently	died	of	MND	quite	recently.	He’s	a	huge	fundraiser.	He’d	put	this	thing	on;	it	was	a	little	short	film.	And	
[consultant	MND	neurologist]	was	in	it.”	P122		Opportunity	to	discuss	emotions	 “I	don’t	talk	about	it	awfully	much,	other	than,	you	know	when	I	come	to	the	clinic,	or	discussing	it	with	the	outreach	team.”	P122		Opportunity	to	support	carers	 “He	talks,	and	if	there's	any	concerns	or	if	I	need	to	talk	to	him	about	anything	then	obviously,	you	know,	I	can	talk	to	him.”	C145	
“There	were	a	time,	I	were	really	upset	because	I	were	really	
worried.	But	I	didn’t	make	a	point.	But	the	[nurses]	were	really	
good.	They	ushered	me	into	a	little	room	and	I	cried.	It	spring-
boarded	a	lot	of	things...	and	they	acted	upon	it.	That’s	when	we	got	
the	physio	and	the	dietician	and	everybody	came....	I	needed	to	talk	
to	somebody	and	it	helped	me.”	P184	Opportunity	to	involve	carer	 “They	have	all	the	knowledge,	the	technical	knowledge	and	how	it	develops	and	how	it’s	best	treated.	I	think	it’s	valuable	to	feel	part	
of	that	team	and	you	can	explain	things	that	are	happening	and	
they	can	explain	to	you	what	might	happen	and	the	things	to	look	
out	for.	And…	[Pauses]	as	apposed	to	being	an	isolated	carer,	if	you	
know	what	I	mean,	to	be	part	of	the	“team”.”	C122		 	
	 255	
	A5.3	Reasons	why	participants	felt	the	clinic	was	not	always	beneficial.		
Clinic	offers	little	perceived	value	Clinic	is	not	going	to	provide	a	cure	
“Q:	And	what	is	it	about	clinic	that	you,	you,	you,	you	find	you	need	to,	
you	need	to	come	for?		
C:...I’ve	got	to	admit	I	like	to	see	[MND	nurse]	but		apart	from	that	
there's	nothing,	they're	not	gonna	give	me	a	miracle	cure.”	C228	
“If	I	could	go	every	three	months	and	it	would	have	a	chance	of	
making	me	better	or	improving	my	life,	I’d	go	every	month,	no	
problem.	It’s	just	so	frustrating	that	nothing’s	happening.”	P184	Clinic	is	just	monitoring	decline	 “...	this	is	not	necessarily	my	belief,	[people]	feel	that	it’s	all	just	an	exercise	of	measuring	and	monitoring	how	the	disease	progresses	in	individual	patients,	and	we	really	want	to	see	something	at	the	end	
that’s	a	bit	more	than	just	a	measurement	of	progress.”	P232	
“All	you’re	doing	currently	is	monitoring	my	progress,	so	at	the	minute	
I’ve	really	got	nothing	out	of	the	clinic.”	P318	
“I	guess	that	would	then	cut	down	my	travel	time	to	clinic,	you	know,	
clinic	doesn’t	really	fulfil	a	great	deal	in	my	life	other	than	ticking	
some	boxes	and	sort	of	knowing	where	the	progression’s	going.”	P134	Physical	exam	not	important	 “Q:	And	how	do	you	sort	of,	do	you,	do	you	monitor	your	progression	or	the	change	in	your	disease?		P:	I	know	myself	that	there’s	things	I	can’t	do	that	I	used	to	be	able	to	
do,	and	that’s	my	benchmark.	Very	early	on	in	my	clinic	we	stopped	
doing	muscle	scores	cos	I	didn’t	wanna	know,	I	knew	that	my	finger	
wasn’t	working,	I	didn’t	need	someone	to	tell	me	that	I	was	a	three	or	
a	four	or	a	five,	and	that	was	all	a	bit	arbitrary	because	you	could	be	a	
five	one	day	and	a	three	the	next	depending	on	how	you	were	feeling;	
and	also	who	was	administering	the	test.	So	it	was	a	pointless	exercise	
for	me.		I	just	know	now	that	I	can’t	walk	or	I	can’t	do	this	or...	that,	
but	I	can	still	hold	a	glass	of	wine	and	do	lots	of	other	things.”	P134	Takes	time	to	develop	relationship	 “Q:	And	did	you	use	the	telephone	service	to	[MND	care	centre	nurse],	the	MND	nurse?	Did	you	use	that?		C:	No	I’ve	not	been	in	touch	with	her	at	all.”	C062	
“C:	You've	had	no	real	contact	with	[MND	nurse].	C381	No	need	for	clinic	nurse	if	community	nurse	sufficient	
“C:	Do	you	think	[MND	nurse]	should	be	playing	more	of	a	part,	role?		
What's	she	gonna	do	differently	to	what	[Community	Nurse]	does	is	
the	question...from	a	locality	perspective	I	suspect	it	would	be	a	bit	out	
of	her	way...it's	all	about	personal	contacts...	
P:	I	guess	[MND	nurse]'s	got	more	hands-on	cos	she's	more	hospital-
based	and	she's	seeing	people	day	after	day	after	day.”	P&C381	Lack	of	psychological	support	in	hospital	clinic	
“To	me,	I	thought	[clinic	has]	never	been	about	psychological	
wellbeing	and	your	mental	wellness	and	therefore;	and	truthfully	I	
thought	I	don't	know	why	these	questions	are	in	here,	because	that	
clinic	isn't	equipped	to	deal	with	that	and	I	know	that.”	P046	Clinic	focus	is	on	patient,	not	carer	
“Q:	Do	people	ask	you	about	sort	of	how	you	are	and	how,	what's	your	
mood	like,	when	you	see,	you	know,	doctors	or	clinic	or...?		
C:	No.		
Q:	What,	what	do	you	think	about	that?		
C:	It's	not	about	me,	it's	about	P	
	Q:	And	do	you	think	people	should	ask	you,	though,	about	it?	
	C:	No	cos	it's	not	about,	at	the	end	of	the	day	it's	not	about	me,	it's	
about	P,	so	no.”	C145	
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A5.4	The	problems	associated	with	the	organization	of	the	hospital	clinic.	
Problems	with	clinic	organisation	Gaps	between	clinic	 “I	know	when	I	come	down	to	Sheffield	I	can	get	to	know	anything	I	want	basically	and	they’ve	been	fantastic.	...It’s	just	that	time	between…[clinics]”	P056	
“It’s	a	good	idea	to	monitor	symptoms	if	they	crop	up	out	of	the	blue	
ans	we’re	not	sure	whether	it’s	anything	or	not...”	C062	
“I	did	feel	that	I’d	been	told	and	left	...like	that	they	give	me	this	
horrible	diagnosis	and	it	were	like,	go	away	and	think	about	it	...I	just	
suddenly	felt	like...:	you’ve	got	this;	go	away,	that’s	it.	.”	P321	Clinic	infrequent	 “So	I	haven’t	been	to	see	[MND	neurologist]	since	the	first	time	that	we	went;	so	he’s	only	been	twice	to	see	him.”	P166	Fixed	appointments		 “P:	I	think	once	they’d	told	me	the	diagnosis	I	didn’t	kind	of	hear	much	after	that,	it	was	kind	of	a	strange	day,	it	was	just;	and,	and	for	
a	good,	probably	a	good	couple	of	weeks	after	that	I	was	quite	down	
and,	yeah,	it	was	like	worried	about	the	future.	
C:	I	suppose	I,	I	felt	like	the	diagnosis	had	been	given	and	then	that	
was	it,	see	you	in	three	months’	time.”	P&C423	Clinic	busy	 “[MND	neurologist]	he’s	always	got	a	very,	very	positive	attitude	but	
you’ve	got	limited	time,	because	he’s	got	a	full	clinic,	he’s	got	a	dozen	
patients	sat	there,	cueing	up	to	get	in.”	P184	Feeling	like	a	burden	 “I've	sometimes	felt	that	I'm	taking	time	up	in	the	clinic	that	somebody	else	could	use	better	than	me.”	P046	
	Privacy	not	always	possible		 “If	I	am	being	honest,	I	remember	thinking:	this	is	all	happening	at	the	same	time,	there's	only	a	curtain	between	us	and;	I	can	hear,	I	could	hear,	I	could	hear,	do	you	know	what	I	mean,	I	could	hear	
other	people	and	what	tests	they	were	having.	I	was	surprised	at	
that,	...	because	everything	up	to	that	point	had	been	as	you	would	
expect	with		a	medical	consultation,	you	know,	it's,	it's	you	in	a	
private	room,	you	know,	out	of	ears.”	P409	Clinical	can	be	emotionally	and	physically	tiring	
“I	know	this	is	horrible,	perhaps	not	a	very	nice	thing	to	say,	but	
when	we’ve	been	we	always	feel	as	though,	at	the	minute,	we’re	quite	
lucky	because	there’s	always	(laughs)	somebody...	that’s	got	another	
side	effect	though	because	you	think:	that’ll	be	us	soon...that’s	the	
only	thing	going	to	the	clinic	...	we	always	feel	a	bit	shattered	by	the	
time	we	get	back	trying	to	hold	everything	going.”	C318	
“Q:	You	mentioned	it	affects	you	afterwards?	Before	as	well?		
P:	Two	days.	For	two	days	after,	mentally	and	physically.	Because	it’s	
such	an	effort	for	everything	to	do	for	me.	“	P184	Distressing	to	see	other	people	in	later	stages	of	disease		
“P:	It	does	get	me	down	sometimes,	in	my	more	quiet	moments;	I	
might	sit	and	think	about	it.	You	are	reminded	about	it	a	lot...”	
Q:	Do	you	compare	yourself	to	other	people	with	MND?		
P:	Yeah,	only	when	I	come	to	your	clinic!	That’s	the	only	time	I	see	
them!		I	remember	the	last	time	I	was	there	when	I	met	you:	there	
was	a	lady	in	a	powered	wheelchair.	She	was	in	the	next	cubicle	to	
me.	Probably	age	similar	to	me...	It’s	the	speech	side	would	really	
annoy	me.	If	I	couldn’t	talk.	That’s	the	thing	more	than	anything	that	
would	worry	me	more....	Not	being	able	to	converse	with	people,	and	
tell	them	how	I	feel...	But	hopefully	that’s	a	long	time	down	the	line...	
So	it	won’t	worry	me.”	P122			
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A5.5	The	practical	barriers	to	attending	clinic	
Practical	barriers	to	attending	clinic	Long	day	for	a	very	short	visit	 “C:	We’re	seeing	his	registrar	now.	He’s	very	good.		P:	They	are	all	good.	I’ve	got	nothing	but	admiration	for	they.		C:	But	you	are	very	quickly	in	and	out,	aren’t	you.?		
P:	Yes.	I’m	only	there	10	minutes.	That’s	11	o’clock	in	the	morning,	'til	
half	past	seven	at	night,	my	day	for	that.”	P184	Travelling		 	“Q:	...You'd	rather	not	come	at	the	moment;	I	think	that	was	the	
travelling,	was	that	right?		
P:	It	was.	It	was	about	two	hours	to	get	there,	about	an	hour	
consultation	and	then	another	two	hours	to	get	back.”	P166	Parking			 “	We	just	park	up...	sometimes	hard	to	find	a	parking	space	(laughs)	
but	that's	same	at	every	hospital”	P145	Clinic	in	unfamiliar	place	 “	...	we've	been	there	that	many	times,	we	always	get	lost.”	P145	“Q:	Is	it	the	travelling	the	main…?		C:	Well	last	time	we	went	we	were	there	about	four	hours	before	we	
got	in	because	it’s	always	busy	there	isn’t	it.	Because	we	left	at	night	
and	it	was	dark	and	I	got	“done”.		
Community	nurse:	...You	got	fined	for	going	through	a	bus	lane.		
C:	I	went	through	a	bus	lane.	I	didn’t	realize	and	I	couldn’t	get	out	of	
it	because	they	had	a	photograph.”	C062	Travel	is	expensive	 “C:	Train	tickets	are	a	bit	expensive,	so	we’ve	driven	the	last	few	times..”	C392	Hard	to	be	punctual	for		appointment	 “C:	I	have	mixed	feelings	about	Sheffield.	It’s	essentially	a	day	out.	If	we’re	going	to	Sheffield,	it	takes	P	quite	a	long	time	to	get	her	sorted	out	in	the	morning..and	the	thoughts	of	setting	off	before	10	or	11	
are	out	unless	you	really	want	to	rush	yourself.	She	gets	upset,	
uptight	because	she	always	likes	to	be	punctual.	Punctuality	is	
something	we’ve	lost	recently	I	think....So	Sheffield	is	a	full	day.	And	
it’s	not	a	pleasant	run	and	it’s	not	a	pleasant	place.”	C172	Clinics	can	be	lengthy	 ““C:	Well	last	time	we	went	we	were	there	about	four	hours	before	we	got	in	because	it’s	always	busy	there	isn’t	it....	
C:	So	I	stopped	[going]	after	that.	We	were	there	quite	a	long	
time”P062																				
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	A5.6	Benefits	of	the	community	multidisciplinary	team.	Benefits	of	the	community	services	Home	visits	are	convenient	 “Q:	And	you’ve	been	quite	poorly	recently	and	had	a	few	things	changed...	how	has	that	been?		
P:	Not	too	much	of	a	problem;	you’ve	got	to	accept	where	you	are.	And	
basically	everybody	comes	here,	they’re	actually	coming	here	to	help	me,	
not	for	any	other	reason...	You	hear	about	all	these	problems	in	the	NHS;	to	
me	it	seemed	brilliant.”	P354	Allows	assessment	of	home	environment	
“There's	an	extremely	good	[local]	team	in	the	neuro	physiological	clinic.	
The	OT	came	to	see	me	at	home	very	soon	after	I	was	diagnosed,	and	
scouted	round	the	house	to	see	what	sort	of	the	place	we	lived	in....and	
made	it	perfectly	clear	that	if	the	stairs	became	too	much	I	should	get	on	to	
them	straight	away	and	they	would	get,	either	a	stair	lift	or	another	
handrail.		You	get	the	feeling	you	only	have	to	ask	and	somebody	will	do	
something	about	it.	Extremely	helpful.”	P166	Allows	assessment	of	physical	problems	
“Q:	What,	have	they	picked	up	anything	else	that	you’ve	found	helpful?		
C:	Well	[district	nurses]	was	the	main	thing,	cos	I	mean	when	I	used	to	do	it	
meself	I	didn’t	have		a	clue	what’s	going	off	because	I	don’t	know	what’s	
going	off	and	(laughs)	but	when	these	people	came	in	they	soon	tried	to	
say,	well	this	is	here,	that’s	there,	and	this	wants	seeing	to	or...		
Q:	So	they’ve	noticed	things	like	her	skin	and	her	bottom...”	P063	Communicating	in	convenient	ways		 “Q:	Does	she	get	support	from	anyone?	P:	Well,	we’ve	got	the	outreach	team,	and	[neurology	community	nurse]	is	really	good	and	[community	physio]	from	the	outreach	team.	They	are	always	sending	us	emails.”	P122	Accessible	 “If	I	wanted	her	to	come	out	she's	only	on	end	of	a	phone.”	P145	Rapid	response	 	“P:	Well	the	last	one	was	the	mattress...	one	came	and	was	fitted	but	we	
didn’t	know	what	to	expect	so	what	came	we	accepted,	but	I	then	got	sores	
in	me	back,	asked	[OT]	to	come	and	look,	as	soon	as	she	saw	it	she	rang	up	
and	ordered	a	different	one	and	it	came	that	day.		
C:	Later	that	day,	yeah,	she	rang	at	four	o’clock,	they	were	here	at	six	with	a	
different	one.		
P:	So	most	of	the	time	things	are	met	very	well.”	P137	Refer	to	local	services	 “Q:	You	mentioned	the	hospice,	that	she	goes	every	week	and	she	has	been	for	some	respite.	How	do	you	find	that	for	yourself?	
	C:	It’s	not	too	bad	really.	I	drop	her	off	at	half	ten	and	pick	her	up	at	three.	I	
just	do	a	few	jobs	around	here.”	P063	Prescriptions	 “C:	They’re	amazing.	[The]	community	matron;	she’ll	call	every	so	often,	if	I	
need	anything	I’ll	just	ring	her,	she’ll	provide	us	with	prescriptions”	P378	Provision	of	practical	solutions		 “And	the	specialist	nurse	with	the	[local]	practice	was	brilliant;	I've	got	the	blue	badge,	which	makes	a	terrific	difference.”	P166	Practical	equipment	is	important	 “Q:	If	we	were	to	give	you	say	£1	million	that	you	would	invest	in	helping	people	around	the	house	with	things,	the	problems	that	you	face,	what	do	you	think,	what	would	be	the	things	that	you	would...?		
C:	It'd	be	things	like	a	chair	and;	just	things	generally,	you	know,	it's,	just	
things	for	P,	make	things	a	bit	easier.”	P228	Right	equipment	 “The	CASS	team	referred	me	to	wheelchair	services	and	they	said,	we	think	you	need	a	[new]	wheelchair.			What	I	had,	they	said	wasn’t	very	adaptable	
for	future	usage,	so	they	said	we’ll	get	you	a	more	suitable	wheelchair...I’ve	
got	more	support	for	me	back...more	support	all	the	way	round”	P056	Right	time	 “In	fact	it’s	getting	solved	ahead	of	the	game	really,	that’s	why	I’ve	got	the	
wheelchair	guys	coming	shortly.”	P313			 	
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A5.7	Psychological	care	provided	by	the	community	team.	Psychological	care	Psychological	support	 “P:	She’s	very	good	for	gently	moving	you	to	the	next	stage	without	saying,	oh	you’re	gonna	be	crippled-up.			You’re	not	(...)	too	far	before	
it	(...)	so	let’s	have	a	look.	C	
:	She’s	looking	ahead	all	the	time	but	in	a,	in	a	good...		
P:	In	a	nice	way.”	P248	Providing	information		 “Q:	Do	you	get	most	of	your	information	from	[MND	community	nurse]	or	do	you	look	on	the	internet?		
C:	Most	through	[MND	community	nurse]”	P063	Helping	patients	accept	the	help	required	
“	P:	Well,	funnily	enough,	it	was	[OT]	from	the	outreach	team	who	
talked	me	into	a	mobility	scooter...	she	had	to	badger	me	for	about	
two	months”		P122	
“Q:	And	what;	do	you,	is	it	something	that	you	needed	a	bit	of	sort	of	
badgering	or	encouragement	to	do?		
C:	Definitely,	definitely,	yeah.	I	tend	to	be	a	puttter-offerer,	I	just	do	
and	I	say,	“oh	yeah,	well	thank	you,	we'll	have	a	think	about	it	and	I'll	
get	back	to	you”.	Say	if	it	was	[OT]	who	was	always,	you	know,	she's	
always	been	a	real	champion	for	us,	hasn't	she,	and......but,	yeah,	I	
would	always	put	it	off	until	there	comes	a	point	where	you	think:	
well	I	can't	put	that	off	any,	anymore	now.”	C409	Promotes	positive	outlook		 “It’s	not	like	going	to	a	physio	and	going	to	a	hospice...	you	go	in	there,	we	come	out,	and	we	have	a	laugh	and,	take	the	Mickey	out	of	each	other	...and	you	come	out	and	you	almost	feel	lifted	emotionally	
as	well	as;	so	it’s	really	good.”	P248	
“We	go	to	[local	hospital];	I've	got	a	really	good	physiotherapist,	
she's	great,	she's	really	positive.	Every	time	I	go	she's	"That's	great,	
yeah,	you	know,	you're	doing	really	good,	there's	no	changes,	your	
legs	are	still	strong"	which	is	great;	that	gives	you	a	bit	of	a	buzz.”	
P317	Promotes	quality	of	life	 “C:	The	work	that	they’ve	got	with	P	and	improved	his	mobility	and	improved	his	quality	of	life.	That’s	helped	us,	hasn’t	it?	It	got	you	
through	summers	with	the	garden,	when	we	went	on	holiday.	It	
meant	he	could	go	for	little	walks	along	the	beach	with	us.	It	just	
made	so	much	difference.”		P184	Promotes	self	efficacy	 “P:	Well	I’ve	had	both	support	from	you,	and,	to	be	honest,	the	physio	after	my	hip	operation	was	great.	She	was	very	positive.	You	know:	
“you	can	do	this”	Q:	So	building	your	confidence	and	things.”	P381	
“C:	At	one	time	he	did	have	a	choking	do	that	he	was	frightened	of	
anyway	(makes	gasping	sound)	and	couldn't	get	his	breath.	
...Although	I	didn't	panic	but	wasn't	sure	what	to	do,	because	the	
suction	machine	wasn't	helping,	wasn't	moving	it.	So	I	got	him	on	the	
nebuliser	and	the	breathing	machine	(laughs)	and	got	him	in	bed	
relaxing	and	eventually	it	came,	came	round.	I	did	ask	[community	
nurse]	what	should	I	do	in;	she	says	"Well	you	did	all	what	you	can	
do"	she	said	"if	you'd	have	sent	for	ambulance	they	would	have	only	
done	what	you	did,	cos	there's	nothing	else	they	could	have	done".		
Q:	Did	that	make	you	feel	a	bit	more	confident	to	do	that	or	a	bit	
more	worried?		
C:	Yeah,	well	a	bit	more	confident,	I	think,	that,	you	know...	But	he	
han't	had	one	as	bad	because	now,	I	suppose	now	that	you	know	
what	to	do	then	you	do	it	automatically.”	C366		
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	A5.8	The	care	coordination	provided	by	the	community	team.	Care	coordination	Community	team	liaises	with	with	hospital	MDT	
“She	usually	phones	me,	[community	nurse];	anyway,	she	phoned	
last	week	and	I	think	she’s	doing	now,	instead	of	her	phoning	me,	if	
I’m	worried	...	I	phone	her,	I	says	that’s	fine;	she's	gonna	let	doctors	
know	and	I	think	she’s	letting	them	know	at	hospital.	I	says	“Yeah,	
that’s	fine,	I’ll	phone	you	if	I	get	in	difficulty”	C228	Communication	between	teams	is	welcome	 “I’m	quite	surprised	that	you’re	all	in	communication	really.		I	didn’t	know	you	spoke	to	[OT],	[Physio],	and	I	didn’t	that	[GP]	and	you	and	the	hospital	were	quite	so	connected,	so	that	seemed	to	be	
a,	quite	a	positive	thing.”	P354	Hospital	can	be	a	backup	 “Q:	And	if	you	had	a	question	now	or	a	problem	what	do	you	do?	C:	Well	I	can	go	to	Jackie	Hill,	our	occupational	therapist	that,	who	
comes	out	to	see	us,	and	we’ve	got	her	email	and	we’ve	got	her	
phone	number;	so	like	[OT]	would	be	the	first	one,	or	if	not	
available	[Telehealth	Nurse]	at	the	Hallamshire.”	P062	Develops	a	good	relationship		 “But	I	really	felt	that,	you	know,	Sheffield	is	there	if	I	really	need	them,	but	on	the	other	hand	[local	team]	is	here.”	P166	Different	individuals	provide	regular	contact	
“The	[community]	team,	she	comes	once	a	month.	I’ve	got	the	
district	nurses	now	coming	once	a	month.	Dietician	comes	
probably	once	every	three	months.”	P056					 	
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A5.9	Participants	experiences	with	lack	of	care	coordination	in	community	MDT.	
Problems	with	the	community	MDT	Lack	of	care	coordination	Dealing	with	multiple	profess-ionals	
“Q:	You	told	me	a	bit	about	the,	the	difficulties	you’ve	had	getting	your	stair	lift.		
P:	Well	yeah,	because	that’s	outta	your	hands	because	it’s	controlled	by	
government	bodies,	it’s	not	controlled	by	you...They’ve	gone	through	four	
different	OTs	to	get	the	same	results.		
C:	Basically	they	should	go	out	with	a	dedicated	MND	team...”	P091	Staff	turnover/	unavailable	 “C:	We’ve	got	that	chair	done		Q:	In	the	bathroom?	Who	got	all	of	that	arranged	for	your?		C:	Its	[OT	from	the	council]		
Q:	Does	she	see	you	regularly?		
C:	She	had	a	baby.	I	think	she	is	back	in	December.	She	finished	in	March.	I	think	
she’ll	be	back	in	December.”	P063	
“Q:	How	do	you	find	having	different	people?		
P:	It’s	all	right.	You	get	to	know	one	person.	When	they	change	you	have	to	
start	again	but	it’s	not	a	big	problem.”	P145	Unsure	who	to	turn	to	 “Q:	Who’s	your	main	point	of	call?		C:	It	just	depends	on	what	problem	it	is,	if	it’s	a	nurses	problem	I’ll	get	hold	of	them,	if	it’s	something	bigger	I’ll…”		P063	
“Q:	So	you've	got	two	people	that	you	feel	you	can	call...?		
C:	That	I	feel	that	I	could	get	in	contact	with.	The	only	thing	I	bother	about	is	at	
what	stage	should	I	ring	for	a	doctor.”	C366	Dealing	with	unexpected	emergencies	out	of	hours	
“Q:	It	sounds	like	you	have	learnt	a	little	bit	more	about	these	things	that	are	
quite	complicated	[referring	to	caring	duties].		Do	you	think	it	would	have	been	
helpful	if	...other	carers	and	husbands	like	yourself	were	taught	about	this	sort	
of	thing	earlier	in	your,	the	course	of	the	illness	or...?		
C:	Yeah,	I	thought	meself	like,	but.	I	suppose	it’d	be	a	good	thing	for	anybody	
now	that.		But	things	are	clearing	up	now.	This	last	night	it	was	bothering	me	
like	that...	I	thought,	and	I	said	to	her:	“You	aren't	bloody	dying	are	yah?"	She	
were	like	funny	[looking	ill]...going	grey	and	funny,	and	I	thought,	then	I	looked	
and	her	eyes	were	looking	glazed,	and	I	thought	what	the	hell’s	going	off	here?	
So	I	phoned	[community	nurse].	”	C063	Needing	to	advocate	for	oneself	 “Q:	Are	there	any	problems	that	you’ve	had	that	you	struggled	to	get	resolved?	P:	Not	really	because	I’m	very	vocal,	I	have	no	problem	going	to	a	meeting,	so	if	we	have	a	problem	or	something	then	we’ll	go	down	to	our	local	[MP],	or	get	
onto	the	council	or	get	onto	MNDA.			I	have	no	problem	rattling	someone’s	pen,	
and	I’m	not	a	person	that	takes	no	for	an	answer...	But	not	everyone’s	like	that	
and	that’s	what	worries	me.”	P134	No	regular	meetings	 Q:	And	you	mentioned	that	you’d	seen	the	physio	in	December	and	then	you	hadn’t	for	a	while...		Do	you	think	you	should	have	been	seen	more	regularly...?	
C:	I	think	so...	I	know	they’re	busy,	but	like	since	the	last	time	P	was	seen	he	was	
left	to	get	on	to	a	new	set	of	exercises	with	no	backup.	Like	P	is	seen	sort	of	
every	three/four	months	at	the	clinic,	I	think	it	would	be	advisable	for	a	physio	
to	come	out	as	well	sort	of	every	three,	four,	five	months	just	to	make	sure	...	
everybody	is	up	to	speed	with	the	exercises...	if	there	is	any	problems	they	can	
be	ironed	out	when	they	come	out	to	check.”	C145	Not	interacting	with	each	other	
“Q:	Cos	they,	cos	they	each	have	their	own	little	environment	of	knowledge	and,	
and	ability	and	then,	in	a	practical	sense,	and	then...		
P:	And	being	the	patient	you	suddenly	got;	and	it's	amazing	how	many	people	
don't	even	know	other	people	in	the	system,	you	know;	I've	got	a	neuro	
casement	manager,	who's	been	great,	she's	helped	me	in	so	many	things,	but	
[PJS]	don't	know	her,	you	know,	it	(sighs)	I	don't	even	know	if	[Telehealth	
Nurse]	knows	her.	But	to	me	she's	been,	she's	a	nurse	by	background,	but	she's	
been	so	much	help	in	so	many	things.	But	I	find	the	fact	that	(interruption)	I	
find	that	she's	not	a	more	integral	part	of	the	MND	world	within	the	hospital	
fascinating.”	P047		
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A5.10	Participants’	experienced	problems	with	community	MDT	due	to	lack	of	expert	staff	
Problems	with	the	community	MDT	Lack	of	expertise	Staff’s	expertise	may	be	limited	
“I've	also	got	the	nurse,	once	a	month,	so	again	I	could	ask	her	advice,	
cos	I	know	that	she's	skilled	in	knowledge	of	MND,	she	just	isn't	up	to	
speed	with	things	that	you	can	do	holistically	or	positive	things,	looking	
at	the	internet,	things	like	that.	”	P317	Staff	unskilled	 “When	the	PEG	nurse	came;	[the	tube]	has	to	be	split,	pulled	out	and	moved...		
He	has	to	twist	it	round	once	a	day.	You've	got	to	split	the	actual	pin,	
and	I	couldn't	do	that,	I	couldn't,	cos	you	have	to	like	squeeze	and	twist	
and	(laughs)	and	I	couldn't	do	it.	So	the	[PEG	nurse]	says	"Well	I'll	get	
the	district	nurse	to	come	and	do	it".	So	the	district	nurse	comes	every	
fortnight	and	does	it,	but	(laughs)	but	when	they	come	they	don't	
always	know	how	to	do	it.	
Q:	Right.	You're	telling	them	what	to	do?		
C:	I'm	telling	them	what	to	do,	although	I	can't	do	it.	If	they	can't	do	it	
they've	sent	somebody	else	to	come	and	do	it	(laughs)	which	is	all	a	bit	
stressful.		When	you	send	for	district	nurse,	she	had	to	come	and	do	
something	and	then	they	don't	know	how	to	do	it.”	C366	
“P:	Oh,	well	that'll	be	it	then,	cos	she	said	my	name	had	come	up	at	a	
meeting	so	they	thought	they’d	come	and	see	me	and;	so	I	said	"Oh	
that's	fine,	OK,	fair	enough".	And,	and	we	said,	I	said	to	her	“What	do	
you	know	about	MND?”	She	said	"Don't	know	anything.””	P380	Bad	experience	at	diagnosis	makes	later	care	harder		
“I	think	the	worst	part	for	me	and	my	husband	was	the	delivery	of	the	
diagnosis,	to	be	honest	with	you,	it	was	very,	it	was,	it	was	done	in	a	very	
negative	manner.”	P317	
Therapists	discharging	patients	making	them	less	accessible	
“	Well	C’s	been	on	at	me	for	a	while	to	see	physio	again,	I	haven’t	seen	
anybody	since	December,	which	is	down	to	me	...	it’s	not	down	to	them,	
they	just	said	give	us	a	ring	when	you	need	us.	So	I	rang	up	...	the	lady	
said	“Well	you	have	to	be	referred	through	your	doctor.”	I	said	“Well	I’ve	
never	had	to	do	that	before”		She	said	“Well	no,	it’s	changed	now,	you	
have	to	be	referred	back	through	your	doctor.””	P145	Carers	not	considered	 “I	think	the	hardest	thing	is	that	you	become...[like]	another	piece	of	the	person’s	equipment.	I	had	a	bit	of	a	to	do	with	the	lady	that	came	to	the	house	from	the	council	who	came	for	a	financial	assessment	or	
something.	She	sat	with	her	back	to	me	talking	to	P	and	I	needed	to	
provide	some	information…	she	was	quite	rude,	and…	she	was	being	
very	hostile	and	I	said;	“I’m	just	asking	a	question.”	I	understand,	it’s	
about	P,	but	the	question	she	was	asking	he	wouldn’t	know	the	answer	
to	anyway.	And,	it	was	a	little	bit	of	a	situation.	I	said	to	[community	
MND	worker]	who	came	later	on:	“I	just	felt	like	a	piece	of	P’s	
equipment:	there	to	fetch	and	carry	and	provide”.	You	become	a	bit	of	a	
non-person	because	the	concentration	is	on	the	person	who	is	diagnosed	
with	MND,	and	rightly	so,	but	then	if	affects	the	partner	in….	it	affects	
them	as	well,	but	they	don’t	suffer	the	symptoms.”	C122		 	
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A5.11	Participants’	positive	experiences	of	general	practice.	
Good	experiences	of	GP	Good	knowledge	of	MND		 “Dr	[GP],	the	previous	one	was	fantastic	GP	and	he	had	a	little	bit	of	knowledge	about	the	disease	as	well.”	P056	“I	suppose	some	doctors	are	totally	clueless	about	the	condition	
and	others	are	quite,	her	doctors	isn’t	that	bad.	She’s	quite	a	
switched	on	lass.		
P:	When	I	first	went,	she	knew	what	was	wrong	with	me.		
Q:	You	think	she	knew	what	was	wrong	when	you	first	went.”	
P172	Accessible	 “I	know	if	I	need...	to	see	her	she’ll	just	come	out	now.”	P056	“I	am	lucky	over	here.	Whenever	C	rings	up	for	an	appointment,	
they	normally	slot	me	in	somewhere	the	same	day	–	which	is	
exceptionally	kind.”	P229	Seeing	patients	regularly	 “The	previous	one	was	a	fantastic	GP	and	he	had	a	little	bit	of	knowledge	about	the	disease..	he	kept	saying	I’ll	see	you	in	three	months,	just	to	keep,	see	how	you’re	doing.”	P056	Knows	the	family	 “P:	Sometimes	I	have	to	wait	for	an	appointment	but	I	always	see	the	same	doctor	every	time	...	he	knows	me	and	he	knows	the	
family.	Well	my	mum	only	died	two	and	a	half	years	ago	and	he	
visits	and	I’d	only	to	ring	up	and	he	was	there	wasn’t	he?	Knows	
my	daughters,	who	looks	after	me,	knows	my	background,	knows	
what’s	going	on.”	P217	Takes	an	interest	 “Q:	If	you	were	going	to	give	advice	to	a	new	nurse	or	a	new	GP	who’s	got	a	patient	for	the	first	time	with	MND,	is	there	any	advice	
that	you’d	give	them,	from	your	experience?		
P:	...to	listen	more	than	anything,	just	to	perhaps	like	my	GP’s	
done:	get	in	touch	with	me	a	bit	and	say:	“make	an	appointment	
every	four	weeks,	come	and	see	me,	see	how	things	are	going.”	Just	
to	be	involved	with	that	person,	keep	up-to-date,	so	you	know	that	
you	kind	of	know	that	they’re	there	in	case	you	do	need	anything.”	
P423	Prioritises	patients	with	MND		
“We	got	a	letter	from	[GP]	saying	that	because	of	the	illness	I’d	got	
I	would	be	put	on	the	priority	list	...	and	since	then	everything’s	
been	pretty	good;	if	I’ve	needed	to	ring	the	doctor	then	this	gives	
you,	if	they	want	a	doctor	to	come	out	to	see	you	they	will	come	
and	see	you...I	think	the	reassuring	thing	for	me	is	the	fact	that	I	
can	ring	up	and	know	that	I’m	gonna	see	the	doctor	within,	if	not	
that	day	the	next	day...even	with	C,	which	is	more,	even	more	
reassuring	for	her,	that	if	I	was	taken	poorly	here	the	doctor	
would	be	here...it’s	reassuring	for	us,	and	hopefully	we’ll	never	
need	it,	but	it’s	nice	to	know	it’s	there.”	P248	GP	can	be	main	point	of	contact	
Q:	Who’s	your	first	point	of	call	if,	if	you	can’t	sort	something	out	
yourself	?		
P:	Probably	GP	or	me	mum.	(laughs)		
Q:	Yeah.	And	you	say	you’ve	got	a	good	relationship	with	your	GP,	
that’s,	that’s	right,	isn’t	it?		
P:	Yeah.	I’ve	not	seen	him	for	a	while	but	I’ve	not	needed	to,	but	
he’s	generally	OK,	yeah,	he’s	a	good	guy.”	P423.	
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	A5.12	Participants	bad	experiences	of	GP	
Bad	experiences	of	GP	Showing	no	interest	 “Q:	How	have	you	found	your	GP	through	all	of	this?		P:	Useless.		
C:	He’s	never	ever	contacted	us	at	all...	He’s	never	seen	him;	he	just	goes	for	his	
blood	tests	and	that’s	it.		
P:	But	all	the	blood	tests	I	arrange,	in	fact	the	first	three	the	nurse	said	“Why	
have	you	come?”		
C:	I	mean	you	don’t	expect	him	to	be	ringing	every	five	minutes,	I	understand	
that,	but	if	he	gets	a	letter	to	say	that,	I	mean	he	can’t	have	that	many	patients	
with	that.”	P381	No	meetings	arranged	 “P:	Can	I	just	tell	you	something,	interrupt	about	that?	Since	I’ve	been	diagnosed	with	motor	neurone	disease	I	have	never	seen	my	doctor	about	it	or	anything	related	to	it.	Not	that	I’ve	requested	to,	to	be	honest.”	P184	No	knowledge	of	MND	 “P:	I	don't	think	GPs,	I	don't	think	the	GPs	know,	I,	I	don't	think	they're	clued	up	as...	C:	No.	P:	...as,	as	what,	as	what	they	can,	what	they	could	be.	Cos	again,	going	back	again,	that	first	doctor	I	saw	just	said	it	were	sciatica.”	P&C145	Never	met	before		 “P:	Well	it’s	in,	this	in	the	fortunate	position	where	I	was	never	ill,	then,	then	I’m	getting	it	all	at	once	now	I	think,	but,	aren’t	I?”	P248	Not	seen	routinely	as	not	seen	to	be	unwell	
“Q:	And	since	the	diagnosis	do	you	have	much	contact	that	way?	P:	No.	I’m	not	
poorly.	I’ve	been	once,	two	or	three	times	since	2004.”	P172	
“Q:	So	do	you	have	a	relationship	with	your	own	GP?	A:	Yeah,	my	own	GP's	a,	a	
very	nice	lady	but	I,	I	don't	go	to	see	her	because	I'm	not	unwell.”	P317	No	regular	visits	for	MND	needed	
“With	my	local	GP,	I	tend	not	to	visit	much	with	MND	related	issues	although	in	
truth,	I	haven’t	had	many	problems	that	couldn’t	be	resolved	or	talked	through	
at	Sheffield	or	with	the	community	team.	But,	nonetheless,	I	know	that	you	do	
keep	her	updated	with	my	progress	because	she	will	chat	about	that	when	I	see	
her.”	P229	
“P:	Well	I	think	from	the	GP	point	I	would	like	at	least	once	for	them	to	contact	
me.	I	appreciate	they’re	busy	but	I	think	long-term	probably	save	time	if	they	
spoke	to	me	once.	“	P381	Appoint-ments	hard	to	access	 “It's	taken	a	week	to	get	in	to	see	the	doctor.	If	it	were,	like	you	were	an	emergency	I	think	you'd	get	one	a	bit	sooner,	but	basic,	basic	appointment		it's	took	seven	days,	just	to	go	in	and	see	a	doctor.”	C145	
“We’ve	got	a	phone	appointment	on	Wednesday	cos	we	couldn’t	get	an	
appointment	to	get	a	sick	note,	so	I’m	just	hoping	that	he	will	issue	a	sick	note	
over	the	phone.	I	couldn’t	get	an	appointment	with	[GP].	In	this	day	and	age,	
when	somebody’s	got	MND	you	would	think	it	would	flash	up	on	the	GP’s	
computer:	this	man	needs	an	appointment...It’s	a	horrendous	diagnosis	then	
not	to	be	able	to	get	an	appointment	at	the	bloody	GPs.”C392	
“C:	I	think	we’ve	just	got	to,	you	know,	be	quite	forceful	when	we	ring	up	for	
appointments…	
P:	The	front	desk	at	doctors	are	legendary	aren’t	they?	A	big	barrier.”	P392	Poor	access	for	carers		 “C:	Yes.	He	can	ring	up	and	speak	to	GP	over	phone,	I’ve	gotta	make	an	appointment	to	see	him,	and	then	when	I	go	see	him	it’s	all	in	my	head.”	P091	Not	wanting	to	bother	GP	 “You	don’t	like	making	an	nuisance	of	the	GP,	normal	people	don’t	make	a	nuisance	at	the	GP	do	they?”	C392	GP	not	point	of	contact	in		an	emergency	
“C:	Well	I	think	until	there’s	an	emergency,	you	know,	that	we	need	to;	but	then	
again	would	we	go	to	the	doctor?	I	don’t	think	we	would,	I,	I	don’t	think	we	
would	because	you	feel	as	though	they	haven’t,	as	I	say,	our	first	thing	is	to	
come	to	you	which	I	suppose	that	you’re	more,	you	are	specialists	and	
everything,	but	I	don’t	think	the	doctors	would,	I	don’t	know.”	C381	Will	need	to	rely	on	them	 “No	contact	with	the	GPs.	Never	ever	had	contact	in	all	the	two	years	he’s	been	diagnosed.	So	you’ve	got	no	confidence.	Eventually	I	know	that	we	both	are	going	to	be	reliant	on	our	GP	at	some	stage.	We	are	going	to	need	our	GP,	
aren’t	we?	And	we’ve	no	confidence	at	this	moment	in	time”	C184	
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A5.13	The	value	of	regular	contact	with	specialist	services.	
The	value	of	regular	contact	with	specialist	services	Patients	want	regular	contact		 “[referring	to	a	drug	trial]	It	was	good	because,	it	meant	I	was	going	to	the	clinic	every	month...	there	was	more	involvement.	They	took	blood	every	
month.	I	did	the	puff	test...	ECG...	weight.	...Maybe	it	was	that	that	made	you	
feel	better.	Maybe	you	knew	that	they	were	hands	on,	that	they	were	doing	
their	best	to	see	if	they	could	sort	out	or	resolve	any	issues	...It	was	quite	
interesting.	I	quite	enjoyed	it,	in	that	perverse	sort	of	way.”	P122	Reassurance	when	faced	with	unfamiliar	problems	
“I	could	have	camped	in	[MND	Consultant]'s	house	for	the	first	six	months,	
just	so	she	was	there,	so	I	could	say:	but	what	about	this?	What	about	that?	
You	imagine	symptoms,	or	I	did,	you	think:	God,	this	is	happening	and	that	
must	be	related	to	the	MND...	and	what	does	this	mean?		I	settled	down,	at	
some	point...to	pretty	much	know	what's	MND	related	and	what's	not.”P046	Reliable	regular	contact		 “I	just	think	when	P	was	diagnosed	that	everybody	came	to	see	us	and	then	everybody’s	left	us,	apart	from	the	clinic...	at	first	I	found	it	a	bit	strange	
that	we	were	just	left	to	get	on	with	things...	I	think	a	little	more	backup	
from	the	physio,	I	think	that	would	help	everybody;	it’d	put	my	mind	at	rest,	
and	it	would	also	give	the	person	suffering	a	bit	more	backup:	I	am	doing	it	
right,	and	it	probably	gives	them	a	bit	more	confidence	in	themselves.”	C145	Builds	personal	relationships		 “Q:	And	you	mentioned	seeing	patients	in	clinic	when	you	came.	What	are	you	feelings	about	coming	to	clinic,	in	general?		P:	It’s	always	beneficial.	It	means	I	can	meet	people	like	[nurse].	I’ve	known	
[nurse]	ever	since	I’ve	started	coming	to	clinic	and,	I	count	of	her	more	as	a	
friend	now	than	a	nurse...	Even	if	it’s	only	just	to	have	a	chat.	People	say,	
“How	are	you	getting	on?	You	are	doing	alright.	We’ll	have	a	laugh.”	P122	Offers	support	even	if	patients	reticent	to	ask		 “I	know	P	is	not	a	one	to	phone	up	and	say,	can	you	come?	I	have	to	keep	pecking	his	head	until	he’s	fed	up	...	and	then	he’ll	go	“I’ll	do	it.”	C145	“I	know	they’re	a	phone	call	away	but	I’m	not	that	sort	of	person...	I’m	
happy	not	to	do	anything,	I	don’t	want	to	do	anything.	I	don’t	want	to;	I	
think	I’m	just	plodding	on,	to	be	honest	with	yah.”	P321	Keeping	in	touch	 “Because	it’s	slow	with	P	and	he	doesn’t	need	as	much	attention	and	care,	it’s	easy	to	feel	detached	from	any	positive	interaction.		Whereas	with	[the	
TiM],	somebody’s	there	and	if	there	was	something	you’d	pick	up	quite	
quickly	as	apposed	to,	you’ve	gotta	wait	until	your	next	12	week	
appointment.”	C122	
Regular	monitoring	Regular	monitoring	of	progress	is	reassuring	
“Like	with	P’s	breathing	tests	or	his	muscle	strength	tests,	and	the	questions	that	
they	ask,	it's	nice	to	know	the	scores.		Yes	P	is	getting	worse	but	only	smidgens	
at	a	time....It's	nice,	to	be	able	to	get	that	input	straight	away.”	C145	
“They’re	not	that	great	in	[local	hospital]	because	they	sit	back	because	I	go	to	
Sheffield.You	do	all	the	tests,	the	blowing	machine…so	I	know[how	I’m	
doing].”P172	Physical	monitoring		 “I	used	to	see	[MND	neurologist]	first,	and	then	I	used	to	come	out	and	then	they	used	to	weigh	me	and	do	me	breathing	tests	and	do	the	physio.”	P145	Assessment	of	progress	 “With	a	Sheffield	neurologist,	we	need	to	give	an	honest	evaluation	about	any	developments/	deterioration”	P229	Respiratory	monitoring	most	important	
Q:	What	are	the	things	that	you	think	are	the	most	important	about	coming	to	
clinic?		
P:	For	me	the	most	important	thing	for	me	going	is	when	they	check	my	
breathing.	I	like	to	know	whether	me	breathing	is	getting	any	worse.	“	P145	Respiratory	monitoring	is	objective		 “The	breathing.		That’s	gone	down.	I	can’t	remember	what	it	was	last	time.	...62	or	59	or	something.	So	that’s	dropped	from;	I	mean	the	first	one	I	ever	did	was	111,	so	that’s	just	over	half	from	where	we	were.”	P248	MND	team	can	anticipate	problems	
C:	Yeah.	And	me	daughter,	she	rang	[MND	nurse]	up	(laughs)	and	said:	"It's	
time	he	got	this	PEG	in.”	
Q:What	did	[MND	nurse]	say;	had	she	already	started	planning	it	or..?		
C:	Well	they	had,	thought	about	it,	and	they	were	very	good	because	she	got	
him	in	quite	quickly.	C366	
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	A5.14	The	information	needs	of	those	with	MND.	
Information	needs		Little	prior	knowledge	of	MND	 “To	be	honest	I	didn’t	know	a	lot	about	MND	at	the	time.	I’d	never	given	it	a	second	thought.	So,	I’m	a	very	positive	person,	generally	speaking.	So,	really,	when	she	told	me	she	said	“It’s	bad	news”	and	I	said	well…	I	
didn’t	know	enough,	I	had	to	come	home	and	Google	it	to	find	out	what	
it’s	all	about.”	P122	No	experience	of	support	services	 “Cos	we’re	in	blind	here,	we	don’t	know...	it’s	all	new	[to	us]”	C423	Negative	attitude	to	MND	 “Q:	Had	you	heard	anything	about	PLS,	MND,	before	you’d	been	to	that	clinic?	
P:	MND:	frightening.”	P217	Patients	felt	alone	after	diagnosis	 “After	we	were	given	the	news,	we	were	just	really	left	to	go	home;	there	was	no	counselling…	I	think	it	took	us	about	three	weeks	to	actually	pull	ourselves	together;	during	that	time	nobody	had	contacted	us”	C317	Once	MDT	involved	patients	felt	supported	 “People	just	came	out	of	the	woodwork	when	I	was	first	diagnosed”	P134	The	involvement	of	the	MDT	could	be	overwhelming	 “	When	you	are	first	diagnosed	you	are	emotional.	.	But	once	you	are	diagnosed	everything	happens:	OT,	physio,	dietician,	all	at	once.	It’s	nice	because	it	feels	like	you	are	being	looked	after.	But	on	the	other	side	
there	were	talking	about	things	I	wasn’t	really	aware	of	and	asking	me	
questions	too	early	to	ask.”	P172	Patients	had	unmet	information	needs	at	diagnosis	that	needed	to	be	addressed	immediately	
“Q:	What	kind	of	information	do	you	find	helpful?	
P:	Not	so	much	now,	because	everything’s	more	or	less	sorted	out,	but	
when,	when,	obviously	when	I	was	first	diagnosed,	just	like	the	benefits	
system	and	everything	like	that”	P145	
“C:	The	immediate	thing	was	to	get	the	Careline	set	up…and	get	[P]	up	
and	downstairs	safely.”	C062	
“...	nobody	told	me	was	you	have	to	tell	DVLA;	so	without	reading	the	
MND	thing	I	wouldn’t	have	done	that.”	P381	Information	could	be	very	complex	 “Q:	And	how,	so	how	did	you	go	about	finding	out	what	sort	of	things	you	might	be	entitled	to?	
C:	We	are	still	not	a	hundred	percent	sure,	to	be	honest,	cos	it’s	very,	very	
complicated.”	C392	Emotions	around	the	time	of	diagnosis	make	information	seeking	very	difficult	
“I	came	out	[the]	surgery	in	a	flat	spin.	It	was	a	real	shock.	For	two	
weeks,	I	didn’t	sleep...	lost	my	appetite,	became	really	anxious.	I	visited	
the	...	GP	twice	because	I	was	hyper	ventilating.	It	was	all	a	result	of	the	
shock.”	P229	
“I	went	online	...	but	it	frightened	me	a	bit	to	read	about	it,	so...I	stopped	
doing	it,	to	be	honest...	it	were	upsetting.	So,	I’ve	learnt	about	it	just	
through	hospital	and	things	like	that...”	P172	Denial	stopped	some	seeking	information	 “In	the	early	stages	of	diagnosis	we	were	in	denial:	[MND	consultant]	had	it	wrong	for	me	as	far	as	I	was	concerned”	P134	“But	at	beginning	...we	didn’t	want	it.”	C228	Learning	about	MND	could	be	a	positive	experience	
“We	just	have	it	in	the	back	of	our	mind	that	we’ve	got	a	long	time	left	
together	now,	but	we	didn’t	think...	that	last	June.		We	were	thinking	that	
was	it	more	or	less...	but	the	more	we’ve	learnt	ourselves	and	the	
progress	that	I’m	making,	I	think	that’s	given	us	renewed	hope.”	C317	Information	can	be	empowering	 “what	[MND	neurologist]	and	her	team	have	said,	I	didn’t	find	them	gloom	merchants,	they	were	very	positive	in	their	approach	and	in	their	
opinions	and	their	comments”	C229	
“I	personally	felt	quite	philosophical	about	it.	I	was	just	strangely	
relieved	that	I	knew	what	I	was	dealing	with.	I	just	thought	it	was	Gods	
will	and	I	knew	that,	once	diagnosed,	the	MND	family	would	wrap	its	
arms	around	me	(and	they	have!)”	C229	
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A5.15	Sources	of	information	about	MND.	
Sources	of	information	Community	MDT	 Q:	Do	you	get	most	of	your	information	from	[MND	community	
nurse]	or	do	you	look	on	the	internet?	
C:	Most	through	[MND	community	nurse]	C063	
“[Community	Nurse]	talked	to	us	for	quite	a	while	immediately	
after	we	got	the	diagnosis.”P360	Hospital	MDT	 “[MND	consultant]	was	very	good	on	putting	us	in	touch	with	
[MND	nurse]	and	so	putting	us	in	the,	in	the	loop,	I	think.”	P134	Hospital	MND	clinic	 “I’ve	learnt	about	it	just	through,	through	hospital	and	things	like	that...”	P145	MND	Association	visitor	 “And	[MNDA	visitor]	and	through	MNDA”	P145	Written	information	 “P:	We	got	a	book	from	Waterstones.	(laughs)	Q:	And,	and	how	did	you	know	about	the	book?	
P:	Because	the	specialist	nurse	mentioned	there	was	a	book.”	
P166	Internet	peer	support		 “I	think	I	was	more	concerned	with	P	on,	on	the,	on	the	web	because	I	was	concerned	about	her	morale.	In	actual	fact	that,	I	
think	that	was	unfounded	because,	of	course,	P’s	gained	an	awful	
lot	of	comfort	from	talking	on	the	web	with	other	patients	and	
getting	their	reactions.”	C229	Some	patients	can’t/don’t	want	to	access	MNDA	and	therefore	rely	on	statutory	services	
“Q:	And	have	you	had	any	contact	with	the	Motor	Neurone	
Disease	Association?	
C:	No...	I’m	not	very	computer	literate	and	...	I	really	don’t	know	
how	to	go	about	it,	and	I	don’t	really	want	to	be	talking	to	other	
people	about	their	illnesses,	if	I’m	being	honest,	...	I	feel	that	I	
know	enough	about	it..	I	don’t	really	want	to,	cos	I	know	that	
would	be	like	...your	worst	nightmare,	wouldn’t	it,	talking	to	
other	people	about	their	illnesses...”	C392				 	
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A5.16	Participants’	experiences	of	information	about	MND	available	on	the	internet.	
Experience	of	information	about	MND	on	the	internet	Internet	information	could	be	upsetting	
“I	don’t	really	go	online	and	research	...cos	I	find	it	quite	
upsetting.”	P145	
“...	you	go	on	some	of	the	sites	and	it’s	always	the	worst	scenario,	
...	and	you	start	reading	it	and	you’re	thinking:	oh	my	God,	I	don’t	
want,	I	can’t	be	doing	with	this.		So	I	didn’t.”	C248	Patients	have	to	desensitize	themselves	to	the	distress	of	reading	about	MND	
“I	had	to	sort	of	desensitise	myself.”	P172	
“	Oh	I	do	now.	Once	it	got	going	a	bit,	I	know	what	sort	of	
things	are	involved	then	I	started	to	go.	I	read	half	an	hour,	
cry,	give	up.	But	now	I	can	read	it	and	it	doesn’t	really	
bother	me.	So	I	go	on	the	MNDA	site,	on	the	forum,	
everything	day	and	read	what	everybody	else	has	put.	So	I	
think	I’ve	become	interested.”	P172	Info	from	MND	Association	could	be	distressing	
“Well	it’s	interesting...	to	read	about	other	people’s	reports	on	
how	they	tackle	it...	and	some	[is]	distressing	...	and	being	so	
young	is	quite	distressing.	C062	Info	from	MND	Association	could	be	helpful	 “I	like	the	MND	website	because	you’ve	got	the	different	things	to	look	at	and	you	can	look	at	them	when	you	want	to,	like	the	end	of	life	care	and	end	of	life	decisions,	and	they’re	not	just	there	in	
your	face	after	some	other	part	of	information	as	well”	P408	Clinicians	had	a	negative	attitude	to	the	internet	 “I	remember	when	...I	was	first	diagnosed...[MND	consultant]	said	“...don’t	go	home	and	turn	the	internet	on	because	...you’ll	just	crumble	in	a	heap	when	you’ve	read	it,	so	forget	it.”	And	so...	I	
never	have	done,	I’ve	just	looked	up	things	that	I’ve	needed	to	
know.”	P248	
“And	they	said	to	me:	“Don’t	got	on	the	internet.”	So	I	didn’t.	So	I	
had	no	idea,	really.”	P172	Needing	to	be	ready	to	learn	 “I	suppose	if	I	read,	“You’ve	got	an	illness	that	might	go	up	and	down,	but	you	might	not	die	next	year”,	that	would	have	been	
nice,	but	I	don’t	think	there	would	have	been	because	I	wasn’t	
ready	to	know.”	P172	The	internet	fills	the	void	when	little	knowledge	given	
“P:	When	we	went	to	see	...[MND	consultant]	a	couple	of	months	
later	and	she	said,	don’t	go	looking	on	the	internet	any	more...	
P:	...and	that	was	fine	but	when	you’re	on	your	own	in	the	first	
stages	that	is	what	you	do.”	P380	Some	wanted	to	research	everything	 “So	I	then	went	home	and	with	the	use	of	the	internet	researched	everything	I	could	find	about	the	disease”	P232								 	
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A5.17	Participants	attitudes	towards	the	frequency	of	TiM	sessions.	
TiM	session	frequency	Weekly	sessions	acceptable	 “Maybe	once	or	twice	a	week	would	be	enough.”	
C063	(Frequent	user)	Weekly	sessions	make	it	part	of	routine	 “I’ll	keep	it	to	Tuesday	and	do	it	every	Tuesday	while	I’m	working	at	home	and	I’ll	have	peace	and	
quiet.”	P122	(Excellent	user)	
“I	was	quite	happy	using	it	weekly,	cos	things	can	
change	so	quickly…I'm	a	terrible,	I'd	forget	when	
I'd	done	it	the	last	time	and	…	doing	it	maybe	on	
the	thirtieth	of	every	month,	I'd	forget…”	C392	
(excellent	user)	Varying	frequency	according	to	speed	of	progression	 “Q:	How	often	do	you	think	you’d	need	to	do	it	to	make	it	worthwhile…?	P:	Probably	every	month.	
Q:	…and	if	things	changed	how	would	you	then	
approach	it,	would	you	go	back	and	do	it	again	or	
would	you	wait	for	the	month…?	
P:	If	things	were	changing	quicker	I’d	go	back	in	
and	do	it	again…”	P423	(Excellent	user)	Carers	may	do	it	less	often	 “Maybe	carers	don't	need	to	do	it	quite	as	often	but	
…	maybe	you	would	ask	people	how	often	they	
wanted	to	do	it	and	maybe	they	would	start	at	once	
a	month	and	then	as	things	progressed	they	did	it	a	
bit	more	often”	C378	(control)					 	
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A5.18	Reasons	for	frequent	and	infrequent	adherence	to	TiM	identified	during	the	interviews.		
Reasons	for	missing	individual	sessions	Forgetting	to	use	the	TiM	 “I	can’t	stand	on	my	own	so	C	has	to	bring	it	in	
here	because	I	don’t	like	to	do	it	when	he’s	
working.		So	then	I	forget.”	P172	(Infrequent	
user)	Patient	and	carer	not	doing	it	together		 “I’ll	do	it	and	just	leave	it	on	the	arm	of	the	chair	or	something	and	say,	“You	need	to	do	it”.		I	don’t	
know	if	she	has	on	not.”	P122	(Excellent	user)	Holidays		 “Oh	dead	easy;	I	know	we	do	miss	some	weeks,	
but	we've	been,	you	know,	if	we,	if	we're	away	
and	we	don't	take	it	with	us,	we	leave	it	here.”	
P317	(Infrequent	user)	Acute	illness	 “We	just	didn't	do	it,	he	weren't	fit	enough	to	do	
it.”	C228	(Frequent	user)	
“…when	he	was	not	very	well	he	just	couldn't	be	
bothered.”	C366	(Excellent	user)	Technical	difficulties	 See	Table	6.1	&	6.2	
Reasons	for	infrequent	adherence	Poor	health	state	at	the	start	of	the	study	 Reported	in	field	notes	made	during	calls	with	relatives.	Being	too	busy	/	having	other	priorities		 “It's	just,	with,	with	all	the	renovations	and	stuff	it's	sort	of	not	become	a	priority	at	the	
moment.”	P134	(Infrequent	user)	Not	receiving	feedback	and	becoming	demoralized	with	the	TiM	system	 “I	have	not	received	any	feedback	/	contact	from	the	STH	MND	team	while	using	the	TiM”	P047	No	current	need	for	MND	services	so	not	seeing	a	benefit	of	TiM	to	their	care	 “Well	there'd	be	no	point,	would	there?”		P317	(Infrequent	user)	Unable	to	access	the	TiM	tablet	out	without	assistance		 “I	can’t	stand	on	my	own	so	C	has	to	bring	it	in	here	because	I	don’t	like	to	do	it	when	he’s	
working.		So	then	I	forget.”	P172	(Infrequent	
user)	
Facilitators	of	frequent	adherence	Using	TiM	on	the	same	day	each	week	 “We	always,	always	remember	that	it's	on	a	
Thursday.”	P392	(Excellent	user)	Phone	alarm	reminders	 “Q:	If	it	sends	you	an	alarm	reminder,	would	
that	be	an	annoyance...?	
P:	No,	it	would	probably	be	more	of	a	trigger	for	
me	to	do	it”	P134	(Infrequent	user)	Family	members	reminding	them	 “Our	grand	daughter	rings	us	at	about	7	o’clock	
to	remind	us.	Then	we	finish	up	doing	it	on	a	
Thursday	morning.”	P217		(Frequent	user)	Being	able	to	use	TiM	on	their	own	device	 “If	it	worked	on	my	phone	there	would	be	no	issue	whatsoever,	cos	I	do	everything	on	there;	I	
shop…	I	can	control	lights,	heating,	everything	
on	the	phone.	I	think	if	TiM	worked	on	there	then	
you	would	get	your	responses	every	week.”	P134	
(Infrequent	user)		
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A5.19	Participants’	initial	impressions	of	using	the	TiM	app.	
Initial	use	of	the	app	Easy	to	use	 “It's	so	easy	to	do;	it	literally	takes	five	minutes	from	home.”	P317	
[daily	technology	user]	Quick	to	use	 “It’s	not	a	problem	is	it?	It	takes	minutes,	it’s	not	like	you	have	to	sit	
there	for	half	a	day	and	do	it,	it	literally,	it’s,	it’s	sort	of	minutes.”	
P248	[daily	technology	user]	TiM	accessible	and	acceptable	to	the	elderly	 “So	this	lady	[P217],	she’s	an	elderly	lady	who	you	thought	wouldn’t	have	embraced	anything	like	this.		But	she	has	done	and	she,	her	and	her	husband	both	send	it	back;	she’s	very	disabled	but	able	to	
use	her	hands	quite	well…they’re	both	in	their	eighties;	and	she’s	a	
very	good	replier,	sends	it	in.”	Telehealth	nurse	TiM	accessible	to	those	with	significant	disabilities		
“[There	are]	some	are	patients	that,	I’m	surprised	they	took	it	up.	
I’m	surprised;	actually	that,	that,	I	never	thought	that	he	would	use	
that…	and	he	sends	his	back	very,	very	well.”	Telehealth	nurse	Confidence	the	information	would	be	held	securely	
“I’m	assuming	that	your	department	is	one	that’s	reasonably	secure	
and	has	got	reasonable	standards…	I	can	only	make	my	judgement	
on	the	people	I	meet	who	are	involved	in	it.”	C166			 	
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A5.20	The	characteristics	of	those	lacking	confidence	in	technology	user	and	their	approach	to	using	technology.	
Characteristics	of	those	with	low	technology	confidence	Unsure	if	they	would	be	able	to	use	the	TiM	 “…we’re	quite	happy	to	deal	with	it,	as	long	as	it	wasn’t	too	techy”		C062	[uses	technology	a	few	times	a	week]	“…as	long	as	I	can	do	it”	P392	[uses	technology	daily]	Lack	of	experience	using	technology		 “I	don’t	use	the	internet	for	my	job	and	it’s	all	still	paperwork	orientated”	C395	[uses	technology	daily]	Difficulties	with	language	 “C:	It’s	the	system	that’s	all.	I	don’t	catch	on	very	well	with	it,	that’s	ok.	Like	phones,	I	don’t	bother	them	really.	
P:	Couldn’t	read	a	text	message.	
C:		couldn’t	do	anything	like	that.”	C217	[never	uses	technology]	Frightened	they	might	make	the	TiM	go	wrong	 “Q:	Have	you	used	any	of	the	other	things	that	are	on	the	tablet,	so	the	education	things	or	the	website?	P:	Oh	I	daren’t	touch	all	that	stuff		in	case	it	goes	wrong.	
(laughs)…I	pressed	that	one	day	and	I	got	a	bit	panicky	
(laughter)	so	I…	left	it…I	just	use	it	for	the	questionnaire	now	and	
that's	it.”	P145	[uses	technology	daily]	Frightened	they	might	break	it	 “…plus	it	doesn't	belong	to	us	and	if	we	broke	it	we'd	be	devastated”		C145	[uses	technology	daily]	Frightened	they	will	enter	wrong	information	 “My	fingers	are	too	heavy.	...	I’ll	end	up	phoning	somebody.”	P378	[once	a	week	technology	user]	Technology	use	is	stressful	 “But	I	can…	if	I’m,	if	I’m	taught	…without	aggravation.”		C380		[uses	technology	every	few	weeks]	Problems	using	technology	perceived	as	failure	
“I	tried	to	order	a	book	on	it	last	week	and	I	can’t	do	it	(laughs)	it	
kept,	I’ve	lost	passwords	and	all	sorts…”	C392	[uses	technology	
daily]	
Low	user’s	approach	to	technology	Use	technology	for	only	a	limited	number	of	familiar	purposes	
“I	have	used	the	computer	for	various	things,	and	if	I’m	using	it	
for	something	and	I	know	what	I’m	doing,	that’s	fine;	I	can	get	on	
for	certain	things	now...”	C380	[uses	technology	every	few	weeks]	Avoids	using	unfamiliar	technology	 “Q:	And,	and	you	say	you	were	a	little	bit	worried	about	the	technical	side?	C:	Well	I	am,	I	was…	I	can	manage	things…	I	use	Kindle	and	a	
laptop.	Computers	are	a	bit	more	of	a	thinker…	(laughs)	and…I	
don’t	do	them	all	the	time	so	I’m	all	right	with	basic	stuff.”		C062	
[uses	technology	a	few	times	a	week]	
“I	know	basically	how	to	navigate	[his	own	device],	whereas	[the	
TiM]	I	don't.”	P145	[uses	technology	daily]	Unable	to	problem	solve:	relies	on	others	 “Q:	And	what	do	you	do	if	you	get,	get	stuck	on	a	problem?	C:	Have	to	wait	till	me	daughter-in-law	comes	up	and	get	her	to	sort	it	out	for	me.”	C392	[uses	technology	daily]				 	
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A5.21	Negative	attitudes	to	technology	expressed	by	participants.	
Negative	attitudes	towards	technology	Lacking	an	interest	in	technology	 “It	doesn’t	really	interest	me,	if	I’m	being	honest.”	C392	[uses	technology	daily]	Not	seeing	a	need	for	technology	 “I'm	not	against	it	but	I	don't	want	it	and	I	can	do	without	it	and	I	don't	need	it.”	C166	[never	uses	
technology]	Feeling	pressured	to	use	technology	 “All	the	time	we're	being	pressured	[by	people]	that	take	all	this	marvellous	technology	up;	and	every	day	
it	is	getting	worse	and	worse,	because	it's	getting	
beyond	the	control	of	the	average	person	how	to	
manage	it	properly.”	C166	[never	uses	technology]	Feeling	excluded/missing	out	if	not	using	technology	 “I	do	feel…a	slight	social	outcast,	but	I	seem	to	be	very	much	in	the	minority.”	C166	[never	uses	
technology]	Worried	about	the	consequences	of	technology	misuse	 “…	certain	things	are	very	useful	[but]	once	it	gets	to	the	mass	market…it	of	gets	exploded	and	misused.	…		You've	got	to	the	point	of	small	businesses	being	
blackmailed	by	hackers.”	C166	[never	uses	
technology]	Worried	about	online	security	 “And	as	for	banking	online,	God,	it’s	a	laugh,	I	would	not	touch	it…if	something	goes	wrong	you	have	the	
devil’s	own	job	to	try	and	put	it	right	because	there’s	
no	proof.”	C166	[never	uses	technology]	Worried	about	intrusion	into	their	privacy		 “I	wouldn’t	have	a	Smartphone	for	a	start,	you	know	cos	Big	Brother’s	up	there	already.”	C166	[never	uses	
technology]	Previous	negative	experience	using	technology	that	was	unreliable	 “…eventually	these	programs	got	more	and	more	complicated	and	the	time	it	was	taking	for	sending	information	down	and	getting	back	was	absolutely	
ludicrous;	the	thing	would	crash	say	at	eleven	o'clock	
on	a	Monday	morning	and	you'd	have	to	start	all	
over	again.”	C166	[never	uses	technology]	Technology	is	an	unwanted	replacement	for	human	contact	 “They	can't	pick	up	a	phone	normally	anymore	because	they're	so	busy	faffing	about	with	their	smart	phones.”	C166	[never	uses	technology]	
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A5.22	Facilitators	for	TiM	use.	
Facilitators	for	TiM	use	
Improving	confidence	using	the	TiM	Face	to	face	training	 “I	would	take	it	up	if	I	was	shown	that	the	program	was	spot	on”	C166	Clear	instructions	 “…That	the	instructions	were	aimed	at	an	idiot	like	me…	and	
not	on	the	assumption	that	I	would	know	what	to	do,	cos	half	
the	instructions	are	based	on	the	person	knowing	what	they're	
gonna	do,	so	it	seems	to	me.”	C166		Participants	realising	it’s	easy	to	use	 “I	thought	I	wouldn't	be	able	to	do	it	(laughter)	but	I	can…	I'm	not	really…	I	don't	want	computer	or	anything	like	that,	you	know,	so	it's	only	that	only	because	of	that.”	C228	
Using	it	weekly	to	develop	skills	 “I	was	quite	happy	using	it	weekly,	cos	things	can	change	so	quickly…I'm	a	terrible,	I'd	forget	when	I'd	done	it	the	last	time,”	
C392		Enabling	others	to	help	them	use	it	 “He’s	got	used	to	it	as	long	as	I	set	it	up.”				P217		Seeing	a	purpose	to	use	technology	 “It’s	unbelievable	that	sort	of	technology,	but	equally	it’s	open	to	anybody	to	get	into	it.	So,	I	might	be	persuaded	eventually,	
but	[laughs]	it’s	a	slow	process”	C166	
Facilitators	to	use	by	those	with	disabilities	Stylus	pen	helped	patients	with	upper	limb	disabled	
“Q:	You	mention	you’ve	got	some	problems	with	your	hands.		
How	do	you	find	using	your	iPad?	
P:	It’s	a	lot	better	since	you	gave	me	this	[stylus]	So	I	don’t	hold	
it	like	a	button.		Other	than	that	it’s	great.			
Q:	Have	you	got	any	other	gadgets	like	that?	
P:	No.	[to	C]	You	ordered	some	more	because	you	liked	it	didn’t	
you?”	P172	[daily	technology	user]	Touch	screen	is	accessible		 “It’s	fine.	I	mean	it’s	getting	more	awkward	to	me,	for	me	cos	obviously	my	hands	are	[weak],	but,	it’s	quite	easy.			Yeah,	the	
touch	screen,	it’s	better	than	if	you	had	to	press	this	keyboard	
sort	of	thing.”	P056	[daily	technology	user]	Use	patients’	own	device	 “I	think	it'll	probably	have	more	of	a	take-up	with	people	using	their	own	device,	because	…	I'm	comfortable	with	my	phone.”	
P134	[daily	technology	user]	Family/carers	enter	information	on	patients’	behalf		 “Q:	...	is	it	something	that	you’d	ask	your	carers	to	do	or	your	family...?	P:	Yeah,	yeah,	definitely.	
Q:	...	would	you	have	any	concerns	in	them	seeing	your	answers	
and	that	sort	of	thing?	
P:	No,	I’d	rather	have	the	family	do	it	rather	than	the	carer	do	
it,	but	I	wouldn't	have	any	problem,	the	family	seeing	it	at	all.”	
P056	[daily	technology	user]				 	
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A5.23	Participants’	expectations	of	the	potential	communication	and	monitoring	benefits	of	the	TiM	service.	
Potential	benefits	of	the	TiM	identified	by	participants	
Improved	communication	with	MND	team	Increase	speed	of	communication		 “If	I	put	it	on	the	tablet	and	I	send	it	to	you,	you	get	it	there	and	then.		So	if	anything	…	happens	to	me	in	that	period	of	time	you	know	straightaway	…	So	the	quicker	you	can	pick	
up	on	so,	something	it’s	better	for	you	as	a	doctor	as	well	as	
me	as	a	patient.”	P091	Increase	frequency	of	communication	 “And	you	know	somebody	within	the	team	is	going	to	look	at	that	information.	So	you	are	connected,	once	a	week.	So	it’s	not	every	three	months.”		C184	Provides	a	direct	connection	with	specialists	
“Well	I’d	read	up	about	the	telemed	and	I	thought,	well	it	
gives	you	a	direct	connection	with	Sheffield	and	the	team.	I	
know	it’s	an	IT	link	but	it’s	a	definite	link	because	once	a	
week	you	are	communicating	with	a	team.”	C184	Improve	communication	and	liaison	with	other	members	of	the	MDT	
“Well	I	can’t	see	there’s	a	different	way	to	what	we’re	doing	
now;	I’m	quite	surprised	that	you’re	all	in	communication	
really….I	didn’t	know	you	spoke	to	[community	MND	team],	
and	I	didn’t	that	[GP]	and	you	and	the	hospital	were	quite	so	
connected,	so	that	seemed	to	be	quite	a	positive	thing.”	P354	
Increased	monitoring	To	identify	problems	quickly	 “It	just	seemed	a	way	of	being	able	to	communicate	with,	with	my	care	team	and	letting	them	know	on	a	regular	basis	how	you’re	doing;	and	no	doubt	at	the	end	of	it	(…)	it	flags	
up	that	I	need	help	or	I	don’t	need	help.”		P134	To	identify	problems	between	clinic	appointments	
“I	thought	it’d	be	a	good	idea	for	both	of	us,	but	mainly	for	P	
and,	because	it	is	a	long	time	between	the	hospital	
appointments,	and	I	thought	well	it’s	a	good	idea	to	monitor	
symptoms	if	they	crop	up	out	of	the	blue	and	we’re	not	sure	
whether	it’s	anything...”	C062		Enables	a	better	understanding	of	the	disease	
	“When,	when	P	started	off	with	the	home	journey	we,	it	was	
obviously	dizzy	spells….	So	I	said	well	we’ll	just	keep	a	diary	
of	what’s	happening	so	you	yourself	know	what’s	happening,	
so	that’s	what	he’s	doing,	and	in	effect,	this	is	what,	your	
telehealth	could	do	eventually	is	sort	of	monitor	people…”	
C091	Enable	self	monitoring	 “So	we	can	monitor	ourselves	as	well	at	the	same	time.	So	it’s	helping	you	in	the	long	run	as	well…I	think	you’ve	gotta	
monitor	yourself	so	you	know	how,	what	you	can	do	and	
what	you	can’t	do.	It’s,	you	can’t	just	rely	on	everybody	on	
the	end	of	a	phone,	pick	up	and	say,	you	know,	I’ve	got	this,	
that	and	the	other.	You’ve	gotta	look	at	health	and	safety	for	
yourself	as	well,	for	whether	you	can	walk	or	whether	you	
can	run	or	whether	you	can	open	a	door	or	open	a	lid	or	
carry	a	glass	or	whatever,	you	know,	at	the	end	of	the	day	
that’s	monitoring	yourself,	so	you’ve	gotta	do	it.”	P091		
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A5.24	Participants’	expectations	of	the	potential	benefits	of	the	TiM	service.		
Potential	benefits	of	the	TiM	identified	by	participants	
Psychological	benefits	Clinicians	take	an	interest			 “Somebody’s	taking	an	interest,	somebody’s	wanting	to	know”	C184	Reducing	isolation	 “You’re	not	going	to	feel	isolated.”	C184	Reassurance	 “Sometimes	it’s	just	the	fact	that,	“should	somebody	know	
about	this?”	or	“should	you	be	telling	somebody	that.”	
Wouldn’t	it	be	nice	if	somebody	knew	this.	Just	small	details	
that	you	sometimes	think,	“Does	it	make	a	difference	if	
somebody	knew	about	it?”	And	that	telemed	makes	that	
difference.”	C184		
Improve	accessibility	of	the	MND	service	Reduce	clinic	appointments	 “If	you	can	glean	enough	information	of	what	I	send	through	so	I	don’t	have	to	come	to	the	hospital,	I	think	that’s	a	
positive”	P354	Provide	access	to	MDT	when	unable	to	travel	to	clinic	
“	We	just	thought	it	would	be	quite	good	cos	not	everybody	
can	get	into	clinic	and	thinking	about	the	later	stages,	but	it’s	
still	important	to	monitor	how	things	are	going”	P480	
	Reduce	travel	time	 “that	would	then	cut	down	my	travel	time	to	clinic,	you	know,	clinic	doesn’t	really	fulfil	a	great	deal	in	my	life	other	than	
ticking	some	boxes	and	sort	of	knowing	where	the	
progression’s	going	but,	you	know,	I	think	most	of	that	now	
can	be	done	through	this	server,	through	TiM.”	P134			 	
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A5.25	The	acceptability	of	the	TiM	questions.	
Acceptability	of	the	TiM	questions	Patients	wanted	the	TiM	to	include	questions	about	all	aspects	of	MND	
“I’ve	found	the	questions,	I	think	they’re	all	relevant.	And,	…	it	
might	be	in	the	future	when	things	do,	if	things	do	get	worse	it	
might	be	I	might	need	those	questions	to	highlight	things	and	
that’s	quite,	quite	comforting.”	P423	
“There's	one	question	about	you	use	a	feeding	PEG.	I	don't	at	the	
minute	so	that's	not	relevant	to	me	at	the	moment.			But	
obviously	as	time	goes	by	it,	it	will	be.	I	think	I	just	put,	“no”,	I	
don't	use	one...	But	I	think	it	should	be	on	there	because,	…	in	
time	I	probably	will	be	using	one.”		P145	Emotional	wellbeing	questions	were	welcomed	
“I	think	it’s	important	to	find	out,	not	just	physically,	how	a	
disease	affects	somebody	but	how,	emotionally,	mentally	it	
affects	them.	As	a	say,	I’m	quite	a	positive	person,	but,	I	have	
some	off	days.”	P122	Carers	happy	sharing	their	sensitive	information	
“Q:	The	sort	of	questions	that	they’re	asking	you,	quite,	they’re	
quite	personal	questions,	aren't	they...?		How	you	feel	about	
sharing	those?	
C:	No	problem.”	C392	Questions	made	patients	think	about	the	consequences	of	their	disease,	but	this	was	not	a	problem	
“Q:	How	does	it	feel	having	to	sort	of	be	faced	with	that	question	
[about	gastrostomy	tubes]?	
P:	…	when	I	first	did	that	it	was	dead	easy	cos	I	just	put	“no”	…	
and	just	moved	on.		But	since	then,	since	we’ve	been	to	this	
Advance	Care	[planning]	thing.	…And	that,	that	sort	of	brought	
it	to	the	fore	….	it’s	a	thought	that	I	wouldn’t	really	wanna	think	
about,	but	you’ve	gotta	think	about,	so	I	think	on	that	one,	is	
that	something	I	shall	maybe	ask	more	to	get	more	advice	on.”	
P248	Reporting	a	deterioration	on	the	TiM	was	not	distressing		
“I	think:	am	I	getting	worse?	But,	yes,	am	I	getting	worse….	I	
don’t	think	any	of	the	questions	are	really	frightening.	You	know	
it	might	happen.”	P172	
“in	a	sense	it’s	good	that	you	can	change,	you	know,	the,	keep	
every,	everybody	up-to-date.	Cos	you	don’t	know	when	things	
are	going	to	change	anyway,	do	we,	we	don’t,	you	know,	it’s	just,	
it’s	like	a	bit	of	a,	a	grey	area	isn’t	it?	…	as	long	as	people	who	
need	to	know	see	that	information	then	it’s	…	not	waiting	till	
your	next	visit	at	the	clinic	is	it...?”	P122	Wanting	questions	that	assessed	how	they	were	coping	
“Maybe	if	they	say,	“No,	I’ve	not	been	out	for	a	fortnight”,	that	it	
makes	them	think:	well,	actually	why	haven’t	I?		And	it	would	
highlight	that	person’s	not	getting	out	of	the	house	and	not	
doing	something	themselves	and	they	are	continually	there.		Do	
they	need	a	bit	more	support?”	C122		Questions	were	repetitive	 “	It's	repetitive.	…	I	pick	it	up	and	I	think	oh	God,	here	we	go	again,	same	old,	same	old.		[I]	put	a	couple	…more	different	ones	
in,…	but	no,	the	questions	are	right...”	C145	Questions	become	irrelevant	if	disability	severe	 “As	I	am	unable	to	use	my	arms	and	legs	at	all,	many	of	the	questions	have	become	irrelevant	to	me	beyond	the	first	time	of	using	it.”	P047		
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A5.26	The	validity	/	accuracy	of	the	TiM	questions.	
The	validity/accuracy	of	the	TiM	questions	Patients	want	answers	to	be	accurate	 	“If	I’ve	got	a	form	I	like	to	fill	it	in	as	accurately	as	possible.”		P248		Patients	were	concerned	that	their	answers	would	be	misleading			
“I	have	lost	weight	[a	few	weeks	ago]	but	I	haven’t	[lost	weight	in	
the	last	week].	The	way	I’m	reading	it	now…	sounds	like	I’m	still	
losing	weight,	well	I’m	not…I	wouldn’t	like	‘em	to	think	looking	at	
it,	or	you	looking	at	it	in	Sheffield	and	thinking	“God,	he’s	still	
losing	weight”	P248	The	answers	are	insufficient	to	reflect	small	changes	
“Sometimes	they	answers	to	chose	are	too	far	apart	so	if	the	
answer	is	one	day	a	week,	I	answer	no,	or	several,	it’s	nearer	
several.	So	it’s	accurate	but	it’s	wide.”	P172	
“The	questions	are	quite	in	a	narrow	band,	and	because	it’s	a	
slow-burner	not	much	changes	unless	there’s	a	step	change,	such	
as	…the	chest	infection	the	other	week.”	P354	The	condition	varied	from	day	to	day	making	weekly	assessments	difficult	
	“I	thought:	if	I	was	doing	the	questionnaire	on	that	day,	“what	
sort	of	assistance	do	you	get	from	your	family?		The	answer	would	
be	off	the	scale	somewhere.		I	thought:	some	of	the	questions	don’t	
quite	fit	the	answer.	So	I	try	to	put	the	most	representative”	C172		
	“I	think	some	of	the	questions	are	a	bit	too	general	and	wide	
rather	than,	for	instance…	what	can	I	not	do	with	my	hand	that	I	
used	to	do,	and	how	am	I	dealing	with	it.”	P166	Informal	care	requirement	questions	were	difficult	to	answer	
“The	margins	are	too	wide.	One	of	the	questions	is,	how	much	
time	do	you	spend	in	the	day	looking	after	her?	And,	there’s	a	sort	
of,	there’s	3-4	hours.	But	I	don’t	even	look	after	myself	for	3-4	
hours,	I	just	potter	around.	That’s	always	gonna	be	the	same	
answer.”	C172	Some	questions	contradicted	each	other	 There	are	some	questions	on	there	that	are	bit	ambiguous	for	me	[for	example]	being	able	to	use	the	stairs.	Well	I	can’t	use	the	stairs	but	I	still	have	a	bathroom	upstairs	so	I	still	walk	from	the	
top	of	the	stairs	to	our	bedroom.”	P134	Patients	wanted	to	provide	more	information	to	clarify	their	answers	
“…	if	you	have	any	more	questions	to	ask	you’ve	got	that…	
availability	to	ask	[the	MND	team]	if	you	have	any	problems…”	
P056	
“If	you	want	to	ask	anything	maybe	you	could	type	it	in	instead	of	
it	just	being	yes/no”	CaT	Patient	317	
“I	think	that,	that	would	be	a	good	addition.	Because	you,	you	
could	answer	a	question	and	at	the	end	of	the	section	just	put	in,	
and	just	expand	on	what,	why	you’ve	answered	that,	if	you	see	
what	I	mean?	I	think	a	comments	box	would	be	a	good	idea.”	
P122	Same	problems	identified	every	week		 “It’s	a	probably	the	same	answer	I	give	every	week…	It	says;	“Do	you	stumble	or	feel	that	you	fall,	or	have	you	fallen?”	And	I	do,	every	single	week,	I	guarantee	that”	P122		Answer	affected	by	other	health	problems	 “So	at	the	minute	I’m	slightly	doctoring	the	answer;	so	I’m	saying	I	can	dress	myself	but	I	can’t,	but	it’s	not	the	MND.”	P381			 	
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A5.27	Participants	understanding	of	the	TiM	service.	
Aims	of	the	TiM	service:	Monitoring	 “For	you	to	be	aware	of	it,	and	monitor	it...”	P402	Relay	information	to	the	MND	team	 “It	shows	how	you’re	feeling	which	gets	then	relays	to	the	nursing	staff.			If	you’ve	any	questions	you’ve	got	the	item	on	it	where	you	can	…	ask	that	as	well…	I	would	think…	it’s	read,	isn't	it,	and	then	
probably	recorded	somewhere.”	P056	Look	for	trends	 “I	would	say	they	are	probably	going	on	to	some	sort	of	graph	
that	detects	a	trend.	I	mean	with	me,	you	wont	get	a	trend	
because	sometimes	you	are	up	and	sometimes	I’m	down.	It’ll	look	
like	a	[gestured	up	and	down].	But	I	would	imagine	the	ideal	
situation	is	when	you	can	detect	a	trend	but	that	does	depend	on	
what’s	happening.”	C172	Provides	trends	and	alerts	to	problems	 “I’m	guessing	that	it	comes	to	someone’s	desk	and	that	they’re	able	to	see	a	chart…	from	week	to	week,	and	I	would	imagine	that	there	would	be	a	series	of	red	flags	for	you	or	some	traffic	light	
system…	that	red’s	intervention	required,	amber’s	a	warning,	
green’s	get	on	with	it..”	P134	Prioritise	patients	in	need	 “I	could	see	the	reason	why	you	were	doing	it;	I	realised	that	all	the	data	was	going	to	be	collated	and	you	can	see	then	at	a	
glance…	you	can	see	the	statistics	and	everything,	and	it	would	
highlight	to	you…	if	I	had	a	dramatic	change.”		P317	Data	would	be	used	for	research	 	“I	didn’t	realise	that	that’s	what	was	going	to	happen,	I	thought	it	was	just	being	used	for	research.”	C392	“I	would	assume	it	goes	to	some	databank	somewhere	and	they	
try	and	correlate	the	answers	I’ve	given	with,	perhaps	somebody	
else	...	to	see	if	there	is	any	common	ground.”P122	
“I	imagine	it	goes	onto	a	database	…	and	then	if	yourself	and	
[Professor]	are	ever	doing	any	research	they	may	be	able	to…or	if	
there's	any	trials	you	might	be	able	to	select	from	that	who	would	
be	suitable	for	that	trial.”	P	317	Both	clinical	care	and	research	 “I	imagine	it	goes	on	a	survey	of	all	the	people	you’re	doing	to	compare	us	with	each	other,	and	also	to	follow	my	own	progress.”	P166	
The	role	of	the	Telehealth	Nurse	TiM	Nurse	looked	at	data	 “It	shows	how	you’re	feeling	which	gets	then	relays	to	the	nursing	staff,	doesn’t	it.”	P056		EH	was	looking	at	data	 “I	didn’t	realise	that	[Telehealth	Nurse]	was	involved	and	she	would	ring	us	if	our	answers	drastically	changed,	cos	obviously	
they’ve	stayed	very	much	the	same.			Then	I’m	quite	encouraged	
by	that,	I	just	presume	that	you	do	it	yourself…and	if	you’d	got	a	
problem	you’d	ring	[Telehealth	Nurse]	up	for	a	bit	of	help.”	C392	Unsure	who	looked	at	data	 “I’m	guessing	that	it	comes	to	someone’s	desk	and	that	they’re	able	to	see	a	chart”	P134	
“The	ones	that	have	spoke	about	it	to	me	I	don’t	think	they	realise	
that	I’m	seeing	their	responses.”	Telehealth	Nurse			 	
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	A5.28	Nurses’	experience	of	using	the	TiM	clinical	portal.	All	quotes	are	from	the	Telehealth	Nurse.	
Using	the	clinical	portal	Easy	to	use	 “The	training	that	I’ve	had	from	seeing	it	this	side	was	brief	
from	Esther	and	it’s,	it’s	never,	it’s	not	difficult	so	it,	I	find	I,	
right	from	the	beginning	I	found	logging	on	has	been	the	
most	difficult	thing,	so;	but	once	you’re	on	finding	your	way	
around	it	is	very,	very	easy,	very	easy,”	Low	burden		 “It	only	takes	minutes”		Easy	to	understand	the	flag	system	 “If	everything’s	OK	it’s	green,	…	[if]	there’s	maybe	some	elements	that	might	need	to	be	looked	at,	it’s	an	orange	or	
yellow,	and	then	if	there’s	an	alert	it’s	a	red	one.”	IT	support	for	passwords	required	 “My	main	problem	was	me	accessing	it	to	begin	with,	and	that	was	very	problematic.	It’s	just	asked	me	to	change	me	
password.”		Nurse	didn’t	know	how	to	use	the	patient	TiM	app	or	resolve	technical	problems		
“	N:	I	have	had	a	couple	of	phone	calls,	cos	[the	participants	
have]	got	my	contact	number	through	this,	and	they’ve	rung	
with	a	problem,	usually	a	logging	on	problem	and…	
Q:	Forgotten	their	password?		
N:	Yeah...I’ve	asked	Esther,	to	be	honest,	because	I’m	not	
familiar	with	their	device.”				 	
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A5.29	The	accuracy	and	sensitive	of	the	TiM	information.		Quotes	are	from	the	Telehealth	Nurse	(N)	unless	otherwise	stated.	
Accuracy	of	the	TiM	information	Information	accurate	to	help	make	some	decisions	
“N:	[EH]	has	led	me	to	believe	that	it’s	quite	easy	to	red	flag	
on	the	carer.	So	this	chap	is	triggering	...	[reads	the	PHQ4	
questions]	So	I	mean	…	the	four	that	are	triggering,	they’re	
all	about…	
Q:	Worry,	stress?	
N:	Yeah,	thoughts:	yeah.	I	know	how	poorly	this	lady	is,	I	
know	how	disabled	she	is,	and	I	do	know	him,	and	when	you	
speak	to	him	he’s	very	blasé	about	it	all,	which	actually	is	
more	of	a	worry.”	Information	in	TiM	wasn’t	sufficiently	detailed	enough	to	be	sensitive	
“N:	…I	think	if	they’re	routinely	sending	us	an	update	every	
week	I	think	you’re	more	likely	to	pick	up	on	problems,	but	I	
don’t...	I	thought	that	would	be	so.	
Q:	Is	that,	do	you	think	that’s	happened?	
N:	No	not	really.		I	don’t	know	that	the	questions	are	sensitive	
enough,	and	I	suppose	the	thing	is	that	it	might,	if	it	triggers	
a	contact	phone	call	then	you	may	well	pick	up	on	things	
sooner.”	(early	interview)	Needed	more	information		 “N:	It’s	almost	like	you	need	a	two-way	thing	(laughs)	you	need	to	ask	them	a	question,	[for	example]	how	long	
have	you	been	coughing...	are	you	bringing	anything	up	
when	you’re	coughing...	you	know,	that	type	of	thing...	
have	you	had	a	temperature...	it’s	almost	like	[laughs]	
you	need	a	two-way	communication,	cos	this	is	just	a	
snapshot,	isn’t	it…”	Discussions	are	required	to	fully	understand	a	problem			
“I	think	some	of	the	problems	with	patients	using	NIV,	very	
specific	problems,	you	only	pick	up	from	a	conversation	with	
them.		I	don’t	think	you	pick	it	up	on	the	Tele,	cos	it’s	[the	
way]	it’s	structured,	it	might	show	a	problem	but	not	a	
specific	problem.”	An	additional	comment	box	would	help	gain	more	detailed	information	
“Q:	Yeah.	Do	you	have,	would	you	have	time	to	read	the	
comment	boxes?	
TW:	I	would	hope	so.	You’d	have	to	make	time.		If	it	was	a	
problem	that	was	coming	up	all	the	time,	yes,	I	would	hope	
that	that;	in	some	ways	that	might	save	you	time.”				 	
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			A5.30	Participants’	experiences	of	how	the	TiM	impacted	on	their	care.		
Impact	on	if	TiM	on	patient	care	Improves	knowledge	 “Because	since	I’ve	done	it	I’m	taking	more	notice	of	my	weight	but	I	didn’t	before	so	I	know	it	very	carefully.	It	made	me	aware	of	that.”	P172	Close	monitoring	 “I'm	certainly	not	left	alone	for	more	than	a	month,	ever…Sheffield	is	there	if	I	really	need	them,	but	on	the	other	hand	[local	team]	is	here.”	P166	Reassurance	to	know	being	monitored	
“I	think	the	benefit	to	P	is	real.		Because…	somebody	is	there	on	hand	looking	at	
things…	Because	it’s	slow	with	P	and	he	doesn’t	need	as	much	attention	and	care,	
it’s	easy	to	feel	detached	from	any	positive	interaction.”	C122		Keeping	in	touch	with	specialist	 “…it’s	knowing	that	somebody	else	is	in	your	corner.”	C423	Q:	Do	you	think	there	might	have	been	a	point	in	your	disease	where	those	questions	…were	useful?	
P:	Nearer	the	beginning,	definitely.	I	think,	and	I	can	only	guess,	that	it	must	be	the	
same	for	lots	of	long-term	conditions;	you	know,	I've	lived	with	this	for	over	five	
years	now…	you	get	to	understand	your	own	body	and	you	know	it's,	it's	normal	for	
me	now	and	for	the	first	year	no	day	was	normal,	no	day	looked	like	any	other	day	
in	my	life	before	that.	So…	if	I	could	have	camped	in	[MND	consultant]'s	house	for	
the	first	six	months	I	would	have	done,	just	so	she	was	there,	so	I	could	say,	but	
what	about	this,	what	about	that;	and	you	imagine	symptoms,	or	I	did,	you	know,	
you	think	God,	this	is	happening	and	that	must	be	related	to	the	MND...	So	in	the	
first	year	I	would	have	filled	that	in	every	day,	just	to	have	that	touch	point,”	P047	Nurse	giving	advice	 “When	I	came	back	on	Tuesday	last	week	and	I	did	the	second	questionnaire,	and	within	a	day	[Telehealth	Nurse]	saying	“I’ve	got	a	red	flag	on	one	of	your	answers.”	
And	it’s	the	fact	that	I’d	fallen	twice	while	I	was	away	on	holiday	and	I’d	put	on	it,	
you	know:	it	said	“have	you	fallen	recently,	how	many	times?”	and	I’d	fallen	twice	
while	I	was	on	holiday.	So	she	phoned	me,	and	said,	“Are	you	ok?	Is	there	a	reason	
why	you	fell?”	No,	just	my	usual	clumsiness....		
Q:	Were	you	expecting	her	to	call?		
P:	No,	I	wasn’t	actually.	It	was	just	a	bolt	out	of	the	view...I	find	that	quite	positive.	
It	shows	that	the	whole	idea	of	it	works.		
Q:	Has	it	changed	your	behaviour	at	all?		
P:	No.	Not	really.”	P122	Nurse	identifying	problems	 “Q:	[Telehealth	Nurse]	called,	I	think	she	spoke	to	you	about	when	you	fell...		P:	Mm.		Q:	...what	did	you	think	about	that	when	that	happened?		
P:	It	was	useful	wasn't	it?		
C:	Well	you	weren't	in	so	she	spoke	to	me.		
P:	Yes,	because	I'd	tripped	over	the	bedroom	chair...		
C:	that's	right	and,	yes,	that	was	the	main	thing,	that's	right,	yeah.	No,	it	was	
interesting	that	that,	that	had	been	picked	up	because	we	weren't,	we	don't	know	
how	it	was	picked	up.”	P&C166	Identifying	problems	between	clinic	visits	
“When	I	filled	it	in	last	week,	and	within	a	day	[Telehealth	Nurse]	was	phoning	me.	
How	much	better	could	you	have	that?	Instead	of,	two	months	down	the	line	and	I	
attend	the	clinic	and	they	say	“how	have	you	been,	have	you	fallen?”	and	I	say	“oh	
yeah	I	did:	two	months	ago”.	See	where	I’m	coming	from?	You’ve	got	that	
instantaneous	contact	with	this	technology	that	perhaps	you	don’t	have	without	it.	
So	I’m	a	great	believer	in	that,	I’m	a	great	believer	in	technology.”	P122	Supporting	important	decision	making	
“Q:	The	other	question	I	had	was	that	we	kept	an	eye	on	your	weight	and	I	wonder	
whether	you	think	that	may	have	influenced	your	decision	to	have	a	feeding	tube	or	
not;	do	you	think	it,	do	you	think	it	had?	
P:	[writing]	I	was	frightened	by	the	speed	of	loss	of	weight	but	was	convinced	how	
much	muscle	I	lost.”	P409	Help	accept	the	disease	 “	The	questions	nudged	me	to	facing	what	I	could	do	and	not	what	I	can't.”	P409	
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	A5.31	The	Telehealth	Nurse’s	attitudes	towards	the	value	of	the	TiM.		Quotes	are	all	from	the	Telehealth	Nurse	
The	Telehealth	Nurses’	attitudes	towards	the	value	of	the	TiM	TiM	could	be	valuable		 “As	a	tool	to	aid	the	patient	and	then	aid	the	nurse”	To	identify	problems	between	clinic	visits	
“A	number	of	patients	with	MND	and	their	carers	will	wait	till	a	
clinic,	instead	of	contacting	us	with,	if	they’re,	they’re	worried	about	
something,	or	there’s	a	change	in	their,	you	know,	their	condition,	
and	I	think	if	they’re	routinely	sending	us	an	update	every	week	I	
think	you’re	more	likely	to	pick	up	on	problems.”	Alerting	to	problems	earlier	 “Q:	So	it	could	have	a	use	maybe	in	alerting	you	to	earlier	need	for	intervention?	N:	Yeah,	yeah.”	Help	monitoring	trends	 “I	mean	the	weights	have	been	quite	interesting,	cos	if	they	can	use	the	weighing	scales	…	that’s	been	quite	interesting,	so	we	can	monitor	their	weight.…	cos	otherwise	you	wouldn’t	necessarily	see	
that	variation.”	TiM	wouldn’t	have	a	negative	impact	on	the	service	
“Q:	do	you	think	a	patient	will	be	concerned	this	is	trying	to	take	
away	a	part	of	the	service,	or	do	you	think	the	clinical	team	might	
feel	it’s	taking	away	part	of	the	service?	
N:	I	don’t	think	either	side	would.	From	a	clinical	side	I	think	that	
anybody	would	be	willing	to	make	it	as	easy	for	the	patient	as	
possible.”	Clinics	are	a	burden	to	patient		 “I	think	from	the	patient’s	point	of	view	I	think	it	becomes	very	burdensome,	the	travel	into	clinic,	very	much	so…But	certainly	the,	the	travel	and	the	amount	of	time	and	effort	for	them	to	come	to	
clinic	to	sit	in	clinic	to	then	go	home	again,	it’s	very	difficult	for	
them.”		Patients	do	not	see	value	in	attending	clinic	
“…	[patients]	sometimes	say;	“nothing,	I	don’t	get	anything	out	of	coming	to	clinic	because	you’re	reiterating	the	same	things,	I	know	I’m	getting	worse...”	So	there	are	some	patients	that	don’t	see	the	
value	of	coming	to	clinic	anyway.	Now	whether	they	would	use	a	
system	like	this	and	see	the	value	of	that	I	don’t	know.”	TiM	could	allow	patients	to	be	managed	remotely	
“	I	think	it	could.		I	think	it’s	one	of	those	difficult	things	that	at	the	
moment,	because	it’s	not	something	we	systematically	do.			And	they	
are	attending	clinic	or	I	have	connections	with	their	community	care	
team,	so	I	am	in	touch	with	what’s	happening	and	things	are	getting	
monitored.		I	don’t	know.”	Some	problems	need	face	to	face	assessment	
“Q:	How	reliable	this	kind	of	technology	would	be	in	deciding	when	
or,	when	to	cancel	an	appointment	for	a	patient?	
A:	Oh	I	don’t	know,	I	don’t	know.	
Q:	Would	you	feel	secure	looking	at	that	saying	that	patient	doesn’t	
need	to	come	in?	
A:	I	think,	I	think	it	depends,	so	when	I	look	at,	if	it’s	a	breathing	
problem	and	if	I	didn’t	know	them	and	they	were	having	problems	
with	their	breathing	…that	would	alert	me	and	I	would	[think]:	right	
we	need…	to	contact,	we	need	to	be	looking	at	this	and	monitoring	
it...I	think	it	depends.”						
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	A5.32	Participants	attitudes	towards	clinician	feedback.		
To	act	upon	problems	and	provide	feedback		Feedback	reinforces	the	benefit	of	the	TiM		 “I	find	that	quite	positive.	It	shows	that	the	whole	idea	of	it	works.”	P122	Not	receiving	feedback	is	demoralising	 “The	emotional	psychological	depths	that	I've	been	to,	I	was	putting	the	stuff	in	Telehealth	and	thinking	but	nobody's	acknowledged	this	or	contacted	me	about	it,	and	I	thought:	
well	they're	not	going	to	because	that	isn't	what	the	clinic's	
about,	and	that	made	me	stop	using	it.”	P047	
“…it’s	like	all	forms	and	all	surveys…	they	say	“your	opinion	
is	important	please	fill	in	the	following…”	and	you	say	
something	that	you	think	is	absolutely	dramatic	and	mind	
blowing	and	nobody	comes	back	to	you	on	it.	And	you	think:	
well	how	important	is	that	survey?”	C172	To	provide	feedback	even	if	nothing	had	changed	
“Q:	And	would	you	expect	perhaps	someone	to	tell	you	
what’s	going	on	with	the	tablet	or	the	answers?	
P:	Yes.	Because	if	I	hadn’t	changed	much,	I	would	have	
thought	I	would	have	had	some	feedback.”P172	To	acknowledge	problems	even	if	nothing	can	be	done	
“[falls]	…	knocks	your	confidence	…I	probably	were	putting	
too	much	onus	on	Sheffield	Hallam	because	(laughs)	we’ve	
got	this	and	there’s	not	jack	shit	they	can	really	do	about	
this	and	we	know	that...	
Q:	But	that	kind	of	acknowledgement’s	quite	important,	do	
you	think,	of	the,	what	happens	…?			
C:	I	do,	yeah,	it’s	a	bit	of	support,	in’t	it,	it’s	knowing	that	
somebody	else	is	in	your	corner.”	C423	MND	team	couldn’t	solve	their	problem	 “Q:	If	your	answers	changed	what	do	you	expect	of	the	MND	service?	P:	I	don’t,	to	be	honest.	Let’s	say	if	I	thought	I’d	got	a	
problem	I	wouldn’t	necessarily	come	to	you	because	I	don’t	
think,	I	think,	you	know,	I,	the	impression	that	it’s	medical	to	
do	with	P,	and	if	I	have	got	a	problem	really;	because	when	
you	flash	up	it	does	say	if	you,	is	to	contact	the,	there	is,	so	I	
would	probably,	I	mean	that’s	not	part	of	your	remit,	is	it,	
me	really	if	I’ve	got	a	problem?”	C381	
“[emotional	support]	That's	not	what	that	clinic's	about,	
that	clinic's	about	physical	wellbeing	and	physical	health…	
truthfully	I	thought	I	don't	know	why	these	questions	are	in	
here,	because	that	clinic	isn't	equipped	to	deal	with	that.”	
P047	Feedback	thought	to	be	pointless	if	nothing	can	be	done	
“But	then	again,	what’s	the	point	of	coming	back	if	you	can’t	
say	anything?”	C172	
		
	 285	
A5.33	The	mismatch	between	the	participants’	and	nurses’	expectations	of	the	TiM	service.	
Mismatch	between	patient	and	nurse	expectations	Patients	expected	contact	if	they	experienced	important	problems:	Falls	 “Q:	...do	you,	do	you	think	they're	important	things	that	she	needs	to	
know	about?	
P:	I	would	say	yeah…	cos	one	of	the	questions	is	have	you	fallen	or	
tripped?		Obviously	if	I	am	falling	more	often,	(well	I	am,	I	fell	a	few	
weeks	ago,	didn't	I?	but	that,	that's	first	time	in	months...).		If	I	was	
falling	…	over	every	week	I	would	say	that,	yeah,	she	needs	to	know	
something	like	that,	or		if	I'm	starting	to	not	eat	me	food	properly,	if	
I'm	starting	to	cough,	I	think	obviously	she	needs	to	know	that”	P145	
Chest	infections	Dysphagia	
Emotional	difficulties	 “Most	of	my	problems	at	the	time	are	emotional,	and	the	TiM	does	not	appear	to	trigger	any	intervention.”	P047		Problems	may	not	be	seen	as	important	to	nurse	
“She	red	flagged	that	she’d	fallen,	which	is	quite	a	common	
occurrence	on	a	lot	of	patients,	and	I	don’t	particularly	worry	unless	
they’ve	been	very,	very	well	and	then	suddenly.”	Telehealth	Nurse	Problems	may	not	be	seen	as	important	to	patients		
“Q:	When	you	put	that	you	had	fallen,	what	were	you	expecting	to	
happen?		
P	:	No.	No.	
Q:	And	when	you	heard	that	[your	OT]	had	heard	about	it,	what	did	
you	think	about	that?	
P:	Nothing	really.	
Q:	And,	do	you	think	in	the	future,	if	something	were	to	happen	to	
you,	and	you	put	on	here,	what	would	you	expect	to	happen,	what	
would	you	like	to	happen?	
P:	I	would	think	[Telehealth	nurse]	would	ring.	But	the	only	thing	is	
the	over	balancing,	so	far,	isn’t	it.”	C217	Problem	may	not	be	seen	to	be	under	the	MND	team’s	remit	
“[emotional	support	is]	not	what	that	clinic's	about,	that	clinic's	
about	physical	wellbeing	and	physical	health.	To	me,	and	in	my	own	
head,	I	thought	it's	never	been	about	psychological	wellbeing	and	
your	mental	wellness	and	therefore;	and	truthfully	I	thought	I	don't	
know	why	these	questions	are	in	here,	because	that	clinic	isn't	
equipped	to	deal	with	that.”		P047	Participants	expecting	contact	when	stable	 “	It	would	be	nice	for	someone	to	phone	occasionally	…	particularly	if	anything	changes.:	C172	Not	expecting	a	particular	action:	expect	nurse	to	decide		
“Q:	And	what	would	you	expect	to	happen	if	you	did	change	your	
answers	like	that	week?	
P:	Not	really,	no,	cos	you	know	more	than	I	do.”	P056	
“I	would	tend	to	leave	it	to	them	to	solve	anything	that	needed	
solving.”	C217			 	
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A5.34	The	problems	associated	with	excessive	TiM	alerts.		All	quotes	are	from	the	Telehealth	Nurse	unless	indicated.	
Excessive	TiM	system	alerts	The	same	alerts	appear	every	week	 “We	have	some	of	our	patients	that	do	this	every	time…	They	...	cough	or	choke	at	least	once	a	week.”	Alerts	increase	the	time	required	to	use	the	system	and	can	cause	frustration	 “Then	when	it	was	coming	up	every	week…	I	knew	I’d	spoken	to	them	about	that	[problem]	and	that	was	their	choice.			And	I’d	kept	putting	[a	comment	
in	the	TiM	notes]	but	you’re	sorta	thinking;	why	do	I	
have	to	keep	putting	it	on	every	time?”	Nurse	can’t	control	the	alerts	 “If	you	know	somebody’s	got	a	problem	and	they’re	
not	really	trying	to	do	anything	about	it,	then	you	
know	that	[alert	is]	gonna	keep	coming	back	every	
week;	and	I	haven’t	been	putting	comments	on	all	
the	time.”	Nurses	may	appear	to	not	be	acting	on	potentially	dangerous	problems	 1“[reads]	“Do	you	ever	cough	or	choke	on	food?”And	then	he’s	put:	“Occasionally”,	and	that’s	fine.”	Problems	flagged	even	though	the	patient	has	chosen	not	to	medical	advice	to	avoid	the	problem	
“cos	I	know	that	patient	and	I	know	that	they’ve	
chosen	to	eat	and	that	it	is	problematic.			But	
they’ve	got	a	feeding	tube	and	they	should	really	be	
using	their	feeding	tube,	but	they’re	[also	eating].			
Then	when	it	was	coming	up	every	week,	I	knew	I’d	
spoken	to	them	about	that	and	that	was	that	
choice?”		Reporting	the	same	problems	without	solutions	could	be	demoralising	to	patients	 “Maybe	to	them	the	fact	that	it’s	the	same	thing	week	in	week	out,	they’ve	got	an	insight	into	that	problem,	it’s	not	changing	and,	so	they’re	not	
looking	for	something	to	help	with	it	really.”		Repeated	problems	on	which	no	action	could	be	taken	should	be	paused	to	avoid	excessive	alerts	
“Q:	Are	there	any	other,	other	things	that	you’d	
change	at	the	moment	to	make	it,	to	improve	the	
system?	
TW:	Apart	from	the,	the	same	red	flags	coming	up	
every	week	with	the	same	problem,	having	some	
way	of	either	taking	them	off	or	say,	or	putting	a	
comment	in	that,	that	would	take	it	off	by	saying	
you’ve	addressed	this	problem,	it’s,	it’s	still	gonna	be	
there,	it’s	not	gonna	change.”			 	
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A5.35	The	problems	associated	with	excessive	TiM	alerts.			All	quotes	are	from	the	Telehealth	Nurse.	
Nurse	reaction	to	alerts	Calls	patient	for	more	information	 	“[I]	ring	the	patient	about	it	and	ask	them”		Liaises	with	the	community	team	to	get	more	information		
“I	try	and	get	a	bit	more	information,	cos	the,	the	community	team	
may	have	been	out	and	seen	them	and	seen	them	face-to-face	and	
have	got	something	a	little	bit	more	useful	back;	so	I	have	used	it	
for	that	circumstance.	And	I’m	in	touch	with	the	community	team	
quite	often,	so	sometimes	if	I’m	ringing	about	something	else	I’ll	ask	
about	one	of	the	patients	that’s	on	here.”		Prefers	to	wait	until	clinic	 “I’ve	seen	somebody	that	was	red	flagged,	cos	they’re	coughing	more..I’ve	put	a	[TiM	note]	that	we’ll	review	in	clinic	next	week.”		Will	chose	not	respond	to	problems	she	thought	were	common	in	MND	
“She	red	flagged	that	she’d	fallen,	which	is	quite	a	common	
occurrence	on	a	lot	of	patients.	I	don’t	particularly	worry	unless	
they’ve	been	very,	very	well	and	then	suddenly.	So	if	it	happens	over	
a	few	weeks	and	I’ve	spoken	to	them	and	I	know	the	situation…I’m	
not	always	alerted	by	that	red	flag.”	Using	all	the	TiM	information	on	the	to	make	a	decision		 “They	were	having	problems	with	their	breathing	but	I	would	look:	are	they	on	a	breathing	machine?	No.		That	would	alert	me.	So	I	think	it	depends.”	Patients	and	nurses	prioritise	different	problems	 “I	did	the	second	questionnaire,	and	within	a	day	the	[Telehealth	Nurse]	calls	saying	“I’ve	got	a	red	flag	on	one	of	your	answers.”		And	it’s	the	fact	that	I’d	fallen	twice	while	I	was	away	on	holiday…	
she	phoned	me,	and	said,	“Are	you	ok?	Is	there	a	reason	why	you	
fell?”		No,	just	my	usual	clumsiness….			
Q:	Were	you	expecting	her	to	call?	
P:	No,	I	wasn’t...It	was	just	a	bolt	out	of	the	view…	I	find	that	quite	
positive.	It	shows	that	the	whole	idea	of	it	works.”	P122	Having	a	relationship	with	the	patient	made	it	easier	for	the	nurse	to	call	the	patient	
“I	think	it	helps	me	that	I	know	the	patients.	So	I	know	this	chap	
very,	very	well,	I	have	a	relationship	with	him	and	his	wife;	ringing	
up’s	quite	easy	to	do,	they	wouldn’t,	they	wouldn’t	be	fazed	by	that.		
My	response	would	be;	“oh	there’s	been	a	red	flag	on	the	Telemedicine	that	you	sent	through,	a	message	that	you’ve	sent	through,	and	that’s	why	I’m	ringing”.	And	that	was	quite	an	easy	
one.”		Harder	to	ring	those	who	she	didn’t	know	 “There	are	a	small	number	of	patients	that	I	don’t	know,	it	just	so	happens	that	they’ve	been	very	well	through,	so	there	hasn’t	really	been	any	major	alerts.”	Ringing	carers	may	be	difficult		 “If	we’ve	had	a	carer’s	response	that’s	red	flagging	I	don’t	always	find	that	an	easy	phone	call	to	make	to	a	carer	who’s	struggling.”	Patients	not	expecting	her	call	 “I	rang	a	lady	who	I	didn’t	know	and	she	red	flagged	that	she’d	fallen…		It	was	the	lady’s	husband	…	he	was	quite	shocked	that	I’d	
rung	cos	I	didn’t	know	them	and	I	just	explained	about	it,	and	he	
just	said	“No,	it	was	just	a	little	trip,	she’s	absolutely	fine,	no	
problem.”		Nurse	doesn’t	feel	her	calls	benefit	patient	 “I’ve	said	“Oh	you’ve	had	some	problem	with	this?...I	know	because	you	sent	a	Telemedicine	and	I’m	the	one	that	looks	at	the	problems	and	sees	what’s	what.”	And	they	said	“Oh	right,	oh	yes,	it’s	nothing,	
it’s	fine.”		I	don’t	know…”						
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A5.36	Participants’	attitudes	towards	the	future	of	the	TiM.		
Preferred	way	to	communicate	with	MND	team		Modes	of	communication	depends	on	the	individual	
Q:	How	do	you	think	is	the	best	way	for	people	contact	you?	
P:	I	think	for	me	it’d	be	by	phone,	but	again	that	will	be	depending	on	
the	carer	and	my	speech.	I	mean	I’m	currently	OK	with	the	phone.	
Q:	And	how	do	you	feel	about	email	contact	or	contact	through	the	
Telehealth?	
P:	Again	that’s	fine	by	me,	I	use	email,	computer	all	the	time,	but	again	
you’d	have	to	judge	that	on	the	individual.”	P381	Contact	needs	to	be	convenient		 “And	phoning	you	up,	I	don’t	know	about	you	but	I	hate	phone	calls:	you	are	just	settling	down	to	have	a	nice	cup	of	tea	or	a	chocolate	biscuit	or	
whatever	and	the	phone	rings,	you	have	someone	trying	to	persuade	you	
to	change	your	heating	systems”	C172	Alternative	methods	of	communication	add	flexibility	
“I'm	really	happy	…communicating	by	email,	because	for	me	I	can	do	it	
then	in	my	own	time,	because	I	haven't	got	use	of	my	hands	and	arms;	so	
if	I	know	that	there's	an	email	that	I	can	read	and	then	reply	to	in	my	
own	time,	that's	far	more	relaxed	for	me	actually	than	the	telephone…	I	
can	speak	fine	but	the	telephone,	somebody	has	to	hold	it	for	me…if	I'm	
not	in	exactly	the	right	position	it's	not	comfortable	to	take	a	r.”	P047	Telephone	may	be	uncomfortable	for	some		 “I	feel	a	bit	awkward	on	the	phone,	and	you	can’t	get	across	how	you’re	really	feeling	on	a	phone	anyway..I	tend	to	get	nervous	when	I’m	on	the	phone	and	stuff	and	I	forget	what	I’m	saying	to	people.”	P423		Dysarthria	makes	telephone	hard	 C:	[to	P]	Well	telephone	calls	aren’t	that	practical	are	they	for	you.		Because	if	you	are	tired,	I	mean	it’s	difficult	to	convey.”C172	Email	may	be	impersonal		 “I	think	that’s	a	bit	impersonal	email,	you	know,	that,	that’s	what	I	thought”	C423	Telephone	useful	for	problems	needing	an	immediate	answer	
“If	it's	something	that	needs	doing,	dealing	with	here	and	now:	the	
telephone,	email	is,	is	my	favourite	way	of	communicating,	because	it	
suits	my	condition..”	P047	Some	subjects	are	better	discussed	face	to	face	 “I	think	it's	not	personal...	 I'd	rather	see	somebody	or	talk	to	somebody	than,	than	read	about	it	on	something	on	a	screen.”	C366	Happy	to	receive	feedback	in	clinic	 “	I	realise	that	you	are	probably	busy	people,	so	I’m	quite	happy	for	someone	to	say,	when	we’re	down	there,	“oh	by	the	way,	your	survey	has	
altered	and,	you	know,	do	you	want	to	talk	to	you	about	it.”	C172	Happy	to	wait	for	a	reply	as	long	as	their	message	had	been	acknowledged	
Q:	And	if	you	put	in	a	question...		How	long	would	you	expect	before	you	
got	an	answer?	
P:	Well	normally	[Telehealth	Nurse]	gets	back	to	me	within	a	day	or	so.		
So	I	would	expect	two	days,	almost	maximum.	
Q:	OK.	So,	reasonably	quickly.	
P:	Even	if,	it	was:	“we’ve	got	your	question	:we’re	thinking	about	it”	
Q:	So,	just	an	acknowledgement	that	you’ve	email?	
P:	Yeah.	 	 It	may	be	 [Telehealth	Nurse]	can’t	answer	me	 first	 time.	Like	
the	 citalopram.	 	What	 she	 said	was:	 “I’ll	 discuss	 it	with,	 (I	 think)	 you”	
and	then	came	back	to	me.”	P381	Importance	of	respiratory	monitoring	 “Q:	What	do	you	think,	how	do	you	think	this	would	fit	in	around	your	clinic	visits	and	the	support	you	would	get	from	[Telehealth	Nurse]?	If	this	was	to	become...rather	than	a	research	project,	part	of	standard	
care,	how	do	you	think	you	would	suggest	using	it?	
P:	Well	I	think	in	my	case	I	would	be	happy	to	use	that	and	lengthen	the	
time	between	visits.		I	mean,	the	only	difference	to	me	is	the	breathing	
test.”	P381	Happy	to	share	the	information	with	other	members	of	the	care	team	
“Q:	And	is	there,	is	there	someone	locally	that	you	think	would	be,	so	that	
would	be	able	to	see	your	answers	...?	
P:	Well	a	good	one	would	be	the	GP,	wouldn’t	they?		Or	even	the	hospice,	
or,	even	the	district	nurses,	probably	more	the	district	nurses,	cos	
obviously	they’ve	got	a	regular	visit	now,	haven’t	they?”	P056	
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A5.37	The	Telehealth	Nurse’s	attitudes	towards	how	the	TiM	might	be	used	in	the	future.		Quotes	are	all	from	the	Telehealth	Nurse		
How	would	the	TiM	be	used?	Delegating	TiM	duties	may	not	be	possible	
“I	agreed	to	do	it	originally	cos	I	said	the	thing	is	when	a	red	flag	
comes	if	it’s	somebody	else	doing	it	and	looking	at	it	they’re	gonna	
come	to	me.”			The	nurse	wants	to	use	her	judgement,	not	follow	a	strict	protocol	
“The	way	this	study	is	run	at	the	moment	I	can	respond	in,	in	the	way	
I	think	is	appropriate”	Telehealth	Nurse		
“if	it	was	written	down,	[that]	I	had	to	ring	and	I	had	to	ring	
straightaway,	…	I	don’t	know	whether,	I	would	have	found	that	quite	
difficult	not	being	able	to	use	my	initiative	and	how	I’m	familiar	with	
the	patients	and,	don’t	know	I	might	not	have,	I	might	have	found	
that	a	bit	more	difficult.”			Some	nurse	may	be	more	willing	to	follow	a	protocol	and	call	more	often	
“N:	It’s	difficult,	I	think	you	would	probably	get	more	useful	
information	out	of	the	research	nurses,	but	you	would	have	to	have	a	
system	where	they’d	be	able	to	go	to	somebody	to	act	upon	what	was	
[needed]”	Telehealth	Nurse	
“I	think	if	it	was	a	bigger	study	and..	it	was	a	very	…	carefully	
monitored	study,	I	think	maybe	the	person	doing	this,	looking	at	this	
…	looking	at	what	the	replies	have	been,	if	they	had	to	contact	them	
that	might	work	better.”				 	
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A5.38	How	the	TiM	might	be	used	by	other	teams		
Use	by	community	teams	Community	teams	would	need	capacity	 “I	think	if	they	have	the	capacity	it	would	be	useful,”	Telehealth	Nurse	It	would	increase	information	available	for	community	teams	 “Q:	Could	[you]	see	[the	TiM]	fitting	into	the	role	you	play	or	whether	you	think	it’s	not	very	helpful?	N:	I	think	it	probably	could	because,	like	you’ve	just	
said..	that	[patient	has]	reported	on	here	that	she’s	…	
coughing/choking	so	many	times	but	she	never	said	
that	to	me.”	Community	nurse	Community	staff	may	not	have	access	to	computers	 “I’m	not	very	good	at	computers.	I	have	to	say,	that	is	the	thing	I	find	most	stressful	about	working	here.		You	I’m	home	based.	I	go	on	NHS	website...so	I’m	not	
on,	well	I	can	get	onto	it	but	I	do	not	cos	I	don’t	spend	
a	lot	of	time	[in	the	hospital].”Community	nurse	Community	staff	happy	to	receive	information	from	Telehealth	Nurse	
“Q:	If	someone	else	was	looking	at	this,	telling	you	
there’s	a	problem?	
N:	Yeah,	no,	that	would	be	fine,	that	would	be	fine,	
yeah,	yeah.”Community	nurse	
Use	by	other	MND	centres	Other	services	would	respond	positively	 “I	think	their	gut	reaction	is	that	that	sounds	something	potentially	helpful	to	us;	I	haven’t	really	
had	any	negativity”	Telehealth	Nurse	Other	services	would	want	TiM	if	it	saved	them	time	 “I	think	that	if	it	saves	them	time	I	think	that	they	would	definitely	embrace	it.”	Telehealth	Nurse		Other	services	would	want	TiM	if	it	benefited	the	patient	 “From	a	clinical	side	I	think	that	anybody	would	be	willing	to	make	it	as	easy	for	the	patient	as	possible,	as	long	as	it	was	useful.”	Telehealth	Nurse		Nurses	would	use	it	if	it	were	part	of	their	usual	role	 “Q:	But	then	if	you	were	thinking	about	implementing	this	into	the	NHS	who	would	you	get	the	most	useful	information	from?	
TW:	I	think	if	it	was	implemented	and	it	was	part	of	
somebody’s	role	every	day	they	would	just	do	it,	they	
would	do	it	automatically;	and,	yes,	I	could	envision	
that	it	would	be	very	useful.	So	I	suppose	I’m	a	bit,	it’s	
half	and	half.”	Telehealth	Nurse				 	
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Appendix	A	Table	5.1	Patient	and	carer	preferred	frequency	of	TiM	use.	
	
		 	
Every few days (n=1)
Weekly (n=10)
Fortnightly (n=1)
Monthly (n=1)
Weekly (n=10)
Fortnightly (n=1)
Monthly (n=3)
Weekly (n=3)
Fortnightly (n=2)
Monthly (n=1)
Weekly (n=1)
Fortnightly (n=1)
Monthly (n=4)
Patient preferred frequency of TiM use 
Three months 12 months
Three months 12 months
Carer preferred frequency of TiM use
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Appendix	A	Table	5.2	Patient	satisfaction	with	Tim	system	at	3	and	12	months.		
			 	
0 25 50 75 10
0
If I were unable to travel to clinic I would like to use the TiM system 
I would recommend the TiM system to a fellow patient 
If something like the TiM was available to use as part of usual NHS care I would like to use it 
If something like the TiM system was available to use as part of another trial I would like to use it 
The questions were upsetting or distressing 
Using the system took a lot of time or energy 
The Knowledge Centre was useful 
The Problem List was useful 
The TiM system respected my privacy and confidentiality 
The MND team contacted me quickly if my condition changed or I had a problem 
The TiM system allowed me to report all the problems with my MND 
The TiM questions were relevant to me 
It was easy to use the TiM system 
Ag
ree
Neutral
Disagree
N/A or blank
If my doctor reviewed the TiM system results and found my condition was stable I would be happy 
for them to delay my appointment until I need it 
% of patients (n=13)
0 25 50 75 10
0
If I were unable to travel to clinic I would like to use the TiM system 
I would recommend the TiM system to a fellow patient 
If something like the TiM was available to use as part of usual NHS care I would like to use it 
If something like the TiM system was available to use as part of another trial I would like to use it 
The questions were upsetting or distressing 
Using the system took a lot of time or energy 
The Knowledge Centre was useful 
The Problem List was useful 
The TiM system respected my privacy and confidentiality 
The MND team contacted me quickly if my condition changed or I had a problem 
The TiM system allowed me to report all the problems with my MND 
The TiM questions were relevant to me 
It was easy to use the TiM system 
Agree
Neutral
Disagree
N/A or blank
If my doctor reviewed the TiM system results and found my condition was stable I would be happy for 
them to delay my appointment until I need it 
% of patients (n=6)
Patient 3 months
Patient 12 months
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	Appendix	A	Table	5.3	Carer	satisfaction	with	Tim	system	at	3	and	12	months.		
	 	
0 25 50 75 10
0
I would recommend the TiM system to a fellow carer 
If something like the TiM was available to use as part of usual NHS care I would like to use it 
If something like the TiM system was available to use as part of another trial I would like to use it 
The questions were upsetting or distressing 
Using the system took a lot of time or energy 
The Knowledge Centre was useful 
The Problem list was useful 
The TiM system respected my privacy and confidentiality 
The MND team contacted me quickly if I had a problem 
The TiM system allowed me to report all the problems I face as a carer 
The TiM questions were relevant to me as a carer 
It was easy to use the TiM system 
Agree
Neutral
Disagree
N/A or blank
% of carers  (n=14)
0 25 50 75 10
0
I would recommend the TiM system to a fellow carer 
If something like the TiM was available to use as part of usual NHS care I would like to use it 
If something like the TiM system was available to use as part of another trial I would like to use it 
The questions were upsetting or distressing 
Using the system took a lot of time or energy 
The Knowledge Centre was useful 
The Problem list was useful 
The TiM system respected my privacy and confidentiality 
The MND team contacted me quickly if I had a problem 
The TiM system allowed me to report all the problems I face as a carer 
The TiM questions were relevant to me as a carer 
It was easy to use the TiM system 
Agree
Neutral
Disagree
N/A or blank
% of carers  (n=6)
Carer 3 months
Carer 12 months
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Appendix	6.1		A6.1	Patient-36	physical	(PCS)	and	mental	(MCS)	sub-scores.	The	mean	and	standard	deviation	(SD)	of	the	mean	scores,	the	mean	change	from	baseline	and	the	95%	confidence	interval	of	the	mean	change	from	baseline.		These	are	standardised	to	a	normative	reference	population	in	which	the	mean	is	50	and	Standard	deviation	is	10.			
Patient		
SF-36	
Base-
line	 3	months	 6	months	 12	months	
Mean	
(SD)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Telehealth	PCS		 n=18	 n=16	 n=15	 n=16	 n=16	 n=6	 n=6	Mean	(SD/CI)	 30.1	(9.1)	 30.7	(7.7)	 -0.7	(-3.3,	1.9)	 28.2	(8.6)	 -3.1	(-7.1,	0.9)	 22.6	(4.1)	 -5.8	(-15.0,	3.4)	MCS		 n=18	 n=16	 n=15	 n=16	 n=16	 n=6	 n=6	Mean	(SD/CI)	 52.3	(10.0)	 50.7	(11.7)	 -1.4	(-5.4,	2.6)	 52.3	(12.3)	 -0.2	(-4.2,	3.8)	 48.8	(15.8)	 -5.7	(-18.8,	7.2)	
Control	PCS		 n=20	 n=14	 n=14	 n=12	 n=12	 n=6	 n=6	Mean	(SD/CI)	 28.0	(8.7)	 26.6	(5.8)	 -0.6	(-5.4,	4.3)	 27.0	(7.9)	 -0.1	(-7.8,	7.6)	 23.7	(3.0)	 -6.6	(-13.8,	0.5)	MCS		 n=20	 n=14	 n=14	 n=12	 n=12	 n=6	 n=6	Mean	(SD/CI)	 54.3	(9.5)	 55.1	(13.5)	 0.9	(-5.4,	7.3)	 50.8	(12.1)	 -3.6	(-10.7,3.6)	 54.7	(9.2)	 -1.3	(-17.8,15.3)	
Total	PCS	 n=38	 n=30	 n=29	 n=28	 n=28	 n=12	 n=12	Mean	(SD/CI)	 29.0	(8.8)	 28.3	(7.2)	 -0.7	(-3.2,	1.9)	 27.7	(8.2)	 -1.8	(-5.5,	1.9)	 23.2	(3.5)	 -6.2	(-11.0,-1.4)	MCS	 n=38	 n=30	 n=29	 n=28	 n=28	 n=12	 n=12	Mean	(SD/CI)	 53.3	(9.7)	 52.7	(12.6)	 -0.3	(-3.8,	3.2)	 51.7	(12.0)	 -1.7	(-5.2,	1.9)	 51.8	(12.7)	 -3.5	(-12.2,	5.2)	
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A6.2	EQ-5D-3L	and	EQ-5D	plus	dignity	bolt-on	and	the	EQ5D	thermometer.		Scores	range	from	1	(best	QoL)	to	-0.59	(worst	QoL).	
Thermometer	scores	range	from	100	(best	QoL)	to	0	(worst	QoL).	 18		
Patient		
EQ
-5D
	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
M
ean	
(SD
)	
M
ean	
(SD
)	
Change	from
	baseline	
M
ean	(CI)	
M
ean	
(SD
)	
Change	from
	baseline	
M
ean	(CI)	
M
ean	
(SD
)	
Change	from
	baseline	
M
ean	(CI)	
Telehealth		
n=17		
n=16	
n=14	
n=16	
n=15	
n=6	
n=6	
EQ5D-3L			 0.52		(0.31)	
0.49		(0.27)	
-0.04	
(-0.13,	0.05)	
0.49	(0.30)	
-0.07	
(-0.20,	0.06)	
0.39		(0.36)	
-0.09	
(-0.38,	0.21)	
EQ5D-3L+D			 0.46		(0.40)	
0.48		(0.30)	
-0.02	
(-0.18,	0.14)	
0.47	(0.35)	
-0.04	
(-0.24,	0.16)	
0.26	(0.54)	
-0.15	
(-0.63,	0.33)	
Thermometer		 61.1	(22.5)	
63.8	(25.0)	
-2.1	
(-8.7,	4.6)	
61.6	(20.5)	
-3.7	
(-9.6,	2.3)	
57.5	(22.3)	
-5.8	
(-12.8,	1,1)	
Control																									n=20	
n=15	
n=15	
n=12	
n=12	
n=6 19	
n=6 3	
EQ5D-3L			 0.53	(0.27)	
0.50	(0.29)	
0.02	
(-0.10,	0.14)	
0.46	(0.25)	
-0.11	
(-0.22,	0.01)	
0.37	(0.33)	
-0.25	
(-0.50,	0.0)	
EQ5D-3L+D			 0.49	(0.37)	
0.44	(0.41)	
0.01	
(-0.10,	0.14)	
0.44	(0.29)	
-0.10	
(-0.21,	0.01)	
0.26	(0.48)	
-0.27	
(-0.59,	0.04)	
Thermometer		 64.5	(20.6)	
64.6	(26.8)	
0.9	
(-13.5,	15.4)	
61.7	(25.3)	
-6.7	
(-19.8,	6.5)	
60.9	(21.6)	
-7.0	
(-37.2,	23.2)	
Total	
n=	37	
n=31	
n=29	
n=28	
n=27	
n=12 3	
n=12 3	
EQ5D-3L			 0.53		(0.29)	
0.50		(0.27)	
-0.01	
(-0.01,	0.06)	
0.47	(0.27)	
-0.09	
(-0.17,	-0.01)	
0.38		(0.33)	
-0.17	
(-0.33,	0.00)	
EQ5D-3L+D			 0.48		(0.37)	
0.46		(0.35)	
-0.01	
(-0.10,	0.08)	
0.46	(0.32)	
-0.07	
(-0.18,	0.05)	
0.26	(0.49)	
-0.21	
(-0.45,	0.03)	
Thermometer	63.0	(21.3)	
64.2	(25.5)	
-0.5	
(-8.2,	7.1)	
61.6	(23.0)	
-5.0	
(-11.2,	1.2)	
59.3	(21.1)	
-6.4	
(-20.7,	7.7)	
																																																								
18	Patients	who	had	died	were	excluded	from	analysis.	The	number	of	patients	for	whom	scores	were	available	was	the	same	for	the	EQ5D-3L,	EQ5D-3L+D.		Three	patients	left	the	Mobility	question	blank,	
writing	that	they	were	neither	able	to	walk	(score	2)	nor	in	confined	to	bed	(score	3).		The	trial	statistician	agreed	to	score	these	as	2.			
19	Control	group	n=6	in	EQ5D	calculations	and	n=7	in	thermometer	calculations	at	both	6	and	12	months.	
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A6.3	EQ-5D-3L	and	EQ-5D	plus	dignity	bolt-on	and	the	EQ5D	thermometer.		In	these	calculations,	patients	who	had	died	were	included	in	the	scoring	and	were	assigned	a	score	of	0.		Thermometer	scores	are	unchanged.	
Patient		
EQ-5D	
Base-
line	 3	months	 6	months	 12	months	
Mean	
(SD)	
Mean	
(SD)	
Change	
from	
baseline	
Mean		
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean		
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Telehealth	n=	*								 17	 17	 15	 17	 16	 8	 8	EQ5D-3L		Mean	(SD/CI)	 0.52	(0.31)	 0.46	(0.29)	 -0.05	(-0.14,	0.03)	 0.46	(0.31)	 -0.08		(-0.20,	0.04)	 0.35	(0.37)	 -0.12	(-0.33,	0.08)	EQ5D-3L+D		Mean	(SD/CI)	 0.46	(0.40)	 0.44		(0.41)	 -0.03		(-0.18,	0.12)	 0.44	(0.35)	 -0.05	(-0.23,0.14)	 0.20	(0.47)	 -0.17	(-0.50,	0.15)	Thermometer	n=	 17	 16	 14	 16	 15	 6	 6	Mean	(SD/CI)	 61.1	(22.5)	 63.8	(25.0)	 -2.1		(-8.7,	4.6)	 61.6	(20.5)	 -3.7	(-9.6,	2.3)	 57.5	(22.3)	 -5.8	(-12.8,	1,1)	
Control	 n=*									20	 15	 15	 14	 14	 8	 7	EQ5D-3L		Mean	(SD/CI)	 0.53	(0.28)	 0.50	(0.28)	 0.02		(-0.10,	0.14)	 0.39	(0.28)	 -0.12		(-0.26,	0.01)	 0.28	(0.33)	 -0.28	(-0.48,	-0.08)	EQ5D-3L+D		Mean	(SD/CI)	 0.49	(0.37)	 0.44	(0.41)	 0.00	(-0.12,	0.12)	 0.38	(0.31)	 -0.08	(-0.23,	0.07)	 0.19	(0.43)	 -0.28	(-0.51,	0.10)	Thermometer	n=	 20	 15	 15	 12	 12	 7	 7	Mean	(SD/CI)	 64.5	(20.6)	 64.6	(26.8)	 0.9	(-13.5,	15.4)	 61.7	(25.3)	 -6.7		(-19.8,	6.5)	 60.9	(21.6)	 -7.0	(32.6)	
Total	 n=	*								 37	 32	 30	 31	 30	 16	 15	EQ5D-3L		Mean	(SD/CI)	 0.53	(0.29)	 0.49	(0.28)	 -0.02		(-0.09,	0.05)	 0.43	(0.29)	 -0.10	(-0.19,	-0.02)	 0.29	(0.33)	 -0.20	(-0.33,	0.08)	
EQ5D-3L+D		Mean	(SD/CI)	 0.48	(0.37)	 0.44	(0.41)	 -0.02	(-0.10,	0.07)	 0.41	(0.33)	 -0.06	(-0.18,	0.05)	 0.20	(0.43)	 -0.23	(-0.40,	-0.05)	Thermometer	n=	 37	 31	 29	 28	 27	 13	 13	Mean	(SD/CI)	 63.0	(21.3)	 64.2	(25.5)	 -0.5	(-8.2,	7.1)	 61.6	(53.0)	 -5.0		(-11.2,	1.2)	 59.3	(21.1)	 -6.4	(-20.7,	7.7)		 	
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Table	6.4:	Patient	ALSFRS-R	scores.		Scores	range	from	0	(severe	disability)	to	48	(no	disability).	Scores	highlighted	in	bold	indicate	
scores	that	have	changed	significantly	from	baseline.	
		ALSFRS-R	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
M
ean	
(SD
)	
M
ean	
(SD
)	
Change	
from
	
baseline	
M
ean		
(CI)	
M
ean	
(SD
)	
Change	from
	
baseline	
M
ean		
(CI)	
M
ean	
(SD
)	
Change	from
	
baseline	
M
ean	
(CI)	
Telehealth			n=18	
n=16	
n=15	
n=16	
n=16	
n=6	
n=6	
Mean				 31.9	(9.7)	
32.1	(10.4)	
-0.06	
(-2.6,	3.4)	 31.1	(9.0)	
-0.3		
(-2.6,	1.9)	
28.7	(7.6)	
-4.7		
(-8.5,	-0.81)	
	
Control			n=20	
n=15	
n=15	
n=12	
n=12	
n=7	
n=7	
Mean			 32.1	(8.0)	
29.8		(8.7)	
-1.5		
(-4.1,	1.0)	 29.4		(9.0)	
-3.7		
(-6.8,	-0.5)	 25.9		(6.0)	
-5.1	
(-12,	1.3)	
	
Total		n=38	
n=31	
n=30	
n=28	
n=28	
n=13	
n=13	
Mean			 32.0	(8.7)	
30.9		(9.5)	
-0.6	
(-2.2,	1.0)	 31.1	(8.9)	
-1.6	
(-3.6	–	0.4)	 27.9	(9.6)	
-4.9		
(-8.4,	-1.4)	
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A6.5	TiM	study	participants’	HADS	sub-scores	and	UK	normal	population	values	for	adults	aged	60-65	years	(258).			
	
	 HADS	Anxiety	sub-score	 HADS	Depression	sub-score	
Mean	
(SD)	
At	least	
mild	
symptoms	
(score	>8)	
Moderate/	
severe	
symptoms	
(score	>11)	
Mean	
(SD)	
At	least	
mild	
symptoms	
(score	>8)	
Moderate/	
severe	
symptoms	
(score	>11)	
Study	patients	Total	(n=37)	 5.4		(4.0)	 11		(30%)	 3		(8%)	 4.8	(3.1)	 8	(22%)	 1	(3%)	Female		(n=11)	 6.9		(4.3)	 5	(46%)	 2		(18%)	 6.1	(2.9)	 5	(46%)	 0	(0%)	Male		(n=26)	 4.8		(3.7)	 6	(23%)	 1		(4%)	 4.2	(3.0)	 2	(8%)	 1	(4%)	
Study	carers	Total		(n=34)	 6.1		(4.0)	 13		(35%)	 4		(11%)	 3.6	(3.0)	 3	(8%)	 2		(5%)	Female		(n=28)	 6.2		(4.1)	 11	(39%)	 4	(14%)	 5.6	(3.7)	 3	(11%)	 2	(7%)	Males		(n=6)	 5.6	(4.0)	 2	(33%)	 0		(0%)	 3.8	(2.0)	 0		(0%)	 0		(0%)	
UK	population	Female	(n=399)	 6.3		(3.9)	 32%	 15%	 4.1	(3.3)	 15%	 5%	Male	(n=364)	 4.9		(3.6)	 22%	 8%	 3.9	(3.5)	 17%	 7%				
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A6.6	Patient	HADS	Anxiety	sub-scores	and	the	number	(%)	of	patients	with	borderline	scores	and	abnormal	scores.		0-7	normal,	8-10	
borderline/mild	symptoms,	11-21	abnormal:	moderate/severe.	
H
AD
S	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
M
ean	(SD
)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline	M
ean	
(CI)	
Telehealth	Anxiety		
n=17	
n=16	
n=16	
n=16	
n=15	
n=6	
n=6	
Mean			
(SD/CI)	
6.0	(4.0)	
5.7	(4.3)	
-0.2	
(-2.3,	1.9)	
4.7	(3.7)	
-0.9	
(-2.1,	0.4)	
5.7	(2.4)	
-.0.7	
(-3.3,	2.0)	
Score	>8	
8	(47%)	
4	(25%)	
-	
3	(19%)	
-	
1	(6%)	
-	
Score	>11	
1	(6%)	
2	(13%)	
-	
1	(6%)	
-	
0	(0%)	
-	
	
Control	Anxiety		
n=20	
n=15	
n=15	
n=12	
n=12	
n=7	
n=7	
Mean			
(SD/CI)	
4.9	(3.9)	
4.6	(4.4)	
-0.5	
(-2.1,	1.2)	
5.1	(5.1)	
-.3	(-1.8,	1.3)	
6.0	(4.8)	
0.9	(4.7)	
Score	>8	
3	(15%)	
4	(27%)	
-	
3	(20%)	
-	
2	(13%)	
-	
Score	>11	
2	(10%)	
3	(20%)	
-	
2	(13%)	
-	
1	(7%)	
-	
	Total	Anxiety	
	
n=37	
n=31	
n=31	
n=28	
n=27	
n=13	
n=13	
Mean		
(SD/CI)	
5.4	(4.0)	
5.2	(4.3)	
-0.3	
(-1.6,	0.9)	
4.9	(4.3)	
-0.6	
(-1.5,	0.3)	
5.8	(3.8)	
0.2	(-2.1,	2.4)	
Score	>8	
11	(30%)	
8	(26%)	
-	
6	(19%)	
-	
3	(10%)	
-	
Score	>	
3	(8%)	
5	(16%)	
-	
3	(10%)	
-	
1	(3%)	
-	
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A6.7	Patient	HADS	Depression	sub-scores	and	the	number	(%)	of	patients	with	borderline	scores	and	abnormal	scores.	0-7	normal,	8-10	
borderline/mild	symptoms,	11-21	abnormal:	moderate/severe.	
H
AD
S	
Baseline	
3	m
onths	
6	m
onths	
12	m
onths	
M
ean	(SD
)	
M
ean	(SD
)	
Change	from
	
baseline	
M
ean	(CI)	
M
ean	(SD
)	
Change	from
	
baseline	M
ean	
(CI)	
M
ean	(SD
)	
Change	from
	
baseline	M
ean	
(CI)	
	
Telehealth	D
epression		
n=20	
n=16	
n=16	
n=16	
n=15	
n=6	
n=6	
Mean		
(SD/CI)	
5.9	(2.9)	
5.6	(2.7)	
-0.3	
(-2.1,	1.6)	
5.8	(3.0)	
0.3	(-1.0,	1.6)	
7.5	(4.3)	
1.7	(-1.0,	4.4)	
Score	>8	
5	(29%)	
6	(38%)	
-	
6	(38%)	
-	
3	(19%)	
-	
Score	>11	
0	(0%)	
0	(0%)	
-	
0	(0%)	
-	
3	(19%)	
-	
	
Control	D
epression		
n=20	
n=15	
n=15	
n=12	
n=12	
n=7	
n=7	
Mean		
(SD/CI)	
3.9	(3.0)	
6.1	(3.8)	
1.5	(-0.4,	3.3)	
5.8	(3.3)	
0.8	(-1.7,	3.3)	
6.4	(3.6)	
0.9	(-3.4,	5.1)	
Score	>8	
3	(15%)	
4	(27%)	
-	
3	(20%)	
-	
3	(20%)	
-	
Score	>11	
1	(5%)	
3	(20%)	
-	
1	(7%)	
-	
1	(7%)	
-	
	
Total	D
epression		
n=37	
n=31	
n=31	
n=28	
n=27	
n=13	
n=13	
Mean		
(SD/CI)	
4.8	(3.1)	
5.8	(3.2)	
0.6	(-0.7,	1.9)	
5.8	(3.1)	
0.5	(-0.7,	1.7)	
6.9	(4.6,	9.2)	
1.2	(-1.0,	3.5)	
Score	>8	
8	(22%)	
10(32%)	
-	
9	(29%)	
-	
6	(19%)	
-	
Score	>11	
1	(3%)	
3	(10%)	
-	
1	(3%)	
-	
4	(13%)	
-	
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	A6.8	“Current”	and	“worst”	pain	scores	over	previous	week	(rated	on	a	modified	Likert	score	from	0-10)		
Pain	
scores	
Base
-line	
3	months	 6	months	 12	months	
Mean	
(SD)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Current	pain	(0-10)	Control				 20	 15	 15	 13	 13	 7	 7	Mean		(SD/CI)		 1.4	(1.4)	 1.6	(2.0)	 0.33	(-0.5,	1.2)	 1.4	(2.0)	 0.2	(-1.1,	1.4)	 2.6	(2.5)	 -0.9	(-2.6,	0.9)	Telehealth			 17	 16	 15	 15	 15	 6	 6	Mean		(SD/CI)			 1.7	(1.9)	 2.1	(2.4)	 0.1	(-1.3,	1.4)	 1.8	(2.3)	 1.8	(0.7,	2.9)	 1.8	(1.6)	 0.8	(-1.2,	2.9)	Total	 37	 31	 30	 28	 28	 13	 13	Mean		(SD/CI)	 1.5	(1.7)	 1.9	(2.2)	 0.2	(-0.5,	0.9)	 1.6	(2.2)	 1.0	(0.2,	1.9)	 2.2	(2.1)	 -0.1	(-1.3,	1.1)	
Worst	pain	(0-10)	Control					 20	 15	 15	 13	 13	 7	 7	Mean		(SD/CI)	 3.2	(2.7)	 3.4	(3.1)	 -0.1	(-1.3,	1.0)	 2.6	(2.7)	 -0.2	(-0.8,	0.4)	 3.9	(3.1)	 0.3	(-1.0,	1.6)	Telehealth							 17	 16	 15	 15	 15	 6	 6	Mean		(SD/CI)	 2.9	(2.8)	 3.4	(3.1)	 0.1	(-1.2,	1.5)	 3.0	(2.8)	 3.1	(1.6,	4.7)	 3.5	(2.2)	 0.3			(-2.4,	2.1)	Total	 37	 31	 30	 28	 28	 13	 13	Mean		(SD/CI)	 3.0	(2.7)	 3.2	(2.9)	 0.0	(-0.8,	0.8)	 2.8	(2.7)	 1.6	(0.5,	2.6)	 3.7	(2.7)	 0.1	(-1.0,	1.1)				
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A6.9	CSS-MND	saliva	severity	scores	(mean,	SD)	and	change	from	baseline	(mean,	95%	confidence	interval).		Scores	range	from	0	(no	problems	with	orophrayngeal	secretions)	to	36	(severe	secretions).		
	
	 	
CSS	MND	
Baseline	 3	months	 6	months	 12	months	
Mean	
(SD)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Mean	
(SD)	
Change	
from	
baselin
e	Mean	
(CI)	Telehealth					 n=17	 n=16	 n=14	 n=16	 n=16	 n=6	 n=6	Mean		(SD)	 4.2	(6.0)	 4.8	(6.4)	 1.9	(0.2,	3.5)	 2.6	(1.2)	 0.0	(-2.8,	2.8)	 2.3	(3.2)	 0.2	(-1.4,	1.9)	Control									 n=20	 n=15	 n=14	 n=12	 n=12	 n=7	 n=6	Mean	(SD)		 4.1	(5.2)	 5.5	(6.2)	 1.0	(-1.5,	3.5)	 2.8	(1.1)	 0.1	(-1.56,	1.7)	 3.4	(4.5)	 -0.7	(-0.7,	3.4)	Total											 n=37	 n=31	 n=29	 n=28	 n=28	 n=13	 n=12	Mean		(SD)	 4.1	(5.5)	 5.1	(6.2)	 1.4	(0-2.9)	 2.6	(1.1)	 0.0	(-1.6,	1.6)	 3.4	(4.5)	 0.2	(-1.4,	1.9)	
	 304	
A6.10	Carer	SF-36	physical	and	mental	sub-scores.		These	scores	are	standardised	to	a	normative	reference	population	in	which	the	mean	is	50	and	standard	deviation	is	10.		
Carer		
SF-36	
Base-
line	 3	months	 6	months	 12	months	
Mean	
(SD)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	(CI)	
Mean	
(SD)	
Change	
from	
baseline	
Mean	
(CI)	
Telehealth	Physical		 n=16	 n=14	 n=13	 n=15	 n=14	 n=4	 n=4	Mean	(SD/CI)	 52.4	(11.1)	 49.0	(9.6)	 -1.9	(-8.0,	4.2)	 51.6	(9.7)	 0.10	(-4.9,	5.2)	 51.0	(3.1)	 -3.6	(-13.8,6.6)	Mental		 16	 14	 13	 15	 14	 4	 4	Mean	(SD/CI)	 47.9	(13.1)	 50.5	(14.5)	 3.3	(-1.1,	7.7)	 48.6	(14.4)	 1.2	(-2.8,	5.2)	 45.3	(14.5)	 -2.9	(-9.6,	3.8)	
Control	Physical		 	 n=18	 n=13	 n=13	 n=11	 n=11	 n=7	 n=7	Mean	(SD/CI)	 52.9	(7.7)	 51.9	(7.0)	 -3.2	(-8.1,	1.8)	 49.1	(8.8)	 -4.7	(-8.9,	-0.4)	 52.2	(9.6)	 -3.0	(-10.2,4.2)	Mental		 n=18	 n=13	 n=13	 n=11	 n=11	 n=7	 n=7	Mean	(SD/CI)	 50.6	(10.3)	 51.2	(8.7)	 1.7	(-2.2,	5.5)	 51.8	(10.5)	 0.70		(-6.8,	8.1)	 51.7	(10.3)	 2.4	(-4.5,	9.3)	
Total	Physical		 n=34	 n=27	 n=26	 n=26	 n=25	 n=11	 n=11	Mean	(SD/CI)	 52.7	(9.3)	 50.4	(8.4)	 -2.5	(-6.1,	1.1)	 50.1	(9.2)	 -2.0	(-5.3,	1.3)	 51.8	(7.6)	 -3.2	(-7.9,	1.5)	Mental		 n=34	 n=27	 n=26	 n=26	 n=25	 n=11	 n=11	Mean	(SD/CI)	 49.3	(11.6)	 50.8	(11.8)	 2.5		(-0.3,	5.2)	 49.9	(12.8)	 1.0	(-2.7,	4.6)	 49.4	(11.7)	 0.4	(-4.1,	5.0)		
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Table	6.7	Patient	estimated	hours	of	paid	and	unpaid	care	received	per	week.			 Baseline	 3	month	 6	months	 12	months	
Telehealth	
	Paid	carer	hours		 	n=17	 	n=16	 	n=15	 	n=5	Mean	(SD)	 12.7	(33.2)	 20.9	(52.4)	 34.7	(64.6)	 66.6	(89.0)	Median	(Range)	 0	(0-110)	 0	(0-168)	 0	(0-168)	 5	(0-168)		Unpaid	carer	hours		 	n=12	 	n=16	 	n=15	 	n=5	Mean	(SD)	 66.6	(70.2)	 43.5	(58.6)	 42.8	(57.4)	 19.6	(20.5)	Median	(Range)	 47.5	(0-168)	 10	(0-168)	 20	(0-168)	 10	(0-168)		
Control		Paid	carer	hours		 	n=18	 	n=13	 	n=12	 	n=6	Mean	(SD)	 3.6	(8.4)	 2.4	(5.7)	 4.3	(11.4)	 2.5	(4.5)	Median	(Range)	 0	(0-28)	 0	(0-20)	 0	(0-40)	 0	(0-11)		Unpaid	carer	hours		 	n=20	 	n=14	 	n=12	 	n=5	Mean	(SD)	 33.4	(64.9)	 36.6	(55.4)	 38.2	(53.3)	 99.8	(90.2)	Median	(Range)	 12.0	(0-168)	 18.5	(0-168)	 18	(0-161)	 161	(0-168)		
Total		Paid	carer	hours		 	n=35	 	n=29	 	n=27	 	n=11	Mean	(SD)	 8.0	(24.0)	 12.6	(39.7)	 21.2	(50.4)	 31.6	(65.6)	Median	(Range)	 0	(0-110)	 0	(0-168)	 0	(0-168)	 0	(0-168)		Unpaid	carer	hours		 	n=32	 	n=30	 	n=27	 	n=10	Mean	(SD)	 52.7	(66.7)	 40.3	(56.3)	 40.7	(54.6)	 59.7	(74.8)	Median	(Range)	 14.5	(0-168)	 14.5	(0-168)	 20	(0-168)	 12	(0-168)			 	
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A6.11	The	adverse	events	recorded	during	the	trial.		
	 Telehealth	 Control	 Total	
	
Number	
of	
events	
Number		of	
patients/c
arers	
(%)	
Number	of	
events	
Number		
of	
patients/
carers	
(%)	
Numb
er	of	
events	
Number		
of	
patients	
/carers	
(%)	
MND	related	Chest	infection/	respiratory	symptoms	 7	 7	(35%)	 4	 4	(20%)	 11	 11	(55%)	Falls	
	
8	 7	(35%)	 3	 3	(15%)	 11	 10	(50%)	Musculoskeletal	symptoms	
	
3	 3	(15%)	 0	 0	(0%)	 3	 3	(15%)	Excessive	saliva	/	choking	
	
2	 1	(5%)	 0	 0	(0%)	 2	 1	(5%)	Elective	PEG		insertion	
	
2	 2	(10%)	 1	 1	(5%)	 3	 3	(15%)	PEG	site	problem	 0	 0	(0%)	 1	 1	(5%)	 1	 1	(5%)	Patient		psychological		distress	
	
0	 0	(0%)	 1	 1	(5%)	 1	 1	(3%)	
Carer	psychological	distress	 11	 5	(29%)	 6	 5	(26%)	 17	 10	(27%)		
Other	adverse	events	Other	medical	 7	 3	(15%)	 5	 5	(25%)	 12	 8	(40%)	Other	surgical	 0	 0	(0%)	 2	 1	(5%)	 2	 1	(5%)					 	
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	A6.12	Summary	of	health	encounters	for	the	three	months	prior	to	baseline		 	 Total	in	3	
months20	
Total	
physicians21	
Total		
nurses22	
Total	
therapists23	
Telehealth		Total	(n=18)	 133	 38	 43	 52	Mean	(SD)	 7.4	(6.3)	 2.1	(2.3)	 2.4	(2.6)	 2.9	(3.1)	Median	 5.5	 1	 1.5	 2	Range	 0-28	 0-8	 0-10	 0-11	
Control	Total	(n=20)	 211	 45	 72	 88	Mean	(SD)	 10.6	(8.5)	 2.3	(2.1)	 3.6	(5.1)	 4.4	(4.3)	Median	 8	 2	 1	 4	Range	 1-30	 0-10	 0-19	 0-13	
Total	Total	(n=38)	 344	 83	 115	 140	Mean	(SD)	 9.1	(7.7)	 2.2	(2.2)	 3.0	(4.1)	 3.7	(3.8)	Median	 7	 2	 1	 2.5	Range	 0-30	 0-10	 0-19	 0-13				 	
																																																								20	Total	excluded	ambulance	journey	and	unrelated/non-NHS	services	21	Physicians	included	were	MND	neurologists,	palliative	care	physicians	and	general	practitioners.	22	Nurses	included	district	nurses,	MND	specialist	nurses	in	hospital	and	community	and	hospice	nurses.			23	Therapists	included	speech	and	language	therapists,	physiotherapists,	occupational	therapists,	respiratory	specialists,	dieticians	and	PEG	nurses.		
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A6.13	Summary	of	patient	reported	MND	related	health-care	encounters	between	months	0-3	of	the	study.			 	 Total24	 Total	
physicians25	
Total		
nurses26	
Total	
therapists27	
Telehealth		Total	(n=16)	 152	 40	 51	 61	Mean	(SD)	 9.5	(9.1)	 2.5	(2.3)	 3.2	(3.6)	 3.8	(4.7)	Median	 8	 2	 2	 3	Range	 2-35	 0-8	 0-13	 0-18	
Control	Total	(n=15)	 160	 38	 55	 59	Mean	(SD)	 10.7	(17.6)	 2.5	(4.2)	 3.7	(9.6)	 3.9	(3.7)	Median	 8	 1	 1	 3	Range	 0-73	 0-17	 0-38	 0-11	
Total	Total	(n=31)	 312	 78	 106	 120	Mean	(SD)	 10.1	(13.6)	 2.5	(3.3)	 3.4	(7.0)	 3.9	(4.2)	Median	 6	 2	 1	 3	Range	 0-73	 0-17	 0-38	 0-18			
																																																								24	Total	excluded	ambulance	journey	and	unrelated/non-NHS	services	25	Physicians	included	MND	neurologists,	palliative	care	physicians	and	general	practitioners.	26	Nurses	included	district	nurses,	MND	specialist	nurses	in	hospital	and	community	and	hospice	nurses.			27	Therapists	included	speech	and	language	therapists,	physiotherapists,	occupational	therapists,	respiratory	specialists,	dieticians	and	PEG	nurses.		
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A6.14	Summary	of	patient	reported	MND	related	health-care	encounters	between	months	3-6	of	the	study.	
		 	
																																																								28	Total	excluded	ambulance	journey	and	unrelated/non-NHS	services	29	Physicians	included	MND	neurologists,	palliative	care	physicians	and	general	practitioners.	30	Nurses	included	district	nurses,	MND	specialist	nurses	in	hospital	and	community	and	hospice	nurses.			31	Therapists	included	speech	and	language	therapists,	physiotherapists,	occupational	therapists,	respiratory	specialists,	dieticians	and	PEG	nurses.		
	 Total28	 Total	
physicians29	
Total		
nurses30	
Total	
therapists31	
Telehealth		Total	(n=16)	 241	 45	 143	 53	Mean	(SD)	 15.1	(29.3)	 2.8	(3.0)	 8.9	(28.3)	 3.3	(4.9)	Median	 8	 2	 1	 1.5	Range	 0-121	 0-12	 0-115	 0-17	
Control	Total	(n=12)	 83	 16	 41	 26	Mean	(SD)	 5.2	(1.5)	 1.3	(0.9)	 3.4	(4.0)	 2.2	(1.6)	Median	 4	 1	 2	 2.5	Range	 2-17	 0-3	 0-12	 0-4	
Total	Total	(n=28)	 310	 61	 184	 79	Mean	(SD)	 11.3	(22.2)	 2.1	(2.4)	 6.8	 2.8	(3.9)	Median	 4	 2	 1	 2	Range	 0-121	 0-12	 0-115	 0-79	
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A6.15	Summary	of	patient	reported	MND	related	health-care	encounters	for	the	six	months	between	months	6-12	of	the	study.					 	 Total	in	6	
months32	
Total	
physicians33	
Total		
nurses34	
Total	
therapists35	
Telehealth		Total	(n=6)	 101	 18	 52	 30	Mean	(SD)	 16.8	(17.2)	 3.0	(1.4)	 8.8	(13)	 5.0	(3.9)	Median	 9.5	 3	 3	 4	Range	 3-49	 1-5	 1-35	 1-10	
Control	Total	(n=7)	 98	 26	 32	 40	Mean	(SD)	 14.0	(10.7)	 3.7	(1.8)	 4.6	(8.0)	 5.7	(6.3)	Median	 8	 4	 1	 5	Range	 5-32	 1-6	 0-22	 1-19	
Total	Total	(n=13)	 199	 44	 87	 70	Mean	(SD)	 15.3	(13.5)	 3.4	(1.6)	 6.5	(10.5)	 5.4	(5.1)	Median	 8	 4	 2	 5	Range	 3-49	 1-6	 0-35	 1-19				 	
																																																								32	Total	excluded	ambulance	journey	and	unrelated/non-NHS	services	33	Physicians	included	MND	neurologists,	palliative	care	physicians	and	general	practitioners.	34	Nurses	included	district	nurses,	MND	specialist	nurses	in	hospital	and	community	and	hospice	nurses.			35	Therapists	included	speech	and	language	therapists,	physiotherapists,	occupational	therapists,	respiratory	specialists,	dieticians	and	PEG	nurses.		
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Table	6.6	The	number	of	admissions	(and	number	of	patients)	and	days	in	hospital	reported	by	patients	in	the	three	months	prior	to	
recruitment.		
			
							
				
Telehealth	(n=18)	
Control	(n=20)	
Total	(n=38)	
N
um
ber	of	
adm
issions	
(num
ber	of	
patients)	
N
ights	in	
hospital	
N
um
ber	of	
adm
issions	
(num
ber	of	
patients)	
N
ights	in	
hospital	
N
um
ber	of	
adm
issions	
(num
ber	of	
patients)	
N
ights	in	
hospital	
Elective															
	
	
	
	
PEG	insertion	
0	
0	
4	(3)	
15	
4	(3)	
15	
Diagnosis	
1	(1)	
1	
0	
0	
1	(1)	
1	
Total	elective	
1	(1)	
1	
4	(3)	
15	
5	(5)	
16	
	
	
	
	
	
Em
ergency		
	
	
	
	
Fall	
0	
0	
1	(1)	
9	
1	(1)	
9	
Choking	
3	(1)	
16	
0	
0	
3	(1)	
16	
Gastrostomy	site	
infection	
0	
0	
1	(1)	
2	
1	(1)	
2	
Total	em
ergency	
3	(1)	
16	
2	(2)	
11	
5	(3)	
27	
	
	
	
	
	
U
nrelated	to	M
N
D	
	
	
	
	
Total	unrelated	
admissions	
0	
0	
0	
0	
0	
0	
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	A6.16	The	total	number	and	reason	for	hospital	admissions	reported	by	all	participants	during	the	first	12	months	of	the	study	and	the	number	of	overnights	stayed	in	hospital.					 Telehealth	 Control	 Total		 Admissio
ns	
(patients)	
Nigh
ts		
Admissio
ns	
(patients)	
Nigh
ts		
Admissio
ns	
(patients)	
Nights		
Elective				PEG	insertion	 2	(2)	 21	 1	(1)	 6	 3	(3)	 27	Symptom	control	 2	(2)	 14*	 0	 0	 2	(2)	 14*	
Total	elective	 4	(4)	 72*	 1	(1)	 6	 5	(5)	 41*		 	 	 	 	 	 	
Emergency		 	 	 	 	 	 	Respiratory	symptoms	 1	(1)	 6	 2	(2)	 15	 3	(3)	 21	Collapse,	poor	oral	intake	 1	(1)	 2	 0	 0	 1	(1)	 2	
Total	
emergency	
2	(2)	 8	 2	(2)	 15	 4	(4)	 23		 	 	 	 	 	 	
Unrelated	to	MND		Elective:	hip	replacement	
	
2	(1)	 6	 0	 0	 2	(1)	 6	Emergency:	lung	cancer	 0	 0	 4	(1)	 50	 4	(1)	 50	Emergency:	postural	hypotension	 0		 0	 1	(1)	 3	 1	(1)	 3	
Total	
unrelated		
2	(1)	 6	 5	(2)	 53	 7	(3)	 59		*It	was	not	possible	to	establish	the	number	of	nights	from	one	patients’	admission	so	these	nights	are	not	included.			 	
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Table	A6.17	Patient	estimated	hours	of	paid	and	unpaid	care	received	per	week.			 Baseline	 3	month	 6	months	 12	months	
Telehealth	
	Paid	carer	hours		 	n=17	 	n=16	 	n=15	 	n=5	Mean	(SD)	 12.7	(33.2)	 20.9	(52.4)	 34.7	(64.6)	 66.6	(89.0)	Median	(Range)	 0	(0-110)	 0	(0-168)	 0	(0-168)	 5	(0-168)		Unpaid	carer	hours		 	n=12	 	n=16	 	n=15	 	n=5	Mean	(SD)	 66.6	(70.2)	 43.5	(58.6)	 42.8	(57.4)	 19.6	(20.5)	Median	(Range)	 47.5	(0-168)	 10	(0-168)	 20	(0-168)	 10	(0-168)		
Control		Paid	carer	hours		 	n=18	 	n=13	 	n=12	 	n=6	Mean	(SD)	 3.6	(8.4)	 2.4	(5.7)	 4.3	(11.4)	 2.5	(4.5)	Median	(Range)	 0	(0-28)	 0	(0-20)	 0	(0-40)	 0	(0-11)		Unpaid	carer	hours		 	n=20	 	n=14	 	n=12	 	n=5	Mean	(SD)	 33.4	(64.9)	 36.6	(55.4)	 38.2	(53.3)	 99.8	(90.2)	Median	(Range)	 12.0	(0-168)	 18.5	(0-168)	 18	(0-161)	 161	(0-168)		
Total		Paid	carer	hours		 	n=35	 	n=29	 	n=27	 	n=11	Mean	(SD)	 8.0	(24.0)	 12.6	(39.7)	 21.2	(50.4)	 31.6	(65.6)	Median	(Range)	 0	(0-110)	 0	(0-168)	 0	(0-168)	 0	(0-168)		Unpaid	carer	hours		 	n=32	 	n=30	 	n=27	 	n=10	Mean	(SD)	 52.7	(66.7)	 40.3	(56.3)	 40.7	(54.6)	 59.7	(74.8)	Median	(Range)	 14.5	(0-168)	 14.5	(0-168)	 20	(0-168)	 12	(0-168)			 	
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A6.18	The	estimated	treatment	effect	for	the	quality	of	life	and	health	utility	measures	and	ALSFRS-R.		Table	and	calculation	prepared	by	trial	statistician.		
Measure	 Baseline	
SD	
Difference	(95%	CI)	at	6	months	Mean	difference*	 Standardised	mean	difference**	
ALSAQ-40	(n=28)	Physical	mobility	 32.3	 -1.5	(-12.7,	9.7)	 -0.05	(-0.39,	0.30)	Activities	of	daily	living	 29.5	 -7.3	(-18.1,	3.4)	 -0.25	(-0.61,	0.12)	Eating	and	drinking	 28.4	 7.2	(-3.7,	18.1)	 0.25	(-0.13,	0.64)	Communication	 35.4	 -1.9	(-10.1,	6.3)	 -0.05	(-0.28,	0.18)	Emotional	 16.9	 1.1	(-9.7,	12.0)	 0.07	(-0.58,	0.71)	Total		 19.6	 -1.6	(-9.1,	5.9)	 -0.08	(-0.47,	0.30)	
SF-36	(n=28)	 PCS	 8.8	 -0.2	(-6.5,	6.1)	 -0.03	(-0.74,	0.68)	MCS	 9.7	 2.9	(-4.3,	10.1)	 0.30	(-0.44,	1.05)		 	 	 	
EQ-5D		(n=27)	
(standard	version)	 0.29	 0.03	(-0.13,	0.20)	 0.11	(-0.46,	0.68)		 	 	 	
ALSFRS-R	(n=28)	 8.7	 2.2	(-1.0,	5.5)	 0.28	(-0.13,	0.69)	*	Derived	from	analysis	of	covariance	with	treatment	group	and	baseline	score	as	the	covariates	**	Mean	difference/Baseline	standard	deviation			 	
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	A6.19	A	Kaplan	-	Meier	plot	reports	survival	recorded	at	the	end	of	the	trial.		This	graph	was	produced	by	the	trial	statistician.		
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		A6.20	Patient	compliance	with	questionnaires.	
	 Base-
line	
3	
month
s	
6	
month
s	
12	
month
s	
18	
month
s	
Telehealth	Patients	available	for	follow	up	 n=20	 n=19	 n=17	 n=9	 n=0	Completed	questionnaire	 n=19	 n=16	 n=16	 n=6	 n/a	
%	Eligible	questionnaires	
completed	
95%	 95%	 94%	 67%	 n/a	Reason	not	completed	 	 	 	 	 	Questionnaire	not	returned	 n=1	 n=3	 n=2	 n=3	 n/a	Patients	not	available	for	follow-up	 	 	 	 	 	Died	 n=0	 n=1	 n=1	 n=1	 n=1	Withdrawn	 n=0	 n=0	 n=2	 n=2	 n=2	Follow-up	complete	 n=0	 n=0	 n=0	 n=8	 n=17	
Control	Patients	available	for	follow	up	 n=	20	 n=20	 n=18	 n=8	 n=2	Completed	questionnaire	 n=20	 n=15	 n=12	 n=6	 n=1	
%	Eligible	questionnaires	
completed	
100%	 79%	 67%	 75%	 50%	Reason	not	completed	 	 	 	 	 	Questionnaire	not	returned	 n=0	 n=4	 n=5	 n=4	 n=1	Trial	administration	error36	 n=0		 n=1		 n=0	 n=0	 n=0	Patients	not	available	for	follow-up	 	 	 	 	 	Died	 n=0	 n=0	 n=2	 n=2	 n=2	Follow-up	complete	 n=0	 n=0	 n=0	 n=10	 n=16	
Total	Patients	available	for	follow	up	 n=40	 n=39	 n=35	 n=17	 n=2	
%	Eligible	questionnaires	
completed	
98%	 87%	 80%	 71%	 50%	
	
	 	
																																																								36	One	carer	questionnaire	data	was	lost	at	the	study	site,	one	patient	and	carer	were	not	sent	follow-up	questionnaire.	
	 317	
A6.21	Carer	compliance	with	questionnaires.	
	
Baseline	
3	
months	
6	
months	
12	
months	
18	
months	
Telehealth	Carers	available	for	follow-up	 n=18	 n=17	 n=15	 n=9	 n=0	Completed	questionnaire	 n=17	 n=14	 n=14	 n=6	 n=0	
%	Eligible	questionnaires	
completed	
100%	 82%	 93%	 67%	 n/a	Reason	not	completed	Questionnaire	not	returned	 n=0	 n=3	 n=1	 n=3	 n/a	Patient	died	 n=0	 n=1	 n=1	 n=1	 n=1	Patient	withdrawn	 n=0	 n=0	 n=2	 n=2	 n=2	Follow-up	complete	 n=0	 n=0	 n=0	 n=8	 n=15	Trial	administration	error	 n=1	 n=0	 n=0	 n=0	 n=0	
Control	Carers	available	for	follow-up	 n=19	 n=18	 n=18	 n=9	 n=2	Completed	questionnaire	 n=18	 n=14	 n=13	 n=6	 n=1	
%	Eligible	questionnaires	
completed	
95%	 78%	 72%	 67%	 50%	Reason	not	completed	Questionnaire	not	returned	 n=0	 n=4	 n=4	 n=4	 n=1	Completed	but	not	within	the	follow-	up	window	 n=1	 n=0	 n=0	 n=0	 n=0	Patient	died	 n=0	 n=0	 n=2	 n=2	 n=2	Follow-up	complete	 n=0	 n=0	 n=0	 n=9	 n=15	
Total	Carers	available	for	follow-up	 n=37	 n=35	 n=33	 n=18	 n=2	
%	Eligible	questionnaires	
completed	
97%	 80%	 82%	 67%	 50%	
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Appendix	6.2		
Q6.1	Participants’	motivations	to	participation	in	research.	
Incentives	to	participating	in	trials	Low	burden	of	the	study	 “	Oh	I	was	interested	in	that	because	it's	so	easy	to	do;	it	literally	takes	five	minutes	from	home.”	P317	Able	to	participate	in	trials	without	leaving	home	 “My	care’s	here.		I	can’t	have	anything	that	takes	it	away	from	what	I’m	doing	with	P.”		It’s	got	to	be	very	simple	things.		I	can	sit	with	my	iPad	and	I	can	fill	in	a	questionnaire.		Done,	dusted,	
finished.”	C184	Clear	information	about	what	is	involved	 “If	it	was	local	and	we	were	going	anywhere	or	people	were	coming	here	and;	I	could	always	look	at	each	one	individually	but	I	think	I	wouldn’t	want	to	spend	a	lot	of	time	away	from	home.	So	that	
would	be	my	main	criteria.	P408	
Motivations	to	participating	in	research	To	help	find	a	cure	 “If	I	can	be	of	any	help	to	any	research,	you	know,	which’ll	
help	try	and	find	a	cure.”	P056	To	help	other	people	with	MND	 “It	might	come	along	too	later	to	help	me	but	it	will	help	people	who	come	after	me.”	P122	
“Just	trying	to	help	other	people;	if	me	pressing	a	few	buttons	
…can	help	in	the	future,	it’s	not	a	problem”	P354	In	gratitude	to	the	clinicians	 “I	think	that	the	people	at	the	Hallamshire	are	just	about	the	best	in	the,	in	the,	in	the	game”	P062	To	do	something	positive	 “…	it's	that	feeling	of	doing	something	positive.”	C402	
“I	like	that	idea	that	moving	forward”	P423	To	learn	about	research	 “I’ve	always	been	interested	in	medical	science…so	I	said	any	
research	that	they’re	doing	I	want	to	get	involved	in.”	P423	To	help	their	family,	who	may	be	at	risk	 	“C:	I	gave	blood	as	well..	because	…we’ve	got	the	boys	…	I	think	that’s	quite	a	big	thing	for	me”	C381	To	have	better	contact	with	MND	team	 “It	was	good	because,	it	meant,	in	the	first	year	I	was	going	to	the	clinic	every	month.”	P122	To	receive	better	treatment	 	“I’m	offering	my	services	…	but	in	return	…	I’m	getting	a	repeating	MOT.”	P313	To	find	out	more	about	their	condition	 “That	led	to	the,	the	obvious	question	“Well	if	you	find	anything	wrong	will	you	tell	me?”.”	P313	To	increase	the	chances	of	them	being	involved	in	a	treatment	trial	 	“I	do	believe	that	if	you’re	not	in	the	loop	then	if	something	comes	along	then	you’re	on	the	wrong	side	of	the	fence.	If	you’re	involved	with	different	…	then	you’re	more	likely	to	be	
selected	for	possible	hopeful	cures...”	P232	
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Q6.2	Barriers	to	participation	in	research.	
Barriers	to	participation	in	research	Additional	burden		 “	Well,	just	another	job….	To	remember”	C217	Research	is	time	consuming	 “Initially	it	is	a	bit	overwhelming	…	we	do	seem	to	have	signed-up	for	absolutely	everything…”	C402	
“It's	difficult,	…	sometimes	you	get	to	the	stage	where	you	think:	you	
know	what?	I	just	don't	feel	like	this,	I've	just	had	enough”	C402	Intrusion	or	disruption	of	family	life	 “C:I	just	don't	think;	…	we,	we	just	try	to	keep	ourself	and	look	after	him,	look	after	him	and	that's	it.	Q:	…Have	any	of	those	worries	been	the	case	during	the	study?		
C:	No.”	C228	
“I	don’t	want	the	family	life	to	be	disrupted,	that’s	really	important	
to	us.”	P408	Time	spent	away	from	home	 “I’d	need	to	know	about	the,	the	time	that	would	be	needed	to	be	spent,	if	I	needed	to	spend	time	away	from	here,	from	home”	P408	Research	can	be	tiring	 “On	Thursday	I	went	for	my	research,	had	the	lumbar	puncture,	the	tissue	sample,	blood	samples	I	think.	So	then	I	came	home.	For	two	
days	after	that	I	was	more	or	less	housebound.”		P184	Travel	to	hospital	is	expensive	 “…the	train	tickets	are	a	bit	expensive,	so	we’ve	driven	the	last	few	times.	But	…	we	got	the	free	parking	and	things	like	that…”	C392	Travel	difficult		 “It’s	gonna	be	a	lot	more	difficult	with	a	wheelchair”	C392	
	
Q6.3	Participants’	attitudes	towards	recruitment	and	randomisation	in	the	TiM	trial.	
Recruitment	and	randomisation	to	the	TiM	trial	Recruitment	process	provided	sufficient	information		 “I	think	it	were	all	pretty	much	straight	forward,		in	the	letter	that	you	sent	out,	plus	when	you	came,	I	think	it	were	all	pretty	straight	forward,	yeah.”	P145	Patients	were	willing	to	be	randomised	as	they	understood	the	research	question	
“Q:	Was	there	a	particular	arm	of	the	study	that	you	
wanted..?	
P:	No,	because	it's	a	subject	that	not	very	much	seems	to	
be	known	about,	so	if	I	can	help	in	any	area	of	it,	I	will.”	
P166	Patients	would	prefer	to	be	in	the	intervention	arm	 “Q:	And	how	did	you	feel	about	being	assigned	to	the	Telehealth	side?		
P:	Well	I’ve	preferred	that	side	of	it.”	P381	Patients	were	not	demoralized	if	they	were	assigned	the	control	arm	 “I	should	think	most	people	would	probably	want	to	have	tablet.		I	think,	they'd	think	"this	is	alright."	But	quite	frankly	it	doesn't	bother	me.”	P070	Involving	the	control	arm	in	interviews	avoided	resentful	demoralization		 “I	read	the	notes.	Some	would	get	the	interview,	some	would	get	the	tablet”	C070		Researchers	could	influence	the	randomisation	process	 “P:	We	thought:	they’ll	put	[my	sister]	on	the	real	drug	because	they	can	monitor	her	for	longer.	
Q:	Do	you	think	that	the	study	researchers	can	have	an	
influence	on	which	arm	of	the	study	you	go	in?		
P:	Probably	not,	no.	Probably	it’s	the	drug	company	who	
are	pulling	the	strings.	They	are	paying	the	money	
aren’t	they?”	P184	
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Q6.4	Participants’	attitudes	towards	and	knowledge	of	research.	
Participants’	attitudes	towards	and	knowledge	of	research	Patients	gain	information	about	research	and	new	treatments	through…	Clinic	 “	I	like	having	a	chat	with	you	and	finding	out	what's	happened,	
what's	new,	because	all	we	have	is	hope,	we	don't	have	a	lot	
more”.”	P134	Friends	and	fellow	patients	 “It’s	really	just	through	word	of	mouth.	“	P122	MND	Association	 “The	MNDA	puts	posts	on	about	research”	P145	Internet	 “I	mean	we	have	found,	for	instance,	a	website;	you	can	actually	
see	it	on	YouTube,	called	Deanna	Protocol”	P317	Social	media/	peer	networks	 	“There's	also	a	long	term	ALS	survivors'	website	where	people,	have	been	diagnosed	with	it…	and	been	told	that	you've	only	
got	a	year	left	to	live,	but	they've	done	radical	changes,	….and	
those	people	have	halted	it”	P317	Patient	seek	out,	evaluate	and	use	unproven	treatments		 “I	don’t	follow	regimes	as	strict	as	the	Deanna	protocol	but	I	just	pick	out	certain	things	that	I	think	would	help	me,	hence	the	reference	to	moringa	and	coconut	oil.”	P232	Frustration	with	the	speed	of	drug	development	 “I	just	feel	like,	after	30	years	with	millions	…	of	pounds	spent	we’ve	still	got	a	tablet	that	[has	little	evidence]”	P184	“We	need	to	be	getting	a	move	on…	Some	day,	we’ve	got	to	stop	
messing	around	with	mice.”	P184	
“I	don’t	hold	out	too	much	confidence	about	the	UK	system	of	
getting	drugs	to	market	and	funding	them	with	the	likes	of	
NICE	posing	usual	financial	constraints.”	P232	Time	is	running	out	for	a	cure	 “Once	you	get	to	what	I	always	call	“frank”	stage	…I	don’t	think	there’s	any	drug	that	would	bring	you	out	of	that.”	P184	Patients	have	little	to	lose	 “We	being	the	patients	with	MND,	have	nothing	to	lose…	There’s	always	risk	in	life.”	P232	Learning	about	research	makes	patients	hopeful		 	“[you	think]	There's	got	to	be	things	that	we	can	do,	come	on,	we're	gonna	really	give	this	a	hundred	percent;	and	the	more	we	looked	the	more	intrigued	we	became….	you	can	see	people	
that	have	had	really	good	benefits	from	it.”	P317	
“We’re	all	kind	of	pinning	our	hopes	…on	GM604”	P232	Patients	recognize	information	may	be	giving	false	hope	 “Too	much	information	could	fill	people	with	a	false	hope	and	you’ve	gotta	manage	people’s	expectations”	P122	Putting	trust	in	the	doctors	to	run	safe	trials	in	the	best	interests	of	the	patient	
“Q:	Did	you	consider	the	downsides,	the	risks	of	having	a	lumbar	
puncture	when	you	came?		
P:	No.	I	just	thought,	well	if	that’s	all	I’ve	got	to	put	up	with.	But	
if	a	doctor	can’t	do	a	lumbar	it’s	a	bad	job.”	P184	
“I	would	have	complete	faith	in	[consultants]	team	saying	
“Right,	lets	get	some	people	in	now	and	let’s	do	it”		P184	Wanting	to	see	tangible	benefits	of	treatments	which	reverse	the	disease	
“No	one	will	ever	convince	me	that	they	know	[riluzole]	works.	
…How	do	they	know	I’ve	had	three	months	more	life?...Who	
would	know?	..	I	can’t	walk	any	better,	I	can’t	speak	any	better,	I	
can’t	do	anything	any	better.”	P184	
“…it	doesn’t	have	to	cure	you	it	just	has	to	make	things	better.”	
C232	
“If	there	was	a	magic	bullet	and	I	had	to	sell	everything	to	
purchase	that	bullet,	I	would.”	P232	
	
	Q6.5	Participant	reaction	to	the	TiM	research	questionnaires.		
Were	questions	acceptable?	Questions	posed	in	the	questionnaire	were	acceptable	 “No.	To	be	quite	frank,	doctor,	I	wouldn't	care	a	monkey's	what	you	ask	…I	have	no	hang-ups	about	any	questions,	however	personal,	the	team	think	it's	necessary	to	ask;	I've	
seen	it	all,	done	it	all	and	got	the	t-shirt.”	C229	
“P:	I	was	fine	about	doing	them.”	P116	There	was	a	limit	to	the	number	of	questions	participants	were	willing	to	answer		
“P:	You	don’t	want	another	one	of	them	hundred	and	fifty	
page	things	to	fill	out,	that	were,	whatever	it	was	last	
year.”	C248	Questions	on	emotions	were	acceptable	to	those	experiencing	emotional	distress	
“It’s	more	the	emotional	ones	that	I	have	trouble	filling	in	
cos	I’ve	been	depressed	for	quite	a	…and	it’s,	it’s	just	hard	
admitting	that	yes,	maybe	some	days	it’s	not	great	and	I	
know	that	I’m	not	great	at	the	moment	but.	But	no,	they	
seemed	good.	They	were	really	clear,	and	it	wasn’t	too,	too	
much	to	do.”	P408	Participants	wanted	questions	to	cover	all	potential	aspects	of	MND	 “At	the	moment	I’ve	not	got	a	lot	of	problems	with	my	legs,	but	in	18	months	I	might	need	a	wheelchair,	or	I	might	be	having	to	use	a	breathing	machine.	So	every	question	is	
relevant.”	P070	Questions	about	future	complications	were	acceptable	because	patients	were	aware	of	what	may	occur		
“When	you	read	things	about	these	questions:	it	brings	
things	home	to	you.		Well	yeah,	I	have	deteriorated….	It	
doesn’t	really	significantly	affect	me	at	all	because,	I	like	to	
think	I’m	a	reasonably	intelligent	man	and	I	know	things	
are	deteriorating.”	P184	
Which	questions	best	reflected	the	experiences	of	patients	and	carers?	Questions	about	mood/emotions	best	reflected	their	experiences		 “I	think	the	best	ones	are	the	ones	about	how	it	makes	you	feel	and	how	it	affects	your	mood	etc.	That’s	very	important	….”	P122	The	carer	burden	accurately	captured	the	experience	of	carers	 “It	was	a	strange	one	cos	[the	ZBI]	was	asking	you	what	I	feel	about	spending	the	time	with	him,	that	I	don’t	have	time	for	meself.…	Yeah,	it	is	quite	a	thing	cos	you’re	always	
thinking…	“Has	he	got	enough	drinks?	…	then	anything	to	
eat?”…	I	don’t	like	to	be	too	far	away	from	him,	even	
though	I’m	in	the	house	…	in	case	summat	happened	and	he	
needs	me.”	C091	Carer	strain	is	linked	to	patient	and	carer	wellbeing	 “…obviously	if	strains	exist,	become	too	much	for	the	carer,	then	the	patient,	to	a	degree,	suffers..”	C229	Mood/emotions	affected	patients	health	and	functional	abilities	 “Feelings	of	anxiousness	can	affect	my	legs,	and	I	know	that.	I	try	not	to	control,	try	not	to	get	anxious	about	situations	but	sometimes	it’s	hard	when	you	know,	your	are	
going	to	move	from	A	to	B,	you’re	going	to	get	anxious	
about	it.”	P076			 	
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Q6.6	Weaknesses	with	the	questionnaires	identified.			
SF-36	questionnaires	failed	to	reflect	the	experience	of	life	with	MND	SF-36	questions	were	too	subjective		 “That’s	sort	of	looking	at	question	[SF-36],	and	putting	down,	you’re	limited	and	then	you	sort	of	realise;	I	can’t	
really	do	that;	and	you	don’t	think	about	it	all	the	time	do	
you?	Some	of	them	I	wanted	to	put	“sometimes”,	you	
know…	sometimes	I	have	but	I’ve	just	gone	for	on	the	
whole”	P408	Patients	found	it	difficult	to	assess	their	global	health	and	were	unsure	whether	to	include	MND	in	the	assessment	
“P:	It’s	slightly	confusing	when	they	ask	about	health	
because	it’s	hard	to	take	the	MND	out	of	the	equation,	I	
think.	Apart	from	that	I	would	be	very	healthy.”	P116	
	“P:	My	health	other	than	the	illness?	(Pause)	Taking	the	
illness	into	account	I	would	say	poor,	but	if	I	ignore	the,	the	
illness	I	would	say	very	good.”	P137	[referring	to	SF-36]	Patients	felt	“healthy”	despite	having	MND	 “	To	be	honest,	I	feel	great.		So	does	that	say	I’m	excellent.		But	you	know	that	you’re	not,	so	you	can’t	be	excellent.”	
P175	[referring	to	SF-36]	Carers	felt	they	had	no	health	problems	and	felt	the	QoL	questions	were	not	relevant	
“I	mean	this:	[reads]	“I	feel	as	if	I’m	slowed	down”;	it’s	not	
because	of	caring	for	you	but	because	I’m	getting	older…		I	
can’t	do	a	forward	roll	over	a	gatepost	anymore!”	C137		
[referring	to	SF-36]	Those	with	severe	disability	had	few	“daily	activities”	on	which	to	assess	the	impact	of	MND	
“P:	It	doesn’t	affect	my	work	because	I	don’t	do	any!	
Q:	It’s	housework	as	well.	
P:	No.	I	don’t	do	any!	I	do	a	little	bit.”	P070	[referring	to	SF-
36]	
Other	weaknesses	Participants	found	it	difficult	to	quantify	the	time	taken	by	domestic	jobs	that	are	usually	shared	
“	But	there	are	things	now…	I’ll	say	“its	time	for	a	cup	of	
tea”.		It	will	always	be	me	that	makes	it.		I’m	not	saying	I	
resent	it,	because	P	can’t	do	it…	But	I	don’t	class	that	as	
care…	C175	[referring	to	informal	care	question]	Questions	should	better	reflect	patients’	functional	abilities	and	coping	strategies	
“It’s	about	monitoring	really,	and	with	these	questionnaires	
you	are	not	able	to	say	how	you	manage.	If	we	know	we	are	
going	out	for	a	full	day,	then	P	knows	not	to	plan	anything	
for	the	next	day	because	he’s	gonna	be	tired.”	C076		Answering	questions	may	be	difficult	if	they	not	want	to	admit	they	have	problems		
“….It’s	like	C	was	saying,	you’ve	just	got	to	be	honest	and	
sometimes	that’s	really	hard	cos	you	don’t	want	to	admit	
that	maybe	you’re	not	as	good	as	you	were”.	P408			
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1.	Telehealth	in	Motor	Neurone	Disease:	The	TiM	TM	Study	Telehealth	in	Motor	Neurone	Disease:	A	single	centre,	randomised	controlled	pilot	study	of	the	use	of	the	TiM	TM	telehealth	system	to	deliver	highly	specialised	care	in	Motor	Neurone	Disease	at	a	distance.	
	
Abstract		
Objectives		People	with	motor	neurone	disease	benefit	from	the	specialist	care	provided	by	multidisciplinary	teams.			As	their	disease	progresses	patients	struggle	to	attend	hospital	and	find	it	difficult	to	access	the	care	they	need.	The	aim	of	the	TiM	system	is	to	improve	access	to	this	specialist	care	by	using	technology	to	monitor,	educate	and	communicate	with	our	patients	and	their	carers.	This	is	a	pilot	study	of	the	TiM	TM	telehealth	system.		The	pilot	study	is	designed	to	assess	the	feasibility,	acceptability	and	safety	of	the	telehealth	system	in	clinical	practice	and	of	conducting	a	full	study	of	the	system.		It	will	also	allow	a	process	evaluation	of	the	system	to	determine	how	the	telehealth	system	could	be	effectively	utilised	within	an	NHS	service.	
Methods	This	is	a	single-centre,	randomized	controlled	mixed	methods	pilot	study	of	the	TiM	TM	telehealth	system.		It	will	recruit	40	patients	along	with	their	primary	informal	carer.			20	will	be	assigned	to	use	the	TiM	system	for	a	minimum	of	6	months	(intervention)	and	20	will	be	assigned	usual	care	(control).			Quantitative	outcome	data	will	be	collected	at	baseline,	three	and	six	months,	six	monthly	thereafter	and	at	the	end	of	the	trial.		Qualitative	interviews	with	participants	and	staff	and	analysis	of	the	system	in	use	will	enable	a	process	evaluation	of	the	system	and	the	trial	methodology.		It	will	also	assess	the	safety	of	the	system	in	a	clinical	setting.	
Results	Results	of	this	pilot	will	determine	whether	a	large,	multi-centre	full	trial	is	appropriate	and	enable	further	development	of	the	TiM	system.			It	is	proposed	that	the	TiM	system	could	be	adopted	into	the	care	of	patients	with	MND	throughout	the	UK.		 	
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2.	Lay	summary		Motor	neurone	disease	is	a	condition	affecting	approximately	5	000	people	in	the	UK.		It	results	in	progressive	weakness	in	muscles	causing	paralysis,	disability,	and	eventually	death	after	an	average	of	only	three	to	five	years.		To	receive	the	expert	care	provided	by	motor	neurone	disease	multidisciplinary	teams	most	patients	have	to	travel	to	regional	centres,	whilst	community-based	care	is	usually	provided	by	non-specialist	teams.		Between	clinic	appointments	and	towards	the	end	of	their	lives	when	patients	are	unable	to	travel	to	clinic	and	they	may	be	unable	to	access	the	specialist	assessment	and	care	provided	in	these	centres.			Telehealth	has	been	shown	to	increase	access	to	specialist	care	in	patients	with	chronic	disease,	regardless	of	geography	or	the	ability	to	travel.		The	overall	purpose	of	this	pilot	study	is	to	test	the	feasibility	and	acceptability	of	the	TiM	telehealth	system.		The	TiM	system	is	web-based	system	that	enables	weekly	monitoring	of	patients	and	carers’	health	and	wellbeing.		It	has	been	developed	by	the	Sheffield	Motor	Neurone	Disease	Care	Centre	team	in	partnership	with	industry	(Abbott	Healthcare	Products	Ltd	and	Carematix)	and	other	experts	within	the	NHS	and	the	University	of	Sheffield.		The	study	will	also	determine	whether	it	would	be	feasible	to	conduct	a	larger	study	of	the	system	to	examine	the	effectiveness	of	the	TiM	system.		Patients	with	motor	neurone	disease	who	are	cared	for	by	the	Sheffield	motor	neurone	disease	clinic	will	be	invited	to	take	part	in	the	trial.		40	patients	will	be	recruited.	Their	primary	informal	carer	(usually	their	spouse	or	close	relative)	will	also	be	invited	to	participate	in	carer	monitoring.		All	patients	will	continue	their	usual	care	but	half	will	also	be	randomised	to	use	the	TiM	telehealth	system	for	a	minimum	of	six	months.					Information	about	the	participants	will	be	collected	at	the	start,	three	and	six	months,	and	then	every	six	months	until	the	end	of	the	trial	by	postal	questionnaires	and	during	routine	appointments.		Up	to	20	participants	in	the	control	group	will	be	interviewed	at	the	start	at	the	trial	to	explore	their	experiences	on	completing	the	postal	questionnaires.		Up	to	20	participants	who	are	using	the	TiM	system	will	be	interviewed	at	one	and	six	months	to	understand	the	effect	the	trial	and	the	system	has	on	their	lives	in	more	depth.		The	clinical	staff	will	also	be	interviewed	at	the	end	of	the	trial.		A	pilot	study	is	a	small-scale	study	that	is	carried	out	to	determine	whether	a	larger	study	is	practical.		It	will	also	enable	the	identification	and	resolution	of	any	problems	with	either	the	telehealth	system	or	the	trial	procedures.			 	
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3.	Background		There	are	approximately	5	000	people	in	the	UK	suffering	from	motor	neurone	disease	(MND)	at	any	one	time	(1).		MND	is	an	incurable	disease	causing	progressive	weakness	of	muscles	involving	the	limbs,	speech	and	swallowing	leading	to	progressive	disability	and	eventual	respiratory	failure.		The	average	life	expectancy	following	diagnosis	is	two	to	three	years	but	the	course	of	MND	can	vary	from	only	a	few	months	to	over	10	years.		The	distress	and	burden	of	the	disease	affects	patients,	their	family	and	carers	and	the	relenting	progression	of	disability	causes	social,	emotional	and	financial	strain	(2,	3).		There	are	22	specialist	multidisciplinary	MND	care	centres	in	the	UK.	Expert	clinicians	and	 therapists	 offer	 interventions	 such	 as	 riluzole	 (which	 can	 improve	 survival	 by	approximately	 two	 to	 three	 months)	 and	 gastrostomy	 feeding	 to	 promote	 good	nutrition	 (4).	 Treatment	 of	 respiratory	 failure	 with	 non-invasive	 ventilation	 (NIV)	improves	 both	 quality	 of	 life	 and	 life-expectancy	 by,	 on	 average,	 11	 months	 (5).			Attendance	 at	 specialist	 MND	 clinics	 has	 also	 been	 reported	 to	 improve	 survival	independent	of	these	other	interventions	(6,	7).			The	 traditional	model	of	 care	 is	 to	 review	patients	at	 the	MND	centre	at	 fixed	regular	intervals.	 This	 model	 is	 not	 responsive	 to	 patient	 or	 carer	 needs	 (which	 can	 change	rapidly)	 and	 requires	 the	 patient	 and	 their	 family	 to	 undertake	 progressively	 more	difficult	journeys	to	clinic	at	a	time	predicted	by	the	clinician	at	their	last	meeting.	Given	the	 burden	 associated	with	 travelling	 to	 clinic,	 it	 is	 important	 that	 visits	 occur	when	they	are	most	needed.	 	Some	patients	whose	needs	have	not	changed	may	not	benefit	from	a	clinic	appointment	at	the	previously	predicted	interval	whereas	others	may	need	more	timely	intervention.			The	highly	specialist	services	provided	by	the	MND	clinic	are	contrasted	by	the	services	most	 patients	 receive	 in	 their	 community	 (8).	 These	 community	 teams,	 who	 have	limited	experience	in	caring	for	patients	with	MND,	are	usually	the	first	point	of	contact	for	patients	between	clinic	visits.	Lack	of	expertise	in	MND	amongst	community	teams	and	limited	access	to	specialist	staff	and	equipment	(particularly	at	the	end	stages	of	the	disease)	 causes	patients	 and	 their	 carers	 to	 experience	 significant	difficulties	 (2,	3,	 9-12).	 Research	 conducted	 in	 SITraN	 and	 by	 others,	 highlights	 the	 major	 impact	 that	caring	for	someone	with	MND	has	on	the	physical	and	emotional	well	being	of	carers,	as	well	 as	 patients	 (3,	 11,	 13-16).	 	 Where	 access	 to	 specialist	 services	 and	 community	support	is	limited,	this	impact	is	even	more	notable	(3,	11,	13-16).	This	is	particularly	a	problem	in	the	later	stages,	when	it	is	usually	impossible	to	attend	clinic,	when	arguably	the	most	care	is	needed.	It	is	therefore	essential	that	the	input	from	the	specialist	centre	is	still	possible	both	between	visits	and	when	patients	become	unable	to	travel.				
	
Telehealth	to	provide	specialist	care	in	MND	
	In	 the	 last	 few	 years,	 technology	 has	 developed	 sufficiently	 to	 allow	 high	 quality	communication	 between	 patient	 and	 their	 care	 team	 at	 a	 potentially	 reasonable	 cost.	
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Trials	have	shown	that	 telehealth	 is	an	acceptable	way	to	 improve	access	to	specialist	expertise	and	facilitate	self-management	patients	with	long-term	health	conditions	(17-21).	 	 In	 some	 cases	 this	 approach	 has	 been	 associated	 with	 a	 reduction	 in	 hospital	admissions	 (17,	 18,	 20).	 	 In	 2012,	 in	 response	 to	 research	 evidence	 and	 the	 need	 to	provide	cost-effective	care	to	an	expanding	population	of	patients	with	chronic	disease,	the	 UK	 government	 created	 the	 “3millionlives”	 campaign	 (22).	 This	 project	 in	 aims	foster	NHS,	academic	and	industry	collaboration	in	order	to	provide	telehealth	services	to	up	to	three	million	people	with	chronic	health	and	social	care	needs	in	the	UK.			The	 problems	 faced	 in	 MND	 are	 unlike	 many	 common	 chronic	 diseases	 in	 which	telehealth	 has	 been	 previously	 trialed.		 Care	 for	 MND	 requires	 holistic	 and	 multi-disciplinary	 expertise	 and	 the	 use	 of	 uncommon	 interventions	 such	 as	 non-invasive	ventilation	 and	 gastrostomy	 feeding.	 To	 date,	 use	 of	 telehealth	 in	 MND	 is	 limited,	although	 small	 studies	 do	 show	 promise	 in	 certain	 niche	 areas.	 Telehealth	 systems	using	 telephone	 consultation	 have	 been	 developed	 with	 some	 success	 in	 Italy	 and	Portugal,	 to	remotely	manage	patients	who	require	home	ventilation.	 	 	These	systems	were	associated	with	a	reduction	in	emergency	healthcare	usage;	more	efficient	use	of	staff	 time	 and	 potential	 cost	 savings	 (23-28)	 In	 Holland	 and	 rural	 Scotland,	 MND	services	 have	 used	 video-conferencing	 (29,	 30).	 	 Both	 approaches	 have	 potential	benefits	but	telehealth	used	in	this	way	is	labour	intensive	and	costly	and	care	is	driven	by	the	priorities	identified	by	the	clinician	rather	than	those	of	the	patient.	No	telehealth	system	 has	 been	 developed	 to	 provide	 frequent,	 holistic	 and	 highly	 specialist	 care	 to	patients	with	MND	at	all	stages	of	their	illness.		We	propose	that	telehealth	could	enable	people	with	MND	to	have	better	access	to	the	specialist	 monitoring	 and	 care	 that	 they	 require.	 Patients	 with	 MND	 are	 able	 to	accurately	 report	 their	 level	 of	 disability	 and	 appropriate	 questions	 can	 identify	 new	symptoms	or	early	signs	of	respiratory	 failure	(31-33).	 	These	 features	would	suggest	that	 a	 system	 of	 remote,	 question-based	 monitoring	 could	 provide	 regular,	 accurate	clinical	 information	 to	 enable	 the	 clinician	 to	 detect	 and	 better	 manage	 problems	without	the	patient	needing	to	attend	hospital.	Telehealth	provides	the	opportunity	to	provide	 education	 and	 reassurance	 and	 support	 to	 enable	 patients	 to	 better	manage	their	own	care	 (a	core	requirement	of	 the	National	Service	Framework	 for	Long-term	Conditions	(34)).				There	 are	 estimated	 to	 be	 10	 million	 people	 in	 the	 UK	 living	 with	 a	 neurological	condition	(1).		Both	the	common	diseases	such	as	Parkinson’s	disease	and	epilepsy	and	rarer	 conditions	 such	 as	 muscular	 dystrophy	 and	 MND	 require	 specialist,	multidisciplinary	support	from	specialist	services.			A	successful	telehealth	system	may	therefore	be	able	to	improve	the	services	provided	to	many	patients	in	the	UK	and	their	families.	
	
4.	Summary	and	hypothesis	
	
	
	
Summary		
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We	will	undertake	a	pilot	study	of	the	use	of	the	TiM	telehealth	system	to	improve	the	care	of	patients	and	their	carers	 living	with	motor	neurone	disease.	 	Whilst	 telehealth	services	have	been	used	 successfully	 in	 other	 long-term	 conditions,	 no	 service	 of	 this	kind	exists	for	patients	with	motor	neurone	disease.		A	pilot	randomised	controlled	trial	will	 employ	 a	mixed	methods	 approach	 to	 explore	 the	 feasibility	 and	 acceptability	 of	using	the	TiM	system	to	improve	access	to	specialist	care	in	MND.		The	pilot	study	will	also	explore	the	feasibility	of	a	full-scale	trial.		
		
Hypothesis		The	TiM	telehealth	system	will:	
• Improve	the	quality	of	life	of	patients	with	MND		
• Improved	clinical	outcomes	for	patients	with	MND		
• Improve	quality	of	life	and	other	measures	of	well	being	for	the	primary	informal	carers	of	patients	living	with	MND.		
• Be	acceptable	to	patients,	carers	and	staff	
• Lead	to	more	cost	effective	utilisation	of	heath	care	resources			
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5	Research	objectives		
	
5a.	Objectives	of	the	pilot	study	
	
• Determine	the	requirements	of	a	full-scale	study	of	the	TiM	system	
o Determine	recruitment,	retention	and	withdrawal	rates.	
o Determine	the	most	acceptable	and	appropriate	outcome	measure(s)	that	reflect	 the	 impact	 of	 the	 TiM	 system	 on	 patients	 and	 carers	 and	 health	resources.	
o Provide	 an	 estimate	 of	 the	 resources	 required	 to	 conduct	 a	 full-scale	study.	
• Study	the	use	of	the	TiM	system	in	clinical	practice		
o Assess	the	relationship	between	the	benefits	of	the	TiM	system	perceived	by	staff	and	participants	with	those	captured	by	the	outcome	measures	
o Assessing	participants’	use	and	compliance	with	the	TiM	system	
o Health-care	staff	qualitative	interviews	and	focus	group	
• Assess	the	safety	of	the	TiM	system	using:	
o A	shadow	monitoring	protocol	
o Health-care	staff	qualitative	interviews	and	focus	group	
o Analysis	of	technical	and	clinical	adverse	events		
	
	
5b.	Objectives	of	the	full-scale	study	
	
Proposed	primary	end-point		
• Patient	quality	of	life	(outcome	measure(s)	to	be	determined	in	the	pilot	trial)	
	
Proposed	secondary	end-points		
	Patient	outcomes	
• Severity	of	pain	
• Severity	of	oropharygeal	secretions		
• Incidence	of	depression	and	anxiety		
• Time	from	diagnosis	to	death		Carer	outcomes	
• Quality	of	life	
• Carer	Burden		
• Incidence	of	depression	and	anxiety			Health	 economic	 outcomes	 involving	 a	 cost	 utility	 analysis	 using	 costs	 of	 the	 system,	costs	of	associated	care	requirements,	EQ5D	and	patient	survival		Safety	of	the	TiM	system		
• Frequency	of	adverse	events		
5c.	Justification	of	the	pilot	study		
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Since	this	type	of	telehealth	has	never	been	evaluated	in	those	with	MND	a	pilot	study	is	necessary	to	determine	how	a	full-scale	evaluation	of	its	clinical	and	cost-effectiveness	could	be	conducted	and	 to	gain	a	better	understanding	of	how	the	TiM	system	would	work.	 	 This	 includes	 evaluating	 recruitment	 and	 retention,	 as	 well	 and	 resource	requirements.	By	evaluating	compliance	and	safety	monitoring	and	using	qualitative	the	study	will	also	enable	a	better	understanding	of	how	the	 telehealth	system	is	used	by	patients,	carers	and	staff.				A	 number	 of	 the	 proposed	 benefits	 of	 telehealth	 such	 as	 improving	 quality	 of	 life,	providing	 reassurance	 and	 support,	 prompting	 self-care	 and	 a	 more	 efficient	 use	 of	resources	(18,	35-40)	may	be	difficult	to	quantify.		The	validated	measures	of	quality	of	life	most	commonly	used	in	research	(EQ5D	and	SF-36)	were	not	specifically	designed	for	 patients	 with	 MND	 or	 their	 carers.	 	 The	 ALSAQ-40	 tool	 better	 encompasses	dimensions	of	 life	 that	 are	particularly	 affected	by	MND	such	as	 social	 and	emotional	function	 but	 it	 is	 unclear	 whether	 the	 ALSAQ-40	 would	 fully	 reflect	 the	 impact	 of	telehealth	(41).					Data	 from	quantitative	elements	of	 a	 randomised	controlled	 trial	will	not,	 in	 isolation	determine	 which	 outcome	 measures	 best	 reflect	 the	 impact	 of	 the	 intervention.	 	 It	would	also	not	 fully	explain	how	the	TiM	system	would	be	used	in	the	real	world	and	what	 factors	would	 influence	 its	 adoption	and	 success.	 	 	Utilising	mixed	methods	will	allow	the	combination	of	quantitative	data	with	more	in-depth	results	from	qualitative	interviews	that	will	explore	participants’	experiences	in	more	depth.	 	It	will	also	allow	explanation	of	 outcomes	 that	 occurred	 (particularly	 those	 that	were	unexpected)	 and	understand	 why	 (and	 in	 what	 context)	 aspects	 of	 the	 system	 were	 successful	 or	unsuccessful	which	could	lead	to	improvements	in	the	TiM	system.			
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6.	Study	Methodology		We	 will	 conduct	 a	 randomised	 controlled	 pilot	 trial	 comparing	 the	 TiM	 telehealth	service	 and	 standard	 care	with	 standard	 care	 alone.	 	 The	 intervention	 and	 follow-up	period	will	be	a	minimum	of	6	months.	Quantitative	data	will	be	collected	at	0,	3	and	6	months	then	every	six	months	until	the	patient	finishes	the	trial.	 	 	Qualitative	data	will	be	 collected	 at	 baseline	 in	 the	 control	 arm	 and	 at	 1	 and	 6	months	 for	 a	 selection	 of	patients	in	the	intervention	arm.			
6a.	Participant	recruitment	and	selection	
		Pre-screening	 will	 identify	 a	 list	 of	 potential	 patients	 who	 cared	 for	 by	 the	 Sheffield	Teaching	 Hospitals	MND	 care	 centre	 clinic	 as	 part	 of	 usual	 care	 using	 the	MND	 care	centre	 “ARC”	 clinical	 database.	 	 Each	patient	will	 be	 assigned	 a	 number.	 	 The	Clinical	Research	Facility	 at	 the	Royal	Hallamshire	Hospital,	 Sheffield	Teaching	Hospitals	NHS	trust	will	 generate	 random	numbers	 to	 identify	 the	patients	 to	 invite.	 	These	patients	will	be	sent	a	letter	of	invitation	to	participate.		This	will	be	accompanied	by	patient	and	carer	information	leaflets	and	a	return	slip	to	indicate	their	interest.			Those	who	do	not	return	the	slip	will	be	followed	up	by	telephone	or	at	clinic,	if	appropriate	a	minimum	of	once	and	a	maximum	of	 twice.	 	A	 log	will	be	kept	 in	order	 to	 complete	 the	CONSORT	diagram	(Appendix	2)	(42).		Patients	and	their	primary	carer	who	express	an	interest	will	be	invited	to	discuss	the	trial	 in	a	 face-to-face	meeting	with	the	PI	and	also	via	telephone	with	their	consultant	neurologist	 (Dr.	 Christopher	 McDermott	 or	 Professor	 Dame	 Pamela	 Shaw,	 Sheffield	Teaching	 Hospitals	 MND	 Care	 Centre).	 The	 Sheffield	 MND	 Care	 Centre	 sees	approximately	 120	 new	 patients	 with	 MND	 per	 year.	 	 At	 any	 time	 there	 are	approximately	300	patients	attending	clinic.		We	expect	to	be	able	to	recruit	a	minimum	of	four	patients	per	month.		Participants	 in	 the	 intervention	 arm	 will	 be	 invited	 to	 participate	 in	 qualitative	interviews,	conducted	at	month	one	and	month	six.		Purposive	sampling	will	be	used	to	reflect	 the	 variation	 and	 predefined	 patient	 prognostic	 factors	 thereby	 capturing	 a	range	of	experiences.	 	 	 Interviews	will	 continue	until	data	saturation	 is	 reached	or	20	interviews	have	been	 conducted.	 	All	 participants	 assigned	 to	 the	 control	 arm	will	 be	invited	to	be	interviewed	after	completion	of	the	baseline	questionnaires	to	determine	the	 feasibility	 and	acceptability	of	 these	measures	 and	 their	 views	on	participating	 in	the	trial.	The	qualitative	component	will	provide	information	not	easily	obtained	from	questionnaires	 that	 will	 facilitate	 understanding	 of	 the	 intervention	 from	 the	perspective	of	all	stakeholder	groups.	
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6b.	Consent	
	Following	indication	of	their	interest	to	participant	potential	participants	will	be	met	at	a	mutually	agreeable	location,	preferably	the	patients’	home.		They	will	have	further	opportunity	to	discuss	the	trial	with	the	PI	and	decide	whether	they	wish	to	participate.		Willing	participants	will	be	asked	to	give	informed	written	consent	or	use	an	appropriate	witnessed	alternative	(which	may	include	verbal	consent	or	via	a	communication	device)	for	screening	and	involvement	in	the	trial.		Carer	consent	will	be	obtained	by	full	written	consent.				In	versions	prior	to	V1.5	of	the	protocol	both	patient	and	carer	consent	were	required.		V1.5.	has	amended	the	inclusion	criteria	to	allow	a	patient	to	participate	with	carer	participation.		If	one	or	both	consent	to	the	study	a	member	of	the	study	team	will	initiate	the	screening	process.	Participants	will	be	screened	and	recruited	by	the	PI	according	to	the	CONSORT	principles	and	Good	Clinical	Practice	(42,	43).				Those	who	decline	participation	will	be	invited	to	give	their	reasons	in	order	to	identify	common	factors;	this	may	help	recruitment	strategies	and	identify	potential	problems	for	compliance.			Basic	anonymised	details	of	these	patients	(age,	gender,	reason	for	exclusion)	will	be	collected	on	all	eligible	patients	in	order	to	fulfill	the	CONSORT	flow	chart	(Appendix	2)	(42,	43).	
	
6c.	Randomisation		
	Once	 recruited,	 randomisation	 will	 be	 performed	 using	 the	 independent	 web-based	system	 http://www.sealedenvelope.com	 using	 block	 randomisation.	 	 All	 patients	 and	carers	will	be	assigned	an	anonymous	individual	study	code,	and	a	recruitment	log	held	by	the	research	team	in	SITraN.			
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6b.	Inclusion	and	exclusion	criteria		Inclusion	criteria:	
• Patients	aged	18	years	or	over	who	have	attended	 the	MND	clinic	at	 the	Royal	Hallamshire	Hospital,	Sheffield.	
• Patients	 with	 amyotrophic	 lateral	 sclerosis	 diagnosed	 by	 a	 consultant	neurologist	with	symptom	onset	within	the	last	three	years.	
o Or	
• Patients	 with	 amyotrophic	 lateral	 sclerosis,	 primary	 muscular	 atrophy	 or	progressive	 lateral	 sclerosis	 diagnosed	 by	 a	 consultant	 neurologist	 with	 a	deterioration	 in	 their	 condition	 as	 evidenced	 by	 a	 deterioration	 in	 the	 ALS	functional	rating	score	(ALSFRS-R)	by	at	least	two	points	during	the	previous	18	months.		
• Live	within	120	minute	drive	from	Sheffield			Exclusion	criteria:	The	main	circumstances	where	patients	or	carers	will	be	excluded	are	 those	 in	which	individuals	would	be	unable	to	use	the	telehealth	system	or	give	informed	consent.		
• Patients	attend	another	MND	care	centre	in	the	UK.	
• Significant	impairment	in	decision	making	capacity	preventing	informed	consent	by	 the	 subject	 due	 to	 a	 major	 mental	 disorder	 including	 fronto-temporal	dementia.		
• Patient	unable	to	use	the	TiM	system	due	to	physical,	intellectual	or	language	difficulties	and	unwilling	to	permit	carer	to	operate	it	on	their	behalf.		Patients	will	be	asked	to	complete	two	questions	used	within	the	TiM	system,	with,	or	without	the	help	to	their	carer	to	verify	their	ability	to	use	the	system.	
• The	patient	has	no	eligible	informal	carer	willing	to	participate	in	the	trial		(V1.5)	
• Insufficient	 mobile	 telephone	 reception	 in	 the	 patients’	 home	 to	 use	 the	 TiM	system.	
• Any	 other	major	 impairment	 that	may	 affect	 their	 ability	 to	 participate	 in	 the	study			Carer	inclusion	criteria	
• Age	18	years	or	older	
• Person	 identified	 by	 the	 patient	 as	 the	 major	 provider	 of	 informal	 care	(emotional	and/or	practical	support)	to	the	patient	and	provides	more	than	one	hour	per	week	of	unpaid	care	
• Carer	 willing	 to	 allow	 data	 they	 provide	 during	 the	 trial	 to	 be	 shared	 by	 the	research	team	with	their	own	doctor	in	the	event	of	serious	clinical	need.		Carer	exclusion	criteria	
• Significant	decision	making	capacity	preventing	informed	consent	due	to	a	major	mental	disorder.	
• Carer	 unable	 to	 use	 the	 TiM	 system	 due	 to	 physical,	 intellectual	 or	 language	difficulties.		Carers	will	be	asked	to	complete	two	questions	used	within	the	TiM	system	to	verify	their	ability	to	use	the	system.	
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• Inability	to	participate	in	the	study	due	to	other	major	physical	or	mental	illness	or	language	difficulties.	
• Professional	carers	receiving	direct	payment	for	their	services.		
6e.	Withdrawal			Participants	will	be	followed	up	until	the	end	of	the	study,	death,	or	withdrawal.		Those	wishing	to	withdraw	will	be	given	the	opportunity	 to	speak	to	a	member	of	 the	study	team.			Participants	are	free	to	withdraw	from	the	intervention	or	study	at	any	time.			As	a	pilot	study,	importance	of	understanding	reasons	for	withdrawal	is	recognised.	 	This	will	 be	 explained	 to	 the	 participants	 in	 the	 information	 leaflets.	 The	 importance	 of	understanding	 reasons	 for	withdrawal	 and	 the	 characteristics	 of	 these	 participants	 is	recognised	given	the	nature	of	the	study.	 	This	will	be	explained	to	the	participants	 in	the	information	leaflets.		
Withdrawal	criteria	1. Patient	request	2. Carer	request	3. Patient	loses	capacity	to	continue	to	provide	consent		If	a	Patient	withdraws	from	the	study	arrangements	will	be	made	for	the	equipment	to	be	collected	or	returned.		Where	appropriate	participants	will	be	invited	to	give	the	reasons	for	withdrawal.		Patients	will	also	be	given	the	option	of:	1. Withdrawal	from	the	intervention	but	remain	within	the	study.		Study	data	will	only	be	collected	at	clinic	visits	at	3	and	6	months	and	six	monthly	until	the	end	of	the	study.	2. Withdrawal	from	the	study.		Unless	the	participant	objects,	any	data	collected	up	to	this	point	would	be	retained	and	used	in	study	analysis.		Participant	agrees	to	allow	contact	to	give	safety	and	survival	data.	3. Withdrawal	from	the	study	entirely.		Unless	the	participant	objects,	any	data	collected	up	to	this	point	would	be	retained	and	used	in	study	analysis.		If	the	participant	does	not	wish	to	be	contacted	with	regard	to	safety	or	survival	data,	no	further	contact	with	regard	to	this	study	will	be	made.		In	the	event	that	the	patient	dies	or	loses	the	capacity	to	provide	consent	they	will	be	withdrawn	from	the	trial	but	any	data	collected	up	to	that	point	would	be	retained	and	used	in	study	analysis.			Carers	would	also	be	withdrawn	at	this	point.					If	the	carer	participant	withdraws	the	patient	can	opt	to	continue	to	use	the	system	or	withdraw.		If	appropriate,	carers	will	be	invited	to	give	reasons	for	withdrawal.		
6f.	Compliance		Steps	have	been	taken	to	encourage	compliance	with	the	weekly	schedule.			Patients	will	receive	regular	messages	on	the	system	to	invite	them	to	complete	a	scheduled	telehealth	session.		They	will	receive	feedback	on	their	compliance	record	and	an	
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encouraging	message	at	the	start	of	each	visit.		Those	who	fail	to	complete	the	session	within	one	day	will	be	reminded	by	text	and	via	the	telehealth	system.		If	after	two	weeks	they	do	not	enter	data	they	will	be	contacted	by	the	PI	and	offered	more	support	and	training.		Compliance	data	will	be	analysed	as	part	of	the	process	evaluation.				Compliance	with	the	patient	reported	outcome	measures	would	be	monitored	by	the	CRF	nurse.		She	will	contact	the	participants	to	support	data	collection,	identify	and	chase	missing	data	and	feedback	to	the	PI.			In	the	event	of	missing	data	the	CRF	nurse	will	telephone	the	patients/carer	after	two	weeks.		She	will	contact	them	a	minimum	of	twice	and	a	maximum	of	three	times	to	chase	the	data.		A	contact	log	will	be	kept.		
6g.	Sample	size		The	study	aims	to	recruit	a	total	of	40	patients	and	their	carers.	 	20	patients	and	their	primary	carer	will	be	randomised	to	the	intervention	arm	(a	minimum	of	6	months	use	of	the	TiM	telehealth	plus	usual	care)	and	20	patents	and	their	carer	in	the	control	arm	(usual	care).				Since	 the	 proposed	 trial	 is	 primarily	 an	 assessment	 of	 the	 acceptability	 of	 the	intervention	and	the	feasibility	of	a	full	trial,	the	proposed	sample	size	is	not	based	on	standard	statistical	parameters	such	as	a	clinically	relevant	difference	between	groups.	Instead,	the	sample	size	is	justified	on	the	grounds	of	quantifying	patient	variance	(i.e.	the	standard	deviation)	in	the	proposed	outcome	measures	(in	particular	quality	of	life	measures)	and	on	feasibility	of	the	full	trial,	as	follows:		
• 	A	 sample	 size	 of	 40	 patients	 allows	 a	 standard	 deviation	 to	 be	 estimated	 to	within	 a	 precision	 of	 ±20%	 of	 its	 true	 underlying	 value	with	 90%	 confidence.	This	 estimate	 will	 be	 synthesised	 with	 standard	 deviations	 observed	 in	 other	published	studies	(e.g.	(41,	44-47)	and	on-going	trials	within	SITraN	(48,	49),	to	provide	a	robust	estimate	for	use	in	the	sample	size	calculation	for	the	full	trial.		
• Given	 the	 rarity	 of	MND,	 any	 definitive	 study	will	 be	 infeasible	 if	 the	 required	sample	 size	 is	 substantial.	 Assuming	 the	 upper	 limit	 for	 feasible	 UK	 study	 is	around	 200-300	 patients	 in	 total,	 it	 follows	 that	 the	 full	 study	 would	 need	powering	to	detect	a	standardised	effect	size	of	at	 least	0.4	SDs.	This	pilot	 trial	will	provide	a	preliminary	assessment	of	whether	the	intervention	might	feasibly	achieve	 this,	 and	 inform	 the	 choice	of	 outcome	measures	 for	 the	proposed	 full	study.			This	sample	size	is	also	in	keeping	with	the	proposal	of	12	evaluable	patients	per	arm	in	a	pilot	study	(after	withdrawal	or	drop-out)	(50).			
	
6h.	Blinding	
	The	PI	will	not	be	blinded	to	the	randomisation	as	they	are	responsible	for	training	the	participants	to	use	the	TiM	system	and	any	on-going	technical	or	training	requirements.	The	treating	clinicians	will	not	be	blinded	to	the	arm	of	the	intervention	as	they	are	responsible	for	the	clinical	care	of	the	patient	and	reviewing	the	data	and	the	Shadow	Monitoring	System.		
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	The	PI	will	enter	screening	baseline	data.		Participant	reported	outcome	measures	after	this	will	be	collected	by	an	independent	research	nurse	from	the	Sheffield	Teaching	Hospitals	Clinical	Research	Facility	who	will	facilitate	collection	of	these	surveys	by	post	or,	if	preferred	by	the	patient,	in	person.		They	will	enter	the	details	into	the	study	database.			Following	the	end	of	the	trial	and	database	lockdown	the	PI	will	analyse	the	two	groups	of	data	whilst	remaining	blinded	to	the	allocation	of	the	two	groups.			The	STH	CRF	will	hold	the	database	code	to	identify	the	allocated	groups.		The	PI	will	conduct	the	qualitative	interviews	and	collect	the	system	use	data	and	will	not	be	blinded	to	these	measures.				
7.	Study	treatment	
	
	Standard	clinical	care	–	Intervention	arm	and	Standard	care	arm	
	Usual	clinical	care	will	continue	throughout	for	participants	in	both	arms	of	the	study.	All	participants	will	continue	to	be	 invited	to	the	Sheffield	MND	Care	Centre	Clinic	 for	routine	 review.	 They	 will	 be	 seen	 by	 their	 consultant	 neurologist	 and	 the	 MND	multidisciplinary	team,	according	to	their	routine	two-	to	three-monthly	schedule.	 	All	patients	will	have	access	to	the	MND	telephone	helpline	provided	by	the	Sheffield	MND	care	team.		
	
The	TiM	system	-	Intervention	arm	Those	in	the	intervention	arm	will	use	the	TiM	system,	in	addition	to	standard	clinical	care.	 	 	 All	 necessary	 hardware,	 software,	 data	 transfer	 and	 support	 costs	 for	 the	 TiM	system	will	be	met	by	Abbott	Healthcare	Products	Ltd	in	collaboration	with	Carematix.		Patients	will	 be	 provided	with	 a	 TiM	 patient	 hub:	 a	 handheld,	 touch	 screen	 Samsung	Galaxy	 tablet	 computer	 that	 communicates	 with	 the	 MND	 specialist	 nurse’s	 TiM	clinician	 system	 at	 the	 Sheffield	MND	 Care	 Centre.	 	 Patients	will	 be	 asked	 to	 use	 the	system	 at	 least	 weekly.	 	 Each	 week	 the	 telehealth	 hub	 asks	 the	 patient	 a	 series	 of	questions	 to	 detect	 common	problems	 found	 in	MND,	 such	 as	worsening	mobility,	 or	swallow,	 symptoms	 of	 depression,	 anxiety,	 pain,	 saliva	 and	 spasms.	 	 Some	 of	 the	questions	closely	match	validated	scoring	scales	(e.g.	the	ALS	Revised	Functional	Rating	Score	(51)	and	the	depression	and	anxiety	short	screen:	PHQ-4)	but	others	have	been	specifically	designed	by	the	clinical	 team	to	be	used	 in	the	telehealth	system.	The	TiM	system	 also	 enquires	 about	 symptoms	 of	 respiratory	 insufficiency	 and	 infection,	nutrition	 and	 social	 care.	 Patients	 using	 specialist	 equipment,	 such	 as	 non-invasive	ventilation	or	gastrostomy	tubes	will	additionally	be	asked	to	report	problems	related	to	 the	 intervention.	 	 The	 TiM	 system	 can	 also	 weigh	 patients	 weekly	 and	 monitor	patients’	overnight	oximetry	using	established	telehealth	monitors.		
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Carers	will	also	be	asked	 to	complete	a	weekly	 telehealth	session	 in	order	 to	monitor	their	 well	 being.	 	 The	 TiM	 system	 includes	 a	 carer	 strain	 screen	 and	 the	 PHQ-4	depression	and	anxiety	screen.	There	is	also	the	opportunity	with	the	telehealth	system	for	patients	or	carers	to	trigger	an	adhoc	session	if	issues	arise	during	the	week	about	which	 they	 wish	 to	 inform	 the	 centre.	 	 	 Interspersed	 through	 the	 questions	 are	educational	messages	and	users	have	access	to	a	bank	of	educational	resources	within	the	hub.		The	patient	and	carer	responses	are	transmitted	(via	an	encrypted	3G	mobile	signal)	to	the	Carematix	server.	The	responses	undergo	immediate	computational	analysis,	using	pre-determined	clinical	algorithms,	which	assigns	an	alert	level	to	each	response.		This	limits	 the	 amount	 of	 nurse’s	 time	 required	 to	 use	 the	 system.	 An	 automated	acknowledgement	is	sent	back	to	the	user	indicating	whether	to	expect	contact	from	the	MND	centre	based	on	the	results	and	the	timescale	for	the	response.			Each	day	 the	MND	nurse	will	 log	 into	 the	TiM	system	and	will	 be	presented	with	 the	responses	from	all	patients	using	the	TiM	system.		They	will	be	automatically	alerted	to	any	important	changes.	Urgent	alerts	include	any	new	and	severe	symptom	or	any	new	problem	that	poses	a	major	risk	to	the	patient	or	carer	(e.g.	choking,	falling,	respiratory	insufficiency).	Routine	alerts	include	any	other	deterioration	in	the	patient’s	ALSFRS-R	or	any	new	symptom.	An	appropriately	timely	response	will	be	made	to	each	alert	level.	Patients	will	be	reminded	to	seek	urgent	medical	attention	in	an	emergency.		The	 information	 on	 patient	 status	 may	 facilitate	 rescheduling	 of	 appointments	according	 to	 patient	 need	 rather	 than	 the	 fixed	 intervals	 used	 at	 present	 (e.g.	 the	appointment	could	be	delayed	if	the	patient	is	well,	and	the	TiM	system	has	activated	no	new	alerts).	 	 	As	 the	 feasibility	 and	 safety	of	 the	TiM	 system	has	not	been	previously	evaluated,	 during	 the	 TiM	 trial	 patients	 will	 continue	 to	 attend	 routine	 clinic	appointments	and	no	patient	will	have	their	clinic	delayed.			The	feasibility	and	safety	of	rescheduling	 appointments	 will	 be	 examined	 using	 a	 shadow	 monitoring	 protocol	(detailed	later).		Patients	and	carers	will	undergo	a	training	session	and	a	follow-up	telephone	call	after	two	weeks.	 	 The	TiM	 system	has	been	designed	 to	be	user	 friendly	 and	 to	 encourage	compliance	with	the	weekly	sessions.		Face-to-face	training	with	the	hub	system	will	be	offered	at	the	start	of	the	intervention.	Support	will	be	available	throughout	the	trial	in	the	 hub.	 	 	 Compliance	 will	 be	 monitored	 and	 should	 patients	 not	 complete	 the	 TiM	system	for	three	weeks	in	a	row,	contact	will	be	made	to	offer	more	training	or	support.		The	 TiM	 system	 has	 been	 designed	 by	 the	 applicant	 in	 collaboration	 with	 her	supervisors,	 the	 Sheffield	MND	 team,	Abbott	Healthcare	Products	 Ltd.	 and	Carematix.		Carematix	have	experience	in	delivering	similar	home	telemonitoring	systems	in	other	diseases.	 	 In	 developing	 the	 system,	 expertise	 has	 also	 been	 sought	 from	 those	developing	telehealth	services	in	other	diseases	in	the	University	of	Sheffield	and	NIHR	CLARHC	 for	 South	 Yorkshire.	 	 	 	 These	 included	 the	 School	 of	 Health	 and	 Related	Research	 (ScHARR)	 SMART	 consortium	 (Self	 Management	 supported	 by	 Assistive,	Rehabilitation	 and	 Telecare	 technologies),	 NIHR	 CLAHRC	 SY	 Telehealth	 &	 Care	Technologies	(TaCT)	for	Long	Term	Conditions	theme,	and	Devices	for	Dignity	(52).			
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8.		Data	collection	
	
8a.	Quantitative	data	collection	
	Data	 collection	will	 occur	 at	 baseline,	 three	months	 and	 six	months	 at	 the	 end	 of	 the	study.		Participant	data	will	be	completed	using	postal	and	telephone	questionnaires	to	minimize	 patient	 burden	 and	 cost.	 	 The	 study	 will	 continue	 for	 a	 minimum	 of	 six	months.	 	Follow-up	will	continue	until	 the	 last	participant	has	used	the	system	for	six	months.		The	maximum	proposed	follow-up	will	be	18	months.		
Patient	measures	Baseline	measures:		
• Age	
• Gender	
• Experience	with	 technology	 	 (frequency	 of	 use	 of	 a	 computer,	 tablet	 or	 smart	phone)	
• Major	 health	 condition	 that	 could	 impact	 on	 the	 use	 of	 telehealth	 (including	mood	disorder,	other	symptomatic	chronic	disease)	
• Medication		Outcome	measures	will	be	collected	at	0,	3	and	6	months,	 then	every	six	months	until	the	end	of	the	study	and	finally	at	the	end	of	the	study:		
• Quality	of	life	measures	
o ALSAQ-40	(an	MND	disease	specific	quality	of	life	score	(41))	
o SF-36-RAND	
o EQ-5D+D	(EQ-5Q-3L	with	a	dignity	bolt-on)	
• Clinical	outcomes	 	
o ALSFRS-R	(an	MND	disease	specific	functional	rating	score	(51)	
o Pain	score	(modified	Likert	scale)		
o CSS-MND	Saliva	Severity	Scale	(designed	for	use	with	MND	patients)	plus	global	change	scale	
o Hospital	Anxiety	and	Depression	Scale	
• Health	resource	usage	questionnaire		
• Patient	experience	questionnaire		
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Carer	measures	Baseline	measures:	
• Age	
• Gender		
• Frequency	of	use	of	a	computer,	tablet	or	smart	phone	
• Major	health	that	could	impact	on	the	use	of	telehealth		
• Relationship	to	patient		
• Number	of	hours	spent	per	week	providing	care	for	patient	Outcome	measures	will	be	collected	at	0,	3	and	6	months	and	at	the	end	of	the	study:		
• SF-36	RAND		
• 12	item	Zarit	Burden	Inventory		(53)	
• Hospital	Anxiety	and	Depression	Scale	(54)	
• Carer	satisfaction	questionnaire				Data	will	be	collected	to	evaluate	the	conduct	of	the	trial	including:	
• Participant	compliance	with	the	weekly	telehealth	session	
• Rate	of	completion	of	outcome	measures	
• Rates	of	recruitment	and	withdrawal	
• Participant	actual	and	perceived	time	burden	associated	with	the	system	
• Time	 spent	 by	 the	 MND	 nurse	 using	 TiM	 system	 and	 responding	 to	 alerts	 or	queries	generated	by	the	system.	
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8b.	Qualitative	sub-study	
	
Intervention	patient	and	carer	interviews	Qualitative	semi-structured	interviews	will	be	conducted	with	patients	and	carers	in	the	intervention	arm.	Participants	randomized	into	the	intervention	arm	will	be	invited	to	take	 part	 in	 interviews.	 	 	 Baseline	 interviews	 will	 occur	 at	 one	 month	 after	 the	intervention	is	started.	A	further	interview	will	be	conducted	at	6	months.			Six	months	is	 considered	 an	 appropriate	 timeframe	 for	 patients	 to	 become	 familiar	 with	 the	intervention	and	its	impact	on	quality	of	life.		Interviews	will	be	conducted	until	data	saturation	is	reached.		The	interviews	will	draw	directly	upon	peoples’	own	experience	and	views,	within	the	context	of	everyday	lives	to	explore	topics	including	
• Participants	experience	and	expectations	of	technology	
• Participants’	expectations	of	telehealth	services	
• Barriers	and	aids	to	recruitment		
• Compliance	with	the	TiM	system	
• How	the	TiM	system	is	used	at	home	by	patients	and	their	carers		
• The	impact	of	using	the	TiM	system	on	their	lives	and	well-being	
• The	impact	of	education	on	their	day-to-day	lives	
• The	experiences	of	carers	monitoring	
• Whether	 the	 outcome	measures	 used	 capture	 the	 changes	 in	 participants	well	being	associated	with	using	the	TiM	system.			
• How	the	system	would	be	used	outside	a	trial			The	early	phase	interview	will	explore	participants’	expectations	of	technology	and	the	TiM	 system,	 the	 views	 on	 the	 system,	 their	 experiences	 of	 training	 and	 using	 the	equipment.	 The	 later	 phase	will	 explore	 further	how	 the	TiM	 system	 influenced	 their	care	and	quality	of	life,	mental	well	being	as	their	condition	changed.		It	will	also	identify	barriers	and	facilitators	to	adoption	of	the	TiM	system.			The	applicant	will	agree	pre-defined	topic	schedules	(see	Appendix	B)	developed	from	the	 literature,	expert	consensus	and	discussion	with	the	trial	management	group	with	supervision	 from	 Dr.	 Wendy	 Baird,	 an	 experienced	 qualitative	 researcher	 (School	 of	Health	 and	Related	Research,	 Sheffield	University).	 	The	PI	will	 conduct	 interviews	 in	the	participants’	home.		The	PI	will	conduct	qualitative	interviews	until	data	saturation	is	reached	(55).	Interviews	will	be	audio-	recorded,	transcribed	verbatim	and	analysed	with	coding	and	retrieval	of	data	supported	by	NVivo	software.			Due	 to	 the	 nature	 of	 MND	 consideration	 will	 be	 given	 to	 participants’	 needs.	 	 The	research	 team	 has	 experience	 in	 conducting	 qualitative	 interviews	with	 patients	 and	carers	and	these	interviews	will	be	conducted	in	a	similar	fashion.		Often	patients	with	MND	prefer	 to	 be	 interviewed	with	 their	 carer.	 	 This	 also	 aids	 communication	where	patients	 have	 speech	difficulties	 and	 allows	participants	 to	 support	 each	 other	whilst	discussing	sensitive	issues.		Patients	can	use	communication	devices	and	all	participants	will	be	provided	with	a	brief	topic	guide	prior	to	the	interview	to	facilitate	participation	for	those	with	communication	difficulties.	 	Interviews	will	be	limited	to	approximately	one	 hour	 to	 reduce	 burden	 and	 fatigue.	 	 	 If	 participants	 prefer	 to	 be	 interviewed	together	carers	will	also	be	offered	separate	interviews	where	possible.		
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	Field	notes	will	also	be	collected	by	the	PI	during	the	face-to-face	training	using	the	TiM	system	to	determine	participants’	early	 reactions	 to	using	 the	system	and	 their	needs	for	training.			
Control	group	interviews		Following	randomization,	 those	patients	and	carers	who	are	assigned	 the	control	arm	will	complete	the	baseline	questionnaires.		They	will	then	have	a	short	(15-20	minute)	semi-structured	interview	with	the	PI.		This	will	focus	on	their	experiences	and	opinions	of	 the	baseline	questionnaires.	 	 It	will	 examine	whether	 they	were	easy	or	difficult	 to	complete,	 whether	 they	 were	 acceptable	 or	 caused	 distress	 to	 complete	 and	 which	questions	most	reflected	their	condition	and	current	quality	of	life.		The	 interviews,	 topic	 guides	 and	 analysis	 will	 be	 conducted	 in	 the	 same	 way	 as	described	 in	 the	 previous	 section.	 Topic	 guides	 will	 not	 be	 provided	 before	 the	interview	but	participants	invited	to	submit	any	further	comments	to	the	research	team	either	in	writing	or	telephone	following	the	interview.		It	is	expected	that	patients	and	carers	will	 be	 interviewed	 together.	 	 Interviews	will	 continue	 until	 data	 saturation	 is	reached	or	a	maximum	of	10	interviews	conducted.	
	
Staff	interviews	At	least	five	staff	that	care	for	the	participants	will	undergo	one-to-one	semi	structured	interview	by	the	PI	during	and	at	the	end	of	the	intervention.		This	will	include	the	two	responsible	consultant	clinicians	(Dr	Chris	McDermott	and	Professor	Pamela	Shaw),	at	least	one	MND	specialist	nurse	who	has	used	the	telehealth	system	and	two	members	of	the	MND	 community	 team	who	have	 cared	 for	 participants.	 	 They	will	 allow	 them	 to	draw	on	their	experiences	of	the	TiM	system	in	more	depth.		A	staff	information	leaflet	will	be	provided	and	written	consent	will	be	required	prior	to	any	interview.		Topics	will	include	
• The	day-to-day	use	of	the	TiM	system	
• The	impact	of	the	TiM	system	on	clinical	care	of	patients	and	carers	
• The	safety	and	accuracy	of	the	system	
• 	Barriers	and	aids	to	adoption	of	the	TiM	system.		
• Views	on	amending	the	appointment	schedule			These	will	be	planned	and	conducted	in	the	same	manner	as	the	participant	interviews	under	 the	 supervision	 of	 Dr	 Wendy	 Baird.	 	 	 An	 interview	 with	 the	 MND	 nurse	 and	clinicians	using	the	system	will	be	scheduled	early	in	the	trial	to	capture	any	problems	with	training	and	set	up	of	the	system.		At	the	end	of	the	trial	further	interviews	will	be	held	with	the	MND	team	as	described	above.					Following	 the	 interviews	 a	 focus	 group	 with	 the	 clinical	 team	 will	 be	 held	 to	 draw	together	all	 the	 information	gathered	 from	the	patient	and	staff	 interviews.	 	 It	will	be	chaired	 by	 Dr	 Wendy	 Baird,	 independent	 qualitative	 researcher,	 transcribed	 and	analysed	by	the	PI	under	her	supervision.		
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The	 qualitative	 findings	 will	 facilitate	 the	 exploration	 of	 any	 issues	 and	 challenges,	which	may	 arise	 from	 using	 TiM	 from	 the	 perspective	 of	 all	 stakeholder	 groups.	 The	findings	will	enhance	understanding	of	 the	 feasibility	of	using	TiM	and	assist	with	the	interpretation	of	the	clinical	data	from	the	perspective	of	patients	and	clinicians.		
	
8c.	Shadow	monitoring	protocol	
	In	 order	 to	 determine	 the	 safety	 of	 a	 remote	 monitoring	 system	 that	 may	 enable	clinicians	to	make	decisions	regarding	a	patient’s	management	the	trial	will	also	collect	data	 on	 clinicians’	 opinion	 on	 the	 accuracy	 of	 the	 data	 displayed	 by	 the	 TiM	 system.		This	is	referred	to	as	the	shadow	monitoring	protocol.		Prior	to	each	patient’s	face-to-face	visit	(depending	on	their	appointment	schedule)	the	treating	MND	doctor	will	 be	 asked	 to	 conduct	 a	 remote	 assessment	 of	 the	 patient	 by	reviewing	the	TiM	system	clinical	information.		They	will	be	asked	to	indicate,	given	the	information	 provided	 by	 the	 TiM	 system,	 whether	 they	 would	 change	 their	 patient’s	appointment.	 	 The	 patient	would	 attend	 the	 appointment	 as	 scheduled	 and	 after	 the	appointment	the	clinician	would	be	asked	whether	the	appointment	schedule	time	was	correct.	 	 They	would	 also	be	 asked	 to	 indicate	whether	 they	 felt	 that	 the	 information	displayed	on	the	TiM	system	was	a	safe	and	accurate	reflection	of	the	patient’s	condition	and	whether	it	influenced	their	clinic	visit.	Clinicians	will	also	indicate	whether	the	TiM	system	 had	 affected	 the	 consultation.	 	 They	 will	 also	 report	 any	 adverse	 events	identified.			Should	patients	be	unable	to	travel	to	clinic	they	will	be	offered	a	telephone	consultation	at	the	usual	scheduled	time.		The	same	Shadow	Monitoring	questions	and	need	to	report	adverse	events	will	apply.		The	 results	 of	 this	 shadow	monitoring	 will	 be	 triangulated	 with	 the	 qualitative	 sub-study	and	will	influence	the	later	interview	topic	guide.	
	
8d	Process	evaluation	
	Data	regarding	the	TiM	system	use	by	patients,	carers	and	staff	will	be	will	be	collected	in	order	to	understand	how	the	system	could	be	used	in	the	NHS	MND	care	process.		It	will	also	collect	data	regarding	the	extra	time	and	resources	required	to	manage	the	problems	generated	by	the	TiM	system.		It	will	be	triangulated	with	data	gained	from	the	qualitative	sub-study,	adverse	event	log	and	shadow	monitoring	protocol.		 	
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9.	Analysis	
	The	PI	will	conduct	analysis	with	regular	supervision	from	the	TMG.	
	
9a.	Feasibility		and	quantitative	analysis	The	feasibility	of	a	full	trial	will	be	determined	by	analysis	of	
• Recruitment	rates		
• Retention	rates		
• Compliance	rates		
• Sample	size	calculations	as	detailed	above			The	safety,	acceptability	and	feasibility	of	use	of	the	TiM	system		
• Incidence	of	adverse	events	(clinical	and	related	to	the	TiM	system	functionality)	
• Information	collected	using	the	Shadow	Monitoring	process	
• Qualitative	data	analysis	
	The	PI	and	the	CRF	study	nurse	will	be	responsible	for	chasing	missing	data.		The	CRF	nurse	is	responsible	for	chasing	the	questionnaire	data	and	will	telephone	the	patients	a	minimum	of	once	and	maximum	of	twice	to	chase	unreturned	questionnaires	or	clarify	missing	data	within	the	questionnaire	packs.		They	will	report	monthly	to	the	PI.		For	the	main	outcome	measures,	(SF-36	and	ALSAQ-40)	protocols	are	provided	for	managing	missing	data	if	necessary.		Participants	who	withdraw	will	be	encouraged	to	continue	to	be	followed	up	and	reasons	for	withdrawal	ascertained	where	possible.			In	the	proposed	larger,	efficacy	trial	intention	to	treat	analysis	will	be	adopted.	
	Quantitative	analysis	will	be	undertaken	in	a	similar	manner	for	all	endpoints.		The	change	from	baseline	at	each	time	point	will	be	analysed	using	analysis	of	covariance	in	which	the	covariates	are	treatment	group	and	the	baseline	value.	For	instance,	the	change	in	ALSFRS-r	at	six	months	will	be	analysed	with	treatment	group	and	baseline	ALSFRS-r	as	covariates.	The	mean	(standard	deviation)	change	in	each	group,	the	difference	between	groups	and	its	associated	95%	confidence	interval	will	be	reported.		No	formal	hypothesis	testing	will	be	undertaken	for	this	pilot	study.			 	
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9b.	Qualitative	analysis		Data	from	the	interviews	will	be	recorded,	transcribed	and	undergo	Framework	analysis	(56).	Although	Framework	analysis	was	developed	for	applied	policy	it	has	proved	useful	in	applied	health	research.	Analysis	will	be	ongoing	and	iterative	involving	concurrent	data	collection	and	analysis,	with	systematics	efforts	to	check	and	refine	developing	categories	of	data.	Themes	and	hypothesis	identified	in	the	early	phases	of	data	collection	will	inform	the	areas	of	investigation	in	later	interviews.	Regular	meetings	with	supervisors	will	review	the	data	analysis,	explore	respondents’	underlying	reasoning,	discuss	deviant	cases	and	reach	agreement	on	recurrent	themes	and	findings.		The	PI’s	field	notes	and	reflexive	diary	will	also	be	reviewed	and	used	to	inform	the	analysis	of	qualitative	data.	Dr	Wendy	Baird,	an	independent,	experienced	qualitative	research,	will	supervise	this	stage	of	the	work.				Results	from	the	qualitative	analysis	will	be	triangulated,	for	example,	to	explore	the	reasons	why	problems	with	the	trial	methodology	or	TiM	system	have	occurred.	Both	themes	and	anonymous	verbatim	comments	will	be	published	to	demonstrate	the	findings.	
	
	 	
	 	
	 28	
10.	Data	entry,	security	and	confidentiality	Clinical	quantitative	data	input	will	be	the	responsibility	of	the	PI	(baseline)	and	CRF	study	nurses	(months	3	and	6,	and	at	the	end	of	the	study).		Data	quality	will	be	the	responsibility	of	CRF	nurses	and	PI	who	will	report	back	to	the	TMC	and	TSC.			The	qualitative	data	and	system	usage	data	will	be	the	responsibility	of	the	PI.		Data	(including	audio-recordings)	will	be	collected	and	retained	in	accordance	with	the	Data	Protection	Act	1998	and	Caldicott	Principles.	Anonymised	study	data	will	be	entered	onto	a	validated	database	system	designed	to	an	agreed	specification	between	the	PI	and	Sheffield	CTRU	and	securely	stored	on	the	SU	intranet.	The	PI	and	the	CRF	research	nurses	will	have	access	to	data	on	the	database	through	the	use	of	usernames	and	encrypted	passwords.	Study	documents	will	be	retained	in	a	secure	location	during	and	after	the	study	has	finished.		All	source	documents	will	be	retained	for	a	period	of	at	least	5	years	following	the	end	of	the	study,	as	per	the	CTRU	SOP.	Where	study	related	information	is	documented	in	medical	records	those	records	will	be	retained	for	at	least	5	years	after	the	last	patient	last	visit		The	data	provided	through	the	TiM	system	will	be	collected	using	a	secure	web-app	accessed	by	the	participants	by	a	unique	username	and	password.		It	will	be	stored	on	a	secure	server	that	will	be	available	through	a	web-portal	hosted	by	Carematix	to	the	clinical	team	using	secure	usernames	and	password.					For	the	purposes	of	the	trial	each	participant	will	be	given	a	unique	TiM	system	code.		This	will	allow	all	data	to	be	relayed	through	the	web-app	without	any	associated	patient	identifiable	features.			This	code	will	be	held	separately	and	stored	securely	on	the	STH	intranet	to	allow	individual	identification	by	the	MND	care	team.		The	clinician	will	display	only	the	anonymous	code.		This	will	be	accessed	through	a	secure	portal	with	usernames	and	passwords.		No	identifiable	information	will	be	stored	on	the	patient	hub	or	on	the	TiM	server.		The	technology	providers	will	have	no	access	to	patient	identifiable	information.		Any	technology	problems	will	be	dealt	with	by	the	research	team	and	participants	will	have	no	contact	with	the	technology	providers.		The	system	has	a	full	electronic	audit	trail	and	will	be	regularly	backed	up	and	will	be	held	in	a	way	that	conforms	to	STH	information	governance	procedures.				
	
Access	to	source	data	Monitoring	and	audit	by	the	relevant	health	authorities	will	be	permitted	by	the	sponsor.	These	include	the	Research	Ethics	Committee	and	local	R&D	departments.	The	sponsor	will	be	allowed	to	monitor	and	audit	the	study	at	each	site	and	be	allowed	access	to	source	data	and	documents	for	these	purposes.	
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11. Safety	and	safety	assessments		We	 do	 not	 envisage	 any	 serious	 safety	 or	 adverse	 events	 associated	 with	 the	intervention.	 	 	The	system	does	not	give	 individual	advice	 to	a	patient	or	 recommend	change	 in	 management	 without	 input	 from	 a	 clinician.	 	 The	 trial	 protocol	 requires	patients	 to	 continue	with	 their	 usual	 care	 including	planned	outpatient	 appointments	and	 the	 Shadow	Monitoring	 Protocol	will	 evaluate	whether	 the	 data	 provided	 by	 the	TiM	system	is	felt	to	accurately	reflect	the	patients’	clinical	condition.		The	responsible	clinician	who	is	a	consultant	neurologist	with	specialist	experience	in	MND	and	research	will	 continue	 to	 review	 the	patient	on	a	 regular	basis	 (unless	 the	patient	 is	unable	 to	attend	clinic)	and	will	have	overall	responsibility	for	their	care	throughout	the	trial.	The	specialist	 MND	 nurses	 using	 the	 TiM	 system	 have	 extensive	 experience	 in	 managing	patients	via	the	existing	MND	helpline.				The	database	will	automatically	alert	the	trial	manager	to	any	carer	scoring	11	or	more	of	the	Hospital	Anxiety	and	Depression	score	collected	as	part	of	the	outcome	measures.		This	 will	 allow	 the	 trial	 manger	 to	 identify	 those	 carers	 who	 may	 require	 further	support.		
Adverse	Event	Reporting	All	 adverse	 events	 will	 be	 reported	 in	 accordance	 with	 the	 Sheffield	 CTRU	 Adverse	Event	and	Serious	Adverse	Events	SOP.			Participants	will	 be	monitored	 for	 adverse	 clinical	 events	 and	 efforts	will	 be	made	 to	ascertain	 whether	 the	 TiM	 system	 influenced	 the	 event	 or	 could	 have	 predicted	 the	event.	These	include	unplanned	admissions	and	deaths.		Non-clinical	events	relating	to	the	use	of	the	telehealth	hub	will	recorded	e.g.	failure	to	record	or	deliver	information	to	and	from	the	clinical	interface.		In	research	other	than	CTIMPs	an	adverse	event	is	defined	as: is	any	unfavorable	and	unintended	sign	(including	an	abnormal	laboratory	finding),	symptom,	or	disease	having	been	absent	at	baseline,	or,	if	present	at	baseline,	appears	to	worsen	AND	is	temporally	associated	with	medical	treatment	or	procedure,	REGARDLESS	of	the	attribution	(i.e.,	relationship	of	event	to	medical	treatment	or	procedure).		
Serious	Adverse	Event	(SAE)	In	research	other	than	CTIMPs,	the	National	Research	Ethics	Service	defines	a	Serious	Adverse	Event	(SAE)	is	defined	as	an	untoward	occurrence	that:	(a)	results	in	death;	(b)	is	life-threatening*;	(c)	requires	hospitalization**	or	prolongation	of	existing	hospitalization**;	(d)	results	in	persistent	or	significant	disability	or	incapacity;	(e)	consists	of	a	congenital	anomaly	or	birth	defect;	or	(f)	is	otherwise	considered	medically	significant	by	the	investigator.		*”life-threatening”	in	the	definition	of	“serious”	refers	to	an	event	in	which	the	patient	was	at	risk	of	death	at	the	time	of	the	event;	it	does	not	refer	to	an	event	which	hypothetically	might	have	caused	death	if	it	were	more	severe.	**Hospitalisation	is	defined	as	an	inpatient	admission,	regardless	of	length	of	stay,	even	if	the	
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hospitalisation	is	a	precautionary	measure	for	continued	observation.		Hospitalisations	for	a	pre-existing	condition,	including	elective	procedures	that	have	not	worsened,	do	not	constitute	an	SAE.			
Adverse	event	exclusions	The	only	adverse	event	that	will	be	excluded	is:		1.	 Standard	or	expected	disease	progression.		
Adverse	event	inclusions		All	serious	adverse	events	will	be	reported.		These	include	deaths	of	participants	and	emergency	admissions.		We	will	attempt	to	determine	whether	the	use	of	the	TiM	system	contributed	to	the	event,	in	particular	whether	there	was	any	delay	in	seeking	help	due	to	the	use	of	the	system.				
Assessment	of	Adverse	Events	The	following	criteria	will	be	used	when	assessing	adverse	events:	Intensity	(severity):	Mild	-	does	not	interfere	with	routine	activities			Moderate	-	interferes	with	routine	activities		Severe	-	impossible	to	perform	routine	activities		Relationship	to	the	study	treatment:		Unrelated	-	There	is	no	evidence	of	any	causal	relationship.	N.B.	An	alternative	cause	for	the	AE	should	be	given		Unlikely	-	There	is	little	evidence	to	suggest	there	is	a	causal	relationship.	There	is	another	reasonable	explanation	for	the	event	(e.g.	the	participant’s	clinical	condition,	other	concomitant	treatment).		Possible	-	There	is	some	evidence	to	suggest	a	causal	relationship.	However,	the	influence	of	other	factors	may	have	contributed	to	the	event	(e.g.	the	participant’s	clinical	condition,	other	concomitant	treatments).		Probable	-	There	is	evidence	to	suggest	a	causal	relationship	and	the	influence	of	other	factors	is	unlikely.		Definite	-	There	is	clear	evidence	to	suggest	a	causal	relationship	and	other	possible	contributing	factors	can	be	ruled	out.		Not	assessable	-	There	is	insufficient	or	contradictory	information	which	cannot	be	supplemented	or	verified		
Reporting	procedures		All	study	participants	will	be	encouraged	to	contact	and	inform	their	site	research	team	if	they	experience	any	new	medical	problem	or	are	admitted	to	hospital.			Those	that	are	not	picked	up	through	general	contact	will	be	identified	at	their	routine	2-3	monthly	outpatient	appointments	either	in	person	or	by	telephone	as	part	of	the	Shadow	Monitoring	Protocol.			The	patients’	consultant	neurologist	(Dr.	Chris	McDermott	or	Professor	Dame	Pamela	Shaw)	will	enquire	about	any	adverse	events	since	the	previous	visit	and	record	these	on	the	adverse	event	paper	CRF	and	database.	For	any	Serious	Adverse	Events	an	SAE	paper	CRF	and	database	entry	will	be	completed.	The	PI	and	consultant	neurologist	will	assess	the	event	and	the	CRF	will	be	kept	in	the	site	file.	Serious	adverse	events	will	be	reported	to	the	TSC,	TMG	and	the	sponsor	if	deemed	by	
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either	to	be	related	to	the	trial.		Reports	of	related	and	unexpected	SAEs	will	be	submitted	to	the	ethics	committee	within	15	days	of	the	chief	investigator	becoming	aware	of	the	event.	This	will	use	the	National	Research	Ethics	Service	Report	of	Serious	Adverse	Event	form.			Information	will	also	be	included	in	the	routine	progress	reports	to	the	sponsor	and	ethics	committee.		Routine	safety	data	and	all	SAEs	that	the	TMG	or	TSC	deems	to	be	related	to	the	trial	will	also	be	reported	to	the	technology	provider	in	the	same	manner.			Any	suspected	adverse	drug	reaction	would	be	assessed	and	reported	to	the	MHRA	as	part	of	clinicians’	routine	pharmacovigilance	responsibilities	using	the	Yellow	Card	Scheme.		The	technology	provider,	Abbott	Healthcare	Products	Ltd.	manufactures	a	number	of	drugs	(listed	in	Appendix	A).		Any	suspected	adverse	drug	reaction	involving	an	Abbott	Healthcare	Products	Ltd.	drug	would	also	be	reported	to	the	manufacturer	in	the	same	manner,	within	24	hours	of	receipt	by	the	CI	or	the	next	working	day	for	reports	received	out	of	hours.	Such	reports	should	be	sent	to	ukpharmacovigilance@abbott.com.	On	a	monthly	basis	the	PI	will	send	a	reconciliation	list	of	all	the	reports	sent	to	the	Abbott	Pharmacovigilance	Department	within	that	month	to	ensure	that	all	the	appropriate	information	has	been	exchanged.	Should	any	discrepancies	arise,	both	parties	will	immediately	seek	to	resolve	them.		
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12. Ethical	considerations		
	The	study	will	be	conducted	in	accordance	to	Good	Clinical	Practice	Guidelines	and	subject	to	Research	Ethics	Committee	favourable	opinion.		The	study	received	a	favorable	approval	from	an	independent	panel	representing	the	NIHR,	which	funds	Dr.	Esther	Hobson’s	NIHR	Doctoral	Fellowship	Award.		The	study	has	approval	from	the	Sheffield	Teaching	Hospitals	NHS	Foundation	Trust’s	Research	and	Development	department.			It	has	also	received	favourable	review	from	Dr.	Mike	Bradburn,	study	statistician	at	ScHARR,	Dr.	Cindy	Cooper,	director	of	CTRU	and	ScHARR,	and	Dr.	Wendy	Baird	of	the	Yorkshire	and	Humber	Research	and	Design	service,	Professor	Alicia	O’Cathain,	Professor	of	Health	Services	Research,	ScHARR	and	Professor	Dame	Pamela	Shaw,	SITraN.			The	application	will	be	submitted	through	the	IRAS	central	allocation	system.	The	approval	letter	from	the	ethics	committee	and	copy	of	approved	patient	information	leaflet,	consent	forms,	CRF’s	and	questionnaires	will	be	present	in	the	site	files	before	initiation	of	the	study	and	patient	recruitment.				It	is	recognized	that	patients	with	MND	may	be	frail	and	nearing	at	the	end	stages	of	their	lives.		The	research	team	has	extensive	experience	in	conducting	clinical	trials	in	this	population.		The	study	design	has	attempted	to	limit	the	burden	imposed	by	the	study	by	avoiding	unnecessary	study	visits	(by	combining	them	with	scheduled	visits),	collecting	data	in	the	participants’	homes	at	their	convenience	and	limiting	the	study	procedures	to	the	minimum	necessary.		The	intervention	has	been	designed	in	collaboration	with	patients	and	carers	to	maximize	ease	of	use	and	minimize	impact	on	participants’	lives.		It	is	appreciated	that	there	are	a	number	of	questionnaires	that	require	completion.		Given	one	aim	of	the	study	is	to	determine	the	most	appropriate	outcome	measures	to	evaluate	efficacy	of	the	TiM	system	there	are	more	questions	than	would	be	used	in	a	large	scale	trial.		These	have	been	reviewed	by	the	Sheffield	MND	Research	Advisory	Group	(the	local	PPI	group)	and	the	lay	members	of	the	TSC	(David	Stelmach)	and	TMG	(Anne	Quinn)	to	ensure	acceptability.		Participants	will	be	supported	by	the	CRF	nurse	to	complete	these	at	their	convenience	in	a	manner	selected	by	the	participant	(either	by	post,	telephone	or	in	person).		There	are	other	clinical	studies	ongoing	in	the	Sheffield	MND	care	centre.		Involvement	in	other	studies	would	not	preclude	patients	from	entering	this	study.		Consideration	of	the	burden	involved	in	the	study,	potential	impact	on	the	outcome	of	the	study	and	the	patients’	expressed	priorities	will	be	considered	before	patients	are	approached	to	be	involved.		If	involvement	in	this	study	excludes	patients	from	entering	another	clinical	trial	patients	will	be	given	the	option	to	withdraw	from	this	study.		The	potential	conflict	of	interest	between	the	role	of	the	clinical	team	in	caring	for	patients	and	their	role	as	researchers	is	recognized.		The	study	design	has	considered	the	impact	of	this	conflict	on	the	participants	choices	and	also	any	potential	bias.		Whilst	PI	is	a	doctor	working	within	the	MND	team	she	is	a	specialty	training	registrar	and	overall	responsibility	for	the	patients’	clinical	care	will	remain	with	the	consultant	neurologist	rather	than	the	PI.		Whilst	she	may	have	already	cared	for	potential	participants,	following	an	invite	to	participate	in	the	trial	will	no	longer	see	these	patients	in	their	routine	clinical	appointments	and	her	role	will	be	as	a	researcher.				
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	The	dual	role	of	the	PI	as	a	doctor	and	researcher	has	been	previously	evaluated.		The	professional	background	of	a	doctor	may	actually	aid	the	building	of	a	research	relationship,	allow	patients	to	be	more	open	and	comfortable	with	discussing	their	health	with	someone	who	they	already	trust	(56).			In	order	successfully	identify	any	potential	bias	the	purpose	of	the	research	and	nature	of	the	PI’s	role	will	be	emphasized	throughout	the	study,	the	PI	will	keep	a	reflexive	diary	and	field	notes	and	identify	any	potential	bias.			Where	bias	is	most	likely,	i.e.	in	the	collection	of	outcome	measures	steps	have	been	taken	to	limit	this:	the	quantitative	outcome	measures	will	be	collected	by	an	independent	study	nurse	and	the	qualitative	interview	structure	and	topic	guides	have	been	planned	with	supervision	from	an	independent	researcher	Dr.	Wendy	Baird.		The	PI	will	be	supervised,	as	part	of	her	PhD	by	independent	academics:	Dr.	Cindy	Cooper	and	Dr.	Mike	Bradburn	(focusing	mainly	on	the	trial	methodology	and	conduct,	and	quantative	data	analysis),	Dr.	Wendy	Baird	and	Professor	Sue	Mawson	(qualitative	work	and	service	evaluation).		If,	during	the	research,	participants	identify	any	medical	problems,	the	PI	has	a	duty	of	care	and	will	make	arrangements	to	deal	with	these	problems.			This	might	involve	signposting	them	to	appropriate	services	or	liaising	with	the	clinical	team.		A	log	of	these	activities	will	be	kept	and	reviewed	by	the	TMG.			When	the	participants	have	prior	knowledge	of	the	researcher	they	may	feel	a	sense	of	duty	and	feel	pressurized	to	participate	(57).		Ground	rules,	informed	consent,	confidentiality,	freedom	to	stop	and	what	to	expect	will	be	discussed	with	all	participants.		Participants	will	be	approached	by	letter	and	they	will	be	required	to	contact	the	study	team	allowing	them	to	consider	the	trial	in	detail	first.		It	will	be	explained	to	the	patient	(both	verbally	and	in	the	information	leaflets	and	consent	forms)	that	participation	is	voluntary	and	will	not	affect	their	ongoing	care.		The	information	leaflet	differentiates	the	research	process	and	their	usual	care.		It	will	be	made	clear,	particularly	in	the	interview	phase	that	the	PI’s	role	is	as	a	researcher	and	the	aim	of	the	study	is	to	critically	analyse	service	provision	and	that	whilst	comments,	particular	negative	comments,	will	be	passed	back	to	the	care	team	they	will	treated	with	confidence	and	respect.			Whilst	the	carer	participant	is	not	a	patient	of	the	Sheffield	MND	team	the	research	team	have	a	duty	of	care	to	the	carer.		There	may	be	circumstances	where	the	carer	may	disclose	information	that	requires	medical	care,	for	example	disclosing	symptoms	of	depression	or	anxiety.		At	the	start	of	the	trial	the	carer	participants’	GP	will	be	informed	of	the	trial.		In	the	event	of	a	serious	risk	being	identified	the	research	team	will	discuss	this	in	confidence	with	the	carer	and	make	arrangements	to	resolve	the	problem.		This	might	include	referral	to	his	or	her	own	GP	or	other	health	professional.		Carer	participants	will	be	informed	of	these	procedures	in	the	Carer	information	leaflet	and	consent	form.		Confidentiality	will	be	maintained	in	accordance	with	the	General	Medical	Council’s	guidance	on	Confidentiality	(58).		Upon	publication	of	the	qualitative	interviews	it	may	be	possible	to	identify	participants’	comments	although	this	will	be	avoided	if	possible.		This	is	explained	to	participants	in	the	Interview	Information	Leaflets	and	on	the	consent	form.		
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13. Finance	and	indemnity	The	trial	has	been	financed	through	an	NIHR	doctoral	fellowship	grant	and	details	have	been	drawn	up	in	a	separate	agreement.	This	is	an	NHS	sponsored	study.	If	there	is	negligent	harm	during	the	clinical	trial	when	the	NHS	body	owes	a	duty	of	care	to	the	person	harmed,	NHS	indemnity	will	cover	NHS	staff,	medical	academic	staff	with	honorary	contracts	and	those	conducting	the	trial.	The	University	of	Sheffield	has	in	place	insurance	against	liabilities	for	which	it	may	be	legally	liable	and	this	cover	includes	any	such	liabilities	arising	out	of	this	clinical	trial.		
	
14.	Reporting	and	dissemination	
	Results	of	the	study	will	be	disseminated	in	peer	reviewed	scientific	journals	and	clinical	and	academic	conferences.		Details	of	the	study	will	also	be	made	available	on	the	SITraN	and	ScHARR	websites,	blogs	and	social	media	and	through	local	MND	groups.	Summaries	of	the	research	will	be	updated	periodically	on	the	SITraN	website	to	inform	readers	of	the	ongoing	progress.		Following	publication	contact	with	other	UK	MND	care	centres	will	be	made	to	disseminate	the	findings	and	assess	buy-in	potential	for	a	full	study	if	this	is	appropriate.		 	
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Appendix	1:	Drugs	produced	by	Abbott	Healthcare	Ltd.		Fenofibrate	Pancreatin	Moxonidine	Estradiol/dydrogesterone	Mebeverine	Betahistine	Fluvoxamine	maleate	Lactulose	Estradiol,	oral	applications	Influenza	virus	vaccine	Eprosartan	mesylate	Ibuprofen	Flurbiprofen	Propafenone	Clarithromycin	Verapamil		 	
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1.	Introduction,	Study	Design	&	Objectives		This	 Statistical	 Analysis	 Plan	 (SAP)	 is	 written	 in	 conjunction	 with	 the	 ICH	 E9	(International	Conference	on	Harmonisation	of	Technical	Requirements	for	Registration	of	 Pharmaceuticals	 for	 human	 use;	 ICH	 Harmonised	 Tripartite	 Guideline:	 Statistical	Principles	for	Clinical	Trials	E9),	applicable	standard	operating	procedures	(SOPs)	from	the	Sheffield	Clinical	Trials	Research	Unit	 (CTRU)	and	 trial	documents	 (Protocol,	 case	report	 form	 (CRF)	 and	 Data	 Validation	 Specifications).	 This	 SAP	 will	 guide	 the	 trial	manager	 (TM)	 and	 Trial	 Statistician	 during	 the	 statistical	 analysis	 of	 all	 quantitative	outcomes	in	order	to	answer	the	objectives	of	the	study.			
1.1 Study	Background		This	is	a	single-centre,	pilot,	mixed	methods,	randomised	controlled	trial	to	explore	the	feasibility	and	acceptability	of	using	the	TiM	(Telehealth	in	Motor	Neurone	Disease	(MND))	system	in	clinical	practice	and	explore	the	feasibility	of	a	larger,	multicentre	trial.		This	plans	refers	to	the	TiM	trial	protocol	V1.5	April	2015.		All	 analyses	 will	 be	 performed	 in	 a	 validated	 statistical	 software	 package	 such	 as	GraphPad	prism.			
1.2 Primary	Objectives	As	this	is	a	pilot	study,	no	formal	primary	clinical	outcome	will	be	defined.	Instead,	the	trial	 will	 assess	 the	 feasibility	 and	 requirements	 of	 a	 full-scale	 study	 of	 the	 TiM	 as	defined	by	the	as	successful	recruitment	of	40	eligible	patients	and	their	primary	carer;	and	 the	 feasibility,	 acceptability,	 safety	 and	 use	 of	 the	 TiM	 system	 within	 a	 health	service.	 The	 specific	 objectives	 and	 outcomes	 of	 this	 study	 are	 separated	 into	 two	groups:	feasibility	and	clinical	outcomes.			
1.2.1 Feasibility	Outcomes	
Feasibility	of	a	full-scale	study	
• To	make	a	decision	on	the	primary	outcome	for	the	main	trial.	 	The	mechanism	for	 choosing	 this	 outcome	will	 be	 informed	by	 statistical	 considerations	which	are	detailed	in	section	6.7.	
• Number	of	potentially	eligible	patients	among	the	pool	of	patients	under	the	care	of	the	Sheffield	MND	care	centre	
• Number/characteristics	of	eligible	patients	approached	for	the	study:	
• List	of	reasons	for	declining/refused	consent;	
• Participant	attrition	rate	
• List	of	reasons	for	attrition	
• Number	of	missing	values/incomplete	cases	.	
• Treatment	receipt/adherence;	
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• Patient,	 carer	 and	 clinician	 views	 on	 intervention/research	 protocol	 (using	qualitative	methods).		Feasibility/safety	of	TiM	system:	
• Treatment	receipt/participant	and	staff	adherence	
• Participant	 and	 clinician	 acceptability	 of	 the	 intervention	 (using	 qualitative	methods	and	the	TiM	system	experience	questionnaire	and	Shadow	monitoring	protocol)	
• Patient,	carer	and	clinician	views	on	intervention	(using	qualitative	methods);		
• Incidence	of	TiM	system	technical	problems;		
• Incidence	of	adverse	events	related	to	intervention.		Participant	 and	 clinician	 views	 will	 be	 investigated	 using	 qualitative	 interviews	(described	 in	 the	 protocol).	 	 	 Participant	 and	 clinician	 acceptability	 will	 be	 reported	based	on	TiM	system	experience	questionnaire	and	Shadow	monitoring	questionnaire.		
1.2.2 Clinical	Outcomes		The	 following	 clinical	 outcomes	will	 be	 reported	 using	 self-completed	 questionnaires	baseline,	3,	6,	12	and	18	months.			Patient	outcomes	
• Quality	of	life	(QoL)	measures	
o ALSAQ-40	(an	MND	disease	specific	quality	of	life	score)	
o SF-36-RAND	
o EQ-5D+D	(EQ-5Q-3L	with	a	dignity	bolt-on)	
• Clinical	outcomes	 	
o ALS-FRS-R	(an	MND	disease	specific	functional	rating	score	
o Pain	score	(modified	Likert	scale)		
o CSS-MND	Saliva	Severity	Scale	(designed	for	use	with	MND	patients)	plus	global	change	scale	
o Hospital	Anxiety	and	Depression	Scale	(HADS)	
• Health	resource	usage	questionnaire		
• Patient	experience	questionnaire	
• TiM	experience	questionnaire		Carer	outcomes	
• SF-36	RAND		
• 12	item	Zarit	Burden	Inventory		(ZBI)	(53)	
• Hospital	Anxiety	and	Depression	Scale	(54)	
• Carer	satisfaction	questionnaire			 	
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	The	following	safety	outcomes	will	be	assessed	at	every	clinical	visit:	
• Incidence	of	adverse	events	(AEs)	
• Clinician	satisfaction		
2 Sample	Size	Estimation		The	study	aims	to	recruit	a	total	of	40	patients	and	their	carers.	 	20	patients	and	their	primary	carer	will	be	randomised	to	the	intervention	arm	(a	minimum	of	6	months	use	of	the	TiM	telehealth	plus	usual	care)	and	20	patents	and	their	carer	in	the	control	arm	(usual	care).				Since	 the	 proposed	 trial	 is	 primarily	 an	 assessment	 of	 the	 acceptability	 of	 the	intervention	and	the	feasibility	of	a	full	trial,	the	proposed	sample	size	is	not	based	on	standard	statistical	parameters	such	as	a	clinically	relevant	difference	between	groups.	Instead,	the	sample	size	is	justified	on	the	grounds	of	quantifying	patient	variance	(i.e.	the	standard	deviation)	in	the	proposed	outcome	measures	(in	particular	quality	of	life	measures)	and	on	feasibility	of	the	full	trial,	as	follows:		
• 	A	 sample	 size	 of	 40	 patients	 allows	 a	 standard	 deviation	 to	 be	 estimated	 to	within	 a	 precision	 of	 ±20%	 of	 its	 true	 underlying	 value	with	 90%	 confidence.	This	 estimate	 will	 be	 synthesised	 by	 combining	 baselines	 measurements	 of	quality	 of	 life	measurement	 standard	 deviations	 with	 those	 observed	 in	 other	published	studies	and	on-going	trials	within	SITraN,	to	provide	a	robust	estimate	for	use	in	the	sample	size	calculation	for	the	full	trial.		
• Given	 the	 rarity	 of	MND,	 any	 definitive	 study	will	 be	 infeasible	 if	 the	 required	sample	 size	 is	 substantial.	 Assuming	 the	 upper	 limit	 for	 feasible	 UK	 study	 is	around	 200-300	 patients	 in	 total,	 it	 follows	 that	 the	 full	 study	 would	 need	powering	to	detect	a	standardised	effect	size	of	at	 least	0.4	SDs.	This	pilot	 trial	will	provide	a	preliminary	assessment	of	whether	the	intervention	might	feasibly	achieve	 this,	 and	 inform	 the	 choice	of	 outcome	measures	 for	 the	proposed	 full	study.			This	sample	size	is	also	in	keeping	with	the	proposal	of	12	evaluable	patients	per	arm	in	a	pilot	study	(after	withdrawal	or	drop-out)	(1).					 	
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3 Randomisation	&	Blinding		Randomisation	is	conducted	according	to	the	protocol.		The	patient,	clinicians,	TM	and	trial	team	are	not	blinded	to	the	outcomes.	 	Data	entry	for	 follow-up	clinical	outcomes	was	performed	by	an	 independent	research	nurse,	not	involved	in	the	study.		Blinding	of	this	nurse	was	impractical	given	additional	measures	were	collected	for	those	in	the	intervention	group.		The	TM	will	undertake	the	analysis	under	the	supervision	of	the	independent	trial	statistician.		Blinding	during	analysis	was	impractical	 given	 the	 small	 number	 of	 participants	 who	 had	 with	 unique	 and	characteristics	which	are	likely	to	be	identifiable	to	the	TM.		This	will	be	reported	as	a	limitation		
4 Interim	Analysis	&	Study	Monitoring.				This	is	a	pilot	study	with	no	planned	interim	analysis	or	early	stopping.	Two	committees	have	been	set	up	to	govern	the	conduct	of	the	study:		
• Trial	Steering	Committee	(TSC)	
• Trial	Management	Group	(TMG)		Decisions	to	stop	the	trial	early	on	grounds	of	safety	will	be	made	by	the	Trial	Steering	Committee	or	funding	body.	There	will	not	be	a	Data	Monitoring	and	Ethics	Committee	for	this	study	as	it	is	considered	low	risk.		No	interim	analysis	is	planned.			The	TM	will	 receive	notifications	of	all	 carers	whose	Hospital	Anxiety	and	Depression	subscores	exceed	11.	 	These	events	will	be	recorded	as	AEs,	reported	to	 the	TMG	and	TSG	during	the	study	and	reported	in	the	analysis.	
	
5 Data	Sources,	Evaluability	&	Study	Populations		
5.1 Data	Sources	Data	used	in	this	study	will	come	from	data	entered	onto	CRFs	and	questionnaires	and	from	data	entered	directly	on	the	CTRU	database	(PROSPECT).	The	data	will	be	stored	on	 the	 database	 with	 the	 exception	 of	 the	 randomisation	 list	 which	 is	 held	 on	www.sealedenvelope.com	 and	 allocation	 verified	 by	 the	 data	 management	 team.	Electronic	 data	will	 be	 extracted	 from	 the	 system	 during	 the	 trial	 for	 the	 purpose	 of	checking	 (validating)	 and	 trial	progress	 reports.	Access	 to	PROSPECT	 is	 controlled	by	usernames	and	encrypted	passwords,	and	a	privilege	management	feature	will	be	used	to	 ensure	 that	 users	 have	 access	 to	 only	 the	 minimum	 amount	 of	 data	 required	 to	complete	their	tasks.	This	will	be	used	to	restrict	access	to	personal	identifiable	data.		
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5.2 Data	Collection			Data	will	be	collected	from	the	participants	and	their	carers	at:		
• Consent	and	Screening,	eligibility	and	baseline	
• Month	3,	6,	12	and	18	
• Each	clinic	visit	(Shadow	monitoring	protocol)	
• End	of	study	(participant	status	alive/dead	and	date	of	death).		
Due	to	the	pilot	nature	of	the	study	there	are	no	predefined	protocol	non	compliances	
other	than	misrandomisation	or	randomisation	in	error.	Intervention	adherence	will	be	
assess	as	an	outcome	(see	section	6.5).	
5.3 Protocol	non	compliances		
Due	to	the	pilot	nature	of	the	study	there	are	no	predefined	protocol	non	compliances	
other	than	misrandomisation	or	randomisation	in	error.	Intervention	adherence	will	be	
assess	as	an	outcome	(see	section	6.5).	
	
5.4 Study	Population		Described	in	the	protocol.		
5.5 Analysis	Populations			The	 intention	 to	 treat	 population	 (ITT)	 includes	 all	 patients	 for	 whom	 consent	 is	obtained	 and	who	 are	 randomised	 to	 treatment.	 This	 is	 the	 primary	 analysis	 set	 and	endpoints	 will	 be	 summarised	 for	 the	 intention	 to	 treat	 population	 unless	 stated	otherwise.				 	
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6 Statistical	Analysis		
6.1 General	considerations	As	 the	 trial	 is	a	pilot	parallel	group	randomised	controlled	 trial,	data	will	be	reported	and	presented	according	to	the	proposed	modifications	for	reporting	pilot	trials	as	well	as	 the	 Consolidated	 standards	 of	 reporting	 trials	 (CONSORT)	 statement	 (2,3).	 	 The	analysis	will	be	performed	on	an	 ITT	basis.	The	 final	analysis	will	be	performed	after	data	 lock	 by	 the	 TM	 under	 the	 supervision	 of	 the	 study	 statistician	who	will	 also	 be	responsible	for	quality	checking	the	results.	
	
Each	planned	follow-up	timepoint	will	use	a	time	window	to	ensure	that	responses	have	
been	collected	within	a	reasonable	time	frame.	The	time	windows	allow	a	slippage	of	four	
weeks	at	3	months	and	six	weeks	thereafter,	as	outlined	below:	
	
3	months:	 within	61-91	days	following	randomisation	
6	months:		 within	140-224	days	following	randomisation	
12	months:		 within	323-407days	following	randomisation	
18	months:		 within	506-590	days	following	randomisation	
	
6.2 Recruitment	and	attrition	rates		Relevant	 summaries	 related	 to	 recruitment,	 consent	 and	 patient	 throughput	 will	 be	reported	and	presented	in	a	CONSORT	flow	diagram	(see	appendix,	Figure	1).		The	following	will	be	reported:		The	number	of	(potential)	participants;	
• Potentially	eligible	as	identified	by	the	study	team	at	participating	centres,		
• Approached	for	the	study,	
• Not	randomised	(with	reasons),	
• Randomised,		
o allocated	to	treatment	
o allocated	to	control		
• Withdrawn	and	lost	to	follow	up	(with	reasons),		
• Discontinuing	TiM	intervention,	
o reasons	for	discontinuation		
• Included	and	excluded	from	analysis,		
o Reasons	for	exclusion.	
6.2.1 Eligibility		Described	in	the	study	protocol	
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6.2.2 Participant	Attrition		The	rate	of	attrition	will	be	reported	(defined	as	 the	proportion	of	 the	consented	and	randomised	 participants	 who	 withdrew	 or	 were	 lost	 to	 follow	 up).	 The	 reasons	 for	attrition,	where	provided,	will	be	reported	as	number	and	percentage	in	each	category.			
6.3 Status	of	participants	and	completion	of	outcome	measures		We	will	report	the	status	of	patients	and	carers	at	each	time	point.		At	each	time-point	we	will	report	the	number	of	patients	and	carers:	
• Returning	the	postal	questionnaire	booklet	
• Completing	each	questionnaire	We	will	report	these	by	treatment	group	and	overall.			For	 the	 patient	 and	 carer	 questionnaires	 the	 response	 rate	 at	 each	 time	 point	(measured	 as	 the	 total	 number	 of	 questionnaires	 completed	 as	 a	 fraction	 of	 total	number	of	patients	alive)	will	be	reported.	An	example	table	is	given	in	section	0	(Table	1).				
	
6.4 Baseline	Characteristics	The	 baseline	 demographics	 and	 clinical	 characteristics	 of	 the	 participants	 will	 be	reported.	 For	 the	 continuous	 variables,	 (e.g.	 age)	 either	mean	 and	 standard	deviation	will	 be	 presented	 or	 median	 and	 inter	 quartile	 range	 (IQR)	 depending	 on	 the	distribution	 of	 the	 data.	 The	 number	 of	 observations	 used	 in	 each	 calculation	will	 be	presented	 alongside	 the	 summaries.	 For	 the	 categorical	 variables,	 the	 number	 and	percentage	 of	 participants	 in	 each	 of	 the	 categories	 and	 the	 total	 number	 of	observations	will	be	presented.			All	baseline	summaries	will	be	presented	and	reported	for	each	treatment	group	and	in	total.	An	example	of	the	table	of	baseline	summaries	is	given	in	section	0	(	 	
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Table	 2).	 No	 statistical	 significance	 testing	 will	 be	 done	 to	 test	 baseline	 imbalances	between	 the	 intervention	 arms	 but	 any	 noteworthy	 differences	 will	 be	 descriptively	reported.			 	
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	The	following	summaries	will	be	presented:		
Demographics	 Age,	gender,	technology	use	
MND	Characteristics		 Age	of	onset,	disease	duration,	classification	of	MND	(e.g.	
ALS,	PMA,	PLS),	clinical	stage	of	MND,	use	of	non-invasive	
ventilation	(NIV)/gastrostomy,	riluzole	use	
Carer	demographics	 Age,	gender,	relationship	to	patient,	technology	use	
Patient	reported	outcomes		 ALS-FRS-R	 (including	 upper	 limb	 function),	 ALSAQ40,	
RAND36	and	subscores,	CSS-MND,	HADS,	pain	score,	EQ-
5D+D,	 patient	 experience,	 health	 resource	 use	 (number	
and	type	of	clinical	encounters	and	hospital	admissions	in	
last	3	months,	carer	requirements)		
Carer	reported	outcomes	 RAND36,	ZBI,	HADS,	carer	experience				
6.5 TiM	Treatment	adherence		
Intervention	adherence	will	be	reported	as	 the	number	of	TiM	sessions	attended	within	
between	 recruitment	 and	 the	 end	 of	 March	 2016	 and	 the	 mean	 and	 SD	 of	 percent	
adherence.		We	will	also	report	adherence	at	1,	3,	6,	9,	12,	15	and	18	months.		
		
	
We	will	also	report		
• The	 number	 and	 percentage	 of	 participants	 that	 completed	 50%	 and	 75%	 of	
expected	sessions.		
• A	description	of	 the	adherence	of	each	patient	and	carer	using	 the	TiM	over	 the	
course	of	the	trial.	
	
Any	 reasons	 for	 poor	 adherence	 will	 be	 reported	 where	 available	 although	 it	 was	 not	
possible	to	identify	reasons	for	all	missed	sessions.	
	
Cumulative	 session	 attendance	 will	 be	 displayed	 for	 each	 participant	 using	 a	 spaghetti	
plot	to	illustrate	intervention	adherence.		
	
The	number	and	percentage	of	participants	that	withdrew	from	the	TiM	intervention	will	
be	reported,	alongside	listings	of:	
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• Reasons	for	withdrawing	from	intervention,	where	provided		
• Number	of	TiM	sessions	(and	%)	before	withdrawing	from	intervention		
		
6.6 Clinical	outcomes		Descriptive	 statistics	 will	 be	 presented	 for	 the	 clinical	 outcomes;	 significance	 testing	will	 not	 be	 undertaken.	 Continuous	 outcome	 measures	 will	 be	 presented	 as	 mean	differences	 between	 groups	 and	 their	 associated	 95%	 confidence	 intervals	 (CI).	 For	categorical	outcomes,	the	number	and	percentages	falling	into	different	categories	and	potential	differences	between	groups	in	terms	of	the	percentages	in	each	category	will	be	 presented,	 together	 with	 their	 confidence	 intervals.	 Clinical	 outcomes	 will	 be	presented	for	the	ITT	set	with	available	6	month	and	12	month	outcome	data.			
6.6.1 Patient	outcomes	The	following	outcomes	measured	at	3,	6,	12,	18	months	will	be	presented	by	group	and	overall.			The	following	patient	–reported	quality	of	life	outcomes	will	be	reported.	
ALSAQ-40	 Individual	 scores	 of	 five	 sub-scales	 and	 a	 summary	
aggregate	score:	
▪	 				physical	mobility		
▪	 				activities	of	daily	living	and	independence			
▪	 				eating	and	drinking		
▪	 				communication			
▪	 				emotional	reactions			
RAND-36	 A summary of the eight	 sub-scales	 and	 two	 aggregated	
scales:	
▪	 Physical	Functioning	
▪	 Role	Limitations	due	to	Physical	Problems	
▪	 General	Health	Perceptions	
▪	 Vitality	
▪	 Social	Functioning	
▪	 Role	Limitations	due	to	Emotional	Problems	
▪	 General	Mental	Health	
▪	 Health	Transition	
▪	 Aggregate	physical	health	
▪	 Aggregate	mental	health	
EQ-5D+D	 Health utility (as derived from the five questions) 
Thermometer health scale 
Health utility plus dignity (as derived five questions plus 
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dignity bolt-on) 	In	 each	 case	 the	 within-group	 results	 will	 be	 summarised	 as	 mean	 (SD),	 and	 the	difference	between	the	two	as	the	mean	difference	together	with	its	CI.	Forest	plots	of	confidence	 intervals	 of	 different	 widths	 (e.g.	 95%,	 90%,	 80%)	 with	 respect	 to	 the	treatment	difference	 in	 the	overall	ALSAQ40	score	and	RAND36	 (mental	 and	physical	domain)	will	be	used	 to	 illustrate	 the	 strength	of	preliminary	evidence	 (see	Figure	2)	(Lee,	2014).				In	each	case,	the	summaries	will	be	presented	by	treatment	group	and	time	point	(see	Table	3	and		 	
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Table	4)	and	will	comprise	the	following:		
• The	number	of	patients	alive	and	the	number	of	patients	completing	the	outcome	
• The	score	mean	and	SD		
• The	mean	and	SD	of	the	change	from	baseline			Each	 outcome	 measure	 will	 be	 scored	 as	 described	 below	 and	 compared,	 where	possible	and	relevant	to	population	values.		The	RAND-36	will	 be	 scored	 as	 described	 in	Ware	 et	 al	 (4).	 	 	 In	 the	 case	 of	 partially	completed	questionnaires,	scores	will	be	calculated	for	domains	in	which	at	least	50%	of	the	questions	have	been	answered.		Taking	physical	functioning	as	example,	if	at	least	five	 of	 the	 ten	 questions	 comprising	 the	 domain	 have	 been	 answered,	 the	 physical	function	score	will	be	calculated	as	PF	=	(total	sum	across	non-missing	questions)	x	(10/	number	of	non-missing	answers).	These	scores	will	be	standardised	to	US	population	norms.	
The ALSAQ-40	will	be	scored	according	to	ALSAQ	Scoring	Algorithms	(5).		There	are	five	domains	plus	an	overall	summary	score.		The	domains	are	physical	mobility	(Q1-10),	activities	of	daily	living/independence	(Q11-20),	eating	and	drinking,	(Q21-23)	communication	(Q24-30),	emotional	functioning	(Q31-40).		Each	question	is	scored	0	(never)	to	4	(always/cannot	do	at	all).				Physical	mobility	=	((Q1	+Q2	+Q3	+Q4	+Q5	+Q6	+Q7	+Q8	+	Q9	+	Q10)/40)	x	100.		Activities	 of	 daily	 living	 /	 independence	 =	 ((Q11	 +Q12	 +Q13	 +Q14	 +Q15	 +Q16	 +Q17	 +	Q18	 +	 Q19	 +	Q20)/40)	x	100.		Eating	and	drinking	=	((Q21+Q22+Q23)/12)	x	100.		Communication	=	((Q24	+Q25	+Q26	+Q27	+	Q28	+Q29	+	Q30)	/28)	x	100.		Emotional	functioning	=	((Q31	+Q32	+Q33	+Q34	+Q35	+Q36	+Q37	+Q38	+Q39	+	Q40)/40)	x	100.			An	overall	total	(ie	total/160	x100)	will	be	reported	as	an	overall	summary	measure.	(6)		As	with	 the	RAND-36,	any	partially	completed	domains	will	be	pro-rated	providing	at	least	50%	of	the	items	have	been	completed.		The	 EuroQol	 5D	 questionnaire	 3-level	 format	 plus	 dignity	 bolt-on	 (EQ-5D+D)	will	 be	used	to	derive	three	health	utility	outcomes:	
• The	standard	EQ-5D	score,	derived	based	on	the	UK	population		{Dolan:1996fw}	
• The	 modified	 EQ-5D+D	 total	 score	 which	 incorporates	 the	 additional	 dignity	question	 and	 is	 scored	 using	 an	 as	 yet	 unpublished	 algorithm	 (Dixon	 et	 al.,	unpublished	data).			
• The	EQ5D	“thermometer”	scale			In	all	three,	an	imputed	score	of	zero	will	be	used	for	patients	who	have	died.	
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	The	following	other	clinical	outcomes	will	be	presented:		
Hospital	anxiety	and	depression	
score		
	The	Anxiety	and	Depression	subscores		
Pain	(Likert	scale)	 Current and average weekly score	
ALS-FRS-R	 Total score 
CSS	MND	 Total score 
% patients reporting a clinically significant improvement 
or worsening (according to Global change CSS-MND 
self-reported statement) 
Clinical	encounters	 The	 number	 of	 clinical	 encounters	 in	 the	 6	 months	
following	randomisation,	by	type	and	location	and	reason		 
Hospital	admissions	 The	 number	 and	 percentage	 of	 patients	 admitted	 to	
hospital,	 and	 the	 number	 of	 hospitalisations,	 by	 type,	
location	and	reason			The	 HADS	 anxiety	 and	 depression	 inventories	 will	 be	 scored	 using	 the	 approach	 of	Zigmond	and	Snaith	(7).	Each	domain	will	be	calculated	as	the	sum	of	seven	questions,	each	of	which	is	scored	0-3,	giving	a	total	score	which	ranges	from	0	and	21.		In	the	case	of	 partially	 completed	 questionnaires,	 the	 domain	 will	 be	 scored	 and	 upweighted	provided	at	least	four	of	the	seven	questions	have	been	answered.		Self-completed	revised	ALS	functional	rating	scale	(ALS-FRS-R)	consists	of	12	questions	scoring	0-4	(8).		Sub-domains	include	upper	limb,	lower	limb,	bulbar	and	respiratory.		Pain	score:	the	current	level	of	pain	(0-10	likely	scale)	and	the	average	current	weekly	level	of	pain	(0-10)	will	be	represented	as	a	mean	and	SD.		Modified	CSS	MND	saliva	score	is	awaiting	validation.		The	total	score	is	the	total	of	all	answers	scoring	0-3	for	each	question	A	to	J	(9).		The	percentage	of	patients	reporting	a	change	on	the	saliva	clinical	change	assessment	will	be	reported.		
6.6.2 Carer	clinical	outcomes		The	 following	 carer-reported	QoL	outcomes	will	 be	presented	 is	 the	 same	manner	 as	described	for	the	patients.	
• RAND	36	
• HADS	
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• Zarit	Burden	Index		The	each	of	the	12	items	in	the	shortened	Zarit	burden	inventory	is	scored	0	(Never)	to	4	(nearly	always)	(10).		A	total	score	between	0	and	48	will	be	reported.			
6.6.3 Health	economic	outcomes		A	 complete	 health	 economic	 analysis	 is	 beyond	 the	 scope	 of	 this	 plan.	 	 However,	descriptions	of	the	following	clinical	outcomes	will	be	reported,	by	group	and	overall:		
Clinical	encounters	 The	 number	 of	 clinical	 encounters	 recorded	 at	 each	
encounter	following	randomisation,	by	type	and	location.	
Hospital	admissions	 The	 number	 and	 percentage	 of	 patients	 admitted	 to	
hospital	 recorded	 at	 each	 encounter.	 the	 number	 of	
hospitalisations	
Informal	care	requirements	 The	 number	 of	 hours	 of	 informal	 care	 recorded	 by	
patients.	
Formal	care	requirements	 The	number	of	hours	of	formal	care	recorded	by	patients.		
6.6.4 Patient	experiences	
	The	following	will	be	reported	by	group	and	overall.		
Patient	care	experience	 Percentage	 of	 patients	 agreeing	 and	 disagreeing	 with	
each	satisfaction	statement	
Carer	care	experience	 Percentage	 of	 carer	 agreeing	 and	 disagreeing	with	 each	
satisfaction	statement	
Patient	 TiM	 experience	
(intervention	only)	
Percentage	 of	 patients	 agreeing	 and	 disagreeing	 with	
each	satisfaction	statement	
Carer	 TiM	 experience	
(intervention	only)	
Percentage	 of	 carer	 agreeing	 and	 disagreeing	with	 each	
satisfaction	statement		All	free	text	responses	will	be	reported.		
6.6.5 Safety		Adverse	events	are	recorded	at	every	clinic	appointment	and	patients	will	report	health	resource	use	and	hospital	admissions.		Reported	admissions	will	be	followed	up	by	the	
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TM	and	 records	 as	 serious	 adverse	 events.	 	HADS	 carer	 scores	will	 be	 calculated	 and	reported	 to	 the	 TM	 for	 action	 on	 an	 ongoing	 basis	 during	 the	 trial	 if	 either	 the	depression	 or	 the	 anxiety	 subscore	 exceeds	 11.	 	 These	 will	 be	 reported	 to	 the	 TSC	during	the	trial	and	reported	in	the	analysis	and	recorded	as	adverse	events.			Advents	Events	(AEs)	will	be	reported	as	number	and	percentage	of	patients	overall	and	by	treatment	group	but	no	formal	statistical	analysis	is	planned.	The	following	summaries	will	be	presented;		
AEs	 The	number	and	percentage*	of	patients	reporting	an	AE	and	the	number	of	AEs	in	total		
AEs	by	
category	
The	number	and	percentage*	of	patients	reporting	an	AE	and	the	number	of	AEs	for	each	pre-defined	category	(pain,	acute	infection,	fractures)	
Serious	AEs	
(SAEs)	
The	number	and	percentage*	of	patients	reporting	an	SAE	and	the	number	of	SAEs	in	total		
Treatment-
related	AEs	
The	number	and	percentage*	of	patients	reporting	a	treatment	related	AE	and	the	number	of	treatment	related	AEs	
All	AEs	 A	listing	of	all	AEs	including		
- Description	/	Site	/	Signs	and	Symptoms	
- Severity	
- Relationship	
- Action	taken	
- Outcome	
- Seriousness	
	 *defined	as	a	percentage	of	all	patients	randomised.			
6.7 Estimation	of	primary	outcome	and	sample	size	for	a	main	trial	The	variability	in	clinical	outcomes	will	be	reported	as	standard	deviation	by	treatment	group	and	overall	alongside	their	upper	80%	confidence	limits	to	get	a	robust	estimate	of	SD	(as	recommended	by	Kieser,	2007),	and	observed	treatment	difference.				Descriptive	assessment	will	be	used	to	inform	sample	size	calculations	for	the	definitive	study.	 These	 assessments	 will	 be	 calculated	 for	 candidate	 measures	 for	 the	 full	 trial	(RAND-36	and	ALSAQ40),	and	will	be	based	on:		
• Observed	treatment	difference	at	6	and	12	months	
• Standard	Deviation;	
• Correlation	between	baseline	and	6	month	measurements;	
• The	extent	of	missing	data	in	each	outcome;	
• Participant	 feedback	 on	 the	 most	 appropriate	 assessment	 (analysed	qualitatively).		
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The	 standard	 deviation	 used	 in	 the	 sample	 size	 calculation	 will	 be	 derived	 from	 the	residual	 variance	 of	 the	 regression	 model	 for	 which	 the	 outcome	 is	 the	 6-month	response	and	the	covariates	are	treatment	group	and	baseline.		A	 table	 of	 sample	 size	 estimates	 for	 a	 definitive	 study	 stratified	 by	 outcome	measure	and	power	(80%,	90%)	will	be	provided.		E.g.	Table	5		
6.8 Economic	Evaluation	Analysis		No	 economic	 analysis	 will	 be	 conducted	 but	 patient	 health	 resource	 use	 will	 be	reported.		
6.9 TiM	process	evaluation	
	The	following	will	be	reported:		Patient	and	carer	feasibility:	
• The	time	taken	to	complete	each	TiM	session	by	patient	and	carer	(mean,	range).		TiM	 session	 time	 is	 automatically	 recorded	 by	 the	 application	 but	 total	 time	between	starting	and	completing	and	session	is	recorded.	This	includes	any	time	delay	because	the	patient	pauses	using	the	session	and	recommences	it	later	e.g.	the	next	day.	 	Outliers	will	be	 identified	and	excluded	with	definition	of	outlier	reported	(e.g.	>	600%	of	the	average	time);	
• Adherence	to	weekly	TiM	sessions	(see	6.5);		Clinical	feasibility:	
• Number,	 range	and	%	of	patient	and	carer	 sessions	 that	 trigger	an	overall	 red,	amber	and	green	flag;	
• Number,	 range	 and	%	of	 patient	 and	 carer	 sub-sections	 that	 trigger	 an	 overall	red,	amber	and	green	flag;	
• Time	taken	for	nurse	to	use	the	telehealth	system	per	week,	collected	by	nurse	diary	(mean,	range,	SD	and	time	per	patient	enrolled	in	the	system);	
• Number	of	notes	entered	per	patient.	
• Shadow	monitoring	protocol	(intervention)	
o Number	of	pre-clinic	shadow	monitoring	forms	completed	
o Number	of	clinic	shadow	monitoring	forms	completed	
o Clinician	satisfaction:	%	agree/disagree	with	each	statement	
o Free	text	comments	will	be	reported.		
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7 Detailed	Statistical	Methods	&	Calculations		
7.1 Missing	Spurious	&	Unused	Data		The	extent	of	missing	data	will	be	reported.	No	sensitivity	analyses	involving	imputation	for	missing	data	will	be	performed.	Any	spurious	data	will	be	queried	and	checked	for	consistency	with	data	management	before	data	lock.			Patient	and	carer	questionnaires	will	be	scored	only	if	all	relevant	items	that	make	up	a	domain	are	completed	with	the	exception	of	RAND	36,	HADS	and	ALSAQ40.		
8 Implementation	of	the	Analysis	Plan		This	SAP	will	be	used	as	a	work	description	for	the	statistician	involved	in	the	trial.	All	analyses	will	be	performed	by	the	TM	(under	the	supervision	of	Trial	Statistician	MB).		Initially,	blinded	data	will	be	delivered	to	the	TM	and	MB	by	the	data	manager	to	define	analysis	 sets	 and	 test	 statistical	 programs.	 Any	 queries	 will	 be	 communicated	 to	 the	study	 and	 data	 manager	 prior	 to	 database	 lock.	 The	 database	 will	 be	 locked	 after	agreement	between	the	statistician,	data	manager	and	study	manager.	No	changes	will	be	made	once	the	data	has	been	locked.	Database	freeze	and	lock	will	be	conducted	in	accordance	with	SOP	DM012.			
	
	
9 Modifications	to	the	Original	Protocol	Analysis	Statement		
	
None	
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10 Appendix		
Figure	1:	CONSORT	flow	diagram				
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Figure	2:	Mean	difference	in	ALSAQ40	with	confidence	intervals		
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10.2	Example	Tables	and	Figures			Note:	The	following	tables	are	examples	and	do	not	include	all	outcome	measures	that	will	be	included	in	the	analysis.			
Table	1:	Participant	status	
 3 months 6 months 12 months 18 months 
Telehealth     
Completed 
Not completed 
N= N=   
  Died 
  Withdrew from study 
  Completed questionnaire but not within 
time window 
    
Incomplete     
 
Control 
    
Completed  
Not completed 
N= N=   
  Died 
  Withdrew from study 
  Completed questionnaire but not within 
time window 
    
Incomplete      
     	*Completed	 includes	 questionnaires	 that	were	 sufficiently	 complete	 to	 be	 used	 in	 the	statistical	 analysis.	 Uncompleted	 refers	 to	 questionnaire	 booklets	 that	 were	 not	returned.	 	 Incomplete	 refers	 to	 questionnaire	 booklets	 that	 were	 returned	 but	insufficiently	complete	to	be	used	in	statistical	analysis.			 	
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Table	2:	Participant	baseline	characteristics	by	treatment	group	
	
Characteristic		 Scoring		 Control	 Intervention	 All		 	 (n=xx)	 (n=xx)	 (n=xx)		 	 	 	 	Age	(years)	 Mean(SD,	range)	 x	(xx)	 x	(xx)	 x	(xx)		 N	 n	 n	 n	Gender	 Male	Female	 n	(%)	n	(%)	 	n	(%)	n	(%)	 	n	(%)	n	(%)		 N	 N	 n	 n	ALS-FRS-R	 Mean(SD,	range)	 x	(xx)	 x	(xx)	 x	(xx)		 N	 n	 n	 n	King’s	 clinical	stage		 Stage	1	Stage	2…etc.	 x	(xx)	 x	(xx)	 x	(xx)		 N	 n	 n	 n		 	 	 	 	
This	will	be	extended	to	include	the	other	baseline	variables	measured.			
Table	3:	Display	of	outcome	data	by	time,	illustrated	for	pain	
 Baseline 3 months   
Outcome  Mean 
(SD) 
Change from 
baseline 
…repeat for 
other 
timepoints 
 
Current pain: 
Mean (SD) 
Mean (SD) N= 
Mean 
(SD) 
Mean (CI)   
Control Mean (SD) N= 
Mean 
(SD) 
Mean (CI)   
Average pain: 
Mean (SD) 
Mean (SD) N= 
Mean 
(SD) 
Mean (CI)   
Control Mean (SD) N= 
Mean 
(SD) 
Mean (CI)   
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Table	4:	Clinical	outcomes	at	six	months:	control	vs	intervention		 Change	from	baseline	 		 Intervention	 Control	 		 	 	 	 	Outcome	 n	 Mean	 SD	 n	 Mean	 SD	 Mean	difference	(95%	CI)	
	 	 	 	 	 	 	 	ALSAQ40	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)		 	 	 	 	 	 	 	RAND	36	(agg.	physical)	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)	RAND	36	(agg.	mental)	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)	HADS	anxiety	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)	HADS	depression	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)	Pain	 x	 xx	 xx	 x	 xx	 xx	 xx	(xx	to	xx)	…	 	 	 	 	 	 	 	
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Table	5:	Sample	size	considerations	for	candidate	primary	outcome	measures		
	 Effect	size	 Standard	
deviation	
Power	
(%)	
Number	
/group	
Number	
/group	+	
attrition	
Outcome	 MCID	 Obse
rved*	
	 	 	 	 	ALSAQ-40	total	 xx	 Xx	 Observed		Upper	80%CI	
xx		xx			
80	90	80	90	
NN	NN	NN	NN	
NN	NN	NN	NN			 	 	 	 	 	 	 	RAND-36		 	 	 	 	 	 	 		Agg	physical	 5	 Xx	 Observed		Upper	80%CI	
xx		xx			
80	90	80	90		
NN	NN	NN	NN	
NN	NN	NN	NN			Agg	mental	 5	 xx	 …	 	 	 	 		 	 	 	 	 	 	 	
…repeat	for	other	candidate	measures		
*nb	Observed	effect	size	is	for	reference	and	is	not	used	in	sample	size	calculation	
	 	Trial	Documents		
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Appendix	4.3	
Patient	information	leaflet	V1.2		
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Study	reference:		STH17165	
NIHR	portfolio	reference:	17022	
INFORMATION	SHEET	FOR	PATIENTS	
	
You	are	being	invited	to	take	part	in	a	research	study.	Before	you	decide	
whether	to	take	part	it	is	important	for	you	to	understand	why	the	research	is	
being	done	and	what	it	will	involve.	Please	take	time	to	read	the	following	
information	carefully	and	discuss	it	with	friends,	relatives	and	your	GP	if	you	
wish.	The	contact	details	of	the	study	team	are	at	the	bottom	of	this	leaflet	if	
you	would	like	more	information.	
	
What	is	the	purpose	of	this	study?	
Motor	Neuron	Disease	(MND)	is	a	disease	affecting	the	nervous	system	that	
causes	progressive	muscular	weakness	as	well	as	other	symptoms	such	as	
fatigue	and	emotional	difficulties.	Currently,	patients	and	their	carers	are	
invited	to	attend	the	specialist	MND	clinic	at	the	Royal	Hallamshire	Hospital	
where	they	receive	care	from	doctors,	nurses	and	therapists.		Patients	and	
their	carers	may	want,	and	may	benefit	from,	better	access	to	this	specialist	
care	on	a	more	regular	basis	without	having	to	travel	to	hospital	more	
frequently.		
	
The	Sheffield	MND	care	team	have	developed	a	telehealth	system	that	can	
allow	patients	and	their	carers	to	keep	in	touch	with	the	MND	clinic	using	a	
handheld	tablet	computer.		It	is	called	the	TiM	(Telehealth	in	Motor	neurone	
disease)	system.		The	TiM	system	allows	patients	and	their	main	carer	(usually	
a	partner	or	close	relative)	to	complete	questions	on	a	weekly	basis	about	
their	condition	and	wellbeing.	The	information	is	transmitted	over	a	secure	
internet	connection	to	alert	the	Sheffield	MND	team	to	any	problem	or	
change	in	patients’	condition	
	
The	aim	of	this	project	is	to	see	whether	using	the	TiM	system	is	acceptable	to	
patients	and	carers	and	if	the	system	can	provide	the	information	we	need	to	
monitor	and	improve	the	care	for	patients	and	their	carers.		If	it	is	found	to	be	
successful	then	we	would	use	the	information	gathered	to	modify	the	TiM	
system	and	to	test	it	in	a	larger	trial	of	many	patients	with	MND.			
	
Why	have	I	been	invited	to	participate?	
You	have	been	chosen	because	you	have	attended	the	Sheffield	Motor	
Neuron	Disorders	Clinic	and	expressed	an	interest	in	contributing	to	our	
research	efforts.			
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What	would	happen	if	I	take	part?	
If,	having	reading	this	information	leaflet	you	and	your	carer	are	interested	in	
taking	part	then	a	member	of	the	study	team	will	arrange	a	mutually	
convenient	time	to	meet,	usually	at	your	own	home.	They	will	discuss	the	
study	in	detail	and	answer	any	questions	you	have	before	you	make	a	
decision.		You	may	wish	to	discuss	it	first	with	your	family,	or	your	medical	
team.		If	you	wish	to	discuss	it	with	your	MND	consultant	neurologist	we	will	
arrange	this.	
	
If	both	you	and	your	main	carer	decide	to	take	part	we	will	ask	you	to	sign	a	
consent	form.		Written	consent	would	take	place	prior	to	any	study	
procedures.			The	study	researcher	will	then	go	through	a	basic	screening	with	
you	and	your	carer	to	check	that	you	are	eligible	to	take	part.		
	
If	you	are	both	eligible	to	take	part	you	will	be	randomly	assigned	to	one	of	
two	groups.		Half	of	the	patients	and	their	carers	will	continue	as	usual	but	
complete	questionnaires	about	their	condition	at	the	start	and	after	three	
months	and	then	six	monthly	during	the	trial.		These	can	be	completed	at	
home	and	take	approximately	20	minutes	for	the	patient,	and	less	time	for	
carers.		Patients	in	this	arm	will	continue	to	be	invited	to	come	to	your	usual	
appointments	as	scheduled	and	have	no	changes	to	the	care	you	receive	from	
the	MND	team.	
After	completing	the	first	questions	you	and	your	carer	will	also	be	invited	to	
take	part	in	a	short	interview	(approximately	15	minutes)	with	the	researcher	
to	discuss	your	opinion	on	the	questionnaires	you	have	filled	in.		This	will	be	
audio-recorded	and	analysed	in	order	to	see	whether	these	questionnaires	
can	be	improved	in	the	future.		This	is	known	as	the	control	arm.			
	
The	other	half	of	the	patients	will	be	assigned	to	use	the	TiM	system.	They	will	
continue	to	be	cared	for	in	the	usual	way	and,	like	the	control	group	also	
asked	to	complete	questionnaires	throughout	the	trial.		They	will	also	be	given	
a	tablet	computer	to	use	during	the	trial.			A	member	of	the	study	team	will	
show	you	how	to	use	it	and	they	will	be	available	during	the	study	for	further	
help.		Patients	may	wish	to	ask	a	carer	to	help	you	use	the	system.		
	
For	those	assigned	to	use	the	TiM	system	we	ask	that	both	you	and	your	carer	
complete	questions	using	the	TiM	system	once	a	week	(and	more	often	if	you	
wish).	There	are	different	questions	for	you	and	your	carer.		They	ask	you	
about	your	condition,	your	mood	and	any	other	symptoms	from	which	you	
may	be	experiencing.	You	may	wish	to	complete	the	questions	together	or	
separately.		The	time	it	takes	to	complete	a	weekly	session	depends	on	
whether	your	condition	is	changing,	usually	taking	about	15	minutes	per	
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week.		You	can	try	out	the	tablet	computer	at	home	with	the	study	team	
before	deciding	whether	to	join	the	trial.	Once	all	the	information	is	entered	it	
is	sent	via	a	secure	internet	connection	to	the	MND	team	in	Sheffield	where	
the	MND	nurse	will	look	at	the	information.		If	the	TiM	system	reports	any	
problems	they	will	contact	you	to	discuss	how	these	can	be	resolved.	
	
Patients	and	carers	assigned	to	use	the	TiM	system	will	be	invited	to	take	part	
in	some	interviews.		These	will	be	scheduled	in	your	own	home	up	to	twice	
during	the	study,	once	at	one	month	after	starting	to	use	the	system	and	
again	at	six	months.		We	would	like	to	understand	your	thoughts	and	
experiences	of	using	the	telehealth	system	and	being	part	of	the	study.		In	our	
experience	many	patients	and	carers	prefer	to	be	interviewed	together	but	
you	can	be	interviewed	separately.	The	interviews	will	last	up	to	one	hour.		
The	study	team	are		experienced	in	interviewing	people	with	MND	and	you	
are	welcome	to	use	a	communication	aid	or	give	written	answers	before	or	
after	the	interview.	
	
This	research	project	does	not	require	any	change	to	your	day-to-day	
activities.		You	will	continue	to	be	invited	to	attend	all	regular	appointments.		
If	you	are	unable	to	attend	your	appointments	we	will	arrange	telephone	
consultations	with	your	consultant.				
	
Do	I	have	to	take	part?	
It	is	up	to	you	to	decide	whether	or	not	to	take	part.	If	you	decide	to	take	part	
you	are	still	free	to	withdraw	at	any	time	and	without	giving	a	reason.	This	
would	not	affect	the	usual	care	you	receive.			To	help	us	identify	problems	
with	the	study	study	we	may	invite	you	to	give	reasons	why	you	decided	not	
to	take	part	or	to	stop	taking	part.			We	would	like	to	invite	your	main,	unpaid	
carer	to	participate.			Your	carer	will	also	sign	a	consent	form,	and	be	free	to	
withdraw	at	any	time.		We	would	ask	that	at	least	initially,	both	you	and	your	
carer	take	part	in	the	study.	
	
How	long	will	the	study	last?	
Participants	will	be	asked	to	complete	questionnaires	at	the	start	of	the	study,	
after	three	and	six	months	and	then	six	monthly.		The	study	will	last	for	a	
minimum	of	six	months	and	a	maximum	of	18	months.	
	
Are	there	any	benefits	or	disadvantages	to	taking	part?	
This	is	a	pilot	study	to	see	if	it	is	possible	to	use	this	type	of	system.		There	
have	been	no	studies	in	patients	with	MND	like	this	before	and,	whilst	we	
hope	it	will	improve	the	way	we	care	for	patients,	we	do	not	know	for	certain.		
We	hope	in	the	future	to	conduct	a	larger	study	to	see	if	it	helps	improve	care	
in	MND.		You	may	be	invited	to	take	part	in	this	study.	
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The	aim	of	the	TiM	system	is	not	to	replace	the	service	that	we	offer	in	
Sheffield,	rather	to	improve	the	service	and	make	it	more	available	to	
patients.		As	such,	we	will	not	be	changing	your	usual	medical	care.			Being	
involved	in	a	study	does	take	some	time	but	you	will	not	be	required	to	attend	
hospital	any	more	frequently.		Both	the	telehealth	questions	and	the	trial	
questionnaires	can	all	be	completed	at	your	convenience	at	home	and	a	
member	of	the	study	team	will	be	available	by	telephone	should	you	need	
help.	
	
Will	it	cost	me	anything	to	take	part?	
All	equipment	including	the	internet	connection	are	provided.		Other	than	
keeping	the	tablet	computer	charged	there	would	be	no	cost	for	using	the	
telehealth	system	or	being	part	of	the	trial.		We	would	ask	that	you	return	the	
equipment	at	the	end	of	the	study.		All	study	visits	will	be	in	your	own	home	
or	during	your	routine	appointments	but	if	you	do	incur	travel	expenses	
coming	to	extra	appointments	these	will	be	reimbursed.		
	
Will	there	be	any	effects	on	my	treatment?	
If	you	are	using	the	telehealth	system	your	MND	nurse	will	have	access	to	the	
information	that	you	record.		Should	they	feel	your	treatment	needs	to	
change	they	will	contact	you	or	your	carer	to	discuss	this.		Whilst	the	some	of	
the	study	team	are	members	of	the	MND	care	team	in	Sheffield	their	care	for	
you	as	a	patient	will	not	change,	whether	or	not	you	decide	to	take	part	in	the	
study.	
	
What	about	my	hospital	appointments?	
You	will	continue	to	be	invited	to	attend	all	your	usual	clinic	visits	at	the	
schedule	agreed	with	your	doctor.		If	you	are	unable	to	attend	clinic	a	
member	your	consultant	will	arrange	a	telephone	interview	with	you	or	your	
carer.		This	will	allow	you	to	discuss	your	condition	and	any	problems	with	
your	doctor.	
	
Will	the	information	obtained	in	the	study	be	confidential?	
All	personal	information	would	be	kept	strictly	confidential.			The	technology	
we	are	using	complies	to	strict	NHS	information	governance	and	security	
regulations	and	the	Data	Protection	Act.		Only	your	usual	MND	team	and	the	
study	team	have	access	to	your	information	and	this	will	be	monitored.			No	
information	would	be	stored	on	the	handheld	computer	so	there	is	no	
possibility	of	anyone	gaining	access	to	the	information	if	it	is	lost	or	stolen.			
The	technology	company	would	not	have	any	access	to	any	identifiable	data.	
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If	you	participate	in	the	interviews	they	will	be	audio-recorded,	transcribed	
and	stored	securely.		Quotes	will	be	anonymised	and	may	be	shared	with	the	
MND	team	and	used	in	publication	and	it	might	be	possible	for	someone	who	
knows	you	well	to	identify	them.			As	this	is	a	research	study	is	important	that	
we	learn	about	both	the	good	and	bad	things	about	your	experiences,	what	
you	say	will	not	affect	your	treatment.	
	
Will	anyone	else	be	told	about	my	participation	in	the	study?	
Your	GP	and	neurologist	looking	after	you	would	be	informed	about	your	
participation	in	the	study.	
	
How	will	this	information	be	used?	
The	results	of	research	will	be	published	in	medical	and	scientific	journals.		
However,	complete	confidentiality	will	be	maintained	and	no	individual	
person	will	be	identified	in	these	publications.			In	the	future	if	this	study	is	a	
success	we	may	be	able	to	use	the	information	to	further	develop	the	
telehealth	system	and	potential	use	it	for	many	patients	with	MND	and	other	
chronic	conditions.	
	
Who	will	profit	from	this	study?	
There	is	a	significant	cost	involved	in	developing	and	maintaining	these	sorts	
of	services.		The	TiM	system	and	the	computers	has	been	provided	by	a	
pharmaceutical	company	called	Abbott	working	together	with	a	telehealth	
company	called	Carematix	with	support	from	the	Motor	Neurone	Disease	
Association.	The	study	is	funded	by	the	National	Institute	for	Health	Research.		
The	results	of	this	study	may	lead	to	the	development	of	patents	and/or	to	
commercial	benefits	for	Abbott,	Sheffield	Teaching	Hospitals	NHS	Trust	and	
the	University	of	Sheffield.			You	would	not	be	entitled	to	receive	any	financial	
benefit.		No	member	of	the	study	team	or	your	MND	care	team	are	entitled	to	
any	financial	benefit.				
	
What	happens	if	something	goes	wrong?	
If	you	have	any	concerns	or	other	questions	about	this	study	or	the	way	it	has	
been	carried	out,	you	should	contact	the	chief	investigator	or	your	consultant	
(address	below)	in	the	first	instance	who	will	do	their	best	to	address	your	
concerns.			You	may	contact	the	hospital	complaints	department	in	the	Chief	
Executives	Office	at	the	Royal	Hallamshire	Hospital	on	(0114)	2713898.				
	
Who	has	reviewed	the	study?	
All	research	in	the	NHS	is	looked	at	by	independent	group	of	people,	called	a	
Research	Ethics	Committee,	to	protect	your	interests.	This	study	has	been	
reviewed	and	given	favourable	opinion	by	the	Leeds	Bradford	Research	Ethics	
Committee		
	 	
	 74	
Study	Investigator	contact	details															
	
Dr	Christopher	McDermott	
Chief	Investigator	and	Honorary	Consultant	Neurologist	
Dr	Esther	Hobson		
Co-investigator	and	NIHR	Doctoral	Research	Fellow	
	
Sheffield	Institute	for	Translational	Neuroscience	
University	of	Sheffield	
385A	Glossop	Road,	Sheffield		S10	2HQ	
	
Telephone	0114-2222260	
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Appendix	4.5	
Topic	guides	
		
Topic	guide	Patients/carers	at	baseline		
Patient	questionnaires	
• Some	are	asking	quite	personal	questions.		How	do	you	feel	about	that?	
• Do	you	think	the	questionnaires	asked	questions	about	your	life	with	MND?	
• Did	you	find	any	of	the	questionnaires	confusing?	
• Did	you	find	any	of	the	questionnaires	upsetting?	
• What	would	you	think	about	filling	in	these	questionnaires	again?	
o If	so,	how	would	you	fill	them	in?			
• If	you	needed	help,	how	would	you	fill	in	your	questionnaire?				
Carer	questionnaires	
• Did	you	find	any	of	the	questionnaires	confusing?	
• Did	you	find	any	of	the	questionnaires	upsetting?	
• Some	are	asking	quite	personal	questions.		How	do	you	feel	about	that?	
• What	would	you	think	about	filling	in	these	questionnaires	again?		
Previous	experiences	in	MND	care	
• Can	you	tell	me	a	little	about	how	you	came	to	get	the	diagnosis	of	MND?	
• What	have	your	experiences	been	since	then?	
• Can	you	tell	me	about	your	last	MND	hospital	clinic	visit?	
• Have	you	used	the	MND	helpline?	
• How	do	you	manage	if	you	have	a	question	or	problem?	
• What	would	you	say	you	are	most	worried	about?	
• How	do	you	think	your	MND	team	have	helped	you?	
• How	do	you	think	your	care	could	be	better?		
• What	problems	do	you	think	have	been	most	troublesome?	
• How	much	do	you	know	about	MND?		
Carer	experiences	
• How	do	you	get	the	support	you	need	as	a	carer?	
• How	do	you	find	the	help	the	MND	team	gives?	
• How	do	you	think	your	care	could	be	better?	
• What	problems	do	you	think	have	been	most	troublesome?	
• How	much	do	you	know	about	MND?		 	
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Topic	guide	Patients/carers	at	one	month		
Previous	experiences	in	MND	care	
• Same	questions	as	baseline	topic	guide		
Carer	experiences	
• Same	questions	as	baseline	topic	guide		
Expectations	of	the	TiM	system	
• Before	the	start	of	the	study	what	technology	did	you	use?	
• What	did	you	expect	the	TiM	system	would	be	like?	
• Is	there	anything	you	would	have	hoped	it	would	have?	
• Is	there	anything	that	worried	you	about	it?		
Experiences	of	training	and	starting	to	use	the	TiM	system	
• What	did	you	think	when	you	first	saw	it?	
• How	did	you	find	the	training?	
• Do	you	remember	what	it	was	like	using	it	for	the	first	time?		
Barriers	and	facilitators	to	using	the	TiM	system	
• Is	there	anything	things	you	like	about	it?	
• Is	there	anything	you	don’t	like?	
• Has	it	worked	every	time	as	you	expected?	
• Do	you	think	you	will	continue	to	use	it	regularly?		Why?	
• What	have	you	told	your	friends	about	it?		
For	the	carer	
• How	have	you	found	using	the	TiM	system?	
• What	was	it	like	using	it	for	the	first	time?	
• How	have	you	found	the	questions?		
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Topic	guide	for	intervention	patients/carers	at	month	6			
Your	illness	
• How	have	you	been	since	we	last	met?	
• How	has	your	illness	changed?	
• How	has	your	life	changed?	
• What	are	the	main	problems	&	priorities	you	face	at	the	moment?		
Telehealth	
• Has	telehealth	made	an	impact	on	this?	
• Can	you	tell	me	what	it	is	like	filling	in	the	telehealth?	
• Can	you	recall	a	time	when	Theresa	has	phoned	your	or	your	nurse	has	spoken	about	the	telehealth?	
• Do	you	think	it	had	an	impact	on	your	condition?	
• What	things	do	you	think	TW	MUST	contact	you	about?	
• What	other	things	do	you	think	it’s	important	that	she	knows	about?	
• What	do	you	think	happens	to	the	data?	
• Has	it	ever	gone	wrong?		Have	you	ever	expected	a	call	and	not	received	one?	
Clinic/medical	care	
• Have	you	spoken	to	your	doctor	about	the	telehealth?	Or	clinic?	Tell	me	about	that?	
• Can	you	tell	me	about	your	most	recent	clinic	visits?		Impact	of	telehealth	on	clinic?	
• Who	do	you	think	holds	the	responsibility	for	your	care?	
• Can	telehealth	help	you	make	those	choices?	
• Do	you	make	choices	about	your	condition?		Who	makes	those	choices?		
Progression	
• People	with	MND	change	at	different	rates.		How	has	your	condition	changed?		Do	you	think	you	can	show	that	on	the	telehealth?	
Self	management	
• What	do	you	think	your	role	is	in	the	management	of	your	condition?	
• Are	there	things	you	don’t	want	to	learn	about?		Or	are	there	times	where	you	didn’t	want	to	know	about	something?	
Compliance	
• How	do	you	think	we	could	encourage	people	to	use	the	system	more?	
• Some	people	might	say	this	was	an	intrusion	in	your	life.		What	do	you	think	about	this?	
Dealing	with	emergencies	
• Can	you	tell	me	about	a	time	when	you’ve	been	unwell	or	something	about	your	condition	changed?		What	happened?	
• If	there	was	an	emergency,	how	would	you	act?	What	would	you	do	about	the	telehealth?	
Feedback	
• Have	you	received	feedback?		Are	there	situations	where	you	would	expect	feedback?	
• How	would	you	improve	the	telehealth?	
• Is	there	anything	that	you	think	is	important?		
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Carer	
• How	do	you	find	filling	it	in	for	you/your	husband/wife?	
• How	are	you	doing	that?	
• How	has	your	life	changed	since	we	last	me?	
• What	do	you	think	could	be	improved?	
• How	has	that	reflected	in	the	questions?	
• How	do	you	think	your	condition	has	impacted	on	your	husband/wife?	
• How	do	you	think	the	TiM	system	has	impacted	on	you?	
• What	do	you	think	is	the	role	of	the	MDT	for	you?	
• If	someone	were	to	call	you	up	with	concerns	about	your	TiM	answers,	how	would	you	feel?	
Information	
• Have	you	used	any	of	the	other	features	of	the	telehealth?	
• Would	you	like	to	see	any	other	features?											 	
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Telehealth	nurse	interview	1	
	
Role	
• Can	you	tell	me	a	bit	about	your	day-to-day	role	as	an	MND	nurse?	
• What	do	you	think	are	the	most	important	aspects	of	the	work	you	do?	
• How	do	you	think	MND	teams	in	the	community	could	best	work	together	with	you?	
Carers	
• How	do	you	think	care	should	be	improved	for	carers?	
• What	do	you	think	there	biggest	problems	are?	
Unmet	needs	
• Do	you	think	MND	care	varies	throughout	the	UK?	
• What	do	you	think	are	the	biggest	priorities	for	improving	care	for	patients	with	MND?	
• How	would	you	improve	care	if	you	had	the	opportunity?	
TiM	initial	use	
• Can	you	tell	me	about	when	you	first	started	using	it?	
• Can	you	tell	me	about	how	you	are	using	the	TiM	on	a	day	to	day	basis?	
• What	happens	when	the	people	you	are	using	it	with	come	to	clinic?	
• Has	it	changed	the	way	you	work?	
• Have	any	of	the	patients	called?	
• Did	they	say	anything	about	it?	
• What	changes	would	you	recommend	making	to	make	it	better?	
Flags	
• What	do	you	do	if	a	flag	is	raised?	
• Have	you	been	calling	people	about	every	flag?	
• How	do	you	decide	who	to	call?	
• What	do	you	think	are	the	most	important	things	you	need	to	know	about?	
Features:	
• Can	you	tell	me	about	using	the	portal?	
• Which	features	do	you	think	are	relevant?	
• Are	there	any	irrelevant	ones?	
• How	does	this	impact	on	your	time?	
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Telehealth	nurse	interview	2	
 Topic	guide	prepared	by	Wendy	Baird	following	suggestions	from	EH	and	Sue	Mawson.		Interview	by	Wendy	Baird.	
	
	
If	I	were	another	MND	nurse		
• What	would	you	say	about	the	system?	
• Walk	me	through	how	I	would	use	it.			Which	would	lead	on	to		
• Tell	me	what	works	
• It	looks	a	bit	complicated,	how	easy	was	it	to	get	used	to	the	system?	
• How	reliable	is	the	information?	
• Can	you	really	rely	on	it	to	make	clinical	decisions?	
• How	do	you	decide	when	to	contact	the	patients?	
• Are	the	flags	useful	-	do	you	always	follow	them	up?	
• Do	patients	realise	that	the	information	they	include	will	raise	a	flag	-	will	they	think	its	unusual	if	you	do/	do	not	respond	to	information?	
• Do	you	worry	about	not	responding	to	flags?		
• What	have	others	said	about	using	this	type	of	technology	
• How	do	you	explain	this	to	patients?	
• What	do	the	patients	think	about	using	this	kind	of	technology?	
• What	kind	of	patients/	carers		are	using	it	the	most?	
• Would	it	be	more	useful	for	some	types	of	patients?	
• Do	you	think	this	would	help	reduce	the	workload	of	MND	nurses	/	teams?	
• Do	you	think	other	MND	nurses	will	be	able	to	use	the	system?	
• What	kind	of	training	do	you	think	they	would	need	-	information	pack?	
• Would	this	be	of	use	to	the	wider	clinical	team?		
• Who	else	might	benefit	from	access	to	this	information?				 	
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Community	nurse	interview				
Community	service	
• Describe	your	role?	How	does	your	day	to	day	job	work?	
• How	often	do	you	visit	patients?	Does	this	change	at	different	periods	e.g.	newly	diagnosed?	Are	you	reactive	or	regular?	
• How	does	this	combine	with	the	rest	of	the	MDT	and	the	hospital	team(s)?	
• What	would	be	their	your	arrangement?	
• What	are	the	limitations	of	their	service?	
• What	is	your	role	with	carers?	
• What	are	the	challenges	in	your	population?			
• How	do	you	keep	up	to	date	with	what	is	going	on?			
Telehealth	
• Review	patients	using	telehealth	
• Have	they	showed	you	the	telehealth	or	mentioned	it?	
• Any	experience	of	patients’	interaction	with	telehealth?		Discuss	specific	patients	
• Patient	at	end	of	life		
• Carer	anxiety	
• Information	withheld/	value	of	additional	information		
Future	of	telehealth	
• Would	you	want	to	have	access	to	this?	Or	someone	to	feed	back	to	you	
• How	do	you	delegate	work?	
• Internet	access	“in	the	field”	
• Attitude	to	technology	
• Attitude	to	new	ways	of	working				
Version 1 _ Draft <Page number> 
<Time-point> 
Thank you for your time, participating in the TiM study. 
  
This is the booklet for the PATIENT to complete. 
  
Please complete ALL the questions in the enclosed booklet.  You do not need to complete it 
all in one sitting but please try to complete it all in the same day and return as soon as 
possible.  It is important that you try to complete the whole booklet if possible.   
  
Some of the questions may seem repetitive.  This is because we are trying to find out which 
are the best questions to ask. 
  
Your answers will only be seen by the research team and will not aﬀect the care you receive. 
  
If you have any questions or problems completing the questionnaires you can contact Staﬀ 
Nurse Charlotte Morgan.  She is a research nurse at the Royal Hallamshire Hospital Clinical 
Research Facility.  She can also help you complete the questionnaires either by telephone or 
in person.  Her telephone number is 01142713339.     
  
Once both booklets have been completed please: 
 1) Check all the questions have been answered 
 2) Place both booklets in the enclosed stamped addressed envelope 
 3) Post them oﬀ as soon as you can 
  
Once again, thank you for your contribution to this research. 
Patient questionnaire 
d d m m y y y y 
Date of completion 
<identifier> Identifier 
Pages	419	to	440	have	been	removed	by	the	author	of	this	thesis	for	copyright	reasons.	
<identifier> 
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Health resource use 
Over the last three months, how many times have you seen any of these people for 
your MND? 
At home 
At hospital / 
surgery / 
hospice 
GP (routine appointment) 
GP (emergency appointment) 
Hospital MND doctor 
Hospice doctor 
Respiratory team 
Attendance at accident & emergency 
Attendance at walk-in centre 
Physiotherapist 
Occupational therapist 
Dietician 
Speech therapist 
MND nurse / care worker 
District nurse 
Palliative care / Macmillan nurse 
Ambulance (routine trip e.g. to a hospital appointment) 
Ambulance (emergency call, treated at home only) 
Ambulance (emergency call, taken to hospital) 
Other (describe) 
Other (describe) 
Other (describe) 
<identifier> 
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Health resource use 
Approximately how many hours a week do you have paid carers help you?  
Approximately how many hours a week do you have unpaid carers help you 
in the house? (this might include friends and family helping with shopping, cooking, dressing etc.)  
In the last 3 months, have you stayed in hospital overnight? Yes No 
Date 
record day if known 
Which 
hospital? Reason for admission 
Number 
of nights 
Emergency? 
Tick “No” if planned 
If “yes“, please complete one line in the table below for each admission 
d d m m y y Yes No 
d d m m y y Yes No 
d d m m y y Yes No 
d d m m y y Yes No 
d d m m y y Yes No 
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Patient experience 
Strongly 
disagree 
Disagree 
Neither 
agree or 
disagree 
Agree 
Strongly 
agree 
1 I am in close contact with my MND team 
2 I feel that my MND is being closely monitored 
3 
I feel that I’m getting the best treatment for my 
MND 
4 
I am satisfied with my hospital MND 
appointments 
5  I am satisfied with my hospital MND nurse 
6 I am satisfied with my community MND nurse 
7 
If I have a problem with my MND I know who to 
contact 
8 
If I have a problem with my MND it gets solved 
quickly 
9 I understand enough about my condition 
10 
My MND team involve me in decisions about my 
treatment and care 
Please consider your MND care over the last 3 months. 
Please tick one box for each question. 
You can use this space to write any other comments 
<identifier> 
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TiM system experience 
Please consider how you have found the TiM system over the last 3 months. 
Please tick one box for each question. 
Strongly 
disagree 
Disagree 
Neither 
agree or 
disagree 
Agree 
Strongly 
agree 
1 It was easy to use the TiM system 
2 The TiM questions were relevant to me 
3 
The TiM system allowed me to report all the 
problems with my MND 
4 
The MND team contacted me quickly if my 
condition changed or I had a problem 
5  The questions were upsetting or distressing 
6 Using the system took a lot of time or energy 
7 
The TiM system respected my privacy and 
confidentiality 
8 The Knowledge Centre was useful 
9 The Problem list was useful 
You can use this space to write any other comments 
<identifier> 
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TiM system experience 
Daily 
Every few 
days 
Weekly Fortnightly Monthly 
15 
If you were to use the TiM system again how often 
would you want to use it? 
In the future something like the TiM system may be used in other trials or to care for 
patients. 
Please tick one box for each question. 
Strongly 
disagree 
Disagree 
Neither 
agree or 
disagree 
Agree 
Strongly 
agree 
10 
If something like the TiM system was available to 
use as part of another trial I would like to use it 
11 
If something like the TiM was available to use as 
part of usual NHS care I would like to use it 
12 
I would recommend the TiM system to a fellow 
patient 
13 
If I were unable to travel to clinic I would like to 
use the TiM system 
14 
If my doctor reviewed the TiM system results and 
found my condition was stable I would be happy 
for them to delay my appointment until I need it 
You can use this space to write any other comments 
<identifier> 
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Thank you!  You have finished all the questions.   
  
Please take a little time to check you have answered 
every question.  Once you have both finished please put 
both booklets in the stamped addressed envelope and 
post them back as soon as you can. 
  
Your contribution to this research is very important to 
improve the care for patients and carers. 
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